

19.10.2018

11:50 - 13:30 **Type: Opening Session** **Hall A2 - Room 18**
Title: Opening session and award lectures
 Chair(s): Josep Tabernero, ES; Emile Voest, NL

11:50 - 12:00 **ESMO Presidential Address**
J. Tabernero, ES

12:00 - 12:06 **ESMO 2018 Scientific Address**
S. Peters, CH

12:06 - 12:12 **EONS Address**
L. Sharp, SE

12:12 - 12:17 **Thanks to ESMO 2018 Officers**
E. Voest, NL

12:17 - 12:20 **Presentation of the ESMO Award**
E. Voest, NL

12:20 - 12:35 **ESMO Award lecture**

12:35 - 12:38 **Presentation of the ESMO Translational Research Award**
E. Voest, NL

12:38 - 12:53 **ESMO Translational Research Award lecture**

12:53 - 12:56 **Presentation of the ESMO Women for Oncology Award**
E. Voest, NL

12:56 - 13:11 **ESMO Women for Oncology Award lecture**

13:11 - 13:14 **Presentation of the ESMO Lifetime Achievement Award**
E. Voest, NL

13:14 - 13:29 **ESMO Lifetime Achievement Award lecture**

13:29 - 13:30 **Closing and Welcome reception in the exhibition**

13:30 - 15:30 **Type: Special session** **Hall B4 - Room 24**
Title: Sharing the power - ESMO Women for Oncology Forum
Chair(s): Solange Peters, CH

13:30 - 13:30 **Session DOI**

13:30 - 13:35 **Welcome**
S. Peters, CH

13:35 - 13:50 **Oceans apart or bridging the gap?**
M. Dosanjh, CH

13:50 - 14:05 **Feminisation and recomposition of professional hierarchies: Challenges and opportunities for medicine**
F. Panese, CH

14:05 - 14:20 **DGHO Women's working group**
A. Letsch, DE

14:20 - 14:35 **Women for Oncology Italy**
M.C. Garassino, IT

14:35 - 14:50 **Women for Oncology Greece**
H. Linardou, GR

14:50 - 15:20 **Discussion in small groups about specific relevant themes**

15:20 - 15:30 **Conclusions and take-home messages**
S. Peters, CH

14:00 - 15:30 **Type: Educational session** **Hall A1 - Room 17**
Title: Standards and advances in rectal cancer
 Chair(s): Miriam Koopman, NL; Karen-Lise Spindler, DK

14:00 - 14:00 **Session DOI**

14:00 - 14:22 **Imaging of rectal tumours: What is standard (and to be known by the clinician)?**
G. Brown, GB

14:22 - 14:44 **Organ preservation and local treatment in localised rectal cancers**
D. Sebag-Montefiore, GB

14:44 - 15:06 **Optimal multimodal treatment in advanced rectal cancers**
M.A. Gambacorta, IT

15:06 - 15:28 **Controlling systemic disease: What is needed, and in which sequence?**
M. Koopman, NL

14:00 - 15:30 **Type: Educational session** **Hall A2 - Room 18**
Title: Emerging opportunities in cancer immunotherapy
 Chair(s): Ignacio Melero, ES

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **Mutanomes and neoantigens**
M. Bassani-Sternberg, CH/CH

14:25 - 14:50 **Host biomarkers that affect response to immunotherapy (microbiomes)**
N. Chaput-Gras, FR

14:50 - 15:15 **Emerging targets for immunotherapy**
I. Melero, ES

15:15 - 15:30 **Discussion**

14:00 - 15:30 **Type: Educational session** **ICM - Room 1**
Title: Clinical implementation of PARP inhibitors
 Chair(s): Andrew Tutt, GB; Serena Di Cosimo, IT

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **Who, when and how to test for BRCA mutations**
D. Stoppa-Lyonnet, CEDEX 5/FR

14:25 - 14:55 **What is the true impact of PARP inhibitors in clinical practice?**
A. Tutt, GB

14:55 - 15:15 **Managing side effects of PARP inhibitors**
S. Paluch-Shimon, IL

15:15 - 15:30 **Discussion**

14:00 - 15:00 **Type: Poster Discussion session** **ICM - Room 14b**
Title: Poster Discussion session - NSCLC, metastatic 1
 Chair(s): Raffaele Califano, GB; Pasi Janne, US; Fedor Moiseyenko, RU

14:00 - 14:00 **Session DOI**

14:00 - 14:00 **LBA57 - Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)**
E. Felip¹, M. Nishio², S. Orlov³, K. Park⁴, C.-J. Yu⁵, C.-M. Tsai⁵, M. Cobo¹, M. McKeage⁶, W.-C. Su⁵, T. Mok⁷, G.V. Scagliotti⁸, D. Spigel⁹, V.Q. Passos⁹, Z. Chen⁹, A.T. Shaw⁹; 1ES, 2JP, 3RU, 4KR, 5TW, 6NZ, 7CN, 8IT, 9US

14:00 - 14:00 **LBA58 - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial**
S. Popat¹, H.R. Kim², M.-J. Ahn², J.C.-H. Yang³, J.-Y. Han², M. Hochmair⁴, K.H. Lee², A. Delmonte⁵, M.R. Garcia Campelo⁶, D.-W. Kim², F. Griesinger⁷, E. Felip⁶, R. Califano¹, A. Spira⁸, S. Gettinger⁹, M. Tiseo⁵, J. Haney¹⁰, D. Kerstein¹⁰, D. Camidge¹¹; 1GB, 2KR, 3TW, 4AT, 5IT, 6ES, 7DE, 8VA/US, 9CT/US, 10MA/US, 11CO/US

14:00 - 14:00 **1379PD - Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK-rearranged; advanced NSCLC (aNSCLC) in the global phase III ALEX study**
R. Dziadziuszko¹, T. Mok², D.R. Camidge³, A. Shaw⁴, J. Noe⁵, M. Nowicka⁵, T. Liu⁵, E. Mitry⁵, S. Peters⁵; 1PL, 2HK, 3US, 4MA/US, 5CH

- 14:00 - 14:00 **1380PD - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations**
B. Solomon¹, J.-F. Martini², S.-H. Ou², R. Chiari³, R. Soo⁴, A. Bearz³, S. Li⁵, H. Thurm², C.-C. Lin⁶, G. Riely⁵, T. Bauer⁷, A. Shaw⁸; ¹VIC/AU, ²CA/US, ³IT, ⁴SG, ⁵US, ⁶TW, ⁷TN/US, ⁸MA/US
- 14:00 - 14:00 **LBA59 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC ASCEND-8)**
B.C. Cho¹, R. Obermannova², S. Orlov³, U. Batra⁴, S. Geater⁵, M. McKeage⁶, C.-T. Yang⁷, P. Postmus⁸, G. de Castro⁹, S.-W. Kim¹, P. De Marchi⁹, G.B. Kanakasetty⁴, V. Sriuranpong⁵, P.J. Voon¹⁰, Y.Y. Lau¹¹, F. Kiertsman¹¹, V. Passos¹¹, Z. Chen¹¹, R. Dziadziuszko¹²; ¹KR, ²CZ, ³RU, ⁴IN, ⁵TH, ⁶NZ, ⁷TW, ⁸Merseyside/NL, ⁹BR, ¹⁰MY, ¹¹NJ/US, ¹²PL
- 14:00 - 14:20 **Invited Discussant LBA57, LBA58, 1379PD, 1380PD and LBA59**
P. Janne, US
- 14:20 - 14:30 **Q&A led by Discussant**
- 14:30 - 14:30 **LBA60 - Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors**
A. Brindel¹, W. Althakfi¹, M. Barritault¹, P.-P. Bringuier¹, E. Watkin¹, J.-M. Maury¹, N. Girard¹, M. Brevet²; ¹FR, ²CEDEX/FR
- 14:30 - 14:30 **1381PD - Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study**
J.C.-H. Yang¹, Y. Cheng², H. Murakami³, P.-C. Yang¹, J. He², K. Nakagawa³, J.H. Kang⁴, J.-H. Kim⁴, X. Wnag², S. Enatsu³, T. Puri⁵, M. Orlando⁶; ¹TW, ²CN, ³JP, ⁴KP, ⁵IN, ⁶AR
- 14:30 - 14:30 **1382PD - Phase III study of gefitinib (G) versus gefitinib&&**
M. Seike¹, A. Inoue¹, S. Sugawara², S. Morita¹, Y. Hosomi¹, S. Ikeda¹, K. Watanabe¹, K. Takahashi¹, Y. Fujita¹, T. Harada¹, K. Minato¹, K. Takamura¹, K. Kobayashi¹, T. Nukiwa¹; ¹JP, ²Miyagi/JP
- 14:30 - 14:30 **1383PD - An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)**
R. Camidge¹, R. Heist², J. Goldman³, E. Angevin⁴, J. Strickler², D. Morgensztern², M. Barve⁵, T. Bauer⁶, E. Vokes⁷, T. Yi⁷, M. Motwani⁷, A. Parikh³, J. Wu⁷, K. Kelly²; ¹CO/US, ²US, ³CA/US, ⁴CEDEX/FR, ⁵TX/US, ⁶TN/US, ⁷IL/US
- 14:30 - 14:30 **LBA61 - Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)**

D. Tan¹, S.-W. Kim², L. Sequist³, S. Ponce Aix⁴, E. Smit⁴, T. Hida⁵, J. Yang⁶, E. Felip⁴, T. Seto⁷, C. Grohe⁸, J. Wolf⁸, J. Ko⁹, E. Marriere¹⁰, R. Belli¹⁰, M. Giovannini⁹, D.-W. Kim²;
1SG, 2KR, 3MA/US, 4ES, 5JP, 6TW, 7Fukuoka/JP, 8DE, 9US, 10CH

14:30 - 14:50 **Invited Discussant LBA60, 1381PD, 1382PD, 1383PD and LBA61**

R. Califano, GB

14:50 - 15:00 **Q&A led by Discussant**

- 14:00 - 15:30** **Type: Proffered Paper session** **ICM - Room 13**
Title: Proffered paper session - Genitourinary tumours, prostate
 Chair(s): Eleni Efstathiou, US; Silke Gillessen, CH
- 14:00 - 14:00 **Session DOI**
- 14:00 - 14:15 **7910 - Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up**
K. Fizazi¹, A. Carmel¹, F. Joly¹, R. Delva¹, G. Gravis², F. Rolland³, F. Priou², J.-M. Ferrero⁴, N. Houede¹, L. Mourey⁵, C. Theodore¹, I. Krakowski³, J.-F. Berdah¹, M. Baciuchka Palmaro⁶, B. Laguerre³, A. Flechon³, A. Ravaud¹, M. Brihoum¹, S. Culine⁷, G. Le Teuff¹; ¹FR, ²CEDEX 9/FR, ³CEDEX/FR, ⁴CEDEX 2/FR, ⁵Haute-Garonne/FR, ⁶CEDEX 20/FR, ⁷CEDEX 10/FR
- 14:15 - 14:30 **Invited Discussant 7910**
E. Efstathiou, TX/US
- 14:30 - 14:45 **LBA30 - ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)**
M. Smith¹, C. Parker², F. Saad³, K. Miller⁴, B. Tombal⁵, Q.S. Ng⁶, M. Bögemann⁴, V. Matveev⁷, J.M. Piulats⁸, L. Zucca⁹, A. Heidenreich⁴, Y. Kakehi¹⁰, A. Zhang¹, H. Krissel⁴, J. Shen¹, V. Wagner⁴, C. Higano¹; ¹US, ²GB, ³CA, ⁴DE, ⁵BE, ⁶SG, ⁷RU, ⁸ES, ⁹BR, ¹⁰JP
- 14:45 - 15:00 **Invited Discussant LBA30**
D. Heinrich, NO
- 15:00 - 15:15 **7920 - A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)**
K. Chi¹, S. Taavitsainen², N. Iqbal³, C. Ferrario⁴, M. Ong², D. Wadhwa², S. Hotte⁵, G. Lo⁶, B. Tran⁷, A. Azad⁷, L. Wood⁸, J. Gingerich⁸, S. North⁸, C. Pezaro⁹, D. Ruether¹⁰, S. Sridhar⁵, M. Annala², J. Bacon², A. Wyatt⁸; ¹British Columbia/CA, ²BC/CA, ³SK/CA, ⁴QC/CA, ⁵Ontario/CA, ⁶ON/CA, ⁷AU, ⁸CA, ⁹VIC/AU, ¹⁰Alberta/CA
- 15:15 - 15:30 **Invited Discussant 7920**
S. Oudard, FR

14:00 - 15:30 Type: Proffered Paper session Hall A1 - Room 15
 Title: Proffered paper session - Gynaecological cancers
 Chair(s): Susana Banerjee, GB; Sandro Pignata, IT

14:00 - 14:00 Session DOI

14:00 - 14:15 **9320 - Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial**

S. Gaillard¹, A. Oaknin², I. Ray-Coquard³, I. Vergote⁴, G. Scambia⁵, N. Colombo⁵, S. Ghamande¹, A. Soto-Matos², C. Fernandez⁶, C. Kahatt², J. Gomez², A. Nieto², N. Torres², B. Pardo-Burdalo², Z. Papai⁷, R. Kristeleit⁸, D. O'Malley¹, I. Benjamin¹, P. Pautier³, D. Lorusso⁵; ¹US, ²ES, ³CEDEX/FR, ⁴BE, ⁵IT, ⁶España/ES, ⁷HU, ⁸GB

14:15 - 14:30 **9330 - Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)**

J. Pfisterer¹, A. Dean², K. Baumann¹, J. Rau¹, P. Harter¹, F. Joly³, J. Sehouli¹, U. Canzler¹, B. Schmalfeldt¹, C. Shannon⁴, A. Hein¹, D. Reimer⁵, L. Hanker¹, T. Petit³, F. Marmé¹, A. El-Balat¹, R. Glasspool⁶, N. de Gregorio¹, S. Mahner¹, J.-E. Kurtz³; ¹DE, ²WA/AU, ³FR, ⁴QLD/AU, ⁵AT, ⁶GB

14:30 - 14:45 **Invited Discussant 9320 and 9330**

S. Pignata, IT

14:45 - 15:00 **9340 - Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) & bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse**

I. Ray-Coquard¹, P. Harter², D. Lorusso³, C. Dalban⁴, I. Vergote⁵, K. Fujiwara⁶, L. Gladieff⁷, H.-J. Lueck², A. Floquet¹, A.F. Lesoin¹, A. Schnelzer², S. Pignata³, F. Selle⁴, J. Sehouli², F. Brocard⁴, G. Mangili³, P. Pautier¹, U. De Giorgi⁸, M. Provansal⁴, P.-E. Heudel⁹; ¹CEDEX/FR, ²DE, ³IT, ⁴FR, ⁵BE, ⁶JP, ⁷Haute-Garonne/FR, ⁸Forlì-Cesena/IT, ⁹Cedex 08/FR

15:00 - 15:15 **9400 - OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer**

S. Blagden¹, G. Bertelli¹, E. Frangou¹, C. Butcher¹, S. Love¹, M. Mackean², R. Glasspool¹, A. Cook¹, S. Nicum¹, R. Lord³, M. Ferguson¹, R. Roux⁴, M. Martinez¹, S. Black¹, A. James¹, H. Palmer¹, S. Hughes¹, C. Marriott¹, L. Howells¹; ¹GB, ²Midlothian/GB, ³Merseyside/GB, ⁴Middlesex/GB

15:15 - 15:30 **Invited Discussant 9330 and 9340**

S. Banerjee, GB

14:00 - 15:30 **Type: Special session** **Hall A1 - Room 16**
Title: Big data in cancer management: Genomics and disease stratification
 Chair(s): Stefan Pfister, DE; Carlos Caldas, GB

14:00 - 14:00 **Session DOI**

14:00 - 14:20 **Lung cancer**
C. Swanton, GB

14:20 - 14:40 **Breast cancer**
C. Caldas, Cambridgeshire/GB

14:40 - 15:00 **CNS tumours**
S. Pfister, DE

15:00 - 15:30 **Discussion**

14:00 - 15:30 **Type: Proffered Paper session** **Hall B3 - Room 21**
Title: Proffered paper session - Sarcoma
 Chair(s): Rick L. Haas, NL

14:00 - 14:00 **Session DOI**

14:00 - 14:12 **16010 - Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017**
J.-Y. Blay¹, M. Toulmonde¹, N. Penel¹, O. Mir², C. Chevreau³, P. Anract², E. Bompas¹, M. Rios¹, N. Firmin², A. Italiano¹, S. Piperno-Neumann⁴, J.-E. Kurtz², F. Duffaud⁴, P. Rosset², F. Bertucci⁵, C. Perrin¹, C. Chemin¹, F. Ducimetiere¹, F. Gouin², A. Le Cesne¹;
 1CEDEX/FR, 2FR, 3Haute-Garonne/FR, 4CEDEX 5/FR, 5CEDEX 9/FR

14:12 - 14:24 **16020 - Outcome following unplanned excision in soft tissue sarcoma: Results of a multicentre study including 728 patients**
M. Smolle¹, P.-U. Tunn², E. Goldenitsch¹, F. Posch¹, J. Szkandera¹, M. Bergovec¹, B. Liegl-Atzwanger¹, A. Leithner¹; 1AT, 2DE

14:24 - 14:36 **LBA66 - A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall**

S. Bonvalot¹, P. Rutkowski², J. Thariat³, S. Carrere³, M.-P. Sunyach³, E. Saada³, P. Agoston⁴, A. Hong⁵, A. Mervoyer³, M. Rastrelli⁶, C. Le Pechoux¹, V. Moreno⁷, R. Li⁸, B. Tiangco⁹, A. Casado Herraes⁷, A. Gronchi⁶, L. Mangel⁴, P. Hohenberger¹⁰, M. Delannes³, Z. Papai⁴; ¹CEDEX/FR, ²PL, ³FR, ⁴HU, ⁵AU, ⁶IT, ⁷ES, ⁸PH, ⁹Metro Manila/PH, ¹⁰DE

14:36 - 14:51 **Invited Discussant 16010, 16020 and LBA66**

R.L. Haas, NL

14:51 - 15:03 **16030 - Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens**

S. George¹, M. Heinrich¹, P. Chi¹, A. Razak², M. von Mehren³, M. Gordon⁴, K. Ganjoo¹, N. Somaiah⁵, J.C. Trent⁶, J. Rodon Ahnert¹, J. Wolf¹, R. Ruiz-Soto⁷, O. Rosen⁷, F. Janku⁶; ¹US, ²ON/CA, ³PA/US, ⁴AZ/US, ⁵SC/US, ⁶TX/US, ⁷MA/US

15:03 - 15:15 **LBA67 - Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study.**

A. Italiano¹, N. Penel¹, M. Toulmonde¹, E. Bompas¹, S. Piperno-Neumann², M. Pulido³, N. Entz-Werle³, A. Le Cesne¹, C. Chevreau⁴, F. Duffaud², I. Ray-Coquard¹, C. Bellera³, S. Mathoulin-Pelissier³, J.-Y. Blay¹; ¹CEDEX/FR, ²CEDEX 5/FR, ³FR, ⁴Haute-Garonne/FR

15:15 - 15:30 **Invited Discussant 16030 and LBA67**

D. Katz, IL

14:00 - 15:30	Type: Educational session Title: Brain and leptomeningeal metastasis: Standard of diagnosis and treatment Chair(s): Frank Winkler, DE; Carmen Balana, ES	Hall B3 - Room 23
---------------	--	--------------------------

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **Challenges in the diagnostic work-up of brain and leptomeningeal metastasis**

P. Wesseling, NL

14:25 - 14:50 **Multimodality treatment of brain metastasis**

F. Winkler, DE

14:50 - 15:15 **Multimodality treatment of leptomeningeal metastasis**

E. Le Rhun, CEDEX/FR

15:15 - 15:30 **Discussion**

14:00 - 15:30 **Type: Joint Symposium** **Hall B3 -**
Title: ESMO-SIOPE: Multidisciplinary management of life-after-cancer **Room 22**
issues in adolescent and young adult survivors: Medicine and beyond
 Chair(s): Giannis Mountzios, GR; Daniel Stark, GB

14:00 - 14:00 **Session DOI**

14:00 - 14:05 **Introduction**

D. Stark, Yorkshire/GB

14:05 - 14:25 **Fertility preservation, parenthood and sexual health in AYA cancer survivors**

F. Peccatori, IT

14:25 - 14:45 **Late cardiovascular toxicity of anti-cancer treatment in adolescents and young adults**

K. Rugbjerg, DK

14:45 - 15:05 **Going back to school or work after cancer diagnosis: Professional and social re-integration of AYA cancer survivors**

P. Riis Olsen, DK

15:05 - 15:25 **Psychosocial, nutritional and physical activity aspects of AYA cancer survivors**

A. Stein, DE

15:25 - 15:30 **Conclusions**

G. Mountzios, Neo Psychiko/GR

14:00 - 15:00 **Type: Special session** **ICM -**
Title: Treatment decisions and side effect management of new drugs **Room 14a**
(including immunotherapy) in lung cancer
 Chair(s): Stefan Rauh, LU; Pilar Garrido Lopez, ES

14:00 - 14:00 **Session DOI**

14:00 - 14:05 **Topic 1 case presentation: Pseudo progression versus true progression: When is it time to switch treatment?**
S. Rauh, LU

14:05 - 14:20 **General Discussion**
P. Garrido Lopez, ES

14:20 - 14:25 **Topic 2 case presentation: Side effects of immunotherapy in lung cancer: Focus on pulmonary toxicity**
S. Rauh, LU

14:25 - 14:40 **General Discussion**
P. Garrido Lopez, ES

14:40 - 14:45 **Topic 3 case presentation: Side effects of TKI's**
S. Rauh, LU

14:45 - 15:00 **General Discussion**
P. Garrido Lopez, ES

14:00 - 15:30 **Type: Special session** **ICM - Room 14c**
Title: ESMO-MCBS in perspective
 Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL

14:00 - 14:00 **Session DOI**

14:00 - 14:05 **Introduction**
E.G.E. de Vries, NL

14:05 - 14:30 **Comparative assessment of clinical benefit using the ESMO-MCBS v1.1 and the ASCO Value Frameworks Net Health Benefit Score**
N. Cherny, IL

14:30 - 14:55 **ESMO-MCBS v1.1 applied in haematological diseases**
B. Kiesewetter-Wiederkehr, AT

14:55 - 15:20 **How to help countries priorities their cancer systemic therapies -report from the WHO**
A. Ilbawi, CH

15:20 - 15:30 **Conclusions**
E.G.E. de Vries, NL

14:30 - 15:45 **Type: Patient Advocacy Track** **ICM - Room 5**
Title: Knowledge is power: Educating patients and advocates
 Chair(s): Jan Geissler, CH; Bettina Ryll, SE

14:30 - 14:30 **Session DOI**

14:30 - 14:45 **Welcome to ESMO2018**
B. Ryll¹, J. Tabernero²; ¹SE, ²ES

14:45 - 15:05 **Reaching patients: The podcast experience**
F. Johansson, Sweden/SE

15:05 - 15:25 **The Myeloma Access Atlas: Training programme**
A. Plate, BE

15:25 - 15:45 **The CML ECABs: Educating for excellence**
J. Geissler, CH

15:45 - 17:30 **Type: Educational session** **ICM - Room 1**
Title: State of the art for systemic treatments in kidney and bladder cancers
 Chair(s): Maria De Santis, DE; Marco Gizzi, BE

15:45 - 15:45 **Session DOI**

15:45 - 16:10 **State of the art of immunotherapy in renal and bladder cancers**
C. Sternberg, IT

16:10 - 16:35 **The current use of TKI in renal cancer**
M. Gizzi, BE

16:35 - 17:00 **Is there still a role for chemotherapy in bladder cancer?**
M. De Santis, DE

17:00 - 17:25 **Abundance of riches in view of health care constraints:**
A. Bex, NL

15:45 - 17:25 **Type: Poster Discussion session** **Hall B3 - Room 21**
Title: Poster Discussion session -Gastrointestinal, non-colorectal
 Chair(s): Florian Lordick, DE; Marcel Verheij, NL; Ann-Lii Cheng, TW; Ian Chau, GB; Eileen O'Reilly, US

15:45 - 15:45 **Session DOI**

15:45 - 15:45 **616PD - Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer**
I. Chau¹, S.-E. Al-Batran², A. Luft³, R. Kowalyszyn⁴, C. Hernandez⁵, P. Pfeiffer⁶, E. Wojcik⁷, G. Bodoky⁸, A. Madi⁹, B. Brenner¹⁰, F. De Vita¹¹, G. Folprecht², K. Peltola¹², S. Lorenzen², C. Denlinger¹³, A. Liepa¹⁴, M. Das¹³, R. Wei¹³, C. Fuchs¹⁵; ¹Surrey/GB, ²DE, ³RU, ⁴AR, ⁵MX, ⁶DK, ⁷PL, ⁸HU, ⁹Merseyside/GB, ¹⁰IL, ¹¹IT, ¹²FI, ¹³PA/US, ¹⁴US, ¹⁵CT/US

15:45 - 15:45 **617PD - A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data**
T. Satoh¹, L.-T. Chen², Y.-K. Kang³, Y. Chao², K. Kato⁴, H.C. Chung⁵, J.-S. Chen², K. Muro⁶, W.K. Kang⁵, T. Yoshikawa⁴, S.C. Oh⁵, T. Tamura⁴, K.-W. Lee⁵, N. Boku⁷; ¹Osaka/JP, ²TW, ³Songpa-gu/KR, ⁴JP, ⁵KR, ⁶Aichi/JP, ⁷Kanagawa/JP

- 15:45 - 15:45 **619PD_PR - Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials**
M. Davidson¹, A. Wagner², K. Kouvelakis¹, N. Starling¹, I. Chau³, D. Watkins¹, S. Rao¹, C. Peckitt¹, D. Cunningham¹; ¹GB, ²CH, ³Surrey/GB
- 15:45 - 15:55 **Invited Discussant 616PD, 617PD and 619PD_PR**
F. Lordick, DE
- 15:55 - 16:05 **Q&A led by Discussant**
- 16:05 - 16:05 **618PD - Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU &&**
A. Barbour¹, E. Walpole², G. Mai², L. Barnes³, D. Watson⁴, S. Ackland³, V. Wills³, J. Martin³, M. Burge², C. Karapetis⁴, J. Shannon³, L. Nott¹, V. GebSKI³, M. Oostendorp³, K. Wilson³, J. Thomas², G. Lampe², J. ZalcbERG⁵, J. Simes³, M. Smithers²; ¹AU, ²QLD/AU, ³NSW/AU, ⁴SA/AU, ⁵VIC/AU
- 16:05 - 16:05 **620PD - Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: A prospective, multicenter, randomized controlled study**
T. Li, J. Lyu, G. Zhu, J. Li, R. Zhao, S. Zhu, J. Wang, L. Xing, D. Yang, C. Xie, L.-F. Shen, H.-P. Shi, J. Lang; CN
- 16:05 - 16:15 **Invited Discussant 618PD and 620PD**
M. Verheij, NL
- 16:15 - 16:25 **Q&A led by Discussant**
- 16:25 - 16:25 **621PD - Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)**
B.-Y. Ryoo¹, Z. Ren², T.-Y. Kim³, H. Pan⁴, K.-M. Rau², H.J. Choi³, J.-W. Park³, J.H. Kim⁵, C.-J. Yen², B.-H. Kim³, D. Zhou², J. Straub⁶, C. Zhao⁷, S. Qin²; ¹Songpa-gu/KR, ²CN, ³KR, ⁴Zhejiang/CN, ⁵Gyeonggi-do/KR, ⁶DE, ⁷US
- 16:25 - 16:25 **622PD - Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)**
A. Zhu¹, R. Finn², P. Galle³, J.M. Llovet⁴, J.F. Blanc⁵, T. Okusaka⁶, I. Chau⁷, D. Cella⁸, A. Girvan⁹, J. Gable¹, L. Bowman¹, Y. Hsu¹, P. Abada¹, M. Kudo⁶; ¹US, ²CA/US, ³DE, ⁴ES, ⁵FR, ⁶JP, ⁷Surrey/GB, ⁸IL/US, ⁹IN/US
- 16:25 - 16:35 **Invited Discussant 621PD and 622PD**

A.-L. Cheng, TW

16:35 - 16:45 **Q&A led by Discussant**

16:45 - 16:45 **LBA28 - Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions**

M. Javle¹, R.K. Kelley², S. Roychowdhury³, K.H. Weiss⁴, G. Abou-Alfa³, T. Macarulla⁵, S. Sadeghi², D. Waldschmidt⁴, A. Zhu⁶, L. Goyal³, M. Borad³, W.P. Yong⁷, I. Borbath⁸, A. El-Khoueiry², P. Philip³, S. Moran³, Y. Ye³, M. Ising³, N. Lewis³, T. Bekaii-Saab³; ¹TX/US, ²CA/US, ³US, ⁴DE, ⁵ES, ⁶MA/US, ⁷SG, ⁸BE

16:45 - 16:45 **623PD - The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer**

C. Morizane¹, Y. Komatsu¹, H. Takahashi², M. Ueno¹, J. Furuse¹, T. Kudo³, S. Itoh¹, S. Shimizu¹, K. Nakamura¹, K. Kamata¹, K. Ohtsubo¹, T. Mizukami¹, Y. Kagawa¹, S. Nomura¹, T. Kuwata¹, S. Fujii¹, W. Okamoto¹, K. Shitara¹, A. Ohtsu¹, T. Yoshino¹; ¹JP, ²Chiba/JP, ³Osaka/JP

16:45 - 16:45 **624PD - Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA)**

Y.-Y. Chen¹, J.O. Park², W.-C. Su¹, D.-Y. Oh², K.-P. Kim², Y.-H. Feng¹, L. Shen³, H. Liao³, J. Nie³, M. Qing³, J. Li³, P. De Porre⁴; ¹TW, ²KR, ³CN, ⁴BE

16:45 - 16:55 **Invited Discussant LBA28, 623PD and 624PD**

I. Chau, Surrey/GB

16:55 - 17:05 **Q&A led by Discussant**

17:05 - 17:05 **LBA29 - CARRIE: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Istratutumab (MM-141) plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer**

A. Ko¹, A. Cubillo², M. Kundranda³, S. Zafar⁴, E. Meiri⁵, J. Bendell⁶, H. Alguel⁷, F. Rivera Herrero², E. Ahn⁸, D. Watkins⁹, U. Pelzer⁷, V. Charu¹, W. Downing¹⁰, B. Wang¹⁰, G. Kuesters¹⁰, J. Pipas¹⁰, S. Santillana¹⁰, V. Askoxylakis¹⁰; ¹CA/US, ²ES, ³AZ/US, ⁴FL/US, ⁵GA/US, ⁶TN/US, ⁷DE, ⁸IL/US, ⁹GB, ¹⁰MA/US

17:05 - 17:05 **625PD - Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study**

M. Ueno¹, H.C. Chung², A. Nagrial³, A. Marabelle⁴, R. Kelley⁵, L. Xu⁶, J. Mahoney⁶, S. Pruitt⁶, D.-Y. Oh²; ¹JP, ²KR, ³NSW/AU, ⁴FR, ⁵CA/US, ⁶NJ/US

- 17:05 - 17:05 **626PD - Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study**
H.-J. Chang, Y.-F. Chiu, J.-S. Chen, C.-P. Li, C.-L. Ho, Y.-M. Shyr, W.-C. Chiou, C.-N. Yeh, R.-K. Hsieh, Y.-L. Lin, Y.-W. Tien, T.-L. Hwang, Y.-S. Shan, L.-T. Chen; TW
- 17:05 - 17:15 **Invited Discussant LBA29, 625PD and 626PD**
E. O'Reilly, NY/US
- 17:15 - 17:25 **Q&A led by Discussant**
- 16:00 - 17:30 Type: Special Symposium Title: Targeting brain metastases** **Hall A1 - Room 17**
Chair(s): Sheila Singh, CA; Dario Marchetti, US
- 16:00 - 16:00 **Session DOI**
- 16:00 - 16:05 **Introduction**
D. Marchetti, US
- 16:05 - 16:25 **Genetic heterogeneity in brain metastases: Therapeutic implications**
P. Brastianos, US
- 16:25 - 16:45 **Therapeutic targeting of the pre-metastatic stage in human lung-to-brain metastasis**
S. Singh, CA
- 16:45 - 17:05 **CTCs: Advancing tools to combat brain metastasis**
D. Marchetti, US
- 17:05 - 17:25 **Lessons from Glioblastoma: DNA repair as a therapeutic target in GBM**
P. Hamerlik, DK
- 17:25 - 17:30 **Conclusions and perspectives**
S. Singh, CA

16:00 - 17:30 **Type: Special Symposium** **ICM - Room 14b**
Title: Toxicities from specific agents
 Chair(s): Inge-Marie Svane, DK; Fiona Thistlethwaite, GB

16:00 - 16:00 **Session DOI**

16:00 - 16:05 **Introduction**
I.-M. Svane, DK

16:05 - 16:25 **Acute and chronic toxicities**
P. Ascierto, IT

16:25 - 16:45 **TILS therapy**
I.-M. Svane, DK

16:45 - 17:05 **TCR and CAR in haematological malignancies**
J. Svoboda, US

17:05 - 17:25 **TCR and CAR in solid tumours**
F. Thistlethwaite, GB

17:25 - 17:30 **Conclusions and perspectives**
F. Thistlethwaite, GB

16:00 - 17:30 **Type: Proffered Paper session** **ICM - Room 13**
Title: Proffered paper session - Breast cancer, early stage
 Chair(s): Suzette Delaloge, FR; Carlos Caldas, GB

16:00 - 16:00 **Session DOI**

16:00 - 16:12 **1840 - Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial**
H. Iwata¹, N. Masuda², Y. Yamamoto², T. Fujisawa², T. Toyama¹, N. Taira², M. Kashiwaba³, S. Ohtani⁴, T. Sakai², Y. Hasegawa², R. Nakamura², H. Akabane², Y. Shibahara², H. Sasano², T. Yamaguchi⁵, Y. Ohashi²; ¹Aichi/JP, ²JP, ³Iwate/JP, ⁴Hiroshima/JP, ⁵Miyagi/JP

16:12 - 16:24 **1850_PR - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort**

B. Pistilli¹, A. PACI¹, S. Michiels¹, A. ferreira², V. poinsignon¹, P. Cottu³, F. Lerebours¹, C. Coutant⁴, A. Lesur¹, O. Tredan¹, P. Soulie¹, L. Vanlemmens⁵, C. Jouannaud⁵, C. Levy³, S. Everhard¹, P. Arveux¹, A. Partridge⁶, S. Delaloge¹, F. André¹, I. Vaz-Luis¹; ¹FR, ²PT, ³CEDEX 5/FR, ⁴Cedex/FR, ⁵CEDEX/FR, ⁶US

16:24 - 16:39 **Invited Discussant 1840 and 1850**

H. Earl, Cambridgeshire/GB

16:39 - 16:51 **LBA12_PR - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results**

C. Hulme¹, P. Hall¹, B. Shinkins¹, F. Chehadah¹, C. McCabe², L. Hiller¹, J. Dunn¹, H. Earl³; ¹GB, ²AB/CA, ³Cambridgeshire/GB

16:51 - 17:03 **1860 - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2⁺ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial**

M.V. Dieci¹, P.F. Conte¹, G. Bisagni¹, A. Brandes¹, A. Frassoldati¹, L. Cavanna¹, A. Musolino¹, F. Giotta¹, A. Rimanti¹, O. Garrone¹, E. Bertone¹, K. Cagossi¹, S. Sarti², A. Ferro¹, C. Omarini¹, A. Maiorana¹, E. Orvieto¹, M. Sanders³, R. D'Amico¹, V. Guarneri¹; ¹IT, ²Forlì-Cesena/IT, ³US

17:03 - 17:15 **1870 - High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥ 4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study**

T. Steenbruggen, L. Steggink, C. Seynaeve, J. van der Hoeven, M. Hooning, A. Jager, I. Konings, J. Kroep, W. Smit, V. Tjan-Heijnen, E. van der Wall, A. Bins, S. Linn, M. Schaapveld, F. van Leeuwen, C.P. Schroder, H. van Tinteren, E.G.E. de Vries, G. Sonke, J. Gietema; NL

17:15 - 17:30 **Invited Discussant one LBA12, 1860 and 1870**

J. Cortes Castan, ES

16:00 - 17:30 **Type: Educational session** **Hall A1 - Room 15**
Title: Exosomes and other EVs, why are they important?
Chair(s): Clotilde Théry, FR; Gerhardt Attard, GB

16:00 - 16:00 **Session DOI**

16:00 - 16:25 **Extracellular Vesicles/Exosomes in Cancer**
R. Kalluri, US

16:25 - 16:50 **Therapeutic potential of exosomes and/or EVs in cancer**
C. Théry, FR

16:50 - 17:15 **Tumour educated platelets as cancer biomarkers**
T. Würdinger, NL

17:15 - 17:30 **Discussion**

16:00 - 17:30 **Type: Joint Symposium** **Hall A1 - Room 16**
Title: ESMO-ASCO Joint Symposium: Precision medicine and accessibility
Chair(s): Josep Tabernero, ES; Monica Bertagnolli, US

16:00 - 16:00 **Session DOI**

16:00 - 16:05 **Introduction**
J. Tabernero, ES

16:05 - 16:25 **Basket studies and rapid development in precision oncology**
A. Drilon, NY/US

16:25 - 16:45 **The European regulator's point of view**
F. Pignatti, GB

16:45 - 17:05 **The potential role of conditional approvals**
P.G. Casali, IT

17:05 - 17:25 **The US regulator's point of view**
G. Blumenthal, MD/US

17:25 - 17:30 **Conclusions**
M. Bertagnolli, US

16:00 - 17:40 **Type: Proffered Paper session** **Hall A2 - Room 18**
Title: Proffered paper session - NSCLC, metastatic
 Chair(s): Tony S.K. Mok, HK; Noemi Reguart, ES

16:00 - 16:00 **Session DOI**

16:00 - 16:15 **LBA50 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study**

S. Ramalingam¹, Y. Cheng², C. Zhou², Y. Ohe³, F. Imamura³, B.C. Cho⁴, M.-C. Lin⁵, M. Majem⁶, R. Shah⁷, Y. Rukazenzov⁸, A. Todd⁷, A. Markovets⁹, J.C. Barrett⁹, J. Chmielecki⁹, J. Gray¹⁰; ¹GA/US, ²CN, ³JP, ⁴KR, ⁵TW, ⁶ES, ⁷GB, ⁸Cheshire/GB, ⁹US, ¹⁰FL/US

16:15 - 16:30 **LBA51 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study**

V. Papadimitrakopoulou¹, Y.-L. Wu², J.-Y. Han³, M.-J. Ahn³, S. Ramalingam⁴, T. John⁵, I. Okamoto⁶, J.C.-H. Yang⁷, K. Bulusu⁸, G. Laus⁸, B. Collins⁸, J.C. Barrett¹, J. Chmielecki¹, T. Mok⁹; ¹US, ²Guangdong/CN, ³KR, ⁴GA/US, ⁵VIC/AU, ⁶JP, ⁷TW, ⁸GB, ⁹HK

16:30 - 16:45 **Invited Discussant LBA50 and LBA51**

C. Rudin, US

16:45 - 17:00 **LBA52 - Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)**

J. Wolf¹, T. Seto², J.-Y. Han³, N. Reguart⁴, E. Garon⁵, H. Groen⁶, D. Tan⁷, T. Hida², M. de Jonge⁶, S. Orlov⁸, E. Smit⁶, P.-J. Souquet⁹, J. Vansteenkiste¹⁰, M. Giovannini¹¹, S. Le Mouhaer¹², A. Robeva¹³, M. Waldron-Lynch¹³, R. Heist¹⁴; ¹DE, ²JP, ³KR, ⁴ES, ⁵CA/US, ⁶NL, ⁷SG, ⁸RU, ⁹CEDEX/FR, ¹⁰BE, ¹¹US, ¹²FR, ¹³GB, ¹⁴MA/US

17:00 - 17:12 **Invited Discussant LBA 52**

J.C.-H. Yang, TW

17:12 - 17:27 **13770 - Phase II study of tepotinib &&**

Y.-L. Wu¹, J. Zhou², S. Lu², Y. Zhang², J. Zhao², H. Pan², Y.-M. Chen³, C.-F. Chian³, R. Bruns⁴, A. Johne⁴, J. Scheele⁴, Y. Cheng⁵; ¹Guangdong/CN, ²CN, ³TW, ⁴DE, ⁵Jilin/CN

17:27 - 17:39 **Invited Discussant 13770**

E. Smit, NL

16:00 - 17:30 **Type: Special session** **Hall B3 - Room 23**
Title: Germline BRCA mutation: Ripe for precision oncology?
Chair(s): Karim Fizazi, FR; Susana Banerjee, GB

16:00 - 16:00 **Session DOI**

16:00 - 16:20 **Breast cancer**
S. Paluch-Shimon, IL

16:20 - 16:40 **Ovarian cancer**
A. George, GB

16:40 - 17:00 **Prostate cancer**
E. Castro Marcos, ES

17:00 - 17:20 **Pancreatic cancer**
T. Golan, IL

17:20 - 17:30 **Discussion**

- 16:00 - 17:30** **Type: Proffered Paper session** **Hall B3 - Room 20**
Title: Proffered Paper session - CNS tumours
 Chair(s): Matthias Preusser, AT; Carmen Balana, ES
- 16:00 - 16:00 **Session DOI**
- 16:00 - 16:12 **3710 - Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial**
E. Le Rhun¹, A. Mailliez², J. Wallet², I. Rodrigues², T. Boulanger², I. Desmoulins³, J. Barriere⁴, M. Fabbro⁵, S. Taillibert², C. Andre², M.C. Le Deley², M. Weller⁶, J. Bonnetterre¹; ¹CEDEX/FR, ²FR, ³Cedex/FR, ⁴CEDEX 2/FR, ⁵CEDEX 5/FR, ⁶CH
- 16:12 - 16:24 **3720 - Mutational and inflammatory microenvironment characteristics in primary and matched local recurrent non-small cell lung cancer brain metastases**
A.S. Berghoff, B. Erguener, M.R. Schuster, U. Rajky, G. Ricken, J. Frischer, B. Gatterbauer, C. Marosi, K. Dieckmann, G. Widhalm, C. Bock, M. Preusser; AT
- 16:24 - 16:39 **Invited Discussant 3710 and 3720**
J. Seoane, ES
- 16:39 - 16:51 **3730 - Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)**
D. Peereboom¹, L.B. Nabors², P. Kumthekar³, M. Badruddoja⁴, K. Fink⁵, F. Lieberman⁶, S. Phuphanich⁴, E. Dunbar⁷, T. Walbert⁸, D. Schiff⁹, D. Tran¹⁰, L. Ashby⁴, N. Butowski¹¹, F. Iwamoto¹², R. Lindsay³, J. Bullington¹², M. Scholder¹², J. Sherman³, C. Brooks³, D. Reardon¹³; ¹OH/US, ²AL/US, ³US, ⁴AZ/US, ⁵TX/US, ⁶PA/US, ⁷GA/US, ⁸MI/US, ⁹VA/US, ¹⁰FL/US, ¹¹CA/US, ¹²NY/US, ¹³MA/US
- 16:51 - 17:03 **3740 - Mismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics**
G. Lombardi¹, M. Caccese¹, M. Simonelli², M. Fassan¹, P. Persico¹, E. Lorenzi¹, R. Bertorelle¹, M.P. Gardiman¹, L. Bellu¹, A. Pambuku¹, A. Santoro², V. Zagonel¹; ¹IT, ²(MI)/IT
- 17:03 - 17:15 **3750 - Radiological phenotyping of IDH mutation status in gliomas using dynamic susceptibility contrast perfusion-weighted MRI**
D. Roettger, E. Sanverdi, C. Sudre, S. Brandner, V. Katsaros, S. Bisdas; GB
- 17:15 - 17:30 **Invited Discussant 3730, 3740 and 3750**
M. van den Bent, NL

16:00 - 17:30	Type: Special session Title: Best integration of supportive and palliative care in the continuum of care Chair(s): Karin Jordan, DE; Stein Kaasa, NO	Hall B3 - Room 22
----------------------	--	--------------------------

16:00 - 16:00 **Session DOI**

16:00 - 16:05 **Introduction**
K. Jordan, DE

16:05 - 16:25 **Highlights of the Lancet Oncology commission paper: Integration of oncology and palliative care**
S. Kaasa, NO

16:25 - 16:45 **Insights of the ESMO position paper on supportive and palliative care**
K. Jordan, DE

16:45 - 17:05 **Palliative care in main stream oncology, how and how much: A Canadian perspective**
C. Zimmermann, CA

17:05 - 17:25 **The place and content of Supportive and palliative care in a comprehensive cancer center in Europe**
A. Caraceni, IT

17:25 - 17:30 **Conclusions**
S. Kaasa, NO

16:00 - 17:30 **Type: Patient Advocacy Track** **ICM - Room 5**
Title: Immune therapies going adjuvant: Benefits versus risks
 Chair(s): John Haanen, NL; Bettina Ryll, SE

16:00 - 16:00 **Session DOI**

16:00 - 16:20 **Immunotherapy checkpoints: What to tell your patients**
B. Ryll, SE

16:20 - 16:40 **Benefits of adjuvant therapies**
J. Haanen, NL

16:40 - 17:00 **Risks of adjuvant therapies**
J. Larkin, GB

17:00 - 17:30 **Discussion: Risk it or not?**

17:30 - 18:30 **Type: Young Oncologist session** **ICM - Foyer - Ground floor**
Title: YO Vesalius: Work / life balance at early stages of young oncologist's career
 Chair(s): Guillem Argiles, ES

17:30 - 17:30 **Session DOI**

17:30 - 17:35 **Introduction**
G. Argiles Martinez, ES

17:35 - 18:30 **Discussion**
M. Piccart¹, A. Cervantes², S. Peters³; ¹BE, ²Valencia/ES, ³CH

17:45 - 19:15 **Type: Patient Advocacy Track** **ICM - Room 5**
Title: Life after cancer
 Chair(s): Isabelle Lebrocqy, NL; Tanja Spanic, SI

17:45 - 17:45 **Session DOI**

17:45 - 18:00 **When is a cancer patient cured?**
L. Dal Maso, IT

18:00 - 18:15 **What is Europe doing in return to work?**
M. Ludwig, NL

18:15 - 18:30 **The right to be forgotten**
A. Dumas, FR

18:30 - 18:45 **Advocating for survivors' rights**
I. Lebrocqy, NL

18:45 - 19:15 **Q&A**

18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 1	Hall A1 - Room 17
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 2	ICM - Room 1
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 3	ICM - Room 14b
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 4	ICM - Room 13
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 5	Hall A1 - Room 15
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 6	Hall A1 - Room 16
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 8	Hall B3 - Room 21
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 7	Hall B3 - Room 20
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 9	Hall B3 - Room 22
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 10	Hall B4 - Room 19
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 11	ICM - Room 14a
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 12	ICM - Room 14c

20.10.2018

08:00 - 09:00 **Type: Controversy Session** **Hall A1 - Room 15**
Title: HIPEC: Is there a role in ovarian cancer?
 Chair(s): Martin Gore, GB

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Introduction and 1st vote**
M. Gore, GB

08:10 - 08:30 **Yes**
G. Scambia, IT

08:30 - 08:50 **No**
A. du Bois, DE

08:50 - 09:00 **2nd vote and conclusions**
M. Gore, GB

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 21**
Title: Treatment of metastatic castration sensitive prostate cancer
 Chair(s): Himisha Beltran, US

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Treatment of metastatic castration sensitive prostate cancer**
N. James, GB

08:10 - 09:00 **Discussion led by**
H. Beltran, US

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**
Title: Skin toxicity of anticancer treatments: How to diagnose, how to treat
 Chair(s): Petra Feyer, DE

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Skin toxicity of anticancer treatments: How to diagnose, how to treat**
V. Sibaud, Haute-Garonne/FR

08:10 - 09:00 **Discussion led by**
P. Feyer, DE

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 20**
Title: Thymic malignancies: Emerging systemic therapy options
 Chair(s): Heather Wakelee, US

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Thymic malignancies: Emerging systemic therapy options**
N. Girard, FR

08:10 - 09:00 **Discussion led by**
H. Wakelee, CA/US

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 22**
Title: Metabolic targets in cancer
 Chair(s): Christian Frezza, GB

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Metabolic targets in cancer**
E. Gottlieb, IL

08:10 - 09:00 **Discussion led by**
C. Frezza, GB

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **ICM - Room 14a**
Title: Management of challenging patients with meningioma
Chair(s): Priscilla Brastianos, US

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Management of challenging patients with meningioma**
M. Preusser, AT

08:10 - 09:00 **Discussion led by**
P. Brastianos, US

08:15 - 09:00 **Type: Keynote lecture** **Hall A1 - Room 17**
Title: Mutation signatures and targeting the DNA damage response
Chair(s): Anton Berns, NL

08:15 - 08:35 **Session DOI**

08:35 - 09:20 **Mutation signatures and targeting the DNA damage response**
T. Helleday, GB

09:00 - 10:30	Type: Educational session Title: Neo-adjuvant therapy management of early breast cancer Chair(s): Javier Cortes Castan, ES; Jean-Marc Classe, FR	ICM - Room 1
09:00 - 09:00	Session DOI	
09:00 - 09:18	Neo-adjuvant therapy for ER+/Her2neg disease with endocrine therapy alone or in combination with targeted therapies <u>M. Ellis</u> , TX/US	
09:18 - 09:36	Neo-adjuvant therapies for HER2 + for breast cancer <u>J. Cortes Castan</u> , ES	
09:36 - 09:54	Neo adjuvant therapies for triple negative in breast cancer <u>A. Tutt</u> , GB	
09:54 - 10:12	Surgical management of breast cancer patients after completion of neo-adjuvant therapies <u>J.-M. Classe</u> , CEDEX/FR	
10:12 - 10:30	Discussion	

09:15 - 10:45 **Type: Proffered Paper session** **Hall A1 - Room 17**
Title: Proffered paper session - Genitourinary tumours, non prostate
 Chair(s): Karim Fizazi, FR; Andrea Necchi, IT

09:15 - 09:15 **Session DOI**

09:15 - 09:27 **LBA31 - Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)**

B. Rini¹, M. Huseni², M. Atkins³, D. McDermott⁴, T. Powles⁵, B. Escudier⁶, R. Banchereau², L.-F. Liu², N. Leng², J. Fan², J. Doss², S. Nalle², S. Carroll², S. Li², C. Schiff², M. Green², R. Motzer⁷; ¹OH/US, ²CA/US, ³US, ⁴MA/US, ⁵GB, ⁶CEDEX/FR, ⁷NY/US

09:27 - 09:39 **8630 - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results**

M. Gross-Goupil¹, T.G. Kwon², M. Eto³, D. Ye⁴, H. Miyake³, S. Seo², S. Byun², J. Lee², V. Master⁵, J. Jin⁴, R. Debenedetto⁶, R. Linke⁶, M. Casey⁵, B. Rosbrook⁵, M. Lechuga Freañ⁷, O. Valota⁷, E. Grande⁸, D. Quinn⁶; ¹FR, ²KR, ³JP, ⁴CN, ⁵US, ⁶CA/US, ⁷IT, ⁸ES

09:39 - 09:54 **Invited Discussant LBA31 and 8630**

M. Schmidinger, AT

09:54 - 10:06 **8640 - Pembrolizumab for high-risk (HR) non&&**

R. de Wit¹, G. Kulkarni², E. Uchio³, E. Singer⁴, L. Krieger⁵, P. Grivas⁶, D. Bajorin⁷, H.K. Seo⁸, L. Mourey⁹, A. Kamat¹⁰, H. Nishiyama¹¹, E. Kapadia⁷, K. Nam⁴, T. Frenkl⁴, A. Balar⁷; ¹NL, ²CA, ³ON/CA, ⁴NJ/US, ⁵NSW/AU, ⁶OH/US, ⁷US, ⁸KR/KR, ⁹Haute-Garonne/FR, ¹⁰TX/US, ¹¹JP

10:06 - 10:18 **Invited Discussant 8640**

S. Shariat, AT

10:18 - 10:30 **LBA32 - Nivolumab (N) Alone or in Combination With Ipilimumab (I) in Patients (pts) With Platinum-Pretreated Metastatic Urothelial Carcinoma (mUC), Including the Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Expansion From CheckMate 032**

J. Rosenberg¹, P. Sharma², F.G. de Braud³, U. Basso³, E. Calvo⁴, P. Bono⁵, M. Morse⁶, P. Ascierto³, J. Lopez-Martin⁴, P. Brossart⁷, K. Rohrberg⁸, N. Reguart⁴, W.H. Lin⁹, S. Meadows-Shropshire⁹, A. Saci², M. Callahan¹, A. Siefker-Radtke¹⁰; ¹NY/US, ²US, ³IT, ⁴ES, ⁵FI, ⁶NC/US, ⁷DE, ⁸DK, ⁹NJ/US, ¹⁰TX/US

10:30 - 10:45 **Invited Discussant LBA32**

C. Sternberg, IT

09:15 - 10:45 **Type: Special Symposium** **Hall A2 - Room 18**
Title: Immunotherapy and targeted therapy in the landscape of non-metastatic NSCLC
 Chair(s): Julie Brahmer, US; Johan Vansteenkiste, BE

09:15 - 09:15 **Session DOI**

09:15 - 09:20 **Introduction**
J. Vansteenkiste, BE

09:20 - 09:40 **Translating advances in stage IV disease to non-metastatic lung cancer**
J. Brahmer, MD/US

09:40 - 10:00 **Immunotherapy approaches in early stage disease**
J. Vansteenkiste, BE

10:00 - 10:20 **TKI approaches in early stage disease**
M. Tsuboi, Chiba/JP

10:20 - 10:40 **Integrating immunotherapy and TKIs in stage III disease management**
W. Eberhardt, DE

10:40 - 10:45 **Conclusions and clinical perspectives**
J. Brahmer, MD/US

09:15 - 10:45 Type: Proffered Paper session ICM - Room 14b
 Title: Proffered paper session - Translational research
 Chair(s): Nicola Normanno, IT

09:15 - 09:15 Session DOI

09:15 - 09:27 **500 - Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) study**

M. Liu¹, E. Klein¹, E. Hubbell¹, T. Maddala¹, A. Aravanis¹, J. Beausang², D. Filippova², S. Gross², A. Jamshidi², K. Kurtzman², L. Shen², N. Zhang², O. Venn², J. Yecies², S. Patel², D. Smith³, T. Yeatman⁴, M. Seiden⁵, A.-R. Hartman², G. Oxnard⁶; ¹US, ²CA/US, ³WA/US, ⁴SC/US, ⁵TX/US, ⁶MA/US

09:27 - 09:39 **13360 - Unbiased genomewide screening of circulating plasma DNA for cancer detection**

L. Lenaerts, N. Brison, M. Neofytou, H. Che, L. Dehaspe, M. Verheecke, C. Maggen, B. Dewaele, S. Vanderschueren, V. Vandecaveye, P. Vandenberghe, J. Vermeesch, F. Amant; BE

09:39 - 09:54 **Invited Discussant 500 and 13360**

C. Abbosh, Yorkshire/GB

09:54 - 10:06 **510 - Pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA)**

N. Agarwal¹, E. Sokol², P. Lara Jr.¹, J. Ross¹, V. Miller², A. Welsh³, J. Gregg⁴, G. Frampton², S. Ali², J. Chung²; ¹US, ²MA/US, ³NJ/US, ⁴CA/US

10:06 - 10:18 **520 - Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma**

L. Tan¹, S. Sandhu¹, R. Lee², J. Li¹, J. Callahan¹, J. Raleigh¹, A. Hatzimihalis¹, P. Middlehurst², M. Henderson¹, M. Shackleton¹, A. Haydon¹, D. Gyorki¹, D. Oudit², R. Hicks¹, P. Lorigan², G. McArthur¹, R. Marais², S. Wong¹, S.-J. Dawson¹; ¹VIC/AU, ²GB

10:18 - 10:30 **18300 - Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study**

L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, M. Verza, L. Pasqualini, G. Pasello, G. Zago, S. Frega, M. Fassan, F. Calabrese, A. Amadori, V. Guarneri, P.F. Conte, S. Indraccolo; IT

10:30 - 10:45 **Invited Discussant 510, 520 and 18300**

C. Dive, GB

09:15 - 10:45 Type: Poster Discussion session ICM - Room 13
 Title: Poster Discussion session - Gynaecological cancers

Chair(s): Mansoor Raza Mirza, DK; Cristiana Sessa, CH; Nicoletta Colombo, IT; Antonio González-Martín, ES

- 09:15 - 09:15 **Session DOI**
- 09:15 - 09:15 **LBA35 - TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A.**
B. You¹, P.A. Bolze¹, J.-P. Lotz¹, J. Massardier¹, L. Gladieff², T. Hajri¹, D. Maucourt-Boulch¹, S. Bin¹, A. Roux¹, P. Rousset¹, G. Freyer³, F. Golfier¹; ¹FR, ²Haute-Garonne/FR, ³CEDEX/FR
- 09:15 - 09:15 **935PD - Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer**
A. Oaknin¹, S. Ellard², C. Leath III³, V. Moreno¹, R. Kristeleit⁴, W. Guo³, S. Lu³, D. Jenkins³, K. McEachern³, K. Yu Jen³, S. Dunlap³, E. Im³, L. Gilbert⁵; ¹ES, ²British Columbia/CA, ³US, ⁴GB, ⁵CA
- 09:15 - 09:27 **Invited Discussant LBA35 and 935PD**
M.R. Mirza, DK
- 09:27 - 09:37 **Q&A led by Discussant**
- 09:37 - 09:37 **LBA36 - Association of PD-L1 Expression and Gene Expression Profiling With Clinical Response to Pembrolizumab in Patients With Advanced Recurrent Ovarian Cancer: Results From the Phase 2 KEYNOTE-100 Study**
J. Ledermann¹, R. Shapira-Frommer², A. Santin³, A. Lisyanskaya⁴, S. Pignata⁵, I. Vergote⁶, F. Raspagliesi⁵, G. Sonke⁷, M. Birrer⁸, D. Provencher⁹, J. Sehouli¹⁰, N. Colombo⁵, A. González-Martín¹¹, A. Oaknin¹¹, P.B. Ottevanger⁷, V. Rudaitis¹², R. Cristescu³, J. Kobie³, J. Ruman³, U. Matulonis⁸; ¹London/GB, ²IL, ³US, ⁴RU, ⁵IT, ⁶BE, ⁷NL, ⁸MA/US, ⁹QC/CA, ¹⁰DE, ¹¹ES, ¹²LT
- 09:37 - 09:37 **936PD - A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)**
J.-M. Lee¹, C. Annunziata², N. Houston², E. Kohn², S. Lipkowitz², L. Minasian², E. Nichols², J. Trepel², K. Trewhitt², F. Zia², A. Zimmer¹; ¹US, ²MD/US
- 09:37 - 09:37 **937PD - A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer**
J. Liu¹, C. Herold¹, W. Luo¹, R. Penson¹, N. Horowitz¹, P. Konstantinopoulos¹, C. Castro¹, J. Curtis¹, U. Matulonis¹, S. Cannistra², D. Dizon³; ¹MA/US, ²US, ³RI/US
- 09:37 - 09:49 **Invited Discussant LBA36, 936PD and 937PD**

A. González Martín, ES

09:49 - 09:59 **Q&A led by Discussant**

09:59 - 09:59 **939PD - Quality of life and symptoms in longterm survivors with ovarian cancer: It&&**

H. Woopen¹, I. Braicu¹, R. Richter¹, K. Schnuppe¹, P. Krabisch¹, T. Boxler¹, G. Emons¹, J. Glajzer¹, M. Rose¹, L. Erdur¹, R. Lindhorst¹, M. Endres¹, P. Hühnchen¹, I. Vergote², R. Berger³, C. Marth³, J. Sehouli¹; ¹DE, ²BE, ³AT

09:59 - 09:59 **941PD - A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study**

A. Gonzalez¹, M.R. Mirza², I. Vergote³, Y. Li⁴, S. Hazard⁴, R. Clark⁴, W. Graybill⁴, B. Pothuri⁴, B. Monk⁴; ¹ES, ²DK, ³BE, ⁴US

09:59 - 10:11 **Invited Discussant 939PD and 941PD**

N. Colombo, IT

10:11 - 10:21 **Q&A led by Discussant**

10:21 - 10:21 **938PD - Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group**

T. de La Motte Rouge¹, F. Derquin¹, A. Floquet², J. Edeline², J.-P. Lotz¹, J. Alexandre³, P. Pautier², G. Ferron⁴, E. Boissier¹, C. Lefeuvre-Plesse¹, H. Vegas⁵, A. Patsouris¹, E. Kalbacher², D. Berton-Rigaud², A.-C. Hardy Bessard¹, V. Lavoué¹, I. Ray-Coquard²; ¹FR, ²CEDEX/FR, ³CEDEX 4/FR, ⁴CEDEX 3/FR, ⁵CEDEX 9/FR

10:21 - 10:21 **943PD - Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment**

A. Clamp¹, I. McNeish¹, A. Dean², D. Gallardo-Rincon³, J.-W. Kim⁴, D. O'Donnell⁵, J. Hook¹, S. Blagden¹, J. Brenton¹, R. Naik¹, T. Perren⁶, S. Sundar¹, A. Cook¹, E. James¹, H. Gabra¹, R. Lord⁷, M. Hall⁸, G. Dark¹, R. Kaplan¹, J. Ledermann⁹; ¹GB, ²WA/AU, ³MX, ⁴KP, ⁵IE, ⁶Yorkshire/GB, ⁷Merseyside/GB, ⁸Middlesex/GB, ⁹London/GB

10:21 - 10:33 **Invited Discussant 938PD and 943PD**

C. Sessa, CH

10:33 - 10:43 **Q&A led by Discussant**

09:15 - 10:45 **Type: Joint Symposium** **Hall B3 - Room 23**
Title: ESMO-DGHO Joint Symposium: Access to anti-cancer drugs
 Chair(s): Alexandru Eniu, RO; Volker Heinemann, DE

09:15 - 09:15 **Session DOI**

09:15 - 09:20 **Introduction**
V. Heinemann, DE

09:20 - 09:40 **The shortage of essential oncology drugs**
A. Eniu, RO

09:40 - 10:00 **Access to innovative/expensive drugs**
R. Sullivan, GB

10:00 - 10:20 **What is a fair price?**
C. Bokemeyer, DE

10:20 - 10:40 **Strategies in Germany**
B. Woermann, DE

10:40 - 10:45 **Conclusions**
A. Eniu, RO

09:15 - 10:30 **Type: Poster Discussion session** **Hall B4 - Room 19**
Title: Poster Discussion session - Public health policy
 Chair(s): Carin Uyl-de Groot, NL; Fredericus Eskens, NL; Hans Westgeest, NL

09:15 - 09:15 **Session DOI**

09:15 - 09:15 **1560PD - Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey**
L. Kandolf Sekulovic¹, S. Agarwala², A. Hauschild³, J. Guo⁴, G. McArthur⁵, P. Lorigan⁶, G. Cinat⁷, C. Caglevich⁸, C. Lebbe⁹, P. Rutkowski¹⁰, H. Gogas¹¹, R. Dummer¹², B. Neyns¹³, L. Bastholt¹⁴, A. Wainstein¹⁵, D. Herceg¹⁶, M. Banjin¹⁷, A. Zhukavets¹⁸, J. Ocvirk¹⁹, C. Garbe²⁰; ¹RS, ²PA/US, ³Schleswig-Holstein/DE, ⁴CN, ⁵VIC/AU, ⁶GB, ⁷AR, ⁸CL, ⁹CEDEX 10/FR, ¹⁰PL, ¹¹Attiki/GR, ¹²CH, ¹³BE, ¹⁴DK, ¹⁵BR, ¹⁶HR, ¹⁷BA, ¹⁸BY, ¹⁹SI, ²⁰DE/DE

09:15 - 09:15 **1561PD - Variation in oncology drug approvals in Canada, the United States and Europe**

O. Khan¹, N. Samuel¹, S. Verma²; ¹CA, ²Alberta/CA

09:15 - 09:25 **Invited Discussant 1560PD and 1561PD**

C. Uyl-de Groot, NL

09:25 - 09:35 **Q&A led by Discussant**

09:35 - 09:35 **1562PD - Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)**

C. Molto Valiente¹, M. Borrell¹, A. Ocana Fernandez¹, A. Templeton², L. del Carpio¹, J. Del Paggio³, A. Barnadas¹, C. Booth⁴, A. Tibau¹, E. Amir⁴; ¹ES, ²CH, ³CA, ⁴ON/CA

09:35 - 09:35 **1563PD - Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval**

M. Borrell Puy¹, C. Molto Valiente¹, K. Vokinger², T. Hwang³, A. Ocana Fernandez¹, A. Templeton², B. Seruga⁴, I. Gich Saladich¹, A. Barnadas¹, E. Amir⁵, A. Tibau¹; ¹ES, ²CH, ³US, ⁴SI, ⁵ON/CA

09:35 - 09:35 **1564PD - Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs**

C. Molto Valiente¹, M. Borrell¹, T. Hwang², I. Gich Saladich¹, A. Barnadas¹, E. Amir³, A. Kesselheim⁴, A. Tibau¹; ¹ES, ²US, ³ON/CA, ⁴MA/US

09:35 - 09:35 **1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores**

U. Janzic, L. Knez, A. Janzic, T. Cufer; SI

09:35 - 09:50 **Invited Discussant 1563PD, 1564PD and 1565PD**

F. Eskens, NL

09:50 - 10:00 **Q&A led by Discussant**

10:00 - 10:00 **1566PD - Cascade BRCA germline mutation (BGM) testing of women with breast (BC) or epithelial ovarian cancer (EOC) and their families with subsequent risk reducing surgery (RRS): A Canadian economics model**

P. Hoskins¹, A. Ecclestone¹, M. Hurry¹, M. Dyer²; ¹CA, ²GB

10:00 - 10:00 **1567PD - Genetic testing of BRCA mutations in breast cancer in six European countries:&&**

M. Thrift-Perry¹, S. Ahmed², S. Wait², J. Tate²; ¹US, ²GB

10:00 - 10:00 **1568PD - Public awareness of cancer in the Gaza-Strip: A cross-sectional study**
M. Elshami¹, M. Alkhatib¹, A. Elshami¹, K. Abu-Nemer¹, A. Qandeel¹, M. Hana¹, N. Alshorbassi¹, G. Matar¹, O. Baraka¹, M. Elblbessy¹, L. Albarqouni², B. Bottcher¹; ¹PS, ²AU

10:00 - 10:15 **Invited Discussant 1566PD, 1567PD and 1568PD**
H. Westgeest, NL

10:15 - 10:25 **Q&A led by Discussant**

09:15 - 10:45	Type: EONS session Title: EONS-ONS Session: Innovation in cancer nursing and leadership Chair(s): Lena Sharp, SE	Hall B4 - Room 24
---------------	--	--------------------------

09:15 - 09:15 **Session DOI**

09:15 - 09:25 **Introduction and welcome**
L. Sharp¹, D. Kelly², K. Paradies³; ¹SE, ²GB, ³DE

09:25 - 09:35 **Recognizing European Cancer Nursing, RECaN: Results from systematic review and meta-analyses (RECaN Phase 1)**
D. Kelly, GB

09:35 - 09:45 **Results from case studies from four contrasting countries in Europe (RECaN Phase 2)**
L. Sharp, SE

09:45 - 09:55 **Promoting cancer nursing across Europe (RECaN Phase 2 qualitative insights and looking ahead to phase 3)**
D. Kelly, GB

09:55 - 10:25 **Supporting cancer nursing leadership development: The USA experience**
L. Fennimore, US

10:25 - 10:45 **Discussion**

09:30 - 10:30 **Type: Controversy Session** **Hall A1 - Room 15**
Title: Will CAR T cell therapy replace allogenic transplantation in lymphoma?
 Chair(s): Martin Dreyling, DE

09:30 - 09:30 **Session DOI**

09:30 - 09:40 **Introduction and 1st vote**
M. Dreyling, DE

09:40 - 10:00 **Yes**
M. Subklewe, DE

10:00 - 10:20 **No**
D. Caballero, ES

10:20 - 10:30 **2nd vote and conclusions**
M. Dreyling, DE

09:30 - 10:35 **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 16**
Title: Malignant pheochromocytoma / paraganglioma
 Chair(s): Alfredo Berruti, IT

09:30 - 09:30 **Session DOI**

09:30 - 09:35 **Case presentation**
A. Berruti, IT

09:35 - 09:45 **The surgical approach**
M. Walz, DE

09:45 - 09:55 **The nuclear medicine specialist perspective**
V. Ambrosini, IT

09:55 - 10:05 **The endocrinologist and oncologist perspective**
E. Baudin, CEDEX/FR

10:05 - 10:35 **Discussion**

09:30 - 10:30	Type: Poster Discussion session Title: Poster Discussion session - Supportive and palliative care 1 Chair(s): Dorothy Keefe, AU; Florian Strasser, CH	Hall B3 - Room 21
09:30 - 09:30	Session DOI	
09:30 - 09:30	1683PD - Factors that influence oncology nutrition efficacy in breast cancer patients under antiestrogenic treatment <u>D. Artene</u> , A. Blidaru; RO	
09:30 - 09:30	1684PD_PR - Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC) <u>A. Di Meglio</u> ¹ , M. El-Mouhebb ¹ , S. Michiels ¹ , D. Carene ¹ , S. Everhard ¹ , A.L. Martin ¹ , P. Cottu ² , F. Lerebours ¹ , C. Coutant ³ , A. Lesur ¹ , O. Tredan ¹ , P. Soulie ¹ , L. Vanlemmens ⁴ , P. Arveux ¹ , S. Delaloge ¹ , P. Ganz ⁵ , F. André ¹ , A. Partridge ⁶ , L. Jones ⁷ , I. Vaz-Luis ¹ ; ¹ FR, ² CEDEX 5/FR, ³ Cedex/FR, ⁴ CEDEX/FR, ⁵ CA/US, ⁶ US, ⁷ NY/US	
09:30 - 09:30	1685PD - Effects of 6-month exercise training on quality of life in pancreatic cancer patients: Results from a randomized controlled trial <u>K. Steindorf</u> ¹ , D. Clauss ¹ , C. Tjaden ¹ , F. Herbolsheimer ¹ , L. Schneider ¹ , C. Ulrich ² , T. Hackert ¹ , J. Wiskemann ¹ ; ¹ DE, ² US	
09:30 - 09:30	1513PD - A prospective study examining cachexia predictors in patients with incurable cancer <u>O.M. Vagnildhaug</u> ¹ , C. Brunelli ² , M. Hjermstad ¹ , F. Strasser ³ , V. Baracos ⁴ , A. Wilcock ⁵ , M. Nabal ⁶ , S. Kaasa ¹ , B. Laird ⁵ , T. Solheim ¹ ; ¹ NO, ² IT, ³ CH, ⁴ CA, ⁵ GB, ⁶ ES	
09:30 - 09:50	Invited Discussant 1683PD, 1684PD, 1685PD and 1513PD <u>D. Keefe</u> , SA/AU	
09:50 - 10:00	Q&A led by Discussant	
10:00 - 10:00	1514PD - Timing of palliative care referral before and after a cluster randomized controlled trial (RCT) of early palliative care <u>D. Hausner</u> ¹ , C. Tricou ² , D. Wadhwa ³ , A. Pope ¹ , M. Giruparajah ¹ , N. Swami ¹ , M. Krzyzanowska ¹ , K. Mah ¹ , C. Zimmermann ¹ ; ¹ CA, ² ON/CA, ³ BC/CA	
10:00 - 10:00	1515PD - Randomized clinical trial of an individualized intervention promotes cancer patients' prognostic awareness and reduces CPR received in the last month <u>C. Chen</u> , J.-S. Chen, F.-H. Wen, J.W.-C. Chang, W.-C. Chou, C.-H. Hsieh, M.-M. Hou, S.T. Tang; TW	

10:00 - 10:15 **Invited Discussant 1514PD and 1515PD**

F. Strasser, CH

10:15 - 10:25 **Q&A led by Discussant**

09:30 - 10:30 **Type: Challenge Your Expert (CYE) session** **Hall B3**
Title: Leiomyosarcomas: How to choose and sequence treatments, **- Room**
targeted vs non-targeted therapies, olaratumab yes or no, and other **22**
controversies
Chair(s): Silvia Stacchiotti, IT

09:30 - 09:30 **Session DOI**

09:30 - 09:40 **Leiomyosarcomas: How to choose and sequence treatments, targeted vs non-targeted therapies, olaratumab yes or no, and other controversies**

I. Ray-Coquard, CEDEX/FR

09:40 - 10:30 **Discussion led by**

S. Stacchiotti, IT

11:00 - 12:30 **Type: Special Symposium** **Hall A1 - Room 17**
Title: New aspects of targeted therapy of NSCLC
 Chair(s): Christian Rolfo, US; Tony S.K. Mok, HK; Lizza Hendriks, NL

11:00 - 11:00 **Session DOI**

11:00 - 11:05 **Introduction**

C. Rolfo¹, L. Hendriks²; ¹US, ²NL

11:05 - 11:25 **Optimal sequencing in patients with EGFR mutations**

T.S.K. Mok, HK

11:25 - 11:45 **Optimal sequencing in patients with ALK/ROS1 alterations**

F. Blackhall, GB

11:45 - 12:05 **New aspects in MET inhibition**

S. Ekman, SE

12:05 - 12:25 **Targets beyond EGFR and ALK inhibition**

F. Cappuzzo, IT

12:25 - 12:30 **Conclusions and perspectives**

T.S.K. Mok, HK

11:00 - 12:45 Type: Proffered Paper session Hall A2 - Room 18
 Title: Proffered paper session - Breast cancer, metastatic
 Chair(s): Nagi El Saghir, LB; Frederique Penault-Llorca, FR

11:00 - 11:00 Session DOI

11:00 - 11:15 **1930 - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45**

V. Bjelic-Radisic¹, A. Bottomley², F. Cardoso³, D. Cameron⁴, E. Brain⁵, K. Kuljanic⁶, R. de Costa⁷, T. Conroy⁵, E. Inwald⁸, S. Serpentine⁹, M. Pinto⁹, J. Weis⁸, O. Morag¹⁰, G. Guro Lindviksmoen Astrup¹¹, K. Tomaszewski¹², K. Pogoda¹², P. Sinai¹³, M. Sprangers¹⁴, N. Aaronson¹⁴, E. Greimel¹; ¹AT, ²BE, ³PT, ⁴Midlothian/GB, ⁵FR, ⁶HR, ⁷BR, ⁸DE, ⁹IT, ¹⁰IL, ¹¹NO, ¹²PL, ¹³GB, ¹⁴NL

11:15 - 11:30 **2900 - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3**

P.A. Fasching¹, F. Esteva², X. Pivot³, A. Nusch¹, J. Beck⁴, A. Chan⁵, A. Pieris-Gunatilaka⁶, Y. Wang⁶, B. Lanoue⁶, D. Chandiwana⁶, P. Neven⁷; ¹DE, ²NY/US, ³CEDEX/FR, ⁴AZ/US, ⁵AU, ⁶NJ/US, ⁷BE

11:30 - 11:45 **2910 - Ribociclib (RIB) &&**

N. Harbeck¹, R. Villanueva², F. Franke³, G. Babu⁴, P. Wheatley-Price⁵, Y.-H. Im⁶, K. Altundag⁷, B. Lanoue⁸, J. Alam⁸, D. Chandiwana⁸, M. Colleoni⁹; ¹DE, ²ES, ³BR, ⁴IN, ⁵ON/CA, ⁶KR, ⁷TR, ⁸NJ/US, ⁹IT

11:45 - 12:00 **2920 - Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation**

H. Rugo¹, R. Quek¹, J. Ettl², S. Hurvitz¹, H. Bhattacharyya³, A. Hannah¹, J. Litton³; ¹CA/US, ²DE, ³US

12:00 - 12:15 **Invited Discussant 1930, 2900, 2910 and 2920**

L. Fallowfield, GB

12:15 - 12:30 **2840 - Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)**

S. Pernas¹, P. Villagrasa¹, A. Vivancos¹, M. Scaltriti², J. Rodon¹, O. Burgues¹, P. Nuciforo¹, J. Canes³, M. Dueñas¹, M. Vidal¹, A. Lluch⁴, A. Perelló¹, A. Llombart¹, J. Dorca¹, Á. Montaña¹, M. Oliveira¹, G. Ribas¹, I. Rapado¹, A. Prat¹, E. Ciruelos¹; ¹ES, ²NY/US, ³BARCELONA/ES, ⁴Valencia/ES

12:30 - 12:45 **Invited Discussant 2840**

C. Le Tourneau, FR

11:00 - 12:30 **Type: Special Symposium** **ICM - Room 1**
Title: The molecular classification of upper GI cancers: Are we ready to translate them into clinical practice?
Chair(s): Yoon-Koo Kang, KR; Ian Chau, GB

11:00 - 11:00 **Session DOI**

11:00 - 11:05 **Introduction**
I. Chau, Surrey/GB

11:05 - 11:25 **Oesophageal cancer**
A. Cervantes, Valencia/ES

11:25 - 11:45 **Gastric cancer**
F. Lordick, DE

11:45 - 12:05 **Primary liver tumours**
M. Ducreux, CEDEX/FR

12:05 - 12:25 **Pancreatic adenocarcinoma**
I. Chau, Surrey/GB

12:25 - 12:30 **Conclusions and clinical perspectives**
Y.-K. Kang, Songpa-gu/KR

11:00 - 12:30 **Type: Special Symposium** **ICM - Room 14b**
Title: Neo-adjuvant and adjuvant strategies in melanoma
Chair(s): Piotr Rutkowski, PL; Paul Lorigan, GB

11:00 - 11:00 **Session DOI**

11:00 - 11:05 **Introduction**
P. Lorigan, GB

11:05 - 11:25 **Pre-clinical data to prepare early treatment of melanoma**
M. Soengas, ES

11:25 - 11:45 **Neo-adjuvant therapy**
C. Blank, NL

11:45 - 12:05 **Should we treat our patients with melanoma in the neoadjuvant, adjuvant or metastatic setting?**
C. Lebbe, CEDEX 10/FR

12:05 - 12:25 **Adjuvant therapy (2018-2020)**
A. Eggermont, FR

12:25 - 12:30 **Conclusions and clinical perspectives**
P. Rutkowski, PL

11:00 - 12:30 **Type: Educational session** **Hall A1 - Room 15**
Title: What is new in the management of recurrent ovarian cancer
Chair(s): Domenica Lorusso, IT; Isabelle Ray-Coquard, FR

11:00 - 11:00 **Session DOI**

11:00 - 11:25 **When should biology drive treatment decisions?**
I. McNeish, GB

11:25 - 11:50 **The role of surgical management in 2018**
S. Mahner, DE

11:50 - 12:15 **Advances in systemic therapy changing practice**
D. Lorusso, IT

12:15 - 12:30 **Discussion**

11:00 - 12:30 Type: Proffered Paper session Hall B3 - Room 21
 Title: Proffered paper session - Basic science
 Chair(s): Anton Berns, NL; Therese Sorlie, NO

11:00 - 11:00 Session DOI

11:00 - 11:12 **18910_PR - Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program**
R. Alvarez, A. MORAN, E. Meiri, A. Loaiza-Bonilla, A. Parikh, P. Crilley, J. Elvin, P. Reddy, V. Miller, S. Zook, S. Ali, M. Markman; US

11:12 - 11:24 **18920 - Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)**
S. Daigle¹, S. Stacchiotti², P. Schöffski³, V. Villalobos¹, G. Cote¹, R. Chugh¹, T.W.-W. Chen⁴, T. Jahan¹, E. Loggers¹, A. Italiano⁵, A. Gupta⁶, M. Agulnik¹, S. Attia¹, R. Jones⁷, B. van Tine⁸, G.D. Demetri⁹, A. Clawson¹, M. Roche¹, S. Blakemore¹, M. Gounder¹⁰; ¹US, ²IT, ³BE, ⁴TW, ⁵CEDEX/FR, ⁶CA, ⁷WA/GB, ⁸Missouri/US, ⁹MA/US, ¹⁰NY/US

11:24 - 11:36 **LBA11 - Defining the lethal subclone in metastatic lung cancer**
M. Jamal-Hanjani, A. Huebner, N. McGranahan, C. Swanton; GB

11:36 - 11:51 **Invited Discussant 18910, 18920 and LBA11**
S. Turajlic, GB

11:51 - 12:03 **10 - KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies**
A. Georgiou¹, A. Stewart¹, P. Thavasulu¹, E. Coker¹, S. Poelster¹, B. Al-Lazikani¹, D. Cunningham¹, S. Whittaker¹, U. Banerji²; ¹GB, ²Surrey/GB

12:03 - 12:15 **20 - Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines**
P.P. Vitiello¹, C. Cardone¹, D. Ciardiello¹, G. Barra¹, N. Matrone¹, V. Belli¹, G. Martini², L. Poliero¹, C. Borrelli¹, M. Terminiello¹, T. Troiani¹, F. Morgillo¹, F. Ciardiello¹, E. Martinelli¹; ¹IT, ²ES

12:15 - 12:30 **Invited Discussant 10 and 20**
A. Bardelli, (TO)/IT

11:00 - 12:30 **Type: Special Symposium** **Hall B4 - Room 19**
Title: How to balance efficacy and toxicity in Hodgkin's Lymphoma
 Chair(s): John Radford, GB; Simonetta Viviani, IT

11:00 - 11:00 **Session DOI**

11:00 - 11:05 **Introduction**
J. Radford, GB

11:05 - 11:25 **Late toxicities**
F. van Leeuwen, NL

11:25 - 11:45 **Limited disease**
J. Radford, GB

11:45 - 12:05 **Advanced disease**
D. Eichenauer, DE

12:05 - 12:25 **Treatment of relapsed disease with novel agents**
S. Viviani, IT

12:25 - 12:30 **Conclusions and perspectives**
S. Viviani, IT

11:00 - 12:00	Type: EONS session Title: Cancer prevention and early detection from a nursing perspective Chair(s): Harald Titzer, AT	Hall B4 - Room 24
11:00 - 11:00	Session DOI	
11:00 - 11:15	Political and commercial barriers to cancer risk reduction <u>W. Yared</u> , BE	
11:15 - 11:30	HPV vaccination for girls and boys <u>A. Castanon</u> , GB	
11:30 - 11:45	Prostate cancer risk in men of different ethnicities <u>D. Kelly</u> , GB	
11:45 - 12:00	Cancer risk reduction in multicultural communities <u>A. Leppänen</u> , SE	
11:00 - 11:45	Type: Young Oncologist session Title: YO Brunch 1: Fertility and pregnancy in cancer Chair(s): Matteo Lambertini, BE; Claudia Cardone, IT	ICM - Room 14c
11:00 - 11:00	Session DOI	
11:00 - 11:45	Fertility and pregnancy in cancer <u>F. Peccatori</u> , IT	
11:15 - 12:15	Type: Poster Discussion session Title: Poster Discussion session - Gastrointestinal tumours, colorectal 1 Chair(s): Fortunato Ciardiello, IT; Sebastian Stintzing, DE	ICM - Room 13
11:15 - 11:15	453PD - 1st-line mFOLFOXIRI & panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109) <u>M. Geissler</u> , T. Klingler, J. Riera Knorrenschild, A. Tannapfel, J. Greeve, T. Seufferlein, S. Kanzler, S. Held, V. Heinemann, A. Reinacher-Schick, U. Martens; DE	
11:15 - 11:15	LBA22 - Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus Pan or single-agent Pan: translational analyses of the VALENTINO study	

F. Morano¹, S. Corallo¹, M. Di Bartolomeo¹, S. Lonardi¹, C. Cremolini¹, L. Rimassa², A. Sartore Bianchi¹, R. Murialdo¹, A. Zaniboni¹, V. Adamo¹, G. Tomasello³, M. Tampellini¹, L. Fanchini¹, M. Schirripa¹, M. Clavarezza¹, F. Petrelli⁴, R. Longarini¹, S. Cinieri¹, F.G. de Braud¹, F. Pietrantonio¹; ¹IT, ²(MI)/IT, ³(CR)/IT, ⁴(BG)/IT

11:15 - 11:15 **454PD - Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer**

H. Taniguchi¹, T. Yamanaka², D. Sakai², K. Yamazaki³, K. Muro¹, M. Peeters⁴, T. Price⁵; ¹Aichi/JP, ²JP, ³Shizuoka/JP, ⁴BE, ⁵SA/AU

11:15 - 11:30 **Invited Discussant 453PD, LBA22 and 454PD**

F. Ciardiello, IT

11:30 - 11:45 **Q&A led by Discussant**

11:45 - 11:45 **455PD - NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)**

S. Winther¹, H. Skuladottir¹, E. Hofslis², C.-H. Shah³, M. Yilmaz¹, P. Österlund⁴, Å. Berglund³, B. Glimelius³, C. Qvortrup¹, H. Sorbye², P. Pfeiffer¹; ¹DK, ²NO, ³SE, ⁴FI

11:45 - 11:45 **LBA23 - Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Metastatic Colorectal Cancer (mCRC)**

J. Hays¹, J. Zhang², J. Berlin³, M. O'Hara⁴, M. Shah⁵, W. Reichmann⁶, W. Senapedis⁶, H. Achour¹, E. Baloglu¹, S. Shacham¹, M. Kauffman¹; ¹US, ²FL/US, ³TN/US, ⁴PA/US, ⁵NY/US, ⁶MA/US

11:45 - 12:00 **Invited Discussant 455PD and LBA23**

S. Stintzing, DE

12:00 - 12:15 **Q&A led by Discussant**

11:15 - 12:15 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 23**
Title: Brain metastases in GU malignancies
 Chair(s): Anna Patrikidou, GB

11:15 - 11:25 **Germ cell case presentation and discussion**
A. Patrikidou, Surrey/GB

11:25 - 11:35 **Kidney case presentation and discussion**
V. Khoo, GB

11:35 - 11:45 **Bladder case presentation and discussion**
J.-C. Tonn, DE

11:45 - 12:15 **Discussion**

11:15 - 12:15 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**
Title: Expanding the neurooncologist's toolbox: Case-based discussions of challenges & opportunities
 Chair(s): Elizabeth Cohen-Jonathan Moyal, FR

11:15 - 11:15 **Session DOI**

11:15 - 11:25 **Methylation-based tumour profiling: A novel tool for improved diagnosis and treatment**
S. Pfister, DE

11:25 - 11:35 **A role for tumor-treating fields?**
P. Roth, CH

11:35 - 11:45 **SRS and novel systemic therapies: A fruitful partnership?**
E. Cohen-Jonathan Moyal, CEDEX 3/FR

11:45 - 12:15 **Dicsussion**

12:00 - 13:00 **Type: Poster Display session** **Hall B4 - Room 24**
Title: EONS Poster display

12:00 - 12:00 **Session DOI**

12:00 - 12:00 **CN5 - Patients: Power sources for cancer nurses**

C. Beisel, DE

- 12:00 - 12:00 **CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: Towards patient-centered care**
J. Koldenhof, S. Vervoort, C. Nierop, K. Suijkerbuijk; NL
- 12:00 - 12:00 **CN7 - Perceptions of rural nurses extending their role to administer chemotherapy**
Q. Alnasser¹, K. Cameron¹, J. Prouse²; ¹SA, ²AU
- 12:00 - 12:00 **CN8 - AYA cancer nursing, an emerging sub-speciality: The first book about AYA cancer nursing, edited and authored by nurses**
S. Smith, DK
- 12:00 - 12:00 **CN9 - Nurse led follow-up for CML patients on oral cancer treatment**
S. De Wilde, J. De Munter, M. Quaghebeur, D. Mazure, A. De Pauw, B. Casteels; BE
- 12:00 - 12:00 **CN10 - Introducing a new role in cancer care, coordinating contact nurses: Patient-reported evaluation**
B. Westman, H. Ullgren, L. Sharp; SE
- 12:00 - 12:00 **CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: Preliminary study**
E. Mahía, G. Simó, E. Heras, M. Pascual, F. Cobo, J. Pujadas, S. Albiol; AD
- 12:00 - 12:00 **CN12 - Systemic anticancer therapy administration safety**
S. Toland, A. Simons; GB
- 12:00 - 12:00 **CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: The role of the nurse practitioner for early recognition and management**
C. Roth, M. Labots, A. Eertwegh; NL
- 12:00 - 12:00 **CN14 - Experiences from a new advanced cancer nursing role in Sweden: An analysis based on EONS Cancer nursing education framework using the Delphi method**
H. Ullgren, SE
- 12:00 - 12:00 **CN15 - Opinions and experiences of patients receiving oral chemotherapy: A qualitative study**
S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR
- 12:00 - 12:00 **CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for adolescents and young adults (AYAs) with an hematological disease**
J. De Munter, S. De Wilde, M. Quaghebeur; BE

- 12:00 - 12:00 **CN17 - Standardising the psychosocial assessment of oncological patients at Donostia university hospital**
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES
- 12:00 - 12:00 **CN18 - Are there differences between nurses&&**
M. Lavdaniti, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. Zioga, K. MARMARA, E. Fradelos; GR
- 12:00 - 12:00 **CN19 - How an empowerment program can touch cancer survivor's life by improving post-traumatic growth?**
Y.S. UZAR OZCETIN, TR
- 12:00 - 12:00 **CN20 - Organising a general oncology nursing outpatient clinic**
C. Lundgren, A. Lagerquist, M. Högman, U. Östlund; SE
- 12:00 - 12:00 **CN21 - Job content of advanced practice nurses in Flanders**
E. Decoene, A. Van Hecke; BE
- 12:00 - 12:00 **CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professional's self-efficacy when supporting parents newly diagnosed with cancer who have dependent children**
C. Semple, E. McCaughan; GB
- 12:00 - 12:00 **CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals**
J. Bird, M. Nolan, S. Danson; GB
- 12:00 - 12:00 **CN24 - Assessing the effect of telephone support on patients with myeloma multiple (MM) in the Catalan oncology institut in Girona**
C. PUIGMARTI, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher; ES
- 12:00 - 12:00 **CN28 - Transmural collaborative care in oncology: Experiences of general practitioners**
M. daem, E. van Roekeghem, M. Grypdonck, P. Pype; BE
- 12:00 - 12:00 **CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review**
S. Colomer-Lahiguera¹, D. Bryant-Lukosius², S. Rietkoetter², L. Martelli², K. Ribic¹, A. Orcurto¹, R. Juergens², M. Eicher¹; ¹CH, ²ON/CA
- 12:00 - 12:00 **CN30 - Laryngectomized patients caregivers's life experience: A phenomenological study**
V. Bressan, E. Dri, S. Stevanin, L. Cadorin, A. Rizzuto, G. Bulfone, L. Ghirotto; IT

- 12:00 - 12:00 **CN31 - Comparing nurses&&**
L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT
- 12:00 - 12:00 **CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy**
A. Psychogyiou, S. KATSARAGAKIS, C. Lemonidou, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 **CN33 - A new beginning of collaboration: The Danish Cancer Nursing Research Network**
K. Dieperink, M. Kjerholt, P. Riis Olsen; DK
- 12:00 - 12:00 **CN34 - Individual network meetings in cancer care: From young people with cancer to adults with brain tumours**
P. Riis Olsen, DK
- 12:00 - 12:00 **CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?**
G. Bagcivan, N. Ozen, D. Bayrak, F.I. Cinar; TR
- 12:00 - 12:00 **CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment**
C. Johnston, M. Tanay; GB
- 12:00 - 12:00 **CN37 - Evaluation of support and information needs for patients with cancer in a phase I trials unit**
S. Stapleton, L. O'Leary, M. van Zyl, J. Hanwell, T. Wiseman; GB
- 12:00 - 12:00 **CN38 - Dignity of Greek patients with advanced cancer: A cross-sectional study**
S. KATSARAGAKIS, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 **CN39 - Development and implementation of national guidelines on lifestyle issues and cancer: Report from an ongoing quality improvement project**
K. Vuollet Karlsson, C. Landegren, B. Westman; SE
- 12:00 - 12:00 **CN40 - Developing a patient reported experience measure (PREM) in secondary breast cancer (SBC)**
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke; GB
- 12:00 - 12:00 **CN41 - Cancer situation in Sub-Saharan countries: Development of educational, diagnosis and treatment plans**
J. de la Torre-Montero, N. Gil-Gómez, J. RIBES BERNAL, N. Domenech Climent, A. OJER PEREA, P. BEORLEGUI MURILLO, J.M. GAVALA ARJONA, R. CUMPLIDO CORBACHO, I. MAGALLON PEDRERA, M.A. PEÑUELAS SAIZ; ES

- 12:00 - 12:00 **CN42 - The Gastrointestinal and Lymphoma Unit lead nurse research role in Royal Marsden Hospital**
J. Duncan¹, V. Michalarea², T. Coyne¹, J. Thomas¹, D. Cunningham¹; ¹GB, ²Surrey/GB
- 12:00 - 12:00 **CN43 - Patients' learning and participation in their breast cancer care**
L. Boman, K. Sandelin, Y. Wengström, C. Silén; SE
- 12:00 - 12:00 **CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration**
S.Y. Oh, J.M. Lee, J.W. Kim, S.H. Kim, J.M. Park, G.Y. Yeo, J.E. Hyun, J.-H. Park; KR
- 12:00 - 12:00 **CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy**
A. Frade, S. Miguel; PT
- 12:00 - 12:00 **CN46 - Safe navigation of CARs in a changing landscape**
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite; GB
- 12:00 - 12:00 **CN47 - Patients' interpretations and experiences of participation in cancer care**
J. Jackson, J. Rundgren; SE
- 12:00 - 12:00 **CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab**
M. Qiu, Y. Chen, B.-L. Zhang, X.-Y. Wang; CN
- 12:00 - 12:00 **CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care**
J. De Munter, P. Crombez; BE
- 12:00 - 12:00 **CN50 - Overview of an acute oncology service in a UK cancer centre**
M. Foulkes, GB
- 12:00 - 12:00 **CN51 - The development and evaluation of an online oncology portal**
J. De Munter, E. Decoene, A. Van Hecke; BE
- 12:00 - 12:00 **CN52 - Pilot study: Nurses' role in management of cutaneous toxicity in patients with targeted therapies anti EGFR-Is' treatment**
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso; IT
- 12:00 - 12:00 **CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?**
D. Oliva, F. Lewin, N. Lewin, M. Nilsson, M. Strandéus, B.-Å. Andersson, L. Sharp; SE

- 12:00 - 12:00 **CN58 - Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin**
N. Izgu, L. Ozdemir, F. Bugdayci Basal; TR
- 12:00 - 12:00 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**
C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 **CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: A qualitative study**
D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT
- 12:00 - 12:00 **CN61 - &&**
M. Tanay, J. Armes; GB
- 12:00 - 12:00 **CN62 - App about chemotherapy: Helping the patient with cancer**
B. Espersen, DK
- 12:00 - 12:00 **CN63 - Usability test for a CINV diary application for smartphones at oncology nursing**
P. Fernández- Ortega, Y. Escobar, E. Trigoso, R. Blat, M. Cantero, A. Alvarez; ES
- 12:00 - 12:00 **CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the memorial symptom assessment scale**
D. Palitzika, E. Fradelos, V. Alikari, P. Charitopoulos, E. Zioga, S. Zyga, M. Lavdaniti; GR
- 12:00 - 12:00 **CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool &&**
M. Belhadj¹, E. Kempf¹, A. Lebel¹, A. Guillemin¹, H. BouSSION¹, C. Joly¹, I. Baumgaertner², E. Assaf², C. Saldana², B. Rousseau², C. Tournigand²; ¹FR, ²CEDEX/FR
- 12:00 - 12:00 **CN66 - Medical makeup in cancer patients and its impact in their quality of life**
R. Lechou, M. Lavdaniti; GR
- 12:30 - 13:30** **Type: Poster Display session** **Hall A3 -**
Title: Poster display session: Biomarkers, Gynaecological cancers, Poster Area
Haematological malignancies, Immunotherapy of cancer, New Networking
diagnostic tools, NSCLC - early stage, locally advanced & metastatic, Hub
SCLC, Thoracic malignancies, Translational research
- 12:30 - 12:30 **Biomarkers**
- 12:30 - 12:30 **66P - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma**

T. Looney¹, G. Lowman², L. Miller², E. Linch³; ¹SG, ²US, ³CA/US

- 12:30 - 12:30 **67P - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors**
A. Awada¹, F. Morschhauser², J.-P. Machiels¹, G. Salles², S. Rottey¹, S. Rule³, D. Cunningham⁴, F. Peyrade⁵, C. Fruchart², H.-T. Arkenau⁴, I. Genvresse⁶, K. Koechert⁶, G. Cisternas⁶, C. Granvil⁷, C. Pena⁷, L. Liu⁷; ¹BE, ²FR, ³Devon/GB, ⁴GB, ⁵CEDEX 2/FR, ⁶DE, ⁷US
- 12:30 - 12:30 **68P - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association**
M. Montesion¹, C. Chung², E. Sokol³, S. Khan⁴, H. Kang⁵, L. Albacker¹, J. Johnson¹, G. Frampton³, V. Miller³, J. Ross³, S. Ali³; ¹US, ²FL/US, ³MA/US, ⁴TX/US, ⁵MD/US
- 12:30 - 12:30 **69P - Toward the standardization of bioinformatics methods for the accurate assessment of tumor mutational burden (TMB)**
H. Chang, S. Srinivasan, A. Sasson, R. Golhar, D. Greenawalt, S. Kirov, J. Szustakowski; NJ/US
- 12:30 - 12:30 **70P - Prediction of primary resistance to anti-PD1 therapy (APD1) in second-line NSCLC**
E. Smit¹, J. Aerts², M. Muller¹, A.-L. Niemeijer¹, H. Roder³, C. Oliveira³, J. Roder³; ¹NL, ²Noord Brabant/NL, ³US
- 12:30 - 12:30 **71P - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM)**
R. Ferguson¹, A. Archambault², D. Simpson², E. Kazlow², R. Lax², U. Moran², M. Wilson², R. Shapiro², A. Pavlick², I. Osman¹, D. Polsky¹, T. Kirchhoff¹; ¹US, ²NY/US
- 12:30 - 12:30 **72P - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma**
M. Yang, J. Li, N. Zhang, H. Xing, J. Liu; CN
- 12:30 - 12:30 **73P - Gene embedding: A novel machine learning approach to identify gene candidates related to immunotherapy responsiveness**
C.T. Choy, C.H. Wong, S. Chan; HK
- 12:30 - 12:30 **74P - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials**
A. Madi¹, D. Fisher², T. Maughan², J. Colley², A. Meade², J. Maynard², V. Humphreys², H. Wasan², R. Adams², S. Idziaszczyk², R. Harris², R. Kaplan², J. Cheadle²; ¹Merseyside/GB, ²GB
- 12:30 - 12:30 **75P - The landscape of NTRK fusions in Chinese patients with solid tumor**

Q. Ling, B. Li, X. Wu, H. Wang, Y. Shen, M. Xiao, Z. Yang, R. Ma, D. Chen, H. Chen, X. Dong, W. Wang, M. Yao; CN

- 12:30 - 12:30 **76P - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma**
C.-H. Lee¹, R. Motzer², H. Glen³, M.D. Michaelson⁴, J. Larkin³, Y. Minoshima⁵, M. Kanekiyo⁵, R. Dairiki⁵, P. Sachdev⁶, C. Dutcus⁶, Y. Funahashi¹, M. Voss²; ¹US, ²NY/US, ³GB, ⁴MA/US, ⁵JP, ⁶New Jersey/US
- 12:30 - 12:30 **77P - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks**
A. Meier¹, K. Nekolla¹, S. Earle², L. Hewitt³, T. Aoyama⁴, T. Yoshikawa⁴, G. Schmidt¹, R. Huss¹, H. Grabsch³; ¹DE, ²GB, ³NL, ⁴JP
- 12:30 - 12:30 **78P - Detection of targetable kinase fusions in 7260 patients in an integrated cancer system**
A. Parikh¹, S. Ali¹, A. MORAN¹, P. Crilley¹, A. Schrock², A. Tan³, P. Reddy¹, V. Miller², J. Ross², S. Zook¹, R. Alvarez¹, M. Markman¹; ¹US, ²MA/US, ³AZ/US
- 12:30 - 12:30 **79P - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies**
Y. Li¹, J. Sun¹, J. Skoletsy², C. Milbury¹, C. Burns², W.-K. Yip¹, N. Dewal², J. He¹, J. Tuesdell², E. Peters¹, E. Schleifman³, J. Noe⁴, S. Jenkins⁵, J. Elvin², G. Otto², D. Lipson¹, J. Ross¹, V. Miller², M. Doherty², C. Vietz²; ¹US, ²MA/US, ³CA/US, ⁴CH, ⁵GB
- 12:30 - 12:30 **80P - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease**
B. Torrejón, M. Pedregal Trujillo, A. Santos, J. Rubio, M. Luque, M. Sanz, C. Carames, S. Zazo, J. Madoz-Gurpide, F. Rojo, J. Garcia Foncillas, C. Ion; ES
- 12:30 - 12:30 **81P - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs**
N. Zhang, M. Yang, H. Xing, J. Liu; CN
- 12:30 - 12:30 **82P - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma**
M. Khattak¹, E. Gray², A. Reid², M. Periera², A. McEvoy², C. Aya-Bonilla², T. Meniawy¹, A. Didan¹, M. Millward¹, M. Ziman²; ¹WA/AU, ²AU
- 12:30 - 12:30 **83P - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer**
Y.-Z. Liu¹, D. Hodgson¹, G. Locker², Z. Lai¹, D. Balcerzak¹, A. Sharpe¹, J.C. Barrett², M. Orr¹, T. Gutjahr¹, B. Dougherty², M. Roudier¹, X. Shi³, R. Miller⁴, W.H. Kim⁵, X. Zeng⁶, A. Ochiai⁷, S.-A. Im⁵, R.-H. Xu⁶, N. Boku⁸, Y.-J. Bang⁵; ¹GB, ²US, ³MD/US, ⁴AZ/US, ⁵KR, ⁶CN, ⁷JP, ⁸Kanagawa/JP

- 12:30 - 12:30 **84P - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: A large-scale, multi-center study**
T. Yang, H. Xing, G. Wang, S. Cai, F. Shen; CN
- 12:30 - 12:30 **85P - Dissecting gastric cancer biology and how and when to use immunotherapy**
M. Das Thakur, K. Okrah, D. Shames, P. Hegde, C. Bais; US
- 12:30 - 12:30 **86P - Longitudinal assessment of multiplex patient-specific ctDNA biomarkers in bladder cancer for diagnosis, surveillance and recurrence**
K. Birkenkamp-Demtröder¹, E. Christensen¹, H. Sethi², S. Sharma², H.-T. Wu², A. Taber¹, M. Agerbæk¹, R. Swenerton², R. Salari², D. Hafez², I. Nordentoft¹, P. Lamy¹, R. Srinivasan², M. Balcioglu², S. Navarro², Z. Assaf², B. Zimmermann³, J. Lin³, J. Bjerggaard Jensen¹, L. Dyrskjøt¹; ¹DK, ²CA/US, ³US
- 12:30 - 12:30 **87P - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas**
E. Imyanitov, T. Sokolova, G. Raskin, A. Ivantsov, A. Iyevleva, A. Sokolenko; RU
- 12:30 - 12:30 **88P - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group**
M. Del Re¹, S. Crucitta¹, A. Sbrana¹, E. Rofi¹, F. Paolieri¹, L. Galli¹, A. Falcone¹, R. van Schaik², G. Jenster², R. Morganti¹, S. Pignata¹, R. Danesi¹; ¹IT, ²NL
- 12:30 - 12:30 **89P - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases**
Y. Zheng, Y. Ding, C. Xiao, W. Zhong, X. Teng, Q. Gao, Q. Wang, Y. Sun, C. Chen, L. Chen, J. Zhu, Q. Xu, N. Xu; CN
- 12:30 - 12:30 **90P - Development of a pan-cancer biomarker panel for improved detection of MSI across all cancer types**
J. Bacher¹, R. Halberg¹, P. Ward¹, E. Udho¹, K. Murphy², M. Uhr¹, L. Dubeau¹, J. Pettersson¹, D. Storts¹, S. Gallinger³, D. Buchanan⁴, M. Jenkins⁴, N. Lindor¹, J. Eshleman⁵; ¹US, ²TX/US, ³CA, ⁴AU, ⁵MD/US
- 12:30 - 12:30 **91P - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients**
Z. Wang, H. Qin, M. Wang, J. Gong, X. Wang, J. Li, J. Gao, Z. Li, D. Wang, S. Cai, Y. Bai, L. Xiong, F. Li, L. Shen; CN
- 12:30 - 12:30 **92P - Vall d'Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)**

C. Hierro¹, I. Matos¹, J. Martin-Liberal¹, M. Ochoa De Olza Amat¹, E. Felip¹, M. Costa Rivas¹, M. Vieito Villar², I. Brana¹, A. Azaro¹, M.C. Perez-Gago¹, A. Gros¹, J. Carles¹, A. Oaknin¹, T. Macarulla¹, C. Saura¹, N. pardo¹, E. Muñoz-Couselo¹, J. Tabernero¹, R. Dienstmann¹, E. Garralda¹; ¹ES, ²La Coruña/ES

- 12:30 - 12:30 **93P - Augmenting TNM staging with machine learning-based immune profiling for improved prognosis prediction in muscle-invasive bladder cancer patients**
N. Brieu¹, C. Gavriel², D. Harrison², G. Schmidt¹, P. Caie¹; ¹DE, ²GB
- 12:30 - 12:30 **94P - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma**
A. Bernard-Tessier¹, E. Jeannot¹, D. Guenat¹, M. Michel¹, C. Proudhon¹, A. Vincent-Salomon¹, I. Bièche¹, J.-Y. Pierga¹, B. Buecher¹, E. Francois², S. Kim¹, T. André³, M. Jary¹, V. Vendrely¹, E. Samalin¹, F. El Hajbi⁴, N. Baba-Hamed¹, A. Meurisse¹, F.-C. Bidard¹, C. Borg¹; ¹FR, ²CEDEX 2/FR, ³CEDEX 12/FR, ⁴CEDEX/FR
- 12:30 - 12:30 **95P - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis**
M. Jafolla¹, C. Yang², V. Chandran¹, M. Pintilie¹, A. Hansen¹, P. Bedard³, S. Lheureux³, A. Spreafico², A. Razak², P. Ohashi¹, S. Hakgor², A. Giesler², T. Pugh¹, L. Siu¹; ¹CA, ²ON/CA, ³Ontario/CA
- 12:30 - 12:30 **96P - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) & cetuximab in RAS wild type (WT) patients (pts)**
C. Cardone¹, B. Blauensteiner², V. Moreno-Viedma², M. Paul², G. Martini³, P.P. Vitiello¹, D. Ciardiello¹, C. Borrelli¹, L. Poliero¹, P. Vitale¹, N. Zanaletti¹, V. Famiglietti¹, A.M. Rachiglio¹, D. Rizzi¹, E. Maiello¹, T. Latiano¹, N. Normanno¹, M. Sibilgia², F. Ciardiello¹, E. Martinelli¹; ¹IT, ²AT, ³ES
- 12:30 - 12:30 **97P - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)**
T. Carr¹, C. Adelman¹, A. Barnicle¹, I. Kozarewa¹, S. Luke¹, Z. Lai¹, S. Menon¹, S. Hollis¹, B. Dougherty², E. Harrington¹, J.C. Barrett², C. Goessl², F. Saad³, N. Sala⁴, N. Clarke¹, D. Hodgson¹; ¹GB, ²US, ³CA, ⁴ES
- 12:30 - 12:30 **98P - Identification of a highly suppressive Treg subset associated to immunotherapy response**
E. Giunta, S. Romano, P. D'Arrigo, A. Rea, M. Tufano, G. Matarese, C. Procaccini, N. Novizio, V. Vigorito, D. Faicchia, G. Argenziano, V. De Falco, F. Ciardiello, M.F. Romano, T. Troiani; IT
- 12:30 - 12:30 **99P - A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)**

J. Evelhoch¹, R. Mogg², R. Cristescu², D. Aurora-Garg², L. Chow³, S. Loi⁴, D. Catenacci⁵, U. Matulonis⁶, P. Ott⁶, E. Antonarakis⁷, C. Poehlein⁸, A. Joe⁹, S. Keefe⁹, P. Kang², V. Karantza², J. Cheng¹⁰, E. Rubin¹¹; ¹AR, ²NJ/US, ³WA/US, ⁴VIC/AU, ⁵IL/US, ⁶MA/US, ⁷MD/US, ⁸New Jersey/US, ⁹US, ¹⁰PA/US, ¹¹Pennsylvania/US

- 12:30 - 12:30 **100P - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC**
J. Garcia¹, A. Delherme¹, F. Geiguer¹, P. Merle¹, C. Tissot¹, F. Jones², D. Edelstein³, P.-J. Souquet⁴, C. Rodriguez-Lafrasse¹, S. Couraud⁴, L. PAYEN¹, Z. Xu⁵; ¹FR, ²California/US, ³MD/US, ⁴CEDEX/FR, ⁵CH
- 12:30 - 12:30 **101P - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer**
O. Hamid¹, A. Vanderwalde¹, C. Szeto¹, S. Reddy¹, S. Pal²; ¹US, ²CA/US
- 12:30 - 12:30 **102P - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1$\#$ non-small cell lung cancer using next generation sequencing: A multicenter study**
Q. Zhang, C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song; CN
- 12:30 - 12:30 **103P - Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples**
D. Moran¹, D. Maurus², C. Rohde², A. Arozullah¹; ¹US, ²DE
- 12:30 - 12:30 **104P - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer**
Y. Liu, C.K. Tham, S. Ong, C.L. Tang, Y. Zhao; SG
- 12:30 - 12:30 **105P - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292**
B. Besse¹, V. Subbiah², A. Drilon³, M. Shah⁴, L. Wirth⁵, T. Bauer⁶, V. Velcheti⁷, N. Lakhani⁷, V. Boni⁸, B. Solomon⁹, M. Johnson⁶, K. Park¹⁰, J. Patel¹¹, M. Cabanillas², E. Sherman³, E. Zhu⁷, K. Gordon⁷, K. Ebata¹², B. Tuch⁷, G. Oxnard⁵; ¹CEDEX/FR, ²TX/US, ³NY/US, ⁴OH/US, ⁵MA/US, ⁶TN/US, ⁷US, ⁸ES, ⁹VIC/AU, ¹⁰KR, ¹¹IL/US, ¹²CA/US
- 12:30 - 12:30 **106P - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma**
N. Shen¹, Y. Pan², X. Mo¹; ¹CN, ²DE
- 12:30 - 12:30 **107P - Novel genomic classifier for early stage colorectal cancer patients**
E. Letellier, M. Schmitz, A. Ginolhac, E. Koncina, M. Marchese, L. Antunes, S. Rauh, S. Haan; LU
- 12:30 - 12:30 **108P - Baseline blood immune profiling to predict response to antiPD-1 in patients with advanced non-small cell lung cancer**

E. Romano¹, T. Le Bourgeois², S. Lopez-Lastra², V. Servois², S. Beaucaire-Danel², C. Daniel², J.-Y. Pierga², F.-C. Bidard², O. Lantz²; ¹CEDEX 5/FR, ²FR

- 12:30 - 12:30 **109P - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient mismatch repair (pMMR) colorectal and endometrial cancers**
J. Cohen¹, B. Rousseau², R. Bourgoïn¹, C. Tournigand², L. Larnaudie¹, A. Dupuy¹, M. Ollier¹, A. PUJALS¹; ¹FR, ²CEDEX/FR
- 12:30 - 12:30 **110P - Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?**
I. Matos Garcia¹, A. Azaro¹, C. Viaplana¹, C. Hierro¹, J. Martin-Liberal¹, I. Brana¹, I. Gardeazabal¹, P. Gomila¹, M. Vieito Villar², M. Ochoa De Olza Amat¹, E. Elez Fernandez¹, M. Oliveira¹, A. Oaknin¹, H. Verdaguer¹, A. Navarro Mendivil¹, M. Alsina¹, J. Tabernero¹, T. Macarulla Mercade¹, R. Dienstmann¹, E. Garralda¹; ¹ES, ²La Coruña/ES
- 12:30 - 12:30 **111P - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies**
M.S. Cona, M. Lecchi, S. Damian, M. Del Vecchio, C. Cimminiello, S. Cresta, M. Duca, A. Necchi, D. Signorelli, M. Poggi, D. Raggi, R. Ratta, P. Verderio, F.G. de Braud, M. Di Nicola; IT
- 12:30 - 12:30 **112P - Effects of concomitant genetic alterations on cancer patient overall survival**
Y. Wang, P. Peng, L. Shang, Y.-A. Dong, Z. Yang, H. Zhong; CN
- 12:30 - 12:30 **113P - Circulating exosomal integrin &&**
D. Chu, CN
- 12:30 - 12:30 **114P - Circulating and tumor-associated caspase-4: A novel diagnostic and prognostic biomarker for non-small cell lung cancer patients?**
R. Sorrentino, M. Terlizzi, C. Colarusso, A. Saccomanno, R. Salvi, R. Aquino, A. Pinto; IT
- 12:30 - 12:30 **115P - Smokers and COPD patients have high circulating caspase-4 levels: Is it an alarm?**
M. Terlizzi, R. Sorrentino, C. Colarusso, A. Molino, A. Saccomanno, R. Aquino, A. Pinto; IT
- 12:30 - 12:30 **116P - Genomic characteristics of standardized uptake value of 18F-fluorodeoxy-glucose positron emission tomography in breast cancer**
S.-K. Kim, S.G. Ahn, S.-H. Leem, J. Jeong, I.-S. Chu; KR

- 12:30 - 12:30 **117P - Characterization of PD-L1, CD8, CD3, CD68 and PanCK in tumor microenvironment of GI tract tumors with respect to patients' mismatch repair status and anti-PD-1 treatment outcome using 5Plex IHC and whole slide image analysis**
W. Zhang¹, M. Khojasteh¹, A. Hubbard¹, J. Martin¹, X. Wang¹, S. Kamthamraju¹, J. Munoz-Rodriguez², D. Jiang¹, Z. Cai¹, J. Li¹, R. Anders¹, L. Diaz¹, L. Pestic-Dragovich¹, L. Tang¹; ¹US, ²AZ/US
- 12:30 - 12:30 **118P - Exhaustion of platelet kinetics and its implication in post-resection HCC recurrence**
B. Aryal, T. Shimizu, J. Kadono, A. Furoi, T. Komokata, K. Gejima, M. Yamakuchi, T. Hashiguchi, Y. Imoto; JP
- 12:30 - 12:30 **119P - Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project**
B. You¹, V. Kepenekian², A. Prieur³, M. Caceres², L. Payen-Gay², P. Liaud³, M. Flaceliere³, M. Tod², L. Villeneuve², F. Bibeau⁴, L. Bernard², P. Jourdan-Enfer², N. Medeghri², D. Dayde², S. Calattini², G. Freyer¹, D. Maucort-Boulch², D. Joubert³, O. Glehen²; ¹CEDEX/FR, ²FR, ³CH, ⁴CEDEX 5/FR
- 12:30 - 12:30 **120P - A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells**
D. Saraiva, A. Jacinto, S. Braga, M. Cabral; PT
- 12:30 - 12:30 **121P - LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients**
P. Garrido Lopez¹, E. Felip¹, L. Paz-Ares¹, M. Majem¹, T. Moran¹, J. Gonzalez-Larriba¹, J. Bosch Barrera¹, J. Trigo Perez¹, M.R. Garcia Campelo¹, J.M. Sanchez Torres¹, D. Isla¹, N. Vinolas Segarra¹, C. Camps¹, A. Insa Molla², O.J. Juan Vidal¹, B. Massutí¹, A. Paredes Lario¹, A. Artal-Cortes¹, M. Lopez-Brea Piqueras¹, J. Palacios Calvo¹; ¹ES, ²Valencia/ES
- 12:30 - 12:30 **122P - Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with colorectal liver metastases**
S. Stremitzer, A. Graf, B. Neudert, M. Herac, A. Beer, C. Schwarz, F. Wrba, K. Kaczirek, J. Stift; AT
- 12:30 - 12:30 **123P - Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)**
N. Radosevic-Robin¹, S. Ong², S. Warren², M. Kossai¹, C. Godfraind¹, M. Masson¹, H. Janicot¹, P. Merle¹, P. Dubray-Longueras¹, X. Durando¹, P. Morel², A. Cesano², F. Penault-Llorca¹; ¹FR, ²US
- 12:30 - 12:30 **124P - Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)**

L. Miller-Phillips¹, L. Fischer von Weikersthal¹, F. Kaiser¹, S.-E. Al-Batran¹, T. Heintges¹, D. Neureiter², C. Kahl¹, F. Kullmann¹, M. Moehler¹, W. Scheithauer², C. Vazart³, K. Fontaine³, S. Held¹, D. Modest¹, J. Neumann¹, A. Jung¹, T. Kirchner¹, V. Heinemann¹, S. Stintzing¹; ¹DE, ²AT, ³FR

- 12:30 - 12:30 **125P - Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study**
H. Blons¹, J.-B. Oudart¹, J.-P. Merlio¹, S. Hominal², F. de Fraipont¹, D. Debieuvre¹, F. Escande¹, C. Audigier Valette², P.-P. Bringuier¹, S. Moreau Fraboulet¹, L. Ouafik¹, D. Moro-Sibilot¹, A. Lemoine¹, A. Langlais¹, P. Missy¹, F. Morin¹, P.-J. Souquet², F. Barlesi³, J. Cadranet¹, M. Beau-Faller¹; ¹FR, ²CEDEX/FR, ³CEDEX 20/FR
- 12:30 - 12:30 **126P - Simultaneous identification and profiling of tumor-specific T cells by mass cytometry**
M. Fehlings, E. Newell; SG
- 12:30 - 12:30 **127P - Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value**
L. Chen, Y. Zhao, X. Hu, H. Wu, J. Liu, X. Mu; CN
- 12:30 - 12:30 **128P - Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02)**
J.L. Ramirez¹, A. Font Pous², J. Garcia-Donas¹, B. Perez Valderrama¹, I. Aguirre Egaña¹, L. Nonell¹, V. Ruiz de Porras Fontdevila¹, M. Mallo¹, D. Balañá¹, J.A. Virizuela¹, U. Anido¹, M.M. Llorente Ostiategui¹, M.A. Gonzalez del Alba Baamonde¹, N. Lainez¹, B. Mellado¹, M.A. Climent Duran¹, J. Bellmunt¹; ¹ES, ²Barcelona/ES
- 12:30 - 12:30 **129P - Pre-diagnostic measurements of high-sensitive C-reactive protein and risk of prostate cancer: The PROCA-life study**
E. Stikbakke, H. Haugnes, I. Thune, T. Wilsgaard, T. Knutsen, E. Richardsen; NO
- 12:30 - 12:30 **130P - Training and validation of a gene expression signature for microsatellite instability**
S. Warren¹, P. Danaher², S. Ong¹, N. Elliott¹, A. Cesano¹; ¹US, ²WA/US
- 12:30 - 12:30 **131P - Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels**
K. Quinn¹, E. Helman¹, T. Nance¹, C. Artieri¹, J. Yen², J. Zhao¹, S. Fairclough¹, M. Sikora¹, D. Chudova¹, R. Lanman¹, A. Talasaz²; ¹US, ²CA/US
- 12:30 - 12:30 **132P - Carbohydrate antigen 19-9 and apolipoprotein A2 isoform as early detection biomarkers for pancreatic cancer: A prospective evaluation by the EPIC study**

K. Honda¹, V. Katzke², A. Hüsing², S. Okaya¹, H. Shoji¹, K. Onidani¹, F. Canzian², R. Kaaks²; ¹JP, ²DE

- 12:30 - 12:30 **133P - Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)**
M. Bilen¹, D. Martini², J. Shabto², Y. Liu², A. Khan², M. Williams², C. Lewis¹, H. Collins¹, H. Kissick², B. Carthon¹, M. Akce¹, W. Shaib¹, O. Alese¹, D. Lawson¹, R. Kudchadkar¹, B. El-Rayes¹, S. Ramalingam², T. Owonikoko², R. Harvey¹, V. Master¹; ¹US, ²GA/US
- 12:30 - 12:30 **134P - Prediction of irAEs in ipilimumab-treated melanoma patients based on serum autoantibodies**
J. Hassel¹, J. Mangana², R. Dummer², C. Pföhler¹, K. Wistuba-Hamprecht¹, B. Weide¹, L. Hakim-Meibodi¹, F. Meier¹, J. Roth¹, H.-D. Zucht¹, P. Budde¹, M. Tuschen¹, P. Schulz-Knappe¹; ¹DE, ²CH
- 12:30 - 12:30 **135P - Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer**
B. Edith¹, A. Leary¹, P. Pautier², E. Santana¹, L. Lacroix¹, O. Cabaret¹, M. Guillaud-Bataille¹, J. Michels¹, A. Auguste¹, C. Genestie¹, E. Rouleau³; ¹FR, ²CEDEX/FR, ³CEDEX 5/FR
- 12:30 - 12:30 **136P - EML4-ALK fusion variants associate with gender and age in Chinese NSCLC patients**
W. Zhao, G. Liang, L. Wang, L. Dai, D. Wu, K. Wang, A. Wang, H. Chen, Y.-A. Dong, M. Wang; CN
- 12:30 - 12:30 **137P - Multi-dimensional immuno-oncology assays for understanding the immune system and tumor microenvironment**
F. Hyland¹, T. Looney², R. Chaudhury³, A. Kamat³, A. Pankov³; ¹US, ²SG, ³CA/US
- 12:30 - 12:30 **138P - Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma**
N. Keegan, S. Toomey, A. Farrelly, A. Carr, G. Calzaferri, J. Walshe, G. Gullo, J. Crown, K. Egan, A. Hernando, A. Teiserskiene, L. Grogan, O. Breathnach, P. Morris, B. Hennessy; IE
- 12:30 - 12:30 **139P - Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study**
M. Boeri¹, F. Nichetti¹, L. Porcu¹, V. Torri², A. Del Conte¹, A. Martinetti¹, E. Sottotetti¹, E. Vattemi¹, F. Verderame¹, M.C. Garassino¹, L. Cavanna¹, A. Tuzi¹, L. Irtelli¹, F.G. de Braud¹, M. Platania¹; ¹IT, ²NA
- 12:30 - 12:30 **140P - Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)**
J. Marquez¹, P. Lucero-Diaz², J.A. Matute-Briseno², M. Rosas-Delgado², A. CAMACHO-HERNANDEZ², Y. Cortez-Vargas², I. Nava-Sanchez², G. MONTANO², L. MONTIJO-FERNANDEZ², M. PEREZ-ASTORGA²; ¹Washington/MX, ²MX

- 12:30 - 12:30 **141P - Tumor mutational burden (TMB) standardization initiative: Establishing a consistent methodology for TMB measurement in clinical samples**
A. Stenzinger¹, J. Allen², J. Maas¹, M. Stewart², D. Merino², M. Dietel¹; ¹DE, ²DC/US
- 12:30 - 12:30 **142P - DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?**
C.M. Della Corte¹, K. Ramkumar², T. Sen², P. Tong², D. Gibbons², J. Heymach², J. Wang², Y.-H. Fan², R. Cardnell², L. Byers²; ¹IT, ²TX/US
- 12:30 - 12:30 **143P - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)**
J. Martin-Liberal¹, F. Pagliuca², C. Hierro¹, C. Viaplana¹, E. Muñoz Couselo¹, J. Capdevila¹, I. Matos¹, L. Fariñas Madrid¹, E. Zamora¹, I. Braña Garcia¹, E. Elez Fernandez¹, M. Ochoa De Olza Amat¹, A. Azaro¹, M. Alsina¹, M. Vieito Villar³, R. Fasani¹, J. Tabertero¹, E. Garralda¹, R. Dienstmann¹, P. Nuciforo¹; ¹ES, ²IT, ³La Coruña/ES
- 12:30 - 12:30 **144P - Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab**
G. Mountzios¹, V. Kotoula², G.-A. Koliou³, K. Papadopoulou³, G. Lazaridis³, C. Christodoulou⁴, G. Pentheroudakis³, M. Skondra³, A. Koutras⁵, H. Linardou³, E. Razis³, P. Papakostas³, S. Chrisafi³, G. Aravantinos⁶, I. Nicolaou³, A. Goussia³, K. Kalogeras³, D. Pectasides³, G. Fountzilias³; ¹Neo Psychiko/GR, ²Central Macedonia/GR, ³GR, ⁴N. Faliro/GR, ⁵Rion/GR, ⁶Attica/GR
- 12:30 - 12:30 **145P - Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer**
S. Crucitta, M. Del Re, A. Fontana, I. Bertolini, E. Rofi, C. De Angelis, L. Diodati, D. Cavallero, B. Salvadori, A. Falcone, R. Morganti, R. Danesi; IT
- 12:30 - 12:30 **146P - HER2 amplification is associated with higher tumor mutation burden in breast cancer**
Y. Yin, W. Li, X. Huang, H. Wu, Y. Zhang, S. Cai, S. Zhou; CN
- 12:30 - 12:30 **147P - Application of CRISPR/Cas9 system for identification of genes involved in the regulation of pancreatic cancer cells platinum sensitivity**
V. Skripova¹, I. Serebriiskii¹, R. Kiyamova¹, I. Astsaturov²; ¹RU, ²PA/US
- 12:30 - 12:30 **148P - Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass**
A. Athanasiou¹, T. Orfanelli², D. Lapolla³, E. Andreopoulou³, T.A. Moo³, J. Marti³, T. Cigler³, A.M. Bongiovanni³, S. Witkin³; ¹US, ²NJ/US, ³NY/US
- 12:30 - 12:30 **149P - Only estrogen receptor &&**

J.M. Ryu, S.K. Lee, J.E. Lee, S.J. Nam, J. Yu, H.J. Choi, I. Kim, S.W. Kim; KR

- 12:30 - 12:30 **150P - Adjuvant radiation therapy leads to an up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) which might contribute to radioresistance in primary breast cancer patients**
D. Schott, M. Pizon, U. Pachmann, K. Pachmann, M. Mäurer; DE
- 12:30 - 12:30 **151P - Recurrent and metastatic carcinomas of the lacrimal gland: High frequency of ERBB2 driven disease**
N. Girard¹, R. Corona², J. Chung³, S. Millis³, L. Gay⁴, J. Elvin³, J.-A. Vergilio³, S. Ramkissoon³, E. Severson³, S. Daniel³, J. Killian³, S. Ali³, A. Schrock³, V. Miller³, J. Ross⁴; ¹FR, ²NY/US, ³MA/US, ⁴US
- 12:30 - 12:30 **152P - Circulating tumour DNA experience in patients with cancer of unknown primary**
H. Winter¹, I. Faull², P. Bains¹, C. Murias¹, M. Kushnir¹, M. Forster¹, A. Kulkarni¹, D. Moore¹, C. Swanton¹, K. Shiu¹, H.-T. Arkenau¹; ¹GB, ²ES
- 12:30 - 12:30 **153P - Reproducibility of the mRECIST criteria for the assessment of HCC treated by anti-VEGFR therapy: Impact of readers’ expertise**
H. Beaumont¹, S. Egels¹, N. Faye¹, C. Klifa¹, A. Iannessi¹, E. Bonnard¹, O. Lucidarme²; ¹FR, ²CEDEX 13/FR
- 12:30 - 12:30 **154P - PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung**
D. damotte¹, M.C. Charpentier¹, M. Bernardi¹, E. Watkin¹, I. Goubin Versini¹, R. Lamy¹, N. Piton¹, L. Geriniere¹, F. Forest¹, R. Gervais², I. Monnet¹, A. Madrosyk¹, F. Guisier¹, C. Serrand¹, C. Locher Genty³, C. Decroisette⁴, J.B. Auliac¹, T. Jeanfaivre¹, H. Doubre¹, D. Arpin¹; ¹FR, ²CEDEX 5/FR, ³Cedex/FR, ⁴CEDEX/FR
- 12:30 - 12:30 **155P - Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC)**
G. Williams¹, A.G. Nicholson¹, D. Snead¹, E. Thunnissen², S. Lantuejoul³, P. Cane¹, K. Kerr¹, M. Loddo¹, M. Scott¹, P. Scorer¹, C. Barker¹; ¹GB, ²NL, ³CEDEX 9/FR
- 12:30 - 12:30 **156P - Relationship between ring-type dedicated breast PET and tumor-infiltrating lymphocytes in early breast cancer**
S. Sasada¹, N. Shiroma², E. Suzuki², S. Sueoka², N. Goda², K. Kajitani², A. Emi², N. Masumoto², T. Kadoya², R. Haruta², T. Kataoka², K. Arihiro², M. Okada²; ¹Hiroshima/JP, ²JP
- 12:30 - 12:30 **157P - Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms**
Y. Fan¹, Y. Xu², X. Tong³, J. Yan¹, X. Wu³, Y.W. Shao³; ¹CN, ²Zhejiang/CN, ³CA

- 12:30 - 12:30 **158P - Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy**
L. Angus¹, E. van Helden², S. van Es¹, E. Boon¹, C. van Herpen¹, D.J. de Groot¹, E.G.E. de Vries¹, C.W. Menke-van der Houven van Oordt¹, S. Sleijfer¹, H. Verheul¹, M. Jansen¹; ¹NL, ²AN
- 12:30 - 12:30 **159P - Quantifying circulating cell-free DNA as clinical biomarker**
M. Romain, Z. Dache, A. Otandault, R. Tanos, B. Pastor, C. Sanchez, J. Azzi, G. Tusch, S. Azan, C. Mollevi, S. Thezenas, P. Blache, A. Thierry; FR
- 12:30 - 12:30 **160P - Gene expression profile (GEP) and survival among patients with advanced ovarian cancer**
E. Høgdall¹, C. Høgdall¹, P.-T. Vo², W. Zhou², L. Huang², M. Marton², S. Keefe², M. Busch-Sørensen², S. Sørensen¹, J. Georgsen¹, E. Mejlgaard¹, L. Nedergaard¹, T. Steiniche¹; ¹DK, ²US
- 12:30 - 12:30 **161P - Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics**
D. Yan¹, M.-H. Ryu², E. An³, Y.S. Park², H. Na², J. Ma², Y. Tian¹, F. Cecchi¹, T. Hembrough¹, Y.-K. Kang⁴; ¹US, ²KR, ³MD/US, ⁴Songpa-gu/KR
- 12:30 - 12:30 **162P - Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study**
B. De Craene¹, J. Van de Velde¹, E. Bellon¹, M. Gazin¹, E. Rondelez¹, L. Vandebroek¹, T. Vanhoey¹, N. Elsen¹, L. Melchior², G.L. Willemoes², E. Watkin³, N. Arens⁴, C. Altmann⁴, K. Decanniere¹, E. Sablon¹, G. Maertens¹; ¹BE, ²DK, ³FR, ⁴DE
- 12:30 - 12:30 **163P - Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel**
T. Jiang¹, S. Zhang², A. Jager², S. Katz², J. Lococo², P. Le², B. Andrian², C. Zhao², D. Baker², T. Pawlowski², S. Bilke²; ¹US, ²CA/US
- 12:30 - 12:30 **164P - Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a phase I/II clinical trial in mCRPC patients**
M. Tan¹, S. Zhang¹, Z. Zhao¹, A. Wang¹, D. Cheung¹, P. Du¹, J. Yu¹, S. Jia², C. Guo³, Y. Tong³, K. Zhou³; ¹CA/US, ²US, ³CN
- 12:30 - 12:30 **165P - The frequency of primary cilia, CD8 α ; tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type**
J. Dvorak¹, B. Rosova², A. Filipova², D. Hadzi Nikolov², L. Dusek², A. Rozsypalova², J. Proks², I. Richter², B. Melichar², T. Buchler¹, R. Zachoal², R. Matej²; ¹4/CZ, ²CZ
- 12:30 - 12:30 **166P - Association of MMR protein expression and MMR gene mutations in Chinese colorectal cancer patients**
S. Wang, S. Zhang, Z. Zeng, Y. Ou, M. Han, J. Guo, D. Chen, X. Dong, J. Hu, G. Chirn, W. Shi, M. Yao; CN

- 12:30 - 12:30 **167P - Somatic and germline mutations of Chinese gastric cancer patients**
Y. Wang, W. Gu, Y. Zhang, K. Li, Z. Niu, Y. Zheng, Q. Cui, A. Wang, H. Chen, W. Shi, K. Wang, M. Yao; CN
- 12:30 - 12:30 **168P - Validation of the MammaTyper[®]; pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)**
P.A. Fasching¹, M. Laible¹, K. Weber¹, R.M. Wirtz¹, C. Denkert¹, K. Schlombs¹, S. Schmatloch¹, O. Camara¹, H.J. Lück¹, J. Huober¹, T. Karn¹, M. van Mackelenbergh¹, F. Marme¹, V. Müller¹, C. Schem², E. Stickeler¹, U. Sahin¹, S. Loibl¹, M. Untch¹; ¹DE, ²Schleswig-Holstein/DE
- 12:30 - 12:30 **169P - Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer**
E. Rofi, M. Del Re, C. Vivaldi, S. Crucitta, E. Arrigoni, G. Pasquini, S. Catanese, I. Pecora, G. Musettini, E. Vasile, A. Falcone, R. Danesi; IT
- 12:30 - 12:30 **170P - Ecological diversity indices as measurements of tumor heterogeneity correlates with clinical outcomes in late stage small cell lung cancer (SCLC)**
S. Yaung¹, L. Xi², C. Woestmann³, S. McNamara³, B. Hinzmann³, S. Froehler³, N. Tikoo², C. Ju², A. Balasubramanyam², H.-P. Adams³, M. Thomas³, F. Lasitschka³, M. Meister³, M. Schneider³, F. Herth³, T. Muley³, B. Wehnl³, J. Palma², X.M. Ma²; ¹US, ²CA/US, ³DE
- 12:30 - 12:30 **171P - MET exon 14 splicing mutation and its correlation with clinicopathological features in subjects with non-small cell lung cancer**
D. Katalinic, I. Aleric, A. Vcev; HR
- 12:30 - 12:30 **172P - Cancer stem cell markers in pancreatic ductal adenocarcinoma**
F. Aksoy, E. Kaya, U. Egeli, H.Z. Dunder, P. Tasar, S. aksoy, Y. Ozen, B. Tunca, G. Cecener, O. Yerci; TR
- 12:30 - 12:30 **173P - Tumor mutation burden assessment on FFPE samples using a targeted next-generation sequencing assay**
R. Chaudhary¹, D. Cyanam², V. Mittal³, W. Tom³, J. Au-Young³, C. Allen⁴, S. Sadis², F. Hyland³; ¹US, ²MI/US, ³CA/US, ⁴GB
- 12:30 - 12:30 **174P - Microsatellite instability-high (MSI-H) colorectal cancers with elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) signature represent a target population for immune checkpoint and DNA damaging therapies**
K.T. Tan, P.-N. Yu, S.-J. Chen, Y.-T. Liu, S.-C. Chang, M.-H. Chen; TW
- 12:30 - 12:30 **175P - Levels of circulating fibroblast growth factor (FGF) 23 and prognosis of cancer patients with bone metastasis**
A. Mansinho, A. Ferreira, S. Casimiro, I. Alho, I. Vendrell, A.L. Costa, R. Sousa, C. Abreu, C. Pulido, D. Macedo, T. Pacheco, L. Correia, L. Costa; PT

- 12:30 - 12:30 **176P - Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era**
N. Tsoukalas¹, E. Aravantinou¹, K. Tsapakidis¹, C. Giaginis¹, M. Tolia¹, I. Binas¹, P. Baxevanos¹, M. Galanopoulos¹, M. Kiakou¹, M. Tsiatas², I. Kostakis¹, C. Nikolaou¹, I. Litos¹, M. Lontos³, E. Tsiambas¹, I. Gioulbasanis¹, I. Sfiniadakis¹, A. Karameris¹, G. Kyrgias¹, S. Theocharis¹; ¹GR, ²Attica/GR, ³Attiki/GR
- 12:30 - 12:30 **177P - Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung**
S. Wang, H. Chen, J. Zhao, J. Zhong, J. Wang; CN
- 12:30 - 12:30 **178P - XmaI-RRBS DNA methylation screening resolves breast cancer epigenetic heterogeneity**
A. Tanas, T. Kekeeva, V. Sigin, E. Kuznetsova, E. Poddubskaya, I. Trotsenko, D. Zaletaev, V. Strelnikov; RU
- 12:30 - 12:30 **179P - Prognostic value of change in neutrophil-lymphocyte ratio during treatment with first-line anti-PD1 therapy in metastatic melanoma**
J. Soon¹, E. Blackley¹, M. Moore¹, L. Lim¹, H.L. Yeoh¹, M. Voskoboynik², A. Haydon¹; ¹VIC/AU, ²AU
- 12:30 - 12:30 **180P - A serum microRNA expression signature for radiosensitivity of non-small cell lung cancer**
L. Fan, B. Li; CN
- 12:30 - 12:30 **181P - Anti-tNASP antibodies as a diagnostic marker for malignant tumors**
O. Alekseev¹, K. Admire², J. Brogdon², B. Gorman², C. Davis², Z. Vaskalis²; ¹US, ²NC/US
- 12:30 - 12:30 **182TiP - EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors**
A. Italiano¹, O. Le Saux¹, F. André², T. Filleron³, D. Spaeth², P.-E. Heudel⁴, L. Albiges¹, T. Bachelot², A. Gonçalves², J.-Y. Pierga², F. Barlesi⁵, V. Boige², C. Lebbe⁶, L. Mortier², J.-S. Frenel¹, O. Tredan², M. Jimenez², F. Legrand², C. Fertet²; ¹CEDEX/FR, ²FR, ³CEDEX 3/FR, ⁴Cedex 08/FR, ⁵CEDEX 20/FR, ⁶CEDEX 10/FR
- 12:30 - 12:30 **183TiP - Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial**
M. Ignatiadis¹, M. Brandao¹, M. Maetens¹, N. Ponde¹, S. Martel², S. Drisis¹, I. Veys¹, S. Mazy¹, E. Bollue¹, P. Neven¹, F. Duhoux¹, J. Chapiro³, A. Awada¹, T. Besse-Hammer¹, M. Paesmans¹, M. Piccart¹, P. Vuylsteke¹, C. Sotiriou¹; ¹BE, ²CA, ³Cedex/FR
- 12:30 - 12:30 **Gynaecological cancers**

- 12:30 - 12:30 **944P - QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset**
K. Moore¹, A. Secord², M. Geller², D. Miller³, N. Cloven², G. Fleming⁴, A. Wahner Hendrickson², M. Azodi², P. DiSilvestro², A. Oza⁵, M. Cristea², J. Berek⁶, J. Chan², B. Rimel², Y. Li², K. Luptakova², R. Clark², U. Matulonis⁷, B. Monk²; ¹Oklahoma/US, ²US, ³TX/US, ⁴IL/US, ⁵CA, ⁶CA/US, ⁷MA/US
- 12:30 - 12:30 **945P - A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)**
R. O'Cearbhaill¹, A. Wolfer², P. Disilvestro³, D. O'Malley³, P. Sabbatini¹, L. Shohara¹, P. Schwarzenberger⁴, T. Ricciardi¹, M. Macri¹, A. Ryan¹, R. Venhaus¹, J. Bryan³, P. Wong¹, K. Homicsko⁵, L. Kandalaft², S. Rusakiewicz², A. Harari², B. Monk³, G. Coukos²; ¹NY/US, ²CH, ³US, ⁴LA/US, ⁵Vaud/CH
- 12:30 - 12:30 **946P - Brain metastases in primary ovarian cancer: Real-world data**
E. Ratner¹, M. Bala², M. Louie-Gao², S. Hazard², P. Brastianos²; ¹CT/US, ²US
- 12:30 - 12:30 **947P - Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3**
D. Lorusso¹, R. Coleman², A. Oza³, C. Aghajanian⁴, A. Oaknin⁵, A. Dean⁶, N. Colombo¹, J. Weberpals³, A. Clamp⁷, G. Scambia¹, A. Leary⁸, R. Holloway⁹, M. Amenedo Gancedo⁵, P. Fong¹⁰, J. Goh¹¹, D. O'Malley¹², S. Banerjee⁷, S. Goble¹², T. Cameron⁷, J. Ledermann¹³; ¹IT, ²TX/US, ³Ontario/CA, ⁴NY/US, ⁵ES, ⁶WA/AU, ⁷GB, ⁸FR, ⁹FL/US, ¹⁰NZ, ¹¹QLD/AU, ¹²US, ¹³London/GB
- 12:30 - 12:30 **948P - Intraperitoneal chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT)**
M. Jimenez-Heredia¹, J.A. Perez Fidalgo², M. Morales Suarez-Varela¹, J. Sanchis¹, M. Aranda¹, A. Cervantes²; ¹ES, ²Valencia/ES
- 12:30 - 12:30 **949P - Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study**
U. Matulonis¹, K. Moore², L. Martin³, I. Vergote⁴, C. Castro¹, L. Gilbert⁵, K. Malek⁶, M. Birrer¹, D. O'Malley⁶; ¹MA/US, ²Oklahoma/US, ³PA/US, ⁴BE, ⁵CA, ⁶US
- 12:30 - 12:30 **950P - Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy**

A. Oza¹, D. Cibula², A. Oaknin³, C. Poole⁴, R. Mathijssen⁵, G. Sonke⁵, N. Colombo⁶, J. Špaček², P. Vuylsteke⁷, H. Hirte¹, J. Pfisterer⁸, M. Plante⁹, L. Hanker⁸, A. Fielding¹⁰, V. Haddad¹⁰, J. Chmielecki¹¹, M. Friedlander¹²; ¹Ontario/CA, ²CZ, ³ES, ⁴West Midlands/GB, ⁵NL, ⁶IT, ⁷BE, ⁸DE, ⁹CA, ¹⁰GB, ¹¹US, ¹²NSW/AU

- 12:30 - 12:30 **951P - A phase Ib study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer**
S. Fu¹, B. Corr², E. Hamilton³, R. Burger⁴, R. Wenham⁵, R. Naumann⁶, R. Stagg⁷, K. Moore⁸; ¹TX/US, ²CO/US, ³TN/US, ⁴PA/US, ⁵FL/US, ⁶NC/US, ⁷CA/US, ⁸Oklahoma/US
- 12:30 - 12:30 **952P - Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial**
J. KORACH¹, G. Freyer², S. Banerjee³, R. Asher⁴, J. Cosin⁵, A. Oza⁶, A.M. Poveda Velasco⁷, M. Di Napoli⁸, C. Scott⁴, M. Lapresa⁸, F. Heitz⁹, K. Takehara¹⁰, G. Sonke¹¹, S. Tjulandin¹², J.-W. Kim¹³, R. Hegg¹⁴, I. Vergote¹⁵, S. Turner³, E. Pujade-Lauraine¹⁶; ¹IL, ²CEDEX/FR, ³GB, ⁴AU, ⁵CT/US, ⁶Ontario/CA, ⁷ES, ⁸IT, ⁹DE, ¹⁰JP, ¹¹NL, ¹²RU, ¹³KP, ¹⁴SP/BR, ¹⁵BE, ¹⁶CEDEX 4/FR
- 12:30 - 12:30 **953P - The impact of lymph node dissection on high risk versus low risk endometrial cancer**
C. ZHANG, A. Soochit, J. Liu; CN
- 12:30 - 12:30 **954P - HOXA9 methylation in circulating tumor DNA as a prognostic biomarker in BRCA-mutated ovarian cancer patients treated with PARP inhibitor**
M. Rusan, R. Fredslund Andersen, A. Jakobsen, K. Steffensen; DK
- 12:30 - 12:30 **955P - Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected endometrial cancer (EC) patients**
C. Orbegoso Aguilar, K. Vroobel, S. Lalondrelle, A. Taylor, M. Nobbenhuis, A. Attygalle, S. Banerjee, A. George; GB
- 12:30 - 12:30 **956P - A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer**
R. Morgan¹, G. Jayson¹, S. Banerjee¹, A. Clamp¹, A. Lyon¹, W.D. Ryder¹, R. Hutson¹, N. Mescallado¹, C. Orbegoso Aguilar¹, S. Taylor¹, J. Tugwood¹, M. Hall², C. Dive¹, G. Rustin²; ¹GB, ²Middlesex/GB
- 12:30 - 12:30 **957P - Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy**
J.-Y. Lee, S. Paik; KR
- 12:30 - 12:30 **958P - Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts**

D. Rischin¹, M. Gil-Martin², A. González-Martín², I. Brana², J. Hou³, D. Cho³, G. Falchook⁴, S. Formenti⁴, S. Jabbour⁵, K. Moore⁶, A. Naing⁷, K. Papadopoulos⁷, J. Baranda⁸, A. Weise⁹, M. Fury⁴, M. Feng⁴, J. Li⁴, I. Lowy⁴, M. Mathias⁴; ¹AU, ²ES, ³NY/US, ⁴US, ⁵NJ/US, ⁶OK/US, ⁷TX/US, ⁸KS/US, ⁹MI/US

- 12:30 - 12:30 **959P - Molecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs)**
S. Scholl¹, L. De Koning², M. Popovic³, D.L.R. Anne¹, A. Floquet⁴, E. Berns⁵, G. Kenter⁵, A. Kereszt⁶, E. Girard¹, H. von der Leyen⁷, S. Dureau¹, V. Fourchette¹, R. Rouzier¹, M. Kamal¹, R. Consortium¹; ¹FR, ²CEDEX 10/FR, ³RS, ⁴CEDEX/FR, ⁵NL, ⁶HU, ⁷DE
- 12:30 - 12:30 **960P - Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma: Safety, clinical activity and immunologic correlates**
C.H. Choi, H.J. Choi, J.-W. Lee, E.-S. Kang, D. Cho, Y.-M. Kim, D. Kim, H. Seo, M. Park, W. Kim, T. Oh, C.-Y. Kang, B.-G. Kim; KR
- 12:30 - 12:30 **961P - Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance**
K. Thein¹, A. Sultan², M. Zaw³, M. Han², R. Yendala², M. Zin³, S. Awasthi², N. D'Cunha², F. Hardwicke², C. Jones²; ¹US, ²TX/US, ³NY/US
- 12:30 - 12:30 **962P_PR - Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey**
T. de La Motte Rouge¹, S. Couraud², F. Eisinger³, M. Roupert¹, L. Brignoli-Guibaudet¹, C. Lhomel¹, L. Greillier¹, J. Viguier¹, J.F. Morère¹; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR
- 12:30 - 12:30 **963P - A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort**
N. Concin¹, I. Vergote², U. Lassen³, Y. Drew⁴, J.-P. Machiels², H.-T. Arkenau⁴, M. Forster⁴, R. Jones⁴, M. Johnson⁵, B. Slomovitz⁶, J. Spicer⁴, N. Cornez², C. Gennigens², R. Coleman⁷, K. Windfeld³, S. Ghatta¹, R. Rangwala⁸, D. Hong¹; ¹US, ²BE, ³DK, ⁴GB, ⁵TN/US, ⁶FL/US, ⁷TX/US, ⁸NJ/US
- 12:30 - 12:30 **964P - Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer**
E.I. Braicu¹, J. Sehouli¹, R. Richter¹, I. Vergote², N. Concin², E. van Nieuwenhuysen², P. Achimas³, A. Berger⁴, B. Fetica³, S. Mahner¹, J. Glajzer¹, A. Papadia⁵, L. Woelber¹, M.L. Gasparri⁵, A. Vanderstichele², P. Benedetti Panici⁶, M. Mueller⁵, I. Ruscito¹, J. Zimmer¹, H. Woopen¹; ¹DE, ²BE, ³RO, ⁴AT, ⁵CH, ⁶IT
- 12:30 - 12:30 **965P - Prognostic factors in patients with uterine leiomyosarcoma: A multiinstitutional retrospective study from the Japanese gynecologic oncology group**

K. Takehara¹, N. Yamashita¹, T. Motohashi¹, K. Harano², T. Nakanishi¹, H. Tokunaga¹, N. Susumu¹, Y. Ueda¹, Y. Yokoyama¹, Y. Watanabe¹, R. Watanabe¹, N. Teramoto¹, H. Tsuda¹, T. Saito¹; ¹JP, ²Kanagawa/JP

- 12:30 - 12:30 **966P - Screening for inherited cancer syndromes in Chinese patients with endometrial cancer**
H. Wang¹, W. Tian¹, R. Bi¹, Y. Ren¹, H. He¹, S. Shi¹, B. Shan¹, Q. Wang²; ¹CN, ²CEDEX/FR
- 12:30 - 12:30 **967P - Clinical relevance of circulating MACC1 and S100A4 transcripts in serum of ovarian cancer patients**
P. Wimberger, T. Link, P. Herrmann, D. Kobelt, Y. Vassileva, F. Kerstin, J. Kuhlmann, U. Stein; DE
- 12:30 - 12:30 **968P - Outcomes of ovarian clear cell carcinoma (OCCC) of the Vall d&&**
F. Amair Pinedo, L. Fariñas-Madrid, V. Rodriguez Freixinos, F.J. Ros Montaña, G. Villacampa, R. Dienstmann, A. Oaknin; ES
- 12:30 - 12:30 **969P - A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance**
K. Thein¹, A. Sultan², M. Zaw³, M. Han², A. Hein³, H. Aung³, S. Awasthi², C. Jones², F. Hardwicke², N. D'Cunha²; ¹US, ²TX/US, ³NY/US
- 12:30 - 12:30 **970P - Evaluation of chemotherapy response score and lymphocytic infiltration as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy**
M. Liontos¹, M. Sotiropoulou², M. Kaparelou², K. Tzannis², G. Tsironis¹, A. Kyriazoglou³, A. Tsiara², R. Zakopoulou⁴, K. Koutsoukos¹, F. Zagouri², D. Vlachos², N. Thomakos², D. Haidopoulos², A. Rodolakis², M. Dimopoulos², A. Bamias¹; ¹Attiki/GR, ²GR, ³Athens/GR, ⁴Attica/GR
- 12:30 - 12:30 **971P - Embryonic protein nodal as a novel marker of progression and drug resistance in ovarian cancer**
O. Bilyk¹, L. Lee², N. Le³, L. Cook⁴, M. Koebel¹, L. Postovit²; ¹CA, ²AB/CA, ³BC/CA, ⁴NM/US
- 12:30 - 12:30 **972P - Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)**
P.E. Brachet¹, F. Joly Lobbedez², M. Fabbro², A. Leary¹, J. Medioni¹, P. Follana³, A.F. Lesoin⁴, J.-S. Frenel⁴, S. Abadie Lacourtoisie¹, A. Floquet⁴, L. Gladieff⁵, B. You⁴, C. Gavaille⁴, E. Kalbacher⁴, M. Briand¹, P.A. Just¹, C. Blanc-Fournier¹, F. Giffard¹, B. Clarisse², L. Poulain¹; ¹FR, ²CEDEX 5/FR, ³CEDEX 2/FR, ⁴CEDEX/FR, ⁵CEDEX 3/FR
- 12:30 - 12:30 **973P - Expression of CD4, CD8 and Foxp3 and its clinical significance in neoadjuvant chemotherapy for locally advanced cervical cancer**

X. Yin, CN

- 12:30 - 12:30 **974P - Clinical study on the efficacy of apatinib treatment for advanced ovarian cancer after second-line chemotherapy failure**
S. Sun, D. Zhai, C. Yu; CN
- 12:30 - 12:30 **975P - Clear cell ovarian cancer (CCOC): Predicting risk of relapse (ROR)**
M.-J. Devlin¹, J. Ledermann², M. Lockley¹, N. Wilkinson¹, J. McDermott¹, R. Kristeleit¹, R. Miller¹; ¹GB, ²London/GB
- 12:30 - 12:30 **976P - Comparison of PARPi with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: A network meta-analysis**
Y. Feng, J. Liu, H. Huang, C. ZHANG, T. Wan, C. Tong, T. Deng, H. Tu, Y. Huang, G. Liu, Q. Huang, Z. Liu; CN
- 12:30 - 12:30 **977P - The role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer**
M. Nikolaou, N. Ziras, I. Athanasiadis, A. Ardavanis, M. Vaslamatzis, N. Kentepozidis, P. Makrantonakis, A. Christopoulou, V. Michalaki, A. Polizos, C. Emmanouilidis, V. Georgoulas; GR
- 12:30 - 12:30 **978P - Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)**
A. Nogueira-Rodrigues, A. de Melo, A. Calabrich, E. Cronenberger, K. Torres, F. Damian, R. Cossetti, C. De Azevedo, A. da Fonseca, Y. Nerón, J. Nunes, A. Lopes, F. Thomé, R. Leal, G. Borges, P.R. Nunes Filho, F. Zaffaroni Caorsi, R. Freitas, G. Werutsky, F. Maluf; BR
- 12:30 - 12:30 **979P - Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort**
J. Chan, S.H. Tan, T.W. Lim, T. Tan, W.Y. Chay, E. Lim, L.T. Soh, S.L. Lim, J. Chia; SG
- 12:30 - 12:30 **980P - Genomic characterization of vulvar squamous cell carcinoma**
K. Prieske, M. Alawi, S.A. Joosse, K. Eylmann, E. Burandt, B. Schmalfeldt, L. Oliveira-Ferrer, L. Woelber; DE
- 12:30 - 12:30 **981P - Economic and humanistic burden of cervical cancer in the United States**
C. Nwankwo, R. Shah, Y. Kwon, S. Corman; US
- 12:30 - 12:30 **982P - Risk of fatigue and neuropathy in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials**
V. Ruiz-Schutz¹, L. Gomes¹, C. Oliveira¹, R. Mariano¹, D. Almeida¹, J. Pimenta¹, G. Dal Molin², F. Kater³, R. Yamamura³, F. Maluf¹, F. Schutz³; ¹BR, ²TX/US, ³SP/BR
- 12:30 - 12:30 **983P - Risk of cancer associated death in younger vs older patients with FIGO stage I endometrial cancer**

J. Ko¹, B. Lester², G. Bowering³, C. Rugayan³, I. Ghement², K. Aalok³; ¹British Columbia/CA, ²CA, ³BC/CA

- 12:30 - 12:30 **984P - Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)**
M. Hall¹, G. Bertelli², L. Li², C. Green², S. Chan², C.C. Yeoh², J. Hasan², A. Ograbek², T. Perren³; ¹Middlesex/GB, ²GB, ³Yorkshire/GB
- 12:30 - 12:30 **985P - Prolonged survival (SV) associated with pulmonary metastasectomy (PM) for carcinomas of the cervix (CC)**
J. Corona-Cruz¹, A. Castillo-Castañon¹, C. Deneken², L. Ramirez-Tirado¹, A. Gonzalez-Enciso¹, D. Gallardo-Rincon¹, E. Jimenez-Fuentes¹, O. Arrieta¹; ¹MX, ²Tlalpan. D.F./MX
- 12:30 - 12:30 **986P - Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200mg/day starting-dose cohort**
J. Gallagher¹, K. Heap², S. Carroll²; ¹US, ²SC/US
- 12:30 - 12:30 **987P - Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study**
S. Pignata¹, G. Scambia¹, T. Mazzei¹, M. Arruti Barbia², E. Naglieri¹, L.M. de Sande²; ¹IT, ²ES
- 12:30 - 12:30 **988P - Benefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM)**
F.J. Ros Montaña, V. Rodriguez Freixinos, L. Fariñas Madrid, F. Amair Pinedo, F. Ruiz-Pace, E. Garralda, R. Dienstmann, A. Oaknin; ES
- 12:30 - 12:30 **989P - Identification research and application for protein phosphorylation modification sites in human ovarian carcinoma**
X. Zhan, N. Li; CN
- 12:30 - 12:30 **990P - Enhancing prognosis prediction using nodal SUVmax and HPV status in cervical squamous cell carcinoma**
S.Y. Jeong, G.O. Chong, C.M. Hong; KR
- 12:30 - 12:30 **991P - Clinical characteristics of ovarian cancer relapse in BRCA1/2 germ-line mutation carriers and non-carriers**
A. Sokolenko, T. Gorodnova, A. Ivantsov, I. Berlev, E. Imyanitov; RU
- 12:30 - 12:30 **992P - Phase Ib study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer**
K. Broekman, A. Reyners, D. Touw, M. Hof, M. Jalving; NL

- 12:30 - 12:30 **993P - Individual and familial phenotype in hereditary ovarian cancer**
M.B. Mira, I. Miguel, S. Fragoso, A. Opinião, A.C. Luís, A. Clara, S. Bento, P. Machado, S. Santos, P. Rodrigues, J. Parreira, F. Vaz; PT
- 12:30 - 12:30 **994P - Role of FGFR2 amplification in prognosis of patients with ovarian cancer**
A. Tyulyandina, I. Demidova, M. Gikalo, S. Tjulandin, I. Tsimafeyeu; RU
- 12:30 - 12:30 **995P - MONITOR VII: Treatment strategies of low grade ovarian carcinomas &&**
S. Alavi, P. Harter, R. Richter, M. Keller, G. Oskay-Özcelik, A. Mustea, B. Schmalfeldt, P. Wimberger, F. Trillsch, S. Mahner, M. Klar, U. Wagner, R. Chekerov, A. du Bois, J. Sehouli; DE
- 12:30 - 12:30 **996P - The ability of whole body SUVmax on F-FDG PET/CT in predicting suboptimal cytoreduction at primary debulking surgery in advanced ovarian cancer**
G.O. Chong, S.Y. Jeong, S.-W. Lee; KR
- 12:30 - 12:30 **997P - Brain metastasis in ovarian cancer patients**
A.A. da Costa¹, E. Dos Santos², L. de Brot¹, A. Ribeiro¹, D. Cotrim¹, N. Carvalho Pandolfi¹, M. Cesca¹, M. Chen¹, G. Baiocchi¹; ¹BR, ²SP/BR
- 12:30 - 12:30 **998TiP - Pamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China**
X. Wu¹, J. Wang¹, Q. Zhou¹, T. Gu¹, K. Zhang², J. Liang¹, S. Mu³, R. Ge¹, H. Yang¹, V. Huang², R. Brachmann², L. Wang¹, M. Li¹; ¹CN, ²CA/US, ³NJ/US
- 12:30 - 12:30 **999TiP - OVARIO: A single-arm, open-label phase II study of maintenance therapy with niraparib + bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo)**
M. Hardesty¹, J. Hope¹, T. Krivak², J. Chen², M. Wainszelbaum², D. Gupta², D. Richardson²; ¹AK/US, ²US
- 12:30 - 12:30 **1000TiP - OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)**
A.M. Poveda Velasco¹, R. Davidson², C. Blakeley², A. Milner²; ¹ES, ²GB
- 12:30 - 12:30 **1001TiP - A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer**
A. Wahner Hendrickson¹, B. Costello¹, A. Jewell², V. Kennedy³, G. Fleming⁴, B. Corr⁵, S. Taylor⁶, J. Lea⁷, J. Reid¹, E. Swisher¹, D. Satele¹, J. Allred¹, J. Lensing¹, S.P. Ivy⁸, C. Erlichman¹, A.A. Adjei⁹, S. Kaufmann¹; ¹US, ²KS/US, ³CA/US, ⁴IL/US, ⁵CO/US, ⁶PA/US, ⁷TX/US, ⁸MD/US, ⁹MN/US

- 12:30 - 12:30 **1002TiP - BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer**
N. Colombo¹, O. Nicoletto¹, P. Benedetti Panici¹, G. Tognon¹, A.A. Lissoni¹, A. Bologna¹, F. Tomao¹, R. Fossati¹, F. Tettamanzi¹, E. Rulli¹, F. Galli¹, M.F. Alvisi¹, V. Torri², E. Biagioli¹; ¹IT, ²NA
- 12:30 - 12:30 **1003TiP - Neoadjuvant chemotherapy and radical surgery versus chemoradiation for stage IB2, IIA2 e IIB cervical cancer: A randomized controlled trial**
P. Reis Filho¹, J. Andrade¹, M. Batista¹, C. Sousa¹, T. Oliveira¹, G. Arruda¹, T. Oliveira¹, F. Gabrielli¹, M.L. Genta¹, A.M. Poveda Velasco², M. Estevez Diz¹, F.J. Candido Dos Reis¹; ¹BR, ²ES
- 12:30 - 12:30 **Haematological malignancies**
- 12:30 - 12:30 **1017P - Estimating the incidence of cryptogenic organising pneumonia in chronic lymphocytic leukaemia patients: A real-world cohort study**
I. Faghmous, H. Ramroth, C. Aguilar, A. Van Troostenburg, P. Badyal; GB
- 12:30 - 12:30 **1018P - Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death**
C. Sortais¹, A. Lok¹, T. Gastinne¹, B. Mahé¹, V. Dubruille¹, N. Blin¹, S. Howlett², A. Tabah², P. Arnaud³, A. Moreau¹, P. Moreau¹, C. Leux¹, S. Le Gouill¹; ¹FR, ²NJ/US, ³CEDEX 18/FR
- 12:30 - 12:30 **1019P - Impact of genetic polymorphisms on prognosis and survival of diffuse large B-cell lymphoma**
O. Novosad, I. Pastushenko, T. Skrypets, I. Tytorenko, T. Kadnikova, O. Skachkova, O. Gorbach, N. Svergun, N. Khranovska, I. Kriachok; UA
- 12:30 - 12:30 **Clinical-radiological features of Methotrexate induced sub-acute leukoencephalopathy in patients with Acute lymphoblastic leukemia: Incremental value of diffusion weighted magnetic resonance imaging.**
T. Vaidya, A. Mahajan, H. Jain, V. Simha, M. Sengar, S. Kumar; IN
- 12:30 - 12:30 **1021P - Long term treatment outcome of patients with refractory or relapsed Hodgkin's lymphoma in the anthracycline era: A single-center intention-to-treat analysis**
T. Bogatyreva, A. Terekhova, S. Shklyayev, V. Pavlov, N. Falaleeva; RU
- 12:30 - 12:30 **1022P - Population-based use of intravenous bisphosphonates in patients newly diagnosed with symptomatic multiple myeloma in Denmark in 2005-2015: Impact of patient characteristics**
V. Ehrenstein¹, A. Ording¹, S. Ulrichsen¹, I. Andersen¹, A. Seesaghur², C. Helleberg¹, T. Silkjær¹, R. Hernandez³, D. Niepel⁴, N. Abildgaard¹; ¹DK, ²GB, ³CA/US, ⁴CH

- 12:30 - 12:30 **1023P - Role of liposomal doxorubicin as a first line agent with VTd regimen in newly diagnosed multiple myeloma**
M. Khanderia, G. Badarkhe, S. Bj, R. Naik; IN
- 12:30 - 12:30 **1024P - The β_2 -microglobulin is associated with the prognosis in patients with peripheral t-cell lymphoma, not otherwise specified**
B.S. Sohn, S.-N. Lim, J. Kim, D.H. Yoon, S. Kim, J. Huh, S.-E. Park, Y.J. Yuh, C. Suh; KR
- 12:30 - 12:30 **1026P - Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: A propensity score-matched multi-institutional cohort study**
S. dote, K. Ito, S. Itakura, T. Yasu, D. Hira, S. Noda, S. Yamada, Y. Kobayashi, T. Terada; JP
- 12:30 - 12:30 **1027P - The significance of FMS-like tyrosine kinase 3 surface receptor expression in acute myeloblastic leukemia and precursor B-acute lymphoblastic leukemia patients**
S. Al Hassanin, I. Ahmedy; EG
- 12:30 - 12:30 **1028P - Prognostic factors of clinical use in acute myeloid leukemia**
P. Chorão, N. Tavares, E. Aguiar, M. Amorim, P. Gomes, F. Príncipe, J. Guimarães; PT
- 12:30 - 12:30 **1029P - Frequency and clinical impact of compound mutation in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitor**
S. BONECKER, M. Carneiro, M. Bonamino, I. Zalcborg; BR
- 12:30 - 12:30 **1030P - Poor outcome of double-protein expressor diffuse large B-cell lymphoma**
E. Kharchenko, T. Semiglazova, A. Artemeva, V. Kushnarev, P. Shilo; RU
- 12:30 - 12:30 **1031P - Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil**
S.-N. Lim, B.S. Sohn, H.-J. Shin, C. Suh, W.S. Kim, W.S. Lee, J.S. Kim; KR
- 12:30 - 12:30 **1032P - The impact of serum microRNA-21 on outcome of diffuse large B-cell lymphoma patients**
S. Gohar, S. Kamal Eldin, F. El-Bassal, A. Shehata, A. Azzam, E. Tawfik, S. Al Hassanin; EG
- 12:30 - 12:30 **1033P - Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: Subgroup analysis from the BELA trial**
H. Malhotra¹, A. Maru¹, N. Khattry¹, M. Ramanan¹, E. Leip², R. Crescenzo³, C. Gambacorti-Passerini⁴, J. Cortes²; ¹IN, ²US, ³PA/US, ⁴IT
- 12:30 - 12:30 **1034P - A prospective multicenter study of primary breast lymphoma in the rituximab era: Prognostic implication of beta 2 microglobulin and interleukin-6 & interlukin-10**

L. Ezz Elarab¹, E. Hamada¹, A. Mostafa¹, A. Saber¹, M. Abdel-Gawad¹, R. Haggag², H. Darwish¹, S. Elhassanin¹, M. Swellam¹; ¹EG, ²ElSharkia/EG

- 12:30 - 12:30 **1035P - Experience in treatment of newly diagnosed multiple myeloma patients with renal failure required dialysis**
S. Semochkin, E. Zhelnova, E. Misyurina, T. Tolstykh, N. Arkhipova, E. Baryakh, E. Grishina, E. Karimova, O. Kochneva, E. Mavrina, Y. Polyakov, E. Yaskova; RU
- 12:30 - 12:30 **1036P - Immunohistochemical (IHC) classification of DLBCL into CGB and non-CGB subtypes to predict survival after chemoimmunotherapy at the Virgen de la Victoria University Hospital**
L. Galvez Carvajal, C. Quero Blanco, M. Robles Lasarte, I. Moreno Perez, L. Vicioso, I. Ramos Garcia, C. Bandera Lopez, J. Baena Espinar, C. Ithurbisquy, E. Alba; ES
- 12:30 - 12:30 **1037P - Quality of life evaluation in acute leukemia patients receiving induction chemotherapy**
T. Lymanets, I. Skrypnyk, G. Maslova, I. Gusachenko; UA
- 12:30 - 12:30 **1038P - PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin lymphoma**
T. Skrypets¹, O. Novosad¹, I. Pastushenko¹, T. Kadnikova¹, O. Gorbach¹, Y. Kmetyuk¹, O. Karpova¹, L. Mykhalska¹, E. Lukjanec¹, V. Kozlov¹, N. Novikov¹, O. Oliinichenko¹, N. Kostiukova¹, O. Tkachenko¹, O. Karnabeda², V. Stratienko¹, I. Kriachok¹; ¹UA, ²Kiev region/UA
- 12:30 - 12:30 **1039P - Assessment to predict survival and risk of progression in patients with newly multiple myeloma in different age groups**
I. Kriachok, O. Novosad, K. Ulianchenko, T. Skrypets, T. Kadnikova; UA
- 12:30 - 12:30 **1040P - Impact of bisphosphonate and anti-myeloma therapy on bone turnover markers in multiple myeloma**
A. JANDIAL, S. H J, K. Mishra, S. Bhadada, A. Sood, M. Prakash, A. Meshram, R. Sandal, D. Lad, R. Aggarwal, G. Prakash, S. Vikas, A. Khadwal, S. Kumari, N. Varma, S. Varma, P. Malhotra; IN
- 12:30 - 12:30 **1041P - Assessment of bleeding risk by sonoclot in acute lymphoblastic leukemia**
K. Mishra, A. JANDIAL, A. Meshram, R. Sandal, D. Lad, G. Prakash, A. Khadwal, R. Dhiman, N. Varma, S. Varma, P. Malhotra; IN
- 12:30 - 12:30 **1042P - Clinically actionable mutations identified in Korean patients with high-risk acute lymphoblastic leukemia**
K.-J. Park, I.-S. Kim; KR
- 12:30 - 12:30 **1043TiP - A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)**
C.H. Ng¹, S. Ting², W. Hwang¹, A. Bajel³, R. Eek³, M. McHale¹, H.-J. Shih⁴, N. McIntyre¹, J. Kwek¹, B. Lindmark¹; ¹SG, ²AT, ³AU, ⁴TW

- 12:30 - 12:30 **Immunotherapy of cancer**
- 12:30 - 12:30 **1143P - Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)**
J.R. Hecht¹, A. Naing², G. Falchook³, M. Patel⁴, R. Aljumaily⁵, D. Wong³, K. Autio⁶, Z. Wainberg³, M. Javle², J. Bendell⁷, S. Pant⁵, A. Hung¹, M. Oft¹, J. Leveque¹, K. Papadopoulos²; ¹CA/US, ²TX/US, ³US, ⁴MN/US, ⁵OK/US, ⁶NY/US, ⁷TN/US
- 12:30 - 12:30 **1144P - Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors**
E. Garon¹, D. Wong², J. Schneider³, R. Aljumaily⁴, W.M. Korn², M. Patel⁵, K. Autio³, K. Papadopoulos⁶, A. Naing⁶, N. Gabrail⁷, P. Munster², J. Goldman¹, A. Hung¹, M. Oft¹, J. Leveque¹, D. Spigel⁸; ¹CA/US, ²US, ³NY/US, ⁴OK/US, ⁵MN/US, ⁶TX/US, ⁷OH/US, ⁸TN/US
- 12:30 - 12:30 **1145P - Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy**
A. Naing¹, K. Autio², G. Falchook³, F. Meric-Bernstam¹, J. Litton³, N. Ibrahim¹, A. Hung⁴, M. Oft⁴, J. Leveque⁴, M. Patel⁵; ¹TX/US, ²NY/US, ³US, ⁴CA/US, ⁵MN/US
- 12:30 - 12:30 **1146P - Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy**
K. Autio¹, A. Naing², A. Hung³, M. Oft³, J. Leveque³, G. Falchook⁴; ¹NY/US, ²TX/US, ³CA/US, ⁴US
- 12:30 - 12:30 **1147P - Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers**
M. Wermke¹, J. Alt¹, J. Kauh², J. Back³, Y. Salhi², V. Reddy², M. Barve⁴, S. Ochsenschreier¹; ¹DE, ²NJ/US, ³CH, ⁴TX/US
- 12:30 - 12:30 **1148P - A phase Ia study of a personalized TSA-CTL (tumor specific antigen-induced cytotoxic T lymphocytes) therapy in metastatic melanoma**
B. Li, S. Qiu; CN
- 12:30 - 12:30 **1149P - Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors**
A. Spira¹, K. Chung², A. Patnaik¹, A. Tolcher³, M. Blaney⁴, A. Parikh⁴, A. Reddy⁴, W. Henner⁴, M. McDevitt⁴, D. Afar⁴, J. Powderly⁵; ¹US, ²SC/US, ³TX/US, ⁴CA/US, ⁵NC/US
- 12:30 - 12:30 **1150P - Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study**

R. Xu¹, F.H. Wang², F.J. Feng², Q. Li², N. Xu², X.C. Hu², W.J. Liao², Y. Jiang², X. Lin², Q.Y. Zhang², X.L. Yuan², H.X. Huang², Y. Chen², G.H. Dai², J.H. Shi², L. Shen², C. Ren², H. Wu², H. Feng², S. Yao²; ¹Guangdong/CN, ²CN

- 12:30 - 12:30 **1151P - Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study**
M. Pishvaian¹, G. Weiss¹, G. Falchook¹, N. Yee¹, M. Gil-Martin², S. Shahda¹, V. Moreno², I. Brana², M. Crittenden¹, S. Formenti¹, R. Al-Rajabi¹, K. Papadopoulos³, E. Stankevich¹, M. Feng¹, J. Li¹, M. Mathias¹, G. Kroog¹, I. Lowy¹, M. Fury¹; ¹US, ²ES, ³TX/US
- 12:30 - 12:30 **1152P - Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors**
B. Glisson¹, R. Leidner¹, R. Ferris², J. Powderly³, N. Rizvi⁴, B. Keam⁵, R. Schneider⁶, S. Goel¹, J. Ohr², Y. Zheng⁷, S. Eck⁷, M. Gribbin⁷, D. Townsley⁷, V. Chiou⁷, S. Patel⁸; ¹US, ²PA/US, ³NC/US, ⁴NY/US, ⁵KR, ⁶TX/US, ⁷MD/US, ⁸CA/US
- 12:30 - 12:30 **1153P - Autologous dendritic-cell vaccine based on cancer-testis antigens &&**
N. Pipia, I. Baldueva, T. Nekhaeva, A. Novik, A. Danilova, N. Avdonkina, S. Protsenko, Y. Komarov, D. Giridyuk, A. Oganessian, A. Belyaev; RU
- 12:30 - 12:30 **1154P - A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors**
C. Denlinger¹, J. Infante², R. Aljumaily³, A. Naing⁴, A. Chintakuntlawar⁵, N. Rizvi⁶, H. Ross⁷, M. Gordon⁷, R. Kumar⁸, M. Ma⁸, L. Yan⁹, P. Vicini¹⁰, N. Standifer⁹, J. Cann⁸, A. Perera¹⁰, N. Durham⁸, S. Krishnan⁸, A. Balmanoukian⁹; ¹US, ²TN/US, ³OK/US, ⁴TX/US, ⁵MN/US, ⁶NY/US, ⁷AZ/US, ⁸MD/US, ⁹CA/US, ¹⁰GB
- 12:30 - 12:30 **1155P - Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8&&**
A.-M. Tsimberidou¹, H. Ma¹, C. Stewart², O. Schoor³, D. Maurer³, R. Mendrzyk³, A. Satelli², J. Fritsche³, G. Stephens¹, A. Mohamed¹, P. Hwu¹, C. Yee², C. Reinhardt³, T. Weinschenk³, K. Gharpure¹, A. Stungis¹, D. Vining¹, H. Singh¹, S. Walter¹, B. Andersson¹; ¹US, ²TX/US, ³DE
- 12:30 - 12:30 **1156P - Initial safety assessment of MAGE-A4 SPEAR T-cells**
D. Hong¹, M. Butler², M. Johnson³, A. Olszanski¹, E. Norry⁴, E. Van Winkle⁴, K. Chagin¹, R. Amado⁴; ¹US, ²CA, ³TN/US, ⁴PA/US
- 12:30 - 12:30 **1157P - Phase I trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms**
J. Spicer, V. Kwatra, C. Verma, K. Ioannou, R. Goldstein, T. Brier, J. Eremin, N. Zareian, L. Walker, D. Lobo, F. Farzaneh, O. Eremin; GB

- 12:30 - 12:30 **1158P - Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer**
C. Drescher¹, K. Moore², J. Liu³, D. O'Malley⁴, E. Wang⁴, J. Wang⁴, V. Subbiah⁵, B. Wilky⁴, G. Yuan⁴, C. Dupont⁴, A. Gonzalez⁴, D. Savitsky⁴, S. Coulter⁴, O. Shebanova⁴, E. Dow⁴, W. Ortuzar³, J. Buell⁴, R. Stein⁴, H. Youssoufian⁴; ¹WA/US, ²Oklahoma/US, ³MA/US, ⁴US, ⁵TX/US
- 12:30 - 12:30 **1159P - Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer**
C.-C. Lin¹, M. Taylor², V. Boni³, P. Brunsvig⁴, S. Geater⁵, S. Salvagni⁶, P. Garrido Lopez³, M. Özgüroğlu⁷, V. Sriuranpong⁵, S. Ponce Aix³, P. Ascierto⁶, A. Fasolo⁶, A. Sezer⁷, D. Kowalski⁸, J. Faris⁹, S. Cameron⁹, J. Mataraza⁹, H. Wu², V. Antona¹⁰, M. Ochoa de Olza³; ¹TW, ²US, ³ES, ⁴NO, ⁵TH, ⁶IT, ⁷TR, ⁸PL, ⁹MA/US, ¹⁰CH
- 12:30 - 12:30 **1160P - Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors**
A. El-Khoeiry¹, L. Siu², N. Azad³, I. Walters³, L. Bender⁴, L. Kamen⁴, A. Olszanski³; ¹CA/US, ²CA, ³US, ⁴CT/US
- 12:30 - 12:30 **1161P - OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments**
M. Fabre¹, C. Ferrer¹, S. Dominguez-Hormaetxe¹, R. Kontermann², K. Pfizenmaier², O. Seifert², P.P. López-Casas¹, M. Abbas³, W. Richter³, L. Simon¹, M. Hidalgo⁴; ¹ES, ²DE, ³AT, ⁴MA/US
- 12:30 - 12:30 **1162P - Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)**
V. Moreno¹, M. Gil-Martin¹, M. Johnson², R. Aljumaily³, P. Lopez Criado¹, D. Northfelt⁴, M. Crittenden⁵, S. Jabbour⁶, L. Rosen⁷, P. Garrido Lopez¹, A. Hervás Morón¹, P. Rietschel⁶, K.K. Mohan⁸, J. Li⁵, E. Stankevich⁵, T. Rowlands⁶, M. Feng⁵, I. Lowy⁵, M. Fury⁵; ¹ES, ²TN/US, ³OK/US, ⁴AZ/US, ⁵US, ⁶NJ/US, ⁷CA/US, ⁸NY/US
- 12:30 - 12:30 **1163P - Study on treatment of stage IV solid tumors with mutant neoantigen specific T cells**
Q. Song, J. Song, H. Sun, W. Du, L. Wu, L. Wang, Z. Wei, Y. Wang, Y. Guan, X. Xia, X. Yi, S. Jiao; CN
- 12:30 - 12:30 **1164P - Efficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients**
M. Hernandez, E. Neninger, E. Santiesteban, K. Camacho, N. Hernandez, R. Amador, S. Acosta, Y. Gonzalez, Y. Jimenez, M. Corella, R.A. Ortiz, L. Bello, A. Calana, G. Pichs, M. Cala, Y. Flores, C. Viada, M. Robaina, T. Crombet Ramos; CU

- 12:30 - 12:30 **1165P - Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors**
L. Shen¹, J. Cao¹, J. Gong¹, D. Ji¹, Z. Qin², H. Dai¹, K. Wu¹, J. Xu¹, J. Yang¹; ¹CN, ²Beijing/CN
- 12:30 - 12:30 **1166P - An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune checkpoint blockade**
C. Kim, N.K. Lee, J.S. Kim, W.R. Kim, D.H. Kim, D.J. Kim, J.S. Oh, S.K. Chang, J.W. Kim, H.J. Chon; KR
- 12:30 - 12:30 **1167P - Phase I, open-label ascending dose trial of anti&&**
B. Wilky¹, P. Kumthekar², R. Wesolowski², J. Hwang², S. Park², G. Yuan², C. Dupont², M. Lim³, O. Shebanova², J.-M. Cuillerot³, E. Dow², W. Ortuzar², J. Raizer³, E. Drouin³, N. Wilson³, A. Gonzalez², J. Goldberg³, J. Buell², R. Stein², H. Youssoufian²; ¹FL/US, ²US, ³MA/US
- 12:30 - 12:30 **1168P - Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors**
J. Coward¹, C. Lemech¹, T. Meniawy², C. Dupont³, A. Gonzalez³, M. Lim⁴, D. Savitsky³, M. Carini³, S. Hu³, O. Shebanova³, E. Dow³, W. Ortuzar³, J. Buell³, R. Stein³, H. Youssoufian³; ¹AU, ²WA/AU, ³US, ⁴MA/US
- 12:30 - 12:30 **1169P - RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial**
D. Camidge¹, S. Gadgeel², H. Wilkins², G. Weems², R. Santana-Davila², M. Johnson³; ¹CO/US, ²US, ³TN/US
- 12:30 - 12:30 **1170P - ABP-100: A tetravalent bispecific T-cell engaging antibody for HER2+ solid tumors**
A. Boudot¹, X. Huang², S. Murphy², V. Appleman², H. Xu¹, N.-K. Cheung¹, G. Macbeath²; ¹US, ²MA/US
- 12:30 - 12:30 **1171P - Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)**
H. Babiker¹, I. Brana², D. Mahadevan³, T. Owonikoko⁴, E. Calvo², D. Rischin⁵, V. Moreno², K. Papadopoulos⁶, M. Crittenden¹, S. Formenti¹, J. Giralt², P. Garrido Lopez², A. Hervás Morón², K.K. Mohan⁷, M. Fury¹, I. Lowy¹, E. Stankevich¹, M. Feng¹, J. Li¹, M. Mathias¹; ¹US, ²ES, ³TN/US, ⁴GA/US, ⁵AU, ⁶TX/US, ⁷NY/US
- 12:30 - 12:30 **1172P - A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors**

A. Awada¹, F. Eskens², D. Robbrecht², U. Lassen³, M. Sorensen³, J. Schellens², J. de Groot², C. Jungels¹, P. Aftimos¹, S. Fretland⁴, L. Thorsson⁵, T.K. Guren⁴; ¹BE, ²NL, ³DK, ⁴NO, ⁵SE

- 12:30 - 12:30 **1173P - Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours**
S. Irenaesus, J. Wenthe, E. Eriksson, J. Krause, A. Sundin, H. Ahlström, T. Tötterman, A. Loskog, G. Ullenhag; SE
- 12:30 - 12:30 **1174P - Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials**
A. Bernard-Tessier¹, C. Baldini², E. Castanon Alvarez³, S. Ammari¹, P. Martin Romano¹, S. Champiat¹, A. Hollebecque¹, S. Postel-Vinay¹, A. Varga², R. Bahleda², A. Gazzah¹, J.-M. Michot¹, V. Ribrag¹, J.-P. Armand¹, A. Marabelle¹, J.-C. Soria⁴, C. Massard²; ¹FR, ²CEDEX/FR, ³ES, ⁴CEDEX/US
- 12:30 - 12:30 **1175P - Prognostic value of response according to tumour growth rate in a phase I trial on vaccine therapy**
A. Bellucci¹, C. Nevoret¹, C. De Bazelaire¹, S. Oudard¹, L. Teixeira², R. Defrance¹, T. Huet¹, L.D. Pierre¹, V. Doppler¹, J. Medioni¹, S. Culine², L. Fournier¹; ¹FR, ²CEDEX 10/FR
- 12:30 - 12:30 **1176P - Oncolytic virotherapy for multiple myeloma targeting CD40, 41BB and/or IL6R**
J. Wenthe, S. Naseri, A.-C. Hellström, E. Eriksson, A. Loskog; SE
- 12:30 - 12:30 **1177P - Humanized knock-in mouse models for evaluating in vivo efficacy of immune-oncology drugs targeting stimulatory immune checkpoint molecules**
T. Gan¹, J. Xiang², C. Guo¹, Y. Guo¹; ¹CN, ²MA/US
- 12:30 - 12:30 **1178P - Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy**
B. Demoulin, B. Eytan, D. Gilham; BE
- 12:30 - 12:30 **1179P - The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer**
S. Agaoglu¹, A. Hargreaves², P. De Sousa³, P. De Waele³, D. Gilham³; ¹FR, ²GB, ³BE
- 12:30 - 12:30 **1180P - Combination of pegilodecakin and docetaxel shows synergy in tumor rejection in immune resistant TNBC model**
N. Ratti¹, N. Shifrin², S. McCauley², R. Verma², P. Van Vlasselaer², M. Oft², J. Leveque²; ¹US, ²CA/US
- 12:30 - 12:30 **1181P - Mutations in interferon gamma and antigen presentation pathways are frequent in hiper/ultra-mutated (HiMut) tumors and could be result of immune-editing processes in HiMut tumors**

J.M. Piulats Rodriguez¹, S. Garcia-Mulero², L. Valle², V. Moreno², X. Matias-Guiu², R. Sanz-Pamplona²; ¹Barcelona/ES, ²ES

- 12:30 - 12:30 **1182P - Anti-CTLA4 toxicity associates with genetic variation correlating with serum antibody diversity**
D. Simpson¹, R. Ferguson², M. Gowen², K. Giles², J. Tchack², H. Zhou¹, U. Moran¹, Z. Dawood², A. Pavlick¹, S. Hu², M. Wilson¹, H. Zhong², M. Krogsgaard², J. Weber², I. Osman², T. Kirchhoff²; ¹NY/US, ²US
- 12:30 - 12:30 **1183P - PD-L1 expression is strongly associated with TIGIT, FOXP3 and LAG3 across advanced cancers, but not OX40, TIM3 and IDO**
S. Pal¹, A. Vanderwalde², C. Szeto², S. Reddy², O. Hamid²; ¹CA/US, ²US
- 12:30 - 12:30 **1184P - Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)**
O. Hamid¹, S. Hu-Lieskovan¹, W. Ros², A. Diab³, A. El-Khoueiry³, J. Thompson⁴, F. Eskens², J.-P. Spano⁵, E. Angevin⁶, N. Rizvi⁷, J. Wasser⁸, P. Ott⁹, A. Chiappori¹⁰, T. Joh⁷, H. Krupka⁷, S. Potluri⁷, X. Wang⁷, B. Ganguli⁷, J. Chou⁷, T. Doi¹¹; ¹CA/US, ²NL, ³US, ⁴WA/US, ⁵FR, ⁶CEDEX/FR, ⁷NY/US, ⁸CT/US, ⁹MA/US, ¹⁰FL/US, ¹¹Chiba/JP
- 12:30 - 12:30 **1185P - Using MultiOmyx® to analyze correlations between immunosuppressive cells and tumor-infiltrating lymphocytes in the pancreatic tumor microenvironment**
A. Juncker-Jensen¹, J. Fang¹, J. Kuo², M. Nagy¹, R.K. Padmanabhan², E. Leones¹, F. Sahafi¹, S. Zhu¹, Q. Au², N. Hoe², J. William¹; ¹US, ²CA/US
- 12:30 - 12:30 **1186P - Interim results from exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients**
T. Kojima¹, T. Marafioti², T. Fujiwara³, Y. Shirakawa³, T. Nakatsura³, K. Kato³, I. Puccio², M. Nagira³, N. Ide³, K. Stoeber², A. Arimura³, H. Daiko³; ¹Chiba/JP, ²GB, ³JP
- 12:30 - 12:30 **1187P - Clinical implication of PDL1 expression and TILs in male breast cancer: More hype or new hope? Results from the UMBREAC trial (NCT03240510)**
S. Abdeljaoued, I. Bettaieb, A. Goucha, O. Adouni, H. El Mokh, H. Bouzaiene, J. Ben Hassouna, H. Boussen, K. Rahal, A. Gamoudi; TN
- 12:30 - 12:30 **1188P - Identification of prognostic and predictive factors for durvalumab efficacy by modeling of tumor response and overall survival (OS) in patients with non-small cell lung cancer (NSCLC)**
Y. Zheng¹, R. Narwal¹, C. Jin¹, P. Baverel², A. Gupta², P. Mukhopadhyay¹, B. Higgs¹, L. Roskos¹; ¹US, ²GB
- 12:30 - 12:30 **1189P - Intrinsic and extrinsic regulation of PD-L2 expression by transcription factor STAT3 or c-FOS in oncogene-driven non-small cell lung cancer**

D. Shibahara¹, K. Tanaka¹, E. Iwama², N. Kubo¹, K. Ota², K. Azuma¹, T. Harada¹, J. Fujita¹, Y. Nakanishi², I. Okamoto¹; ¹JP, ²Fukuoka/JP

- 12:30 - 12:30 **1190P - Microsatellite instability detection by targeted sequencing of cell-free DNA**
A. Artyomenko¹, M. Sikora¹, M. Lefterova¹, V. Raymond¹, D. Gavino¹, C. Barbacioru¹, C. Artieri¹, E. Helman¹, D. Chudova¹, R. Lanman¹, J. Odegaard², J. Willis¹, M. Fakih², S. Kopetz³, A. Talasz²; ¹US, ²CA/US, ³TX/US
- 12:30 - 12:30 **1191P - Immune checkpoints and T-lymphocytes as immunotherapeutic target in the treatment of sebaceous gland carcinoma**
L. Singh¹, M. Singh², N. Pushker², S. Bakhshi², M. Rizvi², S. Sen², S. Kashyap²; ¹Delhi/IN, ²IN
- 12:30 - 12:30 **1192P - Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade**
H. Jackson¹, S. Bhattacharya¹, P. Bojczuk¹, D. Kilian¹, L. Seestaller Wehr¹, A. Hahn¹, H. Shi¹, M. Bi¹, M. Adam¹, J. Jing¹, P. Morley², C. Hopson¹, E. Paul¹, A. Hoos¹, J. Smothers¹, R. Srinivasan¹, N. yanamandra¹; ¹US, ²GB
- 12:30 - 12:30 **1193P - Impact of tissue processing and interferents on the reproducibility and robustness of a multi-plex gene expression assay measuring tumor inflammation**
B. Wallden¹, S. Church¹, I. Pekker¹, S. Zimmerman¹, S. Popa¹, A. Sullivan¹, C. Ngouenet¹, E. Harris¹, N. Dowidar¹, A. Bergdahl¹, C. Schaper¹, P. Danaher², S. Ferree¹; ¹US, ²WA/US
- 12:30 - 12:30 **1194P - Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)**
J. Diamond¹, N. Standifer², M. Ascierto³, C. Morehouse⁴, H. Ghadially⁵, J. Rodriguez Canales³, M. Rebelatto⁴, J. Naidoo³, L. Mazarella⁶, S. Patel⁴, M.J. Flor Oncala⁷, T. Alonso Gordo⁷, D. Wang⁸, X. Song³, D. Jones⁵, X. Li³, S. Marshall³, S. Abdullah³, M. Jure-Kunkel³, M. Hellmann⁹; ¹CO/US, ²CA/US, ³MD/US, ⁴US, ⁵GB, ⁶IT, ⁷ES, ⁸MI/US, ⁹NJ/US
- 12:30 - 12:30 **1195P - Alterations in peripheral T cell subsets, T cell activation markers and immune checkpoint molecules in advanced pancreatic cancer patients receiving FOLFIRINOX or gemcitabine & nab-paclitaxel**
L. Sams, S. Kruger, V. Heinemann, D. Bararia, S. Haebe, S. Alig, B. Westphalen, M. Haas, T. Kirchner, S. Ormanns, S. Endres, O. Weigert, M. von Bergwelt-Baildon, S. Kobold, F. Rataj, S. Boeck; DE
- 12:30 - 12:30 **1196P - Resistance to anti-PD-1 therapy is associated with the retention of CXCR3&&**
X. Han, T. Tan, J. Sun, X. Chen, X. Cai, P. Lin, Y. Tan, B. Wang, Y. Wang, J. Wang, Z. Yu, X. Wu, Q. Xu, Y. Gu; CN

- 12:30 - 12:30 **1197P - Cerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment**
K. Suijkerbuijk, F. De Vos, J. Koldenhof, T. Snijders; NL
- 12:30 - 12:30 **1198P - Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario**
D. Iacono, M.G. Vitale, F. Cortiula, M. Cinausero, A. Tullio, F. Valent, M. Macerelli, A. Follador, A. Vogrig, A. Minisini, F. Puglisi, G. Fasola; IT
- 12:30 - 12:30 **1199P - Clinical and molecular characteristics associated with efficacy of PD-1/PD-L1 inhibitors for solid tumors: A meta-analysis**
M. Peng, Y. Weng, Y. Yao, Q. Song; CN
- 12:30 - 12:30 **1200P - Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer**
T. Ota¹, T. Takeda¹, T. Fukui¹, Y. Nakahara¹, K. Kudo¹, T. Okabe¹, H. Hayashi¹, S. Otani¹, Y. Hiyoshi¹, K. Yonesaka¹, T. Sugiura¹, T. Suzumura¹, M. Terashima¹, Y. Nakano¹, Y. Hasegawa¹, H. Tsukuda¹, K. Matsui¹, N. Masuda², M. Fukuoka¹; ¹JP, ²Minami-li, Sagami-hara/JP
- 12:30 - 12:30 **1201P - Association of immune-related adverse (irAEs) with immune-checkpoint inhibitors (ICIs) efficacy in solid tumors**
M. Riudavets Melia, L. del Carpio, I. Gabriela Sullivan, A. Barba Joaquín, P. Maroto Rey, G. Anguera Palacios, D. Páez López-Bravo, A. Callejo Pérez, C. González Blanco, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, I. Genua Trullós, A. López Pousa, A. Sebio García, C. Martín Lorente, A.C. Virgili Manrique, O. Gallego Rubio, A. Barnadas Molins, M. Majem Tarruella; ES
- 12:30 - 12:30 **1202P - Use of immune checkpoint inhibitors (CPI) in patients with cancer and concomitant myasthenia gravis (MG)**
H. Safa¹, N. Abdel-Wahab¹, V.A. Trinh¹, D. Johnson², T.E. Rodgers¹, M. Suarez-Almazor¹, A. Diab¹; ¹US, ²TX/US
- 12:30 - 12:30 **1203P - Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events**
A. Simonaggio, J.-M. Michot, S. Champiat, A. Vozy, A. Lapera, A. Marabelle, J. Le Pavec, A.-L. Voisin, A. Lallart, G. Cengizalp, O. Lambotte; FR
- 12:30 - 12:30 **1204P - Long term disease control and abscopal effects by stereotactic radiotherapy for growing metastases during anti-PD1**
K. Suijkerbuijk, S. El Sharouni, P. Damen, A. Lindert, G. Groenewegen, J. Verhoeff; NL
- 12:30 - 12:30 **1205P - Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab**
T. Yamamoto, T. Nomizo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, T. Hirai, Y. Kim; JP

- 12:30 - 12:30 **1206P - Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy**
C. Baldini¹, P. Martin-Romano², A.-L. Voisin², F.X. Danlos², S. Champiat², S. Laghouati², M. Kfoury², H. Vincent², C. Nagera², S. Postel-Vinay², A. Varga¹, V. Ribrag², B. Besse¹, A. Hollebecque², O. Lambotte², J.-M. Michot², J.-C. Soria³, C. Massard¹, A. Marabelle²; ¹CEDEX/FR, ²FR, ³CEDEX/US
- 12:30 - 12:30 **1207P - PD-1 inhibitor-related pneumonitis in patients with minimal interstitial lung shadows before treatment**
K. Takahashi¹, C. Kondo¹, A. Inukai¹, G. Asai², M. Okuno¹, H. Saito¹; ¹JP, ²Aichi/JP
- 12:30 - 12:30 **1208P - PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques: A safety study**
R. Carroll¹, J. Zalcborg², H. Tang³; ¹AU, ²VIC/AU, ³SA/AU
- 12:30 - 12:30 **1209P - Immunotherapy in the immunodeficient: A treatment paradox?**
N. Campbell, J. Longley, A. Pascalis, J. Bennett, M. Remer, R. Stone, D. Muller, I. Karydis, O. Donnelly, M. Wheeler, C. Ottensmeier; GB
- 12:30 - 12:30 **1211P - Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?**
E. Farè, S. Sdao, S. Damian, S. Cresta, M. Del Vecchio, M. Di Bartolomeo, L. Di Guardo, M. Duca, A. Indini, A. Necchi, M. Niger, M. Prisciandaro, G. Procopio, D. Raggi, E. Verzoni, G. Pruneri, M. Di Nicola, F.G. de Braud; IT
- 12:30 - 12:30 **1212P - Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study**
L. Au, R. Nathwani, L. Possamai, C. Barlow, T. Tillett, R. Bowen, L. Spain, J. Thomas, M. Backhouse, A. Gurung, R. Morrison, T. Cross, C. Herbert, R. Goldin, M. Gore, J. Larkin, C. Antoniades, S. Turajlic; GB
- 12:30 - 12:30 **1213P_PR - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)**
A. Gobert¹, M. Veyri¹, A. Lavolé¹, H. Montaudié¹, N. Cloarec¹, L. Doucet¹, V. Gounant², M.-A. Massiani¹, C. Helissey¹, S. Bregigeon¹, C. Chouaid¹, C.-H. Poulet¹, M. Dewolf¹, M. Kerjouan¹, S. Beaucaire-Danel¹, S. Brosseau¹, G. Le Garff¹, V. Garrat¹, A.-G. Marcelin¹, J.-P. Spano¹; ¹FR, ²CEDEX 18/FR
- 12:30 - 12:30 **1214P - Establishing the need for immuno-oncology (IO) therapy (tx) in second-line (2L) small cell lung cancer (SCLC)**
L. Schwartzberg¹, J. Penrod², Y. Yuan², T. Gu², T.K. Le³, P. Abraham², B. Korytowsky², G. Selvaggi²; ¹TN/US, ²NJ/US, ³US
- 12:30 - 12:30 **1215P - Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity: From case report to mice model validation**
Y.-J. Chen, W.-C. Huang, S.-Y. Liu, C.-C. Ko; TW

- 12:30 - 12:30 **1216P - Impact of anti-infectious and corticosteroids on immunotherapy: Nivolumab and pembrolizumab follow-up in a French study**
J.-P. Metges¹, E. Michaud², D. Deniel Lagadec², F. Marhuenda², A. Chaslerie², F. Grude²;
¹Cedex 2/FR, ²FR
- 12:30 - 12:30 **1217P - Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance**
Y. Ohe¹, A. Gemma¹, K. Nakagawa¹, N. Yamamoto¹, T. Saito¹, A. Akamatsu¹, K. Kuwano¹,
 Y. Nakanishi²; ¹JP, ²Fukuoka/JP
- 12:30 - 12:30 **1218P - Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy**
N. Duma¹, A.-G. Azzouqa¹, S. Yadav¹, K. Hoversten¹, C. Reed¹, A. Sitek¹, Y. Lou¹, J. Molina¹, T. Halfdanarson¹, K. Leventakos², R. Joseph¹, R. Manochakian¹, R. Dronca¹;
¹US, ²MN/US
- 12:30 - 12:30 **1219P - Evaluation of a possible link between immunotherapy (IO) and acute vascular events**
J. Bar, K. Shulman, T. Kuznetsov, G. Markel, S. Daher, R. Berger, T. Golan, D. Urban, T. Sela, E. Shacham Shmueli, R. Klempfner, A. Talianski, A. Onn, E. Dudnik; IL
- 12:30 - 12:30 **1220P - Real-world experience of pembrolizumab in patients with advanced melanoma: A large retrospective observational study**
F.X. Liu¹, W. Ou², S. Diede², E. Whitman²; ¹US, ²NJ/US
- 12:30 - 12:30 **1221P - Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)**
M. Bilen¹, J. Shabto², D. Martini², Y. Liu², C. Lewis¹, H. Collins¹, M. Akce¹, H. Kissick², B. Carthon¹, W. Shaib¹, O. Alese¹, C. Steuer¹, C. Wu¹, D. Lawson¹, R. Kudchadkar¹, V. Master¹, B. El-Rayes¹, S. Ramalingam², T. Owonikoko², R. Harvey¹; ¹US, ²GA/US
- 12:30 - 12:30 **1222P - Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs)**
N. Shah, J. Puthiamadathil, M. Serzan, A. Belouali, W. Kelly, B. MA, M. Blackburn, A. Knoedler, S. OchoaGonzalez, M. Janni, S. Madhavan, G. Gibney, M. Atkins; US
- 12:30 - 12:30 **1223P - Potential drug cost impact of dual agent immunotherapy (DAIO) with nivolumab (N) plus ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada**
K. Virik¹, R. Wilson²; ¹NS/CA, ²NSW/AU
- 12:30 - 12:30 **1224P - Q-TWiST analysis to assess benefit-risk of pembrolizumab in patients with PD-L1-positive advanced or metastatic NSCLC**

M. Huang¹, M.C. Pietanza², A. Samkari¹, J. Pellissier¹, T. Burke¹, S. Chandwani¹, F. Kong¹, A.S. Pickard³; ¹US, ²NJ/US, ³IL/US

- 12:30 - 12:30 **1225P - Impact of immune-checkpoint inhibitors (ICPIs) as treatment of patients (pts) with metastatic primary uveal melanoma (UM): Results of a single-institution database**
C.L. Lee, G. Gullo, N. Horgan, D. Smith, M. Moran, J. Crown; IE
- 12:30 - 12:30 **1226P - Anti-PD1 inhibitors: Assessment of proper use, efficacy and economic impact in daily practice**
M. VALERY, FR
- 12:30 - 12:30 **1227P - Immune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients**
J. Rogado¹, N. Romero Laorden², J.M. Sanchez Torres¹, A.I. Ballesteros Garcia¹, V. Pacheco-Barcia¹, R. Arranz¹, R. Mondéjar Solís¹, P. Gullón¹, A. Lorenzo¹, R. Colomer Bosch¹; ¹ES, ²Madrid/ES
- 12:30 - 12:30 **1228P - Previous immunotherapy treatments may improve tumor responses with subsequent chemotherapy regimens**
I. Baraibar Argota¹, P. Martin-Romano², M. Sanmamed³, M. Rodriguez-Ruiz¹, J.L. Pérez-Gracia¹, I. Gil-Bazo¹, I. Melero¹, L. Resano¹, A. Chopitea Ortega¹, J. Rodriguez¹, J. Aramendia¹, I. Gardeazabal¹, L. Ceniceros¹, P. Sala Elarre¹, M. Ponz-Sarvisé¹, E. Castanon Alvarez¹; ¹ES, ²FR, ³US
- 12:30 - 12:30 **1229P - Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)**
M. Gutierrez¹, A. Norden², D. Lane³, B. Canavan³, E. Nwokeji³, Y. Xu³, S. Kaur², S. Goldberg¹, L. Noh², L. Siegartel³, J. Whittington³, K. Tuell³, B. Korytowsky³; ¹US, ²NY/US, ³NJ/US
- 12:30 - 12:30 **1230P - Anti-PD-1 therapy combined with chemotherapy or target therapy in patients with advanced biliary tract cancer in real-world clinical setting**
D. Sun, J. Ma, C. Han, J. Wang, Y. Qian, G. Chen, X. Li, J. Zhang, J. Song, X. Zhao, S. Cai, Y. Hu; CN
- 12:30 - 12:30 **1231P - The efficacy and safety of solid tumors combination therapy with immune checkpoint inhibitor: A systematic review and meta-analysis**
M. Peng, Y. Weng, Y. Yao, Q. Song; CN
- 12:30 - 12:30 **1232P - Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types**
X. Zhao¹, J. Shen¹, M. Gopalakrishnan², Y. Feng¹, B. Schmidt¹, P. Statkevich¹, T. Kelleher³, M. Rashford¹, V. Ivaturi², J. Gobburu², S. Agrawal¹, A. Bello¹, A. Roy¹; ¹NJ/US, ²MD/US, ³CT/US

- 12:30 - 12:30 **1233P - Immunotherapy in clinical practice: Real world multicentric Brazilian experience**
J. Cé Coelho, A.C. Zimmer Gelatti, E. Mascarenhas, C. Dutra, T. Rebelato, R. D'Avila, F. Zaffaroni Caorsi, B. Rocha Garcia, A.C. de Miranda e Figueiredo, M. Souto, A. Baldasso Zanon, N. Balzan, G. Werutsky, S. Jobim de Azevedo; BR
- 12:30 - 12:30 **1234P - Correlation, in a real-world setting, between clinical-disease characteristics and compliance with immunotherapy in solid metastatic tumors: First results of an Italian CORE-IMMUNO study**
C. Masini, A. Berselli, M. Banzi, C. Bonelli, A. Romagnani, M. Pagano, A. Damato, G. Prati, E. Gasparini, G. Moretti, I.T. Lorenzetti, F. Zanelli, F. Iachetta, C. Pinto; IT
- 12:30 - 12:30 **1235P - Safety of immunotherapy in elderly patients: A retrospective analysis of a phase I unit**
E. Ferraro¹, G. Viale², B. Achutti Duso², C. Belli², C. Criscitiello², L. Mazzarella², A. Esposito², S. Morganti², D. Trapani², P. Tarantino², P. D'Amico², C. Busacca², M.A. Massaro², G. Curigliano²; ¹(MI)/IT, ²IT
- 12:30 - 12:30 **1236TiP - The safety and efficacy of durvalumab in combination with paclitaxel for the treatment of metastatic triple negative breast cancer**
H. Ghebeh, A. Alsayed, K. Suleman, T. Al-Tweigeri; SA
- 12:30 - 12:30 **1237TiP - VSV-IFN β -NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors**
S. Powell¹, M. Patel², J. Merchan¹, J. Strauss³, T. Cripe⁴, M. Old¹, R. Diaz², M. Reckner¹, B. Brunton¹, N. Packiriswamy¹, D. Upreti¹, L. Suksanpaisan¹, R. Vandergaast¹, R. Khan¹, S. Russell¹, K.W. Peng¹, A. Bexon¹; ¹US, ²MN/US, ³TX/US, ⁴OH/US
- 12:30 - 12:30 **1238TiP - A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma**
R. Jabulowsky, C. Loquai, E. Derhovanessian, H. Mitzel-Rink, J. Utikal, J. Hassel, R. Kaufmann, A. Pinter, M. Diken, M. Gold, L. Heesen, K. Schreeb, D. Schwarck-Kokarakis, S. Kreiter, M. Gaiser, D. Jäger, S. Grabbe, Ö. Türeci, U. Sahin; DE
- 12:30 - 12:30 **1239TiP - MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types**
I. Chau¹, G. Haag², O. Rahma³, T. Macarulla⁴, S. McCune⁵, D. Yardley⁶, B. Solomon⁷, M. Johnson⁶, G. Vidal⁶, P. Schmid⁸, G. Argiles⁴, K. Dimick⁹, S. Mahrus⁹, H. Abdullah⁹, X. He⁹, P. Sayyed⁹, H. Barak⁹, C. Bleul¹⁰, E. Cha⁹, A. Drakaki⁹; ¹Surrey/GB, ²DE, ³MA/US, ⁴ES, ⁵GA/US, ⁶TN/US, ⁷VIC/AU, ⁸GB, ⁹CA/US, ¹⁰CH
- 12:30 - 12:30 **1240TiP - Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HPI) therapy**

K. Lewis¹, M. Fury², E. Stankevich², M. Mathias², K.K. Mohan³, S. Li⁴, K. Nunnink³, C. Perry³, A. Narwal⁴; ¹CO/US, ²US, ³NY/US, ⁴NJ/US

- 12:30 - 12:30 **1241TiP - JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors**
T. Yap¹, J. Beck², R. Stewart³, S. Dahm³, C. Chappey³, R. Cesari⁴, A. Scheuber⁵, M. Galsky³, D. Wise⁶; ¹Surrey/US, ²AZ/US, ³US, ⁴IT, ⁵PA/US, ⁶NY/US
- 12:30 - 12:30 **1242TiP - Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors**
M. Butler¹, H. Majeed², M. Nelles², S. Saibil², L. Bonilla², S. Boross-Harmer², V. Sotov², S. Elston², K. Ross², B. van As², M. Le², M. Fyrsta², C. Lo², J. Yam², J. Nie², L. Scheid², P. Ohashi², L. Nguyen², S. Tanaka³, N. Hirano²; ¹Ontario/CA, ²CA, ³JP
- 12:30 - 12:30 **1243TiP - Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors**
M. Johnson¹, M. Patel², S. Ulahannan³, A. Hansen⁴, B. George³, Q.S.-C. Chu⁴, M. Elgadi⁴, M. Ge⁵, C. Duffy⁵, R. Graeser⁶, S. Khedkar¹, S. Jones¹, H. Burris¹; ¹TN/US, ²MN/US, ³US, ⁴CA, ⁵CT/US, ⁶DE
- 12:30 - 12:30 **New diagnostic tools**
- 12:30 - 12:30 **1337P - Predictive models for CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?**
L. Jun, Q. Chen, L. Tang, L. Yang, E. Han, Y. Chen, L. Yuan; CN
- 12:30 - 12:30 **1338P - Tracking VSV-IFN β -NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy**
J. Merchan¹, M. Patel², S. Powell¹, J. Strauss³, T. Cripe⁴, M. Old¹, R. Diaz², S. Russell¹, A. Bexon¹, L. Suksanpaisan¹, M. O'Connor², K.W. Peng¹; ¹US, ²MN/US, ³TX/US, ⁴OH/US
- 12:30 - 12:30 **1339P - mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort**
M. Filipits¹, M. Rudas¹, C. Singer¹, Z. Bago-Horvath¹, R. Greil¹, M. Balic¹, S.F. Lax¹, N. Wu², S. Zhao², J. Weidler², M. Bates², D. Hlauschek¹, M. Gnant¹, P. Dubsy¹; ¹AT, ²US
- 12:30 - 12:30 **1340P - Clinical utility of complex multi-platform profiling in metastatic cancer patients**

J. Garcia Foncillas¹, P. Aftimos², P. Barthelemy³, J. Bellmunt¹, G. Berchem⁴, C. Camps¹, R. de las Peñas¹, A. Finzel², J.P. Hervonen⁵, T. Joensuu⁵, A. Kong⁶, J. Mackay⁷, C. Mikropoulos⁶, K. Mokbel⁶, J.-L. Mouysset⁸, T. Perren⁹, G. Guitti², J.-F. Laes²; ¹ES, ²BE, ³CEDEX/FR, ⁴LU, ⁵FI, ⁶GB, ⁷London/GB, ⁸FR, ⁹Yorkshire/GB

- 12:30 - 12:30 **1341P - Comparison of tissue-based and liquid biopsy genomic tests to guide lung cancer therapy: Asian experience**
M.-L. Nairismägi¹, K.-C. Tung², Y.-T. Yang², Y.-J. Lu², R.-S. Jhou², P.-N. Yu², Y.-T. Liu², Y.-L. Hsieh², S.L. Poon¹, S.-J. Chen², K.T. Tan²; ¹SG, ²TW
- 12:30 - 12:30 **1342P - 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma**
W. van Boxtel, S. Lütje, I. van Engen-van Grunsven, G. Verhaegh, J. Schalken, M. Janssen, J. Nagarajah, M. Gotthardt, C. van Herpen; NL
- 12:30 - 12:30 **1343P - Histology and detectability on ring-type dedicated breast PET in breast cancer**
Y. Kimura¹, S. Sasada², N. Goda¹, K. Kajitani¹, A. Emi¹, N. Masumoto¹, T. Kadoya¹, R. Haruta¹, T. Kataoka¹, M. Okada¹; ¹JP, ²Hiroshima/JP
- 12:30 - 12:30 **1344P - Thermal liquid biopsy as a new tool for lung cancer patients diagnostic: Pilot study**
A. Rodrigo Cáceres, O. Abian, A. Velazquez-Campoy, A. Callejo, S. Vega, A. Fernandez, O. Sánchez-Gracia, P. Iranzo Gomez, M. Cruellas, E. Quilez Bielsa, D. Isla; ES
- 12:30 - 12:30 **1345P - Data-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center**
P. Heudel¹, T. Durand², B. Fervers², F. Gomez², M. Rivoire², T. Bachelot², L. Claude², C. Chassagne-Clement², F. Pilleul², T. Mognetti², Y. Devaux², J.-L. Soubirou², C. Lasset², D. Perol², G. Chvetzoff², C. Pezet², S. Beaupere², P. Zrounba², J. Blay²; ¹CEDEX/FR, ²FR
- 12:30 - 12:30 **1346P - Real world cfDNA collection in EGFR-mutant NSCLC**
N. Marcoux¹, L. Sequist², A. Hata¹, M. Banwait¹, I. Dagogo-Jack¹, R. Nagy¹, R. Lanman¹, A. Muzikansky¹, S.R. Digumarthy², Z. Piotrowska¹; ¹US, ²MA/US
- 12:30 - 12:30 **1347TiP - Proof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice**
C. Mastier, C. de la Fouchardière, J. Fayette, M. Sarabi, P. Heudel, A. Coulon, N. Banaste, E. Mercier-Bischoff, M. Barma, M. Brahmi, P. Cassier, S. Couchon Thaunat, L. Eberst, G. Fournier-Garin, P. Metral, F. Pilleul, J.-Y. Blay; FR
- 12:30 - 12:50 **NSCLC, early stage**
- 12:50 - 12:50 **1351P - Impact of the 8th edition AJCC classification in early stage lung cancer**

A.S. Cortegoso Mosquera¹, M. Vieito Villar¹, C. Rodriguez Lopez², V. Varela Pose², V. Cebey Lopez², J. Alvarez Fernandez², M. Perez Martelo², S. Aguin Losada², U. Anido Herranz², L. Leon Mateos², F.J. Baron Duarte², J.J. Garcia Gonzalez²; ¹La Coruña/ES, ²ES

- 12:50 - 12:50 **1352P - A serum miRNA biomarker panel for the detection of early stage non-small cell lung cancer**
L. Ying¹, R. Zou¹, L. Du¹, L. Shi¹, N. Zhang¹, J. Jin¹, J. Wu¹, F. Zhang¹, K. Chen¹, M. Huang¹, Y. Zhang¹, A. Lin¹, H. Yu², L. Zhou¹, W. Mao¹, D. Su¹; ¹CN, ²US
- 12:50 - 12:50 **1353P - Split-lobe resections versus lobectomy for stage IA-IB peripheral non-small cell lung cancer**
A. Levitckij, D. Chichevatov, M. Ter-Ovanesov, E. Sinev; RU
- 12:50 - 12:50 **1354P - Patient reported outcomes after the treatment of early stage non-small cell lung cancer by stereotactic body radiotherapy compared to surgery**
L. Alberts, H. Wolff, E.A. Kastelijn, F.J. Lagerwaard, S. Senan, S.Y. El Sharouni, F. Schramel, V. Coupe; NL
- 12:50 - 12:50 **1355P - miR-200s in operated NSCLC: Main drivers of epithelial to mesenchymal transition and independent prognostic factors**
A. Legras, FR
- 12:50 - 12:50 **1356P - The level of circulating NKp46&&**
E. Picard¹, Y. Godet¹, C. Laheurte¹, L. Boullerot¹, E. Lauret Marie Joseph¹, M. Jacquin¹, V. Kaulek¹, G. Eberst¹, B. Gaugler¹, P. Jacoulet¹, M. Gainet-Brun¹, J. Lahoucarde¹, H. Almotlak², F. Le Pimpec-Barthes¹, E. Fabre-Guillevin¹, C. Borg¹, V. Westeel², O. Adotevi²; ¹FR, ²CEDEX/FR
- 12:50 - 12:50 **1357P - A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma**
G. Toyokawa¹, K. Takada², R. Hamamoto², Y. Yamada², T. Tagawa², F. Shoji², K. Yamazaki², Y. Oda², S. Takeo²; ¹Fukuoka/JF, ²JP
- 12:50 - 12:50 **1358P - Comprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules**
K. Takamochi, M. Hosoya, K. Mogushi, T. Hayashi, M. Ito, H. Kawaji, Y. Hayashizaki, K. Suzuki; JP
- 12:50 - 12:50 **1359P - Association between PD-L1 expression and survival in early stage non-small cell carcinoma**
E. Gálvez, C. Gálvez Muñoz, A. Cotes Sanchís, A. Gonzaga López, M.M. Llorente Ostiategui, M. Montero Gómez, I. Aranda López, C. Llorca Ferrandiz; ES
- 12:50 - 12:50 **1360P - Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Initial report of a phase I study, MK3475-223**

A. Ben Nun, N. Golan, E. Ofek, D. Urban, I. Kamer, D. Simansky, A. Onn, A. Ackerstein, S. Raskin, T. Shulimzon, N. Zeitlin, I. Redinsky, S. Halperin, M. Jurkowicz, J. Bar; IL

- 12:50 - 12:50 **1361P - Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: Survival results from a phase II feasibility study (NAVAL)**
Y. Tsutani¹, Y. Miyata², K. Suzuki², K. Takamochi², F. Tanaka², H. Nakayama², Y. Yamashita², M. Oda², M. Tsuboi³, M. Okada²; ¹Hiroshima/JP, ²JP, ³Chiba/JP
- 12:50 - 12:50 **1362P - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung**
Y. Wang, CN
- 12:50 - 12:50 **NSCLC, locally advanced**
- 12:50 - 12:50 **1366P - The impact of the new TNM classification on survival of patients in stage III non-small cell lung cancer**
M. Vrankar, K. Stanic; SI
- 12:50 - 12:50 **1367P - Survival in never-smokers with non-small cell lung cancer: A population-based study from Sweden**
L. Löfling, S. Bahmanyar, A. Karimi, H. Kieler, M. Lambe, K. Lamberg Lundström, F. Sandin, G. Wagenius; SE
- 12:50 - 12:50 **1368P - Clinical features and prognosis of eighty-five patients with primary pulmonary lymphoepithelioma-like carcinoma**
Q. yin, G. Gao, C. Zhou, Z. Zhu, Y. Liu, X. Xie, X. Lin, Z. Xie, J. Zhang, O. Ming, S. li, R. Chen; CN
- 12:50 - 12:50 **1369P - Meta-analysis of prognostic factors of completely resected pathologic N2 stage IIIA non-small cell lung cancer including 11,384 patients**
X. Zhan, N. Li; CN
- 12:50 - 12:50 **1370P - The results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy**
E. Rodionov, S. Miller, S. Tuzikov, M. Tsyganov, N. Litviakov, L. Efteev, I. Deriusheva; RU
- 12:50 - 12:50 **1371P - Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02**
M. Provencio Pulla¹, R. de las Peñas², N. Martinez Banaclocha³, R. MarsÉ Fabregat², A. Insa Molla⁴, T. Moran², M.A. Sala Gonzalez², B. Massuti Sureda², P. Mut Sanchis², A.L. Ortega Granados⁵, J.M. Jurado², J. Gomez Codina², A. Artal-Cortes², F. Vazquez⁶, V. Gutierrez Calderon², P. Diz Tain², N. Vinolas Segarra², I. Maestu Maiques², C. Camps², M.D. Isla Casado²; ¹Madrid/ES, ²ES, ³Alicante/ES, ⁴Valencia/ES, ⁵Jaen/ES, ⁶La Coruña/ES

- 12:50 - 12:50 **1372P - Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018**
Y. Takiguchi¹, K. Yamada², H. Tanaka³, K. Kubota², K. Kishi², T. Shimokawa⁴, H. Saito², Y. Hosomi², T. Kato², N. Nogami², S. Igawa⁵, T. Kasai², Y. Nakamura², T. Yamanaka², H. Okamoto⁴; ¹Chiba/JP, ²JP, ³NA, ⁴Kanagawa/JP, ⁵Minami-li, Sagamihara/JP
- 12:50 - 12:50 **1373P - Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay**
P. Vitazka¹, N. Tikoo², A. Balasubramanyam², L. Xi², S. Yaung², E. Kwok², A. Lovejoy², D. Klass², M. Heibeck³, K. Probst³, A. Rehfeldt³, E. Meldgaard⁴, A. Madsen⁴, M. Clement⁴, J. Palma², B. Sorensen⁴, P. Meldgaard⁴; ¹US, ²CA/US, ³DE, ⁴DK
- 12:50 - 12:50 **1374P - Correlations between Ape1/Ref-1, ICAM-1 and IL-17A levels in serum and radiation pneumonitis for local advanced non-small cell lung cancer patients**
L. Guo, CN
- 12:50 - 12:50 **1375P - Programmed cell death ligand 1 expression and CD8 positive lymphocytes in stage III non-small cell lung cancer after neo adjuvant concurrent chemoradiotherapy and their relation with prognosis**
E. Choe, C. Yoon-Jin, H.-S. Shim, C.-Y. Lee, B.C. Cho, H.-R. Kim; KR
- 12:50 - 12:50 **1376P - The standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists**
A. Bruni, F. Grossi, F. Katia, E. Capelletto, L. Buffoni, S. Badellino, V. Poletti, R. Chiari, N. Giaj Levra, G.L. Banna, S. Vagge, P. Borghetti, E. Baldini, E. Bria, M. Tiseo, M. Paci, P. Ciammella, M. Taraborrelli, U. Ricardi, V. Scotti; IT
- 12:50 - 12:50 **NSCLC, metastatic**
- 12:50 - 12:50 **1387P - Randomized, double-blind, placebo (P)-controlled phase III non-inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) &&**
D. Henry¹, V. Hirsh², K. Kubota³, T. Steinmetz⁴, G. Thomas¹, J.-H. Kang⁵, D. Gordon¹, S. Orlov⁶, A. Fleishman¹, C. De Oliveira Brandao¹; ¹US, ²Quebec/CA, ³JP, ⁴DE, ⁵KR, ⁶RU
- 12:50 - 12:50 **1388P - Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: A combined analysis of two phase III randomized controlled trials**
K. Thein¹, S. Swarup², S. Ball², M. Quirch², Y. Vorakunthada², K. Htwe³, N. D'Cunha², F. Hardwicke², S. Awasthi², L. Tijani²; ¹US, ²TX/US, ³NY/US

- 12:50 - 12:50 **1389P - Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors**
G. Fucà, M. Poggi, G. Galli, M. Imbimbo, G. Lo Russo, D. Signorelli, M. Vitali, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, C. Proto; IT
- 12:50 - 12:50 **1390P - Dose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303**
L. Zhang, X. Si, H. Wang, X. Zhang, M. Wang, B. Han, K. Li, Q. Wang, J. Shi, Z. Wang, Y. Cheng, J. He, Y. Shi, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, B. Li, Y. Chen; CN
- 12:50 - 12:50 **1391P - Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy**
M. Melià Sosa¹, C. Puchades¹, J. Mendez¹, A. Torres¹, C. Rodrigo¹, G. Gimeno¹, E. Rama¹, A. Martínez-Castillo¹, J. Caballero Daroqui¹, J. Gomez Codina¹, O. Juan-Vidal¹, D. Lorente²; ¹ES, ²Surrey/GB
- 12:50 - 12:50 **1392P - Dose-determination results from a phase Ib/II study of ceritinib (CER) &&**
A. Santoro¹, W.-C. Su², A. Navarro³, M. Simonelli¹, J.C.-H. Yang², A. Ardizzoni⁴, F. Barlesi⁵, J.H. Kang⁶, S. Didominick⁷, A. Abdelhady⁸, B. Goswami⁷, A. Crystal⁷, E. Felip³; ¹(MI)/IT, ²TW, ³ES, ⁴IT, ⁵CEDEX 20/FR, ⁶KP, ⁷MA/US, ⁸IN
- 12:50 - 12:50 **1393P - Safety profile and effectiveness of alectinib in the real-world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer**
Y. Ohe¹, N. Yamamoto¹, A. Gemma¹, M. Kusumoto¹, I. Yamada¹, T. Ishii¹, N. Masuda²; ¹JP, ²Minami-li, Sagamihara/JP
- 12:50 - 12:50 **1394P - A multicenter study of mutational profiling of Chinese ALK-positive non-small cell lung cancer patients with acquired resistance to crizotinib using next generation sequencing**
C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, G. Chen, M. Fang, T. Lv, Y. Song; CN
- 12:50 - 12:50 **1395P - Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors**
E. Imyanitov, N. Mitiushkina, V. Tiurin, A. Iyevleva, M. Holmatov, E. Filippova, F. Moiseyenko, N. Levchenko, S. Odintsova, A. Lozhkina, A. Togo, N. Karaseva, V. Moiseyenko, S. Orlov; RU
- 12:50 - 12:50 **1396P - Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)**
D. Moro-Sibilot¹, M.-J. Ahn², B. Halmos³, D.-W. Kim², G. Riely⁴, A. Shaw⁵, P.-C. Yang⁶, S. Lanzalone⁷, A. Polli⁷, K. Wilner⁸, J. De Castro Carpeño⁹; ¹FR, ²KR, ³NY/US, ⁴US, ⁵MA/US, ⁶TW, ⁷IT, ⁸CA/US, ⁹ES
- 12:50 - 12:50 **1397P - Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)**

L. Crinò¹, M.-J. Ahn², J.-Y. Han², X. Liu³, S.-H. Ou⁴, A. Shaw⁵, P.-C. Yang⁶, Y.-K. Shi³, S. Lanzalone¹, A. Polli¹, K. Wilner⁴, D.-W. Kim²; ¹IT, ²KR, ³CN, ⁴CA/US, ⁵MA/US, ⁶TW

- 12:50 - 12:50 **1398P - Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK-positive non-small cell lung cancer (NSCLC)**
M. Jahanzeb¹, H. Lin², X. Pan², Y. Yin², P. Hou², B. Nordstrom², A. Desai², M. Socinski³; ¹FL/US, ²MA/US, ³PA/US
- 12:50 - 12:50 **1399P - Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK-positive NSCLC**
S. Peters¹, A. Shaw², B. Besse³, E. Felip⁴, B. Solomon⁵, R. Soo⁶, A. Bearz⁷, S. Gadgeel⁸, C.-C. Lin⁹, S. Kao¹⁰, T. Seto¹¹, E. Masters¹², A. Abbattista⁷, J. Clancy², H. Thurm¹³, A. Reisman¹², D.R. Camidge⁸; ¹CH, ²MA/US, ³CEDEX/FR, ⁴ES, ⁵VIC/AU, ⁶SG, ⁷IT, ⁸US, ⁹TW, ¹⁰AU, ¹¹JP, ¹²NY/US, ¹³CA/US
- 12:50 - 12:50 **1401P - The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey**
S. Kilickap, Ö. Ölmez, I. Cicin, U. Demirci, O. Alan, D. Cabuk, T. Şakalar, A. Tatlı, F. Başol Buğdaycı, Y. Eralp, M. Uysal, A. Demirkazık, B. Bilgin, B. Yıldız, M. Karaağaç, K. Okutur, A. Sakin; TR
- 12:50 - 12:50 **1402P - Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer**
D. Harada¹, A. Hata², C. Okuda¹, R. Kaji¹, Y. Masuda¹, Y. Takechi¹, T. Kozuki¹, N. Nogami¹, N. Katakami¹; ¹JP, ²Hyogo/JP
- 12:50 - 12:50 **1403P - Open-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (>75 years old) patients (pts) with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC): TORG1323**
T. Honda, T. Kouzuki, Y. Tsunozuka, N. Seki, T. Shibayama, T. Okimoto, H. Taniguchi, Y. Takeda, N. Hata, K. Sugimoto, N. Takahashi, K. Sakai, T. Nishimura, S. Ikeda, S. Watanabe, K. Mori, T. Shinkai; JP
- 12:50 - 12:50 **1404P - Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial**
A.M. Morelli¹, M.R. Migliorino¹, A. Morabito¹, R. Chiari¹, F. Grossi¹, P. Bordi¹, F. Di Costanzo¹, A. Delmonte², G. Romano¹, A. Misino¹, V. Scotti¹, V. Gregorc¹, S. Pisconti¹, G.L. Ceresoli¹, A. Del Conte¹, I. Colantonio¹, L. Ciuffreda¹, E. Capelletto¹, I. Stura¹, S. Novello¹; ¹IT, ²Forlì-Cesena/IT
- 12:50 - 12:50 **1405P - Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA)**

M. Wislez¹, H. Blons¹, C. Domblides¹, F. Barlesi², J. Mazieres¹, I. Monnet¹, L. Kiakouama Maleka³, X. Quantin⁴, L. Taillade¹, H. Lena⁵, P. Fraisse¹, H. Janicot¹, C. Audigier Valette⁵, E. Amour¹, A. Langlais¹, N. Rabbe¹, J. Cadranel¹, P. Laurent puig¹, A. Lavolé¹; ¹FR, ²CEDEX 20/FR, ³CEDEX 4/FR, ⁴CEDEX 5/FR, ⁵CEDEX/FR

- 12:50 - 12:50 **1406P - Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients**
I. Tsimafeyeu, E. Imyanitov, L. Zavalishina, G. Raskin, P. Povilaitite, N. Savelov, E. Kharitonova, A. Rumyantsev, I. Pugach, Y. Andreeva, A. Petrov, G. Frank, S. Tjulandin; RU
- 12:50 - 12:50 **1407P - Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients**
L. Mezquita¹, K. Arbour², E. Auclin¹, D. Saravia², H. Rizvi², L. Hendriks³, D. Planchard¹, W. Park², E. Nadal⁴, J.C. Ruffinelli Rodriguez⁵, S. Ponce⁵, C. Audigier-Valette¹, A.P. Marilniello⁶, G. Zalcman¹, M. Majem⁵, G. Schiavone⁶, A.-M. Dingemans³, G. Lopes⁷, M.D. Hellmann², B. Besse⁸; ¹FR, ²US, ³NL, ⁴Barcelona/ES, ⁵ES, ⁶IT, ⁷FL/US, ⁸CEDEX/FR
- 12:50 - 12:50 **1408P - Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)**
L. Hendriks¹, C. Henon², E. Auclin², L. Mezquita², R. Ferrara², C. Audigier Valette³, J. Mazieres², C. Lefebvre², S. Le Moulec⁴, B. Duchemann³, C. Le Pechoux³, A. Botticella⁵, S. Ammari², A. Gazzah², C. Caramella², J. Adam², D. Planchard², D. De Ruyscher¹, A.-M. Dingemans¹, B. Besse³; ¹NL, ²FR, ³CEDEX/FR, ⁴CEDEX 5/FR, ⁵BE
- 12:50 - 12:50 **1409P - Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)**
M. Riudavets Melia, I. Gabriela Sullivan, A. Barba Joaquín, G. Anguera Palacios, L. del Carpio, C. Molto Valiente, S.D. Camacho Arellano, S. Moron Asensio, P. Gomila Pons, M. Andres Granyó, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, C. González Blanco, A. Barnadas Molins, I. Gich Saladich, M. Majem Tarruella; ES
- 12:50 - 12:50 **1410P - Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)**
T. Ikeda¹, K. Ohashi¹, A. Sekine¹, Y. Ohe¹, T. Tsuda¹, Y. Kataoka¹, S. Hara¹, N. Okamoto¹, M. Kodani¹, S. Matsumoto¹, K. Goto²; ¹JP, ²Chiba/JP
- 12:50 - 12:50 **1411P - Identification of genomic markers of sensitivity and resistance to checkpoint inhibitors in non-small cell lung cancer in a real world clinico-genomic database**
K. Murugesan¹, G. Li², G. Kaushik², G. Singal², V. Miller², G. Frampton², L. Albacker¹; ¹US, ²MA/US
- 12:50 - 12:50 **1412P - HLA-DrbB1 heterozygosis and early auto-antibody rise predict prolonged survival in metastatic NSCLC patients undergoing PD-1 blockade**

P. Correale¹, R. Giannicola¹, C. Botta¹, P.S. Tagliaferri¹, P. Pastina¹, M. Monoriti¹, R. Saladino¹, A. Falzea¹, V. Barbieri¹, G. D'Arrigo¹, G. Tripepi¹, P. Tassone², L. Pirtoli¹; ¹IT, ²Calabria/IT

- 12:50 - 12:50 **1413P - Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients**
X. Mielgo Rubio¹, M. Sereno Moyano², L. Chara², R. López-Castro², J. Rubio-Martínez², A. Velastegui², C. Olier-Garate², S. Falagán², I. Gómez-Barreda², A. Riquelme², J. Silva-Ruiz², J. Moreno-Rubio², C. López², C. Bueno², A. Cardeña², E. Pérez-Fernández², M.P. Martí-Castelló², M. Sotelo-Lezama²; ¹Madrid/ES, ²ES
- 12:50 - 12:50 **1414P - Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model**
H. Wakelee¹, J. Aredo¹, S. Vali¹, N. Singh², S. Vasista², U. Mitra², T. Abbasi¹, S. Padda¹; ¹CA/US, ²IN
- 12:50 - 12:50 **1415P - Association between early immune-related adverse events and clinical outcomes in patients with advanced non-small cell lung cancer treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study**
K. Hosoya, D. Fujimoto, M. Tamiya, A. Tamiya, H. Suzuki, K. Hirano, T. Yokoyama, M. Morita, Y. Fukuda, M. Kanazu, T. Makio; JP
- 12:50 - 12:50 **1416P - Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)**
R. Ferrara¹, M. Naigeon¹, E. Auclin¹, B. Duchemann², L. Cassard¹, J. Medhi¹, L. Boselli¹, J. Grivel¹, A. Desnoyer¹, L. Mezquita¹, F. Aboubakar³, L. Hendriks⁴, D. Planchard¹, C. Caramella¹, J. Remon⁵, M. Ngocamus¹, C. Nicotra¹, B. Besse², N. Chaput²; ¹FR, ²CEDEX/FR, ³BE, ⁴NL, ⁵Barcelona/ES
- 12:50 - 12:50 **1417P - Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations**
S. Pilotto, G. Grizzi, I. Sperduti, M. Simbolo, C. Vicentini, A. Calìò, M. Caccese, A. Mafficini, L. Carbognin, V. Corbo, A. Gkountakos, A. Santo, M. Infante, M. Brunelli, A. Scarpa, G. Tortora, E. Bria; IT
- 12:50 - 12:50 **1418P - The need of re-biopsy: Increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer**
M. Lacour, S.Y. Lee, U. Rulle, A. Soltermann, E.J. Rushing, D. Soldini, S. Hiltbrunner, W. Weder, A. Curioni-Fontecedro; CH
- 12:50 - 12:50 **1419P - Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer**
G. Galli, M. Poggi, G. Fucà, G. Lo Russo, C. Proto, D. Signorelli, M. Vitali, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, M. Imbimbo; IT

- 12:50 - 12:50 **1420P - Soluble immune biomarkers to anti-PD1 treatment in non-small cell lung cancer (NSCLC)**
J. Garde-Noguera, E. Jantus-Lewintre, B. Honrubia Peris, S. Gallach Garcia, F. ZHANG, J. García Sánchez, S. Calabuig Fariñas, A. Blasco Cordellat, N. Piera Molons, J. Vidal-Martinez, J. Murado-Pardo, L.D. Condori Farfan, R. Gisbert-Criado, E. Escorihuela, C. Camps; ES
- 12:50 - 12:50 **1421P - Clinical characterization of rare EGFR mutations in non-small cell lung cancer and in silico prediction of drug sensitivity**
S. Ikemura¹, H. Yasuda¹, S. Matsumoto¹, M. Kamada¹, T. Betsuyaku¹, Y. Okuno¹, K. Goto², K. Tsuchihara¹, K. Soejima¹; ¹JP, ²Chiba/JP
- 12:50 - 12:50 **1422P - Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial**
A. Curioni¹, E. Felip², U. Dafni³, M.-A. Molina², O. Gautschi¹, S. Peters¹, B. Massutí², R. Palmero², S. Ponce², E. Carcereny², M. Früh¹, M. Pless¹, S. Popat⁴, S. Cuffe⁵, N. Karachaliou², R. Kammler¹, M. Kassapian⁶, H. Roschitzki-Voser⁷, R. Stahel¹, R. Rosell²; ¹CH, ²ES, ³Attica/GR, ⁴GB, ⁵IE, ⁶GR, ⁷Bern/CH
- 12:50 - 12:50 **1423P - Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: A positive prognostic factor for survival?**
I. Prediletto, E. Vasile, R. Bruno, E. Macerola, G. Pasquini, G. Fontanini, A. Falcone; IT
- 12:50 - 12:50 **1424P - The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)**
K. Usui, T. Yokoyama, A. Kisohara, Y. Mori, Y. Takeda, H. Ishida, N. Kusano, K. Kishi, U. Katsushima, T. Kuwako, H. Aono, Y. Shikama, K. Minato, H. Matsushima, K. Uemura, Y. Ohashi, H. Kunitoh; JP
- 12:50 - 12:50 **1425P - ABCB1 genetic polymorphism and pharmacokinetic analysis of low dose erlotinib in frail patients with EGFR mutation (mt)-positive, non-small cell lung cancer: TORG1425**
S. Miyamoto¹, T. Tokkito¹, A. Bessho², N. Fukamatsu¹, H. Kunitoh¹, M. Ishii¹, H. Tanaka¹, H. Aono¹, T. Fukui¹, K. Kusaka¹, Y. Hosomi¹, A. Hamada³, K. Yamada¹, H. Okamoto⁴; ¹JP, ²Okayama Prefecture/JP, ³JO, ⁴Kanagawa/JP
- 12:50 - 12:50 **1426P - Longitudinal plasma monitoring of subjects treated with EGFR-TKIs allows better understanding of evolution of acquired resistance and can inform optimal treatment strategies**
J. Palma¹, P. Vitazka², N. Tikoo¹, A. Balasubramanyam¹, L. Xi¹, S. Yaung¹, E. Kwok¹, A. Lovejoy¹, D. Klass¹, M. Heibeck³, K. Probst³, A. Rehfeldt³, E. Meldgaard⁴, A. Madsen⁴, M. Clement⁴, B. Sorensen⁴, P. Meldgaard⁴; ¹CA/US, ²US, ³DE, ⁴DK
- 12:50 - 12:50 **1428P - Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315)**

F. Griesinger, W. Eberhardt, A. Nusch, M. Reiser, C. Bernhardt, N. Marschner, M. Jaenicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, A. Rittmeyer, H. Bischoff, C. Waller, M. Thomas; DE

- 12:50 - 12:50 **1427P - Applicability of lung-molGPA index in non-small cell lung cancer patients with various gene alterations and brain metastases**
K. Chen¹, Y. Fan¹, Z. Huang¹, Y. Xu², X. Yu¹, H. Wang¹; ¹CN, ²Zhejiang/CN
- 12:50 - 12:50 **1429P - Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients**
M.H. Hong¹, M.H. Kim¹, S.-Y. Kim¹, S.G. Heo¹, H.-N. Kang¹, C.-W. Park¹, J.C. Barrett², D. Stetson², J. Chmielecki², A. Markovets², H.R. Kim¹, B.C. Cho¹; ¹KR, ²US
- 12:50 - 12:50 **1430P - Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)**
M. Kushnir¹, H. Winter¹, C. Murias¹, P. Bains¹, C. Abbosh², D. Papadatos-Pastos¹, T. Newsome-Davis¹, T. Ahmed¹, C. Swanton¹, M. Forster¹, D. Moore¹, P. Bennett¹, I. Faull³, R. Lanman⁴, H.-T. Arkenau¹; ¹GB, ²Yorkshire/GB, ³ES, ⁴US
- 12:50 - 12:50 **1431P - TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC**
P. Christopoulos, M. Kirchner, F. Bozorgmehr, V. Endris, M. Elsayed, N. Magios, A.-L. Volckmar, R. Penzel, F. Herth, C. Heussel, H. Winter, T. Muley, M. Meister, J. Fischer, S. Rieken, F. Lasitschka, H. Bischoff, P. Schirmacher, M. Thomas, A. Stenzinger; DE
- 12:50 - 12:50 **1432P - Hybrid capture NGS reliably detects a spectrum of clinically significant genetic aberrations in both, primary diagnostics and the relapse scenario**
S. Schatz¹, M. Falk², R. Menon¹, L. Heukamp¹, J. Roeper¹, F. Griesinger¹, M. Tiemann¹; ¹DE, ²Hamburg/DE
- 12:50 - 12:50 **1433P - Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in advanced non-small cell lung cancer**
K. Adamowicz, A. Romanowska, R. Zaucha; PL
- 12:50 - 12:50 **1434P - A phase II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer (KRSG1302)**
T. Sugiyama, T. Kasai, N. Koyama, K. Kobayashi, E. Hoshi, M. Nakayama, K. Mori; JP
- 12:50 - 12:50 **1435P - Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France: Final results of the AVANTAGE study**
F. Lione¹, D. Perol¹, P.-J. Souquet², H. Le Caer¹, E. Dansin², C. Audigier Valette², J.-L. Mouysset¹, M.L. Uffredi¹, M. Ionescu-Goga¹, K. Veerabudun¹, Y. Lelarge¹, E. Fabre-Guillevin¹; ¹FR, ²CEDEX/FR
- 12:50 - 12:50 **1436P - Randomized phase II study comparing cisplatin &&**

R. Koyama¹, H. Udagawa¹, E. Sugiyama², K. Komuta¹, M. Mori¹, T. Yokoyama¹, T. Sasaki¹, H. Saito¹, H. Ishida¹, H. Nakagawa¹, A. Sekine¹, A. Tamura¹, M. Shingyoji¹, K. Mizuno¹, A. Nakamura¹, A. Kinoshita³, T. Yamanaka¹, K. Goto²; ¹JP, ²Chiba/JP, ³Nagasaki/JP

12:50 - 12:50

1437P - Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. Plummer¹, N. Cook², T. Arkenau³, J. Melear⁴, C. Redfern⁴, A. Spira⁵, K. Chung⁶, T. Haddad⁷, S. Ramalingam⁸, R. Wesolowski⁴, E. Dean³, T. Goddemeier⁹, M. Falk⁹, G. Shapiro⁴; ¹Tyne and Wear/GB, ²Cambridgeshire/GB, ³GB, ⁴US, ⁵VA/US, ⁶SC/US, ⁷MN/US, ⁸GA/US, ⁹DE

12:50 - 12:50

1438P - A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease

Y. Usui¹, H. Kenmotsu², K. Mori¹, A. Ono², K. Yoh³, T. Baba¹, Y. Fujiwara¹, O. Yamaguchi¹, R. Ko¹, H. Okamoto⁴, N. Yamamoto¹, T. Ninomiya¹, T. Ogura¹, T. Kato¹; ¹JP, ²Shizuoka/JP, ³Chiba/JP, ⁴Kanagawa/JP

12:50 - 12:50

1439P - HALO 107-201: A phase Ib, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC)

M. Baumgart¹, M. Muhsin², W. Wu³, N. Gabrail⁴; ¹NY/US, ²US, ³CA/US, ⁴OH/US

12:50 - 12:50

1440P - Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type

F. Grossi¹, P. Jaskiewicz², E. Pichon³, G. Czyzewicz⁴, D. Kowalski², L. Ciuffreda¹, R. Garcia Gomez⁵, S. Caruso⁶, J. Bosch Barrera⁵, C. Ta Thanh Minh⁶, S. Gautier⁶, H. Hervieu⁶, S. Henriet⁶, G. De Castro Jr.⁷; ¹IT, ²PL, ³CEDEX 9/FR, ⁴Krakow/PL, ⁵ES, ⁶FR, ⁷SP/BR

12:50 - 12:50

1441P - Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026

Y. Kawashima, T. Fukuhara, N. Furuya, H. Saito, K. Watanabe, S. Iwasawa, Y. Tsunozuka, O. Yamaguchi, M. Okada, K. Yoshimori, I. Nakachi, A. Gemma, K. Azuma, K. Hagiwara, T. Nukiwa, S. Morita, K. Kobayashi, M. Maemondo; JP

12:50 - 12:50

1442P - Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

G. Goss¹, M. Cobo², S. Lu³, K. Syrigos⁴, K.H. Lee⁵, E. Göker⁶, V. Georgoulas⁴, W. Li³, D. Isla², A. Morabito⁷, Y.J. Min⁵, A. Ardizzoni⁷, A. Cseh⁸, S. Bender⁹, E. Felip²; ¹CA, ²ES, ³CN, ⁴GR, ⁵KR, ⁶TR, ⁷IT, ⁸AT, ⁹CT/US

12:50 - 12:50

1443P - Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset

J.H. Kang, B.C. Cho, D.-W. Kim, K. Park, J.-S. Lee, S.S. Yoo, S.Y. Lee, C.H. Kim, S.H. Jang, Y.-C. Kim, H.-K. Yoon, S.-W. Kim; KR

- 12:50 - 12:50 **1444P - A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)**
T. Stinchcombe¹, P. Janne¹, X. Wang¹, E. Bertino², J. Weiss¹, L. Bazhenova³, L. Gu¹, C. Lau¹, C. Paweletz¹, A. Jaslawski⁴, G. Gerstner¹, M. Baggstrom¹, S. Graziano⁵, J. Bearden, III¹, E. Vokes⁶; ¹US, ²OH/US, ³CA/US, ⁴WI/US, ⁵NY/US, ⁶IL/US
- 12:50 - 12:50 **1445P - A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027**
T. aiba, Y. Minegishi, O. Yamaguchi, S. Kuyama, S. Watanabe, K. Usui, M. Mori, O. Hataji, T. Nukiwa, S. Morita, K. Kobayashi, A. Gemma; JP
- 12:50 - 12:50 **1446P - Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence**
R. Flippot¹, E. Auclin¹, P. Biondani¹, E. Le Rhun², J. Adam¹, D. Planchard¹, C. Caramella¹, C. Le Pechoux², L. Lacroix¹, A. Gazzah¹, L. Mezquita¹, B. Besse²; ¹FR, ²CEDEX/FR
- 12:50 - 12:50 **1447P - Risk of not receiving second-line therapy is high in EGFR mt&&**
J. Roeper¹, M. Falk², S. Schatz¹, M. Tiemann¹, C. Wessler¹, G. Wiest¹, S. Sackmann¹, D. Ukena¹, L. Heukamp¹, F. Griesinger¹; ¹DE, ²Hamburg/DE
- 12:50 - 12:50 **1448P - Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study**
S. Schmid, D. Klingbiel, S. Aeppli, C. Britschgi, O. Gautschi, M. Pless, S. Rothschild, L. Wannesson De Nicola, W.-D. Janthur, D. Foerbs, I. Demmer, W. Jochum, M. Früh; CH
- 12:50 - 12:50 **1449P - Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany**
W. Brueckl, E. Laack, M. Reck, F. Griesinger, H. Schäfer, C. Kortsik, T. Gaska, J. Rawluk, S. Krüger, K. Kokowski, S. Budweiser, A. Schueler, S. Kiessling; DE
- 12:50 - 12:50 **1450P - Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer**
B. van Veggel, A. van der Wekken, S. Hashemi, R. Cornelissen, K. Monkhorst, D. Heideman, T. Radonic, E. Smit, E. Schuurin, J. De Langen; NL
- 12:50 - 12:50 **1451P - The characteristics and clinical outcome of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's tertiary referral center**
J. Chantharasamee, N. Pongvarin, P. Danchaiwijitr, S. Techawatanawanna; TH
- 12:50 - 12:50 **1452P - Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation**

S. Viteri¹, G.-C. Chang², R. Chiari³, B.C. Cho⁴, F. Ciardiello³, G. Curigliano³, T. Hida⁵, D.H. Lee⁴, W. Lim⁶, C.-C. Lin², A. Martinez¹, H. Murakami⁵, I. Natsume⁵, M. Nishio⁵, L. Paz-Ares¹, R. Soo⁶, V. Cattan⁷, E. Gandossi⁷, H. Heck⁷, K. Park⁴; ¹ES, ²TW, ³IT, ⁴KR, ⁵JP, ⁶SG, ⁷FR

- 12:50 - 12:50 **1453P - Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data**
C. Escriu¹, M. Sallam², L. del Carpio³, N. Tokaca², L. Solway², R. Shah², A. Fouzia², Q. Ghafoor², S. Popat², P. Postmus⁴; ¹Merseyside/GB, ²GB, ³ES, ⁴Merseyside/NL
- 12:50 - 12:50 **1454P - EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Nationwide register-based cohort study in Sweden**
S. Bergström, H. Nordahl Christensen, F. Wiklund, M. Bergqvist; SE
- 12:50 - 12:50 **1455P - Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC**
K. Ito¹, K. Murotani¹, A. Kubo¹, E. Kunii¹, H. Taniguchi¹, J. Shindo¹, K. Asada¹, K. Imaizumi¹, K. Tanaka¹, N. Inui¹, M. Okuno¹, O. Hataji¹, S. Hayai¹, T. Abe¹, T. Kimura¹, T. Tsuda¹, T. Yamaguchi¹, Y. Oya¹, T. Yoshida², T. Hida¹; ¹JP, ²US
- 12:50 - 12:50 **1456P - Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged >=70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results**
K. Reckamp¹, P. Gilman², B. Halmos³, M. Jahanzeb⁴, J. McCann⁵, H. Paripati⁶, L. Seneviratne⁷, J. Wallace⁸, B. Rueter⁹, A. Esler¹, E. Dowling¹, M. Koczywas¹; ¹US, ²PA/US, ³NY/US, ⁴FL/US, ⁵MA/US, ⁶AZ/US, ⁷CA/US, ⁸IL/US, ⁹CT/US
- 12:50 - 12:50 **1457P - Is there a difference in PFS or OS of T790M-mutated NSCLC patients treated with osimertinib either after chemotherapy or immediately after previous target therapy?**
C.H. Lai, M.-C. Lin, Y.-H. Tsai, C.-C. Wang; TW
- 12:50 - 12:50 **1458P - Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma**
X. Zheng, C. Huang, G. Lin; CN
- 12:50 - 12:50 **1459P - Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?**
M. Tamiya¹, A. Tamiya², H. Suzuki², K. Nakahama², Y. Taniguchi², K. Kunimasa², M. Kimura², T. Inoue², K. Nishino², T. Hirashima², S. Atagi², F. Imamura², T. Kumagai²; ¹Osaka/JP, ²JP
- 12:50 - 12:50 **1460P - Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience**
Q.S.-C. Chu¹, A. Agha¹, N. Devost¹, R. Walton¹, S. Ghosh¹, C. Ho²; ¹CA, ²British Columbia/CA

- 12:50 - 12:50 **1461P - ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) - European subset**
M. Tiseo¹, A. Santo¹, M. Hochmair², T. Geldart³, G. Metro⁴, E. Hanrahan⁵, K. Lamberg⁶, T. Moran⁷, C. Nyhus⁸, A. Paredes⁹, J. Vansteenkiste¹⁰, D. Vicente⁷, M. Miranda³, J. Rigas¹¹, F. de Marinis¹; ¹IT, ²AT, ³GB, ⁴(PG)/IT, ⁵IE, ⁶SE, ⁷ES, ⁸DK, ⁹OH/US, ¹⁰BE, ¹¹MD/US
- 12:50 - 12:50 **1462P - Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts)**
R. Tay¹, J. Chiramel², E. Montague², F. Wilson², Y. Summers², F. Blackhall², R. Califano²; ¹VIC/AU, ²GB
- 12:50 - 12:50 **1463P - Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF- β 2; and PD-L1, in second-line (2L) NSCLC**
L. Paz-Ares¹, T.M. Kim², D. Vincente¹, E. Felip¹, D.H. Lee², K. Lee², C.-C. Lin³, M. Oncala¹, M. Di Nicola⁴, R.M. Alvarez¹, I. Dussault⁵, C. Helwig⁶, L. Ojalvo⁵, J. Gulley⁷, B.C. Cho²; ¹ES, ²KR, ³TW, ⁴IT, ⁵MA/US, ⁶DE, ⁷MD/US
- 12:50 - 12:50 **1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?**
D. Rodriguez Abreu¹, M.C. Garassino², E. Esteban³, G. Speranza⁴, E. Felip³, M. Domine³, M. Hochmair⁵, S. Powell⁶, S. Cheng⁷, H. Bischoff⁸, N. Peled⁹, R. Hui¹⁰, M. Reck⁸, E. Garon¹¹, M. Boyer¹², F. Grossi², R. Jennens¹³, J. Yang⁶, M.C. Pietanza¹⁴, S. Gadgeel⁶; ¹Canary Islands/ES, ²IT, ³ES, ⁴QC/CA, ⁵AT, ⁶US, ⁷CA, ⁸DE, ⁹IL, ¹⁰NSW/AU, ¹¹CA/US, ¹²AU, ¹³VIC/AU, ¹⁴NJ/US
- 12:50 - 12:50 **1465P - Phase I dose escalation of pembrolizumab given concurrently with palliative thoracic radiotherapy (RT) for NSCLC**
R. Kumar¹, D. Walder², A. Pejanaute², R. Gunapala², J. Bhosle², N. Yousef², S. Popat², F. McDonald², I. Locke², K. Harrington², A. Tree², S. Lalondrelle², R. Huddart², M. O'Brien², M. Ahmed²; ¹Surrey/GB, ²GB
- 12:50 - 12:50 **1466P - Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer**
G. Galli, M. Poggi, G. Fucà, M. Imbimbo, C. Proto, D. Signorelli, M. Vitali, N. Zilembo, M. Ganzinelli, F. de Braud, M.C. Garassino, G. Lo Russo; IT
- 12:50 - 12:50 **1467P - Efficacy and safety of nivolumab for cytotoxic chemotherapy unfit patients with advanced non-small cell lung cancer: A phase II study**
Y. Okuma¹, S. Kitano¹, K. Watanabe¹, M. Yomota¹, Y. Hosomi¹, Y. Zenke², N. Yamamoto¹; ¹JP, ²Chiba/JP

- 12:50 - 12:50 **1468P - GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC**
M. Majem Tarruella¹, J. Campillo¹, J.F. Grau Béjar¹, E. Carcereny¹, R. Bernabe Caro¹, Y. Garcia¹, A. Artal-Cortes¹, M. González Cao¹, P. Lianes¹, A. Paredes Lario¹, M. Sereno Moyano¹, X. Mielgo Rubio², J.A. Macias¹, M. Provencio Pulla², D. Rodriguez-Abreu¹; ¹ES, ²Madrid/ES
- 12:50 - 12:50 **1469P - EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients**
A. Dixmier¹, D. Debieuvre¹, C. Raspaud¹, J.B. Auliac¹, N. Benoit¹, P. Bombaron², B. Asselain¹, A. Dumont¹, P. Lamoureux¹, N. Goyard¹, D. Moro-Sibilot¹, M. Perol³, F. Barlesi⁴, C. Audigier Valette³; ¹FR, ²CEDEX 8/FR, ³CEDEX/FR, ⁴CEDEX 20/FR
- 12:50 - 12:50 **1470P - Fractional polynomial network meta-analysis: A different approach to indirectly assess the comparative efficacy of 2L cancer immunotherapy (CIT) treatments for metastatic NSCLC**
C. Schulz¹, P. Chu², C. Berardo², B. Karthuria², J. Foo³, C. Morel³, C. Watkins⁴, M. Ballinger⁵, D. Gandara⁶; ¹DE, ²CH, ³NL, ⁴GB, ⁵US, ⁶CA/US
- 12:50 - 12:50 **1471P - Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer**
G. Ratnayake¹, M. Shankar², K. Roberts¹, R. Mason², B. Hughes¹, Z. Lwin², V. Jain¹, K. O'Byrne², B. Chua²; ¹AU, ²QLD/AU
- 12:50 - 12:50 **1472P - Immunotherapy in elderly patients (> 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience**
A. Luciani¹, L. Toschi², S. Fava¹, D. Cortinovis¹, V. Filipazzi¹, A. Tuzi¹, A. Marra¹, S. Rossi¹, A. Rossi¹, M. Blasi¹, M. Violati¹, L. Sala¹, F. Agustoni¹, P. Bidoli¹, S. Zonato¹, D. Ferrari¹; ¹IT, ²(MI)/IT
- 12:50 - 12:50 **1473P - Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients**
T. Kubo, H. Watanabe, K. Ninomiya, K. Kudo, D. Minami, E. Murakami, N. Ochi, T. Ninomiya, D. Harada, M. Yasugi, E. Ichihara, K. Ohashi, K. Fujiwara, K. Hotta, M. Tabata, Y. Maeda, K. Kiura; JP
- 12:50 - 12:50 **1474P - Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach**
F. GRUDE¹, R. Corre², T. Urban³, J. Bennouna², G. De Chabot¹, T. Chatellier¹, F. Denis¹, R. Descourt¹, J.-Y. Douillard⁴, C. Ricordel¹, O. Molinier¹, F. Pinguie¹, G. Robinet⁵, M. Travers¹, B. Moiteaux¹, D. Deniel Lagadec¹, F. Marhuenda¹; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR, ⁴CEDEX/CH, ⁵Cedex 2/FR
- 12:50 - 12:50 **1475P - Radiological identification of rapid progressions in advanced NSCLC patients treated with nivolumab**

P. Simões da Rocha, E. Ripoll, A. Corbera, M. Hardy-Werbin, A.F. Fernandez-Alarza, M. Orrillo, Á. Taus, E. Arriola; ES

- 12:50 - 12:50 **1476P - Role of immunotherapy (I) for advanced, pre-treated, non-squamous NSCLC (APNS-NSCLC): Preliminary data of a pooled analysis with network meta-analysis**
C. Cherubini, M. Papi, L. Gianni, C. Gianni, S.V.L. Nicoletti, M. Fantini, L.A. Lazzari Agli, D. Tassinari; IT
- 12:50 - 12:50 **1477P - Evaluation of progression-free survival (PFS) and one-year (1y) survival as surrogate endpoints (SE) in previously treated advanced non-small cell lung cancer (adNSCLC) in the era of immuno-oncology (IO)**
S. Zhao, Z. Zhang, T. Zhou, Y. Zhang, L. Zhang; CN
- 12:50 - 12:50 **1478P - Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)**
T. Ota¹, K. Kirita², H. Udagawa¹, S. Umemura¹, S. Matsumoto¹, K. Yoh², S. Niho¹, K. Goto²; ¹JP, ²Chiba/JP
- 12:50 - 12:50 **1479P - First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)**
E. Carcereny Costa¹, D. Rodriguez-Abreu², M. Guirado³, R. López-Castro², B. Massutí², J. Bosch Barrera², E. Nogueron Martinez², M.A. Sala Gonzalez², M. Domine Gomez², E. Del Barco Morillo², S. Cerezo Gonzalez², M. Dorta Suarez², J. Casal Rubio⁴, C. Camps², M.A. Muñoz², R. de las Peñas², J.A. Ortega dominguez², J. Gonzalez-Larriba², R. Bernabe Caro², M. Provencio Pulla⁵; ¹Barcelona/ES, ²ES, ³Alicante/ES, ⁴Pontevedra/ES, ⁵Madrid/ES
- 12:50 - 12:50 **1480P_PR - Effects of physical exercise in non-operable lung cancer patients undergoing palliative treatment**
J. Wiskemann¹, C. Titz¹, M. Schmidt¹, K. Steindorf¹, C. Ulrich², F. Herth¹, C. Heussel¹, H. Winter¹, M. Steins¹, S. Hummler¹, M. Thomas¹; ¹DE, ²US
- 12:50 - 12:50 **1481P - Extra-cost of brain metastases in patients with non-squamous non-small cell lung cancer (NSCLC): A French national hospital database analysis**
N. Girard, D. Cozzone, L. de Léotoing, C. Tournier, A. Vainchtock, B. Tehard, A. Cortot; FR
- 12:50 - 12:50 **1482P - Localablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients**
N. Frost, A. Tessmer, A. Schmittel, V. van Laak, S. Ochsenreither, B. Temmesfeld-Wollbrück, B. Schmidt, N. Suttorp, M. Witzenrath, C. Grohe; DE
- 12:50 - 12:50 **1483P - Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005-2015: The SCAN-LEAF study**

J. Sørensen¹, S. Ekman², P. Horvat³, D. Layton³, J. Kim³, M. Rosenlund³, A. Juarez-Garcia³, M. Daumont⁴, H. Jacobs³, L. Lacoïn⁵, O.T. Brustugun⁶, M. Planck²; ¹DK, ²SE, ³GB, ⁴BE, ⁵NJ/US, ⁶NO

- 12:50 - 12:50 **1484P - Treatment patterns in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) in Sweden: The SCAN-LEAF study**
S. Ekman¹, M. Planck¹, J. Sørensen², P. Horvat³, D. Layton³, J. Kim³, M. Rosenlund³, A. Juarez-Garcia³, M. Daumont⁴, H. Jacobs³, L. Lacoïn⁵, O.T. Brustugun⁶; ¹SE, ²DK, ³GB, ⁴BE, ⁵NJ/US, ⁶NO
- 12:50 - 12:50 **1485P - NSCLC with well controlled extra-cranial disease but uncontrolled brain metastases**
H.A. Jung¹, K. Park², J.-M. Sun², S.H. Lee², J.S. Ahn², M.-J. Ahn², S. Park²; ¹Gyeong-Ki-Do/KR, ²KR
- 12:50 - 12:50 **1486P - Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partitioning analysis (RPA) model modification**
C. Salvador Coloma, D. Lorente, C. Escoin, J. Mendez, O. Juan-Vidal; ES
- 12:50 - 12:50 **1487P - LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer**
K. Yoh¹, T. Seto², M. Satouchi², M. Nishio², N. Yamamoto², H. Murakami², N. Nogami², S. Kuroda², S. Nomura², A. Sato², K. Tsuchihara², T. Kohno², S. Matsumoto², K. Goto¹; ¹Chiba/JP, ²JP
- 12:50 - 12:50 **1488P - Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcS#x000E9; trial**
J. Mazières¹, L. Montané¹, F. Barlesi², X. Quantin³, J. Trédaniel¹, J. Le Treut¹, V. Avrillon⁴, A. Lavolé¹, V. Westeel⁵, F. Orsini Piocelle¹, E. Pichon⁶, L. Thiberville¹, C. Borel⁵, P. Renault¹, M. Jaffro¹, S. Collot¹, G. Ferretti¹, F. Legrand¹, C. Mahier Ait Oukhatar¹, J. Blay¹; ¹FR, ²CEDEX 20/FR, ³CEDEX 5/FR, ⁴Cedex 08/FR, ⁵CEDEX/FR, ⁶CEDEX 9/FR
- 12:50 - 12:50 **1489P - Treatment patterns and overall survival in patients with BRAF-mutated metastatic non-small cell lung cancer**
R. Goyal¹, A. Kron², J. Wolf², J. Mazieres³, C. Chouaid³, K. Davis⁴, M. Perrinjaquet⁵, S. Knoll⁶; ¹US, ²DE, ³FR, ⁴NC/US, ⁵GB, ⁶NJ/US
- 12:50 - 12:50 **1490P - A prospective observational study of HER2 alterations in NSCLCs: HOT1303-A**
T. Goda¹, I. Kinoshita¹, S. Oizumi², K. Nakano¹, T. Harada¹, Y. Kawai¹, J. Sakakibara-Konishi¹, H. Yokouchi³, N. Morikawa¹, N. Yamada¹, S. Yamazaki¹, S. Sugawara⁴, H. Asahina², T. Amano², Y. Hatanaka¹, Y. Matsuno¹, H. Nishihara¹, H. Isobe¹, M. Nishimura¹, H. Dosaka-Akita¹; ¹JP, ²Hokkaido/JP, ³Fukushima/JP, ⁴Miyagi/JP

- 12:50 - 12:50 **1491P - A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial**
I. Kinoshita¹, T. Goda¹, K. Watanabe¹, M. Maemondo¹, S. Oizumi², T. Amano², Y. Hatanaka¹, Y. Matsuno¹, H. Nishihara¹, H. Asahina², T. Harada¹, K. Goto³, H. Isobe¹, M. Nishimura¹, H. Dosaka-Akita¹; ¹JP, ²Hokkaido/JP, ³Chiba/JP
- 12:50 - 12:50 **1492P - BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study**
X. Hu, X. Zheng, H. Mo, X. Cui, L. Ding, F. Tan, P. Hu, Y. Shi; CN
- 12:50 - 12:50 **1493P - Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations**
P. JAMME¹, F. Escande¹, C. Descarpentries¹, M.C. Copin¹, E. Dansin², T. Vanparis¹, D. Tulasne¹, S. Baldacci¹, Z. Kherrouche¹, A. Cortot¹; ¹FR, ²CEDEX/FR
- 12:50 - 12:50 **1494P - Risk of lung cancer following pulmonary tuberculosis: A nationwide population-based cohort study, South Korea**
S.-S. Han, J. Heo, S.-J. Lee; KR
- 12:50 - 12:50 **1495P - Analysis of the relationship between heading N / L and survival in patients treated with immunotherapy in lung cancer**
N. De Dios Alvare, M. Costa Rivas, S. Agraso Busto, A. Alonso Herrero, M.J. Villanueva Silva, D. Pereiro Corbacho, C. García Benito; ES
- 12:50 - 12:50 **1496P - Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK⁺) non-small cell lung cancer (NSCLC)**
H. Wakelee¹, K. Reckamp², T. Leal², S. Patel¹, G. Blumenschein², E. Shum², J. Nieva², G. Oxnard³, R. Sanborn⁴, S. Waqar², K. Zeman², G. Dukart², K. Harrow⁵, C. Liang², A. Holzhausen², L. Horn⁶; ¹CA/US, ²US, ³MA/US, ⁴OR/US, ⁵FL/US, ⁶TN/US
- 12:50 - 12:50 **1497P - JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results**
B.C. Cho¹, J.-S. Lee¹, J.-Y. Han¹, E.K. Cho¹, E. Haura², K.H. Lee¹, J. Bauml³, R. Sanborn⁴, M. Curtis⁵, E. Attiyeh⁵, N. Haddish-Berhane⁵, K. Bae⁵, R. Knoblauch⁵, L. Sherman⁵, M. Lorenzi⁵, K. Park¹; ¹KR, ²US, ³PA/US, ⁴OR/US, ⁵NJ/US
- 12:50 - 12:50 **1498P - Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): Consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)**
H. Horinouchi, Y. Matsumoto, S. Murakami, Y. Goto, S. Kanda, Y. Fujiwara, N. Yamamoto, Y. Nakayama, Y. Ohe; JP
- 12:50 - 12:50 **1499TiP - Tumor treating fields concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase III LUNAR study**
U. Weinberg¹, O. Farber², M. Giladi², Z. Bomzon², E. Kirson²; ¹CH, ²IL

- 12:50 - 12:50 **1500TiP - eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients**
L. Horn¹, Y.-L. Wu², M. Reck³, H. Wakelee⁴, C. Liang⁵, K. Harrow⁶, V. Oertel⁵, T. Mok⁷;
¹TN/US, ²Guangdong/CN, ³DE, ⁴CA/US, ⁵US, ⁶FL/US, ⁷CN
- 12:50 - 12:50 **1501TiP - Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for advanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study)**
A. Hata¹, N. Katakami², K. Nishino², M. Mori², T. Yokoyama², T. Kurata², M. Tachihara², N. Takase², H. Daga², T. Kijima², S. Morita², K. Sakai², K. Nishio², M. Satouchi², S. Negoro²; ¹Hyogo/JP, ²JP
- 12:50 - 12:50 **1502TiP - Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial**
F. Bozorgmehr, A. Hommertgen, F. Lasitschka, J. Krisam, J. Debus, J. Fischer, M. Bischof, A. Atmaca, S. Wetzels, M. Faehling, D. Bottke, C. Grohe, W. Engel-Riedel, E. Ingenhoff, D. Heigener, N. Reinmuth, C. Schumann, M. Wermke, M. Thomas, S. Rieken; DE
- 12:50 - 12:50 **1503TiP - CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC**
S. Gettinger¹, T. Beck², X. Yang², B. Telivala², D. Morgensztern², V. Velcheti², S. Ramalingam³, K. Schalper¹, M. Dajee², A. Ranck², R. Yang², D. Spigel⁴; ¹CT/US, ²US, ³GA/US, ⁴TN/US
- 12:50 - 12:50 **1504TiP - Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape**
C. Grohe, I. Zander, K. Lütke-Heckenkamp, W. Blau, S. Krüger, C. Franke, H. Mueller-Huesmann, W. Brückl, N. Basara, D. Ukena, S. Lang, J. Atz, R. Kaiser; DE
- 12:50 - 12:50 **1505TiP - A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer**
F. Wu, G. Gao, C. Zhou, X. Kang, Y. Zhou; CN
- 12:50 - 12:50 **1506TiP - Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC**
D. Planchard¹, P. Janne², H. Yu², D. Moro-Sibilot¹, T. Goldberg², X. Gu³, J. Li², J. McGill², C. Yu², E. Slosberg³; ¹FR, ²US, ³NJ/US
- 12:50 - 12:50 **1507TiP - Ultra-early response capturing in the treatment of non-squamous NSCLC using diffusion-weighted MRI: A prospective multicenter study**

G. Heussel, N. Batora, M. Schneider, P. Flechsig, J. Krisam, C. Wiedemann, O. Sedlacek, I. Fellhauer, H.-U. Kauczor, M. Thomas, H. Golpon, J. Vogel-Claussen, A. Tufman, J. Dinkel, A. Guenther, S. Janciauskiene, H. Suelmann, M. Meister, C. Heussel, F. Bozorgmehr; DE

- 12:50 - 12:50 **1508TiP - Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial**
J. Kuon, F. Bozorgmehr, M. Schneider, J. Krisam, F. Lasitschka, M. Serke, W. Schuette, N. Moosmann, W. Gleiber, M. Faehling, M. Wermke, P. Schuett, M. Boesche, V. van Laak, L. Fischer von Weikersthal, M. Ulmer, C. Meyer zum Büschenfelde, J. Fischer, M. Thomas; DE
- 12:50 - 12:50 **1509TiP - Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)**
Y. Elamin¹, M. Antonoff², C. Blakely³, M. Baggstorm¹, T. Bivona¹, X. Le¹, A. Louie⁴, R. Doebele¹, C. Rusthoven¹, P. Lee³, R. Govindan¹, S. Swisher², V. Papadimitrakopoulou¹, J. Heymach², D. Gomez¹; ¹US, ²TX/US, ³CA/US, ⁴CA
- 12:50 - 12:50 **1510TiP - The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors**
E. Garralda¹, M. van Hoef², S. Ochsenreither³, L. Gianni⁴, D. Lorusso⁴, W. Fiedler³, U. Keilholz³, K. Klinghammer³, C. Dicke³, M. Kebenko³, I. Matos¹, J. Taberero¹, F. Raspagliesi⁴, G. Del Conte⁴, B. Habel³, H. Baumeister³, A. Zurlo³; ¹ES, ²CH, ³DE, ⁴IT
- 12:50 - 12:50 **SCLC**
- 12:50 - 12:50 **1668P - A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies**
T. Stinchcombe¹, W. Fan², S. Schild³, E. Vokes⁴, J. Bogart⁵, Q.-T. Le⁶, C. Thomas, Jr.¹, M. Edelman¹, L. Horn⁷, R. Komaki⁸, H. Cohen², A. Ganti⁹, H. Pang¹⁰, X. Wang¹; ¹US, ²NC/US, ³AZ/US, ⁴IL/US, ⁵NY/US, ⁶CA/US, ⁷TN/US, ⁸TX/US, ⁹NE/US, ¹⁰CN
- 12:50 - 12:50 **1669P - Treatment beyond four cycles of first line platinum and etoposide chemotherapy in real-life patients with stage IV small cell lung cancer: A retrospective study of the Merseyside and Cheshire cancer network**
M. Sallam¹, H. Wong¹, C. Escriu²; ¹GB, ²Merseyside/GB
- 12:50 - 12:50 **1670P - Timing of treatment in small cell lung cancer**
S. Bhandari¹, D. Pham², C. Pinkston², M. Oechsli², G. Kloecker²; ¹US, ²KY/US
- 12:50 - 12:50 **1671P - Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy**

J. Sorrentino¹, A. Lai¹, J. Weiss¹, K. Dragnev¹, T. Owonikoko², S. Adler³, J. Antal¹, R. Malik¹, P. Roberts¹; ¹US, ²GA/US, ³NC/US

12:50 - 12:50 **1672P - Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study**

M. Thomas¹, S. Ponce Aix², A. Navarro Mendivil², J. Riera Knorrenschild¹, M. Schmidt¹, E. Wiegert¹, K. Kapp¹, C. Mauri³, M. Domine Gomez², J. Kollmeier¹, P. Sadjadian¹, K.-P. Fröhling¹, R. Huber¹, M. Wolf¹; ¹DE, ²ES, ³GB

12:50 - 12:50 **1673P - Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)**

F. Gelsomino, M. Tiseo, F. Barbieri, F. Riccardi, L. Cavanna, A. Frassoldati, A. Delmonte, L. Longo, C. Dazzi, S. Cinieri, I. Colantonio, M. Tognetto, D. Baldari, L. Tofani, A. Ardizzoni; IT

12:50 - 12:50 **1674P - Safety of belotecan as second-line treatment for recurrent small cell lung cancer: A phase IIb randomized multicenter study**

J.H. Kang¹, H.T. Kim², K.H. Lee³, D.-W. Kim³, S.-W. Kim³, H.R. Kim³, J.-H. Kim³, J.H. Choi³, H.J. An³, J.-S. Kim³, J.S. Jang³, B.-S. Kim³; ¹KP, ²KR/KR, ³KR

12:50 - 12:50 **1675P - Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC**

D. von Eiff, F. Bozorgmehr, P. Christopoulos, I. Chung, D. Bernhardt, S. Rieken, S. Liersch, T. Muley, S. Kobinger, M. Thomas, M. Steins; DE

12:50 - 12:50 **1676P - Over-expression of shh is prognostic marker in patients with extensive stage small cell lung cancer**

S. Lim, J. Kim, S.Y. Park; KR

12:50 - 12:50 **1677P - UCHL1 has prognostic relevance and is a therapeutic target in high-grade neuroendocrine lung cancers**

Y. Shimada, T. Okano, T. Ohira, N. Ikeda; JP

12:50 - 12:50 **1678P - Robustness of DLL3 (SP347) immunohistochemistry assay for detection of DLL3 protein in small cell lung cancer**

C. Powell, E. Elgabry, B. Holmes, D. Tyree, R. Marati, B. Admire, T. Birdi, A. Hanlon Newell, B. Damadzadeh, D. Dalvi, R. Huang; US

12:50 - 12:50 **1679P - Residential radon and small cell lung cancer: A systematic review**

Á. Rodríguez Martínez, A. Ruano Ravina, M. Torres Duran; ES

12:50 - 12:50 **1680P - Nomogram for predicting the benefit of surgery for stage IA-IIB small cell lung cancer**

Y. Wang, Z. Wang, Q. Zheng; CN

12:50 - 12:50 **Thoracic malignancies, other**

- 12:50 - 12:50 **1807P - STELLAR: Final results of a phase II trial of TTFIELDS with chemotherapy for first-line treatment of pleural mesothelioma**
F. Grosso¹, J. Aerts², J. Madrzak³, R. Dziadziuszko³, R. Ramlau³, S. Cedres⁴, B. Hiddinga⁵, J. van Meerbeeck⁵, M. Mencoboni¹, D. Planchard⁶, A. Chella¹, L. Crino¹, M. Krzakowski³, G.L. Ceresoli¹; ¹IT, ²Noord Brabant/NL, ³PL, ⁴ES, ⁵BE, ⁶FR
- 12:50 - 12:50 **1808P - Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma**
L. Losi, F. Bertolini, L. Scurani, G. Guaitoli, C. Baldessari, A. Ambrosini Spaltro, L. Botticelli, A. Maiorana, F. Barbieri, S. Cascinu; IT
- 12:50 - 12:50 **1809P - Development and validation of a deep learning model using biomarkers in pleural effusion for prediction of malignant pleural mesothelioma**
S. Ikegaki, Y. Kataoka, T. Otsu, T. Takemura, M. Shimada; JP
- 12:50 - 12:50 **1810P - Elective nodal irradiation as adjuvant radiotherapy for advanced thymomas and thymic carcinomas**
Y.J. Kim, S.S. Kim, S.Y. Song, E.K. Choi; KR
- 12:50 - 12:50 **1811P - Clinicopathological features of thymoma with the expression of programmed death-ligand 1**
S. Hakiri¹, T. Fukui¹, S. Mori¹, K. Kawaguchi¹, S. Nakamura¹, N. Ozeki¹, T. Kato¹, M. Goto¹, Y. Yatabe², K. Yokoi¹; ¹JP, ²Aichi/JP
- 12:50 - 12:50 **1812P - The impact of PD-L1, TGF-β&&**
J. Duan, X. Liu, H. Chen, H. Bai, T. Xu, S. Cai, J. Wang; CN
- 12:50 - 12:50 **1813P - Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)**
B. Hermans¹, J. Derks¹, E. Thunissen¹, R. van Suylen¹, M. den Bakker¹, H. Groen¹, E. Smit², R. Damhuis¹, E. van den Broek¹, P. PALGA-group¹, C. Stallinga¹, G. Roemen¹, E. Speel¹, A.-M. Dingemans¹; ¹NL, ²ES
- 12:50 - 12:50 **1814P - Computed tomography features of resected lung adenocarcinomas with spread through air spaces**
Y. Yamada¹, G. Toyokawa², T. Tagawa¹, T. Kamitani¹, Y. Yamasaki¹, F. Shoji¹, K. Yamazaki¹, S. Takeo¹, Y. Oda¹; ¹JP, ²Fukuoka/JP
- 12:50 - 12:50 **1816P - Survival outcomes for patients with lobectomy and wedge resection in lung cancer**
S. Alshafie, S. Ahmed; EG
- 12:50 - 12:50 **1815P - Comparative proteomic analysis of acetylation profiles in esophageal squamous carcinoma cells**

Y. Dai, J. Li; CN

- 12:50 - 12:50 **1817TiP - SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial**
Y. Metaxas¹, A. Xyrafas¹, M. Mark¹, M. Pless¹, M. Frueh¹, P. Froesch¹, M. Schneider¹, C. Biaggi Rudolf¹, F. Grosso², R. von Moos¹; ¹CH, ²IT
- 12:50 - 12:50 **1818TiP - Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM**
M. Pagano¹, F. Zanelli², R. Gnani², C. Bonelli², M. Tiseo², L. Boni², G.L. Ceresoli², P.A. Zucali², F. Grosso², G. Pasello², F. Cappuzzo², C. Pinto²; ¹RE/IT, ²IT
- 12:50 - 13:10 **Translational research**
- 13:10 - 13:10 **1838P - CANscript[®] as a patient-derived predictive platform for individualizing treatment in lung cancer**
G. Babu¹, K. Deepak¹, B. Balakrishnan¹, M. Biswas¹, A. Prasath¹, P. Radhakrishnan², A. Chatterjee¹, S. Thiyagarajan¹, P. Chaudhuri¹, P. Majumder²; ¹IN, ²US
- 13:10 - 13:10 **1839P - Whole-exome cfDNA profiling captures the mutational signatures of metastatic breast cancer for monitoring disease evolution**
R. Hastings¹, M. Openshaw¹, M. Vazquez², D. Fernandez-Garcia¹, D. Guttery¹, K. Page¹, B. Toghiani¹, A. Thomas¹, S. Ahmed¹, R. Toledo², J. Shaw¹; ¹GB, ²ES
- 13:10 - 13:10 **1840P - Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody**
S. Brett¹, S. Yadavilli², L. Seestaller-Wehr³, S. Bhattacharya², H. Jackson², M. Bi², J. Willoughby¹, T. Zhang², Y.-B. Liu², Y.K. Katlinskaya², H. Shi², J. Jing², A. Hahn², S. Speller¹, D. David Figueroa², J. Yu², D. Olive⁴, M. Cragg¹, P. Mayes², A. Hoos²; ¹GB, ²US, ³PA/US, ⁴FR
- 13:10 - 13:10 **1841P - Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability**
I. Matos Garcia¹, A. García Ruiz¹, J. Martin-Liberal¹, C. Hierro¹, M. Ochoa De Olza Amat¹, C. Viaplana¹, G. Mur¹, M. Vieito Villar², I. Brana¹, A. Azaro¹, C. Perez¹, V. Rodriguez Freixinos¹, G. Argiles¹, M. Oliveira¹, E. Felip¹, E. Muñoz-Couselo¹, J. Taberner¹, R. Dienstmann¹, E. Garralda¹; ¹ES, ²La Coruña/ES
- 13:10 - 13:10 **1842P - Foretinib circumvents the NTRK1 G667C mutation-associated entrectinib-resistance in the brain and liver metastases produced by NTRK1 fusion-positive tumor cells**
S. Yano¹, A. Nishiyama², K. Kita², S. Takeuchi²; ¹Ishikawa/JP, ²JP
- 13:10 - 13:10 **1843P - Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial**

P. Vuagnat¹, C. Baldini², L. Verlingue¹, P. Martin Romano¹, A. Varga², A. Hollebecque¹, S. Postel-Vinay¹, A. Gazzah¹, R. Bahleda², A. Marabelle¹, V. Ribrag¹, S. Champiat¹, J.-M. Michot¹, J.-C. Soria³, C. Massard²; ¹FR, ²CEDEX/FR, ³CEDEX/US

- 13:10 - 13:10 **1844P - Prognostic implications of mismatch repair deficiency in patients with early-stage colorectal and endometrial cancer**
E. Fountzila¹, V. Kotoula², G. Pentherdoudakis¹, K. Manousou¹, E. Vrettou¹, C. Poullos¹, C. Papadimitriou³, G. Raptou¹, E. Pectasides⁴, G. Polychronidou¹, G. Karayannopoulou¹, S. Chrisafi¹, P. Papakostas¹, T. Makatsoris⁵, A. Psyrri¹, E. Samantas⁶, M. Bobos¹, C. Christodoulou⁷, D. Pectasides¹, G. Fountzilas¹; ¹GR, ²Central Macedonia/GR, ³Attiki/GR, ⁴MA/US, ⁵Rion/GR, ⁶Attica/GR, ⁷N. Faliro/GR
- 13:10 - 13:10 **1845P - Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials**
M. Mau-Sorensen¹, M. van Bussel², M. Kuipers³, D. Nielsen¹, H. Verheul², P. Aftimos⁴, M. de Jonge², B. van Triest², J. Falkenius⁵, J. Debus³, E. Troost³, M. Samuels⁶, B. Sarholz³, V. Budach³, S. Goel⁶, G. Locatelli³, P. Geertsens¹; ¹DK, ²NL, ³DE, ⁴BE, ⁵SE, ⁶US
- 13:10 - 13:10 **1846P - Role of TP53 mutations in relation to response to anti-ALK agents in EML4-ALK-translocated NSCLC patients**
M. Canale¹, A. Delmonte², C. Dazzi¹, A. Gamboni¹, C. Casanova¹, M. Papi¹, M. Mariotti¹, N. De Luigi¹, M. Burgio¹, G. Minuti¹, D. Calistri¹, M. Bonafè¹, L. Crinò¹, P. Ulivi¹; ¹IT, ²Forlì-Cesena/IT
- 13:10 - 13:10 **1847P - Meta-enrichment analysis to identify a higher response patient population to S-1/cisplatin for advanced gastric cancer**
M. Takeuchi¹, M. Takeuchi¹, H. van Laarhoven², X. Fang¹, P. Pfeiffer³, J. Ajani⁴; ¹JP, ²NL, ³DK, ⁴US
- 13:10 - 13:10 **1848P - Predictive significance of tumour angiogenic and anti-angiogenic VEGF-A splice variants in patients with metastatic colorectal cancer**
G. Pentheroudakis¹, V. Kotoula², G.-A. Koliou¹, K. Papadopoulou¹, E. Samantas³, T. Makatsoris⁴, V. Karavasilis², D. Mauri¹, I. Efstratiou¹, D. Bafaloukos¹, P. Papakostas¹, A. Psyrri¹, G. Papatsibas¹, G. Zarkavelis¹, A. Goussia¹, I. Bompolaki¹, G. Oikonomopoulos⁵, A. Christopoulou¹, D. Pectasides¹, G. Fountzilas¹; ¹GR, ²Central Macedonia/GR, ³Attica/GR, ⁴Rion/GR, ⁵Athens/GR
- 13:10 - 13:10 **1849P - ATR inhibition with radiation creates an inflammatory tumour microenvironment**
M. Dillon, K. Bergerhoff, M. Pedersen, H. Whittock, E. Patin, H. Smith, J. Paget, R. Patel, G. Bozhanova, S. Foo, J. Campbell, C. Ragulan, E. Fontana, A. Wilkins, A. Sadanandam, A. Melcher, M. McLaughlin, K. Harrington; GB

- 13:10 - 13:10 **1850P - RNA-based analysis of anaplastic lymphoma kinase (ALK) fusions in non-small cell lung cancer (NSCLC) cases showing immunohistochemistry/fluorescence in-situ hybridisation (IHC/FISH) discordance**
C. Vollbrecht, D. Lenze, M. Hummel, A. Lehmann, M. Moebs, N. Frost, P. Jurmeister, L. Schweizer, U. Kellner, M. Dietel, M. von Laffert; DE
- 13:10 - 13:10 **1851P - The combination of MEK inhibitor and anti PD-L1: Effects on organoid models from NSCLC biopsies**
C.M. Della Corte, G. Barra, V. Ciaramella, R. Di Liello, M. Fasano, F. Ciardiello, F. Morgillo; IT
- 13:10 - 13:10 **1852P - Intraoperative fluorescent image-guided detection of esophageal cancer in rabbit and patient specimens**
J. Rho, Y.H. Quan, B.H. Choi, B.-M. Kim, K.N. Han, Y.H. Choi, H.K. Kim; KR
- 13:10 - 13:10 **1853P - Interaction between cancer associated fibroblasts and cancer cells influence immune infiltrate and is modulated by therapeutic agents**
A. Rullan Iriarte¹, E. Arwert², E. Milford², P. Chakravarty², A. Melcher², K. Harrington², E. Sahai²; ¹Barcelona/ES, ²GB
- 13:10 - 13:10 **1854P - Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer**
T. Mizukami, Y. Sunakawa, H. Arai, M. Chosokabe, A. Doi, Y. Horie, M. Hirakawa, O. Saji, S. Naruki, N. Izawa, T. Ogura, T. Tsuda, T. Enomoto, S. Mikami, T. Fujino, T. Otsubo, T. Nakajima; JP
- 13:10 - 13:10 **1855P - CD5 and CD6: Evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer**
A. Moreno¹, S. Calabuig Fariñas¹, S. Gallach Garcia¹, A. Fernando¹, I. Simoes¹, E. Carreras¹, M. Consuegra-Fernández¹, A. Blasco Cordellat¹, A. Cunquero Tomas¹, M. Martorell¹, C. Camps¹, F. Lozano¹, R. Sirera Perez², E. Jantus-Lewintre¹; ¹ES, ²NA
- 13:10 - 13:10 **1856P - Identification of the rational combination of two epigenetic inhibitors therapy in refractory AML using patient tumor derived ex vivo platform**
P. Majumder¹, G. Babu², C. Rajagowda², S. Thiyagarajan², M. Biswas², P. Radhakrishnan¹, P. Chaudhuri², A. Chatterjee²; ¹US, ²IN
- 13:10 - 13:10 **1857P - Tyrosine kinase inhibitors and acid-inhibitory drugs: Strong concomitant dispensing and drug-drug interaction risk**
F. GRUDE, C. Vigneau-Victorri, D. Deniel Lagadec, E. Michaud, H. Bourgeois, B. Forestier, F. Marhuenda; FR
- 13:10 - 13:10 **1858P - Intraoperative detection of resection margin by inhalation of ICG in lung cancer preclinical study**
Y.H. Quan, C.H. Oh, D. Jung, J.-Y. Lim, B.H. Choi, J. Rho, Y. Choi, K.N. Han, J.-H. Park, H.K. Kim, Y.H. Choi; KR

- 13:10 - 13:10 **1859P - Proteomic-based machine learning computational analysis discovered biomarkers of aberrant vesicle-exosomal trafficking to determine chemotherapeutic responses in breast cancer**
H. Ryu, D.H. Han, K.-M. Lee, K. Kim; KR
- 13:10 - 13:10 **1860P - Carcinoma of unknown origin: Deep genomic profile helps to achieve an accurate diagnosis**
A. Fernandez Díaz¹, V. Iranzo Gonzalez-Cruz¹, A.J. Cunqueiro Tomas¹, C. Avila Andrade¹, E. Jantus-Lewintre¹, S. Calabuig Fariñas¹, J.E. Ales¹, M. Valero¹, G. D'Errico¹, R. Pazo Cid¹, A. Gallego Martínez¹, A. Viana¹, S. Ponce Aix¹, J.A. Pérez-Fidalgo¹, A. Terradez², A. Rodrigo², L. Alvarez², G. Beniuga², M. Martorell¹, C. Camps¹; ¹ES, ²BE
- 13:10 - 13:10 **1861P - Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy**
J. Lee¹, S.Y. Lim², A. Menzies¹, M. Carlino², A. Guminski², K. Nahar¹, D. Palmieri², E. Breen², R. Kefford¹, R. Scolyer¹, G. Long², H. Rizos²; ¹AU, ²NSW/AU
- 13:10 - 13:10 **1862P - A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors**
J. Bendell¹, K. Moore², M. Patel³, C. Chua⁴, H.-T. Arkenau⁵, G. Dukart⁴, K. Harrow⁶, C. Liang⁴; ¹TN/US, ²Oklahoma/US, ³MN/US, ⁴US, ⁵GB, ⁶FL/US
- 13:10 - 13:10 **1863P - Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR$\#$0002B;) non-small cell lung cancer (NSCLC)**
P.N. Ding¹, T. Becker², V. Bray¹, W. Chua¹, Y.F. Ma², A. Luk², J. Po², D. Lynch², N. Caixeiro², P. de Souza², T. Roberts²; ¹NSW/AU, ²AU
- 13:10 - 13:10 **1864P - Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information**
T. Ettrich, D. Schwerdel, A. Dolnik, F. Beuter, T. Blätte, S. Schmidt, N. Stanescu-Siegmund, J. Steinacker, R. Marienfeld, A. Kleger, L. Bullinger, T. Seufferlein, A. Berger; DE
- 13:10 - 13:10 **1865P - Interactions of cancer stem cell and immune microenvironment in non-small cell lung cancer (NSCLC)**
F. ZHANG¹, N. Dong¹, S. Torres¹, S. Calabuig Fariñas¹, R. Sirera Perez², M. Mosqueda¹, E. Escorihuela¹, E. Jantus-Lewintre¹, C. Camps¹; ¹ES, ²NA
- 13:10 - 13:10 **1866P - Association of the rs1883832 variant of CD40 with NSCLC risk and overall survival**
F.-I. Dimitrakopoulos¹, A. Antonacopoulou², A. Kottorou¹, S. Marousi², I. Koukourikou², C. Scopa², D. Dougenis², V. Tzelepi², H. Kalofonos²; ¹Rion/GR, ²GR
- 13:10 - 13:10 **1867P - Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer**

S. Khakoo¹, P. Carter², N. Valeri², R. Shaikh², T. Jones², R. Begum², I. Rana², S. Picchia², M. Bali², G. Brown², A. Wotherspoon², M. Terlizzo², K. von Loga², I. Ahmed², D. Watkins², I. Chau¹, N. Starling², D. Tait², M. Hubank², D. Cunningham²; ¹Surrey/GB, ²GB

- 13:10 - 13:10 **1868P - A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients**
F. Innocenti¹, C. Jiang², A. Sibley², S. Denning², A. Etheridge², D. Watson², D. Niedzwiecki³, A. Hatch², H. Hurwitz², A. Nixon³, Y. Furukawa², M. Kubo⁴, D. Crona², H. Kindler⁵, H. McLeod², M. Ratain⁵, K. Owzar²; ¹US/US, ²US, ³NC/US, ⁴JP, ⁵IL/US
- 13:10 - 13:10 **1869P - Effect of a combined treatment with iPS cells derived dendritic cells and proton beam irradiation in a murine subcutaneous melanoma model**
Y. Wang, L. Sun, X. Li, K. Tsuboi; JP
- 13:10 - 13:10 **1870P - Developing the liquid biopsy in gastroesophageal adenocarcinoma: Disease monitoring and detection of minimal residual disease**
M. Openshaw, B. Ottolini, C. Richards, D. Guttery, J. Shaw, A. Thomas; GB
- 13:10 - 13:10 **1871P - Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>#x0003E;C]) polymorphisms**
J. Huszno, Z. Kolosza; PL
- 13:10 - 13:10 **1872P - Phase I pharmacological study of continuous chronomodulated capecitabine treatment**
J. Roosendaal, B. Jacobs, D. Pluim, H. Rosing, B. Nuijen, J. Beijnen, A. Huitema, J. Schellens, S. Marchetti; NL
- 13:10 - 13:10 **1873P - Head and neck (HN) primary sarcomatoid carcinoma (PSC) profile by high-throughput somatic mutation profiling**
V. Fallet, R. Taouachi, R. Saffroy, A. Ben Lakhdar, N. Rabbe, F. André, S. Temam, A. Lemoine, M. Wislez; FR
- 13:10 - 13:10 **1874P - A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma**
A. Berger, T. Ettrich, D. Schwerdel, A. Reinacher-Schick, H. Algül, A.-O. König, E. Gallmeier, K. Wille, S. Daum, M. Geissler, A. Tannapfel, W. Uhl, T. Seufferlein; DE
- 13:10 - 13:10 **1875P - Acquired chemoresistance of colorectal cancer (CRC) cells is accompanied by pro-invasive VEGF-signaling that can be attenuated by aflibercept**
A. LARSEN, P. van Dreden, B. Chibaudel, A. de Gramont, G. Gerotziafas, S. Thouroude; FR
- 13:10 - 13:10 **1876P - Actionable mutations and overall survival in 3,211 patients with cancer: The Hellenic cooperative oncology group precision medicine initiative**

E. Fountzila¹, V. Kotoula², G.-A. Koliou¹, E. Giannoulatou³, H. Gogas⁴, C. Papadimitriou⁴, I. Tikas¹, K. Papadopoulou¹, F. Zagouri¹, C. Christodoulou⁵, A. Koutras⁶, E. Razis¹, P. Papakostas¹, E. Samantas⁷, G. Aravantinos⁷, A. Psyrris¹, D. Pectasides¹, A. Futreal⁸, A.-M. Tsimberidou⁹, G. Fountzilas¹; ¹GR, ²Central Macedonia/GR, ³AU, ⁴Attiki/GR, ⁵N. Faliro/GR, ⁶Rion/GR, ⁷Attica/GR, ⁸TX/US, ⁹US

13:10 - 13:10 **1877P - DNA repair genetic profiling in epithelial ovarian cancer: An opportunity for clinical improvement?**

J. Assis¹, S. Coelho¹, A. Nogueira¹, R. Pinto¹, M. Brandao², J. Dias¹, S. Alves¹, D. Pereira¹, R. Medeiros¹; ¹PT, ²BE

13:10 - 13:10 **1878P - Strategy to improve the antitumor efficacy of dendritic cell-based nanovaccine under magnetic field control**

O. Gorbach, N. Khranovska, O. Skachkova, M. Inomistova, I. Shumeiko, V. Orel; UA

13:10 - 13:10 **1879P - Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models**

A. Gkoutakos, S. Pilotto, M. Simbolo, C. Vicentini, A. Mafficini, A. del Curatolo, A. Scarpa, G. Tortora, V. Corbo, E. Bria; IT

13:10 - 13:10 **1880P - Final results of the phase I study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response**

L. Seitz¹, D. Ashok², M. Leleti², J. Powers², B. Rosen², D. Miles², E. Sharif², L. Jin², A. Park², S. Young², A. Rieger², U. Schindler², J. Karakunnel¹, M. Walters²; ¹US, ²CA/US

13:10 - 13:10 **1881P - An expression signature characterizes cancer stem cells from lung adenocarcinoma patients**

A. Herreros-Pomares, S. Calabuig Fariñas, J.D. de Maya, E. Escorihuela, E. Durendez-Saez, A. Blasco Cordellat, A. Navarro, E. García-Del-Olmo, R. Lucas, R. Farràs, E. Jantus-Lewintre, C. Camps; ES

13:10 - 13:10 **1882P - Development of primary human NSCLC patient derived xenograft and organoids models as a precision approach to tumor treatment**

O.J. Juan Vidal, C. Gandia, J. Pardo-Sánchez, M. Benet, S. Aparisi, S. Palanca, E. Ansotegui, C. Jordá, J. Cerón, N. Mancheño, M. Sánchez-Céspedes, A. Lahoz, J. Carretero, R. Farràs; ES

13:10 - 13:10 **1883P - PBRM1 is a novel candidate low-penetrance familial cancer predisposition gene**

I. Volodin, V. Kozlova, K. Anoshkin, A. Tanas, D. Zaletaev, V. Strelnikov; RU

13:10 - 13:10 **1884P - Liprin-alpha4 contributes to increased proliferation and decreased chemosensitivity under hypoxia for small cell lung cancer as a downstream mediator of HIF-1alpha**

H. Onishi¹, A. Yamasaki², M. Kawamoto²; ¹Fukuoka/JP, ²JP

- 13:10 - 13:10 **1885P - Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial**
M. Abdelshafy¹, Y. El Dakdouki², L. Verlingue², A. Hollebecque², L. Lacroix², S. Postel-Vinay², A. Varga¹, R. Balheda², J.-M. Michot², A. Marabelle², E. Rouleau³, E. Solary², T. de Baere², E. Angevin¹, V. Ribrag², S. Michiels², F. André², J.-Y. Scoazec², J.-C. Soria⁴, C. Massard¹; ¹CEDEX/FR, ²FR, ³CEDEX 5/FR, ⁴CEDEX/US
- 13:10 - 13:10 **1886P - Streamlining multi-omic and artificial intelligence analysis through interrogative biology and baicis for translational precision medicine applications in clinical oncology**
L. Rodrigues¹, M. Kiebish², G. Miller², L. Zhang², V. Vemulapalli², V. Vishnudas², R. Sarangarajan¹, N. Narain¹, V. Akmaev²; ¹US, ²MA/US
- 13:10 - 13:10 **1887P - Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach**
R. Falcone, P. Paci, A. Verrienti, G. Fiscon, M. Sponziello, F. Conte, V. Pecce, F. Rosignolo, G. Grani, L. Lamartina, V. Ramundo, C. Durante, L. Farina, S. Filetti; IT
- 13:10 - 13:10 **1888P - Improving value for cancer patients: A European study of outcomes in practice**
R. Hazarika¹, T. Albrecht², B. Beger³, D. Duplay⁴, L. Makaroff¹, Z. Maravic¹, R. Mortuza¹, V. Muthu¹, K. Oliver¹, R. Price¹, M. van Meerveld¹, K. Steinmann¹, A. Krukowska¹, R. Catena¹, S. Wait¹, V. Zilli¹; ¹GB, ²SI, ³BE, ⁴US
- 13:10 - 13:10 **1889P - High-throughput screening of new drugs targeting lung CSCs**
H. Amado Labrador, E. Jantus-Lewintre, S. Calabuig Fariñas, C. Aguilar-Gallardo, J. Murga, E. Munera-Maravilla, E. Durendez-Saez, M. Mosqueda, E. Escorihuela, F. ZHANG, E. Masiá, N. Dong, R. Guijarro, C. Camps; ES
- 13:10 - 13:10 **1890TiP - RING observational trial to compare T790M mutation testing in blood by different methodologies**
B. Garcia-Pelaez¹, E. Jantus¹, A. Romero¹, M.-A. Molina¹, A. Blasco Cordellat¹, C. Perez-Barrios¹, R. Rosell², C. Camps¹, M. Provencio Pulla³; ¹ES, ²Barcelona/ES, ³Madrid/ES
- 13:10 - 13:30 **Session DOI**

12:30 - 14:00 **Type: Patient Advocacy Track** **ICM - Room 5**
Title: Pillars of an effective healthcare system in Europe
Chair(s): Ananda Plate, BE; Vlad Voiculescu, RO

12:30 - 12:30 **Session DOI**

12:30 - 12:45 **Key components of a well-functioning healthcare system**
W. Quentin, DE

12:45 - 13:00 **Special focus on healthcare in CEE**
V. Voiculescu, RO

13:00 - 13:15 **Civic participation: How citizens shape the society they live in**
G. Moro, IT

13:15 - 14:00 **Discussion**

12:30 - 13:00 **Type: Special session** **ICM - Foyer - Ground floor**
Title: Let's talk women's cancers

12:30 - 12:30 **Session DOI**

12:30 - 12:34 **Welcome and Introduction**

J. Browning, CH

12:34 - 12:39 **Overview of Patient Guides: Focus on Ovarian Cancer Patient Guide**

N. Colombo, IT

12:39 - 12:44 **Additional perspective: Focus on Breast Cancer Patient Guide**

E. Senkus-Konefka, PL

12:44 - 12:49 **Oncology Nurse's perspective: Cervical Cancer Patient Guide; Shared decision-making; Lifestyle interventions**

L. Bjerrum Thisted, DK

12:49 - 12:54 **Patient Perspectives on Women's Cancers: Adoption of survivorship plan**

K. Apostolidis, Attica/BE

12:54 - 12:59 **Questions**

12:59 - 13:00 **Closing remarks**

J. Browning, CH

13:00 - 14:30	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Hepatocellular carcinoma treatment: Now, next and beyond Chair(s): Jean-Luc Raoul, FR	ICM - Room 1
13:00 - 13:00	Session DOI	
13:00 - 13:05	Introduction <u>J.-L. Raoul</u> , CEDEX/FR	
13:05 - 13:30	Pros and cons of loco-regional therapy options <u>C. Gomez Martin</u> , ES	
13:30 - 13:55	Transitioning to first line systemic treatment; Pros and Cons of initiating early systemic treatment? <u>L. Rimassa</u> , IT	
13:55 - 14:20	Moving beyond monotherapy in first line HCC: What will be the new standard for the expected clinical and patient outcomes? <u>A. Vogel</u> , DE	
14:20 - 14:30	Summary and conclusion <u>J.-L. Raoul</u> , CEDEX/FR	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 14	ICM - Room 14b
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 15	ICM - Room 13
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 16	Hall A1 - Room 15
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 17	Hall A1 - Room 16
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 1	Hall B3 - Room 23
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 18	Hall B3 - Room 20
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 19	Hall B3 - Room 22
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 20	Hall B4 - Room 19
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 2	Hall B4 - Room 24

14:45 - 16:30 **Type: Educational session** **Hall A1 - Room 17**
Title: Novel therapies for small cell lung cancer
 Chair(s): Corinne Faivre-Finn, GB; Noemi Reguart Aransay, ES

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **Genetic background of SCLC**
C. Rudin, US

15:10 - 15:35 **Radiotherapy in SCLC: Lessons to learn**
C. Faivre-Finn, GB

15:35 - 16:00 **Targeted therapies in SCLC: What might we expect?**
N. Reguart Aransay, ES

16:00 - 16:25 **Immunotherapy in SCLC: Current status and future perspectives**
S. Novello, IT

14:45 - 16:05 **Type: Poster Discussion session** **ICM - Room 1**
Title: Poster Discussion session - Genitourinary tumours, non prostate
 Chair(s): Rob Jones, GB; Ignacio Duran, ES; Cristina Suarez, ES

14:45 - 14:45 **Session DOI**

14:45 - 14:45 **LBA33 - A Phase Ib/2 study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced Urothelial Cancer (UC)**
C. Hoimes¹, C. Albany¹, J. Hoffman-Censits², M. Fleming³, E. Trabulsi⁴, J. Picus⁵, C. Cary⁶, M. Koch⁶, R. Walling⁶, W. Kelly¹, J. Godwin⁴, M. Cooney⁷, P. Fu⁷, A. Nelson⁷, K. Patel⁷, C. Eitman⁷, T. Breen⁶, A. Neal⁶, H. Kaimakliotis⁶; ¹US, ²MD/US, ³VA/US, ⁴PA/US, ⁵Missouri/US, ⁶IN/US, ⁷OH/US

14:45 - 14:45 **865PD - RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results**
D. Petrylak¹, C. Sternberg², A. Drakaki³, R. de Wit⁴, H. Nishiyama⁵, A. Necchi², D. Castellano⁶, A. Bamias⁷, K. Chi⁸, M. van der Heijden⁴, N. Matsubara⁹, S. Hussain¹⁰, A. Flechon¹¹, B. Alekseev¹², E. Yu¹³, R. Walgren¹⁴, F. Russo¹⁴, A. Zimmermann¹⁴, K. Bell-Mcguinn¹⁵, T. Powles¹⁰; ¹CT/US, ²IT, ³CA/US, ⁴NL, ⁵JP, ⁶ES, ⁷Attiki/GR, ⁸British Columbia/CA, ⁹Chiba/JP, ¹⁰GB, ¹¹CEDEX/FR, ¹²RU, ¹³WA/US, ¹⁴US, ¹⁵IN/US

14:45 - 14:45 **868PD - Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial**

R. Flippot¹, C. Dalban¹, B. Laguerre², D. Borchiellini¹, G. Gravis³, S. Negrier², C. Chevreau⁴, F. Joly¹, L. Geoffrois², S. Ladoire⁵, H. Mahammedi⁶, F. Tantot¹, B. Escudier², L. Albiges²; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR, ⁴Haute-Garonne/FR, ⁵Cedex/FR, ⁶CEDEX 1/FR

- 14:45 - 15:00 **Invited Discussant LBA33, 865PD and 868PD**
R. Jones, GB
- 15:00 - 15:10 **Q&A led by Discussant**
- 15:10 - 15:10 **866PD - Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC)**
A. Necchi¹, A. Briganti¹, D. Raggi¹, R. Luciano¹, M. Colecchia¹, S. Massa¹, P. Giannatempo¹, R. Colombo¹, A. Gallina¹, R. Salvioni¹, R. Mortarini¹, F. Montorsi¹, R. Madison², S. Ali³, J. Ross², J. Chung³, A. Anichini¹; ¹IT, ²US, ³MA/US
- 15:10 - 15:10 **867PD - Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT)**
A. Necchi¹, G. Bratslavsky², R. Corona², J. Chung³, S. Millis³, L. Gay⁴, J. Elvin³, J.-A. Vergilio³, S. Ramkissoon³, E. Severson³, S. Daniel³, J. Killian³, S. Ali³, A. Schrock³, V. Miller³, J. Ross⁴; ¹IT, ²NY/US, ³MA/US, ⁴US
- 15:10 - 15:25 **Invited Discussant 866PD and 867PD**
I. Duran, ES
- 15:25 - 15:35 **Q&A led by Discussant**
- 15:35 - 15:35 **LBA34 - PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.**
T. Choueiri¹, A. Flaifel², W. Xie², D. Braun¹, M. Ficial², R. Jennings², A. Nassar¹, B. Escudier³, D. George⁴, R. Motzer⁵, M. Morris⁵, T. Powles⁶, E. Wang⁷, Y. Huang¹, G. Freeman¹, S. Signoretti²; ¹US, ²MA/US, ³CEDEX/FR, ⁴NC/US, ⁵NY/US, ⁶GB, ⁷California/US
- 15:35 - 15:35 **869PD - Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk**
B. Beuselinck¹, A. Verbiest¹, G. Couchy², S. Job², A. de Reyniès², S. Caruso², V. Verkarre², N. Rioux-Leclercq², P. Schöffski¹, Y. Vano², R.-T. Elaidi², E. Lerut¹, M. Albersen¹, S. Oudard², J. Zucman-Rossi²; ¹BE, ²FR

- 15:35 - 15:35 **870PD - Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap)**
S. Negrier¹, N. Rioux-Leclercq², A. Ravaud², G. Gravis³, L. Geoffrois¹, C. Chevreau⁴, F. Rolland¹, E. Blanc¹, C. Segura-Ferlay², D. Perol¹, M. Gross Goupil², S. Dermeche³, A. Flechon¹, L. Albiges¹, B. Escudier¹; ¹CEDEX/FR, ²FR, ³CEDEX 9/FR, ⁴Haute-Garonne/FR
- 15:35 - 15:50 **Invited Discussant LBA34, 869PD and 870PD**
C. Suarez, ES
- 15:50 - 16:00 **Q&A led by Discussant**
- 14:45 - 16:05 Type: Poster Discussion session ICM - Room 14b**
Title: Poster Discussion session - Melanoma and other skin tumours
 Chair(s): Georgina Long, AU; Jean Jacques Grob, FR; Susana Puig Sarda, ES
- 14:45 - 14:45 **Session DOI**
- 14:45 - 14:45 **LBA45 - Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy**
G. Long¹, M. Milhem², A. Amin³, C. Hoimes², T. Medina², R. Conry⁴, C. Lao², G. Daniels², S. Reddy⁵, I. Mehmi², R. Andtbacka⁶, M. Barve⁷, M. Shaheen², T. Tueting⁸, M. Chisamore², B. Xing⁵, A. Candia⁵, E. Gamelin⁵, R. Janssen², A. Ribas⁵; ¹NSW/AU, ²US, ³NC/US, ⁴AL/US, ⁵CA/US, ⁶UT/US, ⁷TX/US, ⁸DE
- 14:45 - 14:45 **1245PD - Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study**
A. Diab¹, C. Haymaker², C. Bernatchez², R. Andtbacka³, M. Shaheen¹, D. Johnson¹, J. Markowitz¹, I. Puzanov⁴, R. Murthy¹, D. Johnson², M. James², S. Chunduru¹, J. Geib¹, S. Swann⁵, S. Rahimian¹, P. Hwu¹; ¹US, ²TX/US, ³UT/US, ⁴NY/US, ⁵PA/US
- 14:45 - 14:45 **1246PD - Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study**
H. Gogas¹, I. Samoylenko², D. Schadendorf³, R. Gutzmer³, J.J. Grob⁴, J. Sacco⁵, K. Gorski⁶, A. Anderson⁶, C. Liu⁶, J. Malvehy⁷; ¹Attiki/GR, ²RU, ³DE, ⁴FR, ⁵GB, ⁶US, ⁷ES
- 14:45 - 14:45 **LBA46 - Phase 2 Study Comparing Pembrolizumab (PEM) with Intermittent/short-term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra).**

E. Rozeman, K. Sikorska, L. Grijpink-Ongering, B. Heeres, B. van de Wiel, A. Sari, H. Mallo, S. Adriaansz, W. Uytterlinde, J. Lijnsvelt, L. Pronk, J. Haanen, J.W. de Groot, S. Wilgenhof, M. Vollenbergh, J. van Thienen, C. Blank; NL

14:45 - 15:05 **Invited Discussant LBA45, 1245PD, 1246PD and LBA46**

S. Puig Sarda, ES

15:05 - 15:15 **Q&A led by Discussant**

15:15 - 15:15 **LBA47 - Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)**

C. Lebbé¹, N. Meyer¹, L. Mortier², I. Marquez-Rodas³, C. Robert¹, P. Rutkowski⁴, A. Menzies⁵, T. Eigentler⁶, P. Ascierto⁷, M. Smylie⁸, M. Ajaz⁹, I.-M. Svane¹⁰, R. Gonzalez¹¹, L. Rollin¹¹, A. Saci¹¹, E. Grigoryeva¹¹, J. Pigozzo⁷; ¹FR, ²CEDEX/FR, ³ES, ⁴PL, ⁵AU, ⁶DE, ⁷IT, ⁸CA, ⁹GB, ¹⁰DK, ¹¹US

15:15 - 15:15 **1247PD - Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)**

J.M. Piulats Rodriguez¹, L. De La Cruz Merino², E. Espinosa², L. Alonso Carrión², S. Martin Algarra², R. López-Castro², M.T. Curiel García², D. Rodriguez Abreu², A. Rullan Iriarte¹, A. Berrocal Jaime²; ¹Barcelona/ES, ²ES

15:15 - 15:25 **Invited Discussant LBA47 and 1247PD**

G. Long, NSW/AU

15:25 - 15:35 **Q&A led by Discussant**

15:35 - 15:35 **1248PD - Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis**

O. Hamid¹, A. Ribas¹, A. Daud¹, M. Butler², M. Carlino³, W.-J. Hwu⁴, G. Long³, K. Ancell⁵, F.S. Hodi⁶, N. Khushalani⁷, C. Blank⁸, C. Loquai⁹, J. Lin¹⁰, S. Dieder¹⁰, C. Robert¹¹; ¹CA/US, ²CA, ³NSW/AU, ⁴TX/US, ⁵TN/US, ⁶MA/US, ⁷FL/US, ⁸NL, ⁹DE, ¹⁰NJ/US, ¹¹FR

15:35 - 15:35 **1249PD - Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase**

C. Allayous¹, B. Oriano¹, S. Dalle², L. Mortier², M.-T. Leccia³, B. Guillot¹, G. Jeudy¹, C. Dutriaux¹, J.-P. Lacour¹, P. Saiag¹, F. Brunet-Possenti¹, J. De Quatrebarbes¹, P.-E. Stoeber¹, D. Legoupil¹, M. Beylot-Barry¹, T. Lesimple¹, F. Aubin¹, A. Ballon¹, R. Porcher¹, C. Lebbe¹; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR

15:35 - 15:45 **Invited Discussant 1248PD and 1249PD**

I.J. Grob, FR

15:45 - 15:55 **Q&A led by Discussant**

14:45 - 16:15 **Type: Special session** **Hall A1 - Room 16**
Title: Technologies of the future
 Chair(s): Alex A. Adjei, US; Udai Banerji, GB

14:45 - 14:45 **Session DOI**

14:45 - 15:15 **CRISPR**
R. Bernards, NL

15:15 - 15:45 **CAR T cells**
M. Sadelain, US

15:45 - 16:15 **Oncolytic viruses**
E. Galanis, MN/US

14:45 - 16:15 **Type: Educational session** **Hall A2 - Room 18**
Title: Adjuvant treatment in colon cancer: Standards and next steps
 Chair(s): Julien Taieb, FR; Volker Heinemann, DE

14:45 - 14:45 **Session DOI**

14:45 - 15:07 **Using the standards but when, for what, and for how long?**
R. Labianca, IT

15:07 - 15:29 **Tumour biology: What have we learned from the preceding trials (and what is “ready for daily use”)?**
J. Taieb, FR

15:29 - 15:51 **What are we doing with rare subtypes: Is the time right for treatment stratification?**
C. Montagut, ES

15:51 - 16:13 **Monitoring “molecular residual disease” in colon cancer: Implications for the future**
L. Diaz, US

14:45 - 16:15 **Type: Educational session** **Hall B3 - Room 20**
Title: Precision medicine with chemotherapy
 Chair(s): Stephen Taylor, GB; Anton Berns, NL

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **Precision medicine with conventional therapies in ovarian cancer**
S. Taylor, GB

15:10 - 15:35 **Functional selection assays for precision therapy in breast cancer**
R. Kanaar, NL

15:35 - 16:00 **Therapy, response and resistance in breast cancer**
J. Jonkers, NL

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: EONS session** **Hall B4 - Room 24**
Title: Patient safety
 Chair(s): Cristina Lacerda, GB

14:45 - 14:45 **Session DOI**

14:45 - 15:00 **Patient safety as a current concern for health systems in Europe**
D. Schwappach, CH

15:00 - 15:15 **Cancer's a risky business: Risk assessment in oncology nursing**
J. Richmond, IE

15:15 - 15:30 **Safety in the era of oral chemotherapy**
L. Iacorossi, IT

15:30 - 15:45 **Safety outside of cancer centres: The rise of oral chemotherapy and the safety needs of patients**
C. Oakley, GB

15:45 - 16:15 **Discussion**

14:45 - 16:15	Type: Special session Title: The way to assure sustainable, accessible and affordable cancer care within National Cancer Control Plans (NCCP) Chair(s): Giuseppe Curigliano, IT; Lisa Stevens, US	ICM - Room 14a
14:45 - 14:45	Session DOI	
14:45 - 14:50	Introduction <u>L. Stevens</u> , US	
14:50 - 15:05	To have an NCCP or not: That is issue and where should we begin? <u>A. Eniu</u> , RO	
15:05 - 15:20	Profile from Central Europe - Czech Republic <u>T. Svoboda</u> , Plzen/CZ	
15:20 - 15:35	Kazakhstan: National Cancer Control Plan update on progress made in 2017 - 2018 <u>D. Kaidarova</u> , KZ	
15:35 - 15:50	Belarus: National Cancer Control Plan update on progress made in 2017 - 2018 <u>S. Krasny</u> , BY	
15:50 - 16:15	Interactive Q&A/Wrap up <u>G. Curigliano</u> , IT	
15:00 - 16:00	Type: Young Oncologist session Title: YO Medical students: ESMO for medical students and young physicians Chair(s): Anna Sophie Berghoff, AT; Andrés Cervantes, ES	B11
15:00 - 15:00	Session DOI	
15:00 - 15:20	ESMO-ESO Medical Students Course <u>A. Cervantes</u> , Valencia/ES	
15:20 - 15:40	How to prepare and present your first poster at a congress <u>A.S. Berghoff</u> , AT	
15:40 - 16:00	Guided poster walk	

15:00 - 16:00 **Type: Multidisciplinary interactive sessions** **ICM - Room 13**
Title: Prevention and management in long term chronic cancer care
 Chair(s): Annie Young, GB

15:00 - 15:00 **Session DOI**

15:00 - 15:10 **Case presentation on venous thromboembolism and pain**
M. Ozturk, TR

15:10 - 15:25 **VTE**
A. Young, GB

15:25 - 15:40 **Pain**
A. Caraceni, IT

15:40 - 16:00 **Discussion**

15:00 - 16:15 **Type: Poster Discussion session** **Hall A1 - Room 15**
Title: Poster Discussion session - Breast cancer, early stage
 Chair(s): Hervé Bonnefoi, FR; Marc van de Vijver, NL; Veronique Dieras, FR

15:00 - 15:00 **Session DOI**

15:00 - 15:00 **LBA13 - Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial**

O. Gluz, U. Nitz, C. Liedtke, M. Christgen, E.-M. Grischke, H. Forstbauer, M. BRAUN, M. Warm, J. Hackmann, C. Uleer, B. Aktas, C. Schumacher, C. Lindner, S. Kümmel, R. Kates, J. Potenberg, P. Staib, R. Wuerstlein, H. Kreipe, N. Harbeck; DE

15:00 - 15:00 **LBA14_PR - The HOBEOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.**

F. Perrone¹, M. De Laurentiis¹, S. de Placido¹, M. Orditura¹, S. Cinieri¹, F. Riccardi¹, A.S. Ribocco², C. Putzu¹, L. Del Mastro¹, E. Rossi¹, B. Daniele¹, A.M. Mosconi¹, F. Di Rella¹, G. Landi¹, F. Nuzzo¹, C. Pacilio¹, R. Lauria¹, L. Arenare¹, M.C. Piccirillo¹, C. Gallo¹; ¹IT, ²Italy/IT

- 15:00 - 15:00 **188PD - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)**
M. Untch¹, C. Jackisch¹, A. Schneeweiss¹, S. Schmatloch¹, B. Aktas¹, C. Denkert¹, C. Schem², H. Wiebringhaus¹, S. Kümmel¹, K. Rhiem¹, M. Warm¹, P.A. Fasching¹, M. Just¹, C. Hanusch¹, J. Hackmann¹, J.-U. Blohmer¹, J. Furlanetto¹, V. Nekljudova¹, G. von Minckwitz¹, S. Loibl¹; ¹DE, ²Schleswig-Holstein/DE
- 15:00 - 15:15 **Invited Discussant LBA13, LBA14_PR and 188PD**
H. Bonnefoi, CEDEX/FR
- 15:15 - 15:25 **Q&A led by Discussant**
- 15:25 - 15:25 **189PD - Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)**
A. van Rossum, M. Hoogstraat, M. Opdam, H. Horlings, L. Wessels, R. Kerkhoven, A. van Leeuwen - Stok, H. Oosterkamp, M. Kok, S. Linn; NL
- 15:25 - 15:25 **190PD - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies**
G. Bianchini¹, J. Parker², L. Carey², C. Perou², L. Sica¹, A. Prat³, T. Pieńkowski⁴, Y.-H. Im⁵, G. Bianchi¹, T. Ling-Ming⁶, M.-C. Liu⁶, A. Lluch⁷, V. Semiglazov⁸, J. de la Haba-Rodriguez³, D.-Y. Oh⁵, B. Poirier⁹, J. Pedrini¹⁰, P. Valagussa¹, L. Gianni¹; ¹IT, ²NC/US, ³ES, ⁴PL, ⁵KR, ⁶TW, ⁷Valencia/ES, ⁸RU, ⁹CA, ¹⁰BR
- 15:25 - 15:40 **Invited Discussant 189PD and 190PD**
M. van de Vijver, NL
- 15:40 - 15:50 **Q&A led by Discussant**
- 15:50 - 15:50 **191PD_PR - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio**
P.F. Conte¹, V. Guarneri¹, G. Bisagni¹, F. Piacentini¹, A. Brandes¹, L. Cavanna¹, F. Giotta¹, M. Aieta², V. Gebbia¹, A. Frassoldati¹, A. Musolino¹, O. Garrone¹, C. Taverniti¹, A. Rimanti¹, S. Sarti³, D. Rubino¹, A. Bologna¹, R. Vicini¹, S. Balduzzi¹, R. D'Amico¹; ¹IT, ²(PZ)/IT, ³Forlì-Cesena/IT
- 15:50 - 15:50 **192PD - Randomized trial of lisinopril or carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving trastuzumab**

P. Munster¹, J. Krischer², R. Tamura², L. Bello-Matricaria², A. Fink², W. McCaskill-Stevens³, M. Guglin⁴; ¹US, ²FL/US, ³MD/US, ⁴KY/US

15:50 - 16:05 **Invited Discussant 191PD and 192PD**

V. Dieras, CEDEX 5/FR

16:05 - 16:15 **Q&A led by Discussant**

15:00 - 16:15 Type: Poster Discussion session Hall B3 - Room 23

Title: Poster Discussion session - Head and neck cancers

Chair(s): Marco Merlano, IT; Hisham Mehanna, GB; Esat Mahmut Ozsahin, CH

15:00 - 15:00 **Session DOI**

15:00 - 15:00 **1047PD - Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial**

C. Le Tourneau¹, E. Cohen², K. Harrington³, J. Dinis⁴, L. Licitra⁵, M.-J. Ahn⁶, A. Soria⁷, J.-P. Machiels⁸, N. Mach⁹, R. Mehra², B. Burtness², P. Zhang¹⁰, J. Cheng¹¹, R. Swaby¹⁰, D. Soulières¹²; ¹FR, ²US, ³GB, ⁴PT, ⁵IT, ⁶KR, ⁷ES, ⁸BE, ⁹CH, ¹⁰NJ/US, ¹¹PA/US, ¹²QC/CA

15:00 - 15:00 **1049PD - Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)**

J. Fayette¹, G. Lefebvre¹, M. Posner², J. Bauman³, S. Salas⁴, C. Even⁴, E. Saada-Bouzig⁴, T. Seiwert⁵, D. Colevas³, F. Calmels⁴, R. Zerbib⁴, A. Boyer Chammard⁴, R. Cohen³; ¹CEDEX/FR, ²NY/US, ³US, ⁴FR, ⁵IL/US

15:00 - 15:00 **1050PD - Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)**

E. Cohen¹, A. Algazi², D. Laux³, D. Wong², A. Amin⁴, L. Nabell², M. Chisamore², E. Gamelin⁵, R. Janssen², S. Bishnoi⁶; ¹IL/US, ²US, ³IA/US, ⁴NC/US, ⁵CA/US, ⁶AU

15:00 - 15:15 **Invited Discussant 1047PD, 1049PD and 1050PD**

M. Merlano, IT

15:15 - 15:25 **Q&A led by Discussant**

15:25 - 15:25 **1051PD - Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC)**

M. Scott¹, S. Wildsmith¹, M. Ratcliffe¹, H. Al-Masri², P. Scorer¹, C. Barker¹, M. Rebelatto³, J. Walker⁴; ¹GB, ²IL/US, ³US, ⁴NL

- 15:25 - 15:25 **1052PD - Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC)**
K. Zakeri¹, F. Rotolo², B. Lacas², L. Vitzthum³, Q.-T. Le³, V. Gregoire², J. Overgaard⁴, J. Tobias⁵, B. Zackrisson⁶, M. Parmar⁷, B. Burtneess¹, M.G. Ghi⁸, G. Sanguineti⁹, B. O'Sullivan¹⁰, C. Fortpied¹¹, J. Bourhis¹², H. Shen³, J. Harris¹³, J.-P. Pignon¹⁴, L. Mell¹; ¹US, ²FR, ³CA/US, ⁴DK, ⁵GB, ⁶SE, ⁷London/GB, ⁸Mestre-VE/IT, ⁹IT, ¹⁰CA, ¹¹BE, ¹²CH, ¹³PA/US, ¹⁴CEDEX/FR
- 15:25 - 15:25 **1053PD - Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)**
S. Cavaliere¹, L. De Cecco¹, G. Calareso¹, M. Silva¹, S. Gazzani¹, M. Bologna¹, I. Nauta², F. Wesseling², L. Lopez Perez³, R. Shefi⁴, V. Tountopoulos⁵, G. Fico³, K. Scheckenbach⁶, R. Brakenhoff², F. Hoebbers², S. Canevari¹, T. Poli¹, L. Licitra¹, L. Mainardi¹, B. BD2Decide Consortium¹; ¹IT, ²NL, ³ES, ⁴IL, ⁵GR, ⁶DE
- 15:25 - 15:40 **Invited Discussant 1051PD, 1052PD and 1053PD**
H. Mehanna, West Midlands/GB
- 15:40 - 15:50 **Q&A led by Discussant**
- 15:50 - 15:50 **1054PD - Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional chemo-radiotherapy for locally advanced (LA) head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial**
Y. Tao¹, A. Auperin¹, P. Blanchard¹, M. Alfonsi¹, X.-S. Sun¹, M. Rives¹, Y. Pointreau¹, J. Castelli¹, P. Graff¹, S. Wong Hee Kam¹, J. Thariat¹, O. Veresezan¹, A. Cornely¹, O. Casiraghi¹, M. Lapeyre¹, J. Bourhis²; ¹FR, ²CH
- 15:50 - 15:50 **1055PD - Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)**
G. Koutsodontis¹, G. Papaxoinis², I. Kotsantis¹, P. Economopoulou¹, A. Strati¹, C. Avgerinou¹, N. Spathas¹, E. Kirodimos¹, O. Tsavaris¹, E. Maratou¹, L. Hoxhallari¹, M. Anastasiou¹, M. Prevezanou¹, E. Lianidou¹, A. Psyrri¹; ¹GR, ²GB
- 15:50 - 15:50 **1056PD - Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression**
M. Joerger¹, S. Takahashi², C.M. Sayehli³, S. Slosarczyk³, A. Navarro Mendivil⁴, P. Cassier⁵, H. Nogai³, C. Zhang², F. Sei², S. Bender³, P. Ellinghaus³, M. Tahara⁶; ¹CH, ²JP, ³DE, ⁴ES, ⁵FR, ⁶Chiba/JP
- 15:50 - 16:05 **Invited Discussant 1054PD, 1055PD and 1056PD**

E.M. Ozsahin, CH

16:05 - 16:15 **Q&A led by Discussant**

15:00 - 16:15 **Type: Poster Discussion session** **Hall B3 - Room 22**
Title: Poster Discussion session - Developmental therapeutics /
investigational immunotherapy
 Chair(s): Maria Grazia Daidone, IT; Boon-Cher Goh, SG; Christian Dittrich, AT

15:00 - 15:00 **Session DOI**

15:00 - 15:00 **LBA15 - Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas**

K. Harrington¹, J. Brody², M. Ingham³, J. Strauss⁴, S. Cemerski³, M. Wang⁵, A. Tse⁵, A. Khilnani⁵, A. Marabelle⁶, T. Golan⁷; ¹GB, ²NY/US, ³US, ⁴TX/US, ⁵NJ/US, ⁶FR, ⁷IL

15:00 - 15:00 **LBA16 - Phase 1/2, Multicenter, Open-Label Study of Intratumoral/Intralesional Administration of the Retinoic Acid-Inducible Gene I (RIG-I) Activator MK-4621 in Patients With Advanced or Recurrent Tumors**

M. Middleton¹, M. Wermke², E. Calvo³, E. Chartash⁴, H. Zhou⁵, X. Zhao⁵, M. Niewel², K. Dobrenkov⁴, V. Moreno³; ¹Oxfordshire/GB, ²DE, ³ES, ⁴US, ⁵NJ/US

15:00 - 15:00 **412PD - Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)**

I. Melero¹, E. Castanon Alvarez¹, M. Mau-Sorensen², U. Lassen², M. Lolkema³, D. Robbrecht³, C. Gomez-Roca⁴, J. Martin-Liberal¹, J. Tabernero¹, W. Ros³, S. Ahmed⁵, N. Isambert⁶, H. Piper Lepoutre⁷, C. Boetsch⁷, J. Charo⁷, S. Evers⁷, V. Teichgräber⁷, J. Schellens³; ¹ES, ²DK, ³NL, ⁴Haute-Garonne/FR, ⁵GB, ⁶Cedex/FR, ⁷CH

15:00 - 15:00 **413PD - Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma**

M. Krebs¹, J. Lopez¹, A. El-Khoueiry², Y.-J. Bang³, S. Postel-Vinay⁴, W. Abidah², S.-A. Im³, L. Khoja¹, N. Standifer², G. Jones¹, P. Marco-Casanova¹, P. Frewer¹, A. Berges¹, A. Cheung¹, C. Stephens¹, B. Felicetti¹, E. Dean¹, A. Pierce¹, S. Hollingsworth¹; ¹GB, ²US, ³KR, ⁴FR

15:00 - 15:20 **Invited Discussant LBA15, LBA16, 412PD and 413PD**

M.G. Daidone, IT

15:20 - 15:30 **Q&A led by Discussant**

- 15:30 - 15:30 **414PD - Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors**
B.C. Cho¹, R. Perets², J. Bar², M.-J. Ahn¹, D.-W. Kim¹, K. Yoh³, A. Nagrial⁴, D. Spigel⁵, D.H. Lee¹, M. Gutierrez⁶, D. Kotasek⁷, S. Siddiqi⁶, A. Chain⁶, B. Butts⁶, Y. Zhang⁶, X. Li⁶, J. Cyrus⁶, A. Tse⁶, R. Altura⁶, D. Rasco⁸; ¹KR, ²IL, ³Chiba/JP, ⁴NSW/AU, ⁵TN/US, ⁶NJ/US, ⁷SA/AU, ⁸TX/US
- 15:30 - 15:30 **415PD - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors**
J. Medioni¹, M. Brizard¹, L. Teixeira², L. Doucet¹, Z. Ghrieb¹, A. Angelergues¹, S. Oudard¹, S. Culine², O. Adotevi³, C. Laheurte¹, M.-A. Dragon-Durey¹, P. Laurent-Puig¹, J.-J. Kiladjian¹, V. Doppler¹, B. Souttou¹, S. Wain-Hobson¹, R. Defrance¹, T. Huet¹, P. Langlade-Demoyen¹; ¹FR, ²CEDEX 10/FR, ³CEDEX/FR
- 15:30 - 15:30 **416PD - Final results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer**
L. Nordquist¹, H. Ghanbari², J. Elist³, J. Oliver⁴, W. Gannon⁵, A. Shahlaee², S. Fuller², N. Shore¹; ¹US, ²MD/US, ³CA/US, ⁴MA/US, ⁵DC/US
- 15:30 - 15:45 **Invited Discussant 414PD, 415PD and 416PD**
B.-C. Goh, SG
- 15:45 - 15:55 **Q&A led by Discussant**
- 15:55 - 15:55 **417PD - Combination therapy optimization in gastrointestinal cancers using multi-omic molecular profiling**
M.C. Monge Bonilla¹, E. Blais², W. Chen³, M. Pishvain⁴, E. Petricoin², J. Marshall⁴; ¹US, ²VA/US, ³TX/US, ⁴DC/US
- 15:55 - 15:55 **418PD - NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss**
F. Janku¹, O. Jegede², S. Puhalla³, P. Konstantinopoulos⁴, F. Meric-Bernstam¹, E. Mitchell³, J. Zwiebel⁴, L. McShane⁴, S. Li², L. Rubinstein⁴, L. Doyle⁴, D. Patton⁴, B. Conley⁴, P. O'Dwyer⁴, L. Harris⁴, C. Arteaga⁴, P. Williams⁴, S. Hamilton¹, A. Chen⁴, K. Flaherty²; ¹TX/US, ²MA/US, ³PA/US, ⁴US
- 15:55 - 16:05 **Invited Discussant 417PD and 418PD**
C. Dittrich, AT
- 16:05 - 16:15 **Q&A led by Discussant**

15:00 - 16:00	Type: Poster Discussion session Title: Poster Discussion session - Translational research 1 Chair(s): Sergio Quezada, GB	Hall B4 - Room 19
15:00 - 15:00	Session DOI	
15:00 - 15:00	53PD - Association of PD-L1 expression with prognosis among patients with 10 select cancers <u>T. Steiniche</u> ¹ , M. Ladekarl ¹ , J. Bæhr Georgsen ¹ , S. Andreasen ¹ , M. Busch-Sørensen ¹ , W. Zhou ² , S. Pruitt ³ , A. Joe ³ , K.-L. Liaw ³ ; ¹ DK, ² US, ³ NJ/US	
15:00 - 15:00	54PD - Pre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression <u>M. Zuazo</u> , H. Arasanz, M. Gato-Cañas, G. Fernández-Hinojal, B. Hernández-Marín, M. Martínez-Aguillo, M. Ibáñez-Vea, M.J. Lecumberri Biurrun, Á. Fernández de Lascoiti, R. Vera, G. Kochan, D. Escors; ES	
15:00 - 15:00	55PD - Identification of biological axes associated with stage II/III CRC recurrence risk and outcome after adjuvant therapy revealed a T-effector-independent prognostic role for granzyme B <u>M. Das Thakur</u> ¹ , A. Udyavar ¹ , T. Sandmann ¹ , C. Li ¹ , L. Bosch ² , W. O'Gorman ¹ , Y. Li ¹ , A. Au-Yeung ¹ , C. Takahashi ¹ , R. Bourgon ¹ , A. Daemen ¹ , P. Hegde ¹ , C. Bais ¹ ; ¹ US, ² NL	
15:00 - 15:00	56PD - Analytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer <u>D. Fabrizio</u> ¹ , C. Milbury ¹ , W.-K. Yip ¹ , L. Ramamurthy ¹ , X. Bai ¹ , V. Pattani ¹ , P. Maness ¹ , A. Cowen ¹ , K. Fedorchak ¹ , P. Ma ¹ , G. Frampton ² , C. Connelly ¹ , Y. Li ¹ ; ¹ US, ² MA/US	
15:00 - 15:00	57PD - Tumor mutational burden and prognosis across pan-cancers <u>H. Ding</u> , J. Zhao, Y. Zhang, G. Wang, S. Cai, F. Qiu; CN	
15:00 - 15:20	Invited Discussant 53PD, 54PD, 55PD, 56PD and 57PD	
15:20 - 15:30	Q&A led by Discussant	
15:30 - 15:30	58PD - Pan-cancer analysis of ret fusions (FN) and rearrangements (RE) by genomic profiling of 158,360 tumors <u>L. Gay</u> ¹ , D. Pavlick ¹ , S. Ramkissoon ² , S. Daniel ² , J. Killian ² , J.-A. Vergilio ² , E. Severson ² , G. Frampton ² , J. Elvin ² , J. Ross ¹ ; ¹ US, ² MA/US	

- 15:30 - 15:30 **59PD - Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]**
R. Finn¹, M. Kudo², A.-L. Cheng³, L. Wyrwicz⁴, R. Ngan⁵, J.F. Blanc⁶, A. Baron¹, A. Vogel⁷, M. Ikeda⁸, F. Piscaglia⁹, K.-H. Han¹⁰, S. Qin¹¹, Y. Minoshima², M. Kanekiyo², M. Ren¹², R. Dairiki², T. Tamai¹², C. Dutcus¹³, Y. Funahashi¹⁴, T.R.J. Evans¹⁵; ¹CA/US, ²JP, ³TW, ⁴PL, ⁵HK, ⁶FR, ⁷DE/US, ⁸Chiba/JP, ⁹IT, ¹⁰KP, ¹¹CN, ¹²NJ/US, ¹³New Jersey/US, ¹⁴US, ¹⁵GB
- 15:30 - 15:30 **60PD - Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8**
P. Laurent-Puig¹, L. Marisa¹, M. Ayadi¹, Y. Blum¹, R. Balogoun¹, C. Pilati¹, K. Le Malicot¹, C. Lepage², J.F. Emile¹, R. Salazar³, D. Aust⁴, A. Duval¹, J. Selves¹, D. Guenot¹, G. Milano¹, J.-F. Seitz⁵, J. Taieb¹, V. Boige¹, A. de Reyniès¹; ¹FR, ²Cedex/FR, ³ES, ⁴DE, ⁵CEDEX 5/FR
- 15:30 - 15:30 **61PD - Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3**
M. Berger¹, S. Stintzing², V. Heinemann², S. Cao¹, D. Yang¹, Y. Miyamoto¹, M. Suenaga³, D.L. Hanna¹, S. Soni¹, A. Puccini⁴, R. Tokunaga¹, M. Naseem¹, F. Battaglin¹, M. McSkane¹, W. Zhang¹, H.-J. Lenz¹; ¹CA/US, ²DE, ³JP, ⁴IT
- 15:30 - 15:30 **1831PD - Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors**
A. Puccini¹, K. Poorman², R. Goldberg³, A. Shields⁴, M. Winerip², W.M. Korn⁴, M. Berger⁵, R. Tokunaga⁵, M. Naseem⁵, F. Battaglin⁵, W. Zhang⁵, S. Soni⁵, J. Hwang⁴, P. Philip⁴, J. Marshall⁶, H.-J. Lenz⁵; ¹IT, ²AZ/US, ³SG, ⁴US, ⁵CA/US, ⁶DC/US
- 15:30 - 15:50 **Invited Discussant 58PD, 59PD, 60PD, 61PD and 1831PD**
R. Dienstmann, ES
- 15:50 - 16:00 **Q&A led by Discussant**

16:30 - 18:00 **Type: Educational session** **ICM - Room 1**
Title: Multimodality approaches to hepatobiliary cancers
Chair(s): Eileen O'Reilly, US; Ann-Lii Cheng, TW

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Locoregional treatment of HCC**
J. Ricke, DE

16:55 - 17:20 **Systemic treatment of HCC in the era of immunotherapy**
B. Daniele, IT

17:20 - 17:45 **Targeted therapy for biliary cancer**
E. O'Reilly, NY/US

17:45 - 18:00 **Discussion**

16:30 - 18:00 **Type: Special Symposium** **Hall A1 - Room 15**
Title: Epigenetic alterations and potential clinical implications in sarcomas and other rare tumours
 Chair(s): Olivier Mir, FR; Susan Chi, US

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **Introduction**
O. Mir, FR

16:35 - 16:55 **Epigenetic insights into Ewing sarcoma**
O. Delattre, FR

16:55 - 17:15 **Epigenetic insights into midline carcinoma**
C. French, US

17:15 - 17:35 **Epigenetic insights into rhabdoid tumours**
S. Chi, US

17:35 - 17:55 **Epigenetic insights into epithelioid sarcomas**
O. Mir, FR

17:55 - 18:00 **Conclusions and clinical perspectives**
S. Chi, US

16:30 - 18:20 **Type: Proffered Paper session** **Hall A2 - Room 18**
Title: Presidential Symposium 1
 Chair(s): Andrés Cervantes, ES; Josep Taberner, ES

16:30 - 16:30 **Session DOI**

16:30 - 16:45 **LBA1_PR - IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)**
P. Schmid¹, S. Adams², H. Rugo³, A. Schneeweiss⁴, C. Barrios⁵, H. Iwata⁶, V. Dieras⁷, R. Hegg⁸, S.-A. Im⁹, G. Wright¹⁰, V. Henschel¹¹, L. Molinero¹², S. Chui³, R. Funke², A. Husain³, E. Winer¹³, S. Loi¹⁴, L. Emens¹⁵; ¹GB, ²US, ³CA/US, ⁴DE, ⁵BR, ⁶Aichi/JP, ⁷CEDEX 5/FR, ⁸SP/BR, ⁹KR, ¹⁰FL/US, ¹¹CH, ¹²United States/US, ¹³MA/US, ¹⁴VIC/AU, ¹⁵MD/US

16:45 - 17:00 **Invited discussant**
G. Curigliano, IT

- 17:00 - 17:15 **LBA2_PR - Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3**
M. Cristofanilli¹, D. Slamon², J. Ro³, I. Bondarenko⁴, S.-A. Im³, N. Masuda⁵, M. Colleoni⁶, A. DeMichele⁷, S. Loi⁸, S. Verma⁹, H. Iwata¹⁰, N. Harbeck¹¹, S. Loibl¹¹, F. André¹², K. Puyana Theall¹³, X. Huang², C. Giorgetti⁶, C. Huang Bartlett⁷, N. Turner¹⁴; ¹IL/US, ²CA/US, ³KR, ⁴UA, ⁵JP, ⁶IT, ⁷PA/US, ⁸VIC/AU, ⁹Alberta/CA, ¹⁰Aichi/JP, ¹¹DE, ¹²FR, ¹³MA/US, ¹⁴GB
- 17:15 - 17:30 **Invited discussant**
F. Cardoso, PT
- 17:30 - 17:45 **LBA3_PR - Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial**
F. André¹, E. Ciruelos², G. Rubovszky³, M. Campone¹, S. Loibl⁴, H. Rugo⁵, H. Iwata⁶, P. Conte⁷, I. Mayer⁸, B. Kaufman⁹, T. Yamashita¹⁰, Y.-S. Lu¹¹, K. Inoue¹⁰, M. Takahashi¹², Z. Pápai³, A.-S. Longin¹, D. Mills¹³, C. Wilke¹³, S. Hirawat¹⁴, D. Juric¹⁵; ¹FR, ²ES, ³HU, ⁴DE, ⁵CA/US, ⁶Aichi/JP, ⁷IT, ⁸TN/US, ⁹IL, ¹⁰JP, ¹¹TW, ¹²Hokkaido/JP, ¹³CH, ¹⁴NJ/US, ¹⁵MA/US
- 17:45 - 18:00 **2830_PR - Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer**
Z. Jiang, W. Li, X. Hu, Q. Zhang, T. Sun, S. Cui, S. Wang, Q. Ouyang, Y. Yin, C. Geng, Z. Tong, Y. Cheng, Y. Pan, Y. Sun, H. Wang, T. Ouyang, K. Gu, J. Feng, X. Wang; CN
- 18:00 - 18:20 **Invited discussant**
R. Dent, SG
- 16:30 - 17:45 Type: Poster Discussion session Hall B3 - Room 23**
Title: Poster Discussion session - CNS tumours
 Chair(s): Michael Weller, CH; Priscilla Brastianos, US; Frank Winkler, DE
- 16:30 - 16:30 **Session DOI**
- 16:30 - 16:30 **376PD - Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors**
J.C. Benítez Montañez¹, M. Vieito Villar², C. Hierro¹, M. Gonzalez Rodriguez¹, I. Matos¹, I. Braña Garcia¹, C. Suarez Rodriguez¹, E.A. Martinez Saez¹, M.C. Perez-Gago¹, R. Morales-Barrera¹, C. Ortiz¹, C. Suarez¹, X. Maldonado¹, F. Martinez-Ricarte¹, C. Auger¹, A. Azaro¹, R. Dienstmann¹, J. Carles¹, E. Garralda¹; ¹ES, ²La Coruña/ES
- 16:30 - 16:30 **377PD - Multiplex digital PCR for the diagnostic of pilocytic astrocytoma and glioneuronal tumors**

F. Fina, D. HENAFF, A. Bresson, V. Juline, A. Romain, C. Carole, D. Figarella-Branger; FR

16:30 - 16:40 **Invited Discussant 376PD and 377PD**

M. Weller, CH

16:40 - 16:50 **Q&A led by Discussant**

16:50 - 16:50 **378PD - Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases**

C. Wippel, A. Starzer, A.S. Berghoff, E. Bergen, P. Wolf, G. Widhalm, J. Frischer, B. Gatterbauer, C. Marosi, K. Dieckmann, R. Bartsch, M. Preusser; AT

16:50 - 16:50 **379PD - Androgen receptor expression in breast cancer brain metastases**

E. Bergen, A.S. Berghoff, U. Rajky, M. Rudas, Z. Bago-Horvath, R. Exner, K. Dieckmann, G. Widhalm, M. Gnant, C. Zielinski, G. Steger, M. Preusser, R. Bartsch; AT

16:50 - 17:00 **Invited Discussant 378PD and 379PD**

P. Brastianos, US

17:00 - 17:10 **Q&A led by Discussant**

17:10 - 17:10 **380PD - Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB)**

M. Bexon¹, A. Achrol², K. Bankiewicz², A. Brenner³, N. Butowski², S. Kesari², F. Merchant³, R. Merchant³, D. Randazzo⁴, M. Vogelbaum⁵, M. Zabek⁶, J. Sampson⁴; ¹CH, ²CA/US, ³TX/US, ⁴NC/US, ⁵OH/US, ⁶PL

17:10 - 17:10 **381PD - Comprehensive geriatric assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): A mono-institutional experience**

G. Lombardi, E. Bergo, L. Bellu, M. Caccese, A. Lettieri, G. Tierno, A. Pambuku, A. Brunello, V. Zagonel; IT

17:10 - 17:10 **382PD - Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma**

J. Simões¹, N. Tavares², C. Borges², S. Meireles², C. Fernandes², A. Costa², C. Caeiro², M. Damasceno²; ¹Porto/PT, ²PT

17:10 - 17:25 **Invited Discussant 380PD, 381PD and 382PD**

F. Winkler, DE

17:25 - 17:35 **Q&A led by Discussant**

16:30 - 18:00 **Type: EONS session** **Hall B4 - Room 24**
Title: EONS-ESO: How to stay resilient and lead cancer services successfully
 Chair(s): Daniel Kelly, GB

16:30 - 16:30 **Session DOI**

16:30 - 16:45 **Leading the multiprofessional team**
E. Karlsson, SE

16:45 - 17:00 **Leadership from research to an organisational level**
T. Wiseman, GB

17:00 - 17:15 **Safe staffing**
L. Smeds Alenius, SE

17:15 - 17:30 **CN1 - Evaluation of an education programme on compassion fatigue: Turkish oncology-haematology nurses' perspectives**
T. Pehlivan, P. Güner; TR

17:30 - 17:45 **CN25 - Professional grief in nurses exposed to patient deaths: The reality of a Portuguese institute of oncology**
S. Gomes, PT

17:45 - 18:00 **Discussion**

16:45 - 17:45 **Type: Poster Discussion session** **ICM - Room 14b**
Title: Poster discussion session - Immunotherapy of cancer 1
 Chair(s): Ulrich Keilholz, DE; John Haanen, NL

16:45 - 16:45 **Session DOI**

16:45 - 16:45 **1131PD - Preliminary results of phase I/II study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL)**
F. Ma, J. Li, J. Ren, X. Zhang, F. Wang, X. Guo, J. Zhang, D. Wang, Q. Liu, J. Luo; CN

16:45 - 16:45 **LBA38 - Safety and Anti-Tumor Effects of MAGE-A10c796 TCR T-cells in Two Clinical Trials**

V. Lam¹, D. Hong², J. Heymach¹, G. Blumenschein², M. Butler³, M. Johnson⁴, B. Creelan⁵, J. Gainor², R. Govindan², R. Mudad⁵, J. Neal⁶, F. Brophy⁷, F. Fang⁷, N. Hyland⁷, T. Holdich⁸, T. Trivedi⁷, E. Norry⁷, R. Amado⁷; ¹TX/US, ²US, ³CA, ⁴TN/US, ⁵FL/US, ⁶CA/US, ⁷PA/US, ⁸GB

- 16:45 - 16:45 **1132PD - Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients**
T. Borch, R. Andersen, M.A. Rana, P. Kongsted, M. Pedersen, M. Nielsen, J. Kjeldsen, A. Kverneland, C. Lorentzen, Ö. Met, M. Donia, I.-M. Svane; DK
- 16:45 - 17:05 **Invited Discussant 1131PD, LBA38 and 1132PD**
J. Haanen, NL
- 17:05 - 17:15 **Q&A led by Discussant**
- 17:15 - 17:15 **LBA39 - Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors**
I. Marquez Rodas, F. Longo, M. Rodriguez-Ruiz, A. Calles, J.L. Pérez-Gracia, A. Gomez-Rueda, S. Lopez-Tarruella, M. Ponz-Sarvisé, R.M. Alvarez, A. Soria, E. de-Miguel, J. Gayarre, M.A. Aznar, A. Calvo, P. Lopez-Casas, D. Tersago, M. Quintero, S. Martin-Algarra, M. Martín, I. Melero; ES
- 17:15 - 17:15 **LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients**
C. Rudin¹, H. Pandha², S. Gupta¹, M. Zibelman¹, W. Akerley¹, D. Day³, A. Hill³, R. Sanborn⁴, S. O'Day¹, T. Clay³, G. Wright³, R. Jennens³, D. Gerber¹, J. Rosenberg⁵, C. Ralph², D. Campbell³, B. Curti⁴, E. Schmidt¹, M. Grose³, D. Shafren³; ¹US, ²GB, ³AU, ⁴OR/US, ⁵NY/US
- 17:15 - 17:15 **1133PD - A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)**
M. Hidalgo¹, R. Epelbaum², B. Wolpin³, S. Stemmer², R. Geva², T. Golan², E. Borazanci⁴, M. Borad⁴, K. Pedersen⁵, J.O. Park⁶, R. Ramirez⁷, A. Peled², T. Lustig², O. Bohana Kashtan², O. Rosenfeld², E. Sorani², K. Schlienger¹, A. Vainstein Haras⁸, D. Von Hoff⁴; ¹US, ²IL, ³MA/US, ⁴AZ/US, ⁵MO/US, ⁶KR, ⁷LA/US, ⁸NA
- 17:15 - 17:15 **1134PD - A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy**
T. Choueiri¹, M. Atkins², T. Rose³, R. Alter⁴, E. Tsiroyannis⁵, K. Niland⁵, Y. Wang⁵, S. Parasuraman⁵, L. Gan⁵, D. McDermott⁵; ¹US, ²DC/US, ³NC/US, ⁴NJ/US, ⁵MA/US
- 17:15 - 17:35 **Invited Discussant LBA39, LBA40, 1133PD and 1134PD**
U. Keilholz, DE

17:35 - 17:45 **Q&A led by Discussant**

16:45 - 17:45	Type: Multidisciplinary interactive sessions Title: Management of brain metastases in patients with oncogene drivers Chair(s): Daniel Tan, SG	ICM - Room 13
---------------	---	----------------------

16:45 - 16:45 **Session DOI**

16:45 - 16:50 **Case 1: ALK positive patient with brain oligo-metastasis**
D. Tan, SG

16:50 - 17:00 **Neurosurgeons' perspective on patient selection**
C. Watts, GB

17:00 - 17:10 **Discussion**

17:10 - 17:15 **Case 2: First presentation of multiple brain mets EGFR mutant NSCLC**
D. De Ruyscher, NL

17:15 - 17:25 **Key considerations from the viewpoint of radiation oncologist**
D. De Ruyscher, NL

17:25 - 17:35 **Emerging TKI strategies to tackle brain mets**
D. Tan, SG

17:35 - 17:45 **Discussion**

16:45 - 17:45 **Type: Special session** **Hall A1 - Room 16**
Title: Molecular tumour board and drug access
Chair(s): Teresa Troiani, IT

16:45 - 16:45 **Session DOI**

16:45 - 16:55 **How to select targeted agents for molecular aberrations**
R. Dienstmann, ES

16:55 - 17:05 **Integration of new technology in the identification of molecular targets**
I. Wistuba, TX/US

17:05 - 17:15 **Identifying actionable targets**
Y. Shyr, US

17:15 - 17:25 **Industry reaction to new scientific insights**
S. Galbraith, GB

17:25 - 17:45 **Discussion**

18:00 - 19:30 **Type: Patient Advocacy Track** **ICM - Room 5**
Title: Cancer prevention
Chair(s): Gilberto Morgan, SE; Fredrik Johansson, SE

18:00 - 18:00 **Session DOI**

18:00 - 18:15 **Defining non-cancer**
C. Leaf, US

18:15 - 18:30 **Tobacco control: Saving lives and driving development**
G. Morgan, SE

18:30 - 18:45 **Behavioural aspects of health-related prevention measures**
A. Leppänen, SE

18:45 - 19:00 **Cancer awareness and screening: The challenges**
Z. Maravic, GB

19:00 - 19:30 **Discussion**

18:30 - 20:00 **Type: Industry Satellite Symposium** **ICM - Room 1**
Title: Industry satellite symposium 21

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Systemic therapies in unresectable hepatocellular carcinoma (HCC): 1st and later lines Chair(s): Peter Galle, DE	ICM - Room 14b
18:30 - 18:30	Session DOI	
18:30 - 18:35	Introduction <u>P. Galle</u> , DE	
18:35 - 18:55	Targets Biology in HCC <u>J.-L. Raoul</u> , CEDEX/FR	
18:55 - 19:15	Targeted agents in unresectable HCC: a review of results in 1st and 2nd line <u>L. Rimassa</u> , IT	
19:15 - 19:35	Emerging Immunotherapy in unresectable HCC <u>B. Sangro</u> , ES	
19:35 - 19:55	Future systemic treatments: new agents, targeted drug-combination, immune-drug combination? <u>J. Bruix</u> , ES	
19:55 - 20:00	Conclusion <u>P. Galle</u> , DE	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 23	ICM - Room 13
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 24	Hall A1 - Room 15
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 25	Hall A1 - Room 16
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 3	Hall B3 - Room 23
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 26	Hall B3 - Room 20
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 27	Hall B4 - Room 19
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 4	Hall B4 - Room 24

21.10.2018

08:00 - 09:00 **Type: Controversy Session** **Hall A1 - Room 15**
Title: Should oligosymptomatic brain metastasis patients without oncogene addiction receive upfront systemic therapy?
 Chair(s): Matthias Preusser, AT

08:00 - 08:10 **Introduction and 1st vote**
M. Preusser, AT

08:10 - 08:30 **Pro**
P. Brastianos, US

08:30 - 08:50 **Contra**
S. Combs, DE

08:50 - 09:00 **2nd vote and conclusions**
M. Preusser, AT

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall A1 - Room 16**
Title: The right time for discontinuing immunotherapy
 Chair(s): Jean-Charles Soria, US

08:00 - 08:10 **The right time for discontinuing immunotherapy**
J. Weber, US

08:10 - 09:00 **Discussion led by**
J.-C. Soria, CEDEX/US

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 21**
Title: Challenging germ cell tumour patients
 Chair(s): Kirsten Gedske Daugaard, DK

08:00 - 08:10 **Challenging germ cell tumour patients**
J. Gietema, NL

08:10 - 09:00 **Discussion led by**
K.G. Daugaard, DK

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**
Title: Multiscale tumor heterogeneity: Clinical implications
 Chair(s): Nicola Normanno, IT

08:00 - 08:10 **Multiscale tumor heterogeneity: Clinical implications**
E. Mardis, Missouri/US

08:10 - 09:00 **Discussion led by**
N. Normanno, IT

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 20**
Title: Personalised breast cancer medicine: Should all patients have whole genome sequencing?
 Chair(s): Fabrice André, FR

08:00 - 08:10 **Personalised breast cancer medicine: Should all patients have whole genome sequencing?**
C. Caldas, Cambridgeshire/GB

08:10 - 09:00 **Discussion led by**
F. André, FR

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 22**
Title: Small bowel adenocarcinomas
 Chair(s): Stefano Cascinu, IT

08:00 - 08:10 **Small bowel adenocarcinomas**
T. Aparicio, CEDEX/FR

08:10 - 09:00 **Discussion led by**
S. Cascinu, IT

08:00 - 09:00 **Type: Special session** **Hall B4 - Room 19**
Title: Special session: Summary of the ESMO-ESGO consensus conference on ovarian cancer
 Chair(s): Cristiana Sessa, CH

08:00 - 08:20 **Title to be defined**
N. Colombo, IT

08:20 - 08:40 **Title to be defined**
J. Ledermann, London/GB

08:40 - 09:00 **Q&A**

08:00 - 09:00 **Type: EONS session** **Hall B4 - Room 24**
Title: Self-care for young cancer nurses
 Chair(s): Sara Parreira, PT

08:00 - 08:20 **Compassion fatigue, burn-out, resilience and balance: What does it entail?**
S. Parreira, PT

08:20 - 08:40 **Compassion fatigue, burn-out, resilience and balance: How can cancer nurses support each other?**
L.-L. Aruväli, EE

08:40 - 09:00 **Discussion**

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **ICM - Room 14a**
Title: Follicular and other indolent lymphomas
 Chair(s): Martin Dreyling, DE

08:00 - 08:10 **Follicular and other indolent lymphomas**
M. Ghilmini, CH

08:10 - 09:00 **Discussion led by**
M. Dreyling, DE

08:15 - 09:00 **Type: Keynote lecture** **Hall A1 -**
Title: How do we manipulate the tumour microenvironment for **Room 17**
immunotherapy?
Chair(s): George Coukos, CH

08:15 - 09:00 **How do we manipulate the tumour microenvironment for immunotherapy?**
T. Gajewski, US

09:10 - 10:45 **Type: Special session** **ICM - Room 14a**
Title: Practicing oncologists and rare tumours
 Chair(s): George Pentheroudakis, GR; Stefan Rauh, LU

- 09:10 - 09:10 **Is there still a Cancer of Unknown Primary (CUP) in 2018? Who will mostly guide your decision: Your genetician, pathologist, radiologist, or your “gut feeling”?**
G. Lakatos, HU
- 09:10 - 09:15 **Clinical case presentation**
G. Lakatos, HU
- 09:15 - 09:38 **Do clinical and “standard” pathological decision parameters dominate the treatment algorithms, or do we rely on the genetic signature?**
G. Pentheroudakis, GR
- 09:38 - 09:38 **Adjuvant treatment of GIST: Who should benefit? Is there a need for referral?**
M. Karamouzis, Athens/GR
- 09:38 - 09:43 **Clinical case presentation**
M. Karamouzis, Athens/GR
- 09:43 - 10:06 **State of Art: Recommendation for adjuvant treatment in GIST**
A. Le Cesne, CEDEX/FR
- 10:06 - 10:06 **Rare tumours with recent treatment progresses**
S. Rauh, LU
- 10:06 - 10:11 **New treatment options in NET (incl combined radio nuclides**
S. Rauh, LU
- 10:11 - 10:34 **Should nuclear medicine be a mandatory treatment option for NET’s in 2018?**
A. Beer, DE
- 10:34 - 10:40 **Closing remarks: The role of the PO in rare tumor management / Management issues of rare cancer from a community oncology point of view**
S. Rauh, LU

- | | | |
|----------------------|--|--------------------------|
| 09:15 - 10:55 | Type: Proffered Paper session
Title: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Chair(s): Pieter Postmus, NL; Enriqueta Felip, ES | Hall A1 - Room 17 |
| 09:15 - 09:30 | LBA48_PR - CTONG 1103 Erlotinib versus Gemcitabine plus Cisplatin as Neoadjuvant Treatment for Stage IIIA -N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study
W.-Z. Zhong ¹ , Y.-L. Wu ² , K.-N. Chen ¹ , C. Chen ¹ , C.-D. Gu ¹ , Q. Wang ¹ , J. Wang ¹ , W. Mao ¹ , G.-B. Qiao ¹ , Y. Cheng ¹ , L. Xu ¹ , C.-L. Wang ¹ , M.-W. Chen ¹ , X.-N. Yang ¹ , H.-J. Chen ¹ , H.-H. Yang ¹ , J.-J. Yang ¹ , Q. Zhou ¹ ; ¹ CN, ² Guangdong/CN | |
| 09:30 - 09:45 | LBA49 - Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
T. Cascone ¹ , W. William ² , A. Weissferdt ² , C. Leung ³ , L. Federico ³ , C. Haymaker ³ , C. Bernatchez ³ , F. Fossella ³ , F. Mott ³ , V. Papadimitrakopoulou ² , L. Byers ³ , V. Lam ³ , M. Godoy ³ , B. Carter ³ , J. Lee ² , A. Vaporciyan ³ , D. Gibbons ³ , S. Swisher ³ , J. Heymach ³ , B. Sepesi ³ ; ¹ MO/US, ² US, ³ TX/US | |
| 09:45 - 10:00 | Invited Discussant LBA48_PR and LBA49
S. Ramalingam, GA/US | |
| 10:00 - 10:15 | 16640 - A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
J.-L. Pujol ¹ , L. Greillier ² , C. Audigier Valette ³ , D. Moro-Sibilot ² , L. Uwer ³ , J. Hureauux ⁴ , L. Thiberville ² , D. Carmier ² , J. Madelaine ² , J. Otto ² , V. Gounant ⁵ , P. Merle ² , P. Mourlanette ² , O. Molinier ² , P. Renault ² , J. Mazieres ² , M. Antoine ² , A. Langlais ² , F. Morin ² , P.-J. Souquet ³ ; ¹ CEDEX 5/FR, ² FR, ³ CEDEX/FR, ⁴ CEDEX 9/FR, ⁵ CEDEX 18/FR | |
| 10:15 - 10:27 | Invited Discussant 16640
J. Vansteenkiste, BE | |
| 10:27 - 10:42 | 13630 - Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
C. Faivre-Finn ¹ , D. Spigel ² , S. Senan ³ , C. Langer ⁴ , D. Raben ⁵ , B. Perez ⁵ , M. Özgüroğlu ⁶ , D. Daniel ² , A. Villegas ⁷ , D. Vicente ⁸ , R. Hui ⁹ , S. Murakami ¹⁰ , L. Paz-Ares ⁸ , L. Poole ¹ , C. Wadsworth ¹ , P. Dennis ¹¹ , S. Antonia ⁷ ; ¹ GB, ² TN/US, ³ NL, ⁴ PA/US, ⁵ US, ⁶ TR, ⁷ FL/US, ⁸ ES, ⁹ NSW/AU, ¹⁰ JP, ¹¹ MD/US | |
| 10:42 - 10:54 | Invited discussant 13630
N. Rizvi, NY/US | |

09:15 - 10:45 **Type: Special Symposium** **Hall A2 - Room 18**
Title: Precision cancer medicine in metastatic colorectal cancer
 Chair(s): Tim Maughan, GB; Aurelien Marabelle, FR

09:15 - 09:20 **Introduction**
A. Marabelle, FR

09:20 - 09:40 **Pathological subgroups and molecular characterisation**
S. Tejpar, BE

09:40 - 10:00 **Cell free tumour DNA: Yet a role in treatment monitoring of mCRC?**
K.-L. Spindler, DK

10:00 - 10:20 **Novel therapeutic approaches for specific (rare) subtypes**
T. Maughan, GB

10:20 - 10:40 **Immunotherapy: Checkpoint inhibitors and beyond**
A. Marabelle, FR

10:40 - 10:45 **Conclusions and perspectives**
T. Maughan, GB

09:15 - 10:30 **Type: Poster Discussion session** **ICM - Room 1**
Title: Poster Discussion session - Breast cancer, metastatic
 Chair(s): Lisa Carey, US; Caroline Schroeder, NL; Alessandra Gennari, IT

09:15 - 09:15 **285PD - Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial**
J. Cortes Castan¹, M. Martín¹, S. Pernas Simon¹, P. Gomez Pardo¹, S. Lopez-Tarruella¹, M. Gil Martin¹, L. Manso¹, E. Ciruelos¹, J.A. Perez Fidalgo², C. Hernando¹, F. Ademuyiwa³, K. Weilbaecher³, I. Mayer⁴, T. Pluard³, M. Martinez Garcia¹, L. Vahdat⁵, A. Wach⁶, D. Barker⁶, B. Romagnoli⁶, P. Kaufman⁷; ¹ES, ²Valencia/ES, ³MO/US, ⁴TN/US, ⁵NY/US, ⁶CH, ⁷NH/US

09:15 - 09:15 **286PD - Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients**
J. Specht¹, L. Pusztai², A. Forero-Torres³, M. Mita⁴, A. Weise⁵, I. Krop³, A. Grosse-Wilde³, Z. Wang³, M. Li³, S. Hengel³, P. Garfin³, G. Means³, M. Onsum³, S. Modi³; ¹WA/US, ²CT/US, ³US, ⁴CA/US, ⁵MI/US

09:15 - 09:15 **287PD - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients**

M.-S. DAI¹, T.-Y. Chao¹, T.-C. Chao¹, C.-F. Chiu¹, Y.-S. Lu¹, H.-S. Shiah¹, Y.-Y. Wu¹, G. Gerald Fetterly², N. Hung², D.L. Cutler², R. Kwan², D. Douglas Kramer², W.-K. Chan², T. Hung³; ¹TW, ²US, ³NZ

- 09:15 - 09:30 **Invited Discussant 285PD, 286PD and 287PD**
A. Gennari, IT
- 09:30 - 09:40 **Q&A led by Discussant**
- 09:40 - 09:40 **288PD - PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)**
J. Huober¹, P. Weder², C. Veyret³, B. Thürlimann², A. Xyrafas², L. Vanlemmens⁴, S. Guiu⁵, E. Brain⁵, J. Grenier⁶, F. Dalenc⁷, C. Levy⁸, A.M. Savoye⁴, A. Müller², V. Membrez-Antonioli², M.A. Gerard², J. Lemonnier⁵, H. Hawle², E. Boven⁹, H. Bonnefoi⁴; ¹DE, ²CH, ³CEDEX 1/FR, ⁴CEDEX/FR, ⁵FR, ⁶CEDEX 2/FR, ⁷CEDEX 3/FR, ⁸CEDEX 5/FR, ⁹NL
- 09:40 - 09:40 **289PD - Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial**
R. Hui¹, A. Pearson², J. Cortes Castan³, C. Campbell², C. Poirot⁴, H. Azim Jr.⁵, D. Fumagalli⁶, M. Lambertini⁶, F. Daly², A. Arahmani⁶, J. Perez-Garcia³, P. Aftimos⁶, P. Bedard⁷, L. Xuereb⁴, S. Loibl⁸, S. Loi⁹, M.-J. Pierrat⁴, N. Turner², F. André⁴, G. Curigliano¹⁰; ¹NSW/AU, ²GB, ³ES, ⁴FR, ⁵LB, ⁶BE, ⁷Ontario/CA, ⁸DE, ⁹VIC/AU, ¹⁰IT
- 09:40 - 09:55 **Invited Discussant 288PD and 289PD**
L. Carey, NC/US
- 09:55 - 10:05 **Q&A led by Discussant**
- 10:05 - 10:05 **293PD_PR - Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompleEment-1 trial**
C. Zamagni¹, M. Campone², I. Kudryavcev³, U. Brown-Glaberman⁴, P. Cottu⁵, A. Ring⁶, J. Lu⁴, M. Martín⁷, M. De Laurentiis¹, K. Zhou⁴, J. Wu⁴, L. Menon⁴, H. Azim⁸; ¹IT, ²FR, ³RU, ⁴US, ⁵CEDEX 5/FR, ⁶GB, ⁷ES, ⁸EG
- 10:05 - 10:05 **294PD_PR - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program**

J. Sirieix¹, J. Fraisse¹, S. Mathoulin-Pelissier¹, M. Leheurteur², L. Vanlemmens³, C. Jouannaud³, V. Dieras⁴, C. Levy⁴, F. Dalenc⁵, M.-A. Mouret-Reynier¹, T. Petit¹, B. Coudert⁶, E. Brain¹, B. Pistilli¹, J.-M. Ferrero⁷, A. Goncalves¹, L. Uwer³, S. Gourgou¹, J.-S. Frenel³; ¹FR, ²CEDEX 1/FR, ³CEDEX/FR, ⁴CEDEX 5/FR, ⁵CEDEX 3/FR, ⁶Cedex/FR, ⁷CEDEX 2/FR

10:05 - 10:05 **273PD_PR - Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients**

M. Reinisch, S. Seiler, T. Hauzenberger, S. Schmatloch, H.-J. Strittmatter, D.-M. Zahm, C. Thode, C. Jackisch, D. Strik, V. Moebus, T. Reimer, B. Sinn, E. Stickeler, F. Marme, W. Janni, A. Kamischke, C. Rudlowski, V. Nekljudova, G. von Minckwitz, S. Loibl; DE

10:05 - 10:20 **Invited Discussant 293PD, 294PD and 273PD**

C. Schroeder, NL

10:20 - 10:30 **Q&A led by Discussant**

09:15 - 10:30 Type: Poster Discussion session ICM - Room 14b
Title: Poster Discussion session - Genitourinary tumours, prostate

Chair(s): Joaquin Mateo, ES; Joe O'Sullivan, GB; Aristotelis Bamias, GR

09:15 - 09:15 **793PD - Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations**

W. Abida¹, A. Bryce¹, N. Vogelzang², R. Amato³, I. Percent¹, J. Shapiro⁴, R. McDermott⁵, A. Hussain¹, A. Patnaik¹, D. Petrylak¹, C. Ryan⁶, T. Stanton¹, J. Zhang¹, A. Simmons⁶, D. Despain¹, M. Collins¹, T. Golsorskhi¹, H. Scher⁷, S. Chowdhury⁸; ¹US, ²NV/US, ³TX/US, ⁴VIC/AU, ⁵Belgard Square North/IE, ⁶CA/US, ⁷NY/US, ⁸GB

09:15 - 09:15 **794PD - Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors**

S. Ali¹, J. Chung², N. Dewal¹, L. Gay², Y. He¹, E. Sokol¹, S. Millis¹, J. Killian¹, A. Schrock¹, S. Pal³, V. Miller¹, J. Ross², N. Agarwal²; ¹MA/US, ²US, ³CA/US

09:15 - 09:15 **795PD - Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)**

S. Chowdhury¹, R. McDermott², J.M. Piulats³, J. Shapiro⁴, I. Mejlholm⁵, D. Morris⁶, P. Ostler¹, A. Hussain⁷, I. Dumbadze⁷, E. Goldfischer⁷, E. Pintus¹, A. Benjelloun⁸, M. Gross⁷, S. Tejwani⁹, G. Chatta⁷, A. Font³, A. Loehr⁷, A. Simmons¹⁰, S. Watkins¹, W. Abida⁷; ¹GB, ²Belgard Square North/IE, ³ES, ⁴VIC/AU, ⁵DK, ⁶TN/US, ⁷US, ⁸CA, ⁹MI/US, ¹⁰CA/US

- 09:15 - 09:30 **Invited Discussant 793PD, 794PD and 795PD**
J. Mateo, ES
- 09:30 - 09:40 **Q&A led by Discussant**
- 09:40 - 09:40 **796PD - Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer**
W. Struss¹, G. Vandekerkhove², M. Annala², K. Chi³, M. Gleave¹, A. Wyatt²; ¹CA, ²BC/CA, ³British Columbia/CA
- 09:40 - 09:40 **797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)**
N. Matsubara¹, K. Chi², M. Ozguroglu³, A. Rodriguez Antolin⁴, S. Feyerabend⁵, L. Fein⁶, B. Alekseev⁷, G. Sultur⁸, A. Protheroe⁹, S. Li¹⁰, S. Mundle¹⁰, P. De Porre¹¹, N. Tran¹⁰, K. Fazazi¹²; ¹JP, ²British Columbia/CA, ³TR, ⁴ES, ⁵DE, ⁶AR, ⁷RU, ⁸California/CN, ⁹Oxfordshire/GB, ¹⁰US, ¹¹BE, ¹²FR
- 09:40 - 09:55 **Invited Discussant 796PD and 797PD**
J. O'Sullivan, GB
- 09:55 - 10:05 **Q&A led by Discussant**
- 10:05 - 10:05 **798PD - In-depth assessment of metastatic prostate cancer with high tumour mutational burden**
N. Mehra¹, J. van Riet², M. Smits², H. Westdorp², M. Gorris², T. van Ee², M. van der Doelen², I. van Oort², M. Sedelaar², J. Textor², E. Cuppen², K. Grunberg², M. Ligtenberg², W. Zwart², A. Bergman², H. van de Werken², J. Schalken², I. de Vries², M. Lolkema², W. Gerritsen²; ¹Surrey/NL, ²NL
- 10:05 - 10:05 **799PD - Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)**
S. Tagawa¹, S. Vallabhajosula², Y. Jhanwar², A. Hackett², C. Oromendia², M. Naiz², S. Goldsmith², D.M. Nanus², H. Beltran², A. Molina², B. Faltas², J. Sreekumar², J. Babich², K. Ballman², N. Bander²; ¹US/US, ²US
- 10:05 - 10:20 **Invited Discussant 798PD and 799PD**
A. Bamias, Attiki/GR
- 10:20 - 10:30 **Q&A led by Discussant**

09:15 - 10:45 **Type: Special Symposium** **ICM - Room 13**
Title: Modern tools to optimise therapy for patients with head and neck cancer
 Chair(s): Christophe Le Tourneau, FR; Amanda Psyrri, GR

09:15 - 09:20 **Introduction**
A. Psyrri, GR

09:20 - 09:40 **Biomarkers and next generation sequencing**
B. Solomon, VIC/AU

09:40 - 10:00 **Optimising response to immunotherapy using combinations in the recurrent/metastatic setting**
A. Psyrri, GR

10:00 - 10:20 **Taking the next step - immunotherapy in the curative setting**
E. Cohen, IL/US

10:20 - 10:40 **Response assessment and endpoint selection for immunotherapy studies**
S. Faivre, FR

10:40 - 10:45 **Conclusions and perspectives**
C. Le Tourneau, FR

09:15 - 10:45 **Type: Educational session** **Hall B3 - Room 21**
Title: Opportunities in clinic trial design in the era of genomics and immuno-oncology
 Chair(s): Christian Rolfo, US; Allan Jordan, GB

09:15 - 09:40 **Integration of biomarkers into drug development**
C. Rolfo, US

09:40 - 10:05 **Novel pre-clinical models to design drug combinations**
J. Hoffmann, DE

10:05 - 10:30 **Role of artificial intelligence in drug development**
M. Kris, NY/US

10:30 - 10:45 **Discussion**

09:15 - 10:45 **Type: EONS session** **Hall B4 - Room 24**
Title: Symptom management: Clinical aspects and implementation
 Chair(s): Karin Jordan, DE; Wendy Oldenmenger, NL

09:15 - 09:35 **Guidelines on peripheral neuropathy**
K. Jordan, DE

09:35 - 09:55 **Patient-centered care and self-management**
M. Piredda, IT

09:55 - 10:15 **Essentials of optimal pain management**
J. Wood, GB

10:15 - 10:35 **Oral cryotherapy for the prevention of oral mucositis**
M. Hellberg-Nägele, DE

10:35 - 10:45 **Discussion**

09:30 - 10:30 **Type: Controversy Session** **Hall A1 - Room 15**
Title: Identification of ultra-rare, life-saving molecular subtypes of cancer - NGS for everyone, some or none?
 Chair(s): George Demetri, US

09:30 - 09:40 **Introduction and 1st vote**
G. Demetri, US

09:40 - 10:00 **Yes**
E. Wardelmann, DE

10:00 - 10:20 **No**
S. Sleijfer, NL

10:20 - 10:30 **2nd vote and conclusions**
G. Demetri, US

09:30 - 10:30 **Type: Special session** **Hall A1 - Room 16**
Title: Integration of immunotherapy with disease entities
 Chair(s): Ulrich Keilholz, DE

09:30 - 09:50 **Head and neck**
U. Keilholz, DE

09:50 - 10:10 **Lung cancer**
S. Peters, CH

10:10 - 10:30 **Lymphoma**
C. Arber Barth, TX/CH

09:30 - 10:30 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**
Title: Challenges in the treatment of early stage ovarian cancer
 Chair(s): Jonathan Ledermann, GB

09:30 - 09:40 **Challenges in the treatment of early stage ovarian cancer**
C. Marth, AT

09:40 - 10:30 **Discussion led by**
J. Ledermann, London/GB

09:30 - 10:35 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**
Title: Dissecting mediastinal grey zone lymphomas
 Chair(s): Maurizio Martelli, IT

09:30 - 09:35 **Case presentation**
M. Martelli, IT

09:35 - 09:45 **The pathologist's perspective**
T. Molina, FR

09:45 - 09:55 **The haematologist's perspective**
M. Martelli, IT

09:55 - 10:05 **The radiation oncologist's perspective**
A. Filippi, IT

10:05 - 10:35 **Discussion**

09:30 - 10:30 **Type: Special session** **Hall B3 - Room 22**
Title: Using population data evidence to support policy decisions in cancer
 Chair(s): Andrew Briggs, GB; Bengt Jönsson, SE

09:30 - 09:45 **The role of evidence in alternative frameworks for the valuation of oncology treatments**
B. Jönsson, SE

09:45 - 10:00 **Using real world data for decision-making in R&D and health technology assessment**
A. Forsythe, US

10:00 - 10:15 **Using RWE to identify gaps in the provision of effective - and cost-effective - care**
A. Briggs, GB

10:15 - 10:30 **Discussion**

10:45 - 12:45 **Type: Clinical Practice Guidelines** **Hall A1 - Room 15**
Title: ESMO Clinical Practice Guidelines 1
 Chair(s): George Pentheroudakis, GR; Cristiana Sessa, CH

10:45 - 10:55 **Introduction**
G. Pentheroudakis, GR

10:55 - 11:05 **Questionnaire**
C. Sessa, CH

11:05 - 11:15 **Gastroenteropancreatic neuroendocrine tumours**
J. Hadoux, CEDEX/FR

11:15 - 11:25 **Discussant**
A. Berruti, IT

11:25 - 11:30 **Q&A**

11:30 - 11:40 **Mantle cell lymphoma**
M. Jerkeman, SE

11:40 - 11:50 **Discussant**
M. Dreyling, DE

11:50 - 11:55 **Q&A**

11:55 - 12:05 **Rectal cancer**

F. Sclafani, GB

12:05 - 12:15 **Discussant**

A. Cervantes, Valencia/ES

12:15 - 12:20 **Q&A**

12:20 - 12:30 **Metastatic NSCLC**

M. Früh, CH

12:30 - 12:40 **Discussant**

P. Janne, US

12:40 - 12:45 **Q&A**

11:00 - 12:30 Type: Educational session
Title: The critical need of a multidisciplinary approach for the treatment of prostate cancer

**ICM -
Room 1**

Chair(s): Silke Gillessen, CH; Chris Parker, GB

11:00 - 11:25 **Update on diagnosis and treatment of localised prostate cancer**

M. Emberton, GB

11:25 - 11:50 **Oligometastatic disease**

A. Bossi, FR

11:50 - 12:15 **What is new in metastatic castration resistant prostate cancer (CRPC)?**

R. de Wit, NL

12:15 - 12:30 **Discussion**

11:00 - 12:30 **Type: Educational session** **ICM - Room 14b**
Title: Optimal antineoplastic therapy and supportive care of elderly cancer patients
Chair(s): Jorn Herrstedt, DK; Stein Kaasa, NO

11:00 - 11:02 **Introduction**
J. Herrstedt, DK

11:02 - 11:27 **Anticancer therapy-induced dose-limiting toxicity in elderly cancer patients**
K. Jordan, DE

11:27 - 11:52 **Importance of maintaining dose density and dose intensity**
J. Herrstedt, DK

11:52 - 12:17 **Immunotherapy in the elderly**
M. Aapro, CH

12:17 - 12:30 **Discussion**

11:00 - 12:30 **Type: Special Symposium** **ICM - Room 13**
Title: Novel therapies for brain tumors
Chair(s): Michael Weller, CH; Joerg-Christian Tonn, DE

11:00 - 11:05 **Introduction**
J.-C. Tonn, DE

11:05 - 11:20 **Immunotoxins for gliomas**
M. van den Bent, NL

11:20 - 11:35 **Update on vaccination strategies for gliomas**
M. Weller, CH

11:35 - 11:50 **Immune check-point inhibitors in brain tumors**
A.S. Berghoff, AT

11:50 - 12:05 **Genomically targeted therapies in neuro-oncology**
W. Wick, DE

12:05 - 12:20 **Targeted therapies of pediatric brain tumors**
D. Hargrave, GB

12:20 - 12:30 **Conclusions and clinical perspectives**
M. Weller, CH

11:00 - 12:30 **Type: Special session** **Hall A1 - Room 16**
Title: Integrating radiation in immunotherapy schemes
Chair(s): Ulrich Keilholz, DE; Fernanda Herrera, CH

11:00 - 11:05 **Introduction**
U. Keilholz, DE

11:05 - 11:25 **Checkpoint inhibitors plus radiotherapy to increase cure rates in head and neck cancer**
K. Harrington, GB

11:25 - 11:45 **Abscopal effect of radiotherapy with checkpoint inhibitors**

11:45 - 12:05 **Radiation dose to harness the immune system**
F. Herrera, CH

12:05 - 12:25 **Manipulating the tumour microenvironment through radiation**
S. Demaria, US

12:25 - 12:30 **Conclusions and perspectives**
F. Herrera, CH

11:00 - 12:30 **Type: Special Symposium** **Hall A2 - Room 18**
Title: Safe de-escalation of therapy in the management of early breast cancer
Chair(s): Charlotte Coles, GB; Emiel Rutgers, NL

11:00 - 11:05 **Introduction**
C. Coles, GB

11:05 - 11:25 **Chemotherapy or not: How do you decide?**
S. Delaloge, FR

11:25 - 11:45 **Duration of targeted therapy for HER2 and for hormone therapy**
H. Earl, Cambridgeshire/GB

11:45 - 12:05 **Minimising surgical management of early breast cancer**
E. Rutgers, NL

12:05 - 12:25 **Biomarker-guided radiotherapy in the management of early breast cancer**
T. Whelan, CA

12:25 - 12:30 **Conclusions and perspectives**
E. Rutgers, NL

- 11:00 - 12:30** **Type: Proffered Paper session** **Hall B3 - Room 22**
Title: Proffered paper session - Developmental therapeutics
 Chair(s): Alex A. Adjei, US; Allan Jordan, GB
- 11:00 - 11:12 **4080 - Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL**
L. Bazhenova¹, R. Carvajal², B.C. Cho³, K. Eaton⁴, S. Goel², R. Heist², M. Ingham², D. Wang⁵, T. Werner⁶, S. Neuteboom², D. Potvin², I. Chen¹, J. Christensen¹, R. Chao¹, A. Alva⁵; ¹CA/US, ²US, ³KR, ⁴WA/US, ⁵MI/US, ⁶UT/US
- 11:12 - 11:24 **4090 - Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach**
U. Lassen¹, C. Albert², S. Kummar³, C. van Tilburg⁴, S. Dubois⁵, B. Georger⁶, L. Mascarenhas⁷, N. Federman⁷, R. Schilder⁸, F. Doz⁶, J. Berlin⁹, D.-Y. Oh¹⁰, S. Bielack⁴, R. McDermott¹¹, D. Tan¹², S. Cruickshank⁷, N. Ku⁷, M. Cox⁷, A. Drilon¹³, D. Hong³; ¹DK, ²WA/US, ³US, ⁴DE, ⁵MA/US, ⁶FR, ⁷CA/US, ⁸PA/US, ⁹TN/US, ¹⁰KR, ¹¹Belgard Square North/IE, ¹²SG, ¹³NY/US
- 11:24 - 11:36 **LBA17 - Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors: Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**
G. Demetri¹, L. Paz-Ares², A. Farago¹, S. Liu¹, S. Chawla¹, D. Tosi³, E. Kim¹, C. Blakely⁴, J. Krauss¹, D. Sigal¹, L. Bazhenova⁴, T. John⁵, B. Besse⁶, J. Wolf⁷, T. Seto⁸, E. Chow-Maneval⁹, P. Multani¹, A. Johnson¹, B. Simmons¹, R. Doebele¹; ¹US, ²ES, ³FR, ⁴CA/US, ⁵AU, ⁶CEDEX/FR, ⁷DE, ⁸JP, ⁹GB
- 11:36 - 11:51 **Invited Discussant 4080, 4090 and LBA17**
A. Jordan, GB
- 11:51 - 12:03 **4100 - First-in-human, first-in-class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors**
E. Calvo¹, P. Aftimos², A. Azaro¹, M.J. de Miguel¹, C. Jungels², J. Zeron-Medina Cuairan¹, P. Nuciforo¹, P. Ehmer³, A. Martin³, H. Bender³, K. Dembowski³; ¹ES, ²BE, ³DE
- 12:03 - 12:15 **4110 - Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer**
J. Hilton¹, M. Cristea², M. Voskoboinik³, S. Postel-Vinay⁴, W. Edenfield⁵, A. Gavai⁶, S. Wee⁶, N. Srivastava⁶, A. Klippel⁷, D. Jackson⁶, A. Apfel⁶, S. Chasalow⁸, D. Williams⁶, M. Donovan⁶, B. Fischer⁷, S. Khaldoyanidi⁶, J. Diamond⁷; ¹CA, ²CA/US, ³VIC/AU, ⁴FR, ⁵SC/US, ⁶NJ/US, ⁷US, ⁸New Jersey/US
- 12:15 - 12:30 **Invited Discussant 4100 and 4110**
U. Banerji, Surrey/GB

- 11:00 - 12:30** **Type: Proffered Paper session** **Hall B4 - Room 19**
Title: Proffered paper session - Haematological malignancies
 Chair(s): Marco Ladetto, IT; Maria-Victoria Mateos, ES
- 11:00 - 11:15 **10060 - Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies**
P. Zinzani¹, A. Santoro², L. Mollica³, G. Follows⁴, K. Bouabdallah⁵, F. Morschhauser⁵, A. Patnaik⁶, L. Huang⁶, F. Hiemeyer⁷, A. Benson⁸, I. Genvresse⁷, J. Garcia-Vargas⁸, B. Childs⁹, M. Dreyling⁷; ¹IT, ²(MI)/IT, ³CA, ⁴GB, ⁵FR, ⁶US, ⁷DE, ⁸NJ/US, ⁹New York/US
- 11:15 - 11:30 **10040 - Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study**
F. Cavalli¹, J. Jin², H. Pylypenko³, G. Verhoef⁴, N. Siritanaratkul⁵, J. Drach⁶, M. Raderer⁶, J. Mayer⁷, J. Pereira⁸, G. Tumyan⁹, R. Okamoto¹⁰, S. Nakahara¹⁰, P. Hu¹¹, C. Appiani¹¹, S. Nemat¹², T. Robak¹³; ¹CH, ²CN, ³UA, ⁴BE, ⁵TH, ⁶AT, ⁷CZ, ⁸BR, ⁹RU, ¹⁰JP, ¹¹NJ/US, ¹²GB, ¹³PL
- 11:30 - 11:45 **10050 - A revised international prognostic score system for Waldenstr&&**
M. Gavriatopoulou¹, E. Kastritis¹, P. Morel², A. Duhamel³, M. Kyrtonis¹, E. Durot³, A. Symeonidis¹, K. Laribi³, E. Hatjiharisi¹, L. Ysebaert³, A. Vassou¹, N. Giannakoulas¹, G. Merlini⁴, P. Repousis¹, M. Varettoni³, E. Michalis¹, B. Hivert³, M. Michalis⁵, V. Leblond³, M. Dimopoulos¹; ¹GR, ²Pas de Calais/FR, ³FR, ⁴IT, ⁵CY
- 11:45 - 12:05 **Invited Discussant 10040, 10050 and 10060**
C. Buske, DE
- 12:05 - 12:20 **10070 - Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry**
R. Abonour¹, R. Rifkin², C. Gasparetto², K. Toomey², B. Durie², J. Hardin², H. Terebelo², S. Jagannath², M. Narang², S. Ailawadhi², S. Srinivasan², A. Kitali², A. Agarwal², L. Wagner²; ¹IN/US, ²US
- 12:20 - 12:30 **Invited Discussant 10070**
M.-V. Mateos, ES

11:00 - 12:00	Type: EONS session Title: Symptom management Chair(s): Patrick Jahn, DE	Hall B4 - Room 24
11:00 - 11:15	CN26 - The cost of survival: A mixed-method exploration of healthcare-related factors predicting colorectal cancer survivors' quality of life <u>A. Drury</u> ¹ , S. Payne ² , A.-M. Brady ¹ ; ¹ IE, ² GB	
11:15 - 11:30	CN53 - Rectal cancer survivorship: The struggle of the low anterior resection syndrome (LARS) <u>E. Pape</u> , P. Pattyn, A. van Hecke, N. Somers, D. Van De Putte, W. Ceelen, E. van Daele, W. Willaert, Y. van Nieuwenhove; BE	
11:30 - 11:45	CN54 - Nurse-led approaches to self-management of symptoms in routine Swiss outpatient care: A qualitative exploration <u>K. Ribi</u> , M. Bana, S. Peters, S. Kropf-Straub, E. Näf, S. Zürcher, M. Eicher; CH	
11:45 - 12:00	CN27 - The influence of social networks on cancer survivors' self-management support: A survey analysis <u>G. Howard-Jones</u> , A. Richardson, I. Vassilev, D. Fenlon, S. Ewings; GB	
11:00 - 11:45	Type: Young Oncologist session Title: YO Brunch 2: Breaking bad news: How to deal with end-of-life discussions Chair(s): Mila Petrova, BG; Mehmet Akif Ozturk, TR	ICM - Room 14a
11:00 - 11:15	Breaking bad news: How to deal with end-of-life discussions <u>E. Masel</u> , AT	

11:10 - 12:40 Type: Proffered Paper session **Hall A1 - Room 17**
Title: Proffered paper session - Gastrointestinal tumours, non colorectal
 Chair(s): Yoon-Koo Kang, KR; Florian Lordick, DE

11:10 - 11:25 **LBA25 - TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer**
H.-T. Arkenau¹, J. Tabernero², K. Shitara³, M. Dvorkin⁴, W. Mansoor¹, A. Prokharau⁵, M. Alsina², M. Ghidini⁶, C. Faustino⁷, V. Gorbunova⁴, E. Zhavrid⁵, K. Nishikawa³, A. Hosokawa³, D. Ganea⁸, Ş. Yalçın⁹, G. Beretta¹⁰, R. Winkler¹¹, L. Makris¹², T. Doi¹³, D. Ilson¹⁴; ¹GB, ²ES, ³JP, ⁴RU, ⁵BY, ⁶(MI)/IT, ⁷PT, ⁸RO, ⁹TR, ¹⁰IT, ¹¹NJ/US, ¹²PA/US, ¹³Chiba/JP, ¹⁴NY/US

11:25 - 11:37 **Invited Discussant LBA25**
Y.-K. Kang, Songpa-gu/KR

11:37 - 11:52 **6150 - Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)**
D. Sakai¹, M. Kanai¹, S. Kobayashi¹, H. Eguchi¹, H. Baba¹, S. Seo¹, A. Taketomi¹, T. Takayama¹, H. Yamaue¹, C. Ishioka², M. Sho¹, Y. Takeyama¹, J. Fujimoto¹, M. Toyoda¹, J. Shimizu¹, T. Goto¹, K. Yoshimura³, E. Hatano¹, H. Nagano¹, T. Ioka¹; ¹JP, ²Miyagi/JP, ³Ishikawa/JP

11:52 - 12:04 **Invited Discussant 6150**
J. Valle, GB

12:04 - 12:19 **LBA26 - Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)**
M. Pishvaian¹, M. Lee², B.-Y. Ryoo³, S. Stein⁴, K.-H. Lee⁵, W. Verret¹, J. Spahn⁶, H. Shao⁷, B. Liu¹, K. Iizuka¹, C.-H. Hsu⁸; ¹US, ²NC/US, ³Songpa-gu/KR, ⁴CT/US, ⁵KR, ⁶CA/US, ⁷CN, ⁸TW

12:19 - 12:34 **LBA27 - A Randomized Multicentered Phase 2 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) who Failed or Intolerable to Prior Systemic Treatment**
S. Qin, Z. Ren, Z. Meng, Z. Chen, X. Chai, J. Xiong, Y. Bai, L. Yang, H. Zhu, W. Fang, X. Lin, X. Chen, E. Li, Y. Xia, J. Zou; CN

12:34 - 12:46 **Invited Discussant LBA26 and LBA27**
M. Ducreux, FR

11:10 - 12:15 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 23**
Title: Multidisciplinary perspectives in stage I-II NSCLC management
 Chair(s): Enriqueta Felip, ES

11:10 - 11:15 **Case presentation on stage**
E. Felip, ES

11:15 - 11:25 **The role of medical oncology**
E. Felip, ES

11:25 - 11:35 **The role of radiotherapy**
S. Senan, NL

11:35 - 11:45 **The role of surgery**
W. Weder, CH

11:45 - 12:15 **Discussion**

11:10 - 12:15 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**
Title: Pre-op/neoadjuvant treatments in sarcomas: "Think twice before you open it"
 Chair(s): Paolo G. Casali, IT

11:10 - 11:15 **Case presentation**
P.G. Casali, IT

11:15 - 11:25 **The surgeon's perspective**
P. Rutkowski, PL

11:25 - 11:35 **The radiation oncologist's perspective**
A. Miah, GB

11:35 - 11:45 **The medical oncologist's perspective**
A. Le Cesne, CEDEX/FR

11:45 - 12:15 **Discussion**

11:15 - 12:15 **Type: Poster Discussion session** **Hall B3 - Room 21**
Title: Poster Discussion session - Translational research 2
 Chair(s): Giampaolo Tortora, IT; Gert Attard, GB

- 11:15 - 11:15 **62PD - Could plasma EBV DNA kinetics predict long-term disease-free survival in metastatic nasopharyngeal carcinoma?**
L. guoying, H. Liang, W.-X. Xia, Y.-Q. Xiang, X. Lv, X. Guo, Y.-H. Yu, S.-H. Lv, K.-Y. Liu, W.-Z. Qiu, X.-J. Huang, W.-Z. Li; CN
- 11:15 - 11:15 **63PD - Predictive and pharmacodynamic biomarkers associated with phase II, selective and orally bioavailable AXL inhibitor bemcentinib across multiple clinical trials**
B. Holt¹, D. Micklem¹, A. Brown², M. Yule², J. Lorens²; ¹GB, ²NO
- 11:15 - 11:15 **64PD - Identification and validation of a 23-gene expression signature for subtype classification of medulloblastoma**
Q. Xu, Q. Wang, J. Chen, C. Chen, Y. Sun, L. Chen, Q. Ye, X. Du; CN
- 11:15 - 11:15 **1832PD - Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)**
A. Hollebecque¹, J. de Bono², R. Plummer³, N. Isambert⁴, P. Martin-Romano¹, E. Baudin¹, S. Mora⁵, A. Harding², A. Nguyen⁶, E. Filvaroff⁶, M. Lamba⁷, K. Liu⁷, J. De Alvaro⁵, J. DiMartino⁶, M. Zuraek⁶, Z. Nikolova⁵; ¹FR, ²GB, ³Tyne and Wear/GB, ⁴Cedex/FR, ⁵ES, ⁶CA/US, ⁷US
- 11:15 - 11:15 **1833PD - Lack of efficiency of precision oncology with target-based investigational treatments for patients in early phase clinical trials based on pre-screened molecular alterations**
B. Doger de Spéville, V. Moreno, T. Hernandez, V. Boni, M.J. de Miguel, F. Rojo, F. Lopez-Rios, E. Calvo; ES
- 11:15 - 11:35 **Invited Discussant 62PD, 63PD, 64PD, 1832PD and 1833PD**
G. Tortora, IT
- 11:35 - 11:45 **Q&A led by Discussant**
- 11:45 - 11:45 **65PD - High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4**
B. Higgs, US
- 11:45 - 11:45 **1834PD - Genomic profile and T cell receptor repertoire of lung adenosquamous carcinomas**
G. Lin, C. Li, W.-Z. Fang, W. Chen, C. Huang; CN
- 11:45 - 11:45 **1835PD - Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low**

M. Salem¹, A. Puccini², A. Grothey³, J. Xiu⁴, R. Goldberg⁵, E. Kim⁶, W.M. Korn⁴, H.-J. Lenz⁷, D. Raghavan⁸, J. Marshall¹, M. Hall⁹; ¹DC/US, ²IT, ³MN/US, ⁴US, ⁵SG, ⁶NC/US, ⁷CA/US, ⁸North Carolina/US, ⁹PA/US

11:45 - 11:45 **1836PD - Representative sequencing: Profiling extreme tumor diversity**
K. Litchfield, L. Au, C. Swanton, S. Turajlic; GB

11:45 - 11:45 **1837PD - Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)**
J.L. Perez Gracia¹, M.J. Pajares¹, J.P. Fusco¹, M. Andueza¹, V. Segura¹, M.I. Mora¹, E. Guruceaga¹, R. Sanchez Bayona¹, A. Gurrpide¹, J.M. Lopez-Picazo¹, I. Gil-Bazo¹, J.P. de Torres¹, J. Zulueta¹, R. Pio¹, I. Melero¹, M. Sanmamed², M. Rodriguez-Ruiz¹, A. Gonzalez Neira¹, L. Montuenga¹, A. Patiño-Garcia¹; ¹ES, ²US

11:45 - 12:05 **Invited Discussant 1834PD, 1835PD, 1836PD and 1837PD**
G. Attard, GB

12:05 - 12:15 **Q&A led by Discussant**

12:00 - 13:00 Type: Poster Display session Hall B4 - Room 24
Title: EONS Poster display

12:00 - 12:00 **CN5 - Patients: Power sources for cancer nurses**
C. Beisel, DE

12:00 - 12:00 **CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: Towards patient-centered care**
J. Koldenhof, S. Vervoort, C. Nierop, K. Suijkerbuijk; NL

12:00 - 12:00 **CN7 - Perceptions of rural nurses extending their role to administer chemotherapy**
Q. Alnasser¹, K. Cameron¹, J. Prouse²; ¹SA, ²AU

12:00 - 12:00 **CN8 - AYA cancer nursing, an emerging sub-speciality: The first book about AYA cancer nursing, edited and authored by nurses**
S. Smith, DK

12:00 - 12:00 **CN9 - Nurse led follow-up for CML patients on oral cancer treatment**
S. De Wilde, J. De Munter, M. Quaghebeur, D. Mazure, A. De Pauw, B. Casteels; BE

12:00 - 12:00 **CN10 - Introducing a new role in cancer care, coordinating contact nurses: Patient-reported evaluation**
B. Westman, H. Ullgren, L. Sharp; SE

- 12:00 - 12:00 **CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: Preliminary study**
E. Mahía, G. Simó, E. Heras, M. Pascual, F. Cobo, J. Pujadas, S. Albiol; AD
- 12:00 - 12:00 **CN12 - Systemic anticancer therapy administration safety**
S. Toland, A. Simons; GB
- 12:00 - 12:00 **CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: The role of the nurse practitioner for early recognition and management**
C. Roth, M. Labots, A. Eertwegh; NL
- 12:00 - 12:00 **CN14 - Experiences from a new advanced cancer nursing role in Sweden: An analysis based on EONS Cancer nursing education framework using the Delphi method**
H. Ullgren, SE
- 12:00 - 12:00 **CN15 - Opinions and experiences of patients receiving oral chemotherapy: A qualitative study**
S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR
- 12:00 - 12:00 **CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for adolescents and young adults (AYAs) with an hematological disease**
J. De Munter, S. De Wilde, M. Quaghebeur; BE
- 12:00 - 12:00 **CN17 - Standardising the psychosocial assessment of oncological patients at Donostia university hospital**
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES
- 12:00 - 12:00 **CN18 - Are there differences between nurses&&**
M. Lavdaniti, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. Zioga, K. MARMARA, E. Fradelos; GR
- 12:00 - 12:00 **CN19 - How an empowerment program can touch cancer survivor's life by improving post-traumatic growth?**
Y.S. UZAR OZCETIN, TR
- 12:00 - 12:00 **CN20 - Organising a general oncology nursing outpatient clinic**
C. Lundgren, A. Lagerquist, M. Högman, U. Östlund; SE
- 12:00 - 12:00 **CN21 - Job content of advanced practice nurses in Flanders**
E. Decoene, A. Van Hecke; BE

- 12:00 - 12:00 **CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professional's self-efficacy when supporting parents newly diagnosed with cancer who have dependent children**
C. Semple, E. McCaughan; GB
- 12:00 - 12:00 **CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals**
J. Bird, M. Nolan, S. Danson; GB
- 12:00 - 12:00 **CN24 - Assessing the effect of telephone support on patients with myeloma multiple (MM) in the Catalan oncology institut in Girona**
C. PUIGMARTI, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher; ES
- 12:00 - 12:00 **CN28 - Transmural collaborative care in oncology: Experiences of general practitioners**
M. daem, E. van Roekeghem, M. Grypdonck, P. Pype; BE
- 12:00 - 12:00 **CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review**
S. Colomer-Lahiguera¹, D. Bryant-Lukosius², S. Rietkoetter², L. Martelli², K. Ribic¹, A. Orcurto¹, R. Juergens², M. Eicher¹; ¹CH, ²ON/CA
- 12:00 - 12:00 **CN30 - Laryngectomized patients caregivers's life experience: A phenomenological study**
V. Bressan, E. Dri, S. Stevanin, L. Cadorin, A. Rizzuto, G. Bulfone, L. Ghirotto; IT
- 12:00 - 12:00 **CN31 - Comparing nurses&&**
L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT
- 12:00 - 12:00 **CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy**
A. Psychogyiou, S. KATSARAGAKIS, C. Lemonidou, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 **CN33 - A new beginning of collaboration: The Danish Cancer Nursing Research Network**
K. Dieperink, M. Kjerholt, P. Riis Olsen; DK
- 12:00 - 12:00 **CN34 - Individual network meetings in cancer care: From young people with cancer to adults with brain tumours**
P. Riis Olsen, DK
- 12:00 - 12:00 **CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?**
G. Bagcivan, N. Ozen, D. Bayrak, F.I. Cinar; TR

- 12:00 - 12:00 **CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment**
C. Johnston, M. Tanay; GB
- 12:00 - 12:00 **CN37 - Evaluation of support and information needs for patients with cancer in a phase I trials unit**
S. Stapleton, L. O'Leary, M. van Zyl, J. Hanwell, T. Wiseman; GB
- 12:00 - 12:00 **CN38 - Dignity of Greek patients with advanced cancer: A cross-sectional study**
S. KATSARAGAKIS, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 **CN39 - Development and implementation of national guidelines on lifestyle issues and cancer: Report from an ongoing quality improvement project**
K. Vuollet Karlsson, C. Landegren, B. Westman; SE
- 12:00 - 12:00 **CN40 - Developing a patient reported experience measure (PREM) in secondary breast cancer (SBC)**
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke; GB
- 12:00 - 12:00 **CN41 - Cancer situation in Sub-Saharan countries: Development of educational, diagnosis and treatment plans**
J. de la Torre-Montero, N. Gil-Gómez, J. RIBES BERNAL, N. Domenech Climent, A. OJER PEREA, P. BEORLEGUI MURILLO, J.M. GAVALA ARJONA, R. CUMPLIDO CORBACHO, I. MAGALLON PEDRERA, M.A. PEÑUELAS SAIZ; ES
- 12:00 - 12:00 **CN42 - The Gastrointestinal and Lymphoma Unit lead nurse research role in Royal Marsden Hospital**
J. Duncan¹, V. Michalarea², T. Coyne¹, J. Thomas¹, D. Cunningham¹; ¹GB, ²Surrey/GB
- 12:00 - 12:00 **CN43 - Patients' learning and participation in their breast cancer care**
L. Boman, K. Sandelin, Y. Wengström, C. Silén; SE
- 12:00 - 12:00 **CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration**
S.Y. Oh, J.M. Lee, J.W. Kim, S.H. Kim, J.M. Park, G.Y. Yeo, J.E. Hyun, J.-H. Park; KR
- 12:00 - 12:00 **CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy**
A. Frade, S. Miguel; PT
- 12:00 - 12:00 **CN46 - Safe navigation of CARs in a changing landscape**
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite; GB
- 12:00 - 12:00 **CN47 - Patients' interpretations and experiences of participation in cancer care**

J. Jackson, J. Rundgren; SE

- 12:00 - 12:00 **CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab**
M. Qiu, Y. Chen, B.-L. Zhang, X.-Y. Wang; CN
- 12:00 - 12:00 **CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care**
J. De Munter, P. Crombez; BE
- 12:00 - 12:00 **CN50 - Overview of an acute oncology service in a UK cancer centre**
M. Foulkes, GB
- 12:00 - 12:00 **CN51 - The development and evaluation of an online oncology portal**
J. De Munter, E. Decoene, A. Van Hecke; BE
- 12:00 - 12:00 **CN52 - Pilot study: Nurses' role in management of cutaneous toxicity in patients with targeted therapies anti EGFR-Is' treatment**
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso; IT
- 12:00 - 12:00 **CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?**
D. Oliva, F. Lewin, N. Lewin, M. Nilsson, M. Strandéus, B.-Å. Andersson, L. Sharp; SE
- 12:00 - 12:00 **CN58 - Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin**
N. Izgu, L. Ozdemir, F. Bugdayci Basal; TR
- 12:00 - 12:00 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**
C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 **CN60 - The experience of dysgeusia in allogeneic hematopoietic cell transplantation survivors: A qualitative study**
D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT
- 12:00 - 12:00 **CN61 - &&**
M. Tanay, J. Armes; GB
- 12:00 - 12:00 **CN62 - App about chemotherapy: Helping the patient with cancer**
B. Espersen, DK
- 12:00 - 12:00 **CN63 - Usability test for a CINV diary application for smartphones at oncology nursing**

P. Fernández- Ortega, Y. Escobar, E. Trigos, R. Blat, M. Cantero, A. Alvarez; ES

12:00 - 12:00 **CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the memorial symptom assessment scale**

D. Palitzika, E. Fradelos, V. Alikari, P. Charitopoulos, E. Zioga, S. Zyga, M. Lavdaniti; GR

12:00 - 12:00 **CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool &&**

M. Belhadj¹, E. Kempf¹, A. Lebel¹, A. Guillemin¹, H. BouSSION¹, C. Joly¹, I. Baumgaertner², E. Assaf², C. Saldana², B. Rousseau², C. Tournigand²; ¹FR, ²CEDEX/FR

12:00 - 12:00 **CN66 - Medical makeup in cancer patients and its impact in their quality of life**

R. Lechou, M. Lavdaniti; GR

12:30 - 14:00 Type: Patient Advocacy Track ICM - Room 5
Title: The cancer drugs we need: Incentivising innovation in cancer

Chair(s): Bettina Ryll, SE; Charlotte Roffiaen, FR

12:30 - 12:45 **Shaping policies to drive innovation in cancer**

R. Sullivan, GB

12:45 - 13:00 **Incentivising innovation**

J. Scannell, GB

13:00 - 13:15 **Innovating for Impact: A cancer patient advocacy perspective**

B. Ryll, SE

13:15 - 14:00 **Discussion**

12:45 - 13:45 Type: Poster Display session Hall A3 - Poster Area
Title: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal && Networking Hub

12:45 - 12:45 **Basic science**

12:45 - 12:45 **6P - Molecular characterization and search for founding effects in Canarian families with hereditary breast and ovarian cancer syndrome**

E. Llabres Valenti, A. Sanchez de Abajo, J. Brenes Castro, A. Ramchandani Vaswani, A. Gómez de Liaño, A. Hernández, M. Cejuela, J. Rodriguez Garcia, E. González, E. Vicente; ES

12:45 - 12:45 **7P - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population: Modulation by gender**

J.B. Ramirez Sabio, J.V. Sorlí, I. González-Monje, C. Ortega-Azorín, Ó. Coltell, D. Corella; ES

12:45 - 12:45 **8P - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population**

J.B. Ramirez Sabio, J.V. Sorlí, C. Ortega-Azorín, J.A. Pérez-Fidalgo, E.M. Asensio, D. Corella; ES

12:45 - 12:45 **9P - Association of a genetic variant in cyclin-dependent kinase inhibitor 2A gene with the increased risk of breast cancer**

S. Shahid Sales, M. Mehramiz, S.A. Aledavood, M. Joudi Mashhad, S. Ahmadi Simab, A. Avan; IR

12:45 - 12:45 **10P - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR**

K. BAKSHI, IN

12:45 - 12:45 **11P - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma**

H. Jo, S. Hwang, M. Lee; KR

12:45 - 12:45 **12P - Prediction of and intervention in colorectal cancer risk with artificial intelligent system**

Y. Ge¹, C. Ma², L. Tao¹, M.F. Han¹, L. Ma³, G. Li⁴, L.M. Ma⁴, Q. Lu², Z. Wu⁴, P.F. Yu⁴, Y.F. Yang⁴, Y.Y. Ma², B.B. Song⁴, W. Gao⁴; ¹Ahnui/CN, ²WA/US, ³Beijing/CN, ⁴CN

12:45 - 12:45 **13P - Measuring the efficiency of cancer care in Europe**

R. Althin¹, R. Färe², S. Grosskopf², B. Jönsson¹, N. Wilking¹; ¹SE, ²OR/US

12:45 - 12:45 **14P - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients**

C.-Y. Yang, C.-H. Lin, J.-K. Jiang; TW

12:45 - 12:45 **15P - Clonality of uterine carcinosarcoma as a factor of clinical prognosis**

N. Levitskaya, O. Vostriukhina, I. Poddubnaia; RU

12:45 - 12:45 **16P - ODM-207: A novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER⁺ breast cancer**

A. Moilanen¹, J. Lindqvist¹, M. Björkman¹, R. Riikonen¹, D. Nicorici¹, E. Mattila¹, C. Abbineni², M. Jaleel², J. Eriksson¹, P. Kallio¹; ¹FI, ²IN

12:45 - 12:45 **17P - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch**

R. Dubianski, E. Sarnowska, M. Leszczynski, S. Kubala, W. Olszewski, N. Rusetska, A. Jagiello-Grusfeld, R. Konopinski, T. Sarnowski, J. Siedlecki, Z. Nowecki; PL

- 12:45 - 12:45 **18P - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes**
P.P. Vitiello, C. Cardone, D. Ciardiello, V. Belli, N. Matrone, C. Borrelli, L. Poliero, V. De Falco, E. Giunta, P. Vitale, N. Zanaletti, G. Tirino, T. Troiani, F. Ciardiello, E. Martinelli; IT
- 12:45 - 12:45 **19P - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/AKT pathway**
X. Fu, M. Liu, S. Qu, J. Ma, Y. Zhang, T. Shi, H. Wen, Y. Yang, S. Wang, J. Wang, K. Nan, Y. Yao, T. Tian; CN
- 12:45 - 12:45 **20P - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women**
J.B. Ramirez Sabio, J.V. Sorlí, R. Barragán, F.-C. Rebeca, E.M. Asensio, D. Corella; ES
- 12:45 - 12:45 **21P - Cisplatin in NIPEC or HIPEC?**
I. Alvovsky, V. Bepalov, G. Kireeva; RU
- 12:45 - 12:45 **22P - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment**
M. HIRAI, Y. Kobayashi, M. Miyazawa, H. Kitahara, S. Kawashiri, H. Nakamura; JP
- 12:45 - 12:45 **24P - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis**
P. Sriskandarajah, K. Macleod, N. Carragher, M. Kaiser, S. Whittaker; GB
- 12:45 - 12:45 **25P - Functional inhibition of TGF- β 2; in colorectal cancer cells and its interaction with AXL receptor**
D. Ciardiello¹, G. Martini², N. Matrone¹, V. Belli¹, P.P. Vitiello¹, C. Cardone¹, V. Ciaramella¹, G. Barra¹, L. Poliero¹, C. Borrelli¹, T. Troiani¹, D. Melisi¹, F. Morgillo¹, E. Giunta¹, V. De Falco¹, F. Ciardiello¹, E. Martinelli¹; ¹IT, ²ES
- 12:45 - 12:45 **26P - Isoform-specific AKT inhibition differentially affects cell functions in pancreatic adenocarcinoma**
H. Arasan, M. Gato-Cañas, M. Zuazo, M. Ibáñez-Vea, G. Fernández-Hinojal, J. Fernandez-Irigoyen, E. Santamaria, G. Kochan, R. Vera, D. Escors; ES
- 12:45 - 12:45 **27P - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors**
I. Tsimafeyeu, M. Volkova, A. Olshanskaia, G. Raskin, S. Aschuba, Y. Khochenkova, A. Bondarenko, D. Khochenkov; RU
- 12:45 - 12:45 **28P - Oncogenes analysis using GO-based clustering**
D. Babenko, Y. Babenko; KZ

- 12:45 - 12:45 **29P - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt pathway**
S. Shahid Sales¹, A. Avan¹, F. Rahmani¹, S.M. Hassanian¹, M. Hashemzahi¹, F. Amerizadeh¹, G. A. Ferns², M. Khazaei¹; ¹IR, ²GB
- 12:45 - 12:45 **30P - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer**
M. Iida, M. Nakamura, E. Tokuda, T. Niwa, T. Ishida, S.-I. Hayashi; JP
- 12:45 - 12:45 **31P - Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo**
T. Kozako, T. Ohsugi, M. Yoshimitsu, Y.-I. Uchida, K. Ishitsuka, K. Naho, A. Aikawa, S.-I. Honda; JP
- 12:45 - 12:45 **32P - 9-ING-41, a clinically relevant inhibitor of glycogen synthase kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers**
H. Kuroki¹, T. Anraku¹, V. Bilim¹, M. Tasaki¹, D. Schmitt², A. Mazar³, A. Ugolkov³, Y. Tomita¹; ¹JP, ²TX/US, ³IL/US
- 12:45 - 12:45 **33P - A new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab**
V. De Falco, E. Giunta, V. Belli, N. Matrone, S. Napolitano, E. Martinelli, P. Vitale, N. Zanaletti, M. Terminiello, P.P. Vitiello, F. Ciardiello, T. Troiani; IT
- 12:45 - 12:45 **34P - Multiple myeloma metal levels and proteasome activity**
K.U. Stumpf, H. Einsele, T. Nekova; DE
- 12:45 - 12:45 **35P - A translational drug-screening tool for interrogating the effect of anti-TGF- β 2; therapy on fibroblast activity and the desmoplastic reaction**
N. Nissen, N. Willumsen, N. Gudmann, S. Rønnow, M. Karsdal, D. Leeming, J. Sand; DK
- 12:45 - 12:45 **36P - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors**
H. Kitahara, Y. Kobayashi, M. Hirai, S. Kawashiri, H. Nakamura; JP
- 12:45 - 12:45 **37P - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of smad4 in lung cancer cell lines**
K. Takahashi, S. Nishikawa, R. Miyata, M. Noguchi, H. Ishikawa, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, T. Menju, F. Chen-Yoshikawa, T. Sato, M. Sonobe, H. Date; JP
- 12:45 - 12:45 **38P - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro**
A. Cortez, K. Kujawa, P. Tudrej, K. Lisowska; PL

- 12:45 - 12:45 **39P - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1**
L. Qiu, CN
- 12:45 - 12:45 **40P - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1**
X. Wang, X. Che, Y. Fan, M. Bai, X. Qu; CN
- 12:45 - 12:45 **41P - Risk prediction of metastasis through study of circulating tumor cells**
P. Apostolou, I. Papatotiriou; GR
- 12:45 - 12:45 **42P - First step to metastasis: MiRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells**
V. Halytskiy, UA
- 12:45 - 12:45 **43P - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment**
A. Tsidulko¹, C. Bezier², G. de La Bourdonnaye², A. Suhovskih¹, G. Kazanskaya¹, S. Aidagulova¹, E. Grigorieva¹; ¹RU, ²FR
- 12:45 - 12:45 **44P - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro**
D. Albert Bellver, R. Gil-Benso, A. Martínez, T. San-Miguel, L. Muñoz-Hidalgo, A. Carratalá, D. Gozalbo, C. López-Ginés, M. Cerdá-Nicolás, M.L. Gil, J. Megías; ES
- 12:45 - 12:45 **45P - 5-fluorouracil-induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients**
Z. Min, F. Yibo, C. Xiaofang, H. Kezuo, Q. Xiujuan; CN
- 12:45 - 12:45 **46P - Thrombocytosis and leukocytosis: Are they negative prognostic factors in solid tumours?**
F. Kohutek, B. Bystricky, M. Kohutekova; SK
- 12:45 - 12:45 **47P - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH⁺) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)**
S. Wanandi, G. Wideani, M. Zainuri, R. Putri, E. Bachtiar, S. Jusman; ID
- 12:45 - 12:45 **48P - Estrogen-related receptor β 1; as a potential molecular target for endometrial cancer therapy**
T. KOKABU, T. Mori, H. Matsushima, Y. Tarumi, K. Yoriki, H. Kuroboshi, M. Sawada, S. Umemura, J. Kitawaki; JP
- 12:45 - 12:45 **49P - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies**
J. Gaudreault¹, A. Schmidt¹, P. Altevogt², G. Spohn¹; ¹CH, ²DE

12:45 - 12:45 **Tumour biology and pathology**

12:45 - 12:45 **451P - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma**

A. Jouinot¹, B. Royer¹, S. Moeung¹, E. Chatelut¹, A. Bellesoeur², G. Assié¹, A. Thomas-Schoemann¹, J. Bertherat¹, F. Goldwasser², B. Blanchet¹; ¹FR, ²CEDEX 14/FR

12:45 - 12:45 **Gastrointestinal tumours, colorectal**

12:45 - 12:45 **463P - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study**

J.M. O'Connor¹, M. Ducreux², L.N. Petersen³, L. Öhler⁴, F. Bergamo⁵, J.-P. Metges², J.W. de Groot⁶, J.-Y. Wang⁷, B. García Paredes⁸, E. Dochy⁹, S. Fiala-Buskies¹⁰, A. Cervantes⁸, A. Falcone⁵; ¹AR, ²FR, ³DK, ⁴AT, ⁵IT, ⁶NL, ⁷TW, ⁸ES, ⁹US, ¹⁰DE

12:45 - 12:45 **464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study**

J. Taieb¹, A. Falcone², S. Lonardi², T. Price³, J.-B. Bachet⁴, L. Wyrwicz⁵, F. Ciardiello², M. Becquart¹, N. Mounedji¹, E. van Cutsem⁶; ¹FR, ²IT, ³SA/AU, ⁴CEDEX 13/FR, ⁵PL, ⁶BE

12:45 - 12:45 **465P - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study**

T. Kawakami¹, K. Yamazaki², E. Oki³, M. Shimokawa³, N. Takahashi¹, M. Yokota¹, S. Tokunaga¹, T. Esaki¹, M. Gamoh⁴, A. Maeda¹, Y. Tsuji⁵, A. Sakai¹, K. Hatanaka¹, Y. Shimada¹, M. Shiozawa¹, Y. Komatsu¹, H. Okuda¹, M. Ohue¹, Y. Maehara¹; ¹JP, ²Shizuoka/JP, ³Fukuoka/JP, ⁴Miyagi/JP, ⁵Hokkaido/JP

12:45 - 12:45 **466P - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD**

T. Aparicio¹, A. Darut Jouve¹, F. Khemissa¹, C. Montérymard¹, P. Artru², L. Cany¹, O. Romano³, B. Valenza⁴, C. Le Foll¹, C. Delbaldo¹, C. Falandry³, M. Duluc⁵, Y. Rinaldi¹, J.L. Legoux¹, M. Ben Abdelghani¹, E. Assenat¹, M. Dhooge¹, D. Smith¹, G. Des Guetz³, C. Lepage⁴; ¹FR, ²CEDEX 8/FR, ³CEDEX/FR, ⁴Cedex/FR, ⁵CEDEX 5/FR

12:45 - 12:45 **467P - Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer**

T. Masuishi¹, T. Suzuki², Y. Sukawa², C. Imamura², H. Satake³, Y. Kumekawa², S. Funakoshi², M. Kotaka³, Y. Horie², S. Kawai², H. Okuda², T. Terazawa⁴, C. Kondoh², K. Kato², K. Yoshimura⁵, H. Ishikawa², Y. Hamamoto², N. Boku⁶, T. Kanai², H. Takaishi²; ¹Aichi/JP, ²JP, ³Hyogo/JP, ⁴Osaka/JP, ⁵Ishikawa/JP, ⁶Kanagawa/JP

- 12:45 - 12:45 **468P - Regorafenib for metastatic colorectal carcinoma: A registry-based analysis**
K. Kopeckova¹, R. Chloupkova², B. Melichar², Z. Linke², L. Petruzela³, J. Finek⁴, O. Fiala⁴, J. Tomasek², I. Kiss⁵, J. Prausova¹, T. Buchler⁶; ¹5/CZ, ²2CZ, ³2/CZ, ⁴Plzen/CZ, ⁵South Moravian/CZ, ⁶4/CZ
- 12:45 - 12:45 **469P - The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)**
H. Kamiyama¹, Y. Yoshida¹, H. Yoshida¹, C. Kosugi², K. Ishibashi¹, K. Ihara¹, M. Takahashi¹, H. Kuramochi¹, A. Fukazawa¹, H. Sonoda³, K. Yoshimatsu¹, A. Matsuda², S. Yamaguchi¹, H. Ishida¹, S. Hasegawa¹, T. Yamada¹, K. Sakamoto¹, K. Koda²; ¹JP, ²Chiba/JP, ³Higashiyama-ku/JP
- 12:45 - 12:45 **470P - Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)**
A. Calvo Ferrandiz¹, L. Dahan², A. Hollebecque², G. Prager³, T. Andre², G. Argiles Martinez¹, R. Bordonaro⁴, A. Stein⁵, G. Tortora⁴, C. Leger², N. Amellal⁶, J. Taberero¹; ¹ES, ²FR, ³AT, ⁴IT, ⁵DE, ⁶CEDEX/FR
- 12:45 - 12:45 **471P - A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study**
M. Suenaga, T. Wakatsuki, M. Ogura, T. Ichimura, E. Shinozaki, I. Nakayama, H. Osumi, Y. Ota, K. Chin, T. Mashima, H. Seimiya, D. Takahari, K. Yamaguchi; JP
- 12:45 - 12:45 **472P - Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer**
S. Ueda¹, Y. Tsuboguchi¹, Y. Nakatani¹, A. Tsuya¹, S.-I. Nishina¹, K. Akiyoshi¹, S. Okazaki², S. Tokunaga¹, H. Daga¹; ¹JP, ²Fushimi-ku/JP
- 12:45 - 12:45 **473P - Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib**
F. de Man, K. Hussaarts, M. de With, E. Oomen-De Hoop, H. van Halteren, N. van der Burg-De Graauw, F. Eskens, T. van Gelder, R. van Leeuwen, R. Mathijssen; NL
- 12:45 - 12:45 **474P - A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial**
T. Seufferlein¹, L. Lausser¹, A. Stein¹, G. Prager², S. Kasper¹, M. Niedermeier¹, L. Müller¹, S. Kubicka¹, A.-O. König¹, P. Büchner-Steudel¹, K. Wille¹, L. Perkhofer¹, A. Hann¹, A. Berger¹, D. Arnold¹, H. Kestler¹, T. Ettrich¹; ¹DE, ²AT
- 12:45 - 12:45 **475P - Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer**

M. Nakamura¹, A. Takashima¹, T. Denda², M. Gamoh³, I. Iwanaga⁴, Y. Komatsu⁵, M. Takahashi¹, H. Ohori³, T. Sekikawa¹, M. Tsuda¹, Y. Kobayashi⁵, Y. Miyamoto¹, M. Kotake¹, C. Ishioka³, K. Shimada¹, A. Sato¹, S. Yuki⁵, S. Morita¹, S. Takahashi³, T. Yamaguchi¹; ¹JP, ²Chiba/JP, ³Miyagi/JP, ⁴Hokkaido Prefecture/JP, ⁵Hokkaido/JP

- 12:45 - 12:45 **476P - Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study**
A. Lapeyre-Prost¹, S. Pernot¹, J. Sigrand¹, F. Mary², K. Le Malicot¹, T. Aparicio¹, L. Dahan¹, F.-X. Caroli-Bosc¹, T. Lecomte¹, S. Racine Doat³, L. Marthey¹, J. Desrame⁴, C. Lepage⁵, J. Taieb¹; ¹FR, ²CEDEX/FR, ³CEDEX 13/FR, ⁴CEDEX 8/FR, ⁵Cedex/FR
- 12:45 - 12:45 **477P - Folfiri-aflibercept vs folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice**
A. Ottaiano, M. Capozzi, C. De Divitiis, A. Cassata, A. De Stefano, S. Tafuto, A. Avallone, G. Nasti; IT
- 12:45 - 12:45 **478P - In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?**
E. Mata Velasco, E. González-Flores, I. Juez Martel, V. Alonso, P. Iranzo Gomez, N. Martinez Lago, C. Lopez, J. Cabrera Romero, M.J. Safont Aguilera, A. Ruiz Casado, M. Salgado Fernandez, B. González Astorga, P. Escudero, F. Rivera Herrero, C. Pericay Pijaume, R. Vera; ES
- 12:45 - 12:45 **479P - A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study**
M. Honda¹, C. Matsuda¹, C. Tanaka¹, K. Kondo², T. Takahashi¹, C. Kosugi³, Y. Tokunaga¹, H. Takemoto¹, H. Kim¹, J. Sakamoto⁴, K. Oba¹, H. Mishima²; ¹JP, ²Aichi/JP, ³Chiba/JP, ⁴Gifu/JP
- 12:45 - 12:45 **480P - The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study**
T. Ogata¹, H. Satake², M. Ogata¹, Y. Hatachi¹, M. Hamada¹, H. Yasui³; ¹JP, ²Hyogo/JP, ³Fushimi-ku/JP
- 12:45 - 12:45 **481P - Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial**
H. Osawa¹, E. Shinozaki¹, M. Nakamura¹, Y. Ohhara¹, Y. Shindo¹, M. Shiozawa¹, H. Uetake¹, H. Matsumoto¹, N. Ureshino¹, H. Satake², T. Kobayashi¹, T. Suto¹, S. Kitano¹, Y. Ohashi¹, K. Uemura¹, K. Yamaguchi¹; ¹JP, ²Hyogo/JP
- 12:45 - 12:45 **482P - RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer**
T. Rich¹, K. Clifton¹, A. Grothey², A. Hendifar³, D. Henry¹, Y. Kagawa⁴, Y. Nakamura⁵, W. Okamoto⁴, B. Tan¹, G. Sherrill¹, T. Yoshino⁴, V. Raymond¹, Y. Shiotsu³, R. Lanman¹, V. Morris¹; ¹US, ²MN/US, ³CA/US, ⁴JP, ⁵Chiba/JP

- 12:45 - 12:45 **483P - A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3**
Y. Sunakawa¹, S. Stintzing², S. Cao³, J. Luecke⁴, D. Thompson⁴, M. Moran³, S. Astrow³, J. Hsiang³, C. Stephens³, W. Zhang³, A. Tsuji¹, T. Takahashi¹, T. Denda⁵, K. Shimada¹, M. Kochi¹, M. Takeuchi¹, M. Fujii¹, W. Ichikawa¹, V. Heinemann², H.-J. Lenz³; ¹JP, ²DE, ³CA/US, ⁴AZ/US, ⁵Chiba/JP
- 12:45 - 12:45 **484P - Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)**
A. Sobrero¹, H.-J. Lenz², C. Eng³, W. Scheithauer⁴, G. Middleton⁵, W. Chen⁶, R. Esser⁷, J. Nippgen⁷, H. Burris⁸; ¹IT, ²CA/US, ³TX/US, ⁴AT, ⁵GB, ⁶CN, ⁷DE, ⁸TN/US
- 12:45 - 12:45 **485P - Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study**
L.-J. Palmieri¹, L. Mineur², D. Tougeron³, B. Rousseau³, V. Granger¹, J.-M. Gornet⁴, D. Smith¹, A. Lievre¹, M.P. Galais⁵, S. Racine Doat⁶, S. Pernet¹, A.L. Bignon Bretagne⁷, J.-P. Metges⁸, N. Baba-Hamed¹, M. Hassine¹, S. Obled¹, C. Vitellius⁷, O. Bouche¹, D. Vernerey¹, R. Coriat⁹; ¹FR, ²CEDEX 2/FR, ³CEDEX/FR, ⁴CEDEX 10/FR, ⁵CEDEX 5/FR, ⁶CEDEX 13/FR, ⁷CEDEX 9/FR, ⁸Cedex 2/FR, ⁹CEDEX 14/FR
- 12:45 - 12:45 **486P - Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial**
X. García Albéniz¹, V. Alonso², P. Escudero², M. Méndez², J. Gallego Plazas³, J.R. Rodriguez², A. Salud Salvia², J. Fernández-Plana², H. Manzano Alemany², M. Zanui², E. Falcó², J. Feliu Batlle², M. Gil-Raga², C. Fernández-Martos², U. Bohn Sarmiento⁴, M.C. Alonso López², V. Calderero Aragón², F. Rojo², M. Cuatrecasas², J. Maurel²; ¹US, ²ES, ³Alicante/ES, ⁴Canary Island/ES
- 12:45 - 12:45 **487P - Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study**
R. Laeufle¹, D. Arnold², S. Kopetz³, J. Straub², R. Bruns², G. Massimini², R. Debenedetto⁴, R. Linke¹, E. Elez Fernandez⁵, J. Tabernero⁵; ¹CA/US, ²DE, ³TX/US, ⁴US, ⁵ES
- 12:45 - 12:45 **488P - Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial**
Y. Emi¹, T. Yamanaka¹, K. Muro², H. Uetake¹, E. Oki³, T. Takahashi¹, Y. Katayose⁴, K. Yoshida¹, M. Sakamoto¹, S. Aishima¹, K. Ishida¹, J. Imura¹, M. Unno⁴, I. Hyodo⁵, N. Tomita⁶, K. Sugihara¹, Y. Maehara¹; ¹JP, ²Aichi/JP, ³Fukuoka/JP, ⁴Miyagi/JP, ⁵Ibaraki/JP, ⁶Hyogo/JP

- 12:45 - 12:45 **489P - Verification of guideline conform mCRC treatment with EGFR inhibitors with real-world evidence data from EU5 countries**
L. Hoyer, N. Schmidt; DE
- 12:45 - 12:45 **491P - Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis**
T. Buchler¹, O. Fiala², V. Veskrnova³, R. Chloupkova³, A. Poprach⁴, I. Kiss⁴, K. Kopeckova⁵, L. Dusek³, L. Slavicek⁶, M. Kohoutek⁷, J. Finek², M. Svoboda⁴, J. Dvorak¹, L. Petruzelka⁸, B. Melichar³; ¹4/CZ, ²Plzen/CZ, ³CZ, ⁴South Moravian/CZ, ⁵5/CZ, ⁶Vysocina/CZ, ⁷Zlin/CZ, ⁸2/CZ
- 12:45 - 12:45 **492P - A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+ cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)**
Y. NISHIOKA, K. Hasegawa, A. Saiura, M. Oba, J. Yamamoto, Y. Nomura, T. Takayama, Y. Hashiguchi, M. Shibasaki, H. Sakamoto, S. Yamagata, N. Aoyanagi, H. Kaneko, H. Koyama, S. Miyagawa, Y. Mise, E. Shinozaki, S. Yoshida, H. Nozawa, N. Kokudo; JP
- 12:45 - 12:45 **493P - Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer**
E. Oki¹, H. Samura¹, H. Okumura¹, T. Ohchi¹, H. Orita¹, K. Kobayashi¹, T. Kinjo¹, S. Mori¹, T. Touyama¹, K. Ohgaki¹, H. Kawanaka¹, A. Makiyama², N. Ureshino¹, M. Kotaka³, T. Shimose¹, H. Saeki¹, T. Nishimaki¹, H. Baba¹, Y. Maehara¹; ¹JP, ²Fukuoka/JF, ³Hyogo/JF
- 12:45 - 12:45 **494P - A multi-institutional randomized phase II study on the timing of oxaliplatin plus 5-fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR study**
P. Kavan, I. Barrera, L. Azoulay, A.-G. Martin, C. Vasilevsky, M. Boutros, E. Ferland, G. Batist, T. Vuong; QC/CA
- 12:45 - 12:45 **495P - Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: A phase III clinical study**
A. IDASIAK, K. Galwas-Kliber, K. Behrendt, I. Wziętek, M. Zeman, E. Stobiecka, E. Chmielik, T. Dworzecki, R. Suwiński; PL
- 12:45 - 12:45 **496P - Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): A planned interim analysis**
J. Jin, Y. Tang, S. Liu, Y. Zhu, W. Wang, G. Li, X. Wang, J. Wang, J. Yang, S. Li, N. Li, W. Liu, Y. Li, Y. Chi, A. Zhou, J. Huang, X. Wang, L. Jiang, J. Jiang, S. Zou; CN
- 12:45 - 12:45 **497P - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials**
J. Zhang, Y. Deng, Z. Wu, H. Hu, Y. Cai, J. Ling; CN

- 12:45 - 12:45 **498P - Phase I/II study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3)**
A. Budillon, P. Delrio, B. Pecori, F. Tatangelo, E. Di Gennaro, C. Romano, V. D'Angelo, P. Marone, C. Granata, E. Cavalacanti, A. De Stefano, U. Pace, F. Bianco, A. Petrillo, S. Lastoria, G. Botti, P. Muto, F. Perrone, M.C. Piccirillo, A. Avallone; IT
- 12:45 - 12:45 **499P - A classifier of 53BP1, immune score and texture analysis of MRI images can predict pathological response to chemoradiotherapy in locally advanced rectal cancer**
H. Ma, J. Yao, A. Huang, Y. Xiao, L. Fan; CN
- 12:45 - 12:45 **500P - Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy**
A. Cercek¹, G. Dos Santos Fernandes¹, C. Roxburgh¹, S. Ng¹, R. Yaeger¹, N. Segal¹, K. Ganesh¹, D. Reidy¹, J.J. Smith¹, G. Nash¹, J. Guillem¹, P. Paty¹, J. Shia², J. Garcia-Aguilar¹, L. Diaz¹, C. Crane¹, K. Goodman¹, L. Saltz¹, M. Weiser¹, Z. Stadler²; ¹US, ²NY/US
- 12:45 - 12:45 **501P - Outcomes of chemoradiotherapy plus local excision in patients with clinical T1 or T2, N0 rectal cancer**
T. Suzuki¹, S. Sadahiro², T. Ogimi², H. Miyakita², G. Saito², K. Okada², A. Tanaka²; ¹Kanagawa/JP, ²JP
- 12:45 - 12:45 **502P - Comparison of immune microenvironment between different neoadjuvant radiotherapy regimens for rectal cancer**
J. Wu, Q. Peng, J. Li, L. Tang, Y. Huang, X. Zhang; CN
- 12:45 - 12:45 **503P - Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer**
M. Fedyanin¹, A. Tryakin¹, I. Pokataev¹, A. Bulanov², O. Sekhina¹, D. Chekini¹, S. Gordeev¹, V. Aliev¹, D. Kuzmichev¹, Z. Mamedli¹, Y. Barsukov¹, V. Glebovskaya¹, S. Tkachev¹, M. Chernykh¹, N. Kozlov¹, S. Tjulandin¹; ¹RU, ²IR
- 12:45 - 12:45 **504P - Association of systemic and local inflammation with prognosis in rectal cancer treated with neoadjuvant radiotherapy**
J. Li, X. Zhang, Y. Huang, L. Tang, Q. Peng, J. Wu; CN
- 12:45 - 12:45 **505P - Early prediction of histopathological response by PET/CT after two weeks of neoadjuvant chemoradiotherapy for rectal cancer: Wishful thinking or reality?**
Y. Kundel, G. Natalia, H. Berenshtain, J. Prus, B. Brenner; IL
- 12:45 - 12:45 **506P - Association between obesity and efficacy of chemoradiotherapy in rectal cancer patients**
C. Diaz Romero, R. Calderillo, M. Herrera-Martínez, R. Erika, J.M. Flores Castro; MX
- 12:45 - 12:45 **507P - Treatment outcomes of patients with localized anal squamous cell carcinoma and HIV infection: Systematic review and meta-analysis**

M. Camandaroba, R. Riechelmann, V. Silva, C. Mello, R. Araujo; BR

- 12:45 - 12:45 **508P - p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan**
R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi; JP
- 12:45 - 12:45 **509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): A FIRE-3 analysis**
D. Modest¹, V. Heinemann¹, G. Folprecht¹, T. Denecke¹, J. Pratschke¹, H. Lang¹, M. Bemelmans², T. Becker¹, M. Rentsch¹, D. Seehofer¹, C. Bruns¹, B. Gebauer¹, S. Held¹, U. Neumann¹, I. Ricard¹; ¹DE, ²NL
- 12:45 - 12:45 **510P - Targeted therapies in conversion therapy in mCRC: A systematic review and meta-analysis**
B. Xing¹, B. Cui¹, Z. Gu², H. Peng¹; ¹CN, ²DE
- 12:45 - 12:45 **511P - Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study**
A. Hosokawa¹, K. Yamazaki², C. Matsuda¹, S. Ueda¹, H. Fujii¹, E. Baba¹, S. Okamura¹, M. Tsuda¹, T. Tamura¹, K. Shinozaki¹, T. Tsushima², T. Tsuda¹, T. Shirakawa¹, H. Yamashita¹, S. Morita¹, K. Muro³; ¹JP, ²Shizuoka/JP, ³Aichi/JP
- 12:45 - 12:45 **512P - KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients**
M. Domenech Viñolas¹, C. Santos¹, J. Pérez¹, M. Varela¹, M. Martinez Villacampa¹, A. Teule¹, J. Ruffinelli Rodriguez¹, N. Mulet Margalef¹, G. Soler¹, A. Ortega¹, M. Bergamino², X. SanJuan¹, J. Torras¹, E. Ramos¹, R. Salazar¹; ¹ES, ²Barcelona/ES
- 12:45 - 12:45 **513P - Impact of response to preoperative chemotherapy on the outcome of pulmonary metastasectomy for colorectal cancer: Results of a retrospective multicenter study**
T. Okumura¹, N. Boku², T. Hishida¹, Y. Ohde¹, Y. Sakao¹, K. Yoshiya¹, M. Higashiyama¹, K. Kameyama¹, H. Adachi¹, K. Shiomi¹, M. Kanzaki¹, M. Yoshimura¹, M. Matsuura¹, Y. Hata¹, F. Chen¹, K. Yoshida¹, H. Sasaki¹, I. Hyodo³, K. Mori¹, H. Kondo¹; ¹JP, ²Kanagawa/JP, ³Ibaraki/JP
- 12:45 - 12:45 **514P - Long-term outcomes with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis: 10-year experience in a developing country**
F. Arias, E. Londoño-Schimmer, J. Otero, C.E. Cétares, G.E. Herrera, M. Mora, P. Rodriguez, M. Mejía, J.D. Guerra, A. Ruiz-Patiño, A. Cardona Zorrilla; CO
- 12:45 - 12:45 **515P - Clinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section**

J.J. Garcia-Mosquera¹, L. Layos Romero¹, C. Buges¹, S. España Fernandez², S. Chen², J.M. Velarde², E. Felip², C. Erasun Lecuona², L. Angelats², M. Cucurull Salamero², J.L. Manzano²; ¹Barcelona/ES, ²ES

- 12:45 - 12:45 **516P - Simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis**
Y. Xu, CN
- 12:45 - 12:45 **517P - Clinical factors are unable to accurately predict the absence of benefit of surgery in patients operated for resection of colorectal liver metastasis**
A. Bohlok, H. Tessely, E. Naets, F. Bouazza, D. Germanova, J.L. Van Laethem, A. Hendlisz, V. Lucidi, V. Donckier; BE
- 12:45 - 12:45 **518P - Hepatic arterial infusion (HAI) of oxaliplatin with capecitabine in first line treatment of patients (pts) with liver limited metastases from colorectal cancer (LLmCRC)**
B. Vittrup, H. Nørgaard, M. Bergenfeldt, F.O. Larsen, E. Høgdall, J. Johansen, J. Sidenius Johansen, H. Hermann, D. Nielsen; DK
- 12:45 - 12:45 **519P - Microsatellite instability is associated with distinct clinical and molecular characteristics in early colon cancer: Analysis of a molecular registry of the AIO colorectal study group - Colopredict Plus**
A. Reinacher-Schick, H. Juette, S. Noepel-Duenebacke, D. Arnold, N. Basara, H. Boehner, T. Dahm, I. Feder, T. Herzog, W. Hiller, L. Mueller, L. Engel, M. Senkal, C. Teschendorf, G. Trenn, B. Verdoodt, H. Wolters, W. Uhl, A. Tannapfel; DE
- 12:45 - 12:45 **520P - Prognostic impact of MSI and 18qLOH in stage II colon cancer: A prospective biomarker study in the SACURA trial**
T. Ishikawa, M. Ishiguro, E. Nakatani, H. Ueno, H. Uetake, K. Murotani, S. Matsui, N. Tomita, Y. Shimada, K. Takahashi, K. Kotake, M. Watanabe, H. Mochizuki, S. Teramukai, K. Sugihara; JP
- 12:45 - 12:45 **521P - miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial**
Y. Gaston Mathe¹, S. Martin-Lannerée¹, C. Vazart¹, K. Fontaine¹, C. Mulet¹, A. Caumont¹, F. Montestruc¹, K. Le Malicot¹, C. Lepage², J. Taieb¹, P. Laurent-Puig¹; ¹FR, ²Cedex/FR
- 12:45 - 12:45 **522P - Prognostic value of neutrophil-lymphocyte ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial**
F. Petrelli¹, G. Rosati², M. Banzi², M.G. Zampino², N. Pella², M. Di Bartolomeo², E. Maiello², P. Bidoli², D. Ferrari², L. Rimassa², R. Labianca², M. Scartozzi², S. Lonardi², S. de Placido², A. Zaniboni², A. Sobrero², L. Frassinetti³, N. Silvestris², D. Corsi², F. Galli², S. Barni²; ¹(BG)/IT, ²IT, ³Forlì-Cesena/IT
- 12:45 - 12:45 **523P - Distribution of lymph node metastases can have an impact on survival benefit of oxaliplatin-containing chemotherapy in stage III colon cancer**
Y. Chae, J.G. Kim, J.H. Baek, S.J. Lee, D.W. Baek, B.W. Kang; KR

- 12:45 - 12:45 **524P - Implications of thymidylate synthase gene polymorphisms, KRAS and BRAF mutations in the survival of patients with colorectal cancer treated with adjuvant chemotherapy**
A. Ntavatzikos, A. Spathis, P. Patapis, G. Peros, I. Panayiotides, I. Papadopoulos, A. Koumarianou; GR
- 12:45 - 12:45 **525P_PR - Profile of individuals who never undergo colorectal cancer screening**
J. Viguier¹, J.F. Morère¹, S. Couraud², M. Roupert¹, C. Touboul¹, C. Lhomel¹, L. Greillier¹, T. de La Motte Rouge¹, F. Eisinger³; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR
- 12:45 - 12:45 **526P - Results of the national organised colorectal cancer screening program with FIT in Paris**
A. Pellat¹, R. Coriat², S. Chaussade¹; ¹FR, ²CEDEX 14/FR
- 12:45 - 12:45 **527P - Screening strategy of Lynch syndrome for Chinese colorectal cancer patients with MLH1-immunoloss**
W. Wang, L. Dong, S. Zou, N. Lu; CN
- 12:45 - 12:45 **528P - Early detection of colorectal cancer using breath biomarkers: Preliminary study**
G. Woodfield, I. Belluomo, H. Panesar, G.P. Lin, P. Boshier, A. Romano, J. Martin, C. Groves, B. Saunders, W. Atkin, G. Hanna; GB
- 12:45 - 12:45 **529P - Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation**
J. Uhlig¹, S. Stein², J. Lacy², C. Fuchs², H. Kim¹; ¹US, ²CT/US
- 12:45 - 12:45 **530P - Influence of primary tumour sidedness on survival after upfront primary tumour resection (PTR) in synchronous metastatic colon cancer (mCC)**
K. van Rooijen¹, S. Kurk¹, D. van der Kruijssen¹, S. Elias¹, A. May¹, A. Cats¹, G.-J. Creemers¹, F. Erdkamp¹, O. Loosveld², C. Rodenburg¹, P. Tanis¹, G. Vink¹, J. de Wilt¹, C. Punt¹, M. Koopman¹; ¹NL, ²Noord Brabant/NL
- 12:45 - 12:45 **531P - The clinical features and genomic landscape of elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in patients with colorectal cancer**
M.-H. Chen, S.-C. Chang, P.-C. Lin, S.-H. Yang, C.-C. Lin, Y.-T. Lan, H.-H. Lin, C.-H. Lin, W.-Y. Liang, W.-S. Chen, J.-K. Jiang, J.-K. Lin; TW
- 12:45 - 12:45 **532P - Identification of positively and negatively selected driver gene mutations associated with colorectal cancer with microsatellite instability**
V. Jonchere, L. Marisa, M. Greene, A. Guilloux, A. Collura, A. De Reynies, A. Duval; FR
- 12:45 - 12:45 **533P - Distinct clinico-pathological features of hypermutant colorectal cancers with POLE pathogenic mutations, Lynch syndrome and sporadic MSI analyzed over 1,000 colorectal cancer patients**

T. Nagasaka, A. Nyuya, H. Tanioka, Y. Katata, M. Yokota, F. Taniguchi, T. Kawai, Y. Mori, K. Shigeyasu, M. Okawaki, M. Yamamura, Y. Umeda, A. Tsuruta, T. Ueno, Y. Yamaguchi; JP

- 12:45 - 12:45 **534P - Patterns of germline and somatic mutations in 16 mismatch repair associated genes analyzed with next generation sequencing (NGS) in colorectal cancer with EMAST (x0002B;) and/or MSI-high**
S.-C. Chang, P.-C. Lin, C.-C. Lin, J.-K. Lin, Y.-T. Lan, J.-K. Jiang, S.-H. Yang, C.-H. Lin, W.-S. Chen; TW
- 12:45 - 12:45 **535P - Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC)**
I. Amanam¹, J. Chao¹, D. Lim¹, S. Rahmanuddin¹, A. Schrock², S. Ali², C. Lau¹, D. Chevalier¹, E. Harris¹, J. Saluja¹, C. Wang¹, M. Fakih³; ¹US, ²MA/US, ³CA/US
- 12:45 - 12:45 **536P - Comparison of microsatellite status detections in colorectal carcinoma**
M. Chen, L. Yu, B. Liu, X. Qian, M. Yang; CN
- 12:45 - 12:45 **537P - Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy**
R. Cohen¹, E. Hain¹, O. Buhard¹, A. Guilloux¹, A. Bardier¹, R. Kaci¹, P. Bertheau¹, F. Renaud¹, F. Bibeau², J.-F. Fléjou¹, T. André³, M. Svrcek¹, A. Duval¹; ¹FR, ²CEDEX 5/FR, ³CEDEX 12/FR
- 12:45 - 12:45 **538P - The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection**
S.-H. Cho¹, H.-J. Shim², J.E. Hwang², W.-K. Bae², I.J. Chung³; ¹Jeollanam-do/KR, ²KR, ³Jeonnam/KR
- 12:45 - 12:45 **539P - Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor-infiltrating immune cell composition**
J. Berntsson, J. Eberhard, B. Nodin, A. Larsson, K. Jirstrom; SE
- 12:45 - 12:45 **540P - Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition**
D. Basile, S. Garattini, G. Pelizzari, F. Cortiula, L. Gerratana, M. Cattaneo, C. Corvaja, A. Parnofiello, V. Andreotti, E. Bertoli, C. Lisanti, D. Iacono, M. Casagrande, G. Cardellino, G. Miolo, N. Pella, G. Aprile, A. Buonadonna, G. Fasola, F. Puglisi; IT
- 12:45 - 12:45 **541P - Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis**
H. Osumi, E. Shinozaki, H. Zembutsu, Y. Takeda, T. Wakatsuki, T. Ichimura, Y. Ota, I. Nakayama, M. Ogura, M. Suenaga, D. Takahari, K. Chin, A. Saiura, S. Takahashi, T. Noda, K. Yamaguchi; JP

- 12:45 - 12:45 **542P - Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer**
E. van Cutsem¹, K. Lesniewski-Kmak², M. Saunders³, H. Wasan³, G. Argiles⁴, C. Borg⁵, G.-J. Creemers⁶, M. Fedyanin⁷, R. Glynn-Jones⁸, P. Pfeiffer⁹, C. Punt⁶, D. Stroyakovskiy¹⁰, A. Ten Tije¹¹, A. van de Wouw⁶, V. Cattan⁵, G. Desachy⁵, N. Amellal¹², V. Moiseyenko⁷; ¹BE, ²PL, ³GB, ⁴ES, ⁵FR, ⁶NL, ⁷RU, ⁸Middlesex/GB, ⁹DK, ¹⁰Krasnogorski District/RU, ¹¹Noord Brabant/NL, ¹²CEDEX/FR
- 12:45 - 12:45 **543P - Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation**
Y. Sunakawa¹, J. Usher², H. Satake³, Y. Jaimes², Y. Miyamoto¹, M. Nakamura¹, M. Kataoka¹, M. Shiozawa¹, A. Takagane¹, T. Terazawa⁴, T. Watanabe¹, K. Ishigure¹, C. Tanaka¹, T. Sekikawa¹, M. Takeuchi¹, M. Fujii¹, K. Danenberg², P. Danenberg², H.-J. Lenz², W. Ichikawa¹; ¹JP, ²CA/US, ³Hyogo/JP, ⁴Osaka/JP
- 12:45 - 12:45 **544P - ctDNA assays identify alterations in RAS, EGFR, and cMET that are unique to RAS-WT patients progressing on anti-EGFR therapy**
R. Gupta¹, D. Chevalier¹, J. Saluja¹, C. Lau¹, C. Wang², M. Fakhri²; ¹US, ²CA/US
- 12:45 - 12:45 **545P - Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials**
C. Montagut¹, V. Alonso¹, P. Escudero¹, C. Fernández-Martos¹, A. Salud Salvia¹, M. Méndez¹, J. Gallego Plazas², J.R. Rodriguez¹, M. Martín-Richard¹, J. Fernández-Plana¹, J. Aparicio¹, J. Feliu Batlle¹, X. García de Albéniz³, F. Rojo¹, V. Fernández¹, B. Claes⁴, G. Maertens⁴, E. Sablon⁴, B. Jacobs⁵, J. Maurel¹; ¹ES, ²Alicante/ES, ³MA/US, ⁴BE, ⁵NL
- 12:45 - 12:45 **546P - First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study**
P. García Alfonso, M. Valladares-Ayerbes, J. Muñoz Luengo, P. Pimentel, J.M. Viéitez, J.J. Cruz Hernandez, M. Llanos, C. Garcia Girón, A. Salud Salvia, A. Lloansí Vila; ES
- 12:45 - 12:45 **547P - Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response**
J. Zhou, C. Bai, Z. Sun, Y. Cheng, N. JIA, Y. Zhou; CN
- 12:45 - 12:45 **548P - Cross-platform comparison of NGS and MALDI-TOF for detecting RAS/RAF/PIK3CA mutations in circulating tumor DNA from metastatic colorectal cancer patient plasma**
L. Liang, B.-L. Wang, Q. Yu, T.-S. Liu, W. Guo; CN
- 12:45 - 12:45 **549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type &&**
P. Gazzaniga, C. Raimondi, F. Urbano, E. Cortesi; IT

- 12:45 - 12:45 **550P - Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay**
A. Vivancos, E. Aranda Aguilar, M. Benavides, E. Elez Fernandez, M. Toledano, M. Alvarez, E. Diaz Rubio, A. Gómez-España, V. Garcia-Barberan, M. Chica-Parrao; ES
- 12:45 - 12:45 **551P - Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer (LARC) patients using circulating tumor DNA (ctDNA)**
S. Toomey¹, A. Sartori², D. Irwin³, S. Hummel⁴, A. Carr¹, C.L. Lee¹, P. Armstrong¹, A. Farrelly¹, S. El-Masry¹, D. McNamara¹, P. Morris¹, L. Grogan¹, O. Breathnach¹, L. O'Sullivan¹, S. Bradshaw¹, A. Rashed⁵, R. Smyth¹, J. Workman¹, B. O'Neill¹, B. Hennessy¹; ¹IE, ²DE, ³QLD/AU, ⁴CA/US, ⁵Co. Louth/IE
- 12:45 - 12:45 **552P - Circulating tumor DNA by next generation sequencing as a prognostic and predictive biomarker in metastatic colorectal cancer**
N. JIA, L. Chang, X. Dou, M. Guan, Y. Shao, N. Li, Y. Cheng, H. Ying, Z. Sun, Y. Zhou, L. Zhao, J. Zhou, C. Bai; CN
- 12:45 - 12:45 **553P - Dynamic monitoring of KRAS, NRAS, BRAF and PIK3CA mutations in circulating cell-free DNA for metastatic colorectal cancer patients treated with cetuximab**
L. Liu, Z. Tong, C. Yan, H. Zhang, W. Jiang, Y. Zheng, P. Zhao, W. Fang; CN
- 12:45 - 12:45 **554P - KRAS-dependent and independent mechanisms of progressive disease (PD) in colorectal cancer (CRC) patients (pts) with liver metastases (LM) while monitoring on circulating cell free DNA (cfDNA)**
A. Kirov, Z. Mihaylova, V. Petrova, T. Todorov, D. Petkova, A. Garev, A. Todorova-Georgieva; BG
- 12:45 - 12:45 **555P - Correlation between ctDNA methylation and CEA in colorectal cancer**
W. Tang, H.-X. An, D. Zhou, M. Cai, R. Zeng, X.-J. Lv, L. Chen, F. Ye, Y. Zhang; CN
- 12:45 - 12:45 **556P - Cell free DNA and hepatic arterial infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases**
A. Boysen, J. Schou, B. Jensen, D. Nielsen, B. Sørensen, J. Johansen, K.-L. Spindler; DK
- 12:45 - 12:45 **557P - Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort**
M. ALLART-SAVA¹, F. Le Roy¹, S. Kim¹, D. Sefrioui¹, C. Mariette², A. Zaanani¹, B. Rousseau², M. Ben Abdelghani², C. De La Fouchardière¹, W. Cacheux¹, R. Legros¹, S. Louafi², D. Tougeron², N. Fares¹, G. Roquin¹, A.L. Bignon Bretagne³, M. Maillet¹, B. Tchoundjeu¹, A. Pozet¹, V. Hautefeuille²; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR
- 12:45 - 12:45 **558P - The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer**
F. Ghiringhelli¹, E. Limagne², M. Thibaudin², L. Nuttin², A. Spill², V. Derangere², V. Cattani², E. Peranzoni², N. Amellal³; ¹Cedex/FR, ²FR, ³CEDEX/FR

- 12:45 - 12:45 **559P - Distribution of endocrine tumor marker-positive cells in adenocarcinoma tissue between right-sided and left-sided colon cancer**
T. Ogimi¹, S. Sadahiro², H. miyakita¹, G. Saito¹, K. Okada¹, A. Tanaka¹, T. Suzuki², H. Kajiwar¹; ¹JP, ²Kanagawa/JP
- 12:45 - 12:45 **560P - Prospective DPYD testing in colorectal cancer patients in a realworld UK population**
B. Eccles, A. Harle, S. Pullinger, C. Holling, A. Ingram, S. Stark, M. Bunce, G. Melville, J. Gibbins, N. Calcutt, T. Hickish, M. Flubacher, T. Marinaki; GB
- 12:45 - 12:45 **561P - Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers**
C. Lunenburg¹, L. Henricks¹, E. Dreussi², F. Peters¹, M. Fiocco¹, D. Meulendijks¹, G. Toffoli², H.-J. Guchelaar¹, J. Swen¹, E. Cecchin², J. Schellens¹, H. Gelderblom¹; ¹NL, ²IT
- 12:45 - 12:45 **562P - Determination of DPYD polymorphisms before treatment with chemotherapy with a pyrimidine: Should we continue doing it?**
C. Avila Andrade¹, A.J. Cunqueiro Tomas¹, A.B. Fernandez Diaz¹, M. Meri Abad¹, L.D. Condori Farfan¹, I. Shaheen¹, S. Cervantes Garcia¹, M.J. Safont Aguilera¹, V. Iranzo Gonzalez-Cruz¹, V. Sforza², C. Caballero¹, M.C. Godes de Bremond¹, M. Gil¹, F.D.A. Aparisi Aparisi¹, A. Blasco Cordellat¹, A. Berrocal Jaime¹, I. Ferrer Bolufer¹, M. Lobo de Mena¹, G. Marcaida Benito¹, C. Camps¹; ¹ES, ²IT
- 12:45 - 12:45 **563P - Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer**
T. Yoshino¹, H. Iwata², K. Tamura¹, S. Takahashi¹, C. Redfern³, S. Modi³, T. Doi⁴, H. Kawakami¹, H. Taniguchi², A. Takashima¹, K. Yamaguchi¹, J. Fisher³, B. Li³, K. Saito¹, Y. Fujisaki¹, M. Sugihara¹, J. Tsurutani¹; ¹JP, ²Aichi/JP, ³US, ⁴Chiba/JP
- 12:45 - 12:45 **564P - TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO**
T. Ettrich, A. Berger, T. Decker, R.D. Hofheinz, V. Heinemann, T. Hoffmann, H. Hebart, T. Herrmann, C.-V. Hannig, P. Büchner-Steudel, H. Bartholomäus, M. Güthle, L. Perkhofer, T. Seufferlein; DE
- 12:45 - 12:45 **565P - Dose finding and safety study of reovirus (Reo) with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final results**
S. Goel¹, A. Ocean², R. Parakrama², M. Ghalib², I. Chaudhary², U. Shah², M. Coffey³, E. Kaledzi², R. Maitra²; ¹US, ²NY/US, ³AB/CA
- 12:45 - 12:45 **566P - A first-in-human phase I study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with colorectal cancer and gastric/GEJ cancer**
D.-Y. Oh¹, K.-W. Lee², S.-W. Han¹, J.W. Kim¹, J.-W. Shin¹, S.-J. Jo¹, N.H. Kim¹, A. Woo¹, J. Won¹, S. Hahn¹, H. Lee¹, W.H. Kim¹, Y.-J. Bang¹; ¹KR, ²Gyeonggi-do/KR

- 12:45 - 12:45 **567P - Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer**
H.-J. Lenz¹, H. Park², M. Shah³, J. Berlin⁴, D. Bruetman⁵, J. Chaves⁶, M. Gordon⁷, R. Patel¹, A. Starodub⁵, J. Liu¹, C. Baker Brachmann¹, P. Bhargava¹, Z. Wainberg¹, J. Bendell⁴; ¹CA/US, ²US, ³NY/US, ⁴TN/US, ⁵IN/US, ⁶WA/US, ⁷AZ/US
- 12:45 - 12:45 **568P - A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy**
S.-H. Beom¹, K.-W. Lee¹, S.-H. Cho², Y.S. Park¹, T.W. Kim¹, K.H. Lee¹, M. Jung¹, S.J. Shin¹, J.B. Ahn¹; ¹KR, ²Jeollanam-do/KR
- 12:45 - 12:45 **569P - ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer**
G. Carlsson¹, T.K. Guren², J. Haux¹, P. Pfeiffer³, H. Taflin¹, D. Mavroudis⁴, V. Georgoulas⁴, C. Papadimitriou⁵, N. Kentepozidis⁴, D. Boumpas⁴, L. Skintemo¹, K. Ganlöv¹, B. Gustavsson¹; ¹SE, ²NO, ³DK, ⁴GR, ⁵Attiki/GR
- 12:45 - 12:45 **570P - Detection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool?**
 J. Ruffinelli Rodriguez¹, G. Soler¹, R. Legido¹, M. Martinez Villacampa¹, F. Perez¹, B. Pardo-Burdalo¹, J. Marín¹, I. Morilla Ruiz², L. Heras Lopez¹, S. Vazquez¹, S. Recalde¹, M. Plana Serrahima¹, C. Santos¹, N. Mulet Margalef¹, A. Teule¹, R. Salazar¹, M. Galan¹, J. Saldaña¹; ¹ES, ²Barcelona/ES
- 12:45 - 12:45 **571P - Interim results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC)**
Z. Maravic¹, J. Borrás², E. Espin Basany², Á. Petrányi³, Z. Kapitany³, P. Rakonczai³, A. Benedict³, N. Muszbek¹; ¹GB, ²ES, ³HU
- 12:45 - 12:45 **572P - Socioeconomic discrepancies in survival of stage IV colorectal cancer**
H. Kim¹, J. Uhlig¹, S. Stein², L. Jill², C. Fuchs²; ¹US, ²CT/US
- 12:45 - 12:45 **573P - Influence of not having children on mortality in patients with metastatic (mCRC) colorectal cancer**
S. Ahmed¹, T. Baig¹, A. Zaidi², H. Chalchal¹, K. Haider², T. Asif², N. Iqbal²; ¹CA, ²SK/CA
- 12:45 - 12:45 **574P - Interim quality of life results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC)**
Z. Maravic¹, L. Wyrwicz², B. Karczmarek-Borowska², A. Horvath³, A. Ruiz Casado⁴, A. Carrato Mena⁴, N. Muszbek¹, P. Rakonczai³; ¹GB, ²PL, ³HU, ⁴ES

- 12:45 - 12:45 **575P - Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) &&**
R.D. Hofheinz¹, H.-G. Derigs¹, G. Piringer², R. von Moos³; ¹DE, ²AT, ³CH
- 12:45 - 12:45 **576P - Inhibitory effect of a synthetic bioresorbable adhesion membrane on small bowel obstruction (SBO) in patients undergoing elective surgery for colon cancer: A randomized controlled trial**
G. Saito¹, S. Sadahiro², H. miyakita¹, K. Okada¹, A. Tanaka¹, T. Suzuki²; ¹JP, ²Kanagawa/JP
- 12:45 - 12:45 **577P - Short- and long-term outcomes of high tie versus low tie with lymph node dissection around the inferior mesenteric artery in sigmoid colon or rectal cancer surgery**
X. Li, CN
- 12:45 - 12:45 **578P - Mesenteric vs. antimesenteric colorectal cancer: A single center study**
K.H. Lee, W.R. Kim, J.W. Kim; KR
- 12:45 - 12:45 **579P - The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer**
D. Basile, C. Lisanti, M. Borghi, M. Bartoletti, L. Gerratana, L. Bortot, G. Pelizzari, C. Corvaja, E. Ongaro, S. Garattini, V. Fanotto, A. Parnofiello, F. Cortiula, M. Cattaneo, V. Andreotti, E. Bertoli, M. Guardascione, G. Miolo, F. Puglisi, A. Buonadonna; IT
- 12:45 - 12:45 **580P - Safety and outcomes of self-expandable metal stents (SEMS) versus emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab (BV)**
V. Pacheco-Barcia, R. Mondéjar Solís, O. Martínez-Sáez, F. Longo, E. Bermejo, J.A. Moreno, C. Marin, A. Correa, R. maqueda, J. Rogado, A. García de Paredes, E. Rodriguez de Santiago, V. Pachón Olmos, R. Ferreira Monteagudo, M. Rodriguez Garrote, A. Carrato Mena, O. Donnay, E. Martin Perez, C. Santander, R. Colomer Bosch; ES
- 12:45 - 12:45 **581P - Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei**
A. RAIMONDI, S. Corallo, M. Niger, M. Antista, G. Randon, F. Morano, C. Cremolini, M. Di Bartolomeo, F.G. de Braud, F. Pietrantonio; IT
- 12:45 - 12:45 **582P - Utility of carcinoembryonic antigen (CEA) in appendiceal carcinoma**
A. KARIPPOT¹, S. Groover², J. Ai¹, S. NAMBIAR²; ¹US, ²OK/US
- 12:45 - 12:45 **583P - Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial**
S. Barni¹, G. Rosati¹, V. Zagonel¹, N. Pella¹, M. Banzi¹, M.G. Zampino¹, M. Di Bartolomeo¹, L. Rimassa², P. Marchetti¹, E. Maiello¹, F. Artioli¹, D. Ferrari¹, R. Labianca¹, P. Bidoli¹, A. Zaniboni¹, A. Sobrero¹, V. Iaffaioli¹, S. de Placido¹, L. Frassinetti³, F. Galli¹, F. Petrelli⁴; ¹IT, ²(MI)/IT, ³Forlì-Cesena/IT, ⁴(BG)/IT

- 12:45 - 12:45 **584P - The clinical utility of early follow-up computed tomography in patients with stage II-III colorectal cancer receiving oxaliplatin-based chemotherapy**
Y. Lee¹, S.Y. Kim², J.E. Kim¹, Y.S. Hong¹, T.W. Kim¹; ¹KR, ²Songpa-gu/KR
- 12:45 - 12:45 **585P - Clinical benefit of whole genome and transcriptome analysis (WGTA) in metastatic colorectal cancer (MCRC): Results from the personalized oncogenomics program (POG)**
S. Liu¹, J. Loree², D. Renouf¹, M. Jones³, S. Yip³, M. Marra³, S. Jones³, J. Nelson³, J. Laskin², H. Lim², S. Gill²; ¹CA, ²British Columbia/CA, ³BC/CA
- 12:45 - 12:45 **586P - Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits**
E. Imyanitov, N. Mitiushkina, E. Kuligina, M. Holmatov, G. Yanus, I. Demidova, T. Kekeeva, M. Gordiev, E. Kharitonova, I. Tsimafeyeu, S. Tjulandin; RU
- 12:45 - 12:45 **587P - Patterns of care and of biomolecular characterization of right, transverse, and left colorectal cancer from real-life evidence in Asia Pacific and European countries**
E. Mari¹, S. Mpima², F. Guglielmetti³, P. Nasuti²; ¹MI/IT, ²GB, ³(MI)/IT
- 12:45 - 12:45 **588P - The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer**
M. Rimini, C. Bardasi, F. Gelsomino, K. Andrikou, C. Santini, G. Orsi, M. Salati, M.L. Riggi, S. Pipitone, S. Cascinu, A. Spallanzani; IT
- 12:45 - 12:45 **589P - The prognostic value of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status in left- and right-sided metastatic colorectal cancer (mCRC): A Belgian population-based study**
K. Janssens, G. van Camp, K. Op de Beeck, E. Fransen, F. Calay, N. van Damme, M. Peeters; BE
- 12:45 - 12:45 **590P - Increase in tumor-infiltrating FoxP3-positive regulatory T cells in left-sided colorectal cancer tissues after preoperative oral uracil and tegafur/leucovorin chemotherapy**
S. Sadahiro¹, T. Suzuki¹, A. Tanaka², K. Okada², G. Saito², H. Miyakita², H. Kajiwara², H. Nagase²; ¹Kanagawa/JP, ²JP
- 12:45 - 12:45 **591P - Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically?**
G. Dos Santos Fernandes¹, W. Chatila², R. Yaeger², R. Mendelsohn², Z. Stadler², N. Segal¹, A. Varghese¹, D. Reidy¹, L. Diaz¹, J. Shia², E. Vakiani², J. Hechtman², N. Schultz², M. Berger², D. Hyman¹, D. Solit², L. Saltz¹, J. Garcia Aguilar², A. Cercek¹; ¹US, ²NY/US
- 12:45 - 12:45 **592P - Impact of Charlson comorbidity index on survival of octogenarian patients with colorectal cancer**
E. Inga Saavedra, J.R. Rodriguez, E. Casaut Lora, A. Gonzalez-Haba, V. Serrano Pecos, M.F. Martinez Barragan, E. Blanco, J. Gomez-Ulla; ES

- 12:45 - 12:45 **593P - The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients**
C. Lisanti, D. Basile, S. Garattini, G. Pelizzari, A. Parnofiello, F. Cortiula, E. Ongaro, M. Cattaneo, C. Corvaja, V. Andreotti, M. Bartoletti, M. Casagrande, D. Iacono, M. Bonotto, P. Ermacora, N. Pella, A. Buonadonna, F. Puglisi, G. Fasola, G. Miolo; IT
- 12:45 - 12:45 **594P - Determinants of oncologist's choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer**
S.K. Garattini, M. Bonotto, L. Porcu, E. Ongaro, D. Basile, F. Cortiula, G. Pelizzari, M. Cattaneo, A. Parnofiello, V. Andreotti, C. Corvaja, G. Cardellino, P. Ermacora, M. Casagrande, D. Iacono, N. Pella, A. Buonadonna, A. Minisini, F. Puglisi, G. Fasola; IT
- 12:45 - 12:45 **596P - Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models**
V. Belli¹, N. Matrone¹, S. Napolitano¹, E. Martinelli¹, M. Castellone¹, L. Trusolino², E. Giunta¹, V. De Falco¹, N. Zanaletti¹, P.P. Vitiello¹, D. Ciardiello¹, M. Terminiello¹, F. Ciardiello¹, T. Troiani¹; ¹IT, ²(TO)/IT
- 12:45 - 12:45 **597P - Predictive value of in-vitro testing anti-cancer therapy sensitivity on 3D micro-tumors (tumoroids) from patients with metastatic colorectal cancer: A feasibility study**
L.H. Jensen, C. Dam, G. Hagel, C. Hansen, H. Harling, B. Havelund, A. Jakobsen, J. Lindebjerg, S. Rafaelsen, O. Thastrup, T. Hansen; DK
- 12:45 - 12:45 **598P - Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line**
N. Matrone, A. Chambery, R. Russo, P.V. Pedone, V. Belli, S. Napolitano, E. Martinelli, E. Giunta, V. De Falco, N. Zanaletti, P. Vitale, M. Terminiello, C. Cardone, F. Ciardiello, T. Troiani; IT
- 12:45 - 12:45 **599P - Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study**
T. Kato¹, M. Kotaka¹, H. Satake¹, A. Makiyama², Y. Tsuji³, K. Shinozaki⁴, T. Fujiwara⁴, T. Mizushima⁵, Y. Harihara⁴, N. Nagata⁶, N. Kurihara⁴, Y. Kagawa⁴, G. Kusakawa⁴, T. Sakai⁴, Y. Uchida⁴, M. Takamoto⁴, S. Asami⁴, M. Ando⁴, Y. Saito⁴, I. Hyodo⁷; ¹Hyogo/JP, ²Fukuoka/JP, ³Hokkaido/JP, ⁴JP, ⁵Osaka/JP, ⁶Hukuoka/JP, ⁷Ibaraki/JP
- 12:45 - 12:45 **600P - Development of a nomogram for predicting survival in microsatellite stable patients with resected colorectal cancer**
Y. Li, J. Peng, T. Hou, H. Han-Zhang, H. Liu, J. Xiang, L. Zhang, X. Ma, D. Huang, S. Cai; CN
- 12:45 - 12:45 **601P - Germline mutations in Chinese colorectal cancer patients with mismatch repair deficiency**
Y. Yuan¹, L. Zhu², D. Xu¹, C. Liu², X. Mao²; ¹Zhejiang/CN, ²CN

- 12:45 - 12:45 **602P - Kynurenine 3-monooxygenase as a potential biomarker for colorectal cancer**
C.-Y. Liu, C.-H. Lee, J.-L. Chen, T.-T. Huang, S.-H. Yang, J.-K. Jiang, W.-S. Chen, K.-D. Lee, H.-W. Teng; TW
- 12:45 - 12:45 **603TiP - Induction chemotherapy plus chemoradiotherapy with or without aspirin in high risk rectal cancer (ICAR)**
J. Souza, R. Araujo, M. Valadão, C. Carrara, M. Barbosa, R. Guimarães, J. Carvalho, G. Kowaleski, I. Small, A. Marins, A.P. Victorino, R. Gil, J.P. Jesus, L.H. de Araujo, A. de Melo; BR
- 12:45 - 12:45 **604TiP - Phase II study of surgery after S-1 &&**
T. Yoshida, T. Miura, Y. Sakamoto, H. Morohashi, H. Fujita, K. Sato, K. Hakamada; JP
- 12:45 - 12:45 **605TiP - Phase II study of resection of primary colorectal cancer and synchronous liver metastasis after S-1 &&**
T. Miura, H. Morohashi, Y. Sakamoto, T. Yoshida, K. Sato, K. Ishido, D. Kudo, N. Kimura, K. Hakamada; JP
- 12:45 - 12:45 **606TiP - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G**
Y. Kito¹, T. Yamada¹, T. Matsumoto¹, H. Yasui², K. Murata¹, A. Makiyama³, H. Hara¹, E. Baba³, K. Nishio¹, K. Yoshimura⁴, S. Hironaka⁵, K. Muro⁶, K. Yamazaki⁷; ¹JP, ²Fushimi-ku/JP, ³Fukuoka/JP, ⁴Ishikawa/JP, ⁵Chiba/JP, ⁶Aichi/JP, ⁷Shizuoka/JP
- 12:45 - 12:45 **607TiP - BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib &&**
D. Kotani¹, H. Bando², T. Masuishi³, Y. Komatsu², K. Yamaguchi², T. Nakajima², T. Satoh⁴, T. Nishina², T. Esaki², S. Nomura², S. Sakamoto², S. Iida², S. Matsuda², M. Yonemura², N. Fuse², A. Sato², S. Fujii², H. Ebi², A. Ohtsu², T. Yoshino²; ¹Chiba/JP, ²JP, ³Aichi/JP, ⁴Osaka/JP
- 12:45 - 12:45 **608TiP - BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701)**
T. Masuishi¹, H. Taniguchi¹, D. Kotani², H. Bando³, Y. Komatsu⁴, K. Yamaguchi³, T. Nakajima³, T. Satoh⁵, T. Nishina³, T. Esaki³, M. Wakabayashi³, S. Nomura³, S. Sakamoto³, H. Ono³, N. Hirano³, N. Fujishiro³, N. Fuse³, A. Sato³, A. Ohtsu³, T. Yoshino³; ¹Aichi/JP, ²Chiba/JP, ³JP, ⁴Hokkaido/JP, ⁵Osaka/JP
- 12:45 - 12:45 **609TiP - Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)**
A. De Stefano, G. Nasti, A. Febbraro, G. Rosati, F. Giuliani, D. Santini, G. Aprile, M. Scartozzi, F. Silvestris, G. Luppi, I. Lolli, C. Mastroianni, S. Leo, V. Montesarchio, C. Gridelli, C. Pozzo, E. Sperti, D. Giannarelli, A. Budillon, A. Avallone; IT

- 12:45 - 12:45 **610TiP - Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE)**
A. Avallone¹, P. Delrio¹, G. Nasti¹, A. Cassata¹, L. Silvestro¹, A. De Stefano¹, S. Lastoria¹, R. Casaretti¹, C. Romano¹, A. Ottaiano¹, E. Di gennaro¹, A. Nappi¹, P. Maiolino¹, E. Cavalcanti¹, A. Petrillo¹, F. Tatangelo¹, D. Giannarelli¹, J. Galon², P. Ascierto¹, A. Budillon¹; ¹IT, ²FR
- 12:45 - 12:45 **611TiP - AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)**
M. Español Rego¹, V. Alonso¹, J. Aparicio¹, E. Elez Fernandez¹, P. Escudero¹, C. Fernández-Martos¹, N. Rodríguez¹, A. Ruiz Casado¹, J. Cid¹, R. Cabezón¹, M. Lozano¹, A. Ginés¹, L. Bianchi¹, J. Garcia-Corbacho¹, X. García de Albéniz², J. Maurel¹, D. Benitez Ribas¹; ¹ES, ²MA/US
- 12:45 - 12:45 **612TiP - Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer**
A. Flament, A. Hendlisz, L. Shaza, S. Aspeslagh, M. Vouche, V. Donckier, A. Awada, J.-P. Machiels, M. van den Eynde, J.-L. Canon, J. Carrasco, C. Lonez, F. Lehmann; BE
- 12:45 - 12:45 **613TiP - Serum levels of interleukin 8 (IL-8) and other cytokines as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic colo-rectal cancer patients: The FLIBER study**
C. Buonerba, S. Vecchiarelli, F. Cappuzzo; IT
- 12:45 - 12:45 **614TiP - UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis**
T. Mazard¹, F. Ghiringhelli², C. Mollevi¹, E. Assenat¹, C. Gavaille³, D. Smith¹, V. Pezzella¹, R. Meddeb¹, B. Pastor¹, M. Ychou⁴, A. Thierry¹; ¹FR, ²Cedex/FR, ³CEDEX/FR, ⁴CEDEX 5/FR
- 12:45 - 12:45 **Gastrointestinal tumours, non-colorectal**
- 12:45 - 12:45 **627P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer**
K. Kato, T. Kojima, H. Saeki, H. Hara, T. Kajiwara, S. Hironaka, H. Nakatsumi, S. Kadowaki, Y. Kagawa, T. Esaki, T. Moriwaki, T. Kobayashi, N. Izawa, S. Nomura, T. Kuwata, S. Fujii, W. Okamoto, K. Shitara, A. Ohtsu, T. Yoshino; JP
- 12:45 - 12:45 **628P - Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas**
A. Creemers, S. Meijer, M. Stoffels, G. Hooijer, L. Holtzer, H. van Ooijen, A. Van Brussel, E. Aussems-Custers, M. van Berge Henegouwen, M. Hulshof, K. Krishnadath, A. van de Stolpe, M. Bijlsma, H. van Laarhoven; NL

- 12:45 - 12:45 **629P - Hypoxia gene expression defines a poor prognostic sub-group in oesophageal adenocarcinoma**
R. Douglas, C. McKinney, L. Stevenson, L. Cairns, R. Kennedy, J. Blayney, R. Turkington; GB
- 12:45 - 12:45 **630P - Neoadjuvant radio-chemotherapy for esophageal cancer: A multicenter European study comparing paclitaxel/carboplatin, 5FU/cisplatin and FOLFOX**
P. Allemann¹, S. Mantziari¹, M. Winiker¹, A. Wagner¹, A. Digkila¹, M. van Berge Henegouwen², S. Gisbertz², A. Slaman², R. van Hillegersberg², J. Ruurda², H. Brenkman², M. Nilsson³, K. Satoshi³, G. Piessen⁴, D. Collet⁴, C. Gronnier⁴, N. Carrere⁴, A. Marinho⁴, N. Demartines¹, M. Schafer¹; ¹CH, ²NL, ³SE, ⁴FR
- 12:45 - 12:45 **631P - Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy**
A. Barbour¹, S. Brosda², B. Wijnhoven³, S. van Hootgem³, J. Lanschot³, S. Barbour¹, S. Lagarde³, L. Krause², D. Pryor², J. Thomas², E. Walpole², A. van der Gaast³, M. Smithers²; ¹AU, ²QLD/AU, ³NL
- 12:45 - 12:45 **632P - Induction chemotherapy for locally advanced esophageal cancer**
G. Harada, R. Bonadio, F. de Araújo, C. Victor, F. Takeda, R. Sallum, U. Junior, I. Cecconello, T. de Castria; BR
- 12:45 - 12:45 **633P - The role of comprehensive evaluation for clinical complete response in predicting pathologic complete response in patients treated with neoadjuvant chemoradiation for esophageal squamous cell carcinoma (ESCC)**
H.-S. Im, J. Kang, Y.-H. Kim, H.R. Kim, J.H. Kim, H.-Y. Jung, G.-H. Lee, H.J. Song, D.H. Kim, K.D. Choi, J.H. Lee, J.Y. Ahn, J.-S. Ryu, K.-J. Cho, S.-B. Kim, S.R. Park; KR
- 12:45 - 12:45 **634P - Prognostic impact of inflammation-based scores in esophageal cancer patients achieving pathologic complete response after neoadjuvant chemoradiotherapy followed by surgery**
J. Kang, H.-S. Im, Y.-H. Kim, H.R. Kim, J.H. Kim, H.-Y. Jung, G.-H. Lee, H.J. Song, D.H. Kim, K.D. Choi, J.H. Lee, J.Y. Ahn, J.-S. Ryu, K.-J. Cho, S.-B. Kim, S.R. Park; KR
- 12:45 - 12:45 **635P - Association of sarcopenia with dose-limiting toxicities and survival in oesophageal adenocarcinoma treated with neoadjuvant chemotherapy**
J. Weaver, C. Cipriano, A. McWilliam, Z. Kordatou, M. Abraham, T. Germetaki, G. Papaxoinis, W. Mansoor; GB
- 12:45 - 12:45 **636P - Survival benefit of re-irradiation in esophageal cancer patients with locoregional recurrence: A propensity score matched analysis**
K. Xiangquan, Y. Huang, B. Zheng, Q. Zhuang, X. Zhang, L. Tang, J. Li, J. Wu; CN
- 12:45 - 12:45 **637P - Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy**

M. Davidson, M. Nankivell, D. Cunningham, N. Starling, D.-M. Koh, G. Brown, W. Allum, A. Wotherspoon, E. Smyth, L. Ly, N. Kleovoulou, R. Langley, A. Riddell; GB

- 12:45 - 12:45 **638P - Prognostic value of pretreatment diffusion weighted magnetic resonance imaging based texture in concurrent chemo-radiotherapy of esophageal squamous cell cancer**
B. li, Z. li, C. Han; CN
- 12:45 - 12:45 **639P - Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?**
S. Nagasawa, T. Ogata, K. Hara, Y. Shimoda, M. Nakazono, Y. Kumazu, T. Hayashi, T. Yamada, Y. Rino, M. Masuda, T. Yoshikawa, T. Oshima; JP
- 12:45 - 12:45 **640P - A model using computed tomography-based compactness to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma**
Q. Wang, B. Cao, J. Chen, T. Li, J. Lang, Z. Xiao; CN
- 12:45 - 12:45 **641P - Clinical significance of 18F-fluorodeoxyglucose-positron emission tomography-positive lymph nodes to outcomes of trimodal therapy for esophageal squamous cell carcinoma**
Y. Hamai, M. Emi, Y. Ibuki, M. Okada; JP
- 12:45 - 12:45 **642P - Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor &&**
C.-C. Lin¹, T. Doi², K. Muro³, M.-M. Hou¹, T. Esaki⁴, H. Hara⁴, H.-C. Chung⁵, M. Osada⁴, C. Helwig⁶, S. Kondo⁴; ¹TW, ²Chiba/J, ³Aichi/J, ⁴J, ⁵KR, ⁶DE
- 12:45 - 12:45 **643P - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary results from a phase I cohort**
B. Tan¹, A. Khattak², E. Felip³, K. Kelly⁴, P. Rich⁵, D. Wang⁶, C. Helwig⁷, I. Dussault⁸, L. Ojalvo⁸, N. Isambert⁹; ¹MO/US, ²AU, ³ES, ⁴US, ⁵GA/US, ⁶MI/US, ⁷DE, ⁸MA/US, ⁹FR
- 12:45 - 12:45 **644P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer**
N. Izawa¹, C. Morizane¹, H. Takahashi², M. Ueno¹, Y. Kawamoto³, N. Okano⁴, S. Shimizu¹, K. Sudo¹, S. Itoh¹, A. Asagi¹, Y. Kagawa¹, K. Kamata¹, T. Kudo⁵, S. Nomura¹, T. Kuwata¹, S. Fujii¹, W. Okamoto¹, K. Shitara¹, A. Ohtsu¹, T. Yoshino¹; ¹J, ²Chiba/J, ³Hokkaido/J, ⁴Tokyo/J, ⁵Osaka/J
- 12:45 - 12:45 **645P - Spatial genomic heterogeneity from multi-region endoscopic biopsies in primary gastric cancer: Implications for precision therapy**
S. Klempner¹, J. Chao², K. Kim³, K.-M. Kim³, S.-T. Kim³, J. Lee³, H. Lee³; ¹CA/US, ²US, ³KR

- 12:45 - 12:45 **646P - EGFR amplification (amp) and survival in the REAL-3 trial**
E. Smyth¹, K. Kouvelakis¹, D. Cunningham¹, J.C. Hahne¹, C. Peckitt¹, G. Vlachogiannis¹, D. Watkins¹, S. Rao¹, N. Starling¹, S.H. Wilson¹, T. Waddell¹, A. Okines¹, T. Crosby¹, W. Mansoor¹, J. Wadsley², G. Middleton¹, A. Wotherspoon¹, I. Chau³, N. Valeri¹; ¹GB, ²South Yorkshire/GB, ³Surrey/GB
- 12:45 - 12:45 **647P - The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy**
M. Skupinska, M. Jesiotr, P. Chrom, A. Mroz, S. Cierniak, M. Winiarek, L. Wyrwicz, J. Pieczykolan, M. Wieczorek, A. Stanczak, L. Bodnar; PL
- 12:45 - 12:45 **648P - Changes in CpG methylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A in gastric adenocarcinoma**
N. Timoshkina, O. Kit, D. Vodolazhskiy, N. Soldatkina, Y. Gevorkyan, N. Samoylenko, D. Kharagezov, M. Duritskiy, A. Dashkov, D. Kaymakchi, D. Petrov, S. Ilchenko, V. Sustretov, L. Vladimirova; RU
- 12:45 - 12:45 **649P - The level of somatic mutations as an indicator of overall survival in gastric cancer**
T. Kekeeva, A. Tanas, L. Khashimov, V. Lyadov, Y. Andreeva, G. Frank, L. Zavalishina, D. Zaletaev, V. Strelnikov; RU
- 12:45 - 12:45 **650P - Mechanisms of G9a on promoting tumor invasion and metastasis of gastric cancer**
B. Liu, L. Hu; CN
- 12:45 - 12:45 **651P - Prospective observation: Clinicopathological features and clinical utility of plasma Epstein-Barr virus DNA load of Epstein-Barr virus-associated gastric carcinoma**
M.-Z. Qiu, CN
- 12:45 - 12:45 **652P - Is standard adjuvant chemotherapy effective in patients with Epstein-Barr virus associated gastric cancer?**
J.G. Kim, Y. Chae, J.H. Baek, B.W. Kang; KR
- 12:45 - 12:45 **653P - PD-L1 expression and T-cell inflamed gene expression profile (GEP) in Korean and US patients (pts) with advanced gastric cancer (GC)**
S.Y. Rha¹, G. Ku², H.S. Kim¹, H.C. Chung¹, F.G. Amlashi², D. Maru², C. Fein², L. Tang², M. Savage², W. Zhou², T. Wu², S. Peter², D. Kelsen², J. Ajani²; ¹KR, ²US
- 12:45 - 12:45 **654P - Relationship between immune related molecules and chemosensitivity and prognosis in gastric cancer**
T. Hagi¹, Y. Kurokawa², T. Hashimoto¹, Y. Miyazaki², T. Takahashi¹, K. Tanaka¹, T. Makino¹, M. Yamasaki¹, K. Nakajima¹, M. Mori¹, Y. Doki¹; ¹JP, ²Osaka/JP
- 12:45 - 12:45 **655P - Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma**

C. Siesing, M. Svensson, C. Hedner, B. Nodin, D. Borg, K. Jirstrom; SE

- 12:45 - 12:45 **656P - Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of JCOG1302A**
Y. Sato¹, J. Mizusawa¹, K. Nakamura¹, T. Fukagawa¹, H. Katai¹, S. Haruta¹, M. Yamada¹, M. Takagi¹, S. Tamura¹, T. Yoshimura¹, T. Inada¹, N. Hirabayashi¹, I. Wada¹, Y. Kodaera¹, M. Tokunaga¹, T. Yoshikawa¹, N. Boku², T. Sano¹, M. Sasako³, M. Terashima⁴; ¹JP, ²Kanagawa/JP, ³Hyogo/JP, ⁴Shizuoka/JP
- 12:45 - 12:45 **657P - Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?**
K. Hara, T. Hayashi, Y. Shimoda, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Oshima, T. Yoshikawa; JP
- 12:45 - 12:45 **658P - Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2 adenocarcinoma (GA/GEJA)**
R. Morlock¹, M. Krukas-Hampel¹, Ö. Türeci²; ¹US, ²DE
- 12:45 - 12:45 **659P - Avelumab (anti-PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial**
T. Doi¹, S. Iwasa², K. Muro³, T. Satoh⁴, S. Hironaka², T. Esaki², T. Nishina², H. Hara², N. Machida², Y. Komatsu⁵, Y. Shimada², S. Otsu², S. Shimizu², V. Chand⁶, M. Watanabe²; ¹Chiba/JP, ²JP, ³Aichi/JP, ⁴Osaka/JP, ⁵Hokkaido/JP, ⁶MA/US
- 12:45 - 12:45 **660P - Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies**
S. Klempner¹, J. Bendell², V. Meucci Villaflor³, L. Tenner⁴, S. Stein⁵, C. Sirard⁶, W. Newman³, M. Kagey³, K. Schlienger³, J. Strickler³; ¹CA/US, ²TN/US, ³US, ⁴TX/US, ⁵CT/US, ⁶MA/US
- 12:45 - 12:45 **661P - Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β2, in patients with pretreated recurrent or refractory gastric cancer**
Y.-J. Bang¹, T. Doi², S. Kondo³, H.C. Chung¹, K. Muro⁴, I. Dussault⁵, C. Helwig⁶, M. Osada³, Y.-K. Kang⁷; ¹KR, ²Chiba/JP, ³JP, ⁴Aichi/JP, ⁵MA/US, ⁶DE, ⁷Songpa-gu/KR
- 12:45 - 12:45 **662P - Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2 adenocarcinoma (GEA)**
D. Catenacci¹, H. Park², H. Uronis², Y.-K. Kang³, M. Ng⁴, P. Gold⁵, J. Lacy⁶, P. Enzinger⁷, S. Park⁸, K.-W. Lee⁸, J. Yen⁹, J. Odegaard⁹, A. Franovic⁹, J. Baughman⁹, J. Muth¹⁰, A. Wynter-Horton¹⁰, T. Wu¹⁰, J. Wigginton², J. Davidson-Moncada¹¹, Y.-J. Bang⁸; ¹IL/US, ²US, ³Songpa-gu/KR, ⁴SG, ⁵WA/US, ⁶CT/US, ⁷MA/US, ⁸KR, ⁹CA/US, ¹⁰MD/US, ¹¹NY/US

- 12:45 - 12:45 **663P - HER2 alterations is associated with higher tumor mutation burden in gastric cancer**
B. Wei, Z. Li, Q. Han, X. Xing, Y. Hao, J. Zhou, Y. Zhang, S. Cai, Y. Gu; CN
- 12:45 - 12:45 **664P - Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2⁺; metastatic gastric/gastroesophageal junction cancer (GC/GEJ)**
M. Alsina¹, A. Varga², A. Amatu³, J. Schellens⁴, P. Witteveen⁴, V. Boni¹, V. Moreno¹, K. Bol⁴, A. Lourbakos⁴, M. Magin Ferrer⁴, E. Wasserman⁵; ¹ES, ²FR, ³IT, ⁴NL, ⁵US
- 12:45 - 12:45 **665P - NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer**
V. Gambardella¹, F. Gimeno-Valiente², N. Tarazona Llaveró¹, T. Fleitas Kanonnikoff², P. Tolosa², M. Belda Moscardó², B. Garcia-Mico², M. Huerta², S. Roselló², D. Roda², A. Cervantes¹, J. Castillo²; ¹Valencia/ES, ²ES
- 12:45 - 12:45 **666P - Discordance between HER2 expression status in primary tumor and matched malignant ascites in gastric adenocarcinoma**
Y. Yang, H. Kim, S.-M. Son, H.S. Han; KR
- 12:45 - 12:45 **667P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX)**
K. Chin¹, A. Takashima¹, K. Minashi¹, S. Kadowaki¹, T. Nishina¹, T. Nakajima¹, K. Amagai², N. Machida¹, M. Gotoh³, K. Taku¹, N. Ishizuka¹, D. Takahari⁴; ¹JP, ²Ibaraki/JP, ³Osaka/JP, ⁴Aichi/JP
- 12:45 - 12:45 **668P - Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B**
S. Yuki¹, K. Shinozaki², T. Kashiwada², T. Kusumoto², M. Iwatsuki², H. Satake³, S. Tokunaga², Y. Emi², A. Makiyama⁴, Y. Kawamoto¹, Y. Komatsu¹, M. Shimokawa², H. Saeki², E. Oki⁴, H. Baba², Y. Maehara²; ¹Hokkaido/JP, ²JP, ³Hyogo/JP, ⁴Fukuoka/JP
- 12:45 - 12:45 **669P - Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)**
N. Martinez Lago¹, S. Candamio Folgar¹, C. Grande Ventura¹, M. Salgado Fernandez¹, J. De la Camara Gomez¹, J.C. Méndez Méndez¹, D. Arias Ron¹, F. Vazquez², M. Reboredo Lopez¹, Y. Vidal Insua¹, B. Graña Suarez¹, M. Jorge Fernandez¹, M.E. Brozos Vazquez¹, M.L. Pellon Augusto¹, J. Prato Varela¹, P. Gonzalez Villarroel¹, A. Fernandez Montes¹; ¹ES, ²La Coruña/ES
- 12:45 - 12:45 **670P - Phase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)**

K. Kobayashi¹, M. Iwatsuki¹, H. Orita¹, S. Hidaka¹, T. Arigami¹, T. Kusumoto¹, H. Satake², E. Oki³, K. Satoshi⁴, K. Tobimatsu¹, M. Shimokawa¹, H. Saeki¹, A. Makiyama³, Y. Kakeji¹, S. Natsugoe¹, H. Baba¹, S. Eguchi¹, Y. Maehara¹; ¹JP, ²Hyogo/Jp, ³Fukuoka/Jp, ⁴SE

- 12:45 - 12:45 **671P - A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)**
R. Kawabata¹, T. Terazawa², J. Matsuyama³, S. Endo⁴, O. Shiraishi⁴, S. Fujita⁴, Y. Akamaru⁴, H. Taniguchi⁴, M. Tatsumi⁴, M. Gotoh², S.-W. Lee⁴, Y. Kurokawa², T. Shimokawa⁴, D. Sakai⁴, T. Kato⁵, K. Fujitani⁴, T. Satoh²; ¹Osaka Prefecture/Jp, ²Osaka/Jp, ³Osaka pref./Jp, ⁴Jp, ⁵Hyogo/Jp
- 12:45 - 12:45 **672P - Comparison of preoperative neoadjuvant chemotherapy (SOX) with different courses of treatment on the patients with advanced gastric cancer**
X. Wang, CN
- 12:45 - 12:45 **673P - Phase II trial of neoadjuvant therapy using apatinib plus SOX regimen in locally advanced gastric cancer: Updated results**
Y. Zheng, X. Yang, H. Shi, Z. Yang, C. Yan, Z. Ni, M. Li, B.K. Sah, W. Liu, W. Xu, X. Yao, Z. Zhu, M. Yan, Z. Zhu, C. Li; CN
- 12:45 - 12:45 **674P - The efficacy and safety of (neo)adjuvant therapy for gastric cancer: A network meta-analysis**
T. van den Ende, E. Ter Veer, M. Machiels, R. Mali, F. Abe Nijenhuis, L. Waal, M. Laarman, S. Gisbertz, M. Hulshof, M. van Oijen, H. van Laarhoven; NL
- 12:45 - 12:45 **675P - Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)**
E. Obarevich, N. Besova, E. Trusilova, V. Gorbunova; RU
- 12:45 - 12:45 **676P - Efficacy and safety for apatinib combined with oxaliplatin and S1 in initially treated metastatic gastric cancer: A single-center observational study**
J. Peng¹, L. Peng², H. Wu², K. Wu², W. Chen², C. Xie², J. Xu², X. Zhang², D. Chen², S. Cai², Y. He²; ¹Guangdong/CN, ²CN
- 12:45 - 12:45 **677P - Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer: A phase II study by the Hellenic Cooperative Oncology Group**
T. Makatsoris¹, E. Samantas², K. Manousou³, V. Karavasilis⁴, G. Aravantinos², D. Tryfonopoulos³, A. Psyrri³, D. Pectasides³, E. Pazarli³, C. Petraki³, A. Tsipoura³, I. Kaklamanos³, G. Fountzilas³, G. Pentheroudakis³; ¹Rion/GR, ²Attica/GR, ³GR, ⁴Central Macedonia/GR
- 12:45 - 12:45 **678P - Treatment patterns and changes in quality of life during first-line palliative chemotherapy in Korean patients with advanced gastric cancer**

K.-W. Lee¹, J.W. Kim¹, J.G. Kim¹, B.W. Kang¹, I.J. Chung², Y.S. Hong¹, T.-Y. Kim¹, K.H. Lee¹, D.Y. Zang¹, Y.H. Ko¹, E.-K. Song¹, J.H. Baek¹, D. Koo¹, S.Y. Oh¹, H. Cho¹; ¹KR, ²Jeonnam/KR

- 12:45 - 12:45 **679P - Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer**
K. Nishikawa¹, W. Koizumi², A. Tsuburaya³, T. Yamanaka¹, S. Morita¹, K. Fujitani¹, Y. Akamaru¹, K. Shimada¹, H. Hosaka¹, N. Nakayama¹, Y. Miyashita¹, T. Tsujinaka⁴, J. Sakamoto⁵; ¹JP, ²Minami-li, Sagamihara/JP, ³Minami-ku/JP, ⁴Osaka/JP, ⁵Gifu/JP
- 12:45 - 12:45 **680P - A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01)**
K.-W. Lee, C.H. Maeng, T.-Y. Kim, D.Y. Zang, Y.H. Kim, I.G. Hwang, S.C. Oh, J.S. Chung, H.S. Song, J.W. Kim, S.J. Jeong, J.Y. Cho; KR
- 12:45 - 12:45 **681P - Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study**
T. Masuishi¹, S. Kadowaki², H. Hirano², S. Kawai², T. Yamada², T. Moriwaki², N. Machida², N. Boku³, K. Muro¹; ¹Aichi/JP, ²JP, ³Kanagawa/JP
- 12:45 - 12:45 **682P - Identification of patients who benefit from apatinib in advanced gastric cancer: Data derived from a real-world study**
J. Feng, B. Shen, H. Jiang, L. Wang, J. Qian, Y. Shu, P. Chen, G. Mao, B. Liu, X. Zhang, C. Liu, J. Wu, X. Li, W. Cai, W. Shen, Q. Wang, J. He, D. Hua, Z. Zhang, Y. Zhang; CN
- 12:45 - 12:45 **683P - A real world study of apatinib treatment in gastric cancer: Current status and clinical benefit**
G. Sun, D. Li, Z. Ning, Y. He, J. Chang, F. Zhang, C. Jiang, Y. Cheng, L. Xia, B. Hu, C. Yu, Z. Wang, D. Wang, G. Wang, Y. Zhao, J. Wang, H. Liang, M. Xiong, W. Peng, H. Qian; CN
- 12:45 - 12:45 **684P - An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake**
S. Kadowaki¹, H. Ishigami¹, K. Muro², S. Yoshida¹, Y. Hirono¹, T. Tomita¹, H. Yabusaki¹, T. Kusumoto¹, M. Ota¹, Y. Koderu¹, Y. Tsuji³, A. Hidemura¹, O. Hachiya¹, K. Oba¹, J. Kitayama¹; ¹JP, ²Aichi/JP, ³Hokkaido/JP
- 12:45 - 12:45 **685P - Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer**
M. Takeuchi¹, W. Ichikawa¹, K. Shitara¹, Y. Sunakawa¹, K. Oba¹, W. Koizumi², Y. Sakata³, H. Furukawa¹, M. Takeuchi¹, M. Fujii¹; ¹JP, ²Minami-li, Sagamihara/JP, ³Aomori/JP

- 12:45 - 12:45 **686P - Immune gene expression profiling (GEP) of resected gastric adenocarcinomas (GAs) to identify biomarkers associated with immune checkpoint inhibitor (ICPI) response in early stage disease**
J. Chao¹, H. Yin¹, J. Lee², S. Klempner³, R. Pillai¹; ¹US, ²KR, ³CA/US
- 12:45 - 12:45 **687P - Significant prognostic markers related to lymphocytes in gastric cancer**
T. Hashimoto¹, Y. Kurokawa², T. Takahashi¹, Y. Miyazaki², K. Tanaka¹, T. Makino¹, M. Yamasaki¹, K. Nakajima¹, M. Mori¹, Y. Doki¹; ¹JP, ²Osaka/JP
- 12:45 - 12:45 **688P - Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers**
M. Ratti¹, N. Valeri², J.C. Hahne², A. Lampis², M. Ghidini³, G. Tomasello⁴, G. Tanzi¹, L. Toppo¹, C. Pizzo¹, B. Donida¹, C. Senti¹, M. Salati¹, M. Trombatore¹, M. Fassan¹, R. Passalacqua⁴; ¹IT, ²GB, ³(MI)/IT, ⁴(CR)/IT
- 12:45 - 12:45 **689P - Neutrophil-lymphocyte ratio (NLR) as an important prognostic factor for paclitaxel as a second line chemotherapy in advanced gastric cancer (AGC): Results from phase III DREAM study**
M.-H. Ryu¹, J.H. Kim¹, S.C. Oh¹, S. Park¹, J.G. Kim¹, J.W. Kim¹, S.-H. Cho¹, K.-E. Yoon¹, Y.-K. Kang²; ¹KR, ²Songpa-gu/KR
- 12:45 - 12:45 **690P - Combination versus single-agent as palliative chemotherapy for gastric cancer: Significance of age and platelet-to-lymphocyte ratio**
M.S. Ahn, Y.W. Choi, H. Lee, S.Y. Kang, J.-H. Choi; KR
- 12:45 - 12:45 **691P - Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial**
A. Slagter, K. Sikorska, C. Grootsholten, H. van Laarhoven, H. Boot, E. Meershoek-Klein Kranenbarg, C. van de Velde, N. van Grieken, E. Jansen, M. Verheij, A. Cats; NL
- 12:45 - 12:45 **692P - The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients**
T. Hayashi, T. Oshima, K. Hara, Y. Shimoda, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Yoshikawa; JP
- 12:45 - 12:45 **693P - Gastric cancer in young patients**
M.M. Seker, A. Bahceci, T. Kacan; TR
- 12:45 - 12:45 **694P - Differences in presentation and outcomes among young and old patients with gastric cancer**
M. Al Otaibi, J. Al Barak, J. Al Abbad, A. Akbar; KW
- 12:45 - 12:45 **695P - Prospective observational cohort study of oesophagogastric cancer patients (POCOP): A Dutch nationwide cohort**

I.J. van Kleef, L. van de Poll-Franse, R. Verhoeven, M. Slingerland, J. Ruurda, J. Heisterkamp, C. Rosman, J.W. de Groot, E. Kouwenhoven, M. van Dijk, E. de Graaf, T. van Voorthuizen, F. Daams, S. Lagarde, G. Nieuwenhuijzen, J. Vincent, M. van Berge Henegouwen, M. van Oijen, M. Sprangers, H. van Laarhoven; NL

- 12:45 - 12:45 **697P - A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma**
A.-L. Cheng¹, C.-J. Yen¹, T. Okusaka², M. Ikeda³, C.-H. Hsu¹, S.-Y. Wu¹, C. Morizane², Y. Hashimoto², K. Ueshima², T. Ohtomo², T. Tanaka², M. Kudo²; ¹TW, ²JP, ³Chiba/JP
- 12:45 - 12:45 **698P - Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)**
T. Decaens¹, C. Barone², E. Assenat¹, M. Wermke³, A. Fasolo², P. Merle¹, J.F. Blanc¹, V. Grando¹, R. Bruns³, J. Straub³, C. Zhao⁴, S. Faivre¹; ¹FR, ²IT, ³DE, ⁴US
- 12:45 - 12:45 **699P - Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma**
S.E. Yoon, J.Y. Hur, K.K. Lee, S.J. Lee, J. Lee, S. Paik, H.Y. Lim; KR
- 12:45 - 12:45 **700P - Stemness in hepatocellular carcinoma reduced by inhibition of WEE1 expression**
K.U. Park, M.J. Ko, H.M. Ryoo, Y.-H. Lee; KR
- 12:45 - 12:45 **701P - Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)**
K. Köchert¹, G. Meinhardt², J. Bruix³, M. Teufel²; ¹DE, ²NJ/US, ³ES
- 12:45 - 12:45 **702P - Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)**
R. Kelley¹, A. El-Khoueiry², T. Meyer³, L. Rimassa⁴, P. Merle⁵, S. Chan⁶, A. Tran⁶, F. Parnis⁷, V. Tam⁸, S. Cattani⁵, D. Markby², D. Clary², A.-L. Cheng⁹, G. Abou-Alfa¹⁰; ¹CA/US, ²US, ³GB, ⁴IT, ⁵FR, ⁶CN, ⁷AU, ⁸CA, ⁹TW, ¹⁰NY/US
- 12:45 - 12:45 **703P - Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)**
J.F. Blanc¹, T. Meyer², A.-L. Cheng³, A. El-Khoueiry⁴, I. Cicin⁵, Y. Chen³, L. Bolondi⁶, V. Dadduzio⁶, A. Baron⁴, Z.-Z. Lin³, J. Adriani⁴, R. Kelly⁴, G. Abou-Alfa⁷; ¹FR, ²GB, ³TW, ⁴US, ⁵TR, ⁶IT, ⁷NY/US
- 12:45 - 12:45 **704P - Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)**

T. Yau¹, A.-L. Cheng², T. Meyer³, B.-Y. Ryoo⁴, J.-W. Park⁵, H.-J. Klumpen⁶, H.Y. Lim⁵, S. Kim⁷, J. Knox⁸, M. Patel⁹, A. El-Khoueiry¹⁰, R. Kelley⁹, G. Abou-Alfa¹¹; ¹CN, ²TW, ³GB, ⁴Songpa-gu/KR, ⁵KR, ⁶NL, ⁷FR, ⁸ON/CA, ⁹CA/US, ¹⁰US, ¹¹NY/US

- 12:45 - 12:45 **705P - Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib**
L. Fonseca¹, A. Díaz², V. Sapena², Á. Díaz-González², L. Boix², M. Sanduzzi-Zamparelli², C. Fuster², N. Llarch², G. Iserte², F. Torres², J. Bruix², M. Reig²; ¹SP/BR, ²ES
- 12:45 - 12:45 **706P - Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database**
D. Meyers¹, R. Lee-Ying¹, M. Alghamdi¹, H.-W. Sim², V. Zaborska¹, Y.-J. Ko¹, T. Raycraft¹, E. Batuyong¹, W. Cheung³, H. Samawi¹, J. Davies¹, V. Tam¹; ¹CA, ²Ontario/CA, ³AB/CA
- 12:45 - 12:45 **707P - Efficacy and safety of sorafenib (SFN) in elderly patients with hepatocellular carcinoma (HCC)**
L. Gomes Da Fonseca, G. Nader Marta, M.I. Braghiroli, P. M. Hoff, J. Sabbaga; BR
- 12:45 - 12:45 **708P - Relationship between change in α-fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): A real-world electronic medical records (EMR) database study**
L. Hess¹, Z. Cui¹, T. Sugihara¹, Y. Fang¹, A. Girvan², P. Abada¹; ¹US, ²IN/US
- 12:45 - 12:45 **709P - Antiviral therapy improves outcomes after radiofrequency ablation for HBV-related hepatocellular carcinoma: A propensity score matching analysis**
K. Wang, F. Shen, J. Liu, Z. Yan, J. Li, Y. Xia, L. Shi, G. Qian, Z. Lu, Y. Chen, X. Wan, M. Wu, Y. Zhang; CN
- 12:45 - 12:45 **710P - Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada**
J.-L. Raoul¹, T. Decaens², K. Burak³, J. Koskinas⁴, G.E. Villadsen⁵, A. Heurgue-Berlot², I. Bayh⁶, A.-L. Cheng⁷, M. Kudo⁸, H.C. Lee⁹, K. Nakajima¹⁰, M. Peck-Radosavljevic¹¹; ¹CEDEX/FR, ²FR, ³AB/CA, ⁴GR, ⁵DK, ⁶DE, ⁷TW, ⁸JP, ⁹KR, ¹⁰NJ/US, ¹¹AT
- 12:45 - 12:45 **711P - Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy**
M. Pracht¹, E. Chajon², T. de Baere², F. Nguyen², J.-P. Bronowicki², V. Vendrely², A.-S. Baumann², V. Croisé-Laurent², E. Rio², Y. Rolland², S. Le Sourd¹, P. Gustin², C. Perret², F. Mornex¹, D. Peiffert², P. Merle², E. Deutsch¹; ¹CEDEX/FR, ²FR
- 12:45 - 12:45 **712P - Molecular profiling of PDAC and response to chemotherapy: An update from the COMPASS trial**
G. O'Kane¹, S. Fischer¹, R. Denroche¹, G.H. Jang¹, A. Zhang¹, A. Dodd¹, H. Albaba¹, S. Moura¹, S. Holter², K. Aung¹, R. Grant¹, P. Krzyzanowski¹, E. Elimova¹, N. Dhani¹, D. Hedley¹, F. Notta¹, J. Wilson¹, S. Gallinger¹, J. Knox¹; ¹CA, ²ON/CA

- 12:45 - 12:45 **713P - Analysis of BRCAness with MLPA in pancreatic ductal adenocarcinoma patients using FFPE sample obtained via EUS-FNAB**
K. Okuwaki¹, H. Imaizumi¹, H. Masutani¹, T. Yoshida¹, M. Kida¹, T. Iwai¹, H. Yamauchi¹, T. Kaneko¹, R. Hasegawa¹, E. Miyata¹, K. Adachi¹, M. Tadehara¹, W. Koizumi²; ¹JP, ²Minami-li, Sagamihara/JP
- 12:45 - 12:45 **714P - Repeated mutKRAS ctDNA measurements in patients with advanced pancreatic cancer patients: Kinetics, response prediction and therapy monitoring in comparison to protein-based tumor markers**
S. Kruger, V. Heinemann, C. Ross, F. Diehl, S. Ormanns, S. Liebmann, C. Westphalen, M. Haas, A. Jung, T. Kirchner, M. von Bergwelt-Baildon, S. Holdenrieder, S. Boeck; DE
- 12:45 - 12:45 **715P - Clinical utility of plasma cell-free DNA in patients with pancreatic cancer**
I. Chen, K. Wind, C. Dehlendorff, B. Sørensen, B. Vittrup, A. Johansen, P. Pfeiffer, J. Bjerregaard, S. Bojesen, S. Nielsen, N. Holländer, M. Yilmaz, L. Rasmussen, N. Pallisgaard, J. Johansen, K.-L. Spindler; DK
- 12:45 - 12:45 **716P - Cell free tumor-DNA can predict treatment outcome in advanced PDAC**
S. Payr, J. Beck, U. König, M. Brunner, J. Gaedcke, A. Azizian, M. Ghadimi, V. Ellenrieder, E. Schütz, A.-O. König; DE
- 12:45 - 12:45 **717P - Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX**
A. Sehdev¹, O. Gbolahan², B. Hancock², M. Stanley², S. Shahda¹, J. Wan², H. Wu², M. Radovich², B. O'Neil¹; ¹US, ²IN/US
- 12:45 - 12:45 **718P - A three-gene signature to predict lymph node metastasis of pancreatic cancer**
C. Liang, X. Yu; CN
- 12:45 - 12:45 **719P - Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)**
M. Haas, D. Waldschmidt, M. Stahl, A. Reinacher-Schick, J. Freiberg-Richter, F. Kaiser, S. Kanzler, N. Frickhofen, T. Seufferlein, T. Dechow, R. Mahlberg, P. Malfertheiner, G. Illerhaus, S. Kubicka, S. Held, C. Westphalen, S. Kruger, S. Boeck, V. Heinemann; DE
- 12:45 - 12:45 **720P - SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component**
S. Mukherjee¹, P. Virdee¹, R. Shaw¹, J. Bridgewater¹, G. Radhakrishna¹, S. Falk¹, M. Scott-Brown¹, V. Strauss¹, C. Brooks¹, R. Gillmore¹, N. Patel¹, B. Tranter¹, P. Parsons¹, D. Sebag-Montefiore¹, M. Hawkins¹, P. Corrie², T. Maughan¹; ¹GB, ²Cambridgeshire/GB
- 12:45 - 12:45 **721P - A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer**

E. MIYATA¹, K. Okuwaki¹, H. Imaizumi¹, M. Kida¹, T. Iwai¹, H. Yamauchi¹, T. Kaneko¹, R. Hasegawa¹, K. Adachi¹, M. Tadehara¹, W. Koizumi²; ¹JP, ²Minami-li, Sagamihara/JP

- 12:45 - 12:45 **722P - Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer**
J. Taieb¹, J.M. Phelip², Y. Rinaldi¹, E. Barbier¹, O. Bouche¹, F. Khemissa Akouz¹, A. Grattet¹, C. Petorin³, L. Miglianico¹, D. Malka¹, H. Laharie Mineur¹, C. Rebischung⁴, C. Lepage⁵, E. Francois⁶, L. Dahan¹; ¹FR, ²cédex 2/FR, ³CEDEX 1/FR, ⁴CEDEX 9/FR, ⁵Cedex/FR, ⁶CEDEX 2/FR
- 12:45 - 12:45 **723P - First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe**
J. Taieb¹, A. Carrato², B. Westphalen³, D. Melisi⁴, G. Prager⁵, T. Macarulla Mercade², Å. Mellbring⁶, N. d'Esquermes¹, A. Ferreras¹, F. de Jong⁷; ¹FR, ²ES, ³DE, ⁴IT, ⁵AT, ⁶SE, ⁷CH
- 12:45 - 12:45 **724P - Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)**
E.G. Chiorean¹, W. Cheung², G. Giordano³, G. Kim⁴, S.-E. Al-Batran⁵; ¹WA/US, ²AB/CA, ³IT, ⁴FL/US, ⁵DE
- 12:45 - 12:45 **725P - Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis**
K. Lee¹, I. Hwang¹, J. Kang¹, C. Yoo², K.-P. Kim¹, J.H. Jeong¹, H.-M. Chang³, B.-Y. Ryoo²; ¹KR, ²Songpa-gu/KR, ³KP
- 12:45 - 12:45 **726P - FOLFIRINOX for recurrent pancreatic cancer after resection: Nationwide multicenter observational study by Japan adjuvant study group of pancreatic cancer (JASPAC)**
S. Morinaga¹, M. Takita¹, A. Yoshizawa¹, K. Kamei¹, S. Nakamori¹, S. Ishihara¹, H. Kuramochi¹, Y. Yokoyama¹, T. Uchiyama¹, G. Murohisa¹, M. Kobayashi¹, A. Todaka¹, A. Fukutomi²; ¹JP, ²Shizuoka/JP
- 12:45 - 12:45 **727P - A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer**
S.J. Lee, D.-Y. Oh, J.-H. Kang, H.J. Choi, M.A. Lee, S.Y. Oh, S.-T. Kim, Y.S. Park, B.-Y. Ryu, J.O. Park; KR
- 12:45 - 12:45 **728P - Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis**
Y. Zhang, S. Shi, X. Yu; CN

- 12:45 - 12:45 **729P - Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)**
I. Hwang¹, J. Kang¹, C. Yoo², J.H. Jeong¹, K.-P. Kim¹, H.-M. Chang³, B.-Y. Ryoo²; ¹KR, ²Songpa-gu/KR, ³KP
- 12:45 - 12:45 **730P - A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis**
K. Yu¹, S. Mantha¹, C. Tjan¹, E. Kaufmann¹, R. Brenner¹, M. Lowery¹, G. Ku¹, N. Raj¹, M. Shcherba¹, Z. Goldberg¹, J. Li¹, A. Zervoudakis¹, A. Hamilton¹, E. Won¹, R. Do¹, E. O'Reilly²; ¹US, ²NY/US
- 12:45 - 12:45 **731P - Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)**
H. Takahashi¹, C. Morizane², S. Nomura², N. Okano³, M. Tsuda², N. Mizuno², H. Satake⁴, K. Tsuji², K. Shioji², H. Ishii², K. Yasui², H. Miyakawa², A. Ishiguro², T. Ogura², M. Ueno², A. Ikeda², T. Terashima⁵, M. Ikeda¹, T. Okusaka², J. Furuse³; ¹Chiba/JP, ²JP, ³Tokyo/JP, ⁴Hyogo/JP, ⁵Ishikawa/JP
- 12:45 - 12:45 **732P - GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: Results from a phase II study**
A. Passardi¹, E. Scarpì², E. Neri², E. Parisi², G. Ghigi², G. Ercolani², A. Gardini², G. La Barba², F. Pagan², A. Casadei Gardini², L. Frassinetti¹, F. Ferroni², M. Valgiusti², S. Darwish³, A. Romeo²; ¹Forlì-Cesena/IT, ²IT, ³EG
- 12:45 - 12:45 **733P - NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)**
T. Macarulla Mercade¹, G. Bodoky², J. Siveke³, K.-H. Lee⁴, J. Chen⁵, B. Mirakhur⁶, A. Dean⁷, L.-T. Chen⁸, F. de Jong⁹; ¹ES, ²HU, ³DE, ⁴KR, ⁵MA/US, ⁶NJ/US, ⁷WA/AU, ⁸TW, ⁹CH
- 12:45 - 12:45 **734P - Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI) and 5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1**
L.-T. Chen¹, T. Macarulla², J. Blanc³, B. Mirakhur⁴, F. de Jong⁵, B. Belanger⁴, T. Bekaii-Saab⁶, J. Siveke⁷; ¹TW, ²ES, ³FR, ⁴US, ⁵CH, ⁶AZ/US, ⁷DE
- 12:45 - 12:45 **735P - Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics**
D. Ahn¹, A. Barzi², R. Miksad³, A. Surinach⁴, F. Corvino⁴, A. Valderrama⁵, K. Mamlouk⁵, S. Pulgar⁵, T. Bekaii-Saab¹; ¹AZ/US, ²CA/US, ³NY/US, ⁴US, ⁵NJ/US
- 12:45 - 12:45 **736P - Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study**

N.-J. Chiang, K.K. Tsai, J.-S. Chen, S.-H. Yang, H.-H. Hsiao, Y.-S. Shan, L.-T. Chen; TW

- 12:45 - 12:45 **737P - A phase II trial of gemcitabine, S-1 and LV combination therapy in patients with advanced pancreatic cancer**
K. Saito, Y. Nakai, H. Isayama, K. Ishigaki, T. Saito, N. Takahara, S. Mizuno, H. Kogure, K. Koike; JP
- 12:45 - 12:45 **738P - Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer**
Y. Sunakawa, H. Arai, N. Izawa, T. Mizukami, Y. Horie, A. Doi, M. Hirakawa, T. Ogura, T. Tsuda, T. Nakajima; JP
- 12:45 - 12:45 **739P - Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON**
C. Schönherr¹, T. Götze¹, G. zur Hausen¹, A. Reichart¹, C. Pauligk¹, R. Schlag², G. Siegler¹, S. Dörfel¹, A. Aldaoud¹, L. Hahn¹, J. Schubert¹, M.-O. Zahn¹, H.-G. Höffkes¹, M. Reiser¹, M. Koenigsmann¹, W. Blau¹, O. Waidmann¹, N. Homann¹, J. Trojan¹, S.-E. Al-Batran¹; ¹DE, ²Bayern/DE
- 12:45 - 12:45 **740P - Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC**
G. Chiritescu¹, K. Dumon¹, C. Verslype¹, G. Houbiers¹, M. Peeters¹, J. Janssens¹, D. van Daele¹, S. Laurent¹, J. Arts², K. Hendrickx³, I. Borbath¹, M. Ferrante¹, F. Bastin¹, J.-C. Goeminne¹, J.-L. van Laethem¹, E. Vanderstraeten¹, J. Decaestecker¹, W. van Vaerenbergh¹, B. Delhougne¹, E. van Cutsem¹; ¹BE, ²Assebroek/BE, ³Oost VI/BE
- 12:45 - 12:45 **741P - Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR)**
T. Macarulla Mercade¹, A. Hendifar², C.-P. Li³, M. Reni⁴, H. Riess⁵, M. Tempero⁶, A. Dueck⁷, M. Botteman⁸, C. Deshpande⁸, E. Lucas⁸, D.-Y. Oh⁹; ¹ES, ²CA/US, ³TW, ⁴IT, ⁵DE, ⁶US/US, ⁷AZ/US, ⁸US, ⁹KR
- 12:45 - 12:45 **742P - Outcome following centralisation of pancreatic cancer care in Ireland**
R. Abdul Rahman¹, M. Moriarty², G. McVey², P. Ridgway², D. Maguire², E. Hoti², J. Geoghegan², K. Conlon², R. McDermott¹; ¹Belgard Square North/IE, ²IE
- 12:45 - 12:45 **743P - Initial treatment and survival in a national unselected Danish cohort of 4161 patients with pancreatic cancer**
L. Rasmussen, B. Vittrup, M. Ladekarl, P. Pfeiffer, M. Yilmaz, L. Poulsen, K. Østerlind, H. Skuladottir, C. Hansen, M. Mortensen, F. Mortensen, M. Sall, U. Falkmer, C. Fristrup; DK
- 12:45 - 12:45 **744P - Trends of care of non-metastatic pancreas cancer patients in Ireland**
R. Abdul Rahman¹, G. McVey², M. Moriarty², D. Maguire², E. Hoti², P. Ridgway², K. Conlon², J. Geoghegan², R. McDermott¹; ¹Belgard Square North/IE, ²IE

- 12:45 - 12:45 **745P - Anti-hypertensive medication, sRAGE, and risk of pancreatic cancer: Results from the women's health initiative study**
Z. Wang, D. White, L. Chen, E. Whitsel, P. Richardson, J. Garcia, H. El-Serag, L. Jiao; US
- 12:45 - 12:45 **746P - Usefulness of the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic cancer and its risk diseases**
Y. Sato, T. Kobayashi, S. Nishiumi, S. Okaya, M. Yoshida, Y. Kodama, K. Nagashima, K. Honda; JP
- 12:45 - 12:45 **747P - Survival-associated factors and a prognostic nomogram in resected pancreatic cancer: A large international population-based cohort study**
L. Huang¹, Y. Balavarca¹, L. van der Geest², V. Lemmens², L. van Eycken³, H. De Schutter³, T. Johannesen⁴, V. Zadnik⁵, M. Primic-Žakelj⁵, M. Mägi⁶, R. Grützmänn¹, M. Besselink², P. Schrotz-King¹, H. Brenner¹, L. Jansen¹; ¹DE, ²NL, ³BE, ⁴NO, ⁵SI, ⁶EE
- 12:45 - 12:45 **748P - Predicting survival of pancreatic cancer using supervised machine learning**
M. Osman, EG
- 12:45 - 12:45 **749P - The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI);5-fluorouracil and leucovorin (5-FU/LV)**
L.-T. Chen¹, T. Macarulla², B. Belanger³, B. Mirakhur⁴, F. de Jong⁵, J. Siveke⁶; ¹TW, ²ES, ³MA/US, ⁴NJ/US, ⁵CH, ⁶DE
- 12:45 - 12:45 **750P - Prognostic value of the neutrophil-lymphocyte ratio and CA 19-9 in predicting survival inpatients with metastatic pancreatic cancer**
I. Dede, M. Cetin, S. Cetin; TR
- 12:45 - 12:45 **751P - Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)**
R. Pihlak, R. Almond, P. Srivastava, H. Raja, R. Broadbent, L. Hopewell, C. Higham, A. Lamarca, R. Hubner, J. Valle, M. McNamara; GB
- 12:45 - 12:45 **752P - Clinical utility of serum type III collagen in patients with pancreatic carcinoma**
I. Chen, N. Willumsen, C. Dehlendorff, A. Johansen, B. Vittrup, M. Krüger, P. Pfeiffer, J. Bjerregaard, S. Bojesen, S. Nielsen, N. Holländer, M. Yilmaz, L. Rasmussen, M. Karsdal, J. Johansen; DK
- 12:45 - 12:45 **753P - Venous thromboembolism in Asian patients with pancreatic cancer who underwent palliative chemotherapy: Low prevalence, but a poor prognostic factor for early onset**
W.-C. Chou¹, J.-S. Chen¹, Y.-Y. Chen¹, C.-H. Lu², P.-H. Chang¹; ¹TW, ²Chiayi County/TW

- 12:45 - 12:45 **754P - Targeted therapy based on the genetic alterations prolongs the progression-free survival of patients with advanced biliary tract cancer**
F. Feng, Q. Cheng, D. Zhang, B. Li, H. Qin, C. Xu, M. Han, Y. Yu, Z. Li, J.-Y. Li, Z. Qiu, L. Xiong, C. Liu, F. Li, B. Yi, X. Jiang; CN
- 12:45 - 12:45 **755P - Evaluation of genetic alterations in biliary tract cancer using targeted exome sequencing**
H. Chae¹, C. Yoo², D. Kim¹, J.H. Jung¹, H.-M. Chang³, B.-Y. Ryoo², K.-P. Kim¹; ¹KR, ²Songpa-gu/KR, ³KP
- 12:45 - 12:45 **756P - Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations**
A. Hollebecque¹, M. Borad², V. Sahai³, D. Catenacci⁴, A. Murphy³, G. Vaccaro³, A. Paulson³, D.-Y. Oh⁵, L. Féliz⁶, C. Lihou³, H. Zhen³, G. Abou-Alfa⁷; ¹FR, ²AZ/US, ³US, ⁴IL/US, ⁵KR, ⁶CH, ⁷NY/US
- 12:45 - 12:45 **757P - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial**
C. Yoo¹, D.-Y. Oh², H.J. Choi², M. Kudo³, M. Ueno³, S. Kondo³, L.-T. Chen⁴, M. Osada³, C. Helwig⁵, I. Dussault⁶, M. Ikeda⁷; ¹Songpa-gu/KR, ²KR, ³JP, ⁴TW, ⁵DE, ⁶MA/US, ⁷Chiba/JP
- 12:45 - 12:45 **758P - A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)**
M. McNamara, J. Bridgewater, D. Palmer, H. Wasan, W.D. Ryder, C. Gnanaranjan, E. Ghazaly, T.R.J. Evans, J. Valle; GB
- 12:45 - 12:45 **759P - Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer**
J.S. YOON, K.-H. Lee, G.J. Cheon, Y.-J. Bang, D.-Y. Oh; KR
- 12:45 - 12:45 **760P - PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial**
J. Trojan¹, R. Sturgess², D. Harrison Palmer², B. Neu¹, S. Kasper¹, A. Dechene¹, C. Jürgensen¹, J. Schirra¹, R. Jakobs¹, A. Högset³, L. Finnesand³, H. Olivecrona³; ¹DE, ²GB, ³NO
- 12:45 - 12:45 **761P - FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)**
A. Ulusakarya, W. Karray, J. Abdou, A. Karaboué, M. Haydar, S. Krimi, Y. Gumus, W. Almohamad, E. Goldschmidt, P. Biondani, J.F. Morère; FR
- 12:45 - 12:45 **763P - Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis**

S. Yadav¹, H. Xie², I. Riaz², P. Sharma³, A. Mahipal⁴, R. McWilliams¹; ¹US, ²MN/US, ³CT/US, ⁴FL/US

- 12:45 - 12:45 **762P - A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)**
H. Terajima¹, S. Kobayashi¹, H. Nagano¹, A. Tomokuni¹, K. Gotoh¹, D. Sakai¹, E. Hatano¹, S. Seo¹, Y. Uchida¹, T. Ajiki¹, H. Satake², K. Kamei¹, T. Tohyama¹, T. Hirose¹, I. Ikai¹, S. Morita¹, T. Ioka¹; ¹JP, ²Hyogo/JP
- 12:45 - 12:45 **764P - Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience**
V. Dadduzio¹, M. Rizzato¹, G. Ramondo¹, C. Vivaldi¹, M. Milella¹, G. Brandi¹, S. Cereda¹, S. Murgioni², G. Cardellino¹, R. Filippi³, D. Santini¹, G. Pasquini¹, R. Intini¹, V. Vaccaro¹, A. Palloni¹, M. Reni¹, G. Musettini¹, E. Gringeri¹, C. Aliberti¹, V. Zagonel¹; ¹IT, ²OG/IT, ³(TO)/IT
- 12:45 - 12:45 **765P - Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations**
C. Neuzillet¹, A. Casadei Gardini², B. Brieu³, C. Vivaldi², C. Smolenschi¹, G. Brandi², D. Tougeron⁴, R. Filippi⁵, A. Vienot¹, N. Silvestris², A.-L. Pointet¹, S. Murgioni⁶, B. Rousseau⁴, M. Scartozzi², L. Dahan¹, T. Boussaha⁷, S. Crusz⁸, A. Meurisse¹, A. Lievre¹, D. Vernerey¹; ¹FR, ²IT, ³CEDEX 14/FR, ⁴CEDEX/FR, ⁵(TO)/IT, ⁶OG/IT, ⁷Vaud/CH, ⁸GB
- 12:45 - 12:45 **766P - Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)**
J. Hyung¹, C. Yoo², K.-P. Kim¹, B.J. Kim¹, J.H. Jeong¹, H.-M. Chang³, B.-Y. Ryoo²; ¹KR, ²Songpa-gu/KR, ³KP
- 12:45 - 12:45 **767P - Predictive factors of outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy**
Y. Suzuki¹, M. Kan¹, G. Kimura¹, K. Umemoto¹, K. Watanabe¹, M. Sasaki¹, H. Takahashi¹, Y. Hashimoto¹, H. Imaoka¹, I. Ohno¹, S. Mitsunaga¹, M. Ikeda²; ¹JP, ²Chiba/JP
- 12:45 - 12:45 **768P - Nomograms predicting survival of patients with advanced or recurrent biliary tract cancer receiving a first-line chemotherapy**
N. Takahara, Y. Nakai, K. Saito, M. Sato, H. Ooyama, S. Kanai, T. Suzuki, T. Sato, R. Hakuta, K. Ishigaki, T. Takeda, S. Mizuno, H. Kogure, M. Tada, K. Koike; JP
- 12:45 - 12:45 **769P - Stromal progesterone receptor expression and long-term survival in patients with resected periampullary adenocarcinoma**
G. Andersson, S. Olsson-Hau, S. Lundgren, M. Heby, B. Nodin, K. Jirstrom; SE

- 12:45 - 12:45 **770P - A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht)**
M. Salati, F. Caputo, A. Spallanzani, M. Rimini, F. Gelsomino, K. Andrikou, S. Cascinu; IT
- 12:45 - 12:45 **771P - &&**
T. Götze, V. Paolucci, S.-E. Al-Batran; DE
- 12:45 - 12:45 **772P - ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort**
T. Aparicio¹, S. Manfredi¹, D. Tougeron¹, J. Henriques², O. Bouche², D. Pezet², G. Piessen², R. Coriat³, A. Zaanani², J.L. Legoux², E. Terrebone², M. Pocard², J.-M. Gornet⁴, D. Vernerey², P. Afchain²; ¹CEDEX/FR, ²FR, ³CEDEX 14/FR, ⁴CEDEX 10/FR
- 12:45 - 12:45 **773P - Impact of the number of nodes examined on survival in node negative small bowel adenocarcinoma: A SEER database analysis**
M. Thiessen, P. Tang, R. Lee-Ying, J. Monzon; CA
- 12:45 - 12:45 **774P - The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome**
G. Orsi¹, K. Andrikou¹, F. Bergamo¹, F. Nappo¹, C. Manai¹, A. Passardi², M. Puzzone¹, S. Vallarelli¹, M. Libertini¹, M.L. Riggi¹, G. Pugliese¹, A. Zaniboni¹, M. Schirripa¹, L. Procaccio¹, N. Silvestris¹, M. Scartozzi¹, A. Casadei Gardini¹, V. Zagonel¹, S. Cascinu¹; ¹IT, ²Forlì-Cesena/IT
- 12:45 - 12:45 **775TiP - A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)**
L. Shen¹, J. Ajani², S.-B. Kim³, E. van Cutsem⁴, B. Guo¹, J. Song⁵, V. Paton⁶, K. Kato⁷; ¹CN, ²TX/US, ³KR, ⁴BE, ⁵NJ/US, ⁶CA/US, ⁷JP
- 12:45 - 12:45 **776TiP - Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress**
S. Qin¹, R. Finn², M. Kudo³, T. Meyer⁴, A. Vogel⁵, M. Ducreux⁶, T. Macarulla⁷, G. Tomasello⁸, F. Boissier⁹, J. Hou², C. Li¹, J. Song⁹, A. Zhu¹⁰; ¹CN, ²CA/US, ³JP, ⁴GB, ⁵DE, ⁶CEDEX/FR, ⁷ES, ⁸(CR)/IT, ⁹NJ/US, ¹⁰US
- 12:45 - 12:45 **777TiP - A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy**
F. Ciardiello¹, Y.-J. Bang², J. Bendell³, A. Cervantes⁴, R. Brachmann⁵, K. Zhang⁵, M. Raponi⁵, H. Farin⁶, L. Shen⁷; ¹IT, ²KR, ³TN/US, ⁴ES, ⁵CA/US, ⁶MA/US, ⁷CN

- 12:45 - 12:45 **778TiP - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastatic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)**
E. Goekkurt, M. Binder, S. Lorenzen, P. Thuss-Patience, S.-E. Al-Batran, A. Hinke, S. Hegewisch-Becker, S. Nilsson, C. Bokemeyer, A. Stein; DE
- 12:45 - 12:45 **779TiP - TRIANgLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus**
H. Daiko, H. Hara, H. Ogawa, K. Hori, J. Mizusawa, S. Ozawa, M. Takagi, M. Tanaka, H. Baba, Y. Shirakawa, M. Tsuda, S. Nakagawa, H. Takeuchi, T. Abe, Y. Ito, T. Kojima, T. Kadota, H. Fukuda, K. Kato, Y. Kitagawa; JP
- 12:45 - 12:45 **780TiP - Phase II trial of perioperative PD-L1 inhibition with avelumab and mDCF chemotherapy for resectable locally advanced gastric and esophago-gastric adenocarcinoma**
T. Alcindor, A. Awan, T. Opu, J. Asselah, M. Vanhuyse, C. Mueller, L. Ferri; CA
- 12:45 - 12:45 **781TiP - PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)**
M. Ducreux¹, R. Desgrippes², M. Texier², F. Di Fiore², P. Vanelslander², O. Capitain², R. Guimbaud³, J. Forestier², F. El Hajbi¹, P. Follana⁴, A. Parzy², N. Baba Hamed², Y. Rinaldi², T. Brotelle², J.-P. Pignon¹, C. Jouffroy², L. Dahan², O. Bouche²; ¹CEDEX/FR, ²FR, ³CEDEX 3/FR, ⁴CEDEX 2/FR
- 12:45 - 12:45 **782TiP - Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150**
M. Ducreux¹, A.-L. Cheng², S. Qin³, A. Zhu⁴, M. Ikeda⁵, T.-Y. Kim⁶, D.-Z. Xu³, W. Verret⁴, J. Liu³, R. Finn⁷, P. Galle⁸; ¹CEDEX/FR, ²TW, ³CN, ⁴US, ⁵JP, ⁶KR, ⁷CA/US, ⁸DE
- 12:45 - 12:45 **783TiP - CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation**
M. Jimenez Exposito¹, M. Akce¹, J. Montero Alvarez², E. Assenat³, L. Balart¹, A. Baron⁴, T. Decaens³, A. Heurgue-Berlot³, A. Martin², S. Paik⁵, V. Poulart⁶, A. Sehbai¹, N. Takemura⁷, J.-H. Yoon⁵; ¹US, ²ES, ³FR, ⁴CA/US, ⁵KR, ⁶BE, ⁷JP
- 12:45 - 12:45 **784TiP - Phase III KEYNOTE-585 study of chemotherapy (Chemo) &&**
Y.-J. Bang¹, E. van Cutsem², C. Fuchs³, A. Ohtsu⁴, J. Tabernero⁵, D. Ilson⁶, W.J. Hyung¹, V.E. Strong⁶, T.O. Goetze⁷, T. Yoshikawa⁴, L. Tang⁶, P.M.T. Hwang⁶, D. Adelberg⁸, K. Shitara⁴; ¹KR, ²BE, ³CT/US, ⁴JP, ⁵ES, ⁶NY/US, ⁷DE, ⁸NJ/US
- 12:45 - 12:45 **785TiP - Phase III KEYNOTE-590 study of chemotherapy &&**

K. Kato¹, M. Shah², P. Enzinger³, J. Bennouna⁴, L. Shen⁵, A. Adenis⁴, J.-M. Sun⁶, B.C. Cho⁶, M. Ozguroglu⁷, T. Kojima¹, V. Kostorov⁸, C. Hierro⁹, Y. Zhu¹⁰, S. Shah¹⁰, P. Bhagia¹⁰, T. Doi¹¹; ¹JP, ²NY/US, ³MA/US, ⁴FR, ⁵CN, ⁶KR, ⁷TR, ⁸RU, ⁹ES, ¹⁰NJ/US, ¹¹Chiba/JP

- 12:45 - 12:45 **786TiP - Prospective multicenter feasibility study of laparoscopic sentinel basin dissection after endoscopic submucosal dissection for early gastric cancer**
K.W. Ryu, B.W. Eom, H.M. Yoon, Y.-W. Kim, J.S. Min, G.S. Cho, I. Cho, Y.J. Lee, J.-H. Park, H. Hur, Y.K. Park, O. Jeong, M.R. Jung, J.H. Lee, J.Y. An; KR
- 12:45 - 12:45 **787TiP - A phase III study of adjuvant docetaxel, capecitabine and oxaliplatin triplet vs capecitabine and oxaliplatin doublet in patients with curatively resected stage IIIB or IV(M0) (AJCC 6th ed) gastric adenocarcinoma (TRIUMPH, KCSG ST14-05)**
M.-H. Ryu¹, D.Y. Zang¹, K.-W. Lee¹, B.Y. Shim¹, M.H. Lee¹, S.Y. Rha¹, Y.-K. Kang²; ¹KR, ²Songpa-gu/KR
- 12:45 - 12:45 **788TiP - ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma**
D. Harrison Palmer¹, P. Ross¹, P. Silcocks¹, W. Greenhalf¹, O. Faluyi¹, Y.T. Ma¹, J. Wadsley¹, C. Rawcliffe¹, J. Neoptolemos², J. Valle¹, H. Wasan¹, N. Starling¹, K. Patel¹, J. Bridgewater¹; ¹GB, ²DE
- 12:45 - 12:45 **789TiP - HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA)**
E. van Cutsem¹, P. Corrie², M. Ducreux³, D. Sigal⁴, V. Sahai⁴, D.-Y. Oh⁵, A. Bullock⁶, Y.-J. Bang⁵, A. Baron⁷, A. Hendifar⁷, C.-P. Li⁸, P. Philip⁴, M. Reni⁹, M. Zalupski¹⁰, L. Zheng¹¹, C. Berman⁴, D. Chondros⁷, M. Tempero¹²; ¹BE, ²Cambridgeshire/GB, ³CEDEX/FR, ⁴US, ⁵KR, ⁶MA/US, ⁷CA/US, ⁸TW, ⁹IT, ¹⁰MI/US, ¹¹MD/US, ¹²US/US
- 12:45 - 12:45 **790TiP - A phase II clinical investigation of BPM31510-IV (ubidecarenone) in patients with advanced pancreatic cancer**
A. Niewiarowska¹, D. Lucius², R. Sarangarajan², N. Narain², R. Ramanathan³, P. Ritch⁴, J. Strauss⁵, M. Kundranda³, D. Propper⁶; ¹PA/US, ²US, ³AZ/US, ⁴WI/US, ⁵TX/US, ⁶GB
- 12:45 - 12:45 **1936P - Survival effect of lncRNA-X expression in EGFR-mutant adenocarcinoma**
Y. Nakano, K. Isobe, A. Kakimoto, H. Kobayashi, K. Kaburaki, G. Sano, S. Sakamoto, Y. Takai, N. Tochigi, T. Mikami, A. Iyoda, S. Homma; JP
- 12:45 - 12:45 **Head and neck cancer**

- 12:45 - 12:45 **1057P - Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)**
C. Le Tourneau¹, M. Ghiani², M. Cau², R. Depenni², G. Ronzino², P. Bonomo², V. Montesarchio², L. Leo², J. Schulten³, D. Messinger³, A. Sbrana², M.G. Ghi⁴; ¹FR, ²IT, ³DE, ⁴Mestre-VE/IT
- 12:45 - 12:45 **1058P - Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3 nanoparticles activated by radiotherapy: A phase I trial**
C. Le Tourneau¹, V. Calugaru¹, V. Moreno², X. Mirabel¹, B. Dodger², E. Calvo², T. Jouffroy¹, J. Rodriguez¹, A. Chilles¹, M. Yemi¹, C. Hoffmann¹; ¹FR, ²ES
- 12:45 - 12:45 **1059P - Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma**
S. Secondino, P. Bossi, A. Gurrado, S. Basso, I. Imarisio, A. Pagani, M. Zecca, I. Pisani, J. Bagnarino, M. Casanova, C. Bergamini, C. Perotti, L. Licitra, P. Comoli, P. Pedrazzoli; IT
- 12:45 - 12:45 **1060P - Radiotherapy alone for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma: A single-arm, phase II study**
N. Takemoto, M. Suzuki, Y. Seo, K. Ogawa, H. Inohara; JP
- 12:45 - 12:45 **1061P - Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial**
A. Houessinon¹, L. Verlingue¹, A. Hollebecque¹, C. Even¹, L. Lacroix¹, S. Postel-Vinay¹, A. Varga², Y. El Dakdouki¹, R. Balheda¹, J.-M. Michot¹, A. Gazzah¹, A. Marabelle¹, S. Michiels¹, E. Rouleau³, I. Breuskin¹, T. de Baere¹, E. Angevin², J.-Y. Scoazec¹, J.-C. Soria⁴, C. Massard²; ¹FR, ²CEDEX/FR, ³CEDEX 5/FR, ⁴CEDEX/US
- 12:45 - 12:45 **1062P - Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma**
H.-F. Kao, R.-L. Hong; TW
- 12:45 - 12:45 **1063P - A multicenter phase II trial of paclitaxel, carboplatin and cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN)**
T. Enokida¹, T. Ogawa², A. Homma², K. Okami², S. Minami², S. Iwae², A. Nakanome³, Y. Shimizu², A. Motegi², D. Maki², Y. Ueda², T. Fujisawa², S. Nomura², S. Okano¹, M. Tahara¹; ¹Chiba/JP, ²JP, ³Miyagi/JP
- 12:45 - 12:45 **1064P - Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study**
M. Hecht, D. Hahn, P. Wolber, M. Hautmann, D. Reichert, J. Weniger, C. Belka, T. Bergmann, T. Göhler, M. Welslau, D. Hofmann, R. Fiektkau; DE

- 12:45 - 12:45 **1065P - TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC**
C. Even¹, A. Daste¹, E. Saada-Bouزيد¹, J. Fayette², M.-C. Kaminsky-Forrett², S. Zanetta³, A. Prevost¹, G. Lefebvre², C. Borel², D. Cupissol⁴, F. Huguet¹, J.-P. Delord⁵, N. Baste Rotllan⁶, J. Delaye¹, I. Jallut¹, N. Vintonenko¹, J. Bourhis⁷, J. Guigay⁸, M. Texier¹, A. Auperin¹; ¹FR, ²CEDEX/FR, ³Cedex/FR, ⁴CEDEX 5/FR, ⁵Haute-Garonne/FR, ⁶ES, ⁷CH, ⁸CEDEX 2/FR
- 12:45 - 12:45 **1066P - A phase II trial of docetaxel plus cisplatin in recurrent and/or metastatic non-squamous cell carcinoma of head and neck**
Y. Imamura¹, N. Kiyota¹, K. Tanaka¹, H. Hayashi¹, I. Ota¹, K. Nario¹, S. Hirano¹, A. Arai¹, S. Iwae¹, T. Onoe¹, S. Minami¹, T. Shimada², K. Yane¹, T. Yamazaki¹, Y. Nagatani¹, M. Toyoda¹, N. Otsuki¹, K.-I. Nibu¹, H. Minami³; ¹JP, ²Tokyo/JP, ³Hyogo/JP
- 12:45 - 12:45 **1067P - Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC)**
D. Adkins¹, J. Ley¹, H. Gay¹, M. Daly¹, R. Jackson¹, J. Rich¹, P. Pipkorn¹, R. Paniello¹, K. Trinkaus¹, P. Neupane², J. Zevallos¹, W. Thorstad¹, P. Oppelt¹; ¹MO/US, ²KS/US
- 12:45 - 12:45 **1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX**
J. Ham¹, E. Meerten¹, E. Fiets¹, F. Jeurissen Mc Haaglanden², M. Slingerland¹, W. van der Graaf³, C. van Herpen¹, L. Beerepoot¹; ¹NL, ²VA/NL, ³Surrey/GB
- 12:45 - 12:45 **1069P - Phase II study of biweekly TPFL induction chemotherapy for locally advanced squamous cell carcinoma of head and neck**
C.Y. Hsieh, M.Y. Lein, C.-H. Hua; TW
- 12:45 - 12:45 **1070P - Evaluate the role of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era**
T. Jin, P.-J. Li; CN
- 12:45 - 12:45 **1071P - Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results**
R. Mesia Nin¹, P. Bossi², A. Hansen³, C. Hsieh⁴, L. Licitra², E.H. Tan⁵, P. Chen⁶, J. Miller⁷, L. Siu³, R. Haddad⁸; ¹Barcelona/ES, ²IT, ³CA, ⁴TW, ⁵SG, ⁶NJ/US, ⁷US, ⁸MA/US
- 12:45 - 12:45 **1072P - Concurrent cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy for p16-positive, locally advanced oropharyngeal cancer: A meta-analysis**
P. Sutton, M. Skelin, I. Luksic; HR

- 12:45 - 12:45 **1073P - Survival benefit of adjuvant chemotherapy vs active surveillance in locally advanced nasopharyngeal carcinoma: A multicenter retrospective study**
P. Danchaivijitr, A. Dechaphunkul, C. Poin, J. Setakornnukul, T. Dechaphunkul, R. Jiratrachu, S. Niyomnaitham, B. Suktitipat, C. Sookthon, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon; TH
- 12:45 - 12:45 **1074P - Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)**
J. Marín¹, M. Oliva Bernal¹, M. Plana Serrahima¹, M. Ferrer¹, N. Vilariño Quintela¹, S. Vazquez¹, E. Vilajosana¹, A. Lozano¹, J. Nogués¹, A. Marí¹, O. Bermejo¹, R. Mesia Nin², M. Taberna Sanz¹; ¹ES, ²Barcelona/ES
- 12:45 - 12:45 **1075P - Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastatic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience**
G. Bruixola, J. Caballero Daroqui, A.J. Cunquero Tomas, S. Sandiego, J. García Sánchez, S. Blasco, S. Ochendusko, A. Iranzo, J. Lavernia, A. Berrocal Jaime, M. Pastor Borgoñón; ES
- 12:45 - 12:45 **1076P - Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT): A multicenter retrospective study**
A. Dechaphunkul, P. Danchaivijitr, R. Jiratrachu, T. Dechaphunkul, C. Sookthon, C. Jiarpinitnun, C. Poin, J. Setakornnukul, S. Niyomnaitham, B. Suktitipat, P. Pattaranutaporn, N. Ngamphaiboon; TH
- 12:45 - 12:45 **1077P - Comparison of concurrent chemoradiation therapy plus induction chemotherapy with cisplatin, fluorouracil and docetaxel versus gemcitabine and cisplatin in advanced nasopharyngeal carcinoma**
Z. Zeng, R. Yan, L. Tu, Y. Wang, P. Chen, F. Luo, L. Liu; CN
- 12:45 - 12:45 **1078P - Genomic profiling and matched therapy for recurrent or metastatic malignant salivary gland tumors**
E. Malone¹, R. Jang², A. Spreafico², I. Weinreb², S. Jennings², L. Siu³, A. Hansen³; ¹IE, ²ON/CA, ³CA
- 12:45 - 12:45 **1079P - Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma**
W. van Boxtel, I. van Engen-van Grunsven, D. van Strijp, J.B.A. van Zon, M. Ligtenberg, G. Verhaegh, J. Schalken, S. Neerken, A. van de Stolpe, C. van Herpen; NL
- 12:45 - 12:45 **1080P - Prognostics factors in adenoid cystic carcinoma of the head and neck (ACCHN): Retrospective study of 15 years**
P. Neji, R. Conde, S. Esteves, M.T. Alexandre, M. Ferreira, E. Netto, J. Santos, M. Magalhães, A. Moreira; PT
- 12:45 - 12:45 **1081P - Molecular analysis of NRAS, BRAF, C-KIT, ROS1, ALK and RET alterations in serial biopsies in sinonasal mucosal melanoma**

G. Anguera Palacios, L. del Carpio, M.-A. Molina, C. Aguado, J.R. Gras-Cabrerizo, X. Leon, M. Gonzalez-Cao, N. Karachaliou, A. Mozos, A. Gonzalez, A. Barnadas, R. Rosell, M. Majem; ES

- 12:45 - 12:45 **1082P - Programmed death-ligand 1 (PD-L1) expression and HPV-associated p16 in oropharyngeal squamous cell carcinoma (OSCC) treated with primary curative radiotherapy (RT)**
T. Steiniche¹, J. Eriksen¹, J. Lilja-Fischer¹, J. Georgsen¹, P.-T. Vo², M. Busch-Sørensen², D. Chirovsky³, J. Cheng⁴, D. Aurora-Garg⁵, R. Swaby⁵, J. Overgaard¹; ¹DK, ²US, ³New Jersey/US, ⁴PA/US, ⁵NJ/US
- 12:45 - 12:45 **1083P - Dynamics of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)**
A. Grages, S. Jeske, L. Puntigam, C. Brunner, J. Kraus, H. Kestler, J. Döscher, T. Hoffmann, P. Schuler, S. Laban; DE
- 12:45 - 12:45 **1084P - Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and human papilloma virus status in head and neck squamous cell carcinoma**
S. Laban, G. Völkel, J. Ezic, T. Hoffmann, H.-G. Rammensee, J. Döscher, P. Schuler, C. Brunner, J. Kraus, H. Kestler; DE
- 12:45 - 12:45 **1085P - The use of HPV16-E5, EGFR and pEGFR as prognostic biomarkers for oropharyngeal cancer patients**
M. Taberna¹, M. Torres¹, M. Alejo¹, M. Mena¹, S. Tous¹, S. Marquez¹, M.A. Pavon¹, X. Leon¹, J. Garcia¹, M. Guix¹, R. Hijano¹, T. Bonfill¹, A. Aguilà¹, A. Lozano¹, R. Mesia Nin², L. Alemany¹, I.G. Bravo³; ¹ES, ²Barcelona/ES, ³FR
- 12:45 - 12:45 **1086P - Combined analysis of gene expression profiles in 2 preoperative trials with afatinib and cetuximab in head and neck squamous cell carcinoma**
P. Bossi¹, S. Schmitz², J.-P. Machiels², L. Licitra¹, C. Fortpied Lefevre², C. Caballero², S. Canevari¹, L. De Cecco¹; ¹IT, ²BE
- 12:45 - 12:45 **1087P - Association of LIPI score with immune checkpoint inhibitors (ICI) outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (pts)**
R.G. Herrera Gomez¹, L. Mezquita¹, E. Auclin¹, K. Saleh¹, N. Baste Rotllan², M. Jacobs¹, S. Bursuc³, L. Mayache Badis¹, F.R. Ferrand⁴, O. Casiraghi¹, S. Temam¹, I. Breuskin¹, Y. Tao¹, B. Besse⁵, C. Even¹; ¹FR, ²ES, ³RO, ⁴CEDEX 5/FR, ⁵CEDEX/FR
- 12:45 - 12:45 **1088P - Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study**
M. Oliva Bernal¹, S. Lien², B. Wang², S.C. Yang², A. Spreafico², R. Jang², S. Elston², S. Jennings², H. Jiang³, B. Haibe-Kains², T. Pugh³, P. Ohashi³, L. Siu³, A. Hansen³; ¹ES, ²ON/CA, ³CA

- 12:45 - 12:45 **1089P - C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer**
M.-C. Lin, P.-H. Chien, H.-Y. Wu, S.-T. Chen, H.-F. Juan, N.-Y. Lin, P.-J. Lou, M.-C. Huang; TW
- 12:45 - 12:45 **1090P - Frequency of PIK3CA mutations in head and neck squamous cell carcinoma (HNSCC) in southern Thailand**
P. Thongwatchara, P. Thongsuksai, T. Dechaphunkul, A. Dechaphunkul; TH
- 12:45 - 12:45 **1091P - Comparison between the 7th and the proposed 8th editions of the UICC staging system for nasopharyngeal carcinoma patients without cervical lymph node metastasis: A retrospective analysis**
C. Hu, CN
- 12:45 - 12:45 **1092P - Validation of the clinical AJCC/UICC TNM 8th edition for human papillomavirus related oropharyngeal squamous cell carcinoma**
S. Deschuymer, R. Dok, A. Laenen, E. Hauben, S. Nuyts; BE
- 12:45 - 12:45 **1093P - Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)**
K. Xu¹, A. Lo¹, V. Chin¹, C. Gzell¹, C. O'Connor¹, D. Forstner¹, R. Gallagher¹, R. Bova¹, J. Crawford¹, R. Harvey¹, A. Lochhead², P. Earls², M. Qiu², E. Hsu¹, G. Bigg-Wither¹, L. Chan¹, H. Bao¹, P. Foltyn¹, H.-W. Sim¹, A. Prawira³; ¹AU, ²NSW/AU, ³Ontario/CA
- 12:45 - 12:45 **1094P - Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy**
P. Bossi, R. Depenni, M. cossu rocca, D. Ferrari, G. Azzarello, M. Alù, F. Nolè, C. Codecà, G. Boscolo, M. Piccininni, S. Cavalieri, G. Pugliese, L. Licitra; IT
- 12:45 - 12:45 **1095P - Prognostic value of MRI-derived residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma and a nomogram for the prediction of it**
W.-Z. Li, H. Liang, X. Lv, L.-R. Ke, Y.-F. Ye, Y.-H. Yu, W.-Z. Qiu, G.-Y. Liu, X.-J. Huang, K.-Y. Liu, S.-H. Lv, X. Guo, Y.-Q. Xiang, W.-X. Xia; CN
- 12:45 - 12:45 **1096P - Proteomic comparison based on 18FDG-PET/CT defined metabolic tumor volume in non-metastatic nasopharyngeal carcinoma**
C. Chen, L. Li, Z. Fei, J. Wang, T. Chen; CN
- 12:45 - 12:45 **1097P - Prognostic value of metabolic tumor volume in recurrent and/or metastatic head and neck squamous cell carcinoma treated with platinum-based chemotherapy**
M. Suzuki, N. Takemoto, T. Fukuzumi, M. Yamamoto, S. Otozai, T. Yoshii, T. Fujii, H. Inohara; JP

- 12:45 - 12:45 **1098P - The prognostic value of early tumor response in metastatic nasopharyngeal carcinoma patients treated with first-line chemotherapy**
W.-X. Xia, L. guoying, X. Lv, S.-H. Lv, X.-J. Huang, W.-Z. Qiu, H. Liang, W.-Z. Li, K.-Y. Liu, Y.-H. Yu, Y.-Q. Xiang, X. Guo; CN
- 12:45 - 12:45 **1099P - Potential clinical management changes in patients harboring locally advanced squamous-cell carcinoma of head and neck by incorporating pre and post chemoradiotherapy 18.FDG PET/CT: A prospective trial**
U. Nicolau, A.C. Queiroz, T. Felismino, E. Lima, V.H. Jesus, L. Cezana, M. Alves, A.C. Pellizzon, P. Pinto, G. Porto, G. Carvalho, C.A. Pinto, V. Silva, A. Guimarães, T. Oliveira, M. Ikeda, T. Paiva Jr, P. Bes, L.P. Kowalski; BR
- 12:45 - 12:45 **1100P - Patterns of local failures and suggestions for reduction of clinical target volume for nasopharyngeal carcinoma patients without cervical lymph node metastasis**
C. Hu, Y. Li; CN
- 12:45 - 12:45 **1101P - Target delineation and dose prescription for adaptive replanned intensity-modulated radiotherapy in nasopharyngeal carcinoma**
X. Huan, CN
- 12:45 - 12:45 **1102P - Significance of pre-treatment F-18 FDG PET/CT parameters in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy**
Y. Huang, C. Chen, Y. Li, X. Qiu, T. Chen; CN
- 12:45 - 12:45 **1103P - Sentinel lymph node biopsy for clinically N0 oral squamous cell carcinoma**
H. Goda, K.-I. Nakashiro; JP
- 12:45 - 12:45 **1104P - An insight on head and neck cancer management in China**
Y. Xiaoshi, D. Weiyi; CN
- 12:45 - 12:45 **1105P - Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck**
A. Lafuma, F.-E. Cotté, C. Le Tourneau, C. Emery, A.-F. Gaudin, E. Torreton, J. Gourmelen, J. Bonastre; FR
- 12:45 - 12:45 **1106P - Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results from an EORTC led survey**
S. Oosting¹, I. Desideri², D. Staelens³, C. Caballero³, S. Tribius⁴, C. Simon⁵, S. Singer⁴, V. Gregoire⁶, C. Fortpied³, A. Luciani²; ¹NL, ²IT, ³BE, ⁴DE, ⁵CH, ⁶FR
- 12:45 - 12:45 **1107P - The importance of comorbidity assessment in patients with oral squamous cell carcinoma (OSCC): Could the adult comorbidity evaluation – 27 (ACE-27) provide an additional information?**
U. Jariod Ferrer, S. Blanco Sanfrutos, M. Gavin Clavero, T. Uson Bouthelier, B. Nadal Cristobal, I. Moral Saez, I. Pajares Bernad, A. Cisneros Gimeno, J. Martinez Trufero; ES

- 12:45 - 12:45 **1108P - Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial**
J. Dunst¹, G. Hildebrandt¹, M. Becker-Schiebe¹, T. Kuhnt¹, F. Weykamp¹, F. Martucci², D. Vordermark¹, M. Pless², D. Hofmann¹, V. Bühler², S. Rothschild²; ¹DE, ²CH
- 12:45 - 12:45 **1109P - Comparison of acute hematologic and renal toxicities in two chemotherapy schedules of cisplatin for epithelial cell carcinoma of head and neck**
A. Ameri, S. Norouzi, A. Sourati, K. Novin, S. Azghandi; IR
- 12:45 - 12:45 **1110P - Patient reports of mouth symptoms after radiotherapy treatment for head and neck cancer: An international survey**
C. Curtis, A. Nicotera, C. Griseri, H. Roddam; GB
- 12:45 - 12:45 **1111P - Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer**
H. Shirasu¹, T. Yokota², K. Fushiki¹, H. Inoue¹, M. Shibata¹, M. Furuta¹, T. Kawakami¹, S. Kawai¹, S. Hamauchi¹, A. Todaka¹, T. Tsushima², N. Machida¹, K. Yamazaki², A. Fukutomi², Y. Onozawa², H. Yasui¹; ¹JP, ²Shizuoka/JP
- 12:45 - 12:45 **1112P - Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: A supplementary analysis of a phase II trial (JCOG0706S1)**
Y. Imamura¹, N. Kiyota¹, T. Akimoto¹, G. Ogawa¹, J. Eba¹, S. Minami¹, Y. Hasegawa¹, S. Iwae¹, N. Monden¹, K. Matsuura¹, H. Fujii¹, Y. Onozawa², A. Homma¹, R. Hayashi¹, M. Tahara³; ¹JP, ²Shizuoka/JP, ³Chiba/JP
- 12:45 - 12:45 **1113P - The retrospective analysis of nephrotoxicity for cisplatin dose of CRT compared 100&&**
T. Oguri, K. Nakano, N. Fukuda, K. Kawaguchi, T. Urasaki, M. Nishizawa, M. Yunokawa, M. Ono, S. Taira, J. Tomomatsu, T. Toshiyasu, H. Mitani, S. Takahashi; JP
- 12:45 - 12:45 **1114P - Comparison of treatment outcomes and tolerability of patients with recurrent (R) nasopharyngeal carcinoma (NPC) and metastatic disease at diagnosis (M1): A retrospective analysis**
C. Sookthon, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon; TH
- 12:45 - 12:45 **1115P - Impact of the multidisciplinary approach on the survival of squamous head and neck cancer in our institution**
M.J. Martínez-Ortiz, Á. Martínez-Ortiz, G. Marín-Zafra, P. Cerezuela-Fuentes, J. Balsalobre, J.A. Díaz-Manzano, J. Trujillo-Santos, M.T. García-García; ES
- 12:45 - 12:45 **1116TiP - A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)**
N. Hanai, T. Asakage, N. Kiyota, A. Homma, N. Monden, H. Fukushima, T. Fujii, T. Ogawa, K. Tanaka, J. Mizusawa, J. Eba, R. Hayashi; JP

- 12:45 - 12:45 **1117TiP - IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)**
R. Haddad¹, D. Wong², Y. Guo³, J. Fayette⁴, E. Cohen², M. Kowgier⁵, A. Sandler⁶, C. Matheny², F. Kabbinavar², D. Raben²; ¹MA/US, ²US, ³CN, ⁴FR, ⁵CA, ⁶OR/US
- 12:45 - 12:45 **1118TiP - A phase I/II dose escalation study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN)**
N. Ngamphaiboon, S. Lukerak, C. Jiarpinitnun, A. Jinawath, N. Jinawath, J. Juengsamarn, L. Arsa, J. Konmun, N. Kongsuphon, N. Sankaseam, E. Sirachainan, P. Witoonpanich, A. Kositwattanarek, P. Pattaranutaporn; TH
- 12:45 - 12:45 **1119TiP - Randomized phase II multicenter study comparing modified PFE regimen with modified TPEX regimen in recurrent or metastatic squamous cell carcinoma of the head and neck: TEMPER study**
M. Shimokawa¹, M. Suzuki¹, M. Sugasawa¹, K. Shiga¹, T. Satoh², H. Inohara¹; ¹JP, ²Osaka/JP
- 12:45 - 12:45 **1120TiP - Randomized phase III study in EBV positive locally advanced nasopharyngeal carcinoma treated with concurrent chemo-radiotherapy with or without anti-viral drug**
K. Alsaleh, A. Elbasmi, A. Hussein, F. Alshaflan, M. El-Sherify; KW
- 12:45 - 12:45 **1121TiP - KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)**
J.-P. Machiels¹, L. Licitra², Y.G. Tao³, C.-J. Yen⁴, D. Rischin⁵, J. Waldron⁶, B. Burtness⁷, V. Gregoire¹, S. Agarwala⁸, J. Yorio⁷, J.-P. Delord³, S. Aksoy⁹, S. Ikeda¹⁰, R.-L. Hong⁴, J.Y. Ge⁷, H. Brown⁷, B. Bidadi⁷, L. Siu¹¹; ¹BE, ²IT, ³FR, ⁴TW, ⁵VIC/AU, ⁶ON/CA, ⁷US, ⁸PA/US, ⁹TR, ¹⁰JP, ¹¹CA
- 12:45 - 12:45 **1122TiP - Pembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study**
L. Licitra¹, L. Siu², E. Cohen³, P. Zhang⁴, B. Gumuscu⁴, R. Swaby⁴, K. Harrington⁵; ¹IT, ²CA, ³US, ⁴NJ/US, ⁵GB
- 12:45 - 12:45 **1123TiP - A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)**
A. Spreafico¹, K. Sultanem¹, B. Chen¹, S. Bratman¹, J. Ringash¹, A. Louie¹, A. McNiven¹, K. Whelan¹, J. Hilton¹, J. Yoo¹, J.-P. Machiels², L. Licitra³, S. Oosting⁴, J. Waldron⁵, L. Siu¹, W. Parulekar¹; ¹CA, ²BE, ³IT, ⁴NL, ⁵ON/CA

- 12:45 - 12:45 **1124TiP - Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)**
J. Bauman, PA/US
- 12:45 - 12:45 **1125P - Prophylactic versus reactive nutritional supplement in local advanced nasopharyngeal carcinoma patients receiving radical chemo-radiotherapy**
Y.-Y. Chen, S. Huang, X. Chen, Q. Hu; CN
- 12:45 - 12:45 **1126TiP - Nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced head and neck cancer**
J. Johnson¹, V. Bar Ad¹, E. Lorber², A. Luginbuhl¹, J. Curry¹, D. Cognetti¹, S. Keith², R. Axelrod², R. Zinner², U. Rodeck², L. Harshyne¹, A. Argiris³; ¹US, ²PA/US, ³GR
- 12:45 - 12:45 **Melanoma and other skin tumors**
- 12:45 - 12:45 **1250P - Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial**
R. Dummer¹, D. Schadendorf², A. Hauschild³, M. Santinami⁴, V. Atkinson⁵, M. Mandala⁴, V. Chiarion Sileni⁴, J. Larkin⁶, M. Nyakas⁷, C. Dutriaux⁸, A. Haydon⁹, L. Mortier⁸, C. Robert⁸, J. Schachter¹⁰, X. Feng¹¹, E. de Jong¹¹, B. Mookerjee¹², R. Kefford⁵, J. Kirkwood¹³, G. Long¹⁴; ¹CH, ²DE, ³Schleswig-Holstein/DE, ⁴IT, ⁵AU, ⁶GB, ⁷NO, ⁸FR, ⁹VIC/AU, ¹⁰IL, ¹¹US, ¹²NJ/US, ¹³PA/US, ¹⁴NSW/AU
- 12:45 - 12:45 **1251P - Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial**
V. Atkinson¹, A. Hauschild², M. Santinami³, M. Mandala³, V. Chiarion Sileni³, J. Larkin⁴, M. Nyakas⁵, C. Dutriaux⁶, A. Haydon⁷, L. Mortier⁶, C. Robert⁶, J. Schachter⁸, D. Schadendorf⁹, X. Feng¹⁰, E. de Jong¹⁰, B. Mookerjee¹¹, R. Kefford¹, R. Dummer¹², J. Kirkwood¹³, G. Long¹⁴; ¹AU, ²Schleswig-Holstein/DE, ³IT, ⁴GB, ⁵NO, ⁶FR, ⁷VIC/AU, ⁸IL, ⁹DE, ¹⁰US, ¹¹NJ/US, ¹²CH, ¹³PA/US, ¹⁴NSW/AU
- 12:45 - 12:45 **1252P - Management of melanoma recurrence following adjuvant anti-PD1 therapy**
C. Owen¹, D. Palmieri², A. Guminski², M. Carlino², A. Menzies¹, G. Long²; ¹AU, ²NSW/AU
- 12:45 - 12:45 **1253P - High response rate with T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)**
V. Franke, D. Berger, W. Klop, B. van der Hiel, B. van de Wiel, S. Ter Meulen, M. Wouters, W. van Houdt, A. van Akkooi; NL
- 12:45 - 12:45 **1254P - Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR trial**

S. Blankenstein, M. Rohaan, W. Klop, B. van der Hiel, B. van de Wiel, D. Peeper, A. van Akkooi, J. Haanen; NL

- 12:45 - 12:45 **1255P - Impact of intralesional interleukin 2 (IL2) for in-transit melanoma in two Canadian centres**
D.S. Ernst¹, V. Hayward², H. McConkey³, X. Teng³, E. Saettler³, T. Cheng⁴, C. Temple-Oberle⁴, F. Gwadry-Sridhar³; ¹Ontario/CA, ²BC/CA, ³ON/CA, ⁴AB/CA
- 12:45 - 12:45 **1256P - Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients**
H. Dearden¹, R. Mason², B. Nguyen³, J. Soon⁴, J. Smith⁵, M. Randhawa⁶, A. Mant⁴, L. Warburton³, S. Lo¹, T. Meniawy³, A. Guminski⁵, P. Parente⁴, S. Ali⁶, A. Haydon⁴, G. Long⁵, M. Carlino⁵, M. Millward³, V. Atkinson¹, A. Menzies¹; ¹AU, ²QLD/AU, ³WA/AU, ⁴VIC/AU, ⁵NSW/AU, ⁶ACT/AU
- 12:45 - 12:45 **1257P - KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma**
L. Si¹, X. Zhang¹, Y. Shu¹, H. Pan², D. Wu¹, J. Liu¹, F. Lou¹, X. Wang¹, X. Wen¹, Y. Gu¹, L. Zhu¹, S. Lan¹, X. Cai¹, Y. Zhou¹, J. Ge¹, J. Li¹, H. Wu¹, J. Guo¹; ¹CN, ²Zhejiang/CN
- 12:45 - 12:45 **1258P - Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study**
R. Marconcini¹, E. Tanda¹, L. Di Guardo¹, O. Nigro¹, P. Fava¹, A. Todisco¹, F. Morgese¹, A. Cortellini¹, E. Stroppa¹, G. Gallizzi¹, L. Festino¹, E. Grego¹, S. Quadri², C. Orlandini¹, A. Nuzzo¹, S. Manacorda¹, F. Bloise¹, A. Indini¹, C. Astrua¹, A. Falcone¹; ¹IT, ²Frosinone/IT
- 12:45 - 12:45 **1259P - Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma**
I. Reijers, E. Rozeman, H. Mallo, W. Uytterlinde, S. Adriaansz, J. Lijnsvelt, S. Wilgenhof, J. van Thienen, J. Haanen, C. Blank; NL
- 12:45 - 12:45 **1260P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma**
P. Saiag¹, C. Robert¹, J.J. Grob¹, L. Mortier², O. Dereure¹, C. Lebbe³, S. Mansard⁴, F. Grange¹, E.-M. Neidhardt², T. Lesimple¹, L. Machel¹, C. Bedane², G. Jeudy¹, F. Aubin¹, B. Dreno⁴, A. Sznik¹, A. Denden¹, C. Dutriaux¹; ¹FR, ²CEDEX/FR, ³CEDEX 10/FR, ⁴CEDEX 1/FR
- 12:45 - 12:45 **1261P - Loss of HLA class I expression and T-cell infiltration or PD-L1 expression are associated with different response patterns to pembrolizumab in melanoma**
A. Degraeuwe, N. van Baren, F. Cornelis, P. van Eeckhout, J.-F. Baurain; BE
- 12:45 - 12:45 **1262P - Soluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma**

X. Wang, C. Cui, J. Yu, Y. Kong, L. Si, Z. Chi, X. Sheng, L. Mao, B. Lian, B. Tang, X. Yan, J. Guo; CN

- 12:45 - 12:45 **1263P - The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice**
A. Czarnecka¹, P. Teterycz¹, I. Lugowska¹, P. Rogala¹, T. Switaj², P. Rutkowski¹; ¹PL, ²IR
- 12:45 - 12:45 **1264P - Long-term survivors among patients with metastatic melanoma treated with targeted agents and/or checkpoint inhibitors**
H. Linardou, A. Laskarakis, A. Molfeta, K. Sakellariou, A. Tarampikou, E. Soroli, K. Gkiati, D. Bafaloukos; GR
- 12:45 - 12:45 **1265P - Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy**
A. Ribas¹, I. Mehmi², T. Medina², C. Lao², S. Kummar², A. Amin³, S. Deva⁴, A. Salama³, T. Tueting⁵, M. Milhem², C. Hoimes², G. Daniels², M. Shaheen², S. Jang², M. Barve⁶, A. Powell⁷, S. Chandra², E. Schmidt², R. Janssen², G. Long⁸; ¹CA/US, ²US, ³NC/US, ⁴NZ, ⁵DE, ⁶TX/US, ⁷AU, ⁸NSW/AU
- 12:45 - 12:45 **1266P - Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma**
C. Schuster, G. Gausdal, B. Gjertsen, J. Lorens, O. Straume; NO
- 12:45 - 12:45 **1267P - Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy**
T. Isei¹, K. Yokota¹, H. Uhara¹, Y. Fujisawa², T. Takenouchi¹, Y. Kiyohara¹, H. Uchi¹, H. Saruta¹, H. Ihn¹, T. Inozume¹, D. Watanabe¹, A. Takahashi¹, S. Fukushima¹, M. Tanaka³, N. Yamazaki¹; ¹JP, ²Ibaraki/JP, ³Shiga/JP
- 12:45 - 12:45 **1268P - NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)**
S. Moschos¹, Z. Eroglu², N. Khushalani², K. Kendra³, G. Ansstas⁴, G. In⁵, P. Wang⁶, G. Liu⁷, F. Collichio⁸, C. Arrowood⁸, J. Reed¹, N. Garrett-Mead⁸, N. Thomas⁸, D. Ollila⁸, S.P. Ivy⁹, A. Ivanova⁸, E. Dees⁸, J. Abbuzzese⁸; ¹US, ²FL/US, ³OH/US, ⁴MO/US, ⁵CA/US, ⁶KY/US, ⁷WI/US, ⁸NC/US, ⁹MD/US
- 12:45 - 12:45 **1269P - Initial cohort expansion results of sustained arginine depletion with pegzilarginase in melanoma patients in a phase I advanced solid tumor trial**
B. Chmielowski¹, M. Gordon², E. Buchbinder³, R. Sullivan³, J. Cohen³, B. Curti⁴, D. Davar⁵, J. Homsy⁶, K. Komatsubara⁷, H. Lara-Guerra⁸, S. Alters⁸, S. Ferrati⁶, S. Eckert⁶, S. Rowlinson⁶, J. Wooldridge⁸, A. Ribas¹, R. Carvajal⁷; ¹CA/US, ²AZ/US, ³MA/US, ⁴OR/US, ⁵PA/US, ⁶TX/US, ⁷NY/US, ⁸US

- 12:45 - 12:45 **1270P - Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma**
C. Mignard, A. Deschamps-Huvier, A.-B. Duval-Modeste, C. Dutriaux, A. Khammari, M.-F. Avril, L. Mortier, T. Lesimple, C. Gaudy-Marqueste, C. Lesage, L. Machet, F. Aubin, N. Meyer, N. Beneton Benhard, G. Jeudy, H. Montaudié, J.-P. Arnault, M.-T. Leccia, P. Joly, S.F.D. Oncology Research Group Of The French Society Of Dermatology; FR
- 12:45 - 12:45 **1271P - Retrospective analysis of the treatment of metastatic uveal melanoma comparing systemic chemotherapy and transarterial chemoembolization**
C.A. Peuker, L. Polzin, S. Ochsenreither, M. De Bucourt, S. Leyvraz, U. Keilholz, A. Jousen, J. Eucker; DE
- 12:45 - 12:45 **1272P - Outcome of an active surveillance programme for patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): Single institution 10-year experience**
C.L. Lee, G. Gullo, N. Horgan, D. Smith, M. Moran, J. Crown; IE
- 12:45 - 12:45 **1273P - Activation of non-canonical NF&&**
M. Singh, R. Meel, N. Pushker, S. Sen, K. Chodsol, S. Bakhshi, S. Kashyap; IN
- 12:45 - 12:45 **1274P - The use of PD-1 inhibitors for the advanced melanoma of esophagus**
L. Mao, X. Wang, L. Si, Y. Kong, Z. Chi, X. Sheng, C. Cui, B. Lian, B. Tang, X. Yan, J. Guo; CN
- 12:45 - 12:45 **1275P - Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma**
M. Nomura¹, M. Andoh¹, T. Yokota², T. Miyazaki¹, H. Satake³, S. Iwasawa¹, A. Sonoda¹, K. Kato¹, M. Muto¹; ¹JP, ²Shizuoka/JP, ³Hyogo/JP
- 12:45 - 12:45 **1276P - Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population**
M. van Zeijl¹, M. Wouters¹, A. van den Eertwegh¹, M. Aarts¹, A. van Akkooi¹, F. van den Berkmortel¹, M. Franken¹, J.W. de Groot¹, K. Herbschleb¹, J. van der Hoeven¹, G. Hospers¹, E. Kapiteijn¹, D. Piersma¹, R. van Rijn¹, K. Suijkerbuijk¹, A. Ten Tije², A. Van der Veldt¹, G. Vreugdenhil¹, J. Haanen¹; ¹NL, ²Noord Brabant/NL
- 12:45 - 12:45 **1277P - Stereotactic radiation therapy in melanoma brain metastasis: A European, multicentric cohort**
A. paix¹, F. Thillays¹, F. Courtault-Deslandes¹, I. Popp², H. Herrscher¹, J. Biau¹, O. Briard¹, A.-L. Grosu², G. Noël¹; ¹FR, ²DE
- 12:45 - 12:45 **1278P - Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial**

C. Coens¹, A. Bottomley¹, C. Blank², M. Mandala³, G. Long⁴, V. Atkinson⁵, S. Dalle⁶, A. Haydon⁷, M. Lichinitser⁸, A. Khattak⁵, M. Carlino⁴, S. Sandhu⁷, J. Larkin⁹, S. Puig Sarda¹⁰, P. Ascierto³, D. Schadendorf¹¹, N. Ibrahim¹², S. Suci¹, C. Robert¹³, A. Eggermont¹³; ¹BE, ²NL, ³IT, ⁴NSW/AU, ⁵AU, ⁶CEDEX/FR, ⁷VIC/AU, ⁸RU, ⁹GB, ¹⁰ES, ¹¹DE, ¹²NJ/US, ¹³FR

- 12:45 - 12:45 **1279P - The real-world impact of modern treatments on the survival of patients with metastatic melanoma**
M. Donia, E. Ellebaek, T. Øllegaard, L. Duval, J. Aaby, L. Højberg, U. Kehler, H. Schmidt, L. Bastholt, I.-M. Svane; DK
- 12:45 - 12:45 **1280P - Treatment patterns of melanoma by BRAF mutation status in the US in 2011-2017: A retrospective cohort study**
L. Raskin, S. Shah, M. Braunlin, J. Buchanan, D. Cohan; US
- 12:45 - 12:45 **1281P - Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort study**
M. Freeman, K. Gupte-Singh, M. You, T.K. Le, C. Ritchings, S. Rao, S. Jang; US
- 12:45 - 12:45 **1282P - Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab**
S. D'Angelo¹, F. Fofana², M. Schlichting³, M. Henry-Szatkowski⁴, M. Hennessy⁵, M. Bharmal³; ¹NY/US, ²NL, ³DE, ⁴FR, ⁵US
- 12:45 - 12:45 **1283P - Treatment pattern and clinical outcomes of patients with locally advanced and metastatic melanoma in a real-world setting in China**
C. Cui¹, X. Yan¹, S. Liu¹, A. Deitz², L. Si¹, Z. Chi¹, X. Sheng¹, B. Lian¹, J. Li¹, J. Ge¹, X. Wang¹, L. Mao¹, B. Tang¹, L. Zhou¹, X. Bai¹, S. Li¹, B. Li¹, H. Wu¹, J. Guo¹; ¹CN, ²NJ/US
- 12:45 - 12:45 **1284P - Real life costs associated with the management of unresectable metastatic melanoma (uMM)**
D. Strens, M. Peeters, P. Specenier; BE
- 12:45 - 12:45 **1285P - Drug treatment in melanoma: A real-world analysis across Europe and Japan**
A. Martinez de Pinillos, P. Nasuti, C. Anger; GB
- 12:45 - 12:45 **1286P - EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma**
M. Weichenthal¹, A. van Akkooi², P. Mohr¹, E. Ellebaek³, I.-M. Svane³, S. Ugurel-Becker⁴, U. Leiter¹, L. Højberg³, J. Haanen², H. Schmidt³, T.H. Oellegaard³, M. Wouters², D. Schadendorf¹, L. Bastholt³; ¹DE, ²NL, ³DK, ⁴AT
- 12:45 - 12:45 **1287P - Advanced melanoma treatment patterns in the modern era: United Kingdom (UK) real world retrospective chart review study**

J. Sacco¹, P. Corrie², O. Oladipo¹, M. Payne¹, J. Larkin¹, T. Talbot¹, J. Wagstaff¹, S. Cheetham¹, D. Stein¹, M. Soni¹, C. Coombs³, A. Amadi¹, M. Wang¹, J. Ellis¹; ¹GB, ²Cambridgeshire/GB, ³MD/US

- 12:45 - 12:45 **1288P - The national melanoma research registry: A fundamental for disease characterization and epidemiology**
F. Gwadry-Sridhar¹, H. McConkey², X. Teng², D.S. Ernst³; ¹CA, ²ON/CA, ³Ontario/CA
- 12:45 - 12:45 **1289P - Assessment of quality of life in patients with metastatic melanoma in real clinical practice in France**
M. Kandel¹, C. Allayous¹, S. Dalle², L. Mortier², S. Dalac Rat³, C. Dutriaux¹, M.-T. Leccia⁴, B. Guillot¹, P. Saiag¹, J.-P. Lacour¹, D. Legoupil¹, F. Brunet-Possenti¹, B. Dreno⁵, A. Ballon¹, A. Bardet¹, S. Michiels¹, C. Lebbe¹, I. Borget¹; ¹FR, ²CEDEX/FR, ³Cedex/FR, ⁴CEDEX 9/FR, ⁵CEDEX 1/FR
- 12:45 - 12:45 **1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP)**
P. Nathan¹, V. Kasturi², L. Dirix³, E. Fenig⁴, P. Ascierto⁵, M. Hennessy², J. Reed², A. Engelsberg⁶, S. Hariharan², C. Lebbé⁷; ¹Middlesex/GB, ²US, ³BE, ⁴IL, ⁵IT, ⁶DE, ⁷FR
- 12:45 - 12:45 **1291P - Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)**
M. Bharmal¹, A. Amin², C. Stapelkamp², C. Pescott¹, A. Hatswell², C. Lilley², A. Bullement², A. Willis²; ¹DE, ²GB
- 12:45 - 12:45 **1292P - Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data**
T. Owonikoko¹, K. Papadopoulos², M. Gil-Martin³, V. Moreno³, A. Salama⁴, E. Calvo³, H. Safran⁵, A. González-Martín³, R. Aljumaily⁶, D. Mahadevan⁷, J. Niu⁸, K. Kal Mohan⁹, J. Li¹⁰, E. Stankevich⁵, M. Mathias⁵, I. Lowy⁵, M. Fury⁵, H. Babiker⁵; ¹GA/US, ²TX/US, ³ES, ⁴NC/US, ⁵US, ⁶OK/US, ⁷TN/US, ⁸AZ/US, ⁹NY/US, ¹⁰NJ/US
- 12:45 - 12:45 **1293P - Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: A real-life analysis**
F. Peyrade¹, M. Kogay², J. Viotti², P. Combemale², C. Dutriaux², N. Dupin², C. Robert², L. Mortier³, A.-B. Duval-Modeste², S. Dalle³, J. De Quatrebarbes², A. Stefan², F. Brunet-Possenti², A. Picard², G. Poissonnet², H. Montaudié²; ¹CEDEX 2/FR, ²FR, ³CEDEX/FR
- 12:45 - 12:45 **1294P - Sonidegib preplanned subgroups analyses of objective response rates: Final 42-month results from the BOLT study**
R. Dummer, CH
- 12:45 - 12:45 **1295P - Treatment of advanced basal cell carcinoma with sonidegib: Duration of response and quality of life evaluation from BOLT**
M. Migden, US

- 12:45 - 12:45 **1296P - Discovery of novel germline genetic biomarkers of melanoma recurrence impacting exonic and long non-coding RNA (lncRNA) transcripts**
T. Kirchhoff¹, D. Simpson², T. Hekal², R. Ferguson¹, E. Kazlow², U. Moran², Y. Lee¹, A. Izsak¹, M. Wilson², R. Shapiro², A. Pavlick², I. Osman¹; ¹US, ²NY/US
- 12:45 - 12:45 **1297P - Pilot study: Localizing target lymph node using a magnetic marker allows reliable and representative judgement of pathological responses after neo-adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma**
A. van Akkooi, B. Schermers, V. Franke, M. Wouters, C. Zuur, W. Klop, E. Rozeman, B. van de Wiel, T. Ruers, C. Blank; NL
- 12:45 - 12:45 **1298P - Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma**
S. Lundgren, H. Fagerström-Vahman, L. Ben-Dror, B. Nodin, K. Jirstrom; SE
- 12:45 - 12:45 **1299P - BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation**
M. Wasylecka-Juszczyńska, P. Górniak, M. Szydłowski, A. Polak, P. Juszczyński; PL
- 12:45 - 12:45 **1300TiP - A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)**
P. Corrie¹, R. Matin², A. Gupta², W. Qian¹, S. Wordsworth², E. Gibbons², A. Chhabra², C. Harman², C. Mather², M. Middleton³; ¹Cambridgeshire/GB, ²GB, ³Oxfordshire/GB
- 12:45 - 12:45 **1301TiP - A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)**
I. Glitza¹, M. Rohlfs¹, M. Iqbal¹, J. Richard¹, E. Burton¹, S. Duncan¹, C. Brown¹, J. Anderson¹, P. Hwu², W.-J. Hwu¹, M. Wong¹, C. Yee¹, S. Patel¹, S. Woodman¹, R. Amaria¹, A. Diab², H. Tawbi¹, M. Davies²; ¹TX/US, ²US
- 12:45 - 12:45 **1302TiP - CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti&&**
E. Lipson¹, G. Long², H. Tawbi³, D. Schadendorf⁴, V. Atkinson⁵, M. Maurer⁶, K. Simonsen⁷, C. Harbison⁷, F.S. Hodi⁸; ¹MD/US, ²NSW/AU, ³TX/US, ⁴DE, ⁵QLD/AU, ⁶US, ⁷NJ/US, ⁸MA/US
- 12:45 - 12:45 **1303TiP - Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma**
M. Rohaan¹, T. Borch², J. van den Berg¹, M. Geukes Foppen¹, M. Donia², Ö. Met², B. Nuijen¹, M. van Zon¹, E. Bakker¹, R. de Boer¹, L. Pronk¹, S. Wilgenhof¹, C. Blank¹, J. van Thienen¹, A. van Akkooi¹, I.-M. Svane², J. Haanen¹; ¹NL, ²DK

- 12:45 - 12:45 **1304TiP - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)**
J. Weber¹, G. Long², J. Haanen³, A. Arance⁴, R. Dummer⁵, P. Nathan⁶, A. Ribas⁷, P. Ascierto⁸, C. Robert⁹, E. Gasal¹, A. D'Amelio Jr¹, S. Bettinger⁵, A. Boran¹, D. Schadendorf¹⁰; ¹US, ²NSW/AU, ³NL, ⁴ES, ⁵CH, ⁶Middlesex/GB, ⁷CA/US, ⁸IT, ⁹FR, ¹⁰DE
- 12:45 - 12:45 **1305TiP - Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors**
P. Terheyden, C. Weishaupt, L. Heinzerling, U. Klinkhardt, J. Krauss, P. Mohr, F. Kiecker, J. Becker, A. Dähling (Submitter), F. Döner, R. Heidenreich, B. Scheel, O. Schönborn-Kellenberger, T. Seibel, U. Gnad-Vogt; DE
- 12:45 - 12:45 **1306TiP - ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma**
P. Ascierto¹, P. Arenberger², V. Atkinson³, J. Hansson⁴, E. Kapiteijn⁵, C. Loquai⁶, S. Negrier⁷, H. Shaw⁸, A. Tarhini⁹, J. Walker¹⁰, J. Geib¹¹, S. Rahimian¹², S. Swann¹², A. Diab¹¹; ¹IT, ²CZ, ³QLD/AU, ⁴SE, ⁵NL, ⁶DE, ⁷CEDEX/FR, ⁸GB, ⁹OH/US, ¹⁰CA, ¹¹US, ¹²PA/US
- 12:45 - 12:45 **Endocrine and neuroendocrine tumors**
- 12:45 - 12:45 **1314P - Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies**
D. Hörsch¹, R. Garcia-Carbonero², J. Valle³, P. Perros³, S. Welin⁴, L. Keeber³, A. Houchard⁵, P. Lapuerta⁶; ¹DE, ²ES, ³GB, ⁴SE, ⁵FR, ⁶US
- 12:45 - 12:45 **1315P - Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study**
R. Garcia-Carbonero¹, V. Alonso¹, J. Capdevila¹, M. Sanchez Canovas¹, T. Alonso¹, M. Benavent¹, A. Custodio¹, G. Crespo Herrero¹, C. Lopez¹, J. Hernando¹, M.C. Riesco Martinez², P. Escudero¹, J. Gallego Plazas³, M. Marazuela¹, J.A. Diaz¹, M. Llanos-Munoz⁴, A. La Casta¹, J.C. Percovich¹, P. Jimenez-Fonseca¹, A. Carmona-Bayonas¹; ¹ES, ²Ontario/ES, ³Alicante/ES, ⁴Santa Cruz de Tenerife, Canary Islands/ES
- 12:45 - 12:45 **1316P - Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study**
J. Strosberg¹, A. Hendifar², J. Yao³, M. Kulke⁴, T. O'Dorisio¹, M. Caplin⁵, R. Baum⁶, P. Kunz², T. Hobday¹, E. Wolin¹, E. Mittra¹, K. Oberg⁷, P. Ruszniewski⁸, B. Polack¹, B. He⁹, D. Barton¹, P. Santaro¹, E. Krenning¹⁰; ¹US, ²CA/US, ³TX/US, ⁴MA/US, ⁵GB, ⁶DE, ⁷SE, ⁸FR, ⁹CH, ¹⁰NL

- 12:45 - 12:45 **1317P - Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)**
L. Apostolidis, D. Jäger, E. Winkler; DE
- 12:45 - 12:45 **1318P - Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence**
M. Frizziero¹, F. Spada², A. Lamarca³, Z. Kordatou⁴, J. Barriuso³, C. Nuttall³, M. McNamara³, R. Hubner³, W. Mansoor³, P. Manoharan³, N. Fazio², J. Valle³; ¹Bolzano/GB, ²IT, ³GB, ⁴Nicosia/GB
- 12:45 - 12:45 **1319P - Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)**
S. Pusceddu¹, C. Vernieri¹, M. Di Maio¹, N. Prinzi¹, M. Torchio², R. Buzzoni¹, X.-M. Truong-Thanh³, V. Mazzaferro¹, F.G. de Braud¹; ¹IT, ²Pavia/IT, ³FR
- 12:45 - 12:45 **1320P - The prognostic role of morphology and Ki67 in grade 3 gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN)**
A. Hayes, M. Furnace, C. Rundell, R. Shah, G. Muller, C. Thirlwell, T.V. Luong, C. Toumpanakis, M. Caplin, D. Mandair; GB
- 12:45 - 12:45 **1321P - Surgical resection of primary tumor is prolonged survival in metastatic pancreatic neuroendocrine carcinoma**
T. Feng, CN
- 12:45 - 12:45 **1322P - The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)**
E. Segelov¹, E. Bergsland², C. Card³, T. Hope², P. Kunz², D. Laidley⁴, B. Lawrence⁵, S. Leyden⁶, M. Michael⁶, L. Modahl⁵, S. Myrehaug⁴, S. Padda², R. Pommier⁷, R. Ramirez⁸, M. Soulen⁹, J. Strosberg¹⁰, A. Thawer¹¹, B. Wei¹², S. Singh⁴; ¹NSW/AU, ²CA/US, ³AB/CA, ⁴ON/CA, ⁵NZ, ⁶VIC/AU, ⁷OR/US, ⁸LA/US, ⁹PA/US, ¹⁰US, ¹¹CA, ¹²AL/US
- 12:45 - 12:45 **1323P - Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in patients with pulmonary carcinoid tumours: Prevalence and prognosis of an under-recognised disease**
A. Hayes¹, J. Banks¹, H. Shah¹, T.V. Luong¹, S. Navalkisoor¹, A. Grossman², D. Mandair¹, C. Toumpanakis¹, M. Caplin¹; ¹GB, ²Oxfordshire/GB
- 12:45 - 12:45 **1324P - The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)**

N. Prinzi¹, E. Seregni¹, A. RAIMONDI¹, M. Maccauro¹, F. Corti¹, G. Lo Russo¹, F. Nichetti¹, M. Torchio², J. Coppa¹, G. Peverelli¹, F. Pagani¹, M. Di Bartolomeo¹, V. Mazzaferro¹, F. de Braud¹, S. Pusceddu¹; ¹IT, ²Pavia/IT

- 12:45 - 12:45 **1325P - Prognostic importance of lymph node (LN) yield after curative resection of gastroenteropancreatic neuroendocrinetumours (GEP NETs)**
J. Chiramel¹, R. Almond¹, A. Slagter², A. Khan¹, K.H.J. Lim¹, B. Chakrabarty¹, A. Minicozzi¹, A. Lamarca¹, W. Mansoor¹, R. Hubner¹, J. Valle¹, M. McNamara¹; ¹GB, ²NL
- 12:45 - 12:45 **1326P - Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors**
A. Koumariou¹, D. Pectasides¹, K. Manousou¹, D. Dionysopoulos¹, G. Kaltsas¹, D. Kolomodi¹, C. Poulis¹, M. Skondra¹, E. Samantas², G. Pentheroudakis¹, G. Fountzilas¹; ¹GR, ²Attica/GR
- 12:45 - 12:45 **1327P - Improved quality of life in patients with GEP-NETs treated with 177Lu-dotatate**
B. Saravana-Bawan¹, M. Wieler², T. McMullen², A. McEwan²; ¹CA, ²AB/CA
- 12:45 - 12:45 **1328P - Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals**
C. Bouvier¹, M. Caplin¹, S. Conroy², P. Davies¹, S. Dureja³, M. Falconi⁴, P. Ferolla⁴, G. Fisher⁵, G. Goldstein⁶, R. Hicks⁷, R. Hollander⁶, T. Kolarova⁶, B. Lawrence², S. Leyden⁷, Y. Majima⁸, D. Metz⁶, D. O'Toole⁹, P. Ruzniewski¹⁰, B. Wiedenmann¹¹; ¹GB, ²NZ, ³IN, ⁴IT, ⁵CA/US, ⁶US, ⁷VIC/AU, ⁸JP, ⁹IE, ¹⁰FR, ¹¹DE
- 12:45 - 12:45 **1329P - Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy**
J. Hernando Cubero¹, E. Grande¹, P. Jimenez Fonseca¹, C. Villabona¹, J. Trigo Perez¹, J. Martinez Trufero¹, I. Pajares Bernad¹, C. Lopez¹, T. Alonso¹, J. Biarnes¹, T. Ramón Y Cajal¹, M. Duran¹, J. Grau¹, S. Arevalo Lobera¹, R. Mesia Nin², M. Llanos¹, E. Dalmau Portulas¹, C. Alvarez¹, C. Zafon¹, J. Capdevila¹; ¹ES, ²Barcelona/ES
- 12:45 - 12:45 **1330P - Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry**
S. Thyparambil¹, E. An², S. Sellappan², E. Wertheimer¹, S. Landolfi³, J. Capdevila³, F. Cecchi¹, P. Nuciforo³, R. Heaton², T. Hembrough¹; ¹US, ²MD/US, ³ES
- 12:45 - 12:45 **1331P - Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)**
V. Prasad¹, R. Srirajaskanthan², C. Grana³, S. Baldari³, T. Shah², A. Lamarca², F. Courbon⁴, K. Scheidhauer¹, E. Baudin⁵, X.-M. Truong-Thanh⁴, A. Houchard⁴, L. Bodei⁶; ¹DE, ²GB, ³IT, ⁴FR, ⁵CEDEX/FR, ⁶US

- 12:45 - 12:45 **1332P - Detection of mutations and copy number alterations in circulating DNA from pancreatic neuroendocrine tumor patients**
G. Boons, K. Op de Beeck, T. Vandamme, M. Beyens, G. Roeyen, K. Janssens, K. Zwaenepoel, G. van Camp, M. Peeters; BE
- 12:45 - 12:45 **1333TiP - CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)**
A. Bongiovanni¹, S. Pusceddu², S. Leo², G. Di meglio², F. Gelsomino², F. Pucci², R. Berardi², S. Ricci², I. Lolli², F. Bergamo², D. Campana², D. Santini², S. Tamberi³, D. Pastorelli², M. Cives⁴, N. Silvestris², A. Russo², A. Buonadonna², F. FOca², T. Ibrahim¹; ¹Forlì-Cesena/IT, ²IT, ³Ravenna/IT, ⁴FL/IT
- 12:45 - 12:45 **1334TiP - A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose bengal disodium**
T. Price¹, G. Cehic¹, I. Kirkwood¹, G. Maddern¹, E. Wachter², D. Sarson³, R. Sebben¹, L. Leopardi¹, J. Reid¹, S. Neuhaus¹; ¹SA/AU, ²TN/US, ³NSW/AU
- 12:45 - 12:45 **1335TiP - COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-edotreotide vs. everolimus in progressive GEP-NET**
M. Pavel, A. Rinke, R. Baum; DE
- 12:45 - 12:45 **Thyroid cancers**
- 12:45 - 12:45 **1823P - Synergistic anti-cancer effect of histone deacetylase inhibition and blockade of the glycolytic pathway**
S.Y. Kim, Y.S. Lee, H. Chang, H.-S. Chang, C.S. Park; KR
- 12:45 - 12:45 **1824P - Lenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)**
C. Dierks, C. Miething, O. Thomusch, N. von Bubnoff, J. Duyster; DE
- 12:45 - 12:45 **1825P - Both HIF-1 α and GAB1 can regulate pim-1 in the papillary thyroid carcinoma**
X. Zhu, Q. Wen, M. Ge; CN
- 12:45 - 12:45 **1826P - Increase in thyroid cancer (TC) incidence in Cyprus: Overdiagnosis or true increase of clinically relevant TC?**
H. Charalambous¹, A. Demetriou², S. Frangos², P. Pavlou²; ¹Nicosia/CY, ²CY
- 12:45 - 12:45 **1827P - Surgery for lymph node metastases of sporadic medullary thyroid carcinoma**
W. fan, H. Jiang; CN

- 12:45 - 12:45 **1828P - Role of SPECT-CT somatostatin-receptor scintigraphy in the management of medullary thyroid cancer (MTC)**
S. Sergieva, M. Atanasova, A. Fakirova, S. Velchova; BG
- 12:45 - 12:45 **Tumour biology and pathology**
- 12:45 - 12:45 **1829TiP - A noninferiority trial of cabozantinib (C) comparing 60&&**
J. Krajewska¹, B. Robinson², B. Keam³, J. Capdevila⁴, A. Klochikhin⁵, H. Gan², E. Kapiteijn⁶, R. Elisei⁷, J. Partyka⁸, A. Borgman⁸, M. Schlumberger⁹; ¹PL, ²AU, ³KR, ⁴ES, ⁵RU, ⁶NL, ⁷IT, ⁸US, ⁹FR
- 12:45 - 12:45 **1898P - The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC**
I. Jancewicz, N. Rusetska, A. Armatowska, M. Stachowiak, K. Pogoda, A. Niwińska, W. Olszewski, Z. Nowecki, T. Sarnowski, E. Sarnowska, J. Siedlecki; PL
- 12:45 - 12:45 **1899P - Fluoropyrimidine and inflammatory genes promoter methylation in Egyptian CRC patients**
M. Fouad, S. Salem, M. Hussein, A. Zekri, D. Badr, H. Hafez, E. Eldesouky, S. Shouman; EG
- 12:45 - 12:45 **1900P - Real-world prospective data of small biopsy samples for tumor PD-L1 expression in non-small cell lung cancer**
K. Morikawa, A. Tsunoda, T. Inoue, M. Mineshita; JP
- 12:45 - 12:45 **1901P - ATM as a DNA damage response protein in uveal melanoma: Association with clinicopathological factors and prognostic outcome**
J. Jha, M. Singh, N. Pushker, S. Sen, S. Kashyap; IN
- 12:45 - 12:45 **1902P - BRCA mutation and castration-resistant prostate cancer**
L. Spirina, RU
- 12:45 - 12:45 **1903P - Prevalence of KRAS mutation subtypes and MSI status in pancreatic cancer**
P. Gultawatvichai¹, I. Puthawala¹, K. Tomaszewicz¹, V. Bathini², L. Hutchinson¹; ¹US, ²MA/US
- 12:45 - 12:45 **1904P - Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study**
F. Zanelli, M. Pagano, C. Bonelli, R. Gnani, L. Boni, G.L. Ceresoli, M. Larocca, M. Tiseo, P. Zucali, F. Grosso, F. Cappuzzo, A. CIARROCCHI, F. TORRICELLI, C. Pinto; IT

- 12:45 - 12:45 **1905P - N-Myc and STAT interactor (NMI) as a key determinant of chemosensitivity in breast cancer: Proteomic-based computing network mapping and in vivo verification with a mouse model**
H. Lee, K.-M. Lee, D. Han, H. Ryu; KR
- 12:45 - 12:45 **1906P - Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing**
F. Grossi, C. Genova, D. Cittaro, S. Bonfiglio, S. Boccardo, I. Vanni, M. Mora, M.G. Dal Bello, F. Biello, E. Rijavec, C. Sini, G. Rossi, M. Tagliamento, A. Alama, G. Burrafato, G. Barletta, A. Ballestrero, S. Coco; IT
- 12:45 - 12:45 **1907P - Discordance of the PAM50 intrinsic subtypes compared with IHC-based surrogate in breast cancer patients: Potential implication of genomic alterations of discordance**
Y.H. Park, H.K. Kim, J.H. Cho; KR
- 12:45 - 12:45 **1908P - Impact of invasive lobular carcinoma in Latin American breast cancer patients; disease-free survival: The new paradox**
D. Flores-Díaz, C. Arce Salinas, L. Flores, F. Lara, J.A. Matus Santos, J.E. Bargallo Rocha, V. Perez, N. Reynoso-Noveron, P.A. Cabrera, A. Mohar; MX
- 12:45 - 12:45 **1909P - Clinical validation of an NGS-based assay for the detection of BRCA1 and BRCA2 variants in Chinese patients with breast cancer or ovarian cancer**
Q. Gao, G. Zhu, H. Ge, X. Li, L. Ruan; CN
- 12:45 - 12:45 **1910P - Correlation between the expression of androgens receptor (RA) and histopathological characteristics and survival parameters of breast cancer**
I. Sillero, A. López González, L.F. Sanchez Cousido, M. López-Flores, E. Honrado Franco, L. Lopez Gonzalez, O. Sanz, C. Castañón López, A. García Palomo; ES
- 12:45 - 12:45 **1911P - Metabolic syndrome in breast cancer patients: An observational study**
S. Khare, IN
- 12:45 - 12:45 **1912P - The prognostic value of different molecular subtypes of breast cancer in relation to enhancer-of-zeste homologue 2 expression**
Z. Sanaat¹, R. Dolatkah²; ¹East Azarbaijan/IR, ²IR
- 12:45 - 12:45 **1913P - A guided and personalised treatment in metastatic breast cancer: Optimisation of gene and protein expression in tumor tissue**
E. Seront, S. Lejeune, B. Petit, V. Samartzy, S. Sauvage, J.-F. Laes; BE
- 12:45 - 12:45 **1914P - HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer**
H. Yi-Hsuan, L. Yen-Shu, H. Chih-Yi, T. Ling-Ming; TW
- 12:45 - 12:45 **1915P - Does the minimal axillary approach lead to loss of prognostic factors in breast cancer?**

R. de Araujo¹, C. Nascimento², C. Da Cunha², E. Marinho², E. Mosca², F. Da Luz², P. Delfino², R. Antonioli², T. Mendes², M. Silva²; ¹MG/BR, ²BR

- 12:45 - 12:45 **1916P - The influence of the surgical approach in women diagnosed with breast neoplasia**
R. de Araujo¹, C. Nascimento², C. Da Cunha², E. Marinho², E. Mosca², F. Da Luz², P. Delfino², R. Antonioli², T. Mendes², M. Silva²; ¹MG/BR, ²BR
- 12:45 - 12:45 **1917P - Use of comparative proteomics to identify potential cisplatin-resistance mechanisms in neuroblastoma**
M.A. Merlos Rodrigo, H. Buchtelova, V. Strmiska, Z. Heger, V. Adam; CZ
- 12:45 - 12:45 **1918P - Acquired resistance mechanism of osimertinib targeting EGFR in human lung cancer**
V. Ciaramella, C.M. Della Corte, G. Barra, R. Di Liello, G. Viscardi, M. Orditura, E. Martinelli, F. Ciardiello, F. Morgillo; IT
- 12:45 - 12:45 **1919P - Interaction of oncostatin M and its receptor OSMR promotes gastric cancer progression via STAT3/FAK/Src signaling**
L. Su, X. Wu, J. Li, Z. Yu, B. Liu; CN
- 12:45 - 12:45 **1920P - Role of pioglitazone on gene/protein expression profile, bioenergetics and TGF β 2/SMAD signaling pathway in NSCLC**
R. Di Liello, G. Viscardi, V. Ciaramella, G. Barra, G. Esposito, M. Fasano, F. Ciardiello, F. Morgillo; IT
- 12:45 - 12:45 **1921P - Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma**
S. Han, J. Yeong, C. Lim, M.-K. Ang, W. Lim, C.K. Toh, Q.S. Ng, D. Tan, T. Lim, J.H. Loh, A. Tanako, R. Kanesvaran, W.L. Tan, T. Rajasekaran, W. Nei, A. Jain; SG
- 12:45 - 12:45 **1922P - The role of neurotrophic factors in nerve-cancer crosstalk**
A. Planken, L. Truu, K. Oselin, V. Valvere; EE
- 12:45 - 12:45 **Thyroid hormone negatively regulates tumorigenicity by suppression of BC200 in liver cancer**
K.-H. Lin, M.-H. Wu, Y.H. Lin; TW
- 12:45 - 12:45 **1924P - Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells**
S.Y. Cheng, W.-F. Chen, Z.-H. Wen; TW
- 12:45 - 12:45 **1925P - Combining 2D angiogenesis and 3D osteosarcoma microtissues to improve vascularization**
H. Chaddad, FR

- 12:45 - 12:45 **1926P - Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy**
Z. Zhang, Y. Huang, Y. Zhou, J. Yang, K. Hu, Z. Wang; CN
- 12:45 - 12:45 **1927P - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer**
K. Saeki¹, H. Onishi², Y. Oda¹, M. Nakamura¹; ¹JP, ²Fukuoka/JP
- 12:45 - 12:45 **1928P - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)**
A. Weissferdt¹, B. Sepesi², A. Pataer², N. Kalhor¹, C. Moran¹, W. William¹, X. Le¹, B. Glisson¹, F. Skoulidis², G. Blumenschein¹, J. Zhang¹, M. Altan¹, D. Rice², R. Mehran², J. Lee¹, A. Vaporciyan², D. Gibbons², S. Swisher², J. Heymach¹, T. Cascone³; ¹US, ²TX/US, ³MO/US
- 12:45 - 12:45 **1929P - Tumor-infiltrating CD3&&**
M.H. Hong, S.-J. Shin, Y.-L. Choi, B.C. Cho, H.R. Kim; KR
- 12:45 - 12:45 **1930P - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma**
M.-W. Lee, N. Kim, S. Kim, M. Joo, H. Ryu, H.J. Lee; KR
- 12:45 - 12:45 **1931P - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis**
T. Mrowiec¹, F. Wilm¹, E. Frick-Krieger¹, M. Silva¹, L. Terracciano², I. Dussault³, C. Ihling¹; ¹DE, ²CH, ³MA/US
- 12:45 - 12:45 **1932P - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis**
N. Sato, T. Tasaki, H. Noguchi, K. Irie, T. Nakayama; JP
- 12:45 - 12:45 **1933P - Autofluorescence: A new marker for identifying cancer stem cells (CSCs) in primary tumors**
M. López Gómez, E. Casado, M. Muñoz, S. Alcalá, J. Moreno-Rubio, S. Salinas, F. Zambrana, A.M. Jiménez-Gordo, B. Sainz Jr; ES
- 12:45 - 12:45 **1934P - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells**
K. Morita¹, T. Fujii², K. Shimada¹, H. Itami¹, K. Hatakeyama¹, M. Miyake¹, K. Fujimoto¹, C. Ohbayashi¹; ¹JP, ²634-8522/JP
- 12:45 - 12:45 **1935P - Somatic-stem transition of tumor cells is a key link in the metastasis**
N. Litviakov, M. Ibragimova, E. Slonimskaya, E. Skurikhin, M. Tsyganov, O. Pershina, I. Deriusheva, P. Kazantseva; RU

13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 28	ICM - Room 1
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 29	ICM - Room 14b
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 30	ICM - Room 13
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 31	Hall A1 - Room 16
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 5	Hall B3 - Room 23
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 32	Hall B3 - Room 20
13:00 - 14:30	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Immune check point inhibitors: Are we ready for combination? Chair(s): John Haanen, NL	Hall B3 - Room 22

13:00 - 13:05	Introduction <u>J. Haanen</u> , NL
13:05 - 13:15	Mechanisms of chemotherapy-induced increased immune response <u>J. Vansteenkiste</u> , BE
13:15 - 13:40	Achievements and present development in lung cancer <u>M.C. Garassino</u> , IT
13:40 - 14:05	Where do we stand in TNBC breast cancer? <u>S. Loi</u> , VIC/AU
14:05 - 14:25	Which patients do benefit? How to select and for which benefit? <u>J. Haanen</u> , NL
14:25 - 14:30	Conclusion <u>J. Haanen</u> , NL

13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 34	Hall B4 - Room 19
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 6	Hall B4 - Room 24
14:30 - 16:30	Type: Clinical Practice Guidelines Title: ESMO Clinical Practice Guidelines 2 Chair(s): George Pentheroudakis, GR; Cristiana Sessa, CH	Hall A1 - Room 15

14:30 - 14:40	Introduction to the ESMO Clinical Practice Guidelines <u>G. Pentheroudakis</u> , GR
---------------	---

- 14:40 - 14:50 **Questionnaire**
C. Sessa, CH
- 14:50 - 15:00 **Early HER2-positive breast cancer**
S. Volovat, Iasi/RO
- 15:00 - 15:10 **Discussant**
E. Senkus-Konefka, PL
- 15:10 - 15:15 **Q&A**
- 15:15 - 15:25 **Soft tissue sarcoma**
B. Lopes David, BR
- 15:25 - 15:35 **Discussant**
S. Stacchiotti, IT
- 15:35 - 15:40 **Q&A**
- 15:40 - 15:50 **Cancer cachexia**
T. Solheim, NO
- 15:50 - 16:00 **Discussant**
J. Arends, DE
- 16:00 - 16:05 **Q&A**
- 16:05 - 16:15 **Prostate cancer**
M. Serra, GB
- 16:15 - 16:25 **Discussant**
C. Parker, GB
- 16:25 - 16:30 **Q&A**

14:30 - 17:30 **Type: Young Oncologist session** **ICM -**
Title: YO Masterclass: From genetic data to clinical trial design: **Room 14c**
Joint session EACR and ESMO YOC
Chair(s): Therese Sorlie, NO; Guillem Argiles, ES

14:30 - 15:10 **Next generation sequencing of cancer**
N. Normanno, IT

15:10 - 15:50 **Fighting cancer with biomarker data analysis**
S. Michiels, FR

15:50 - 16:10 **Break**

16:10 - 16:50 **Immuno genetics & immuno genomics**
N. Halama, DE

16:50 - 17:30 **Crystallising Knowledge, new trial designs in the molecular oncology era**
J. Rodon, ES

14:45 - 16:15 **Type: Special Symposium** **Hall A1 - Room 17**
Title: Tumour heterogeneity in gynaecological cancers
Chair(s): David Huntsman, CA; Susana Banerjee, GB

- 14:45 - 14:50 **Introduction**
D. Huntsman, British Columbia/CA
- 14:50 - 15:10 **The molecular classification of endometrial cancer: Applications for treatment decisions**
C. Creutzberg, NL
- 15:10 - 15:30 **Intratumour heterogeneity in high grade serous ovarian cancer and beyond**
B. Davidson, NO
- 15:30 - 15:50 **The immune response and heterogeneity in gynaecological cancers: Treatment opportunities**
A. González Martín, ES
- 15:50 - 16:10 **Genomics of rare ovarian cancers: What have we learned and who how can it influence practice?**
D. Huntsman, British Columbia/CA
- 16:10 - 16:15 **Conclusions and perspectives**
S. Banerjee, GB

14:45 - 16:15 **Type: Special Symposium** **Hall A2 - Room 18**
Title: Combination strategies of immunotherapy in breast cancer
 Chair(s): Giuseppe Curigliano, IT; Shinji Ohno, JP

14:45 - 14:50 **Introduction**
S. Ohno, Fukuoka/JP

14:50 - 15:10 **Integrating genomic data and immuno-markers in breast cancer**
G. Curigliano, IT

15:10 - 15:30 **Combining chemotherapy and immunotherapy in TNBC**
L. Carey, NC/US

15:30 - 15:50 **Combining anti HER2 with immunotherapy in HER2+ patients**
S. Loi, VIC/AU

15:50 - 16:10 **Immunotherapy strategies for luminal breast cancer**
M. Kok, NL

16:10 - 16:15 **Conclusions and perspectives**
G. Curigliano, IT

14:45 - 16:00 **Type: Poster Discussion session** **ICM - Room 1**
Title: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
 Chair(s): Wilfried Eberhardt, DE; Pieter Postmus, NL; Jean-Louis Pujol, FR; Cécile Le Pechoux, FR

14:45 - 14:45 **1348PD - Genomic landscape and its correlation with TMB, CD8 TILs and PD-L1 expression in Chinese lung squamous cell carcinoma**
C. Zhou, T. Jiang; CN

14:45 - 14:45 **1349PD - Gene expression signature of DNA damage response to predict the prognosis of early stage lung adenocarcinoma**
Z. Wang, C. Xu, J. Zhao, X. Zhao, S. Cai, Y. Song, J. Wang; CN

14:45 - 14:45 **1350PD_PR - Social and behavioral indicators of undergoing a screening test for lung cancer**
S. Couraud¹, J.F. Morère², J. Viguier², M. Roupert², L. Brignoli-Guibaudet², C. Lhomel², T. de La Motte Rouge², F. Eisinger³, L. Greillier²; ¹CEDEX/FR, ²FR, ³CEDEX 9/FR

14:45 - 15:00 **Invited Discussant 1348PD, 1349PD and 1350PD_PR**
W. Eberhardt, DE

- 15:00 - 15:10 **Q&A led by Discussant**
- 15:10 - 15:10 **1364PD - Cardiac events in stage III non-small cell lung cancer (NSCLC) treated in daily clinical practice: Is it time for cardiovascular screening and follow-up?**
J. Degens, D. De Ruyscher, B. Kietselaer, G. Bootsma, A. Schols, A.-M. Dingemans; NL
- 15:10 - 15:10 **1806PD - Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome**
S. Cedres Perez¹, M. Sanso¹, A. Hernando-Calvo¹, A. Callejo¹, N. Pardo Aranda¹, A. Navarro Mendivil¹, A. Martinez¹, J. Remon², J.M. Miquel¹, G. Rodriguez¹, V. Monton¹, G. Villacampa¹, R. Dienstmann¹, A. Vivancos¹, E. Felip¹; ¹ES, ²Barcelona/ES
- 15:10 - 15:20 **Invited Discussant 1364PD and 1806PD**
P. Postmus, Merseyside/NL
- 15:20 - 15:25 **Q&A led by Discussant**
- 15:25 - 15:25 **1665PD - Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study**
I. Bondarenko¹, O. Juan-Vidal², G. Pajkos³, A. Kryzhanivska¹, Z. Pápai Székely³, D. Vicente², I. Vynnychenko¹, S. Jones⁴, Y. Wang⁴, H. Jiang⁴, N. Reinmuth⁵; ¹UA, ²ES, ³HU, ⁴MD/US, ⁵DE
- 15:25 - 15:25 **1666PD - Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy**
K. Dragnev¹, T. Owonikoko², T. Csozsi³, M. Maglakelidze⁴, J. Beck⁵, M. Domine Gomez⁶, A. Lowczak⁷, A. Fulop³, R. Hoyer¹, W. Hanna¹, P. Lowry¹, R. Aljumaily⁸, V. Chiu¹, I. Bulat⁹, Z. Yang¹, P. Roberts¹, J. Antal¹, R. Malik¹, S. Morris¹, J. Weiss¹; ¹US, ²GA/US, ³HU, ⁴GE, ⁵AZ/US, ⁶ES, ⁷PL, ⁸OK/US, ⁹MD
- 15:25 - 15:35 **Invited Discussant 1665PD and 1666PD**
J.-L. Pujol, CEDEX 5/FR
- 15:35 - 15:40 **Q&A led by Discussant**
- 15:40 - 15:40 **1667PD - Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)**
H. Veer¹, F. Caparrotti¹, A. Xyrafas¹, A. Fuhrer¹, U. Meier¹, M. Mark¹, O. Elicin¹, D. Aebersold¹, D. Betticher², C. Biaggi Rudolf¹, K. Ribi¹, T. Finazzi¹, D. Zwahlen¹; ¹CH, ²CH/CH

- 15:40 - 15:40 **1365PD - Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study**
J. Schoenmaekers, P. Hofman, G. Bootsma, M. Westenend, M. De Booi, W. Schreurs, R. Houben, D. De Ruyscher, A.-M. Dingemans, L. Hendriks; NL
- 15:40 - 15:50 **Invited Discussant 1667PD and 1365PD**
C. Le Pechoux, CEDEX/FR
- 15:50 - 15:55 **Q&A led by Discussant**

14:45 - 16:15	Type: Educational session Title: Revisiting systemic therapy in HNSCC in the era of immunotherapy Chair(s): Ezra Cohen, US; Ana Castro, PT	ICM - Room 13
----------------------	--	--------------------------

- 14:45 - 15:10 **New data from randomised studies in recurrent metastatic setting**
M. Merlano, IT
- 15:10 - 15:35 **Management of toxicities**
A. Castro, PT
- 15:35 - 16:00 **Patients selection**
I. Braña Garcia, ES

14:45 - 16:15 **Type: Educational session** **Hall B3 - Room 21**
Title: Sarcomas as a key foundation for molecular-targeted basket trials
 Chair(s): George D. Demetri, US; Sebastian Bauer, DE

14:45 - 15:10 **Targeting translocations in sarcomas: From EWS to NTRK-translocated sarcomas**
G. Demetri, US

15:10 - 15:35 **A basket of epigenetic changes in sarcomas: EZH2 inhibitor development and targeting the SWI/SNF complex in synovial sarcomas**
R. Jones, WA/GB

15:35 - 16:00 **Current and emerging spectra of kinase targeting: From PDGFRA in STS to mTOR in PEComas**
S. Bauer, DE

16:00 - 16:15 **Discussion**

- 14:45 - 16:15** **Type: Proffered Paper session** **Hall B3 - Room 20**
Title: Proffered paper session - Supportive and palliative care
 Chair(s): Karin Jordan, DE; Jorn Herrstedt, DK
- 14:45 - 14:57 **16810 - Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data**
M. Aapro¹, F. Scotté², Y. Escobar³, L. Celio⁴, R. Berman⁵, A. Franceschetti⁵, D. Bell⁶, K. Jordan⁷; ¹CH, ²FR, ³ES, ⁴IT, ⁵GB, ⁶US, ⁷DE
- 14:57 - 15:09 **16820_PR - Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving fluoropyrimidines and/or irinotecan based therapy**
A. Sharma, S. Chaudhary, V. Raina, N. Shukla, V. Sreenivas, S. Prakash, P. Priyatma, S. Bharti; IN
- 15:09 - 15:24 **Invited Discussant 16810 and 16820**
J. Herrstedt, DK
- 15:24 - 15:36 **15110 - Training oncologists and preparing patients for shared decision making about palliative systemic treatment: Results from the randomized controlled CHOICE study**
H. van Laarhoven, I. Henselmans, P. van Maarschalkerweerd, H. de Haes, D. Sommeijer, P.B. Ottevanger, H.-B. Fiebrich, S. Dohmen, G.-J. Creemers, F. De Vos, E. Smets; NL
- 15:36 - 15:48 **15120 - Automated survival prediction in metastatic cancer patients using high-dimensional electronic medical record data**
M. Gensheimer¹, A. Henry², D. Wood², T. Hastie², S. Aggarwal¹, S. Dudley¹, P. Pradhan¹, I. Banerjee², E. Cho¹, K. Ramchandran¹, E. Pollom¹, A. Koong¹, D. Rubin², D. Chang¹; ¹US, ²CA/US
- 15:48 - 16:00 **15390 - Post-traumatic growth and death anxiety in caregivers of cancer patients: PHOENIX study**
A. Alkan, E.B. Köksoy, E. Karıcı, H. Burgaç, A. Arıkanoğlu Soğancı, D. Yaman, F. Çay Şenler; TR
- 16:00 - 16:15 **Invited Discussant 15120 and 15390**
L. Travado, PT

14:45 - 16:15 **Type: Special Symposium** **Hall B3 - Room 22**
Title: Emerging therapies in neuroendocrine and endocrine malignancies
 Chair(s): Marianne Pavel, DE; Eric Baudin, FR

14:45 - 14:50 **Introduction**
M. Pavel, DE

14:50 - 15:05 **Immunotherapy in NETs: Where are we now?**
K. Oeberg, SE

15:05 - 15:20 **Novel targeted therapies in NETs**
R. Garcia-Carbonero, ES

15:20 - 15:35 **Novel targeted therapies in thyroid carcinoma**
S. Leboulleux, FR

15:35 - 15:50 **Novel therapies in adrenal malignancies**
M. Fassnacht, DE

15:50 - 16:05 **Novel approaches in mixed adenoneuroendocrine carcinoma**
A. Berruti, IT

16:05 - 16:15 **Conclusions and clinical perspectives**
E. Baudin, CEDEX/FR

14:45 - 16:15 **Type: EONS session** **Hall B4 - Room 24**
Title: The essential elements of safety standards for systemic cancer therapies
Chair(s): Theresa Wiseman, GB

14:45 - 15:00 **The pharmacist's perspective**
K. Meier, DE

15:00 - 15:15 **The oncologist's perspective**
F. Overkamp, DE

15:15 - 15:30 **The nurse manager's perspective**
C. Lacerda, GB

15:30 - 15:45 **The clinical nurse's perspective**
H. Titzer, AT

15:45 - 16:00 **The patient's perspective**
M. Järvinen, FI

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Special session** **ICM - Room 14a**
Title: Are there enough cancer services and oncologists in your country?
 Chair(s): Alexandru Eniu, RO; André Ilbawi, CH

14:45 - 14:50 **Introduction**
A. Eniu, RO

14:50 - 15:10 **Where does the world stand on global cancer control?**
A. Ilbawi, CH

15:10 - 15:30 **Tools that show how investing in cancer care pays off**

15:30 - 15:50 **How many patients can one oncologist care for?**
D. Trapani, IT

15:50 - 16:10 **WHO-ESMO Workforce Survey: How can your country assure enough oncologists for the future?**
G. Curigliano, IT

16:10 - 16:15 **Conclusions**
A. Ilbawi, CH

15:00 - 16:05 **Type: Multidisciplinary interactive sessions** **ICM - Room 14b**
Title: Locally advanced pancreatic cancer
 Chair(s): Michel Ducreux, FR

15:00 - 15:05 **Case presentation**
M. Ducreux, FR

15:05 - 15:15 **The surgical point of view: What is resectable?**
A. Sa Cunha, FR

15:15 - 15:25 **The radiation oncologist's point of view**
M. Verheij, NL

15:25 - 15:35 **The medical oncologist's point of view**
M. Ducreux, CEDEX/FR

15:35 - 16:05 **Discussion**

15:00 - 16:00 **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 16**
Title: Management of toxicities of immunotherapy
 Chair(s): James Larkin, GB

15:00 - 15:10 **GI toxicity**
H. Gogas, Attiki/GR

15:10 - 15:20 **Neurotoxicity**
C. Robert, FR

15:20 - 15:30 **How to treat beyond acute toxicity**
J. Larkin, GB

15:30 - 16:00 **Discussion**

15:00 - 16:00 **Type: Special session** **Hall B3 - Room 23**
Title: Precision medicine in daily practice: Recommendations from the ESMO Precision Medicine Working Group
 Chair(s): Fabrice André, FR

15:00 - 15:05 **Multigene sequencing for hard-to-treat cancers**
F. André, FR

15:05 - 15:20 **A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)**
J. Mateo, GB

15:20 - 15:35 **Detecting MSI and TRK fusion using NGS: ESMO recommendations**
J. Reis-Filho, NY/US

15:35 - 15:50 **How to handle with genetic variants detected by multigene sequencing in practice**
A. George, GB

15:50 - 16:00 **Discussion**

16:30 - 18:00 **Type: Educational session** **ICM - Room 1**
Title: Unresolved questions in melanoma
 Chair(s): Helen Gogas, GR; Marisol Soengas, ES

16:30 - 16:55 **Emerging prognostic factors in primary melanoma**
P. Lorigan, GB

16:55 - 17:20 **Treatment in advanced melanoma patients with a worse prognosis**
R. Dummer, CH

17:20 - 17:45 **Patient treatment resistance in melanoma**
J. Haanen, NL

17:45 - 18:00 **Discussion**

16:30 - 17:30 **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 16**
Title: Molecular tumour boards in the practice of precision oncology
 Chair(s): Pierre Saintigny, FR

16:30 - 16:40 **The clinician's perspective**
D. Planchard, FR

16:40 - 16:50 **The bioinformatician's perspective**
F. Mancuso, ES

16:50 - 17:00 **The germline genetician's perspective**
M. Krebs, GB

17:00 - 17:20 **Discussion**

16:30 - 18:10 **Type: Proffered Paper session** **Hall A2 - Room 18**
Title: Presidential Symposium 2
 Chair(s): Fortunato Ciardiello, IT; Josep Tabernero, ES

16:30 - 16:45 **LBA4 - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer**
A. Hoyle¹, S.A. Ali¹, N. James¹, C. Parker¹, A. Cook¹, G. Attard¹, S. Chowdhury¹, W. Cross¹, D. Dearnaley¹, J. de Bono¹, C. Gilson¹, S. Gillessen², R. Jones¹, D. Matheson¹, M. Mason¹, A. Ritchie¹, M. Russell¹, M. Parmar³, M. Sydes⁴, N. Clarke¹; ¹GB, ²CH, ³London/GB, ⁴UK/GB

16:45 - 16:55 **Invited discussant**

K. Fizazi, FR

16:55 - 17:10 **LBA5_PR - Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476)**

C. Parker¹, N. James¹, C. Brawley¹, N. Clarke¹, G. Attard¹, S. Chowdhury¹, W. Cross¹, D. Dearnaley¹, C. Gilson¹, R. Jones¹, M. Mason¹, R. Millman¹, S. Gillessen², C. Eswar¹, J. Gale¹, J. Lester¹, D. Sheehan¹, A. Tran¹, M. Parmar³, M. Sydes⁴; ¹GB, ²CH, ³London/GB, ⁴UK/GB

17:10 - 17:20 **Invited discussant**

R. Bristow, GB

17:20 - 17:35 **LBA6_PR - JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)**

R. Motzer¹, K. Penkov², J. Haanen³, B. Rini⁴, L. Albiges⁵, M. Campbell⁶, C. Kollmannsberger⁷, S. Negrier⁵, M. Uemura⁸, J.L. Lee⁹, H. Gurney¹⁰, R. Berger¹¹, M. Schmidinger¹², J. Larkin¹³, M. Atkins¹⁴, J. Wang¹⁴, P. Robbins¹⁵, A. Chudnovsky¹⁶, A. Di Pietro¹⁷, T. Choueiri¹⁶; ¹NY/US, ²RU, ³NL, ⁴OH/US, ⁵CEDEX/FR, ⁶TX/US, ⁷British Columbia/CA, ⁸JP, ⁹KR, ¹⁰NSW/AU, ¹¹IL, ¹²AT, ¹³GB, ¹⁴US, ¹⁵CA/US, ¹⁶MA/US, ¹⁷IT

17:35 - 17:45 **Invited discussant**

V. Grünwald, DE

17:45 - 18:00 **LBA7_PR - Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial**

K. Moore¹, N. Colombo², G. Scambia², B.-G. Kim³, A. Oaknin⁴, M. Friedlander⁵, A. Lisyanskaya⁶, A. Floquet⁷, A. Leary⁸, G. Sonke⁹, C. Gourley¹⁰, S. Banerjee¹⁰, A. Oza¹¹, A. González-Martín⁴, C. Aghajanian¹², W. Bradley¹³, E. Lowe¹⁴, R. Bloomfield¹⁰, P. DiSilvestro¹⁵; ¹Oklahoma/US, ²IT, ³KR, ⁴ES, ⁵NSW/AU, ⁶RU, ⁷CEDEX/FR, ⁸FR, ⁹NL, ¹⁰GB, ¹¹Ontario/CA, ¹²NY/US, ¹³WI/US, ¹⁴MD/US, ¹⁵US

18:00 - 18:10 **Invited discussant**

J. Ledermann, London/GB

16:30 - 17:45 Type: Poster Discussion session Hall B3 - Room 21
Title: Poster Discussion session - Haematological malignancies

Chair(s): Marion Subklewe, DE; Andres Ferreri, IT; Michele Ghilmini, CH

16:30 - 16:30 **1008PD - CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies**

K. Lee¹, K. Gowrishankar¹, D. Gottlieb², E. Blyth², K. Micklethwaite²; ¹AU, ²NSW/AU

- 16:30 - 16:30 **1009PD - The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS**
H. Medyouf, I. Tirado-Gonzalez, A. Mies, A. Nevmerzhitskaya, A.-S. Kubasch, U. Platzbecker; DE
- 16:30 - 16:45 **Invited Discussant 1008PD and 1009PD**
M. Subklewe, DE
- 16:45 - 16:55 **Q&A led by Discussant**
- 16:55 - 16:55 **1010PD - ALK positive anaplastic large cell lymphoma: Molecular diagnosis and minimal residual disease monitoring**
M. Kalinova, L. Krskova, M. Mrhalova, E. Kabickova, P. Riha, R. Kodet; CZ
- 16:55 - 16:55 **1011PD - Intensified 14-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A systematic review and meta-analysis of randomized controlled trials**
J. Sandoval-Sus¹, S. Dalia², R. Mhaskar³, J. Chavez¹, A. Ausekar⁴, K. Purnapatre⁴, J. Scheiber⁴, L. Sokol¹; ¹FL/US, ²MO/US, ³US, ⁴DE
- 16:55 - 16:55 **1012PD - Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice**
M. Dreyling¹, G. Hess¹, M. Woike², G. Krekeler¹; ¹DE, ²NA
- 16:55 - 16:55 **1013PD - A comparative study of 18F-FDG PET/CT with bilateral bone marrow trephine biopsy for assessment of bone marrow infiltration by lymphoma**
D. Arjunan, G. Prakash, P. Malhotra, N. Varma, S. Varma, A. Das, B. Mittal, R. Basher, D. Lad, S. Kumari, A. Khadwal, S. Vikas, S. Naseem, A. Bal; IN
- 16:55 - 17:10 **Invited Discussant 1010PD, 1011PD, 1012PD and 1013PD**
A. Ferreri, IT
- 17:10 - 17:20 **Q&A led by Discussant**
- 17:20 - 17:20 **1014PD - Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies**
W. Jurczak¹, S. Rule², W. Townsend³, D. Tucker³, B. Sarholz⁴, J. Scheele⁴, J. Gribben³, P. Zinzani⁵; ¹PL, ²Devon/GB, ³GB, ⁴DE, ⁵IT
- 17:20 - 17:20 **1015PD - A prospective study of first-line Helicobacter pylori eradication therapy in treating localized extragastric mucosa-associated lymphoid tissue lymphoma**

S.-H. Kuo, M. Yao, C.-H. Tsai, C.-W. Lin, J.-M. Liou, W.-L. Ma, A.-L. Cheng; TW

17:20 - 17:20 **1016PD - Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma: A preliminary analysis of a multicenter, prospective phase II study (BRiZ2012)**

M. Kanno¹, K. Miura¹, Y. Masaki¹, H. Tsujimura², M. Iino¹, J. Takizawa¹, Y. Maeda¹, K. Yamamoto¹, S. Tamura¹, A. Yoshida¹, H. Yagi¹, I. Yoshida¹, K. Kitazume¹, T. Masunari¹, I. Choi¹, Y. Kakinoki¹, T. Yoshino¹, S. Nakamura¹, T. Yoshida¹; ¹JP, ²Chiba/JP

17:20 - 17:35 **Invited Discussant 1014PD, 1015PD and 1016PD**

M. Ghelmini, CH

17:35 - 17:45 **Q&A led by Discussant**

16:30 - 18:00	Type: EONS session Title: Improving communication in cancer nursing Chair(s): Patrick Crombez, BE	Hall B4 - Room 24
----------------------	---	--------------------------

16:30 - 16:50 **How to communicate well with people with advanced disease**

E. Patiraki, GR

16:50 - 17:10 **Be silent, or say something better than silence**

E. Masel, AT

17:10 - 17:30 **Dealing with impending death in young adult cancer patients: How to communicate and offer effective support in practice**

M. Bisset, GB

17:30 - 18:00 **Discussion**

16:30 - 18:30	Type: Special session Title: Improving research, education and clinical practice in oncology and palliative care - 5th ESMO Designated Centres Community Session and Awards Chair(s): Stein Kaasa, NO; Gudrun Kreye, AT	ICM - Room 14a
16:30 - 16:40	Can we arrive at common research projects? <u>S. Kaasa</u> , NO	
16:40 - 16:55	Education of palliative care specialists in oncology and palliative care to oncologists <u>J. Wood</u> , GB	
16:55 - 17:00	How can the designated centers and ESMO collaborate? - Discussion	
17:00 - 17:15	What is specialised cancer palliative care? Professional competences needed and how to organise the services? <u>C. Zimmermann</u> , CA	
17:15 - 17:20	What are the standards? - Discussion	
17:20 - 17:50	Panel Discussion - Future of the DC Programme how can we improve in research, education and standards of organization? <u>S. Kaasa</u> ¹ , <u>G. Kreye</u> ² , <u>R. Catane</u> ³ , <u>F. Strasser</u> ⁴ , <u>J.H. Loge</u> ¹ ; ¹ NO, ² AT, ³ IL, ⁴ CH	
17:50 - 18:00	Conclusions <u>G. Kreye</u> , AT	
18:00 - 18:30	Designated Centre and Palliative Care Fellowship Awards	
16:45 - 17:45	Type: Poster Discussion session Title: Poster Discussion session - Gastrointestinal tumours, colorectal 2 Chair(s): Silvia Marsoni, IT; Richard Adams, GB	ICM - Room 14b
16:45 - 16:45	456PD - Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer <u>T. Reinert</u> ¹ , T. Henriksen ¹ , M. Rasmussen ¹ , H. Sethi ² , R. Salari ² , S. Shchegrova ² , R. Swenerton ² , H.-T. Wu ² , S. Sharma ² , E. Christensen ¹ , P. Natarajan ² , S. Dashner ² , T. Tin ² , A. Olson ³ , H. Pawar ³ , B. Zimmermann ³ , L. Iversen ¹ , M. Madsen ¹ , J. Lin ³ , C. Andersen ¹ ; ¹ DK, ² CA/US, ³ US	

- 16:45 - 16:45 **457PD - Kinase fusions in colorectal cancers: A unique biologic subset**
R. Madison¹, F. Pietrantonio², L. Juckett¹, C. Cremolini², J. Chung³, L. Albacker¹, V. Miller³, S. Klempner⁴, M. Resnick⁵, E. Yakirevich⁵, S.-H. Ou⁴, M. Fakih⁴, A. Schrock³, J. Ross³, S. Ali³; ¹US, ²IT, ³MA/US, ⁴CA/US, ⁵RI/US
- 16:45 - 16:45 **LBA24 - A Multi-Omic Analysis for Prospective Patient Stratification in Localised Colorectal Cancer (CRC).**
N. Tarazona Llaveró¹, E. Fontana², V. Gambardella³, F. Gimeno-Valiente³, J. Castillo³, A. Calon³, C. Martínez-Ciarpaglini³, L. Peiró-Chova³, M. Huerta³, S. Zuñiga³, P. Rentero-Garrido³, J. Montón-Bueno³, D. Roda³, S. Roselló³, B. Bellosillo³, A. Vivancos³, G. Nyamundana², C. Montagut³, A. Sadanandam², A. Cervantes¹; ¹Valencia/ES, ²GB, ³ES
- 16:45 - 16:45 **458PD - Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)**
R. Das¹, L. Furchtgott¹, F.-S. Ou², D. Swanson³, B. Hayete¹, B. Harms¹, D. Cunha¹, J. Latourelle¹, D. Wuest¹, I. Khalil¹, C. Washburn¹, K. Rich¹, C. Blanke⁴, J. Meyerhardt⁵, D. Niedzwiecki⁶, A. Nixon⁶, E. O'Reilly⁷, F. Innocenti⁸, H.-J. Lenz⁹, A. Venook⁹; ¹US, ²MN/US, ³NO, ⁴OR/US, ⁵MA/US, ⁶NC/US, ⁷NY/US, ⁸US/US, ⁹CA/US
- 16:45 - 17:00 **Invited Discussant 456PD, 457PD, LBA24 and 458PD**
S. Marsoni, (TO)/IT
- 17:00 - 17:15 **Q&A led by Discussant**
- 17:15 - 17:15 **459PD - Long-term results of postoperative chemoradiation therapy with capecitabine and oxaliplatin versus capecitabine alone for locally advanced rectal cancer: A randomized, multicenter, phase III trial**
N. Li, J. Jin, Y. Li, Y. Zhu, W. Wang, J. Wang, Y. Feng, L. Liu, S. Wang, Y. Song, Y. Liu, Y. Tang, W. Liu, H. Ren, H. Fang; CN
- 17:15 - 17:15 **460PD - The value of chemotherapy in stage II colon cancer: Much less than we thought**
L. Wu¹, J. Fu¹, W. Fu², J. Du¹, L. Wang¹; ¹CN, ²US
- 17:15 - 17:15 **461PD - Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial)**
S. Pernot¹, P. Artru², D. Tougeron³, C. Montérymard¹, D. Smith¹, C. De La Fouchardière¹, J.-L. Raoul³, L. Dahan¹, R. Guimbaud¹, P. Michel¹, J.-L. Jouve¹, O. Pellerin¹, J. Taieb¹; ¹FR, ²CEDEX 8/FR, ³CEDEX/FR
- 17:15 - 17:15 **462PD - Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial**

E. Auclin¹, T. Andre¹, J. Taieb¹, M. Banzi², J.-L. van Laethem³, J. Tabernero⁴, T. Hickish⁵, A. De Gramont¹, D. Vernerey¹; 1FR, 2IT, 3BE, 4ES, 5GB

17:15 - 17:30 **Invited Discussant 459PD, 460PD, 461PD and 462PD**

R. Adams, GB

17:30 - 17:45 **Q&A led by Discussant**

16:45 - 17:45 Type: Poster Discussion session ICM - Room 13

Title: Poster Discussion session - NSCLC, metastatic 2

Chair(s): Sanjay Popat, GB; Simon Ekman, SE

16:45 - 16:45 **LBA62 - Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407**

J. Mazieres¹, D. Kowalski², A. Luft³, D. Vicente⁴, A. Tafreshi⁵, M. Gümüş⁶, K. Laktionov³, B. Hermes⁷, I. Cicin⁶, J. Rodríguez-Cid⁸, J. Wilson⁹, T. Kato¹⁰, R. Ramlau², S. Novello¹¹, S. Reddy¹², B. Piperdi¹³, X. Li¹³, T. Burke¹³, L. Paz-Ares⁴; 1FR, 2PL, 3RU, 4ES, 5NSW/AU, 6TR, 7DE, 8MX, 9ON/CA, 10JP, 11IT, 12GA/US, 13US

16:45 - 16:45 **LBA63 - Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro)**

R.S. Herbst¹, E. Garon², D.-W. Kim³, B. Chul Cho³, J.L. Pérez Gracia⁴, J.-Y. Han³, C. Dubos Arvis⁵, M. Majem⁴, M. Forster⁶, I. Monnet⁵, S. Novello⁷, Z. Szalai⁸, M. Gubens⁹, W.-C. Su¹⁰, G.L. Ceresoli⁷, A. Samkari⁹, E. Jensen¹¹, G. Lubiniecki¹¹, P. Baas¹²; 1CT/US, 2CA/US, 3KP, 4ES, 5FR, 6GB, 7IT, 8HU, 9US, 10TW, 11NJ/US, 12NL

16:45 - 16:45 **1384PD - Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial**

G. Middleton, K. Brock, Y. Summers, J. Connibear, R. Shah, C. Ottensmeier, P. Shaw, S. Ming-Lee, S. Popat, C. Barrie, G. Barone, R. Mant, J. Savage, L. Billingham; GB

16:45 - 17:05 **Invited Discussant LBA62, LBA63 and 1384PD**

S. Ekman, SE

17:05 - 17:15 **Q&A led by Discussant**

17:15 - 17:15 **1385PD - A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial**

S. Peters¹, S. Danson², B. Hasan³, N. Reinmuth⁴, M. Majem⁵, K. Tournoy³, M. Mark¹, M. Pless¹, M. Cobo⁵, D. Rodriguez-Abreu⁵, L. Falchero⁶, B. Massutí⁵, L. Coate⁷, R. von Moos¹, C. Zielinski⁸, E. De Maio³, M. O'Brien², H. Roschitzki-Voser⁹, U. Dafni¹⁰, R. Stahel¹; ¹CH, ²GB, ³BE, ⁴DE, ⁵ES, ⁶FR, ⁷IE, ⁸AT, ⁹Bern/CH, ¹⁰Attica/GR

17:15 - 17:15 **LBA64 - nab-Paclitaxel + Carboplatin Induction Followed by nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Results From the ABOUND.sqm Study**

D. Spigel¹, R. Jotte², S. Ponce Aix³, L. Gressot⁴, D. Morgensztern⁵, M. McCleod⁵, M. Socinski⁶, D. Daniel¹, O. Juan-Vidal³, E. Kim⁷, H. West⁸, T. Chen⁹, R. Bhore⁹, T. Ong⁵, C. Gridelli¹⁰, M. Thomas¹¹; ¹TN/US, ²CO/US, ³ES, ⁴TX/US, ⁵US, ⁶PA/US, ⁷NC/US, ⁸WA/US, ⁹NJ/US, ¹⁰IT, ¹¹DE

17:15 - 17:15 **LBA65 - IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC**

M. Socinski¹, A. Rittmeyer², D. Shapovalov³, F. Orlandi⁴, M. McCleod⁵, R. Soo⁶, R. Palmero⁷, T. Kozuki⁸, M.R. Migliorino⁹, K. Koynov¹⁰, H. Berard¹¹, B. Hughes¹², W. Yu¹³, V. Graupner¹⁴, S. Sun¹³, M. Kowanetz¹⁵, T. Hoang⁵, W. Lin¹⁴, R. Jotte¹⁶; ¹PA/US, ²DE, ³UA, ⁴CL, ⁵US, ⁶SG, ⁷ES, ⁸JP, ⁹IT, ¹⁰BG, ¹¹FR, ¹²AU, ¹³CA/US, ¹⁴CH, ¹⁵CALIFORNIA/US, ¹⁶CO/US

17:15 - 17:15 **1386PD - IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) &&**

M. Reck¹, T. Wehler¹, F. Orlandi², N. Nogami³, C. Barone⁴, D. Moro-Sibilot⁵, M. Shtivelband⁶, J. González Larriba⁷, J. Rothenstein⁸, M. Frueh⁹, G. Shankar⁶, A. Lee⁶, Y. Deng⁶, H. Patel⁶, C. Kelsch⁶, W. Lin⁶, M. Socinski¹⁰; ¹DE, ²CL, ³JP, ⁴IT, ⁵FR, ⁶US, ⁷ES, ⁸Ontario/CA, ⁹CH, ¹⁰PA/US

17:15 - 17:35 **Invited Discussant 1385PD, LBA64, LBA65 and 1386PD**

S. Popat, GB

17:35 - 17:45 **Q&A led by Discussant**

16:45 - 17:45	Type: Controversy Session Title: Gene expression signatures should be used in luminal node negative breast cancer Chair(s): Suzette Delaloge, FR	Hall A1 - Room 15
16:45 - 16:55	Introduction and 1st vote <u>S. Delaloge</u> , FR	
16:55 - 17:15	Pro <u>N. Harbeck</u> , DE	
17:15 - 17:35	Contra <u>P. Pharoah</u> , GB	
17:35 - 17:45	2nd vote and conclusions <u>S. Delaloge</u> , FR	
18:00 - 19:30	Type: Patient Advocacy Track Title: Snake oil sold as science: How to protect patients from Pseudoscience Chair(s): Matthias Preusser, AT; Gilliosa Spurrier, FR	ICM - Room 5
18:00 - 18:15	Pseudoscience and having to destroy false hope: The oncologist's perspective <u>P. Wolter</u> , BE	
18:15 - 18:30	Characteristics of pseudoscience <u>E. Ernst</u> , GB	
18:30 - 18:45	The responsibility of journalism in science reporting <u>H. Scowcroft</u> , GB	
18:45 - 19:00	Preventing pseudoscience on patient forums <u>G. Spurrier</u> , FR	
19:00 - 19:30	Discussion	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 35	ICM - Room 1
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 36	ICM - Room 14b
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 37	ICM - Room 13

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Acute Myeloid Leukemia - Focus on FLT3-ITD mutation Chair(s): Jorge Cortes, US	Hall A1 - Room 15
18:30 - 18:35	Introduction <u>J. Cortes</u> , US	
18:35 - 18:55	Molecular profile of AML and prognostication/risk classification <u>L. Bullinger</u> , DE	
18:55 - 19:10	Are present clinical practice GL for the management of AML obsolete? <u>M. Heuser</u> , DE	
19:10 - 19:25	FLT3-ITD mutated AML: A special entity? <u>K. Metzeler</u> , DE	
19:25 - 19:45	New approaches on the management of relapsed or refractory FLT3-ITD mutated AML <u>J. Cortes</u> , US	
19:45 - 19:55	Q&A and discussion led by Chair and Speakers	
19:55 - 20:00	Conclusion <u>J. Cortes</u> , US	

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice? Chair(s): E.G. Elisabeth de Vries, NL; Martina Weise, DE	Hall A1 - Room 16
18:30 - 18:35	Introduction <u>E.G.E. de Vries</u> , NL	
18:35 - 18:45	Acceptance of oncology biosimilars in supportive care: a success story <u>M. Weise</u> , DE	
18:45 - 18:55	Existing challenges for uptake of oncology biosimilars - ESMO survey results <u>M. Vyas</u> , CH	
18:55 - 19:05	In practice (UK): patients being switched from a biologic to a biosimilar - UK <u>S. Scowcroft</u> , GB	
19:05 - 19:15	One year on - state of play in the EU on oncology biosimilars <u>M. Aitken</u> , US	
19:15 - 19:25	Supplementary Protection Certificates & their potential impact on availability of biosimilars <u>R. Romandini</u> , DE	
19:25 - 19:55	Panel with industry representatives <u>J. Coindreau</u> ¹ , <u>J. Hippenmeyer</u> ² , <u>D. Khanna</u> ³ , <u>A. Krendyukov</u> ⁴ ; ¹ US, ² CH, ³ GB, ⁴ DE	
19:55 - 20:00	Conclusion <u>E.G.E. de Vries</u> , NL	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 40	Hall B3 - Room 20
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 41	Hall B4 - Room 19
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 7	Hall B4 - Room 24

22.10.2018

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall A1 -**
Title: Optimal treatment of patients with metastatic colorectal cancer: Planned sequencing, or just taking the next best option? **Room 16**
 Chair(s): Alfredo Falcone, IT

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Optimal treatment of patients with metastatic colorectal cancer: Planned sequencing, or just taking the next best option?**
A. Stein, DE

08:10 - 09:00 **Discussion led by**
A. Falcone, IT

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 21**
Title: Optimal management of luminal advanced breast cancer
 Chair(s): Nadia Harbeck, DE

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Optimal management of luminal advanced breast cancer**
F. Cardoso, PT

08:10 - 09:00 **Discussion led by**
N. Harbeck, DE

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**
Title: Clinical application of liquid biopsy in metastatic lung cancer
 Chair(s): Sanjay Popat, GB

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Clinical application of liquid biopsy in metastatic lung cancer**
C. Rolfo, US

08:10 - 09:00 **Discussion led by**
S. Popat, GB

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 20**
Title: Salivary gland cancers
Chair(s): Lisa Licitra, IT

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Salivary gland cancers**
A. Ho, US

08:10 - 09:00 **Discussion led by**
L. Licitra, IT

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 22**
Title: What is the role of intratumour therapy?
Chair(s): Caroline Robert, FR

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **What is the role of intratumour therapy?**
O. Michielin, CH

08:10 - 09:00 **Discussion led by**
C. Robert, FR

08:00 - 09:00 **Type: EONS session** **Hall B4 - Room 24**
Title: Assessments and monitoring in advanced cancer nursing
 Chair(s): Christian Wylegalla, DE

08:00 - 08:00 **Session DOI**

08:00 - 08:20 **How to observe and manage the acutely ill patient**
C. Diez de los Rios, GB

08:20 - 08:40 **Reflections on systematic symptom assessment and monitoring in advanced cancer patients in the late palliative phase/terminal phase in hospital, at home and/or hospice**
S. Teunissen, NL

08:40 - 09:00 **Discussion**

08:00 - 09:00 **Type: Challenge Your Expert (CYE) session** **ICM - Room 14a**
Title: Health care decision making and the international context
 Chair(s): Francesco Perrone, IT

08:00 - 08:00 **Session DOI**

08:00 - 08:10 **Health care decision making and the international context**
H. Severens, NL

08:10 - 09:00 **Discussion led by**
F. Perrone, IT

08:15 - 09:00 **Type: Keynote lecture** **Hall A1 - Room 17**
Title: Beyond resistance in immuno-oncology
 Chair(s): Solange Peters, CH

08:15 - 08:15 **Session DOI**

08:15 - 09:00 **Beyond resistance in immuno-oncology**
A. Ribas, CA/US

09:15 - 11:00 **Type: Proffered Paper session** **Hall A1 - Room 17**
Title: Proffered paper session- NSCLC, metastatic

Chair(s): Martin Reck, DE; Benjamin Besse, FR

09:15 - 09:15 **Session DOI**

09:15 - 09:30 **LBA53 - IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC**

F. Cappuzzo¹, M. McCleod², M. Hussein³, A. Morabito¹, A. Rittmeyer⁴, H. Conter⁵, H.-G. Kopp⁴, D. Daniel⁶, S. McCune⁷, T. Mekhail³, A. Zer⁸, N. Reinmuth⁴, A. Sadiq⁹, V. Archer¹⁰, T. Ochi Lohmann¹¹, L. Wang², M. Kowanetz¹², W. Lin², A. Sandler¹³, H. West¹⁴; ¹IT, ²US, ³FL/US, ⁴DE, ⁵Ontario/CA, ⁶TN/US, ⁷GA/US, ⁸IL, ⁹IN/US, ¹⁰GB, ¹¹CH, ¹²CALIFORNIA/US, ¹³OR/US, ¹⁴WA/US

09:30 - 09:45 **LBA54 - IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)**

F. Barlesi¹, M. Nishio², M. Cobo³, N. Steele⁴, V. Paramonov⁵, B. Parente⁶, R. Dear⁷, H. Berard⁸, N. Peled⁹, L. Seneviratne¹⁰, E. Baldini¹¹, S. Watanabe², K. Goto¹², D. Mendus¹⁰, H. Patel¹³, Y. Deng¹⁰, M. Kowanetz¹⁴, T. Hoang¹³, W. Lin¹⁰, V. Papadimitrakopoulou¹³; ¹CEDEX 20/FR, ²JP, ³ES, ⁴GB, ⁵UA, ⁶PT, ⁷NSW/AU, ⁸FR, ⁹IL, ¹⁰CA/US, ¹¹IT, ¹²Chiba/JP, ¹³US, ¹⁴CALIFORNIA/US

09:45 - 10:00 **LBA55 - Primary efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)**

E. Kim¹, V. Velcheti¹, T. Mekhail², T. Leal¹, J. Dowell³, M. Tsai⁴, C. Dakhil⁵, P. Stella⁶, V. Shen⁷, S. Hu⁸, S. Paul⁸, D. Shames⁸, E. Schleifman⁸, D. Fabrizio⁹, C. Yun⁸, S. Phan⁸, M. Socinski¹⁰; ¹US, ²FL/US, ³TX/US, ⁴MN/US, ⁵KS/US, ⁶MI/US, ⁷ON/CA, ⁸CA/US, ⁹MA/US, ¹⁰PA/US

10:00 - 10:15 **Invited Discussant LBA53, LBA54 and LBA55**

B. Besse, CEDEX/FR

10:15 - 10:30 **13780 - ARCTIC: Durvalumab &&**

D. Kowalski¹, N. Reinmuth², S. Orlov³, J. Fischer², S. Sugawara⁴, S. Mandziuk¹, D. Medine⁵, S. Novello⁶, Y. Takeda⁷, R. Soo⁸, K. Park⁹, M. McCleod¹⁰, S. Geater¹¹, M. Powell¹⁰, R. May¹⁰, P. Stockman¹², D. Planchard¹³; ¹PL, ²DE, ³RU, ⁴Miyagi/JP, ⁵ES, ⁶IT, ⁷JP, ⁸SG, ⁹KR, ¹⁰US, ¹¹TH, ¹²GB, ¹³FR

10:30 - 10:45 **LBA56 - Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial**

E. Quoix¹, C. Audigier Valette¹, A. Lavolé², O. Molinier², V. Westeel¹, F. Barlesi³, J. Le Treut², E. Pichon⁴, J. Dauba², J. Otto², P. Dumont¹, L. Moreau¹, J. Madelaine², J. Margery², D. Debieuvre², P. Renault², A. Langlais², F. Morin², D. Moro-Sibilot², P.-J. Souquet¹; ¹CEDEX/FR, ²FR, ³CEDEX 20/FR, ⁴CEDEX 9/FR

10:45 - 11:00 **Invited Discussant 13780 and LBA56**

N. Rizvi, NY/US

09:15 - 10:45 **Type: Proffered Paper session** **ICM - Room 1**
Title: Proffered paper session - Melanoma and other skin tumours
 Chair(s): Reinhard Dummer, CH; Caroline Robert, FR

09:15 - 09:15 **Session DOI**

09:15 - 09:30 **LBA42 - OpACIN-neo - A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO).**
 E. Rozeman¹, A. Menzies², B. van de Wiel¹, C. Adhikari³, K. Sikorska¹, O. Krijgsman¹, H. Eriksson⁴, C. Bierman¹, L. Grijpink-Ongering¹, M. Gonzalez², A. Broeks¹, A. Guminski³, A. Spillane², W. Klop¹, R. Saw², R. Scolyer², A. van Akkooi¹, J. Hansson⁴, G. Long³, C. Blank¹; ¹NL, ²AU, ³NSW/AU, ⁴SE

09:30 - 09:45 **LBA43 - Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma**
G. Long¹, A. Hauschild², M. Santinami³, V. Atkinson⁴, M. Mandala³, V. Chiarion-Sileni³, J. Larkin⁵, C. Robert⁶, D. Schadendorf⁷, K. Dasgupta⁸, M. Shilkrut⁹, J. Garrett⁹, J.C. Brase¹⁰, R. Kefford⁴, J. Kirkwood¹¹, R. Dummer¹⁰; ¹NSW/AU, ²Schleswig-Holstein/DE, ³IT, ⁴AU, ⁵GB, ⁶FR, ⁷DE, ⁸IN, ⁹US, ¹⁰CH, ¹¹PA/US

09:45 - 10:00 **Invited Discussant LBA42 and LBA43**
C. Robert, FR

10:00 - 10:15 **LBA44 - Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)**
F. Hodi¹, V. Chiarion-Sileni², R. Gonzalez³, J.J. Grob⁴, P. Rutkowski⁵, C.L. Cowey³, C. Lao³, D. Schadendorf⁶, J. Wagstaff⁷, R. Dummer⁸, P.F. Ferrucci², M. Smylie⁹, A. Hill¹⁰, D. Hogg⁹, I. Marquez-Rodas¹¹, J. Jiang³, J. Rizzo³, J. Larkin⁷, J. Wolchok³; ¹MA/US, ²IT, ³US, ⁴FR, ⁵PL, ⁶DE, ⁷GB, ⁸CH, ⁹CA, ¹⁰AU, ¹¹ES

10:15 - 10:30 **12440 - KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma**
P. Ascierto¹, P.F. Ferrucci¹, R. Stephens², M. Del Vecchio¹, V. Atkinson³, H. Schmidt⁴, J. Schachter⁵, P. Queirolo¹, G. Long⁶, A. Di Giacomo¹, I. Svane⁴, M. Lotem⁵, G. Bar-Sela⁵, F. Couture⁷, B. Mookerjee⁸, R. Ghorri⁹, N. Ibrahim⁹, B. Homet Moreno⁹, A. Ribas¹⁰; ¹IT, ²NZ, ³QLD/AU, ⁴DK, ⁵IL, ⁶NSW/AU, ⁷QC/CA, ⁸US, ⁹NJ/US, ¹⁰CA/US

10:30 - 10:45 **Invited Discussant LBA44 and 12440**
R. Dummer, CH

09:15 - 10:45 **Type: Special Symposium** **ICM - Room 14b**
Title: Strategies to improve the outcome of advanced prostate cancer
 Chair(s): Johann de Bono, GB; Scott Tomlins, US

09:15 - 09:15 **Session DOI**

09:15 - 09:20 **Introduction**
J. de Bono, GB

09:20 - 09:40 **Heterogeneity in prostate cancer**
S. Tomlins, US

09:40 - 10:00 **Improving treatment outcome by dissecting heterogeneity**
J. de Bono, GB

10:00 - 10:20 **Improving outcome by optimising combination and/or sequencing of treatments**
E. Efstathiou, TX/US

10:20 - 10:40 **Improving treatment outcome by manipulating the immune system**
W. Gerritsen, NL

10:40 - 10:45 **Conclusions and perspectives**
S. Tomlins, US

09:15 - 10:45	Type: Special Symposium Title: Minimising potentially futile treatments in advanced disease Chair(s): Florian Scotté, FR; Matti Aapro, CH	ICM - Room 13
----------------------	---	----------------------

09:15 - 09:15 **Session DOI**

09:15 - 09:20 **Introduction**
M. Aapro, CH

09:20 - 09:40 **Monitoring toxicities**
C. Ruhlmann, DK

09:40 - 10:00 **Prediction of relevant toxicities using the example of neuro toxicities**
G. Cavaletti, IT

10:00 - 10:20 **Decisional processes (with patients) to minimise futility**
F. Strasser, CH

10:20 - 10:40 **Integration of palliative care based on (ESMO) guidelines**
S. Kaasa, NO

10:40 - 10:45 **Conclusions and perspectives**
F. Scotté, FR

09:15 - 10:45 **Type: Educational session** **Hall A1 - Room 15**
Title: Multiple myeloma
 Chair(s): Meletios Dimopoulos, GR; Hervé Avet-Loiseau, FR

09:15 - 09:15 **Session DOI**

09:15 - 09:40 **Next generation diagnostics**
H. Avet-Loiseau, FR

09:40 - 10:05 **Frontline treatment**
M.-V. Mateos, ES

10:05 - 10:30 **Relapsed disease**
M. Dimopoulos, GR

10:30 - 10:45 **Discussion**

09:15 - 11:00 **Type: Proffered Paper session** **Hall A2 - Room 18**
Title: Proffered paper session - Gastrointestinal tumours, colorectal
 Chair(s): Dirk Arnold, DE; Alfredo Falcone, IT

09:15 - 09:15 **Session DOI**

09:15 - 09:27 **LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC)**
H.-J. Lenz¹, E. van Cutsem², M.L. Limon³, K.Y. Wong⁴, A. Hendlisz², M. Aglietta⁵, P. Garcia-Alfonso³, B. Neyns², G. Luppi⁵, D. Cardin⁶, T. Dragovich⁶, U. Shah⁶, A. Atasoy⁶, R. Postema⁷, Z. Boyd⁶, J.-M. Ledezine⁶, M. Overman⁶, S. Lonardi⁵; ¹CA/US, ²BE, ³ES, ⁴AU, ⁵IT, ⁶US, ⁷GB

09:27 - 09:39 **LBA19 - Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy**
A. Grothey¹, J. Tabernero², D. Arnold³, A. De Gramont⁴, M. Ducreux⁵, P. O'Dwyer⁶, E. van Cutsem⁷, I. Bosanac⁸, S. Srock⁸, C. Mancao⁸, F. Gilberg⁸, J. Winter⁸, H.-J. Schmoll³; ¹MN/US, ²ES, ³DE, ⁴FR, ⁵CEDEX/FR, ⁶US, ⁷BE, ⁸CH

09:39 - 09:54 **Invited Discussant LBA18_PR and LBA19**
J. Taieb, FR

- 09:54 - 10:06 **LBA20 - TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).**
C. Cremolini¹, C. Antoniotti¹, S. Lonardi¹, D. Rossini¹, F. Pietrantonio¹, S.S. Cordio¹, S. Murgioni², F. Marmorino¹, E. Maiello¹, A. Passardi³, G. Masi¹, E. Tamburini¹, D. Santini¹, R. Grande¹, A. Zaniboni¹, C. Granetto¹, F. Loupakis¹, L. Delliponti¹, L. Boni¹, A. Falcone¹; ¹IT, ²OG/IT, ³Forlì-Cesena/IT
- 10:06 - 10:18 **4520 - DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD&&**
L. Henricks, C. Lunenburg, F. de Man, D. Meulendijks, G. Frederix, E. Kienhuis, G.-J. Creemers, A. Baars, V. Dezentjé, H. Rosing, J. Beijnen, E. van Werkhoven, A. van Kuilenburg, R. van Schaik, R. Mathijssen, J. Swen, H. Gelderblom, A. Cats, H.-J. Guchelaar, J. Schellens; NL
- 10:18 - 10:30 **LBA21 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial.**
S. Rao¹, F. Sclafani¹, C. Eng², M. Grønlie Guren³, R. Adams¹, A. Benson⁴, D. Sebag-Montefiore¹, E. Segelov⁵, A. Bryant¹, C. Peckitt¹, A. Roy⁶, M. Seymour⁷, J. Welch⁸, M. Saunders¹, R. Muirhead¹, J. Bridgewater¹, S. Falk¹, R. Glynne-Jones⁹, D. Arnold¹⁰, D. Cunningham¹; ¹GB, ²TX/US, ³NO, ⁴IL/US, ⁵NSW/AU, ⁶AU, ⁷Yorkshire/GB, ⁸US, ⁹Middlesex/GB, ¹⁰DE
- 10:30 - 10:50 **Invited Discussant LBA20, 4520 and LBA21**
C.-H. Koehne, DE

09:15 - 10:45 **Type: EONS session** **Hall B4 - Room 24**
Title: Complex symptom burden and management related to multimodality cancer treatment
 Chair(s): Wendy Oldenmenger, NL

09:15 - 09:15 **Session DOI**

09:15 - 09:30 **Effects of lavender oil on sleep quality of patients with cancer: A RCT of lavender oil versus sweet almond oil**
C. Wylegalla, DE

09:30 - 09:45 **Advanced care planning**
I. Korfage, NL

09:45 - 10:00 **Cancer pain and associated symptoms**
A. Koller, AT

10:00 - 10:15 **CN55 - Evaluation of a nursing aftercare intervention for patients with head and neck cancer treated with chemoradiation**
C. Braat, G. Verduijn, H. van der Stege, M. Offerman, M. Peeters, A. van Staa, W. Oldenmenger; NL

10:15 - 10:30 **CN56 - When symptom complexity is the norm: A mediation analysis between pain, anxiety, depression and fatigue**
A. Charalambous, CY

10:30 - 10:45 **Discussion**

09:30 - 10:40 **Type: Poster Discussion session** **Hall B3 - Room 21**
Title: Poster Discussion session - Immunotherapy of cancer 2
 Chair(s): Pedro Romero, CH; Aurélien Marabelle, FR; Inge-Marie Svane, DK

09:30 - 09:30 **1135PD - Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations**
J. Luke¹, R. Edwards², C. Hedvat², D. Pandya², S. Ely², R. Meier¹, D. McDonald¹, C. Harbison³, V. Baxi², G. Lee², P. Szabo², T. Garcia¹, R. Bao¹, T. Reilly¹, E. Jaffee⁴, F. Hodi⁵; ¹US, ²NJ/US, ³New Jersey/US, ⁴MD/US, ⁵MA/US

09:30 - 09:30 **1136PD - Discrepancy of tumor neoantigen burden between primary lesions and matched metastases in lung cancer**
T. Jiang, C. Zhou; CN

09:30 - 09:30 **1137PD - Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444**

S. Willingham¹, A. Hotson², G. Laport¹, L. Kwei¹, L. Fong², M. Sznol¹, J. Powderly³, R. Miller¹; ¹US, ²CA/US, ³NC/US

- 09:30 - 09:45 **Invited Discussant 1135PD, 1136PD and 1137PD**
P. Romero, CH
- 09:45 - 09:55 **Q&A led by Discussant**
- 09:55 - 09:55 **1138PD - First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1**
A. Hansen¹, T. Bauer², V. Moreno³, M. Maio⁴, S. Groenland⁵, J. Martin-Liberal³, H. Gan⁶, D. Rischin⁶, M. Millward⁷, A. Olszanski⁸, D. Cho⁹, E. Paul⁸, M. Ballas⁸, C. Ellis⁸, H. Zhou⁸, S. Yadavilli⁸, J. Sadik Shaik⁸, E. Schmidt⁸, A. Hoos⁸, E. Angevin¹⁰; ¹CA, ²TN/US, ³ES, ⁴IT, ⁵NL, ⁶AU, ⁷WA/AU, ⁸US, ⁹NY/US, ¹⁰CEDEX/FR
- 09:55 - 09:55 **1139PD - Novel small-molecule ROR γ ; agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial**
J. Wang¹, S. Liu², H. Uronis², C. Wu², D. Mahalingam², A. Spira³, L. Carter⁴, X. Hu⁴, G. Weems², H. Wilkins², L. Duska², K. Kelly²; ¹FL/US, ²US, ³VA/US, ⁴MI/US
- 09:55 - 09:55 **1140PD - Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA**
K. Papadopoulos¹, W. Harb², N. Lu³, X. Ma³, Y. He³, L. Yuan³, M. Fu³, Y. Lin³, W. Xu³, X. Wang³, P. Wang³, T. Xu³, R. Dong³, J. Gong³; ¹TX/US, ²IN/US, ³CN
- 09:55 - 10:10 **Invited Discussant 1138PD, 1139PD and 1140PD**
A. Marabelle, FR
- 10:10 - 10:20 **Q&A led by Discussant**
- 10:20 - 10:20 **1141PD - Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1**
M. Kfoury¹, A.-L. Voisin¹, M. Najean¹, S. Champiat¹, S. Laghouati¹, J.-M. Michot¹, C. Robert¹, C. Mateus¹, L. Albiges¹, B. Besse², C. Massard², M. Texier¹, O. Lambotte¹, A. Marabelle¹; ¹FR, ²CEDEX/FR
- 10:20 - 10:20 **1142PD - Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort**

C. Domblides¹, I. Monnet¹, J. Mazieres¹, F. Barlesi², V. Gounant³, S. Baldacci¹, B. Mennecier⁴, A.C. Toffart¹, C. Audigier Valette⁴, L. Doucet¹, E. Giroux-Leprieur¹, F. Guisier¹, O. Molinier¹, M. Perol⁴, E. Pichon⁵, G. Robinet⁶, D. Templement Grangerat⁴, A.-M. Ruppert¹, M. Wislez¹; ¹FR, ²CEDEX 20/FR, ³CEDEX 18/FR, ⁴CEDEX/FR, ⁵CEDEX 9/FR, ⁶Cedex 2/FR

10:20 - 10:30 **Invited Discussant 1041PD and 1042PD**

I.-M. Svane, DK

10:30 - 10:40 **Q&A led by Discussant**

09:30 - 10:30 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 23**
Title: Managing early breast cancer during pregnancy
 Chair(s): Sabine Linn, NL

09:30 - 09:40 **Pathology of breast cancer and pregnancy**

E. Provenzano, Cambridgeshire/GB

09:40 - 09:50 **Chemotherapy during pregnancy**

F. Amant, BE

09:50 - 10:00 **Her2-targeted therapy during pregnancy**

S. Linn, NL

10:00 - 10:30 **Discussion**

09:30 - 10:30 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**
Title: At the heyday of molecular classification of cancer
 Chair(s): Rebecca Fitzgerald, GB

09:30 - 09:35 **Introduction**

R. Fitzgerald, GB

09:35 - 09:50 **Pathology**

M. Sobrinho Simões, PT

09:50 - 10:05 **Molecular classification**

R. Bristow, GB

10:05 - 10:30 **Moderated panel discussion with Q&A by audience**

R. Fitzgerald, GB

09:30 - 10:30 **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 22**
Title: Tumour sequencing in drug development
 Chair(s): Matthew Krebs, GB

09:30 - 09:40 **Tumour sequencing in drug development**
C. Le Tourneau, FR

09:40 - 10:30 **Discussion led by**
M. Krebs, GB

09:30 - 10:30 **Type: Challenge Your Expert (CYE) session** **ICM - Room 14a**
Title: Neuroendocrine tumours: Role of theranostics and nuclear medicine
 Chair(s): Marianne Pavel, DE

09:30 - 09:40 **Neuroendocrine tumours: Role of theranostics and nuclear medicine**
R. Baum, DE

09:40 - 10:30 **Discussion led by**
M. Pavel, DE

09:30 - 10:30 **Type: Young Oncologist session** **ICM - Room 14c**
Title: YO Mentorship Session: Career paths in oncology
 Chair(s): Teresa Amaral, PT; Jesus Corral, ES

09:30 - 09:30 **Clinical**
E. Martinelli¹, C. Zielinski²; ¹IT, ²AT

09:30 - 09:30 **Basic science**
M. Sibilgia¹, R. Pio²; ¹AT, ²ES

09:30 - 09:30 **Translational research**
M. Hegi¹, A. Prat²; ¹CH, ²ES

09:30 - 09:30 **Industry**
E. Thalmann¹, W. Pao²; ¹AT, ²NY/CH

11:00 - 12:30 **Type: Special session** **ICM - Room 13**
Title: Liquid biopsies in cancer management
 Chair(s): Klaus Pantel, DE; Michael Speicher, AT

11:00 - 11:25 **What are the limitations of liquid biopsies**
M. Speicher, AT

11:25 - 11:50 **Circulating tumour cells**
K. Pantel, DE

11:50 - 12:15 **Liquid biopsies in haematological malignancies**
G. Gaidano, IT

12:15 - 12:30 **Discussion**

11:00 - 12:30 **Type: Special session** **Hall B3 - Room 21**
Title: The changing scenario of drug registration
 Chair(s): Christian Dittrich, AT; Ian Tannock, CA

11:00 - 11:05 **Introduction**
I. Tannock, Ontario/CA

11:05 - 11:25 **Accelerated / conditional approval as a new regular way of drug registration**
F. Pignatti, GB

11:25 - 11:45 **Reasons for not lowering the bar for new drugs registration**
I. Tannock, Ontario/CA

11:45 - 12:05 **Patients expectations from drug regulators: The view of the patient advocate**
B. Ryll, SE

12:05 - 12:15 **Conclusions**
C. Dittrich, AT

11:00 - 12:15 **Type: Poster Discussion session** **Hall B3 - Room 23**
Title: Poster Discussion session - Sarcoma
 Chair(s): Maud Toulmonde, FR; Anastasia Constantinidou, CY; Eva Wardelmann, DE

11:00 - 11:00 **1604PD - Health-related quality of life in patients with advanced soft tissue sarcoma (ASTS): Results from the TSAR randomized phase III trial of the French Sarcoma Group**
A. LE CESNE, R. KAPSO KAPNANG, S. FOULON, J. BONASTRE; FR

- 11:00 - 11:00 **1605PD - Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line**
V. Grünwald¹, M. Schuler¹, P. Schöffski², H.-G. Kopp¹, S. Bauer¹, B. Kasper¹, L. Lindner¹, J. Chemnitz¹, M. Crysandt¹, A. Stein¹, B. Steffen¹, S. Richter¹, M. Kneba¹, G. Egerer¹, S. Zimmermann¹, A. Karch¹, A. Kunitz¹; ¹DE, ²BE
- 11:00 - 11:00 **1606PD - Quality of life in patients with soft tissue sarcoma undergoing palliative treatment: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12)**
L. Hentschel, S. Richter, H.-G. Kopp, B. Kasper, A. Kunitz, V. Grünwald, T. Kessler, J.-M. Chemnitz, U. Pelzer, U. Schuler, J. Freitag, A. Schilling, B. Hornemann, K. Arndt, G. Ehninger, M. Bornhäuser, M. Schuler; DE
- 11:00 - 11:15 **Invited Discussant 1604PD, 1605PD and 1606PD**
A. Constantinidou, CY
- 11:15 - 11:25 **Q&A led by Discussant**
- 11:25 - 11:25 **1607PD - Immune response, safety, and overall survival of NY-ESO-1[®] soft tissue sarcoma patients treated with CMB305 therapy**
S. Chawla¹, S. Pollack², M. Block³, M. Druta⁴, K. Do³, J. Morris⁵, J. Kim⁶, C. Bohac⁷, H. Lu³, S. Gnjatic⁸, R. Jones⁹, P. Hwu³, N. Somaiah¹⁰; ¹CA/US, ²WA/US, ³US, ⁴FL/US, ⁵OH/US, ⁶CT/US, ⁷California/US, ⁸NY/US, ⁹WA/GB, ¹⁰SC/US
- 11:25 - 11:25 **1608PD - Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients**
J.-B. Delhorme¹, E. Nassif¹, G. Ferron², E. Bompas³, J. Adam¹, O. Glehen¹, A. Italiano³, F. Bertucci⁴, D. Orbach¹, A. Le Cesne³, J. Blay¹, C. Chevreau⁵, O. Mir¹, C. Honoré¹; ¹FR, ²CEDEX 3/FR, ³CEDEX/FR, ⁴CEDEX 9/FR, ⁵Haute-Garonne/FR
- 11:25 - 11:25 **1609PD - Preoperative hypofractionated radiotherapy (RT) in patients with locally advanced myxoid liposarcomas: Interim analysis of prospective phase II clinical trial**
H. Kosela Paterczyk¹, M. Spalek¹, M. Wagrodzki¹, A. Borkowska¹, A. Szumera-Cieckiewicz², A. Cieszanowski¹, T. Morysinski¹, J. Palucki¹, P. Rutkowski¹; ¹PL, ²PL/PL
- 11:25 - 11:25 **1610PD - A phase II study of pazopanib with oral topotecan in patients with metastatic osteosarcoma**
B. van Tine¹, N. Mohindra², M. Milhem², S. Attia², S. Robinson³, A. Rademaker⁴, S. Okuno², M. Agulnik²; ¹Missouri/US, ²US, ³MN/US, ⁴IL/US
- 11:25 - 11:40 **Invited Discussant 1607PD, 1608PD, 1609PD and 1610PD**
M. Toulmonde, CEDEX/FR

11:40 - 11:50 **Q&A led by Discussant**

11:50 - 11:50 **1611PD - A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)**

S. Stacchiotti¹, J.-Y. Blay², R. Jones³, G.D. Demetri⁴, O. Mir⁵, A. Italiano², D. Thomas⁶, T.W.-W. Chen⁷, P. Schöffski⁸, T. Gil⁸, T. Jahan⁹, G. Cote⁹, R. Ratan⁹, S. Attia⁹, M. Roche⁹, S. Daigle⁹, I. Sapir⁹, A. Clawson⁹, M. Gounder¹⁰; ¹IT, ²CEDEX/FR, ³WA/GB, ⁴MA/US, ⁵FR, ⁶AU, ⁷TW, ⁸BE, ⁹US, ¹⁰NY/US

11:50 - 11:50 **1612PD - A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)**

R. Jones¹, J.-Y. Blay², M. Agulnik³, R. Chugh³, O. Mir⁴, A. Italiano², D. Thomas⁵, A. Gupta⁶, T. Jahan³, G. Cote³, V. Villalobos³, G.D. Demetri⁷, M. Roche³, I. Sapir³, S. Daigle³, A. Clawson³, M. Gounder⁸; ¹WA/GB, ²CEDEX/FR, ³US, ⁴FR, ⁵AU, ⁶CA, ⁷MA/US, ⁸NY/US

11:50 - 11:50 **1613PD - mTOR inhibitors in uterine and extra-uterine malignant PEComas: A multicenter international case series retrospective analysis**

R. Sanfilippo¹, R. Jones², S. Provenzano¹, G. Antoniou³, J.-Y. Blay⁴, E. Fumagalli¹, S. Stacchiotti¹, R.M. Bertulli¹, O. Mir⁵, N. Hindi⁶, M. Brahmi⁵, A. Dufresne⁵, A.P. Dei Tos¹, P.G. Casali¹; ¹IT, ²WA/GB, ³GB, ⁴CEDEX/FR, ⁵FR, ⁶ES

11:50 - 11:50 **1614PD - A phase II study of preoperative chemoradiation plus sorafenib (S) for high-risk extremity soft tissue sarcomas (STS)**

C. Ryan, L. Davis, Y.-C. Doung, J. Davis, A. Hung, J. Hayden, K. Gundle, J. Vetto, A. Mansoor, B. Beckett, P. Norr, S. Bertolone-Smith, W. Huang; US

11:50 - 11:50 **1615PD - A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)**

M. Gounder¹, P. Schöffski², V. Villalobos¹, G. Cote¹, R. Chugh¹, T.W.-W. Chen³, T. Jahan¹, E. Loggers¹, A. Italiano⁴, A. Gupta⁵, M. Agulnik¹, S. Attia¹, R. Jones⁶, B. van Tine⁷, G.D. Demetri⁸, M. Roche¹, I. Sapir¹, S. Daigle¹, A. Clawson¹, S. Stacchiotti⁹; ¹US, ²BE, ³TW, ⁴CEDEX/FR, ⁵CA, ⁶WA/GB, ⁷Missouri/US, ⁸MA/US, ⁹IT

11:50 - 12:05 **Invited Discussant 1611PD, 1612PD, 1613PD and 1614PD**

E. Wardelmann, DE

12:05 - 12:15 **Q&A led by Discussant**

11:00 - 12:30 **Type: Special Symposium** **Hall B3 - Room 20**
Title: Global surveillance of cancer survival: Impact on cancer control
 Chair(s): Michel Coleman, GB

11:00 - 11:05 **Introduction: Global surveillance of cancer survival will stimulate policy and improve equity**
M. Coleman, GB

11:05 - 11:25 **Trends and inequalities in cancer survival world-wide: The latest results**
C. Allemani, GB

11:25 - 11:45 **Information for cancer patients, their families and care-givers: Improving outcomes in low- and middle-income countries**
S. Cowal, US

11:45 - 12:05 **Cancer survival comparisons as a tool to improve the quality of health care: The experience from OECD**
N. Klazinga, FR

12:05 - 12:25 **Delivering affordable cancer care in developed and developing countries**
R. Sullivan, GB

12:25 - 12:30 **Panel discussion led by chair**

11:00 - 12:15 **Type: Poster Discussion session** **Hall B3 - Room 22**
Title: Poster Discussion session - NETs and endocrine tumours
 Chair(s): Aldo Scarpa, IT; Rossella Elisei, IT; Enrique Grande, ES

11:00 - 11:00 **450PD - Potential therapeutic targets in recurrent and metastatic parathyroid carcinomas revealed by next-generation sequencing**
M. Cui, Y. Hu, Q. Liao, Y. Zhao; CN

11:00 - 11:00 **1310PD - Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms**
L. Apostolidis, S. Kreutzfeldt, M. Oles, L. Geldon, C. Heining, P. Horak, B. Hutter, M. Fröhlich, B. Klink, M. Lamping, S. Uhrig, A. Stenzinger, E. Winkler, B. Wiedenmann, D. Jäger, E. Schröck, U. Keilholz, M. Pavel, H. Glimm, S. Fröhling; DE

11:00 - 11:15 **Invited Discussant 450PD and 1310PD**
A. Scarpa, IT

11:15 - 11:25 **Q&A led by Discussant**

- 11:25 - 11:25 **1820PD - Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo**
Y.S. Lee, H. Chang, S.Y. Kim, H.-S. Chang, C.S. Park; KR
- 11:25 - 11:25 **1821PD - Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC)**
B. Keam¹, R. Kreitman², Z. Wainberg³, M. Cabanillas⁴, D. Cho⁵, A. Italiano⁶, A. Stein⁷, J.Y. Cho¹, J. Schellens⁸, P. Wen³, C. Zielinski⁹, A. Boran³, B. Mookerjee¹⁰, P. Burgess¹¹, F. Rangwala¹², V. Subbiah⁴; ¹KR, ²MD/US, ³US, ⁴TX/US, ⁵NY/US, ⁶CEDEX/FR, ⁷DE, ⁸NL, ⁹AT, ¹⁰NJ/US, ¹¹CH, ¹²NC/US
- 11:25 - 11:40 **Invited Discussant 1820PD and 1821PD**
R. Elisei, IT
- 11:40 - 11:50 **Q&A led by Discussant**
- 11:50 - 11:50 **1311PD - Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial**
A. Rinke¹, M. Neary², J. Eriksson², M. Hunger¹, T. Doan³, D. Karli³, R. Arnold¹; ¹DE, ²SE, ³IE
- 11:50 - 11:50 **1312PD - Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study**
T. Walter¹, C. Lepage², R. Coriat³, E. Barbier¹, G. Cadiot¹, F.X. Caroli Bosc⁴, T. Aparicio¹, K. Bouhier Leporrier⁴, O. Hentic Dhome¹, A.-C. Dupont-Gossart⁵, M. Duluc⁶, C. Lepere¹, T. Lecomte¹, D. Smith¹, C. Petorin⁷, I. Iwanicki Caron¹, M. Ducreux⁵, C. Lombard Bohas⁸, T. de Baere¹; ¹FR, ²Cedex/FR, ³CEDEX 14/FR, ⁴CEDEX 9/FR, ⁵CEDEX/FR, ⁶CEDEX 5/FR, ⁷CEDEX 1/FR, ⁸CEDEX 3/FR
- 11:50 - 11:50 **1313PD - A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy**
H. Okuyama¹, M. Ikeda², T. Okusaka¹, J. Furuse¹, M. Furukawa¹, S. Ohkawa¹, A. Hosokawa¹, Y. Kojima¹, K. Yamaguchi¹, G. Murohisa¹, K. Shioji¹, H. Ishii¹, N. Mizuno¹, M. Kojima¹, T. Yamanaka¹; ¹JP, ²Chiba/JP
- 11:50 - 12:05 **Invited Discussant 1311PD, 1312PD and 1313PD**
E. Grande, ES
- 12:05 - 12:15 **Q&A led by Discussant**

11:00 - 12:30 **Type: Educational session** **Hall B4 - Room 19**
Title: Epigenetics
 Chair(s): Anton Berns, NL

11:00 - 11:25 **Novel technologies to study cancer epigenetics**
E. Shema, IL

11:25 - 11:50 **Epigenetic reprogramming in paediatric malignancies**
S. Armstrong, US

11:50 - 12:15 **Epigenetic regulation of cancer**
F. Di Nicolantonio, (TO)/IT

12:15 - 12:30 **Discussion**

11:00 - 12:30 **Type: EONS session** **Hall B4 - Room 24**
Title: Nurse-led cancer services
 Chair(s): Daniel Kelly, GB

11:00 - 11:20 **Nurse led acute oncology service developments**
M. Fowler, GB

11:20 - 11:40 **Introduction of a new advanced cancer nursing role in Sweden**
L. Sharp, SE

11:40 - 12:00 **Towards implementation of an eHealth-powered integrated model of care in allogeneic hematopoietic stem cell transplantation: The SMILE project**
L. Leppla, DE

12:00 - 12:20 **Psychosexual support service development**
I. White, GB

12:20 - 12:40 **Discussion**

11:00 - 11:45 **Type: Young Oncologist session** **ICM - Room 14a**
Title: YO Brunch 3: Biosimilars: What they are and their use in oncology
 Chair(s): Radu Vidra, RO; Ioannis Litos, GR

11:00 - 11:45 **Biosimilars: What they are and their use in oncology**
R. Giuliani, IT

11:15 - 12:45 **Type: Special Symposium** **Hall A1 - Room 17**
Title: Changing landscape in renal and bladder cancer
 Chair(s): Karim Fizazi, FR; Manuela Schmidinger, AT

11:15 - 11:20 **Introduction**
K. Fizazi, FR

11:20 - 11:40 **Challenging established frontline therapies in renal cancer**
L. Albiges, CEDEX/FR

11:40 - 12:00 **Challenging established frontline therapies in bladder cancer**
T. Powles, GB

12:00 - 12:20 **Can biology help guide treatment decisions in renal cancer?**
M. Schmidinger, AT

12:20 - 12:40 **Can biology help guide treatment decisions in bladder cancer?**
M. Galsky, US

12:40 - 12:45 **Conclusion and perspectives**
K. Fizazi, FR

- 11:15 - 12:45** **Type: Proffered Paper session** **Hall A2 - Room 18**
Title: Proffered paper session - Immunotherapy of Cancer
 Chair(s): George Coukos, CH; Inge Svane, DK
- 11:15 - 11:27 **LBA37_PR - Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer**
M. Chalabi, L. Fanchi, J. Van den Berg, G. Beets, M. Lopez-Yurda, A. Aalbers, C. Grootsholten, P. Snaebjornsson, M. Maas, M. Mertz, E. Nuijten, M. Kuiper, M. Kok, M. Van Leerdam, T. Schumacher, E. Voest, J. Haanen; NL
- 11:27 - 11:39 **11270 - A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer**
P. Ott¹, R. Govindan², A. Naing³, T. Friedlander², K. Margolin², J. Lin², N. Bhardwaj², M. Hellman², L. Srinivasan², J. Greshock², M. Moles², R. Gaynor², M. Goldstein², S. Huelieskov²; ¹MA/US, ²US, ³TX/US
- 11:39 - 11:54 **Invited Discussant LBA37_PR and 11270**
G. Coukos, CH
- 11:54 - 12:06 **11280 - Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients**
D. Hale¹, E.A. Mittendorf², T. Brown², G. Clifton¹, T. Vreeland², J. Myers¹, K. Peace¹, D. Jackson¹, J. Greene¹, J. Holmes³, G. Peoples¹; ¹TX/US, ²US, ³CA/US
- 12:06 - 12:18 **11290 - Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy**
T. Leal¹, A. Spira², C. Blakely³, K. He¹, D. Berz³, D. Richards⁴, J. Uyeki¹, A. Savage¹, T. Roque¹, E. Massarelli¹, R. Jotte⁵, I. Chen¹, J. Christensen³, P. Olson¹, V. Tassell¹, L. Horn⁶; ¹US, ²VA/US, ³CA/US, ⁴TX/US, ⁵CO/US, ⁶TN/US
- 12:18 - 12:30 **11300 - Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors**
N. Tannir¹, A. Naing¹, K. Papadopoulos¹, D. Wong², W.M. Korn², R. Aljumaily³, K. Autio⁴, S. Pant³, T. Bauer⁵, A. Drakaki⁶, N. Daver¹, A. Hung⁶, M. Oft⁶, J. Leveque⁶; ¹TX/US, ²US, ³OK/US, ⁴NY/US, ⁵TN/US, ⁶CA/US
- 12:30 - 12:45 **Invited Discussant 11280, 11290 and 11300**
D. Jäger, DE

11:15 - 12:15 **Type: Multidisciplinary interactive sessions** **ICM - Room 1**
Title: The paradigm of oligometastatic disease and ablative treatment
 Chair(s): Gerald Prager, AT

11:15 - 11:25 **Choice of systemic therapy in oligometastatic disease**
G. Prager, AT

11:25 - 11:35 **Local ablative treatments: Which instruments - and why used?**
T. Helmberger, DE

11:35 - 11:45 **Surgery in mCRC: How invasive should our patients be treated in a non-curative setting?**
P. Naredi, SE

11:45 - 12:15 **Discussion**

11:15 - 12:15 **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 15**
Title: Different approaches and advances in the management of HPV+ patients
 Chair(s): Jean-Pascal Machiels, BE; Esat Mahmut Ozsahin, CH; Hisham Mehanna, GB

11:15 - 11:25 **New staging system (for HPV+ patients)**
H. Mehanna, West Midlands/GB

11:25 - 11:35 **Unique radiation considerations (in HPV+ patients)**
E.M. Ozsahin, CH

11:35 - 11:45 **Integrating systemic therapy (in HPV+ patients)**
J.-P. Machiels, BE

11:45 - 12:15 **Discussion**

- 12:30 - 12:30 **CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: Preliminary study**
E. Mahía, G. Simó, E. Heras, M. Pascual, F. Cobo, J. Pujadas, S. Albiol; AD
- 12:30 - 12:30 **CN12 - Systemic anticancer therapy administration safety**
S. Toland, A. Simons; GB
- 12:30 - 12:30 **CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: The role of the nurse practitioner for early recognition and management**
C. Roth, M. Labots, A. Eertwegh; NL
- 12:30 - 12:30 **CN14 - Experiences from a new advanced cancer nursing role in Sweden: An analysis based on EONS Cancer nursing education framework using the Delphi method**
H. Ullgren, SE
- 12:30 - 12:30 **CN15 - Opinions and experiences of patients receiving oral chemotherapy: A qualitative study**
S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR
- 12:30 - 12:30 **CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for adolescents and young adults (AYAs) with an hematological disease**
J. De Munter, S. De Wilde, M. Quaghebeur; BE
- 12:30 - 12:30 **CN17 - Standardising the psychosocial assessment of oncological patients at Donostia university hospital**
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES
- 12:30 - 12:30 **CN18 - Are there differences between nurses&&**
M. Lavdaniti, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. Zioga, K. MARMARA, E. Fradelos; GR
- 12:30 - 12:30 **CN19 - How an empowerment program can touch cancer survivor's life by improving post-traumatic growth?**
Y.S. UZAR OZCETIN, TR
- 12:30 - 12:30 **CN20 - Organising a general oncology nursing outpatient clinic**
C. Lundgren, A. Lagerquist, M. Högman, U. Östlund; SE
- 12:30 - 12:30 **CN21 - Job content of advanced practice nurses in Flanders**
E. Decoene, A. Van Hecke; BE

- 12:30 - 12:30 **CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professional's self-efficacy when supporting parents newly diagnosed with cancer who have dependent children**
C. Semple, E. McCaughan; GB
- 12:30 - 12:30 **CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals**
J. Bird, M. Nolan, S. Danson; GB
- 12:30 - 12:30 **CN24 - Assessing the effect of telephone support on patients with myeloma multiple (MM) in the Catalan oncology institut in Girona**
C. PUIGMARTI, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher; ES
- 12:30 - 12:30 **CN28 - Transmural collaborative care in oncology: Experiences of general practitioners**
M. daem, E. van Roekeghem, M. Grypdonck, P. Pype; BE
- 12:30 - 12:30 **CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review**
S. Colomer-Lahiguera¹, D. Bryant-Lukosius², S. Rietkoetter², L. Martelli², K. Ribi¹, A. Orcurto¹, R. Juergens², M. Eicher¹; ¹CH, ²ON/CA
- 12:30 - 12:30 **CN30 - Laryngectomized patients caregivers's life experience: A phenomenological study**
V. Bressan, E. Dri, S. Stevanin, L. Cadorin, A. Rizzuto, G. Bulfone, L. Ghirotto; IT
- 12:30 - 12:30 **CN31 - Comparing nurses's**
L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT
- 12:30 - 12:30 **CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy**
A. Psychogyiou, S. KATSARAGAKIS, C. Lemonidou, D. Protogiros, E. Patiraki; GR
- 12:30 - 12:30 **CN33 - A new beginning of collaboration: The Danish Cancer Nursing Research Network**
K. Dieperink, M. Kjerholt, P. Riis Olsen; DK
- 12:30 - 12:30 **CN34 - Individual network meetings in cancer care: From young people with cancer to adults with brain tumours**
P. Riis Olsen, DK
- 12:30 - 12:30 **CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?**
G. Bagcivan, N. Ozen, D. Bayrak, F.I. Cinar; TR

- 12:30 - 12:30 **CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment**
C. Johnston, M. Tanay; GB
- 12:30 - 12:30 **CN37 - Evaluation of support and information needs for patients with cancer in a phase I trials unit**
S. Stapleton, L. O'Leary, M. van Zyl, J. Hanwell, T. Wiseman; GB
- 12:30 - 12:30 **CN38 - Dignity of Greek patients with advanced cancer: A cross-sectional study**
S. KATSARAGAKIS, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki; GR
- 12:30 - 12:30 **CN39 - Development and implementation of national guidelines on lifestyle issues and cancer: Report from an ongoing quality improvement project**
K. Vuollet Karlsson, C. Landegren, B. Westman; SE
- 12:30 - 12:30 **CN40 - Developing a patient reported experience measure (PREM) in secondary breast cancer (SBC)**
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke; GB
- 12:30 - 12:30 **CN41 - Cancer situation in Sub-Saharan countries: Development of educational, diagnosis and treatment plans**
J. de la Torre-Montero, N. Gil-Gómez, J. RIBES BERNAL, N. Domenech Climent, A. OJER PEREA, P. BEORLEGUI MURILLO, J.M. GAVALA ARJONA, R. CUMPLIDO CORBACHO, I. MAGALLON PEDRERA, M.A. PEÑUELAS SAIZ; ES
- 12:30 - 12:30 **CN42 - The Gastrointestinal and Lymphoma Unit lead nurse research role in Royal Marsden Hospital**
J. Duncan¹, V. Michalarea², T. Coyne¹, J. Thomas¹, D. Cunningham¹; ¹GB, ²Surrey/GB
- 12:30 - 12:30 **CN43 - Patients' learning and participation in their breast cancer care**
L. Boman, K. Sandelin, Y. Wengström, C. Silén; SE
- 12:30 - 12:30 **CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration**
S.Y. Oh, J.M. Lee, J.W. Kim, S.H. Kim, J.M. Park, G.Y. Yeo, J.E. Hyun, J.-H. Park; KR
- 12:30 - 12:30 **CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy**
A. Frade, S. Miguel; PT
- 12:30 - 12:30 **CN46 - Safe navigation of CARs in a changing landscape**
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite; GB
- 12:30 - 12:30 **CN47 - Patients' interpretations and experiences of participation in cancer care**

J. Jackson, J. Rundgren; SE

- 12:30 - 12:30 **CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab**
M. Qiu, Y. Chen, B.-L. Zhang, X.-Y. Wang; CN
- 12:30 - 12:30 **CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care**
J. De Munter, P. Crombez; BE
- 12:30 - 12:30 **CN50 - Overview of an acute oncology service in a UK cancer centre**
M. Foulkes, GB
- 12:30 - 12:30 **CN51 - The development and evaluation of an online oncology portal**
J. De Munter, E. Decoene, A. Van Hecke; BE
- 12:30 - 12:30 **CN52 - Pilot study: Nurses' role in management of cutaneous toxicity in patients with targeted therapies anti EGFR-Is' treatment**
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso; IT
- 12:30 - 12:30 **CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?**
D. Oliva, F. Lewin, N. Lewin, M. Nilsson, M. Strandéus, B.-Å. Andersson, L. Sharp; SE
- 12:30 - 12:30 **CN58 - Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin**
N. Izgu, L. Ozdemir, F. Bugdayci Basal; TR
- 12:30 - 12:30 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**
C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protogiros, E. Patiraki; GR
- 12:30 - 12:30 **CN60 - The experience of dysgeusia in allogeneic hematopoietic cell transplantation survivors: A qualitative study**
D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT
- 12:30 - 12:30 **CN61 - &&**
M. Tanay, J. Armes; GB
- 12:30 - 12:30 **CN62 - App about chemotherapy: Helping the patient with cancer**
B. Espersen, DK
- 12:30 - 12:30 **CN63 - Usability test for a CINV diary application for smartphones at oncology nursing**

P. Fernández- Ortega, Y. Escobar, E. Trigo, R. Blat, M. Cantero, A. Alvarez; ES

12:30 - 12:30 **CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the memorial symptom assessment scale**

D. Palitzika, E. Fradelos, V. Alikari, P. Charitopoulos, E. Zioga, S. Zyga, M. Lavdaniti; GR

12:30 - 12:30 **CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool &&**

M. Belhadj¹, E. Kempf¹, A. Lebel¹, A. Guillemin¹, H. Boussion¹, C. Joly¹, I. Baumgaertner², E. Assaf², C. Saldana², B. Rousseau², C. Tournigand²; ¹FR, ²CEDEX/FR

12:30 - 12:30 **CN66 - Medical makeup in cancer patients and its impact in their quality of life**

R. Lechou, M. Lavdaniti; GR

12:30 - 14:00 Type: Patient Advocacy Track ICM - Room 5
Title: The Hans Keulen Memorial Debate - Cancer heroes: Do they exist? And who are they?
 Chair(s): Kathy Oliver, GB

12:30 - 12:40 **Introduction**

K. Oliver, GB

12:40 - 13:20 **Debate**

13:20 - 13:20 **Debate: Team 1**

A. Waldman¹, M. Inderbitzin²; ¹DE, ²CH

13:20 - 13:20 **Debate: Team 2**

F. Strasser¹, A. Charalambous²; ¹CH, ²CY

13:20 - 13:50 **Discussion with the audience**

13:50 - 14:00 **Conclusions and take-home messages**

12:45 - 13:45 Type: Poster Display session Hall A3 - Poster Area
Title: Poster display session: Breast cancer - early Networking Hub
stage, locally advanced &&

12:45 - 12:45 **Breast cancer, early stage**

- 12:45 - 12:45 **194P - Real-life utilization of genomic testing for invasive breast cancer patients in Italy and France reduces chemotherapy recommendations**
S. Barni¹, E. Curtit², F. Cognetti³, D. Bourgeois², R. Masetti³, S. Zilberman², G. Naso³, J. Gligorov²; ¹(BG)/IT, ²FR, ³IT
- 12:45 - 12:45 **195P - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast**
A. De Nonneville¹, C. Jauffret², A. Gonçalves², J.-M. Classe³, M. Cohen², F. Reyat², C. Mazouni², M.-P. Chauvet², N. Chopin², P.-E. Colombo², E. Jouve², E. Darai², R. Rouzier², C. Coutant⁴, P. Gimbergues², A.-S. Azuar², C. Tunon de Lara², E. Lambaudie², G. Houvenaeghel²; ¹CEDEX 9/FR, ²FR, ³CEDEX/FR, ⁴Cedex/FR
- 12:45 - 12:45 **196P - Baseline lymphocyte counts predict distant recurrence in early breast cancer**
G.M. Kim, H.D. Koh, J.H. Kim, B.-W. Park, Y.U. Cho, S.I. Kim, H.S. Park, J.Y. Kim, M.J. Kim, J.H. Jeong, J. Sohn; KR
- 12:45 - 12:45 **197P - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)**
L. Carbognin¹, I. Sperduti¹, G. Arpino¹, M.V. Dieci¹, F. Schettini¹, G. Griguolo², M. Brunelli¹, V. Guarneri¹, R. Nortilli¹, E. Fiorio¹, S. Pilotto¹, E. Orvieto¹, E. Manfrin¹, P. Conte¹, S. de Placido¹, G. Scambia¹, G. Tortora¹, E. Bria¹; ¹IT, ²CH
- 12:45 - 12:45 **198P - Benefit of adjuvant systemic therapies in HR⁺; HER2- pT1ab node-negative breast carcinomas**
A. De Nonneville¹, A. Gonçalves², J.-M. Boher², J.-M. Classe³, M. Cohen², P.-E. Colombo², F. Reyat², M.-P. Chauvet², E. Jouve², E. Darai², G. Blache², C. Coutant⁴, P. Gimbergues², C. Mazouni², R. Rouzier², R. Villet², P. Crochet², A.-S. Azuar², E. Lambaudie², G. Houvenaeghel²; ¹CEDEX 9/FR, ²FR, ³CEDEX/FR, ⁴Cedex/FR
- 12:45 - 12:45 **199P - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study**
A. Prat¹, B. Adamo², J.A. Perez Fidalgo³, S. Blanch¹, N. Martinez¹, P. Gomez Pardo¹, A. López González¹, L. Murillo Juso¹, K. Amillano⁴, M. Vidal¹, T. Pascual¹, L. Pare¹, J. Canes⁵, P. Galvan¹, B. Gonzalez Farre¹, V. Ortega Cebrian¹, X. Gonzalez¹, M. Bellet Ezquerria¹, P. Villagrasa¹, E. Ciruelos¹; ¹ES, ²IT, ³Valencia/ES, ⁴Tarragona/ES, ⁵BARCELONA/ES
- 12:45 - 12:45 **200P - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer**
E.Y. Kim, C.H. Park, S.-I. Do; KR
- 12:45 - 12:45 **201P - The outcomes of early breast cancers utilizing the oncotype Dx recurrence score (RS) instead of clinico-pathological (CP) factors for prognostic risk assessment: A single institution experience**

A. Alsayed, T. Al-Twejeri, K. Suleman, A. Tulbah, D. Ajarim; SA

- 12:45 - 12:45 **202P - Circulating tumor cells as a prognostic marker in non-metastatic breast cancer patients**
S. Elmorshidy, O. Abd Elffatah, H. Essa, A. Ibrahim, D. Sayed, S. Shehata; EG
- 12:45 - 12:45 **203P - Molecular subtyping of breast cancer by dedicated breast PET**
S. Sueoka¹, S. Sasada², E. Suzuki¹, N. Goda¹, K. Kajitani¹, A. Emi¹, N. Masumoto¹, T. Kadoya¹, R. Haruta¹, T. Kataoka¹, M. Okada¹; ¹JP, ²Hiroshima/JP
- 12:45 - 12:45 **204P - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer**
T. Loughman¹, A. Chan-Ju Wang¹, P. Dynoodt¹, B. Fender¹, C. Lopez Ruiz¹, S. Barron², S. Stapleton¹, D. O'Leary³, A. Fabre¹, C. Quinn¹, B. Nodin⁴, K. Jirstrom⁴, A. Bracken¹, W. Gallagher¹; ¹IE, ²Dublin/IE, ³Ireland/IE, ⁴SE
- 12:45 - 12:45 **205P - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts**
G.E. Lee, W.H. Hor; SG
- 12:45 - 12:45 **206P - TNBC universe: A monocentric retrospective analyses of TILs and AR as prognostic markers**
A. Losurdo¹, R. De Sanctis¹, B. Fernandes¹, V. Errico¹, A. Sagona¹, G. Masci², M. Zuradelli¹, E. Agostinetto¹, R. Torrasi¹, W. Gatzemeier¹, A. Testori¹, M. Roncalli¹, M. Alloisio¹, C. Tinterri¹, A. Santoro²; ¹IT, ²(MI)/IT
- 12:45 - 12:45 **207P - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer**
C. Cha, S.J. Bae, C.-I. Yoon, S.E. Park, Y. Kim, S.G. Ahn, K.A. Lee, J. Jeong; KR
- 12:45 - 12:45 **208P - The impact of the 21 gene recurrence score (RS) on chemotherapy (CHemoRx) prescribing in hormone receptor (HR) positive, lymph node positive (LN+) early-stage breast cancer (BC) in Ireland: A national, multi-centre, prospective study (CTRIAL-IE 15-34)**
A. Hassan¹, N. Keegan², C. O'Leary², L. McSorley², T. Mahgoub², S. O'Reilly², J. Walshe², M. Kennedy², L. Coate², M. O'connor², M. Keane², C. Kelly², M. Milewski², S. Molloy², K. Eagan², V. Murphy², O. Breathnach², L. Grogan², B. Hennessy², P. Morris²; ¹Dublin/IE, ²IE
- 12:45 - 12:45 **209P - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases**
D.Y. Lee, S.E. Park, C. Cha, C.-I. Yoon, S.J. Bae, S.G. Ahn, J. Jeong; KR
- 12:45 - 12:45 **210P - Genetic alterations of early-stage breast cancers by next-generation sequencing (NGS)**

Y. Xu, M. Zhang, R. Chen, X. Xia; CN

- 12:45 - 12:45 **211P - Oncotype Dx results in patients ≥ 40 years: Does age matter? New insights**
F. Namuche¹, R. Ruiz², Z. Morante Cruz², D. Urrunaga², G. Ziegler², R. Mantilla², M. Leon Rivera³, M. Chavez Mac Gregor⁴, H. Gomez Moreno²; ¹PE/PE, ²PE, ³LIMA/PE, ⁴TX/US
- 12:45 - 12:45 **212P - Impact of BRCA status on outcomes and survival in high-risk early breast cancers**
E. Klajer¹, S. Paget-Bailly¹, G. Meynard¹, A. Meurisse¹, F. Bazan¹, L. Chaigneau¹, E. Dobi¹, N. Meneveau¹, P. Montcuquet¹, C. Villanueva¹, A. Thiery-Vuillemin¹, E. Kalbacher², C. Populaire¹, M.-A. Collonge-Rame¹, J. Gligorov¹, E. Curtit¹, X. Pivot², L. Mansi¹; ¹FR, ²CEDEX/FR
- 12:45 - 12:45 **213P - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy**
N. Hajjaji¹, Y.M. Robin², D. Bertin², J. Bonneterre³; ¹CEDEX 9/FR, ²FR, ³CEDEX/FR
- 12:45 - 12:45 **214P - Ki67 as an important predictor for oncotype Dx recurrence score risk groups in early breast cancer**
F. Namuche¹, R. Ruiz², Z. Morante Cruz², D. Urrunaga², A. Aguilar Cartagena³, H. Gomez Moreno²; ¹PE/PE, ²PE, ³San Borja/PE
- 12:45 - 12:45 **215P - Genetic signatures always suggest undertreatment? Experience with PAM50**
C. Sales, I. Vieira, M. Cassiano, C. Oliveira, C. Vieira, M. Ferreira, A. Rodrigues, A. Ferreira, M.I. Pousa, R. Couto, C. Leal, J. Abreu, M. Teixeira, D. Pereira, S. Sousa, M. Abreu; PT
- 12:45 - 12:45 **216P - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score**
M. Nesrine, H. El Benna, Y. Berrazegua, S. Labidi, N. Daoud, H. Boussen; TN
- 12:45 - 12:45 **217P - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients**
J. Cortes Castan¹, M. Pegram², X. Pivot³, G. Curigliano⁴, J.Y. Lim⁵, S. Song⁵, Y.C. Yoon⁵; ¹ES, ²US, ³CEDEX/FR, ⁴IT, ⁵KR
- 12:45 - 12:45 **218P - Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial**
A. Sonnenblick¹, A. Bailey², B. Uziely¹, M. Untch³, I. Smith², L. Gianni⁴, J. Baselga⁵, C. Jackisch³, D. Cameron⁶, R. Bell⁷, D. Zardavas⁸, N. Al-Sakaff⁹, R. Gelber¹⁰, M. Dowsett², B. Leyland-jones¹¹, M. Piccart⁸, E. de Azambuja⁸; ¹IL, ²GB, ³DE, ⁴IT, ⁵NY/US, ⁶Midlothian/GB, ⁷VIC/AU, ⁸BE, ⁹CH, ¹⁰MA/US, ¹¹SD/US

- 12:45 - 12:45 **219P - Impact of hormone receptor status in HER2-positive early breast cancer: A paradigm shift in the trastuzumab era**
A. De Nonneville¹, A. Gonçalves², J.-M. Boher², M. Cohen², F. Reyal², J.-M. Classe³, S. Giard², P.-E. Colombo², X. Muracciole², E. Darai², E. Jouve², C. Mazouni², P. Gimbergues², A.-S. Azuar², E. Barranger⁴, R. Rouzier², R. Villet², N. Chopin², E. Lambaudie², G. Houvenaeghel²; ¹CEDEX 9/FR, ²FR, ³CEDEX/FR, ⁴CEDEX 2/FR
- 12:45 - 12:45 **220P - Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERMIONE non-interventional prospective study**
J.-P. Jacquin¹, L. Uwer², A. Savignoni¹, J.-M. Ferrero³, A. Lortholary³, D. Solub⁴, H. Attar-Rabia¹, S. Deblay¹, S. Pibre¹, Y. Belkacemi¹; ¹FR, ²CEDEX/FR, ³CEDEX 2/FR, ⁴Eure et Loire/FR
- 12:45 - 12:45 **221P - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer**
R. De Sanctis¹, F. D'Antonio¹, E. Agostinetti¹, A. Marinello¹, G. Masci², M. Zuradelli¹, A. Losurdo², D. Guiducci¹, C. Tinterri¹, A. Testori¹, W. Gatzemeier¹, V. Errico¹, R. Torrisci¹, A. Santoro²; ¹IT, ²(MI)/IT
- 12:45 - 12:45 **222P - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab**
X. Pivot¹, Y.J. Lee², J.Y. Lim², S.J. Song², H.S. Kim², Y.C. Yoon²; ¹CEDEX/FR, ²KR
- 12:45 - 12:45 **223P - The impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience**
S. Forner¹, V.R. Sim¹, J. Glendenning¹, R. Burcombe²; ¹GB, ²Kent/GB
- 12:45 - 12:45 **224P - Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)**
J. Litton¹, S. Moulder², K. Hess¹, S. Damodaran¹, G. Rauch¹, R. Candelaria², B. Adrada¹, F. Symmans², R. Murthy¹, T. Helgason¹, A. Clayborn², S. Prabhakaran¹, V. Valero², A.M. Thompson², E.A. Mittendorf¹; ¹US, ²TX/US
- 12:45 - 12:45 **225P - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)**
C. Hall¹, K. Hess¹, L. Ravenberg¹, A. Clayborn², G. Rauch¹, R. Candelaria², E.A. Mittendorf¹, S. Moulder², A. Thompson¹, A. Lucci¹; ¹US, ²TX/US
- 12:45 - 12:45 **226P - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients**
L. Häberle, R. Erber, P. Gaß, A. Hein, S. Jud, H. Langemann, C. Rauh, C. Hack, R. Schulz-Wendtland, A. Hartmann, M. Beckmann, M. Lux, P.A. Fasching; DE

- 12:45 - 12:45 **227P - Evaluation of the MammaTyper[®] as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes**
P.A. Fasching¹, M. Laible¹, K. Weber¹, R.M. Wirtz¹, C. Denkert¹, K. Schlombs¹, S. Schmatloch¹, O. Camara¹, H.J. Lück¹, J. Huober¹, T. Karn¹, M. van Mackelenbergh¹, F. Marme¹, V. Müller¹, C. Schem², E. Stickeler¹, U. Sahin¹, S. Loibl¹, M. Untch¹; ¹DE, ²Schleswig-Holstein/DE
- 12:45 - 12:45 **228P - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)**
C. Yam¹, S. Seth¹, K. Hess¹, E.A. Mittendorf¹, R. Murthy¹, S. Damodaran¹, T. Helgason¹, L. Huo¹, A.M. Thompson², M. Barton¹, M. Huang¹, E. Arribas¹, D. Lane¹, G. Rauch¹, B. Adrada¹, M. Gilcrease¹, J. Chang¹, S. Moulder²; ¹US, ²TX/US
- 12:45 - 12:45 **229P - Evaluation of human epidermal growth factor receptor 2 overexpression (HER2⁺) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)**
D. Machado, F. Branco, F. Silva, S. André, M. Brito, M. Casanova, M. Nave, A. Moreira, J. Passos-Coelho; PT
- 12:45 - 12:45 **230P - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens**
M. Marin Alcala, G. Lloret Pursals, J.H. Del Riego Ferrari, J. Giner, F.X. Andreu Navarro, S. Medina, O. Aparicio, E. Dalmau Portulas, P. Ribera Fernandez, H. Oliveres, C. Martinez Vila, J. Cabrera Romero, M.A. Segui Palmer, L.A. Fernandez Morales; ES
- 12:45 - 12:45 **231P - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)**
B. Seliger, DE
- 12:45 - 12:45 **233P - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer**
Y.-C. Tsai, H.C. Cheng, C.C. Horng; TW
- 12:45 - 12:45 **234P - Survival outcomes of dose dense neoadjuvant and adjuvant chemotherapy in triple-negative breast cancer patients: Indian scenario**
T. Sood¹, A. Rauthan², P. Patil¹, S. Kulkarni¹, S.P. Somashekhar¹, S. Zaveri¹, V. Ahuja¹, K.R. Ashwin¹; ¹IN, ²Karnataka/IN
- 12:45 - 12:45 **235P - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: The importance of Ki-67 and molecular subtype**
B. Rapoport, J. Barnard-Tidy, T. Smit, S. Nayler, C. Benn; ZA

- 12:45 - 12:45 **236P - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience**
N. Sistany Allahabadi, H. Yahyazadeh, M. Hashemian, M. Rajabpour, S. Aminmozaffari, M. Zaree, A. Rezazadeh Mafi; IR
- 12:45 - 12:45 **237P - Index BRCA1/2 testing under a multidisciplinary program**
D. Machado, S. Fragoso, A. Opinião, A. Clara, S. Bento, A.C. Luís, I. Miguel, S. Santos, P. Machado, P. Rodrigues, J. Parreira, F. Vaz; PT
- 12:45 - 12:45 **238P - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients**
A. Friedlaender¹, A. Vuillemier¹, V. Viassolo¹, A. Ayme¹, S. De Talhouet², J.-D. Combes³, J. Peron³, A. Bodmer¹, S. Giraud³, A. Buisson³, V. Bonadona³, I. Gauchat-Bouchardy¹, O. Tredan³, P. Chappuis¹, S.I. Labidi-Galy¹; ¹CH, ²Cedex 08/FR, ³FR
- 12:45 - 12:45 **239P - PALB2 germ-line mutations in Russian breast cancer patients: Identification of recurrent alleles and analysis of phenotypic characteristics of the tumors**
E. Imyanitov, E. Preobrazhenskaya, A. Shlejina, A. Sokolenko, E. Anisimova, A. Ivantsov, A. Togo; RU
- 12:45 - 12:45 **240P - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing**
E. Shagimardanova, L. Shigapova, R. Enikeev, M. Druzhkov, A. Nikitin, O. Gusev, M. Gordiev; RU
- 12:45 - 12:45 **241P - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: Results from Russian Hereditary Oncogenomics project**
M. Gordiev, L. Shigapova, O. Brovkina, R. Enikeev, M. Druzhkov, A. Nikitin, E. Shagimardanova, O. Gusev; RU
- 12:45 - 12:45 **242P - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)**
N. OLYMPIOS¹, M. Lambertini², C. Calbrix¹, M. Saint-Ghislain¹, M. Fontanilles¹, A. Loeb¹, M. Leheurteur³, I. Demeestere², F. Di Fiore¹, A. Perdrix¹, F. Clatot³; ¹FR, ²BE, ³CEDEX 1/FR
- 12:45 - 12:45 **243P - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study**
E. Pohl, A. Schneeweiss, J. Hauke, V. Moebus, J. Furlanetto, C. Denkert, P.A. Fasching, C. Hanusch, H. Tesch, N. Weber-Lassalle, V. Müller, K. Rhiem, M. Untch, K. Luebbe, B. Lederer, C. Jackisch, V. Nekljudova, R. Schmutzler, E. Hahnen, S. Loibl; DE
- 12:45 - 12:45 **244P - BRCA1/BRCA2 predictive genetic testing in an Irish population: A missed opportunity**

D. O Reilly, L. Dooley, G. Watson, R. Clarke, A. Nolan, C. Nolan, E. Berkeley, M. Farrell, D. Gallagher; IE

- 12:45 - 12:45 **245P - Incidence and survival among young women with stage I-III breast cancer**
A. Thomas¹, A. Rhoads², E. Pinkerton², M. Schroeder², J. Oelson², L. McNally¹, W. Hundley¹, K. Conway², C. Lynch², P. Romitti²; ¹US, ²IA/US
- 12:45 - 12:45 **246P - Toxicity and clinical outcomes of partial breast irradiation (PBI) compared to whole breast irradiation (WBI) for early stage breast cancer: A systematic review and meta-analysis**
H. Goldvaser¹, A. Fyles¹, D. Shepshelovich¹, E. Amir², Y. Korzets¹; ¹CA, ²ON/CA
- 12:45 - 12:45 **247P - Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)**
R. Caparica¹, M. Bruzzone², F. Poggio², M. Ceppi², E. de Azambuja¹, M. Lambertini¹; ¹BE, ²IT
- 12:45 - 12:45 **248P - Taxane &&**
P. Ntellas¹, N. Spathas¹, D. Zylis¹, S. Agelaki¹, E. Zintzaras¹, E. Saloustros²; ¹GR, ²Crete/GR
- 12:45 - 12:45 **249P - Risk of cardiovascular late effects in breast cancer survivors: A population-based study**
J. Lee, I.Y. Chung, Z. Kim, H. Hur, J.W. Lee, H.J. Youn; KR
- 12:45 - 12:45 **250P - Diagnostic value of contrast enhanced digital mammography versus contrast enhanced MRI for preoperative evaluation of breast cancer**
E.Y. Kim, I. Youn, C.H. Park, S.H. Kook; KR
- 12:45 - 12:45 **251P_PR - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients**
J. Martin-Babau¹, F. Toudic-Emily², A.-H. Boivin², P. Burbhan-Provost², B. Vie³, P.-L. Etienne², B. Lamezec², E. Le Fur², A. Vincent², D. Besson², A.-C. Hardy-Bessard²; ¹Cedex 2/FR, ²FR, ³Cedex 4/FR
- 12:45 - 12:45 **252P - Relationship between androgen receptor and tumor-infiltrating lymphocytes in triple-negative breast cancer**
L.F. Sánchez-Cousido, A. López-González, E. Honrado Franco, E. Vallejo Pascual, O. Sanz, L. Lopez Gonzalez, I. Delgado, M. López-Flores, A. García Palomo; ES
- 12:45 - 12:45 **253P - Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: Biological and clinical implications from a randomized clinical trial**
C. Ferraris, B. Ballestra, V. Cappelletti, C. Listorti, P. Miodini, I. Pulice, L. Mariani, E. Ferrari, A. Gambaro, I. Maugeri, G. Martelli, S. Folli; IT

- 12:45 - 12:45 **254P - PROMs following breast-conserving therapy for breast cancer: Results from a prospective longitudinal monocentric study**
I. Kindts¹, A. Laenen¹, M. van den Akker², C. Weltens¹; ¹BE, ²NL
- 12:45 - 12:45 **255P - Impact on disease-free survival (DFS) of the surgical waiting time (SWT) for patients (Pts) with early breast cancer (BC)**
R. Nakamura¹, N. Yamamoto¹, T. Miyaki²; ¹JP, ²Chiba/JP
- 12:45 - 12:45 **256P - Oncological outcome of fat grafting for breast reconstruction after cancer**
G. Griguolo¹, F. Miglietta², M.V. Dieci², V. Vindigni², F. Bassetto², E. De Antoni², I. Polico², A. Marchet², E. Baldan², G. Vernaci², T. Saibene², S. Michieletto², V. Guarneri²; ¹CH, ²IT
- 12:45 - 12:45 **257P - Changes in body weight over 18-months follow-up among Chinese patients after breast cancer diagnosis**
W. Yeo, Y. Lei, A. Cheng, C. Kwok, K. Cheung, I. Lee, R. Lee, S. Ho; HK
- 12:45 - 12:45 **258P - Incidence of clinically significant toxicities in patients with high endoxifen concentrations**
S. Groenland, A. Sanchez-Spitman, D.J.A.R. Moes, S. Koolen, V. Dezentjé, N. van Erp, R. Mathijssen, H.-J. Guchelaar, A. Huitema, N. Steeghs; NL
- 12:45 - 12:45 **259P - Male breast cancer: Clinical and epidemiological patterns in the United States**
M. Gouda, Menoufia Governorate/EG
- 12:45 - 12:45 **260P - The aesthetic results after oncoplastic surgery in early breast cancer**
A. ZIKIRYAHODJAEV, A. Sukhotko, A. Tukmakov; RU
- 12:45 - 12:45 **261P - The application of indocyanine green fluorescence navigation method to a sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer**
K. Yamagami, H. Matsumoto, T. Hashimoto, S. Yanai, S. Yuen, Y. Yata, Y. Ichinose, T. Deai, M. Toi; JP
- 12:45 - 12:45 **262P - Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis**
H.J. Choi, S.M. Jung, J.M. Ryu, I. Kim, S.J. Nam, S.W. Kim, J. Yu, S.K. Lee, J.E. Lee; KR
- 12:45 - 12:45 **263P - Omission of axillary lymph node dissection after positive sentinel lymph node: Validity and safety among early breast cancer patients treated with mastectomy**
A. Matsumoto, Y. Umemoto, H. Jinno; JP

- 12:45 - 12:45 **264P - Pathologic response as a strong predictor of survival irrespective of phenotype in early breast cancer**
A. Gasol Cudos, S. Morales Murillo, J. Veas Rodriguez, F. Vilardell Vilellas, D. Sanchez Guzman, E. Iglesias Martinez; ES
- 12:45 - 12:45 **265P - Nomogram to predict non-sentinel lymph node status of breast cancer using total tumor load determined by one-step nucleic acid amplification (OSNA)**
P. O-charoenrat, D. Sa-nguanraksa, A. Kulprom; TH
- 12:45 - 12:45 **266P - Detecting bone density in early breast cancer survivors: The arm-DXA method**
Y. Al-Farhat, HU
- 12:45 - 12:45 **267P - Voluntary deep inspiration breathhold (DIBH) experience in the radiotherapy for left sided breast cancer**
I. Gueorguiev, N. Nedev, A. Avramov, A. Tonev, N. Velikova; BG
- 12:45 - 12:45 **268P - Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study**
N.,. Fernández-De-Larrea, B. Pérez-Gómez, A. Ruiz, A.M. Casas, B. Bermejo, J.M. Baena-Cañada, S. Antolin, P. Sánchez Rovira, M. Ramos Vázquez, J.A. Garcia-Saéñz, A. Anton Torres, M. Muñoz, C. Jara, M. Gil-Gil, E. Adrover, A. Oltra, J. Brunet, S. Bezares, M. Martín, M. Pollán; ES
- 12:45 - 12:45 **232TiP - A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study)**
J.-M. Nabholz¹, K. Al Saleh¹, A. Bounedjar², H. Abdel-Razek³, H. Errihani⁴, A. Saadeddin¹, M. Al Foheidi¹, M. Ghosn⁵, H. El Zawahry⁶, A. Kandil⁶, N. Abdel-Aziz¹, F. Dabouz⁷, S. Kullab¹; ¹SA, ²DZ, ³JO, ⁴MA, ⁵LB, ⁶EG, ⁷AE
- 12:45 - 12:45 **269TiP - Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer (RAFAELO study)**
T. Kinoshita¹, S. Ohtani², H. Doihara¹, M. Takahashi³, T. Fujisawa¹, N. Yamamoto¹, K. Aogi¹, T. Hojo¹; ¹JP, ²Hiroshima/JP, ³Hokkaido/JP
- 12:45 - 12:45 **270TiP - Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)**
L. Heesen¹, K. Frenzel¹, S. Bolte¹, V. Bukur¹, M. Diken¹, E. Derhovanessian¹, S. Kreiter¹, A. Kuhn¹, K. Köhlcke¹, M. Löwer¹, H. Lindman², S. Pascolo³, M. Schmidt¹, A. Schneeweiss¹, T. Sjöblom², K. Thielemans⁴, L. Zitvogel⁵, Ö. Türeci¹, U. Sahin¹; ¹DE, ²SE, ³CH, ⁴BE, ⁵CEDEX/FR
- 12:45 - 12:45 **271TiP - Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC)**

H. McArthur¹, R. Basho², S. Shiao², D. Park², C. Dang², S. Karlan², S. Knott², M. Mita², C. Dilauro Abaya², A. Giuliano², F. Dadmanesh², A. Ho³; ¹US, ²CA/US, ³MA/US

- 12:45 - 12:45 **272TiP - Development of mPRO Mamma mobile application and its impact on the quality of life and health resource usage in patients with early stage and locally advanced breast cancer receiving chemotherapy**
C. Grasic Kuhar, T. Gortnar, E. Drmota, T. Kovač, M. Kukar; SI
- 12:45 - 12:45 **Breast cancer, locally advanced**
- 12:45 - 12:45 **274P - CD8&&**
N. Verovkina, S. Lyalkin, L. Syvak, A. Askolskyi, N. Majdanevych; UA
- 12:45 - 12:45 **275P - Multiplex immunoassays analysis of plasma biomarker levels and response to neoadjuvant chemotherapy for locally advanced breast cancer**
J.H. Cho, K. Park, E. Lee, Y. Kim, S. Park, S.E. Yoon, K.K. Lee, J.Y. Hur, S.K. Lee, J.E. Lee, S.W. Kim, S.J. Nam, J. Yu, J.-Y. Kim, H.H. Jung, Y.H. Park; KR
- 12:45 - 12:45 **276P - Prognostic role of changes in neutrophil-to-lymphocyte ratio, tumor-infiltrating lymphocyte with programmed death ligand-1 in triple-negative breast cancer**
E.K. Joung, J.E. Lee; KR
- 12:45 - 12:45 **277P - Expression of Sp17 and its association with clinicopathological parameters of breast cancer**
Y.-T. Zhou, CN
- 12:45 - 12:45 **278P - Intratumoral heterogeneity on dedicated breast positron emission tomography before chemotherapy predicts the outcome of neoadjuvant chemotherapy in breast cancer**
N. masumoto¹, T. Kadoya¹, E. Suzuki¹, S. Sueoka¹, N. Goda¹, S. Sasada², A. Emi¹, R. Haruta¹, T. Kataoka¹, M. Okada¹; ¹JP, ²Hiroshima/JP
- 12:45 - 12:45 **279P - Results from NRG oncology/NSABP protocol DMP-1: Physician counseling**
C. Holmberg¹, H. Bandos², W. McCaskill-Stevens³, D.L. Wickerham², T. Battaglia², T. Bevers², A. Fagerlin²; ¹DE, ²US, ³MD/US
- 12:45 - 12:45 **280P - Neoadjuvant eribulin plus carboplatin vs. paclitaxel plus carboplatin in patients with triple-negative breast cancer (TNBC)**
L. Gigolaeva, P. Krivorotko, S. Khadzhimatova, E. Zhiltsova, S. Yerechshenko, M. Nikitina, V. Ni, A. Emelyanov, E. Imyanitov, A. Sokolenko, T. Tabagua; RU
- 12:45 - 12:45 **Breast cancer, metastatic**

- 12:45 - 12:45 **281TiP - A phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)**
A. Devaux, J.-L. Canon, F. Duhoux, P. Delrée, C. Galant, P. Coulie, I. Bar, M. Constant, S. Haussy, O. Bricard, K. Missault, M. Berlière, T. Willems, J. Carrasco; BE
- 12:45 - 12:45 **282TiP - Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study**
P.A. Fasching, T. Decker, G. Guderian, J. Heim, C. Jackisch, H.-J. Lueck, D. Lüftner, F. Marmé, T. Reimer, A. Woeckel; DE
- 12:45 - 12:45 **295P - Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia**
T. Decker¹, A. Mündlein², N. Marschner¹, A. Welt¹, T. Riedt¹, V. Hagen¹, J. Rauh¹, D. Klein¹, K. Potthoff¹, P. Jähmig¹, H. Schröder¹, S. Hegewisch-Becker¹, C. Lerchenmüller¹; ¹DE, ²AT
- 12:45 - 12:45 **296P - Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)**
A. Vozy¹, A. Simonaggio¹, E. Auclin¹, L. Mezquita¹, C. Baldini², P. Martin-Romano¹, B. Pistilli¹, A. Gazzah¹, R. Bahleda², V. Ribrag¹, S. Postel-Vinay¹, S. Champiat¹, J.-C. Soria³, F. André¹, C. Massard², B. Besse², S. Delaloge¹, A. Varga²; ¹FR, ²CEDEX/FR, ³CEDEX/US
- 12:45 - 12:45 **297P - Peripheral blood mononuclear cell biomarkers predict response to immune checkpoint inhibitor therapy in metastatic breast cancer**
Y. Yuan¹, W. Hou², S. Padam², P. Frankel², M. Sedrak², J. Portnow², J. Mortimer², C. Yeon², A. Hurria², A. Tang², N. Martinez², P. Lee²; ¹US, ²CA/US
- 12:45 - 12:45 **298P - Circulating exosomal microRNA profiling to depict mechanisms of chemotherapy resistance among triple negative breast cancer**
Y. He, T. Jinhai; CN
- 12:45 - 12:45 **299P - The prevalence of PIK3CA mutations in HR&&**
K. Wan¹, Y. Wang², M. Kaper³, M. Fritzeimer², N. Babbar⁴; ¹CH, ²MA/US, ³NJ/US, ⁴US
- 12:45 - 12:45 **300P - Differential molecular signature in patients from African origin with triple-negative breast cancer**
A. Matias, A. Jacinta-Fernandes, R. Magno, J. Xavier, M. Cabral, A. Jacinto, A. Maia, S. Braga; PT
- 12:45 - 12:45 **301P - Analysis of the JAK2 gene in triple-negative breast cancer (TNBC)**
L. Stanek¹, P. Tesarova¹, M. Vocka¹, L. Petruzelka²; ¹2/CZ, ²CZ

- 12:45 - 12:45 **302P - A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients**
G. Pelizzari, L. Gerratana, D. Basile, S. Zago, M.G. Vitale, M. Bartoletti, C. Lisanti, V. Fanotto, C. Corvaja, L. Bortot, A. Liguori, M. Cinausero, S. Russo, C. Andreetta, M. Bonotto, M. Mansutti, A. Minisini, F. Curcio, G. Fasola, F. Puglisi; IT
- 12:45 - 12:45 **303P - EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment**
M. Martín¹, W. Eiermann², H. Rugo³, J. Ettl⁴, S. Hurvitz³, A. Gonçalves⁵, R. Yerushalmi⁶, D. Markova⁷, I.C. Tudor⁷, J. Blum⁷, A. Hannah³, J. Litton⁷; ¹ES, ²IR, ³CA/US, ⁴DE, ⁵FR, ⁶IL, ⁷US
- 12:45 - 12:45 **304P - EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis**
A. Gonçalves¹, W. Eiermann², H. Rugo³, J. Ettl⁴, S. Hurvitz³, R. Yerushalmi⁵, M. Martín⁶, M. Al-Adhami⁷, I.C. Tudor⁷, J. Blum⁷, A. Hannah³, J. Litton⁷; ¹FR, ²IR, ³CA/US, ⁴DE, ⁵IL, ⁶ES, ⁷US
- 12:45 - 12:45 **305P - Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial**
Y. Yu¹, M. Elmeliegy², J. Litton¹, I.C. Tudor¹, A. Czibere¹, J. Zheng¹, D. Wang¹; ¹US, ²NJ/US
- 12:45 - 12:45 **306P - Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials**
M. Elmeliegy¹, Y. Yu², J. Litton², N. Turner³, A. Czibere², G. Wilson², I.C. Tudor², J. Zheng², D. Wang²; ¹NJ/US, ²US, ³GB
- 12:45 - 12:45 **307P - An international systematic review (SR) of breast cancer (BC) BRCA mutation (BRCAm) prevalence**
N. Armstrong¹, S. Ryder¹, C. Forbes¹, A. Chalker¹, J. Ross¹, R. Quek²; ¹GB, ²CA/US
- 12:45 - 12:45 **308P - Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: A systematic review (SR) of international breast cancer (BC) guidelines**
C. Forbes¹, D. Fayer¹, C. Clar¹, K. Reid¹, S. de Kock¹, R. Quek²; ¹GB, ²CA/US
- 12:45 - 12:45 **309P - Efficacy and toxicity of endocrine therapy + cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status**

L. Bruno, M. Costanzo, C. Ostinelli, A. Nervo, J. Nadal, F. Colo, J. Loza, C. Loza, C. Ponce, V. Fabiano, A. Blanco, C. Perez de la Puente, R. Chacon; AR

- 12:45 - 12:45 **310P - Clinical outcomes, treatment patterns and health resource utilization (HRU) among metastatic breast cancer (mbc) patients (pts) with germline BRCA mutation (gBRCAm)**
R. Quek, J. Mardekian; CA/US
- 12:45 - 12:45 **311P - Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)**
M. Shum¹, V. Assikis², C. Savulsky³, W. Zhu⁴, P. Iyer⁴, D. Xing⁴, C. Berman¹, N. Lokker⁵, R. Alvarez¹; ¹US, ²GA/US, ³GB, ⁴NJ/US, ⁵CA/US
- 12:45 - 12:45 **312P - Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer**
K. Sakaguchi, K. Nakatsukasa, T. Taguchi; JP
- 12:45 - 12:45 **313P - Eribulin in metastatic breast cancer the UK experience: A multi-centre retrospective 577 patient study**
M. Jafri¹, H. Kristeleit¹, V. Misra¹, M. Baxter¹, S. Ahmed¹, A. Jegnnathen¹, A. Jain¹, D. Maskell¹, U. Barthakur¹, G. Edwards¹, H. Walter¹, R. Walter¹, M. Khan¹, A. Borley¹, P. Nightingale¹, D. Rea²; ¹GB, ²West Midlands/GB
- 12:45 - 12:45 **314P - Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study**
M. Takahashi¹, K. Inoue², H. Mukai², T. Yamanaka², C. Egawa², Y. Sakata², H. Ikezawa², T. Matsuoka², J. Tsurutani²; ¹Hokkaido/JP, ²JP
- 12:45 - 12:45 **315P - Prospective cohort study of real world chemotherapy sequence for metastatic breast cancer (KBCRN A001: E-SPEC study)**
K. Nakatsukasa, Y. Kikawa, T. Kotake, K. Yamagami, S. Tsuyuki, H. Yamashiro, H. Suwa, T. Sugie, T. Okuno, H. Kato, S. Takahara, I. Nakayama, N. Ogura, Y. Moriguchi, M. Takata, E. Suzuki, H. Yoshibayashi, H. Ishiguro, T. Taguchi, M. Toi; JP
- 12:45 - 12:45 **316P - Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice**
T. Luhn¹, S. Chui², A. Hsieh², J. Yi³, A. Mecke⁴, P. Bajaj², W. Hasnain¹, A. Falgas⁴, T. Ton², A. Kurian²; ¹US, ²CA/US, ³NJ/US, ⁴CH
- 12:45 - 12:45 **317P - Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)**
K.-I. Watanabe¹, K. Aogi¹, M. Kitada¹, T. Sangai¹, S. Ohtani², T. Aruga¹, H. Kawaguchi¹, T. Fujisawa¹, S. Maeda¹, T. Morimoto¹, S. Morita¹, N. Masuda¹, M. Toi¹, S. Ohno³; ¹JP, ²Hiroshima/JP, ³Fukuoka/JP

- 12:45 - 12:45 **318P - Clinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: A review of a single institution**
M. Furuta¹, J. Watanabe², T. Aramaki¹; ¹JP, ²Shizuoka/JP
- 12:45 - 12:45 **319P - A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)**
P. Krivorotko¹, B. Karaszewska², S. Chan³, M. Wieczorek-Rutkowska¹, T. Sarosiek², M. Shomova¹, E. Ovchinnikova¹, J.P. Zarate⁴, C. Babanrao Pisal⁵, A. Manikhas¹, L. Smith⁴; ¹RU, ²PL, ³GB, ⁴US, ⁵IN
- 12:45 - 12:45 **320P - Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study)**
V. Adamo¹, G. Ricciardi¹, S. Schifano¹, A. Russo¹, V. Gebbia¹, L. Blasi², D. Giuffrida¹, G. Scandurra¹, A. Savarino¹, A. Butera¹, N. Borsellino¹, F. Verderame¹, M. Caruso¹; ¹IT, ²(PA)/IT
- 12:45 - 12:45 **321P - Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: A single arm phase II study of whole-body magnetic resonance imaging**
M. Kosmin¹, A. Padhani², A. Gogbashian², D. Woolf², M.-L. Ah-See², P. Ostler², S. Sutherland², D. Miles², J. Noble², A. Marshall², J. Dunn², A. Makris²; ¹Middlesex/GB, ²GB
- 12:45 - 12:45 **322P - Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide**
J. Zimmermann, T. Remus, G. Lemercier, D. Barker, D. Obrecht, G. Gambino, G. Douglas; CH
- 12:45 - 12:45 **323P - Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis**
S. Kümmel¹, C. Tondini², J. Abraham³, Z. Nowecki⁴, B. Itrych⁴, E. Hitre⁵, B. Karaszewska⁴, A. Juarez⁶, F. Morales-Vásquez⁶, J. Pérez García⁷, S. Cardona-Huerta⁶, D. Heinzmann⁸, J. He⁹, A.N. Duc⁸, A. Crepelle-Fléchais⁸, M. Martín⁷; ¹DE, ²IT, ³GB, ⁴PL, ⁵HU, ⁶MX, ⁷ES, ⁸CH, ⁹US
- 12:45 - 12:45 **324P - Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review**
H. Rugo¹, G. Curigliano², F. Cardoso³, W. Gradishar⁴, M. Pegram⁵, C.H. Barrios⁶, J. Cortes Castan⁷, E. Pennella⁵, R. Muniz⁵; ¹CA/US, ²IT, ³PT, ⁴IL/US, ⁵US, ⁶BR, ⁷ES
- 12:45 - 12:45 **325P - Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results**

E. Esin¹, O.B. Cakmak Oksuzoglu¹, A. Bilici¹, I. Cicin¹, S. Aksoy¹, A. Alacacioglu¹, M.A. Kaplan¹, D. Cabuk¹, A. Sumbul¹, S. Paydas¹, A. Sakin¹, Ö. Er², T. Korkmaz¹, N. Yildirim¹, M. Artac¹, H. Harputluoglu¹, P. Yumuk¹, G. Basaran¹, B. Oyan Uluc¹, U. Demirci¹; ¹TR, ²Sariyer/TR

- 12:45 - 12:45 **326P - Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab**
B. Conte¹, A. Fabi¹, F. Poggio¹, E. Blondeaux¹, C. Dellepiane¹, A. D'Alonzo¹, A. Staiano¹, G. Buono¹, G. Arpino¹, V. Magri¹, G. Naso¹, D. Presti¹, S. Mura¹, A. Fontana¹, F. Cognetti¹, C. Molinelli¹, S. Pastorino¹, C. Bighin¹, M. Lambertini², L. Del Mastro¹; ¹IT, ²BE
- 12:45 - 12:45 **327P - Survival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine: A national population-based study: Long-term analysis**
B. Jagielska¹, P. Tokajuk², T. Pieńkowski¹, A. Czubek¹, M. Krzakowski¹, M. Wojtukiewicz²; ¹PL, ²Podlaskie/PL
- 12:45 - 12:45 **328P - Ribociclib (RIBO) &&**
H. Abdel-Razek¹, P. Cottu², A. Ring³, M. De Laurentiis⁴, J. Lu⁵, H. Azim⁶, C. Zamagni⁴, K. Zhou⁵, J. Wu⁵, L. Menon⁵, M. Martín⁷; ¹JO, ²CEDEX 5/FR, ³GB, ⁴IT, ⁵US, ⁶EG, ⁷ES
- 12:45 - 12:45 **329P - Abemaciclib with fulvestrant in patients with HR⁺, HER2-advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)**
E.-M. Grischke¹, P. Neven², Y. Lin³, P. Kaufman⁴, G. Sledge³; ¹DE, ²BE, ³US, ⁴NH/US
- 12:45 - 12:45 **330P - Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR⁺)**
A. Bardia¹, S. Campos-Gomez², S. Hurvitz³, Y.-S. Lu⁴, S.-A. Im⁵, F. Franke⁶, L. Chow⁷, P. Wheatley-Price⁸, F. Melo Cruz⁶, J. Alam⁹, O. Kong⁹, I. Diaz-Padilla¹⁰, M. Miller⁹, D. Tripathy¹¹; ¹MA/US, ²MX, ³CA/US, ⁴TW, ⁵KR, ⁶BR, ⁷HK, ⁸ON/CA, ⁹NJ/US, ¹⁰CH, ¹¹TX/US
- 12:45 - 12:45 **331P - Ribociclib (RIB) && fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3**
G. Jerusalem¹, P.A. Fasching², M. Martín³, X. Pivot⁴, K. Petrakova⁵, G. Bianchi⁶, A. Nusch², G. Sonke⁷, L. De La Cruz Merino³, E. Vagnon⁸, J. Alam⁹, O. Kong⁹, D. Chandiwana⁹, M. De Laurentiis⁶; ¹BE, ²DE, ³ES, ⁴CEDEX/FR, ⁵South Moravian/CZ, ⁶IT, ⁷NL, ⁸CH, ⁹NJ/US
- 12:45 - 12:45 **332P - Clinical outcomes in patients (pts) with estrogen receptor&&**

H. Rugo¹, R. Finn¹, K. Gelmon², A.A. Joy³, O. Lipatov⁴, N. Harbeck⁵, A. Castrellon⁶, H. Mukai⁷, J. Walshe⁸, A. Mori⁹, E. Gauthier¹, D. Lu¹, E. Bananis¹⁰, M. Martín¹¹, V. Dieras¹²; ¹CA/US, ²British Columbia/CA, ³Alberta/CA, ⁴RU, ⁵DE, ⁶FL/US, ⁷JP, ⁸IE, ⁹IT, ¹⁰NY/US, ¹¹ES, ¹²CEDEX 5/FR

12:45 - 12:45 **333P - Ribociclib (RIBO) &&**

F. Cardoso¹, K. Papazisis², M. De Laurentiis³, A. Ring⁴, J. Lu⁵, M. Martín⁶, H. Azim⁷, C. Zamagni³, K. Zhou⁵, J. Wu⁵, J.P. Zarate⁵, P. Cottu⁸; ¹PT, ²GR, ³IT, ⁴GB, ⁵US, ⁶ES, ⁷EG, ⁸CEDEX 5/FR

12:45 - 12:45 **334P - Health related quality of life in women with HR⁺/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany**

M. De Laurentiis¹, A. König², K. Davis³, D. Mitra⁴, C.M.A. Nuzzo¹, M. Ajmera³, S. de Placido¹, S. Brucker², N. Harbeck²; ¹IT, ²DE, ³NC/US, ⁴NY/US

12:45 - 12:45 **335P - Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR⁺)**

C. Villanueva¹, G. Yazbek¹, P. Beuzeboc², E. Viel¹, N. Dohollou³, E. Luporsi¹, J.-C. Eymard³, E. Levy¹, M.-A. Mouret-Reynier¹, L.-M. Dourthe¹, E. Malaurie¹, M. Madelenat¹, A. Denden¹, E.-C. Antoine¹; ¹FR, ²CEDEX 5/FR, ³CEDEX/FR

12:45 - 12:45 **336P - Everolimus in advanced breast cancer: A systematic review and meta-analysis**

J. Raphael¹, C. Lefebvre², A. Allan², J. Helou², G. Boldt², T. Vandenberg²; ¹Ontario/CA, ²CA

12:45 - 12:45 **337P - First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?**

A. Toss, M. Venturelli, I. Sperduti, C. Isca, E. Barbieri, F. Piacentini, C. Omarini, L. Cortesi, S. Cascinu, L. Moscetti; IT

12:45 - 12:45 **338P - Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS study**

D. Mitra¹, G. Taylor-Stokes², J. Waller², K. Gibson², G. Milligan², S. Iyer³; ¹NY/US, ²GB, ³US

12:45 - 12:45 **339P - Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR⁺), HER2- advanced breast cancer: Analysis of the MONARCH trials**

H. Rugo¹, S. Tolaney², J. Huober³, M. Toi⁴, V. André⁵, S. Barriga⁶, T. Forrester⁷, G. Sledge⁸, M.P. Goetz⁸; ¹CA/US, ²MA/US, ³DE, ⁴JP, ⁵FR, ⁶GB, ⁷IN/US, ⁸US

- 12:45 - 12:45 **340P - Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR⁺; HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials**
V. Rossi, D. Giannarelli, P. Berchiolla, C. Nisticò, G. Ferretti, S. Gasparro, P. Malaguti, M. russillo, G. Catania, L. Vigna, R. Mancusi, F. Cognetti, A. Fabi; IT
- 12:45 - 12:45 **341P - Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR⁺/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study**
M. Welslau, M. Zaiss, U. Söling, M. Untch, L. Müller, D. Lüftner, J. Meiler, A. Welt, J. Sahlmann, L. Houet, E. Runkel, N. Marschner; DE
- 12:45 - 12:45 **342P - Response to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: A multicenter study of 236 recurrent metastatic patients**
J. Yamamura, S. Kamigaki, M. Tsujie, J. Fujita, H. Osato, C. Higashi, H. Kanaizumi, Y. Tanaka, M. Hamada, W. Shinzaki, Y. Hasimoto, Y. Komoike; JP
- 12:45 - 12:45 **343P - Application of CDK4/6 inhibitors in practice: Effect of online education on clinician competence and confidence**
C. Day¹, D. Middleton², S. Loibl³; ¹GB, ²US, ³DE
- 12:45 - 12:45 **344P - First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR⁺;) advanced breast cancer: A prospective, multicenter, noninterventional study**
J. Blum¹, S. McCune², M. Salkeni³, D. Anderson⁴, J. Migas⁵, S. Lakhanpal⁶, K. Patel⁷, A. Bardia⁸, G. Rocque⁶, J. Wang⁸, J. Cappelleri⁹, G. Comstock¹⁰, Y. Wang¹¹, D. Tripathy¹²; ¹US, ²GA/US, ³WV/US, ⁴MN/US, ⁵IL/US, ⁶AL/US, ⁷AR/US, ⁸MA/US, ⁹CT/US, ¹⁰CA/US, ¹¹NY/US, ¹²TX/US
- 12:45 - 12:45 **345P - Everolimus-based therapy versus conventional therapy for refractory breast cancer patients with PI3K/AKT/mTOR mutations**
Z. Chen, Y. Zheng, W. Cao, Y. Zhang, S. Cai, X. Shao, J. Huang, W. Ye, Y. Huang, Y. Yin, X. Wang; CN
- 12:45 - 12:45 **346P - Ribociclib (RIB) &&**
P. Neven¹, K. Petrakova², G. Bianchi³, L. De La Cruz Merino⁴, G. Jerusalem¹, J. Beck⁵, G. Sonke⁶, S. Chia⁷, S. Brucker⁸, Y. Wang⁹, W. He¹⁰, K. Rodriguez Lorenc¹¹, F. Su¹², S.-A. Im¹³; ¹BE, ²South Moravian/CZ, ³IT, ⁴ES, ⁵AZ/US, ⁶NL, ⁷CA, ⁸DE, ⁹CH, ¹⁰MA/US, ¹¹US, ¹²NJ/US, ¹³KR
- 12:45 - 12:45 **347P - Potential survival gains from first-line (1L) systemic therapy advances in metastatic triple-negative breast cancer (mTNBC)**
P. Bajaj, J. Roth, S. Sullivan, A. Stein, R. Mahtani, S. Ramsey; US

- 12:45 - 12:45 **348P - Economic evaluation of eribulin in the treatment of triple negative breast cancer in the United Kingdom**
J. Wex, C. Bodnar, C. Simon, F. Fernandes, N. Tanova; GB
- 12:45 - 12:45 **349P - Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC)**
M. Chavez Mac Gregor¹, X. Lei², H. Zhao², C. van Poznak², S. Giordano¹; ¹TX/US, ²US
- 12:45 - 12:45 **350P - Liver surgery of breast cancer liver metastases: Rapid surgical decision after diagnosis does not negatively impact long-term results**
V. Lucidi, G. Liberale, D. Germanova, M. Bez, V. Donckier; BE
- 12:45 - 12:45 **351P - Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort**
W. Jacot¹, G. Louvel², A. Darlix², J. Fraisse², E. Brain², M. Debled³, M.A. Mouret Reynier⁴, A. Goncalves⁵, F. Dalenc⁶, P. Augereau², J.-M. Ferrero⁷, C. Levy¹, J.-D. Fumet², C. Jouannaud³, C. Veyret⁴, V. Dieras¹, M. Robain², C. Courtinard², D. Pasquier², T. Bachelot²; ¹CEDEX 5/FR, ²FR, ³CEDEX/FR, ⁴CEDEX 1/FR, ⁵CEDEX 9/FR, ⁶CEDEX 3/FR, ⁷CEDEX 2/FR
- 12:45 - 12:45 **352P - Features associated with long-term survival in metastatic breast cancer**
N. Klar¹, M. Rosenzweig², B. Diergaard², A. Brufsky²; ¹US, ²PA/US
- 12:45 - 12:45 **353P - Physical activity and lifestyle in women with metastatic breast cancer: The ABLE study**
B. Fervers¹, L. Delrieu¹, O. Pérol¹, O. Febvey-Combes¹, A. Dufresne², T. Bachelot¹, P. Heudel³, O. Tredan¹, M. Touillaud¹, V. Pialoux¹; ¹FR, ²CEDEX 3/FR, ³CEDEX/FR
- 12:45 - 12:45 **What Research questions matters most to patients? Final Results of the Metastatic Breast Cancer Priority Setting Partnership**
N. Nixon¹, C. Simmons¹, J. Lemieux¹, S. Verma²; ¹CA, ²Alberta/CA
- 12:45 - 12:45 **355P - Establishment and validation of M1 stage subdivisions for patients with de novo metastatic breast cancer: A population-based study**
C. Lin, J. Wu, L. Zhu; CN
- 12:45 - 12:45 **356P - A prospective observational study of mobile application-based patient-reported outcomes (PRO) in advanced breast cancer: Interim baseline data from the MADELINE study**
D. Odom¹, D. Mitra², K. Hollis¹, D. Richardson¹, J. Kaye¹, L. McRoy²; ¹NC/US, ²NY/US
- 12:45 - 12:45 **357P - Stereotactic radiosurgery (SRS) for brain metastases (BM) from breast cancer (BC): A single centre experience of factors influencing survival**
T. Wilson, T. Robinson, C. Macfarlane, T. Spencer, C. Herbert, J. Braybrooke; GB

- 12:45 - 12:45 **358P - Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer**
E. Curtit¹, F. Bazan¹, L. Chaigneau¹, G. Mouillet¹, E. Dobi¹, L. Mansi¹, N. Meneveau¹, M.-J. Paillard¹, G. Meynard¹, E. Klajer¹, C. Villanueva¹, P. Montcuquet¹, X. Pivot², L. Cals²; ¹FR, ²CEDEX/FR
- 12:45 - 12:45 **359P - Surgery of the primary tumor for de novo metastatic breast cancer: The controversy continues**
B. López de San Vicente, E. Galve Calvo, A. Zumarraga, F. Pikabea, J.F. Arango Arteaga, M. López Santillan, C. Figaredo, M.A. Sala Gonzalez, M. Nuño Escolastico, P. Novas Vidal, J. Legaspi, P. Martinez del Prado; ES
- 12:45 - 12:45 **360P_PR - Breast cancer in Twitter: a real-world data exploratory study**
R. Sanchez Bayona, L. Chang-Azancot, M.A. Alvarez de Mon, M. Llaverro, M. Vallejo, I. Gardeazabal, D. Salas, P. Sala Elarre, I. Baraibar Argota, I. Eguren, M. Santisteban Eslava, L. Ceniceros, E. Castanon Alvarez; ES
- 12:45 - 12:45 **361TiP - A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)**
A. Shimomura¹, K. Tamura¹, T. Mizutani¹, T. Shibata¹, F. Hara¹, T. Fujisawa¹, N. Niikura², T. Hojo¹, C. Kambayashi¹, S. Saji³, N. Masuda¹, M. Sawaki¹, N. Yamamoto¹, F. Nagashima¹, T. Shien¹, H. Iwata⁴; ¹JP, ²Kanagawa/JP, ³Fukushima/JP, ⁴Aichi/JP
- 12:45 - 12:45 **362TiP - ATTAIn: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)**
D. Tripathy¹, S. Tolaney², A. Seidman³, C. Anders⁴, N. Ibrahim¹, H. Rugo⁵, C. Twelves⁶, V. Dieras⁷, V. Müller⁸, A. Hannah⁵, M. Tagliaferri⁹, J. Cortes Castan¹⁰; ¹TX/US, ²MA/US, ³NY/US, ⁴NC/US, ⁵CA/US, ⁶Yorkshire/GB, ⁷CEDEX 5/FR, ⁸DE, ⁹US, ¹⁰ES
- 12:45 - 12:45 **363TiP - Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear β -catenin translocation in patients with triple negative breast cancer**
J. Diamond¹, E. Andreopoulou², A. Favret³, R. Nanda⁴, C. Peterson¹, E. Benaim⁵; ¹US, ²NY/US, ³VA/US, ⁴IL/US, ⁵MD/US
- 12:45 - 12:45 **364TiP - Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97**
T. Decker, C. Denkert, K. Lübke, V. Müller, C. Mundhenke, J. Furlanetto, M. Schmidt, M. Thill, V. Tierbach, F. Seither, S. Loibl; DE
- 12:45 - 12:45 **365TiP - SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC)**

G. Steger¹, F. Puglisi², C. Timcheva³, L. Costa⁴, M. Casa-Nova⁴, D. Hitzl¹, B. Dampier¹, N. Lindegger⁵; ¹AT, ²IT, ³BG, ⁴PT, ⁵CH

- 12:45 - 12:45 **366TiP - The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer**
S. Langkjer¹, J. Kenholm¹, J. Jensen¹, K. Wedervang¹, A. Brixen¹, M. Grunnet¹, L. Stenbygaard¹, H. Danø¹, V. Glavicic¹, E. Jacobsen¹, A. Brems-Eskildsen¹, H. Kruse¹, T. Dongsgaard¹, J. Neimann¹, J. Geisler²; ¹DK, ²NO
- 12:45 - 12:45 **367TiP - LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation**
K. Gelmon¹, G. Walker², G. Fisher³, S. McCutcheon³; ¹British Columbia/CA, ²Bedfordshire/GB, ³GB
- 12:45 - 12:45 **368TiP - START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)**
H. Bonnefoi¹, C. Levy², G. MacGrogan³, T. Grellety³, B. Asselain³, M. Pulido³, S. Everhard³, J. Lemonnier³, A. Gonçalves³; ¹CEDEX/FR, ²CEDEX 5/FR, ³FR
- 12:45 - 12:45 **369TiP - PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib &&**
S. Loibl¹, O. Metzger², S. Mandrekar², C. Mundhenke¹, S. Seiler¹, P. Valagussa³, A. DeMichele⁴, E. Lim⁵, D. Tripathy⁶, E. Winer⁷, C. Huang², L. Carey⁸, P. Francis⁹, K. Miller¹⁰, M.P. Goetz², A. Prat¹¹, S. Loi⁹, I. Krop², L. Gianni³, E. Ciruelos¹¹; ¹DE, ²US, ³IT, ⁴PA/US, ⁵NSW/AU, ⁶TX/US, ⁷MA/US, ⁸NC/US, ⁹VIC/AU, ¹⁰IN/US, ¹¹ES
- 12:45 - 12:45 **370TiP - A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer**
S. Hurvitz¹, M. Galsky², J. Shahidi³, G. Zhang³, S. Raza³, A. Necchi⁴; ¹CA/US, ²US, ³NJ/US, ⁴IT
- 12:45 - 12:45 **CNS tumours**
- 12:45 - 12:45 **383P - Worldwide trends in survival from adult glioma 2000-2014 (CONCORD-3): Impact of morphology**
F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M. Coleman, CONCORD Working Group; GB
- 12:45 - 12:45 **384P - Clinical characteristics of 3,030 glioblastoma multiforme (GBM) patients in high, upper middle and lower middle economic regions based on real-world data (RWD)**
L. Mitrofan¹, M. Krukas-Hampel², L. Mendoza³; ¹FR, ²US, ³CZ

- 12:45 - 12:45 **385P - Radiotherapy versus combined radiochemotherapy for unresectable glioblastoma: A SEER based analysis**
M. Osman, EG
- 12:45 - 12:45 **386P - Clinical characteristics of glioblastoma multiforme (GBM) patients who reached 400 days post diagnostic from a retrospective real-world data**
L. Mitrofan¹, M. Krukas-Hampel², L. Mendoza³; ¹FR, ²US, ³CZ
- 12:45 - 12:45 **387P - Corticosteroids administration as a prognostic factor in glioblastoma patients: An Egyptian experience**
K. Abdel Karim, M. Kelany, O. Abdelrahman, A. El-Adawy; EG
- 12:45 - 12:45 **388P - Impaired survival in resected glioblastoma multiforme patients treated with early chemoradiation**
L. del Carpio, P. Gomila, S.D. Camacho, S. Moron, M. Riudavets, C. Molto, A. Bujosa, M. Borrell, R. Teres, B. Martin, P. Gallardo, E. Acosta, L. Tilea, A. Soto, C. De Quintana, J. Craven-Bartle, A. Gallardo, B. Gomez, S. Bonilla, O. Gallego; ES
- 12:45 - 12:45 **389P - Bevacizumab-induced hypertension correlation with survival in recurrent glioblastoma multiforme**
N. Tavares, J. Simões, C. Borges, S. Meireles, A. Costa, C. Fernandes, C. Caeiro, M. Damasceno; PT
- 12:45 - 12:45 **390P - &&**
I. Djan, M. Djan, N. Vucinic, B. Nikolin, S. Salma, S. Lucic, N. Vuckovic, M. Lucic; RS
- 12:45 - 12:45 **391P - Expression and clinical prognostic role of ZWINT in glioma: Analysis based on data-mining and integration of gene databases**
Z. Mengxian, CN
- 12:45 - 12:45 **392P - Lipid peroxidation and cognitive impairment in patients with brain cancers**
S. Kim, S. Kim; KR
- 12:45 - 12:45 **393P - FAT1 on YAP1-TEAD1 interaction augments oncogenic potential of GBM cells**
Y. Gupta, S. Shivajirao, K. Irshad, B. Dikshit, T. Srivastava, P. Chattopadhyay, S. Sinha, K. Chosdol; IN
- 12:45 - 12:45 **394P - Extracts of Cerbera manghas L. effectively inhibit the growth of glioblastoma cells and their stemloids**
Y.-J. Lai, J.-C. Tsai, W.-S. Liu, H.-I. Lam; TW
- 12:45 - 12:45 **395P - Contrast enhancement in low grade gliomas: A classic prognostic factor in the molecular age**
F. Castet¹, E. Alanya², M. Gil-Gil¹, N. Vidal¹, C. Izquierdo³, C. Mesia¹, J. Bruna¹; ¹ES, ²PE, ³FR

- 12:45 - 12:45 **396P - Can diffusion tensor MR imaging identify glioma IDH mutation status?**
S. Bisdas, J. Yuan, L. Mancini, D. Roettger; GB
- 12:45 - 12:45 **397P - Comparative assessment of orthotopic brain tumor growth using bioluminescence and magnetic resonance imaging**
Y. Tsvetkova, C. Green, G. Schuetz, J. Hoffmann, D. Zopf, P. Lejeune; DE
- 12:45 - 12:45 **398P - Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications**
H. Gan¹, C. Murone², M. Wong², G. Fitt², E. Kennedy³, D. Maag⁴, K. Aldape⁵; ¹VIC/AU, ²AU, ³IL/US, ⁴US, ⁵ON/CA
- 12:45 - 12:45 **399P - Melanoma with brain metastases: Experience of immunotherapy in a single center**
D. Naskhletashvili, L. Demidov, A. Bekyashev, V. Aloshin, E. Prozorenko; RU
- 12:45 - 12:45 **400P - Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between ocreotide in combination with everolimus compared to sunitinib**
A. Cardona Zorrilla¹, A. Ruiz-Patiño¹, O. Arrieta², L. Zatarain-Barron², F. Hakim¹, E. Jimenez¹, J.A. Mejia¹, F. Ramon¹, N. Useche¹, S. Bermudez¹, D. Pineda¹, H. Cifuentes¹, L. Rojas¹, L.E. Pino Villareal³, C. Balana⁴; ¹CO, ²MX, ³Cundinamarca/CO, ⁴Barcelona/ES
- 12:45 - 12:45 **401P - Impact of postoperative residual tumor and meningeal dissemination in adult medulloblastoma: A retrospective analysis**
R. Barreto, P. Viveiros, M. Mesquita, V. Santos, O. Feher; BR
- 12:45 - 12:45 **402P - Adult medulloblastoma: An oncology radiation therapy department experience with 22 cases**
M. Kallel, Z. Fessi, W. Siala, W. mnejja, N. Fourati, H. daoud, T. Boudawara, Z. Boudawara, M. Frikha, J. Daoud; TN
- 12:45 - 12:45 **403P - Pineal parenchymal tumors: Patterns of care from a tertiary cancer centre in India**
B. Devnani, S. Gupta, H. Kp, P. Julka, G. Rath; IN
- 12:45 - 12:45 **404P - Advantages of next-generation sequencing in revealing low-level somatic mosaicism in blood samples of retinoblastoma patients**
E. Alekseeva, V. Kozlova, T. Ushakova, A. Tanas, O. Babenko, T. Kazubskaya, V. Strelnikov, D. Zaletaev; RU
- 12:45 - 12:45 **405TiP - Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study**
F. Jacques¹, G. Nicholas², I. Lorimer²; ¹CA, ²ON/CA

- 12:45 - 12:45 **406TiP - Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade gliomas patients: OLA-TMZ-RTE-01**
D. Stefan¹, P. Lesueur¹, J. Lequesne¹, E. Coquan², P.E. Brachet¹, L. Castera¹, N. Goardon¹, J. Lacroix¹, M. Lange¹, A. Capel¹, B. Andre¹, J.-M. Grellard¹, B. Clarisse²; ¹FR, ²CEDEX 5/FR
- 12:45 - 12:45 **407TiP - Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600E mutant high-grade glioma (HGG) or low-grade glioma (LGG)**
D. Hargrave¹, O. Witt², K. Cohen³, R. Packer⁴, A. Lissat², U. Kordes², T. Laetsch⁵, L. Hoffman⁶, A. Lassaletta⁷, N. Gerber⁸, S. Gilheeny⁹, S. Holm¹⁰, C. Kramm², D. Sumerauer¹¹, C. Reitmann¹², M. Russo¹², E. Bouffet¹³; ¹GB, ²DE, ³MD/US, ⁴DC/US, ⁵US, ⁶CO/US, ⁷ES, ⁸CH, ⁹NY/US, ¹⁰SE, ¹¹CZ, ¹²NJ/US, ¹³ON/CA
- 12:45 - 12:45 **419P - Double blind concordance study of colo-rectal cancer treatment recommendations between artificial intelligence advisory programme watson for oncology (WFO) & multidisciplinary tumor board (MDT)**
S. Sampige Prasannakumar¹, M. Sepulveda², C. Rohit Kumar³, A. Rauthan¹, P. Patil³, Y. Ramya³; ¹Karnataka/IN, ²NY/US, ³IN
- 12:45 - 12:45 **Developmental therapeutics**
- 12:45 - 12:45 **420P - Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours**
P. Bono¹, C. Massard², K. Peltola¹, A. Azaro³, A. Italiano², R. Kristeleit⁴, U. Lassen⁵, H.-T. Arkenau⁴, P. Hakulinen¹, C. Garratt⁶, T. Ikonen¹, M. Mustonen¹, J. Rodon³; ¹FI, ²CEDEX/FR, ³ES, ⁴GB, ⁵DK, ⁶NG1 1AH/GB
- 12:45 - 12:45 **421P - Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors**
M. Johnson¹, M. Galsky², M. Barve³, S. Goel², H. Park², B. Du², S. Mu⁴, V. Ramakrishnan², K. Wood², V. Wang², N. Lakhani²; ¹TN/US, ²US, ³TX/US, ⁴NJ/US
- 12:45 - 12:45 **422P - First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies**
P. Lorusso¹, S. Chawla², J. Bendell³, A. Shields⁴, G. Shapiro⁴, P. Rajagopalan⁴, C. Cyris⁴, I. Bruns⁴, J. Mei⁴, F. Souza⁴, D. Rasco⁵, J.P. Eder⁶, A. Tolcher⁵; ¹CT/US, ²CA/US, ³TN/US, ⁴US, ⁵TX/US, ⁶CH
- 12:45 - 12:45 **423P - Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors**

N. Yamamoto¹, Y. Fujiwara¹, S. Kondo¹, S. Iwasa¹, K. Yonemori¹, A. Shimomura¹, S. Kitano¹, T. Shimizu¹, T. Koyama¹, T. Ebata², N. Sato¹, K. Nakai¹, M. Inatani¹, K. Tamura¹; ¹JP, ²Chiba/JP

- 12:45 - 12:45 **424P_PR - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?**
A. Vozy¹, P. Berlanga Charriel², B. Georger¹, C. Massard³, N. Gaspar¹; ¹FR, ²ES, ³CEDEX/FR
- 12:45 - 12:45 **425P - SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer**
S. Crabb, S. Danson, D. Dunkley, M. Kalevras, A. Whitehead, S. Hill, K. Fines, C. Robb, J. Bennett, L. Ksiazek, S. Brown, L. Evans, M. Serra, K. Jones, C. McDowell, J. Catto, R. Huddart, G. Griffiths; GB
- 12:45 - 12:45 **426P - Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas**
K. Moek, S. Waaijer, I.C. Kok, F.V. Suurs, A. Brouwers, C.W. Menke-van der Houven van Oordt, T.T. Wind, J. Gietema, C.P. Schroder, S.V.K. Mahesh, A. Jorritsma-Smit, M.N. Lub-De Hooge, R. Fehrmann, D.J. de Groot, E.G.E. de Vries; NL
- 12:45 - 12:45 **427P - Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma**
K. Moek¹, W. Fiedler², J.C. von Einem², H. Verheul¹, T. Seufferlein², D.J. de Groot¹, V. Heinemann², M. Kebenko², C.W. Menke-van der Houven van Oordt¹, T. Ettrich², E. Rasmussen³, P. Bogner², B. Sable³, S. Stienen², E.G.E. de Vries¹; ¹NL, ²DE, ³US
- 12:45 - 12:45 **428P - Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors**
T. Bauer¹, M. Barve², E.G. Chiorean³, P. Lorusso⁴, K. Courtney², D. Qi⁵, A. Olguin⁵, J. Bullington⁵, M. Sardone⁵, V. Dunn⁵, S. Shemesh⁵, J. Chen⁵, C. Brooks⁶, J. Wang⁷; ¹TN/US, ²TX/US, ³WA/US, ⁴CT/US, ⁵NY/US, ⁶US, ⁷FL/US
- 12:45 - 12:45 **429P - NEO2734: A novel potent oral dual BET and P300/CBP inhibitor**
F. Giles¹, M. Witcher², B. Brown³; ¹US/US, ²IL/US, ³QC/CA
- 12:45 - 12:45 **430P - Phase I study: Safety and tolerability of varlitinib (VAR) in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours**
A. Seet¹, S.P. Choo¹, D. Tai¹, Y.C.J. Lam¹, W.T. Teng¹, C. Lim¹, T. Lim¹, I. Tan¹, E. Petricoin², M. Ng¹; ¹SG, ²VA/US
- 12:45 - 12:45 **431P - Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers**

V. Heong, M.L. Goh, W.P. Yong, R. Soo, C.E. Chee, S. Raghav, B.-C. Goh, S.C. Lee, J. Lim, A. Wong, D. Tan; SG

- 12:45 - 12:45 **432P - Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients**
Y. Yu¹, C. Durairaj¹, H. Shi², D. Wang¹; ¹CA/US, ²CT/US
- 12:45 - 12:45 **433P - An open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors**
J. Palshof, I. Kümler, P. Sørensen, B. Jensen, D. Nielsen; DK
- 12:45 - 12:45 **434P - Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (&& G. Vassal¹, N. Cozic¹, R. Houot¹, L. Brugières¹, T. Aparicio², J.-Y. Blay², M. Perol², P. Brice¹, E. Meriaux², B. Geoerger¹, M. El Bejjani¹, S. Moalla¹, I. Bièche¹, S. Lantuejoul³, C. Mahier Ait Oukhatar¹, N. Hoog Labouret¹, D. Moro-Sibilot¹; ¹FR, ²CEDEX/FR, ³CEDEX 9/FR**
- 12:45 - 12:45 **435P - Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors**
V. Boni¹, J. Garcia-Corbacho¹, P. Ott², D. Cho³, K. Autio³, N. Uboha⁴, A. Spira⁵, R. Humphrey⁶, M. Will⁶, A. Naing⁷, F. Thistlethwaite⁸, E.G.E. de Vries⁹, H.-T. Arkenau⁸; ¹ES, ²MA/US, ³NY/US, ⁴WI/US, ⁵VA/US, ⁶CA/US, ⁷TX/US, ⁸GB, ⁹NL
- 12:45 - 12:45 **436P - Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors**
R. Plummer¹, R. Sanborn², E.G.E. de Vries³, P. Lorusso⁴, H.-T. Arkenau⁵, N. Uboha⁶, J. Wydmanski⁷, M.J. Fidler⁸, V. Boni⁹, J. Garcia-Corbacho⁹, R. Humphrey¹⁰, M. Will¹⁰, K. Autio¹¹, A. El-Khoueiry¹², C.W. Menke-van der Houven van Oordt³, F. Thistlethwaite⁵; ¹Tyne and Wear/GB, ²OR/US, ³NL, ⁴CT/US, ⁵GB, ⁶WI/US, ⁷PL, ⁸IL/US, ⁹ES, ¹⁰CA/US, ¹¹NY/US, ¹²US
- 12:45 - 12:45 **437P - PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors**
D. Karp¹, D. Camidge², J. Infante³, T. Ames⁴, J. Jimeno⁵, A. Bryce⁴; ¹TX/US, ²CO/US, ³TN/US, ⁴US, ⁵NY/US
- 12:45 - 12:45 **438P - Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891**
J. Powderly¹, P. Cassier², A. Cervantes³, B. Gao⁴, A. Gazzah², A. Italiano⁵, C.-C. Lin⁶, J. Luke⁷, V. Moreno⁸, K. Peltola⁹, D. Rasco¹⁰, A. Spira¹¹, M. Tanner⁹, D. Tosi², D. Afar¹², S. Englert⁷, A. Parikh¹², A. Reddy¹², G. Vosganian⁷, A. Tolcher¹⁰; ¹NC/US, ²FR, ³Valencia/ES, ⁴NSW/AU, ⁵CEDEX/FR, ⁶TW, ⁷US, ⁸ES, ⁹FI, ¹⁰TX/US, ¹¹VA/US, ¹²CA/US

- 12:45 - 12:45 **439P - Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials**
C. Massard¹, N. Segal², D. Cho³, V. Papadimitrakopoulou², N. Rizvi³, B.C. Cho⁴, L. Yu⁵, H. Yang⁵, H.-J. Hsieh⁵, J. Zhang⁵, W. Zhao⁵, G. Gao⁵, X. Guo⁵, S. Abdullah⁵, J. Englert⁵, J.-C. Soria⁶, M. Dar⁵, L. Roskos², C. Ferte⁵, S. Antonia⁷; ¹CEDEX/FR, ²US, ³NY/US, ⁴KR, ⁵MD/US, ⁶CEDEX/US, ⁷FL/US
- 12:45 - 12:45 **440P - Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect**
A. Karlsson-Parra, G. Fotaki, D. Yu, M. Essand; SE
- 12:45 - 12:45 **441P - OT-1096: A first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral tregs in a humanized TNBC-PDX model**
O. Orwar, I. Lowstedt, K. Andersson, G. Gannedahl, G. Willman, M. Davidsson, W. Stafford, C. Trkulja; SE
- 12:45 - 12:45 **442TiP - A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies**
S. Blagden¹, P. Spiliopoulou¹, L. Spiers², C. Gnanaranjan¹, C. Qi¹, V. Woodcock², J. Moschandreas¹, H. Tyrrell¹, L. Griffiths¹, C. Butcher¹, E. Ghazaly¹, T.R.J. Evans¹; ¹GB, ²Oxfordshire/GB
- 12:45 - 12:45 **443TiP - First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population**
C. Gomez-Roca¹, E. Garralda-Cabanas², F. Cruzalegui³, F. Ausseil³, G. Zorza³, O. Delfour³, J. Besse³, B. Akla³, S. Gautier³, J. Adam³, M. Lacroix-Triki¹, A. Passiukov³, R. Roche³, M. Pavlyuk³, C. Massard⁴; ¹Haute-Garonne/FR, ²ES, ³FR, ⁴CEDEX/FR
- 12:45 - 12:45 **444TiP - Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors**
J. Desai¹, M. Voskoboynik², B. Markman¹, J. Hou³, D. Zeng³, T. Meniawy⁴; ¹VIC/AU, ²AU, ³CA/US, ⁴WA/AU
- 12:45 - 12:45 **445TiP - Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy**
A. Krämer¹, F. Losa², L. Gay³, D. Page⁴, S. Foser⁴, T. Mughal³, J. Ross³, G. Baciarello⁵, L. Mileschkin⁶, S. Osborne⁴, H. Moch⁴; ¹DE, ²ES, ³MA/US, ⁴CH, ⁵CEDEX/FR, ⁶AU

- 12:45 - 12:45 **446TiP - REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies**
A. Diab¹, M. Marcondes¹, M. Tagliaferri¹, U. Hoch², J. Zhang¹, W. Rubas¹, S. Kivimae¹, J. Zalevsky¹, A. Conley¹, E. Borazanci³, S. D'Angelo⁴; ¹US, ²CA/US, ³AZ/US, ⁴NY/US
- 12:45 - 12:45 **447TiP - The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies**
S. Thavaneswaran¹, L. Sebastian², M. Ballinger², M. Cowley², J. Grady², A. Joshua², C. Lee², K. Sjoquist², W. Hague², J. Simes², D. Thomas²; ¹AU, ²NSW/AU
- 12:45 - 12:45 **448TiP - MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts**
R. Penson¹, Y. Drew², M. de Jonge³, S.-H. Hong⁴, Y.H. Park⁴, A. Wolfer⁵, J. Brown², M. Ferguson², M. Gore², R. Alvarez¹, B. Kaufman⁶, C. Gresty², H. Angell², K. Meyer⁷, M. Lanasa¹, P. Herbolzheimer¹, S. Domchek¹; ¹US, ²GB, ³NL, ⁴KR, ⁵CH, ⁶IL, ⁷MD/US
- 12:45 - 12:45 **449TiP - MASTER KEY project: A basket/umbrella trial for rare cancers in Japan**
S. Noda, K. Yonemori, N. Shirakawa, H. Okuma, T. Shimizu, A. Hirakawa, T. Shibata, T. Sukigara, N. Okita, A. Kawai, N. Yamamoto, K. Nakamura, H. Mano, T. Nishida, Y. Fujiwara; JP
- 12:45 - 12:45 **Genitourinary tumours, prostate**
- 12:45 - 12:45 **800P - The prognostic value of the proportion and subtype patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer: A propensity score matching study**
J. Zhao, J. Liu, G. Sun, P. Shen, J. Chen, X. Zhang, H. Zhang, Z. Liu, Y. Bao, Y. Yang, P. Zhao, K. Shu, H. Zeng; CN
- 12:45 - 12:45 **801P - Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +- orteronel**
P. Lara¹, E. Mayerson², E. Gertz¹, C. Tangen², A. Goldkorn³, M. van Loan¹, M. Hussain³, S. Gupta³, J. Zhang⁴, P. Twardowski¹, D. Quinn¹, N. Vogelzang⁵, I. Thompson⁶, N. Agarwal³; ¹CA/US, ²WA/US, ³US, ⁴FL/US, ⁵NV/US, ⁶TX/US
- 12:45 - 12:45 **802P - Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China**
W. Jiang, S. Qu, Y. Liu, X. Yao, M. Liu; CN
- 12:45 - 12:45 **803P - Randomized trial of androgen deprivation therapy (ADT) &&**

U. Vaishampayan¹, L. Heilbrun², P. Monk³, G. Sonpavde⁴, S. Tejwani², E. Heath¹, J. Fontana², S. Chinni²; ¹US, ²MI/US, ³OH/US, ⁴MA/US

- 12:45 - 12:45 **804P - Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)**
E. Small¹, D. Cella², K. McQuarrie¹, F. Saad³, B. Hadaschik⁴, J. Graff¹, H. Uemura⁵, S. Oudard⁶, M. Yu¹, S. Hudgens¹, A. Lopez-Gitlitz¹, B. Rooney⁷, M. Morris⁷, M. Smith¹; ¹US, ²IL/US, ³CA, ⁴DE, ⁵JP, ⁶FR, ⁷GB
- 12:45 - 12:45 **805P - A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region**
K. Fizazi¹, M. Hussain², F. Saad³, N. Shore², U. De Giorgi⁴, E. Efstathiou⁵, U. Ferreira⁶, P. Ivashchenko⁷, K. Madziarska⁸, M. Al-Adhami², K. Modelska², D. Phung⁹, J. Steinberg¹⁰, C. Sternberg⁴; ¹FR, ²US, ³CA, ⁴IT, ⁵TX/US, ⁶BR, ⁷UA, ⁸PL, ⁹NL, ¹⁰IL/US
- 12:45 - 12:45 **806P - Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN**
M. Smith¹, C. Perez-Ruixo², O. Ackaert², D. Ouellet¹, C. Chien¹, H. Uemura³, D. Olmos⁴, P. Mainwaring⁵, J.Y. Lee⁶, M. Yu⁷, J.-J. Perez-Ruixo², E. Small¹; ¹US, ²BE, ³JP, ⁴ES, ⁵QLD/AU, ⁶KR, ⁷CA/US
- 12:45 - 12:45 **807P - Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study**
B. Tombal¹, M. Hussain², D. Penson², G. Attard¹, C. Sternberg³, D. Phung⁴, R. Morlock², K. Modelska², K. Ramaswamy², C. Ivanescu⁴, F. Saad⁵; ¹GB, ²US, ³IT, ⁴NL, ⁵CA
- 12:45 - 12:45 **808P - Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide**
D. Almeida¹, C. de Oliveira¹, R. Mariano¹, F. Kater², M.C. Souza¹, V. Ruiz-Schutz¹, R. Yamamura², R. Saraiva De Carvalho², F. Maluf¹, A. Morgans³, S. Srinivas⁴, S. Gupta⁵, T. Dorff⁴, E. Yu⁶, F.A. Schutz²; ¹BR, ²SP/BR, ³US, ⁴CA/US, ⁵FL/US, ⁶WA/US
- 12:45 - 12:45 **809P - Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial**
D. Lorente¹, G.A. De Velasco Oria², J. Carles³, S. Gillessen⁴, K. Fizazi⁵, A. Joshua⁶, M. Eisenberger⁷, O. Sartor⁷, J. de Bono⁸; ¹Surrey/GB, ²MA/ES, ³ES, ⁴CH, ⁵FR, ⁶NSW/AU, ⁷US, ⁸GB
- 12:45 - 12:45 **810P - Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)**

C. Ohlmann, Z. Roger, C. Rüssel, E. Hellmis, H. Suttmann, M. Janssen, A. Hübner, J. Dahm, J. Gleißner, M. Scheffler, S. Feyerabend, J. Telle, J. Klier; DE

- 12:45 - 12:45 **811P - Association of grade 3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel**
A. Meisel¹, R. de Wit², S. Oudard³, O. Sartor⁴, F. Stenner-Liewen¹, Z. Shun⁴, A. Ozatilgan⁵, M. Eisenberger⁴, J. de Bono⁶; ¹CH, ²NL, ³FR, ⁴US, ⁵MA/US, ⁶GB
- 12:45 - 12:45 **812P - Post hoc responder analysis of health&&**
A. Thiery Vuillemin¹, K. Fizazi², O. Sartor³, S. Oudard², D. Bury³, S. Guillonnet², A. Ozatilgan⁴, M. Eisenberger³, J. de Bono⁵; ¹CEDEX/FR, ²FR, ³US, ⁴MA/US, ⁵GB
- 12:45 - 12:45 **813P - Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment**
D. Robbrecht¹, R. van Soest¹, I. Tannock², S. Oudard³, B. Tombal⁴, M. Eisenberger⁵, F. Mercier³, R. de Wit¹; ¹NL, ²Ontario/CA, ³FR, ⁴BE, ⁵US
- 12:45 - 12:45 **814P - Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis**
S. Gillessen¹, S. Schmid¹, H. Beltran², D. Almeida³, N. Mehra⁴, P. Lavaud⁵, R. Morales Barrera⁶, D. Pignataro⁷, E. Castro Marcos⁶, V. Conteduca⁸, E. Efstathiou⁹, H.M.L. Le¹⁰, C. Pezaro¹¹, H. Suzuki¹², A. Zivi⁷, D. Klingbiel¹, A. Omlin¹; ¹CH, ²US, ³BR, ⁴Surrey/NL, ⁵FR, ⁶ES, ⁷IT, ⁸Forlì-Cesena/IT, ⁹TX/US, ¹⁰AE, ¹¹VIC/AU, ¹²JP
- 12:45 - 12:45 **815P - Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: Results from CAPRI**
M. Kuppen¹, H. Westgeest¹, A.J.M. van den Eertwegh¹, J. Van Moorselaar¹, N. Mehra², I. van Oort¹, A. van den Bergh¹, J.L. Coenen¹, K. Aben¹, R. Somford¹, J. Lavalaye¹, A. Bergman¹, C. Uyl-de Groot¹, W. Gerritsen¹; ¹NL, ²Surrey/NL
- 12:45 - 12:45 **816P - Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)**
C. Ryan¹, S. Dutta¹, W. Kelly¹, M. Morris², M.-E. Taplin³, S. Halabi⁴; ¹US, ²NY/US, ³MA/US, ⁴NC/US
- 12:45 - 12:45 **817P - Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: An observational study in the Netherlands**
H. Westgeest¹, M. Kuppen¹, A. van den Eertwegh¹, J. Van Moorselaar¹, N. Mehra², I. van Oort¹, A. van den Bergh¹, J.L. Coenen¹, K. Aben¹, R. Somford¹, R. de Wit¹, A. Bergman¹, J. Lavalaye¹, C. Uyl-de Groot¹, W. Gerritsen¹; ¹NL, ²Surrey/NL

- 12:45 - 12:45 **818P - Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry**
Z. Malik¹, A. Pichler², G. Di Lorenzo³, U. De Giorgi⁴, S. Hitier⁵, E. Ecstein-Fraisse⁵, A. Ozatilgan⁶, J. Carles⁷; ¹GB, ²AT, ³IT, ⁴Forlì-Cesena/IT, ⁵FR, ⁶MA/US, ⁷ES
- 12:45 - 12:45 **819P - Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide**
F. López Campos¹, I. Moreno¹, A. Conde-Moreno¹, A. Gómez-Iturriaga¹, M. Ruiz Vico¹, N. Romero Laorden², I. Henríquez López¹, P. Peleteiro Higuero¹, R. Lozano Mejorada¹, T. Piquer¹, M. Couselo¹, J. Gómez Ramos¹, J. Navarro¹, P. Barrionuevo Castillo¹, R. García¹, R. Villatoro¹, A. Montesa¹, M. Saez¹, B. Herrera¹, E. Castro Marcos¹; ¹ES, ²Madrid/ES
- 12:45 - 12:45 **820P - Cabazitaxel under routine conditions for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC): Interim results of the non-interventional SCOPE study**
J. Gschwend, C. Lange, C. Bokemeyer; DE
- 12:45 - 12:45 **821P - Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)**
S. España Fernandez¹, J.M. Piulats¹, N. Sala¹, J.M. Velarde¹, U. Ferrandiz¹, O. Etxaniz Ulazia², L. Heras Lopez¹, M.P. Barretina Ginesta¹, X. Garcia del Muro¹, A. Font¹; ¹ES, ²Barcelona/ES
- 12:45 - 12:45 **822P - Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate & docetaxel treatment in comparison to docetaxel**
J. Puente¹, M.J. Mendez Vidal¹, M. Saez¹, A. Font Pous², I. Duran¹, D. Castellano¹, M.J. Juan Fita¹, C. Santander¹, J. Arranz Arija¹, A. Sanchez-Hernandez¹, B. Mellado¹, T. Alonso¹, M.A. Gonzalez del Alba Baamonde¹, P. Maroto¹, M. Lazaro¹, E. Esteban¹, J. Cassinello¹, M.A. Climent Duran¹; ¹ES, ²Barcelona/ES
- 12:45 - 12:45 **823P - Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)**
P. Gajate Borau¹, A. Martin Marino², I. Gallegos Sancho², J.C. Villa Guzman³, A. Velastegui², T. Alonso Gordoa², D. Castellano², G. Rubio Romero², A. Pinto Marin², L. Villalobos Leon², C. Maximiano Alonso¹, M. Sotelo-Lezama², M. Sereno Moyano², J.F. Rodríguez², C. Perezagua Marin², J. Ballesteros², D. Marrupe Gonzalez¹, L. Rodriguez Lajusticia², J.J. Tafalla García², C. Aguado²; ¹Madrid/ES, ²ES, ³Ciudad Real/ES
- 12:45 - 12:45 **824P - Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)**

K. Miller¹, D. Heinrich², J. O'Sullivan³, J. Carles⁴, M. Wirth¹, S. Nilsson⁵, L. Huang⁶, J. Kalinovsky⁷, A. Heidenreich¹, F. Saad⁸; ¹DE, ²NO, ³GB, ⁴ES, ⁵SE, ⁶US, ⁷CH, ⁸CA

- 12:45 - 12:45 **825P - Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (mCRPC)**
B. Maughan¹, A. Hahn², J. Hoffman¹, K. Morton¹, S. Gupta¹, J. Batten¹, J. Thorley¹, J. Hawks¹, G. Nachaegari¹, R. Nussenzeveig¹, K. Boucher¹, N. Agarwal¹; ¹US, ²UT/US
- 12:45 - 12:45 **826P - Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE**
C. Sternberg¹, B. Tombal², K. Miller³, F. Saad⁴, O. Sartor⁵, J.P. Sade⁶, C. Logothetis⁵, J. Bellmunt⁷, S. Dizdarevic⁸, L. Harshman⁹, J. Logue⁸, S. Baldari¹, T. Richardson⁵, D. Bottomley⁸, M. Schostak³, I. Bayh³, J. Kalinovsky¹⁰, C. Higano⁵; ¹IT, ²BE, ³DE, ⁴CA, ⁵US, ⁶AR, ⁷ES, ⁸GB, ⁹MA/US, ¹⁰CH
- 12:45 - 12:45 **827P - Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)**
C. Higano¹, B. Tombal², K. Miller³, F. Saad⁴, O. Sartor¹, K. Tangirala¹, X. Jiao¹, J. Kalinovsky⁵, C. Sternberg⁶; ¹US, ²BE, ³DE, ⁴CA, ⁵CH, ⁶IT
- 12:45 - 12:45 **828P - Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO)**
T. Poeppe¹, S. Eschmann¹, A. Werner¹, I. Selinski¹, M.-O. Möllers¹, T. Neußer¹, A. Benson², J. Kalinovsky³, H. Palmedo¹; ¹DE, ²NJ/US, ³CH
- 12:45 - 12:45 **829P - Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry): A prospective observational registry in a non-study population**
R. Louhanepessy, S. Badrising, V. Vd Noort, J.L. Coenen, A. Oostdijk, P. Hamberg, J.M. Zuetenhorst, A. Beeker, N. Wagenaar, M. Lam, F. Celik, E. Vegt, W. Zwart, A. Bergman; NL
- 12:45 - 12:45 **830P - Synthetic DNA immunotherapy in biochemically relapsed prostate cancer**
N. Shore¹, E. Heath¹, L. Nordquist¹, H. Cheng¹, K. Bhatt¹, M. Morrow¹, T. McMullan¹, K. Kraynyak¹, J. Lee¹, B. Sacchetta¹, L. Liu¹, S. Rosencranz¹, S. Tagawa², L. Appleman³, R. Tutrone¹, J. Garcia⁴, Y. Whang⁵, W. Kelly¹, I. Csiki¹, M. Bagarazzi¹; ¹US, ²US/US, ³PA/US, ⁴OH/US, ⁵NC/US
- 12:45 - 12:45 **831P - Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis**
R. Tauber, K. Knorr, S. Schwaiger, M. Retz, T. Maurer, C. D'Alessandria, H.-J. Wester, J. Gschwend, W. Weber, M. Schwaiger, M. Heck, M. Eiber; DE

- 12:45 - 12:45 **832P - Association between patient reported quality of life (QOL) and survival: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer**
A. Morgans¹, Y.-H. Chen¹, D. Jerrard¹, M. Carducci², R. Dipaola¹, L. Wagner¹, D. Cella³, C. Sweeney⁴; ¹US, ²MD/US, ³IL/US, ⁴MA/US
- 12:45 - 12:45 **833P - AZD8186, a potent and selective inhibitor of PI3K&&**
J. de Bono¹, A. Hansen², A. Choudhury³, N. Cook⁴, E. Heath⁵, C. Higano⁵, M. Linch¹, J. Martin-Liberal⁶, D. Rathkopf⁷, K. Wisinski⁵, S. Barry¹, E. de Bruin¹, W. Brugger¹, S. Colebrook¹, T. Klinowska¹, M. Moschetta¹, P. Mortimer¹, L. Siu², G. Shapiro⁵; ¹GB, ²CA, ³MA/US, ⁴Cambridgeshire/GB, ⁵US, ⁶ES, ⁷NY/US
- 12:45 - 12:45 **834P - Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer**
F. Saad¹, K. Chi², N. Shore³, J. Graff³, E. Posadas⁴, S. Freeman⁴, J. Tryon³, G. Trudel⁴, J. de Jong³, J. Meltzer³, X. Zhao³, N. Tran³, A. Rezazadeh³; ¹CA, ²British Columbia/CA, ³US, ⁴CA/US
- 12:45 - 12:45 **835P - CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer**
R. Oksala, K. Räsänen, M. Karimaa, R. Riikonen, M. Ramela, P. Vehmaan-Kreula, O. Simola, P. Rummakko, G. Wohlfahrt, M. Mustonen; FI
- 12:45 - 12:45 **837P - Prediction of prostate cancer gleason score upgrading from biopsy to radical prostatectomy (RP) using a validated 17-gene panel assay**
J. Cullen, H. Lawrence, Y. Chen, R. Lu, S. Srivastava, I. Rosner, T. Brand, I. Sesterhenn; US
- 12:45 - 12:45 **836P - Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)**
H. Scher¹, R. Graf², M. Hulling¹, E. Carbone¹, R. Dittamore³; ¹NY/US, ²CA/US, ³US
- 12:45 - 12:45 **838P - PI3K/AKT pathway deleterious mutations in lethal prostate cancer**
P. Rescigno¹, M. Rediti², D. Dolling², D.N. Rodrigues², D. Bianchini², R. Riisnaes², C. Messina², M. Barrero², A. Petremolo², A. Sharp², S. Sumanasuriya², G. Seed², I. Figueiredo², S. Miranda², J. Goodall², J. Mateo², R. Chandler², W. Yuan², S. Carreira², J. de Bono²; ¹IT, ²GB
- 12:45 - 12:45 **842P - CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)**
M. Morris¹, N. Vogelzang², O. Sartor³, A. Armour³, R. Messmann³, M. Groaning³, A. Robarts¹, A. Tolcher⁴, M. Gordon⁵, H. Babiker³, P. Kuo³, M. Kearney³, A. Jendrisak³, Y. Wang³, M. Landers³, D. Petrylak⁶; ¹NY/US, ²NV/US, ³US, ⁴TX/US, ⁵AZ/US, ⁶CT/US

- 12:45 - 12:45 **843P - The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study**
T. LOUBERSAC¹, S. Chakak², M. Nguile-Makao², V. Fradet², P. Toren²; ¹FR, ²QC/CA
- 12:45 - 12:45 **845P - Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)**
S. Tagawa¹, T. Dai², D. Jandial²; ¹US/US, ²US
- 12:45 - 12:45 **844P - The clinical impact of targeted next generation sequencing (tNGS) in the treatment of metastatic prostate cancer**
P.M. Coelho Barata¹, P. Mendiratta², M. Sadaps², S. Klek², M. Ornstein², T. Gilligan², P. Grivas², B. Rini², D. Sohal², J. Garcia²; ¹PT, ²OH/US
- 12:45 - 12:45 **840P - Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC)**
C. Reuter, S. Brunotte, P. Ivanyi, M. Morgan, V. Grünwald; DE
- 12:45 - 12:45 **846P - Patterns of therapy in pelvic lymph node positive prostate cancer in Europe and Asia: A real-world data analysis**
M. Prentice, S. Mpima, P. Nasuti, A. Martinez-Pinillos, I. Wong, K. Durno, R. Davda, H. Payne; GB
- 12:45 - 12:45 **841P - Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC)**
A. Hahn¹, A. Kapron¹, J. Boyle¹, W. Kohlmann², A. Poole², D. Gill², S. Greenberg², P. Hale², C. Teerlink¹, B. Maughan², L. Cannon-Albright¹, N. Agarwal¹, K. Cooney²; ¹US, ²UT/US
- 12:45 - 12:45 **848P - Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems**
J. Hornberger¹, R. Graf¹, M. Hulling², G. Attard³, A. Allan⁴, R. Dittamore⁵, H. Scher²; ¹CA/US, ²NY/US, ³GB, ⁴CA, ⁵US
- 12:45 - 12:45 **853P - Long-term adverse effects (AEs) after dose-escalation with high-dose rate brachytherapy in combination with external beam radiation therapy (BT/RT). Comparison to external beam radiation therapy alone (RT)**
T. Wedde, S. Fosså, A. Dahl, M.-B. Schulz, W. Lilleby; NO
- 12:45 - 12:45 **851P - Pharmacokinetic/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients**
M.-L. Joulia¹, E. Carton Vienet Legue¹, M. Allard¹, O. Huillard², M. Peyromaure¹, M. Zerbib¹, M. Vidal¹, F. Goldwasser², J. Alexandre³, B. Blanchet²; ¹FR, ²CEDEX 14/FR, ³CEDEX 4/FR

- 12:45 - 12:45 **849P - Quality of docetaxel toxicity reporting for castration resistant prostate cancer (CRPC): A systematic review**
S. Cheng¹, M. Qureshi², V. Arciero², K.K.-W. Chan², U. Emmenegger³; ¹CA, ²ON/CA, ³Ontario/CA
- 12:45 - 12:45 **839P - Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)**
V. Conteduca¹, C. Oromendia², M. Sigouros², A. Sborner², D.M. Nanus², S. Tagawa³, K. Ballman², H. Beltran²; ¹Forlì-Cesena/IT, ²US, ³US/US
- 12:45 - 12:45 **850P - Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability**
M. Al Harthy¹, H. Singh¹, F. Karzai¹, P. Arlen¹, M. Theoret¹, J. Marte¹, M. Bilusic², A. Couvillon¹, H. Owens¹, A. Hankin³, L. Cordes³, I. Rosner¹, J. Strauss³, W. Figg¹, J. Schlom¹, W. Dahut³, J. Gulley³, R. Madan¹; ¹US, ²PA/US, ³MD/US
- 12:45 - 12:45 **847P - The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system in patients with high-risk prostate cancer**
J. Liu, J. Zhao; CN
- 12:45 - 12:45 **854P - Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate (NEPC)**
L. Apostolidis, C. Nientiedt, E. Winkler, A. Berger, C. Kratochwil, A. Kaiser, D. Jäger, M. Hohenfellner, C. Hüttenbrink, S. Pahernik, F. Distler, C. Grüllich; DE
- 12:45 - 12:45 **852P - Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)**
A. tripathi¹, J. Supko², K. Gray², Z. Melnick², M.-E. Taplin², A. Choudhury², M. Pomerantz², J. Bellmunt³, C. Yu², Z. Sun⁴, S. Srinivas⁴, P. Kantoff², C. Sweeney², L. Harshman²; ¹US, ²MA/US, ³ES, ⁴CA/US
- 12:45 - 12:45 **855P - Effect of prednisone on docetaxel pharmacokinetics in metastatic prostate cancer: A randomized drug-drug interaction study**
B. Belderbos, K. Hussaarts, L. van Harten, E. Oomen-De Hoop, P. de Bruijn, P. Hamberg, R. van Alphen, B. Haberkorn, R. van Soest, R. de Wit, R. Mathijssen; NL
- 12:45 - 12:45 **857P - United in fight against prostate cancer registry (UFO): First results from a large, multi-center, prospective, longitudinal cohort study in Asia**
H. Uemura¹, D. Ye², R. Kanesvaran³, H. Zeng², Y.-S. Pu⁴, E. Chiong³, B. Lojanapiwat⁵, S.K. Rawal⁶, B.H. Chung⁷, A.H.A. Razack⁸, Y.-S. Tsai⁴, Y. Liu⁹, M. Asinas-Tan³, W. Liu², G.K.M. Low³, M. van Kooten Losio¹⁰; ¹JP, ²CN, ³SG, ⁴TW, ⁵TH, ⁶IN, ⁷KR, ⁸MY, ⁹US, ¹⁰AU

- 12:45 - 12:45 **856P - Differences in treatment recommendations for advanced prostate cancer according to region and medical specialization: Analysis of the APCCC 2017 voting results**
S. Fischer¹, S. Gillessen¹, M. Sydes², A. Omlin¹; ¹CH, ²UK/GB
- 12:45 - 12:45 **858P - Deployment of advanced real-world data (RWD) analytics for the accelerated recruitment of patients into an ongoing metastatic castrate-resistant prostate cancer (mCRPC) trial, together with the development of a sophisticated patient referral network**
M. Cushion, GB
- 12:45 - 13:05 **859TiP - TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on&&**
J. de Bono¹, C. Higano², F. Saad³, K. Miller⁴, M. Casey², A. Czibere², C. Healy², K. Fizazi⁵; ¹GB, ²US, ³CA, ⁴DE, ⁵FR
- 13:05 - 13:05 **860TiP - Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response**
M.J. Juan Fita, L. Heras Lopez, B. Mellado, M.J. Mendez Vidal, U. Anido, D. Lorente, J.M. Sepulveda, C. Alvarez; ES
- 13:05 - 13:05 **861TiP - Multimodality treatment for pN1 prostate cancer: Adding elective para-aortic radiation in the PART trial**
C. Berghen, S. Joniau, C. Draulans, G. De Meerleer; BE
- 13:05 - 13:05 **862TiP - ReCab II: A phase II trial of Cabazitaxel +/- Rhenium -188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment**
E. Bouman-Wammes, J.M. van Dodewaard-De Jong, H. Bloemendal, H. Verheul, J.M.H. de Klerk, A.J.M. van den Eertwegh; NL
- 13:05 - 13:05 **Genitourinary tumours, non-prostate**
- 13:05 - 13:05 **871P - KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)**
F. Donskov¹, D. McDermott², J. Lee³, C. Szczylik⁴, J. Malik⁵, B. Alekseev⁶, J. Larkin⁵, V.B. Matveev⁶, R. Airatovich Gafanov⁶, P. Tomczak⁴, S. Tykodi⁷, P. Geertsens¹, P. Wiechno⁴, S.J. Shin³, F. Pouliot⁸, T. Alonso Gordo⁹, R. Kloss Silverman¹⁰, R. Perini¹⁰, C. Schloss¹⁰, M. Atkins¹¹; ¹DK, ²MA/US, ³KR, ⁴PL, ⁵GB, ⁶RU, ⁷US, ⁸CA, ⁹ES, ¹⁰NJ/US, ¹¹DC/US
- 13:05 - 13:05 **872P - Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)**
N. Agarwal¹, U. Vaishampayan², M. Green³, F. di Nucci³, P.-Y. Chang³, C. Scheffold⁴, S. Pal³; ¹US, ²MI/US, ³CA/US, ⁴California/US

- 13:05 - 13:05 **873P - Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151**
C. Suarez¹, T. Choueiri², D. McDermott³, B. Escudier⁴, M. Atkins², T. Powles⁵, B. Rini⁶, R. Motzer⁷, S. Pal⁸, L. Fong⁸, U. De Giorgi⁹, Y. Wang⁸, T. Khaznadar¹⁰, F. Di Nucci⁸, C. Kaiser⁸, D. Tayama², F. Donskov¹¹; ¹ES, ²US, ³MA/US, ⁴CEDEX/FR, ⁵GB, ⁶OH/US, ⁷NY/US, ⁸CA/US, ⁹IT, ¹⁰CH, ¹¹DK
- 13:05 - 13:05 **874P - Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis**
D. McDermott¹, B. Rini², R. Motzer³, N. Tannir⁴, B. Escudier⁵, C. Kollmannsberger⁶, H. Hammers⁷, C. Porta⁸, S. George³, F. Donskov⁹, H. Gurney¹⁰, M.-O. Grimm¹¹, M. Harrison¹², T. Hutson⁴, J. Doan¹³, S. Yang¹², S. Rao¹², S. Mekan¹², A. Ambavane¹⁴, T. Powles¹⁴; ¹MA/US, ²OH/US, ³NY/US, ⁴TX/US, ⁵CEDEX/FR, ⁶British Columbia/CA, ⁷MD/US, ⁸IT, ⁹DK, ¹⁰NSW/AU, ¹¹DE, ¹²US, ¹³FL/US, ¹⁴GB
- 13:05 - 13:05 **875P - Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214**
B. Rini¹, N. Tannir², B. Escudier³, D. McDermott⁴, M.-O. Grimm⁵, C. Porta⁶, T. Powles⁷, C. Kollmannsberger⁸, H. Gurney⁹, S. Tykodi¹⁰, M. Harrison¹⁰, D. Heng¹, V. Grünwald⁵, T. Choueiri¹⁰, S. Mekan¹⁰, M.B. McHenry¹⁰, H. Hammers¹¹, R. Motzer¹², S. George¹²; ¹OH/US, ²TX/US, ³CEDEX/FR, ⁴MA/US, ⁵DE, ⁶IT, ⁷GB, ⁸British Columbia/CA, ⁹NSW/AU, ¹⁰US, ¹¹MD/US, ¹²NY/US
- 13:05 - 13:05 **876P - A new prognostic model for overall survival (OS) in second line (2L) for metastatic renal cell carcinoma (mRCC): Development and external validation**
L. Derosa¹, M.A. Bayar¹, L. Albiges², G. Le Teuff¹, B. Escudier²; ¹FR, ²CEDEX/FR
- 13:05 - 13:05 **877P - First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial**
U. Vaishampayan¹, P. Schöffski², A. Ravaud³, C. Borel⁴, T. Song⁵, S. Guenther⁶, J. Grewal¹, J. Gulley⁷; ¹US, ²BE, ³FR, ⁴CEDEX/FR, ⁵MA/US, ⁶DE, ⁷MD/US
- 13:05 - 13:05 **878P - TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC)**
P. Barthelemy¹, B. Escudier¹, A. Ravaud², S. Negrier¹, M. Needle³, L. Albiges¹; ¹CEDEX/FR, ²FR, ³US
- 13:05 - 13:05 **879P - Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)**
B. McGregor¹, A.-K. Lalani², W. Xie³, J. Steinharter¹, D. Martini⁴, P. Nuzzo¹, N. Martinez Chanza¹, L. Harshman³, M. Bilen¹, T. Choueiri¹; ¹US, ²CA, ³MA/US, ⁴GA/US

- 13:05 - 13:05 **880P - Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy**
G. Procopio¹, F. Cognetti¹, R. Miceli¹, M. Milella¹, A. Mosca¹, V. Chiuri¹, A. Bearz¹, F. Morelli¹, C. Ortega², F. Atzori³, R. Passalacqua⁴, R. Ratta¹, F.G. de Braud¹, V. Cappelletti¹, E. Verzoni¹; ¹IT, ²(TO)/IT, ³(CA)/IT, ⁴(CR)/IT
- 13:05 - 13:05 **881P - Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial**
D. George¹, A. Pantuck², R. Figlin³, B. Escudier⁴, S. Halabi¹, M. Casey³, X. Lin², L. Serfass⁵, M. Lechuga Freañ⁶, A. Ravaud⁵; ¹NC/US, ²CA/US, ³US, ⁴CEDEX/FR, ⁵FR, ⁶IT
- 13:05 - 13:05 **882P - Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)**
E. Verzoni¹, S. Ferro¹, G. Procopio¹, A. Cova¹, R. Ratta¹, A. RAIMONDI¹, P. Sepe¹, P. Squarcina¹, L. Lalli¹, V. Huber¹, D. Rinchai², D. Bedognetti², L. Rivoltini¹; ¹IT, ²QA
- 13:05 - 13:05 **883P - Metastatic clear cell renal cell carcinoma patients with ECOG performance status 2 treated with pazopanib: The Pazo2 trial of efficacy and safety**
E. Porfiri¹, S. Pirrie¹, A.-M. Hodgkins¹, D. Farrugia¹, K. Fife², C. McDonald-Smith¹, N. Vasudev³, G. Nixon¹, N. James¹, C. Stubbs¹; ¹GB, ²Cambridgeshire/GB, ³Yorkshire/GB
- 13:05 - 13:05 **884P - Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)**
G. Procopio¹, A. Bamias², M. Schmidinger³, R. Hawkins⁴, A. Rodriguez Sanchez⁵, S. Vazquez⁵, N. Srihari⁴, H. Kalofonos⁶, P. Bono⁷, C. Pisal⁸, Y. Hirschberg⁹, L. Dezzani⁹, Q. Ahmad⁹, C. Suarez Rodriguez⁵, E. Jonasch¹⁰; ¹IT, ²Attiki/GR, ³AT, ⁴GB, ⁵ES, ⁶GR, ⁷FI, ⁸IN, ⁹US, ¹⁰TX/US
- 13:05 - 13:05 **885P - Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)**
E. Verzoni¹, G. Carteni¹, E. Cortesi¹, F. Roila¹, M.G. Vitale¹, S. Buti¹, S. Pignata¹, F. Cognetti¹, L. Giustini¹, A. Damiani¹, D. Turci¹, C. Sternberg¹, C. Porta¹, F. Carrozza¹, G. Tortora¹, D. Tassinari¹, R. Passalacqua², A. Pazzola¹, G. Surico¹, G. Procopio¹; ¹IT, ²(CR)/IT
- 13:05 - 13:05 **886P - Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance**
G. Sun, X. Zhang, J. Zhao, J. Chen, P. Shen, Z. Liu, H. Zeng; CN
- 13:05 - 13:05 **887P - Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)**
A. Guida¹, G. Le Teuff², E. Colomba², G. Baciarello³, L. Derosa², Y. Loriot², K. Fizazi², C. Massard³, B. Escudier³, L. Albiges²; ¹IT, ²FR, ³CEDEX/FR

- 13:05 - 13:05 **888P - Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)**
S. Verhoeff¹, S. Es¹, E. Boon¹, E. van Helden¹, L. Angus¹, S. Elias¹, S. Oosting¹, E. Aarntzen¹, A. Brouwers¹, S. Heskamp¹, O. Hoekstra¹, H. Verheul¹, A. Van der Veldt¹, E.G.E. de Vries¹, O. Boerman¹, W. van der Graaf², W. Oyen¹, C. van Herpen¹; ¹NL, ²Surrey/GB
- 13:05 - 13:05 **889P - Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors**
J. Graham¹, J. Wells¹, R. McKay², U. Vaishampayan², A. Hansen¹, F. Donskov³, G. Bjarnason⁴, B. Beuselinck⁵, G. De Velasco⁶, M. Duh², L. Huynh², R. Chang², G. Zanotti², K. Ramaswamy², T. Choueiri², D. Heng⁷; ¹CA, ²US, ³DK, ⁴Ontario/CA, ⁵BE, ⁶ES, ⁷OH/US
- 13:05 - 13:05 **890P - Everolimus as first-line or after cytokine therapy in patients with metastatic recurrent and/or unresectable renal cell carcinoma (RCC) (EVERMORE)**
A. Abdel Hakim¹, Y. Nouria², R. Taran³, D. Amokrane⁴, M. Ghosn⁵, B. Larbaoui⁴, C. Pripatnanont⁶, K. Slimane⁷, V. Pilipovic⁸, H. Boussen²; ¹EG, ²TN, ³IN, ⁴DZ, ⁵LB, ⁶TH, ⁷FR, ⁸CH
- 13:05 - 13:05 **891P - Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study**
M.G. Vitale, S. Pipitone, S. Scagliarini, P.A. Zucali, L. Galli, S. Rossetti, C. Caserta, R. Iacovelli, C. Masini, C. Ficorella, S. Di Girolamo, S. Buti, B. Benedetti, M. Santoni, C. Porta, S. Bracarda, C. Baldessari, S. Giaquinta, S. Cascinu, R. Sabbatini; IT
- 13:05 - 13:05 **892P - Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS)**
J. Finek¹, R. Demlova², K. Kopeckova³, T. Buchler⁴, B. Melichar⁵, J. Prausova³, A. Poprach², T. Hrnčiarova⁵, T. Mlcoch⁵, T. Dolezal⁵; ¹Plzen/CZ, ²South Moravian/CZ, ³5/CZ, ⁴4/CZ, ⁵CZ
- 13:05 - 13:05 **893P - Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)**
A. Gomez de Liano Lista¹, B. Venugopal², K. Fife³, S. Symeonides², N. Vasudev⁴, S. Rudman², S. Vohra², L. Khasati², C. Pettinger², B. Szabados², L. Morrison², T. Powles², E. Boleti²; ¹ES, ²GB, ³Cambridgeshire/GB, ⁴Yorkshire/GB
- 13:05 - 13:05 **894P - Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)**
N. Dizman¹, P. Bergerot², C. Bergerot², E. Philip¹, M. Salgia¹, J. Hsu², J. Adashek², S. Pal²; ¹US, ²CA/US

- 13:05 - 13:05 **895P - Advanced treatment line (ATL) with lenvatinib and everolimus (Len+Eve) for metastatic renal cell carcinoma (mRCC): Analysis of a national early access program (EAP)**
A. Peer, M. Kolin, K. Rouvinov, D. Keizman, D. Sarid, R. Leibowitz-Amit, R. Berger, A. Sella, A. Rasco, E. Rosenbaum, C. maurice-dror, A. Neumann, V. Neiman; IL
- 13:05 - 13:05 **1656P - Should we consider altering our patterns of care for elderly sarcoma patients?**
S. Vari¹, C. Zoccali², V. Anelli², A. Annovazzi², M.G. Petrongari², G. Maggi², D. Giannarelli², N. Salducca², L. Favale², M. Zeuli², R. Biagini², A. Latini², W. Faltyn², M. Anza², R. Covelto², J. Baldi², D. Pellegrini², E. Checcucci², F. Cognetti², V. Ferraresi²; 1GB, 2IT
- 13:05 - 13:05 **896P - Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)**
H.-W. Sim¹, A. Stundzia², S. Pierre², U. Metser², M. O'Malley², E. Elimova², S. Sridhar¹, A. Hansen²; 1Ontario/CA, 2CA
- 13:05 - 13:05 **897P - A phase Ib study of safety and preliminary efficacy of extracranial stereotactic body radiation therapy (SBRT) in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy**
N. Dengina¹, T. Mitin², S. Gamayunov¹, S. Safina¹, Y. Kreinina¹, I. Tsimafeyeu¹; 1RU, 2OR/US
- 13:05 - 13:05 **898P - VOTRAGE study pazopanib in a population of &&**
L. Mourey¹, A. Ravaud¹, L. Digue¹, B. Cabarrou¹, C. Gomez-Roca², T. Valentin¹, P. Olivier¹, A. Fabre¹, M. Mounier¹, L. Balardy¹, T. Filleron³; 1FR, 2Haute-Garonne/FR, 3CEDEX 3/FR
- 13:05 - 13:05 **899P - A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS)**
D. Castellano¹, I. Duran¹, A. Rodríguez-Vida¹, S. Crabb², M. van der Heijden³, A. Font Pous⁴, G. Gravis⁵, U. Anido Herranz¹, A. Protheroe⁶, A. Ravaud⁷, D. Maillet⁸, M. Mendez-Vidal¹, C. Suarez¹, A. Lorch⁹, C. Sternberg¹⁰, M. Linch², S.-J. Sarker², J. Notta², K. Mousa², T. Powles²; 1ES, 2GB, 3NL, 4Barcelona/ES, 5CEDEX 9/FR, 6Oxfordshire/GB, 7FR, 8CEDEX/FR, 9DE, 10IT
- 13:05 - 13:05 **900P - Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)**
A. Necchi¹, D. Pouessel², R. Leibowitz-Amit³, A. Flechon², S. Gupta⁴, P. Barthelemy², M. Maio¹, X. Zhu⁵, E. Asatiani⁶, G. Serbest⁴, H. Zhen⁴, Y. Loriot⁷; 1IT, 2CEDEX/FR, 3IL, 4US, 5NY/US, 6DC/CH, 7FR

- 13:05 - 13:05 **901P - Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045**
J. Bellmunt¹, R. de Wit², D. Vaughn³, Y. Fradet⁴, J.L. Lee⁵, L. Fong⁶, N. Vogelzang⁷, M. Climent⁸, D. Petrylak⁹, T. Choueiri¹, A. Necchi¹⁰, W. Gerritsen², H. Gurney¹¹, D. Quinn⁶, S. Culine¹², C. Sternberg¹⁰, E. Jensen¹³, T. Frenkl¹³, R. Perini¹³, D. Bajorin⁹; ¹MA/US, ²NL, ³PA/US, ⁴QC/CA, ⁵KR, ⁶CA/US, ⁷NV/US, ⁸ES, ⁹US, ¹⁰IT, ¹¹NSW/AU, ¹²CEDEX 10/FR, ¹³NJ/US
- 13:05 - 13:05 **902P - Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)**
M. Galsky¹, R. Banchereau², E. Kadel, III², T. Ramirez-Montagut², S. Mariathasan¹, A. Thåström², J. Rosenberg³, T. Powles⁴, M. van der Heijden⁵, A. Necchi⁶; ¹US, ²CA/US, ³NY/US, ⁴GB, ⁵NL, ⁶IT
- 13:05 - 13:05 **903P - Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium**
M. Sroussi¹, M. Lorcet¹, M. Tardy¹, M. Guerin², F. Estrade¹, R. Delva¹, P. Barthelemy³, P. Lavaud¹, Y. Neuzillet¹, N. Penel³, N. Houede¹, D. Pouessel¹, E. Mussat¹, M. Gross Goupil¹, H. Gauthier¹, A. Gobert¹, O. Huillard⁴, Y. Allory¹, R.-T. Elaidi¹, S. Oudard¹; ¹FR, ²CEDEX 9/FR, ³CEDEX/FR, ⁴CEDEX 14/FR
- 13:05 - 13:05 **904P - Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC)**
J. Walker¹, M. Zajac², J. Ye³, M. Scott², M. Ratcliffe², P. Scorer², C. Barker², H. Al-Masri⁴, M. Rebelatto³, A. Gupta², P. Mukhopadhyay³, S. Ferro³, T. Powles², J. Williams²; ¹NL, ²GB, ³US, ⁴IL/US
- 13:05 - 13:05 **905P - CD103&&**
Z. Liu, J. Zhang, B. Dai; CN
- 13:05 - 13:05 **906P - Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: A systematic review and meta-analysis**
E. De Luca, V. Di Nunno, C. Buttigliero, M. Tucci, F. Vignani, C. Zichi, A. Ardizzoni, F. Massari, M. Di Maio; IT
- 13:05 - 13:05 **907P - Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy**
C. Hoyle¹, A. Klein¹, K. Patel¹, N. Shire¹, H. Wang¹, B.C. Chu², M. Ouwens¹, B. Nordstrom³, L. Horne¹, H.-T. Arkenau¹; ¹GB, ²CA/US, ³MA/US

- 13:05 - 13:05 **908P - Comparative effectiveness of neoadjuvant chemotherapy followed by cystectomy versus cystectomy followed by adjuvant chemotherapy versus palliative chemotherapy versus cystectomy for node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03**
J.H. Byun¹, H.A. Jung², W.-K. Bae¹, H.-J. Lee¹, S.H. Park¹, H.J. Kim¹, C.H. Maeng¹, I. Park¹, B.S. Sohn¹, J.A. Kim¹, K.H. Lee¹, D.H. Im¹, J.H. Kim¹, H. Jang¹, S.M. Kim¹; ¹KR, ²Gyeong-Ki-Do/KR
- 13:05 - 13:05 **909P - Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer**
L. Nappi¹, M. Thi¹, B. Eigl², A. Lum¹, D. Huntsman², C. Martin³, B. O Neil³, D. Khalaf⁴, K. Chi², M. Gleave⁴, A. So¹, P. Black¹, S. Daneshmand⁵, C. Nichols⁶, C. Kollmannsberger²; ¹BC/CA, ²British Columbia/CA, ³UT/US, ⁴CA, ⁵CA/US, ⁶US
- 13:05 - 13:05 **910P - Increased risk of non-germ cell second cancer (SC) after cisplatin-based chemotherapy (CBCT) in 1-year testicular cancer (TC) survivors (TCS)**
R. Hellesnes, Ø. Kvammen, R. Bremnes, A. Karlsdottir, T.Å. Myklebust, H. Negaard, T. Tandstad, T. Wilsgaard, S. Fosså, H. Haugnes; NO
- 13:05 - 13:05 **911P - Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy (CT)**
J. Stelwagen, S. Lubberts, L. Steggink, G. Steursma, L. Kruyt, J. Donkerbroek, A. van Roon, A. van Gessel, S. van de Zande, C. Meijer, J. Wempe, C. Gräfin zu Eulenburg, J. Nuver, A. Walenkamp, J. Lefrandt, J. Gietema; NL
- 13:05 - 13:05 **912P - Sexual function and quality of life in a national cohort of bilateral testicular cancer survivors**
M. Bandak, J. Lauritsen, C. Johansen, M. Kreiberg, J. Skøtt, M. Agerbaek, N. Holm, K.G. Daugaard; DK
- 13:05 - 13:05 **913P - The prognostic value of DNA damage level in peripheral blood lymphocytes in germ cell cancer patients**
M. Mego¹, Z. Sestakova¹, K. Kalavska¹, L. Hurbanova¹, D. Jurkovicova¹, J. Gursky¹, M. Chovanec¹, D. Svetlovska¹, V. Miskovska², J. Obertova¹, P. Palacka¹, K. Rejlekova¹, Z. Sycova-Mila¹, J. Mardiak¹, M. Chovanec¹; ¹SK, ²Slovak republic/SK
- 13:05 - 13:05 **914P - Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic stratification**
C. Seidel¹, K.G. Daugaard², A. Tryakin³, A. Necchi⁴, G. Cohn Cedermark⁵, O. Ståhl⁵, M. Hentrich¹, M. Brito⁶, C. Albany⁷, F. Taza⁷, A. Gerl¹, K. Oechsle¹, C. Oing¹, C. Bokemeyer¹; ¹DE, ²DK, ³RU, ⁴IT, ⁵SE, ⁶PT, ⁷US
- 13:05 - 13:05 **915P - Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)**
R. Huddart¹, F. Cafferty², J. White², J. Shamash², I. Hennig³, M. Cullen², S. Stenning²; ¹Surrey/GB, ²GB, ³Nottinghamshire/GB

- 13:05 - 13:05 **916P - Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study**
D. George¹, R. Figlin², R. Motzer³, J. Paty², M. Lechuga Freañ⁴, G. Zanotti², H. Bhattacharyya², K. Ramaswamy², L. Deannuntis⁵, A. Ravaud⁶; ¹NC/US, ²US, ³NY/US, ⁴IT, ⁵PA/US, ⁶FR
- 13:05 - 13:05 **917TiP - Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations**
A. Rodríguez-Vida¹, J.L. Pérez-Gracia¹, A. Taus¹, T. Bonfill¹, F. Vázquez-Mazón¹, S. Galtes¹, B. Pons¹, L. Cano¹, S. Macia², P. Maroto¹, J. Bellmunt¹; ¹ES, ²Madrid/ES
- 13:05 - 13:05 **918TiP - EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy**
J. Rosenberg¹, A. Balar², P. O'Donnell³, E. Heath², N. Hahn², N. Cavazos⁴, A. Melhem-Bertrandt³, D. Petrylak⁵; ¹NY/US, ²US, ³IL/US, ⁴WA/US, ⁵CT/US
- 13:05 - 13:05 **919TiP - The potential of patient reported outcomes in urothelial cancer patients receiving immuno- or chemotherapy: A feasibility study of electronic reporting in an aging and comorbid population**
G. Taarnhøj, H. Lindberg, H. Pappot, L. Dohn, C. Johansen; DK
- 13:05 - 13:05 **920TiP - Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study**
Y. Loriot¹, A. Necchi², S.H. Park³, R. Huddart⁴, E. Burgess⁵, B. Zhong⁶, A. Santiago-Walker⁷, S. Little⁶, T. Roccia⁸, P. De Porre⁹, A. Siefker-Radtke¹⁰; ¹FR, ²IT, ³KR, ⁴Surrey/GB, ⁵NC/US, ⁶PA/US, ⁷US, ⁸New Jersey/US, ⁹BE, ¹⁰TX/US
- 13:05 - 13:05 **921TiP - An open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma**
E. Jonasch¹, E. Park², S. Thamake³, M. Hirmand², R. Srinivasan²; ¹TX/US, ²US, ³CA/US
- 13:05 - 13:05 **922TiP - EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)**
D. Petrylak¹, J. Rosenberg², I. Duran³, Y. Loriot⁴, G. Sonpavde⁵, C. Wu⁶, E. Gartner⁷, A. Melhem-Bertrandt⁶, T. Powles⁸; ¹CT/US, ²NY/US, ³ES, ⁴FR, ⁵MA/US, ⁶IL/US, ⁷US, ⁸GB
- 13:05 - 13:05 **923TiP - A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations**
A. Necchi¹, J.L. Pérez-Gracia², Y. Loriot³, W. Witjes⁴, F. Montorsi¹, A. Bjartell⁵, S. Shariat⁶; ¹IT, ²ES, ³FR, ⁴NL, ⁵SE, ⁶AT

- 13:05 - 13:05 **924TiP - A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)**
R. Nadal, E. Cherkasova, S. Barisic, D. Granadier, G. Aue, B. Wells, G. Hawks, T. Hughes, R. Shalabi, D. Stroncek, S. Highfill, G. Scurti, L. Chen, R. Reger, M. Nishimura, R. Childs; US
- 13:05 - 13:05 **925TiP - Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression**
J. Rosenberg¹, A. Necchi², R. Sweis³, K. Nakajima⁴, C. Lu⁴, H. Nogai⁵; ¹NY/US, ²IT, ³IL/US, ⁴NJ/US, ⁵DE
- 13:05 - 13:05 **926TiP - Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)**
N. van Dijk, C. Blank, P. Kvistborg, T. Schumacher, E. Hooijberg, K. Sikorska, B. Rhijn, M. van der Heijden; NL
- 13:05 - 13:05 **927TiP - A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)**
A. Bex¹, V. Grünwald², P. Russo³, Y. Tomita⁴, E. Berghorn³, M.B. McHenry³, R. Motzer⁵; ¹NL, ²DE, ³US, ⁴JP, ⁵NY/US
- 13:05 - 13:05 **928TiP - ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma**
S. Chowdhury¹, S. Feyerabend², Y. Loriot³, A. Necchi⁴, S. Gupta⁵, D. Josephs¹, A. Rodríguez-Vida⁶, S. Srinivas⁷, Y. Zakharia⁵, D. Nepert⁵, K. Wride⁵, D. Thomas⁵, A. Loehr⁵, A. Simmons⁷, P. Grivas⁸; ¹GB, ²DE, ³FR, ⁴IT, ⁵US, ⁶ES, ⁷CA/US, ⁸OH/US
- 13:05 - 13:05 **929TiP - BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)**
J. Rosenberg¹, D. Bajorin², A. Smith³, C. D'cruz², M. Lanasa²; ¹NY/US, ²US, ³GB
- 13:05 - 13:05 **930TiP - Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression**
C. Sternberg¹, J. Bellmunt², H. Nishiyama³, D. Petrylak⁴, D. Quinn⁵, K. Nakajima⁶, C. Lu⁶, A. Holynskij⁷; ¹IT, ²MA/US, ³JP, ⁴CT/US, ⁵CA/US, ⁶NJ/US, ⁷US
- 13:05 - 13:05 **931TiP - PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma**
F. Collinson¹, S. Brown¹, H. Buckley¹, G. Ainsworth¹, H. Howard¹, H. Poad¹, G. Carr¹, R. Banks¹, J. Brown¹, G. Velikova², J. Larkin¹, P. Nathan³, T. Powles¹, N. Vasudev²; ¹GB, ²Yorkshire/GB, ³Middlesex/GB

- 13:05 - 13:05 **Palliative care**
- 13:05 - 13:05 **1516P - Effectiveness of a randomized control trial of an individualized, interactive advance care planning intervention in improving terminally ill cancer patients's psychological symptoms, quality of life and concordance between preferred and received life-sustaining treatments**
S.T. Tang, J.-S. Chen, W.-C. Chou; TW
- 13:05 - 13:05 **1517P - Current status of the integration of oncology and palliative care in Japan: A nationwide survey**
U. Yu, K. Sato, T. Morita, M. Mori, C. Shimizu, Y. Horie, M. Hirakawa, T. Nakajima, S. Tsuneto, M. Muto; JP
- 13:05 - 13:05 **1518P - Access to palliative care before death in French cancer patients during the first two years after diagnosis: The national cancer cohort**
M. Bendiane, A. Janah, D. Leufeuve, P.-J. Bousquet; FR
- 13:05 - 13:05 **1519P - Anticancer therapy at the end of life of breast, prostate, and colorectal cancer patients**
V. Heidt, K. Hermes-Moll, K. Blaschke, V. Lappe, P. Ihle, I. Schubert, W. Baumann; DE
- 13:05 - 13:05 **1520P - Perspectives and attitudes towards the integration of oncology and palliative care in Japan: A nationwide survey**
U. Yu, K. Sato, T. Morita, M. Mori, C. Shimizu, Y. Horie, M. Hirakawa, T. Nakajima, S. Tsuneto, M. Muto; JP
- 13:05 - 13:05 **1521P - Evolving concurrent integration of oncology and palliative care at an ESMO designated center over a decade**
F. Strasser, T. Silzle, E. Schmidt; CH
- 13:05 - 13:05 **1522P - The impact of inclusion in home palliative program and distance to hospital on chemotherapy near end of life**
J. Balsalobre, A. Checa-Soriano, P. Cerezuela-Fuentes, M. Martínez-Penella, M.J. Martínez-Ortíz, J.L. Alonso-Romero, M.I. Luengo-Alcázar, M.T. García-García; ES
- 13:05 - 13:05 **1523P - Cancer patients's perceptions of palliative care**
J. Yoong¹, B. Chosich², M. Burgess², A. Earnest², F. Runacres², L. William¹, M. Franco², P. Poon¹; ¹AU, ²VIC/AU
- 13:05 - 13:05 **1525P - Palliative care in advanced cancer: A clinical and ethical goal achieved?**
J. Sanchez¹, R. Gomez-Bravo¹, A. Morito Aguilar¹, A. Royuela¹, B. Núñez García¹, T. Tojar¹, A. Ruano Ravina¹, C. Parejo¹, B. Cantos¹, M. Provencio Pulla²; ¹ES, ²Madrid/ES

- 13:05 - 13:05 **1524P - Multicenter feasibility study of physician orders for life-sustaining treatment (POLST) for terminal cancer patients**
H.J. An, H.J. Jeon, J. Cheon, S.H. Chun, H.A. Jung, H.K. Ahn, K.H. Lee, M.-H. Kim, J.H. Kim, S. Kim, S.-J. Koh; KR
- 13:05 - 13:05 **1526P - The experience of onco-palliative care multidisciplinary meetings in Hotel Dieu de France University Hospital, an ESMO designated center of integrated oncology and palliative care**
A. Houchan¹, T. Assi², Z. Bakouny¹, E. El Rassy¹, A. Tohme¹, M.C. Mouhaweij¹, J. Kattan¹; ¹LB, ²FR
- 13:05 - 13:05 **1527P - End of life resource utilization among patients receiving immunotherapy for advanced cancer**
J. Burkart¹, S. Patel², A. Noonan², P. Monk², C. Presley², T. Olencki², K. Kendra², G. Otterson², J. Gustin², L. Wei², D. Owen¹; ¹US, ²OH/US
- 13:05 - 13:05 **1528P - Palliative chemotherapy for patient with advanced tumor and poor performance status: Are oncologists' hopes of benefit justified?**
V. Vasconcellos, R. Bonadio, G. Avanco, M. Negrão, R. Riechelmann; BR
- 13:05 - 13:05 **1529P - Integration of oncology and palliative care**
S. Kaasa¹, J.H. Loge¹, T. Albrecht², E. Bruera³, A. Caraceni⁴, A. Cervantes⁵, I. Higginson⁶, K. Jordan⁷, P. Sjögren⁸, P. Stone⁶, C. Zimmermann⁹, T. Lundebj¹; ¹NO, ²SI, ³US, ⁴IT, ⁵ES, ⁶GB, ⁷DE, ⁸DK, ⁹CA
- 13:05 - 13:05 **1530P - Understandability of the standard arabic translation of the EORTC QLQ-C15-PAL questionnaire by Egyptian patients with incurable cancer**
H. Masoud, S.-E. Abdelmoneim, M. Ismael, S. Alsirafy; EG
- 13:05 - 13:05 **1531P - How to practice oncology with a supportive and palliative care ambulatory unit: A French experience (HOASIS)**
A. Gonzalez Moya, H. Bourgeois; FR
- 13:05 - 13:05 **1532P - Prognostic impact of end-of-life chemotherapy in the last weeks for patients with advanced cancer**
S. Hiramoto¹, A. Kikuch², T. Hori², A. Yoshioka², T. Tamaki²; ¹Shiga Otsu/JP, ²JP
- 13:05 - 13:05 **1533P - A novel electronic tool to implement palliative sedation (PS) in a department of oncologic medicine**
A. Saviola, S. Cascinu, M. Salati, G. Longo, C. Fiorani, L. Ferrara, N. Malavasi, R. Postiglione, F. Cantile, L. Scarabelli, M. Rimini, F. Ferri; IT
- 13:05 - 13:05 **1534P - Congruence between actual place of death and preferences of Egyptian patients with advanced cancer and their family caregivers**
S. Alsirafy¹, O. Zaki², N. Ibrahim¹, W. Elsherief¹, A. Hammad¹; ¹EG, ²Cairo/EG

- 13:05 - 13:05 **1535P - Sarawak: Healthcare professionals' perception of palliative care at end of life**
C. Cheah¹, L. Winnie¹, A. Merriman², N.I. Mohd Naseri¹, S. Chew³; ¹MY, ²UG, ³GB
- 13:05 - 13:05 **1536P - Factors associated with length of stay in an acute palliative care unit: A retrospective analysis**
D. Hausner¹, A. Pope¹, N. Kevork², L. Le², C. Zimmermann¹; ¹CA, ²ON/CA
- 13:05 - 13:05 **1537P - Medical-aid-in-dying use in the US Pacific Northwest**
C. Blanke¹, M. Leblanc¹, D. Hershman¹, F. Meyskens¹, L. Taylor², L. Ellis³; ¹OR/US, ²US, ³TX/US
- 13:05 - 13:05 **1538TiP - Brain metastases in Norway: A prospective cohort study**
O. Yri, M. Smebye, M. Hjermstad, A. Karlson, N. Aass, J.H. Loge, S. Kaasa; NO
- 13:05 - 13:05 **Psycho-oncology**
- 13:05 - 13:05 **1541P - Partners&&**
L. Bai, B. Arver, H. Johansson, M. Wickman, K. Sandelin, Y. Brandberg; SE
- 13:05 - 13:05 **1542P - The effect of music on the instant anxiety levels of oncologic patients receiving chemotherapy treatment**
A. Alacacioglu, G. Dissiz, S. iriz, A. USLUOGLU, N. ASIK; TR
- 13:05 - 13:05 **1544P - Cognitive functions, coping strategies and psychological distress in patients with resected non-advanced cancer receiving chemotherapy: NEOcoping study data**
O. Higuera Gomez, C. Calderón, I. Ghanem, A. Carmona-Bayonas, C. Jara, R. Hernández, B. Castelo, M.M. Muñoz, C. Beato, S. García, E. Martínez, M. Mut, A. Ramchandani Vaswani, M. Mangas, O. Donnay, M.T. García-García, M.C. Soriano, R. Carrión, C. Iglesias Gomez, P. Jimenez Fonseca; ES
- 13:05 - 13:05 **1543P - Ostracism in adolescent cancer patients and predictors (OSTRACA Study): A study of the palliative care working committee of the Turkish Oncology Group (TOG)**
A. Alkan, Z.G. Güç, T. Şakalar, G. Zengin, A. Yaşar, Y. Karakas, T. Yavuzsen, O. Oksuzoglu, F. Çay Şenler; TR
- 13:05 - 13:05 **1545P - Cancer stigma related to beliefs of patients and care providers**
G.S. Bhattacharyya¹, H. Malhotra², G. Babu², A. Vora², S. Bhattacharyya²; ¹West Bengal/IN, ²IN
- 13:05 - 13:05 **1546P - Relationship between depressive symptoms at social cognitive processing in partners of long term breast cancer survivors**

G.S. Bhattacharyya¹, H. Malhotra², G. Babu², A. Vora², T. Shahid², S. Misra Ghosh²;
¹West Bengal/IN, ²IN

- 13:05 - 13:05 **1547P - Evaluation of the distinction and temporal relationship between prolonged grief disorder and depression in terminally ill cancer patients&&**
W.-I. TSAI, S.-C. Kuo, F.-H. Wen, J.-S. Chen, S.T. Tang; TW
- 13:05 - 13:05 **1548P - Patients&&**
S. Catt, L. Matthews, H. Payne, M. Mason, V. Jenkins; GB
- 13:05 - 13:05 **1549P - Exploring the effectiveness of crisis counselling and psycho-education in relation to improving mental wellbeing, quality of life and treatment compliance of breast cancer patients in Qatar**
R. Alsulaiman¹, S. Bujassoum¹, A. Bener², L. Doodson³, S. Ghuloum¹, A. Lemaux¹, H. Bugrein¹, R. Alasaam¹, A. Karim¹; ¹QA, ²TR, ³GB
- 13:05 - 13:05 **1550P - Pilot study of anxiety, depression, and quality of life in patients with the diagnosis of metastatic uveal melanoma**
R. Nshimiyimana¹, C. Guzzetta¹, M.-M. Brown¹, Q. Zhou², J. Johnson¹, T. Sato¹, S. Keith³;
¹US, ²VA/US, ³PA/US
- 13:05 - 13:05 **1551P - Making sense of self-conscious and emotion: Linking theory of mind and emotion in women with breast cancer**
A. Datta¹, P. (Chaudhuri)²; ¹West Bengal/IN, ²IN
- 13:05 - 13:05 **1552P - Characteristics of the psychosomatic state of patients with lung cancer**
G. Zhukova, A. Shikhlyarova, E. Shirnina, M. Zinkovich, N. Maschenko, E. Zlatnik, S. Pyltsin, P. Anistratov, M. Bragina, A. Zhadobina, L. Vladimirova; RU
- 13:05 - 13:05 **1553P - Perception, magnitude and implications of cancer related fatigue in breast cancer survivors: Study from a developing country**
A. Gupta, S. Hussain, R. Manaktala; IN
- 13:05 - 13:05 **1554P - Impact of cancer on the quality of life of Tunisian pediatric patients**
F. Letaief-Ksontini, T. Dorra, S. Masmoudi, K. Meddeb, A. Mokrani, Y. Yahyaoui, A. Gabsi, M. Ayadi, N. Chraiet, H. Raies, A. Mezlini; TN
- 13:05 - 13:05 **Public health policy**
- 13:05 - 13:05 **1569P - The impact of primary care access on mortality in lung cancer patients from Bronx, New York**
C. Su, H. Cheng; US

- 13:05 - 13:05 **1570P - Are socioeconomic position and region of residence barriers for referral to phase I trials?**
K. Gad, S.O. Dalton, A.K. Duun-Henriksen, A. Krøyer, C. Johansen, M. Mau-Sorensen, U. Lassen; DK
- 13:05 - 13:05 **1571P - Breast cancer treatment waiting time, patient and provider contributions: An Egyptian breast cancer centre experience**
A. Abdelaziz, A. Abdou, C. Habeeb; EG
- 13:05 - 13:05 **1572P - Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study**
N. Battisti¹, M. Wallington², A. Ring², S. Payne², R. Birch², M. Bomb², J. Seligmann³, T. Kalsi², L. Hounsome², D. Dodwell², S. Underhill², L. Mensah², E. Morris², P. Selby³, J. Mansi²; ¹Surrey/GB, ²GB, ³Yorkshire/GB
- 13:05 - 13:05 **1573P - Awareness and attitude towards breast cancer among Egyptian nurses at university affiliated hospitals: Tanta University Hospitals experience**
M. Alm El-Din¹, S. Amer², M. Elsayed², A. Elgohary², A. Ismael², A. Zakzouk², K. Emara², F. Elkady², S. Elnahrawy², F. Nada², A. Eissa²; ¹Gharbia/EG, ²EG
- 13:05 - 13:05 **1574P - Women oncologists participation at the Spanish Society of Medical Oncology (SEOM) annual meetings from 2009 to 2017 and their position in Spanish scientific societies**
J. Hidalgo Coloma, A. Ruiz Hernández; ES
- 13:05 - 13:05 **1575P - Working arrangements after cancer diagnosis: Who, what, when and how?**
C. Alleaume, A.-D. Bouhnik, M. Bendiane, P. Peretti-Watel; FR
- 13:05 - 13:05 **1576P_PR - Financial toxicity in German cancer patients. How does a chronic disease impact the economic situation?**
E. Winkler, K. Mehlis, B. Surmann, J. Witte, R. Lingnau, L. Apostolidis, J. Walther, W. Greiner; DE
- 13:05 - 13:05 **1579P - Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada**
P. Blanchette¹, H. Chung¹, K. Pritchard², C. Earle¹, M. Campitelli¹, N. Crowcroft¹, J. Gubbay¹, T. Karnauchow¹, K. Katz¹, A. McGeer¹, D. McNally¹, D. Richardson¹, S. Richardson¹, L. Rosella¹, A. Simor¹, M. Smieja¹, G. Zahariadis¹, A. Campigotto¹, J. Kwong¹; ¹CA, ²Ontario/CA
- 13:05 - 13:05 **1577P - Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study**
N. Flaum, G. Papaxoinis, K. Hockenhull, J. Barriuso, W. Mansoor; GB

- 13:05 - 13:05 **1580P - How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience**
W. Evans¹, W. Flanagan², C. Gauvreau², P. Manivong², S. Memon², N. Fitzgerald², J. Goffin², R. Garner², E. Khoo², N. Mittmann²; ¹Ontario/CA, ²CA
- 13:05 - 13:05 **1581P - Anticoagulant treatment of patients (pts) with cancer associated thromboembolism (CAT) in Germany: Real world data from a 4 million people sample generated by insurance captured data**
A. Kretzschmar, M. May, A. Heinken, H. Riess; DE
- 13:05 - 13:05 **1583P - Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location**
C. Ho¹, B. Leung², H. Rennie², J. Laskin¹, J. Wu², A. Bates²; ¹British Columbia/CA, ²CA
- 13:05 - 13:05 **1582P - Age distribution for different types of cancer in the United States (1996-2015)**
M. Gouda, Menoufia Governorate/EG
- 13:05 - 13:05 **1584P - Overview on the use of patient reported outcomes in colorectal cancer care**
L. Neamtiu¹, S. Deandrea¹, L. Pylkkanen², Z. Saz Parkinson³; ¹IT, ²FI, ³Varese/IT
- 13:05 - 13:05 **1585P - Completeness of staging investigation for colorectal cancer: Exploring the role of increasing age and comorbidity using mediation analysis**
S. Benitez Majano¹, S. Vansteelandt², C. Di Girolamo¹, M. Morris¹, S. Walters¹, B. Rachet¹; ¹GB, ²BE
- 13:05 - 13:05 **1586P - The quality oncology practice initiative program: Experience in Spain**
R. Lopez Lopez¹, A. Anton Torres², E. Aranda Aguilar², A. Carrato Mena², M. Constenla Figueiras², J.J. Cruz Hernandez², E. Diaz Rubio², M. Feyjoo², J. Garcia Foncillas², P. Gascon², V. Guillem Porta², I. Lugo Cuan², A. Rogado², C. Camps²; ¹La Coruña/ES, ²ES
- 13:05 - 13:05 **1587P - Can measuring quality lead to improvement? Evidence from international participants of ASCO&&**
M. Jahanzeb¹, T. Gilmore², A. Roach², S. Grubbs³, D. Blayney³, J. Hamm⁴, A. Kamal⁵, R. Kelly³, E. Martin⁶, J. Sanchez⁷, R. Siegel⁸, S.T.S. Crist², J. Rosenthal², C. Hendricks⁹; ¹FL/US, ²VA/US, ³US, ⁴KY/US, ⁵NC/US, ⁶DE/US, ⁷HN, ⁸SC/US, ⁹MD/US
- 13:05 - 13:05 **1588P - Treatment algorithm for multiple myeloma: Real-world insights across five European countries**
A. Rocci, P. Bulger, A. Martinez de Pinillos, P. Nasuti, C. Anger, F. Manuguid; GB
- 13:05 - 13:05 **1589P - Are treatment recommendations provided by cognitive computing supported by real world data (Watson for Oncology with Cota RWE) concordant with expert opinions?**

D. Atieh Graham¹, D. McNamara¹, S. Waintraub¹, S. Goldberg², A. Norden³, J. Hervey³, A. Pecora³, C. Landstrom³, J. Snowdon⁴, P. Francis⁴, N. Jungbluth⁴, C. Wang⁴, L. Latts⁴; ¹NJ/US, ²US, ³NY/US, ⁴MA/US

- 13:05 - 13:05 **1590P - Body shape trajectories and risk of breast cancer: Results from the SUN study project**
R. Sanchez Bayona, C. Sayon, I. Gardeazabal, M.A. Martínez-González, M. Santisteban Eslava, E. Toledo-Atucha; ES
- 13:05 - 13:05 **1591P - Total polyphenol intake and breast cancer risk in the SUN project**
I. Gardeazabal, A. Romanos-Nanclares, R. Sanchez Bayona, J. Graforio, M.A. Martínez-González, E. Toledo-Atucha; ES
- 13:05 - 13:05 **1592P - No effect of length time bias on the genomic risk in ER-; HER2-stage I-IIA breast cancer (BC) patients according to diagnosis in a screening programme: An exploratory analysis**
I. Gonzalez Barrallo¹, J.A. Perez Fidalgo², J. Ramirez¹, O. Burgues¹, J.V. Sorlí¹, O. Portoles¹, C. Hernando¹, D. Salas¹, A. Lluch²; ¹ES, ²Valencia/ES
- 13:05 - 13:05 **1593P - Breast cancer screening: Impact on care pathways**
D. Lefeuvre, N. Catajar, C. Le Bihan Benjamin, F. De Bels, J. Viguier, P.-J. Bousquet; FR
- 13:05 - 13:05 **1594P_PR - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey**
J.-F. Morere¹, J. Viguier², L. Greillier², M. Roupret², C. Touboul², C. Lhomel², S. Couraud¹, T. de La Motte Rouge², F. Eisinger³; ¹CEDEX/FR, ²FR, ³CEDEX 9/FR
- 13:05 - 13:05 **1595P - 10-year results of the breast cancer screening program in Khanty-Mansiysk state region Ugra**
N. Zakharova¹, A. Brentnall², J. Belaya¹, E. Bilan¹; ¹RU, ²AE
- 13:05 - 13:05 **1596P - Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan**
T. Nakamura¹, M. Ikeda², S. Shibata², Y. Kon², K. Konuma², T. Sanada², H. Gonda², Y. Suto², K. Kobayashi², H. Tamura², M. Kobayashi², A. Hasegawa², Y. Amagasa², A. Suzuki², M. Fukuda², C. Aoyagi², N. Matsuura², Y. Kawashima², M. Shimura², N. Takita²; ¹Gunma/JP, ²JP
- 13:05 - 13:05 **1597P - Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): Preliminary findings and plans for further research**
F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M. Coleman, CONCORD Working Group; GB
- 13:05 - 13:05 **1598P - Referral patterns and predictors of survival for stage IV pancreatic ductal adenocarcinoma**
A. Suo¹, P. Tang², D. Tilley², W. Cheung³, R. Lee-Ying²; ¹CA/CA, ²CA, ³AB/CA

- 13:05 - 13:05 **1599P - Gender difference in cancer survivors' perceived information 5-years after diagnosis: Data from the French national study - VICAN 5**
G. Gravis¹, R. Touzani², A.-D. Bouhnik², P. Marino², G. Pignot², M. Bendiane²; ¹CEDEX 9/FR, ²FR
- 13:05 - 13:05 **1600P - Survival difference between microscopically confirmed and microscopically non-confirmed cancers**
M. Gouda, Menoufia Governorate/EG
- 13:05 - 13:25 **Sarcoma**
- 13:25 - 13:25 **1616P - Quantitative multiplexed immune profiling of advanced gastrointestinal stromal tumors (GISTs): Impact of tyrosine kinase inhibitors on immune environment**
C. Yoo¹, S.-Y. Kim², J. Kim², Y.-M. Ryu², M.-H. Ryu², Y.-K. Kang¹; ¹Songpa-gu/KR, ²KR
- 13:25 - 13:25 **1617P - Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST**
A. Callejo Goena¹, S. Faouzi², O. Bouche², T. Chevalier², N. Isambert³, F. Duffaud⁴, O. Collard², O. Mir², P. Terrier², J.-Y. Blay², A. Le Cesne⁵; ¹ES, ²FR, ³Cedex/FR, ⁴CEDEX 5/FR, ⁵CEDEX/FR
- 13:25 - 13:25 **1618P - Prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced gastrointestinal stromal tumor (GIST)**
H. Cho¹, M.-H. Ryu¹, H. Chae¹, S.M. Lee¹, Y. Park¹, K.-H. Kim¹, C.W. Kim¹, B.S. Kim¹, M.-W. Yoo¹, J. Ma¹, M.Y. Beck¹, M. Kim¹, Y.-K. Kang²; ¹KR, ²Songpa-gu/KR
- 13:25 - 13:25 **1619P - Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study**
E. Kim¹, M.-H. Ryu¹, S.R. Park¹, M.Y. Beck¹, W.J. Lee¹, M.W. Lee¹, Y.-K. Kang²; ¹KR, ²Songpa-gu/KR
- 13:25 - 13:25 **1620P - Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib**
H. Cho¹, M.-H. Ryu¹, B.J. Kim¹, Y. Park¹, Y.-S. Na¹, J. Ma¹, M.Y. Beck¹, Y.-K. Kang²; ¹KR, ²Songpa-gu/KR
- 13:25 - 13:25 **1622P - Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors**
M. Yamamura, A. Yamauchi, N. Katase, Y. Katata, H. Tanioka, M. Okawaki, T. Nagasaka, Y. Yamaguchi; JP

- 13:25 - 13:25 **1623P - Correlation of ctDNA and response in patients (pts) with PDGFR β ; D842 GIST treated with avapritinib**
S. George¹, S. Bauer², R. Jones³, C. Serrano⁴, M. von Mehren⁵, Y.-K. Kang⁶, P. Schöffski⁷, P. Cassier⁸, F. Eskens⁹, O. Mir⁸, W. Tap¹⁰, S. Chawla¹¹, P. Rutkowski¹², H. Shi¹⁰, O. Schmidt-Kittler¹, B. Mar¹⁰, M. Heinrich¹⁰; ¹MA/US, ²DE, ³WA/GB, ⁴ES, ⁵PA/US, ⁶Songpa-gu/KR, ⁷BE, ⁸FR, ⁹NL, ¹⁰US, ¹¹CA/US, ¹²PL
- 13:25 - 13:25 **1624P - Pathological grade of tumor regression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma**
G.-E. Schuebbe, T. Knösel, H.R. Dürr, M. Angele, F. Röder, S. Abdel-Rahman, A. Alig, R. Issels, D. Di Gioia, L. Lindner; DE
- 13:25 - 13:25 **1625P - Efficacy of metastasectomy on survival in patients with metachronous soft tissue sarcoma-metastasis: Results of a bi-centre study including 135 patients**
A. Leithner¹, V. van Praag², F. Posch¹, M. Bergovec¹, L. Leitner¹, J. Friesenbichler¹, R. Heregger¹, F.-M. Smolle-Jüttner¹, M. Fiocco², M. van de Sande², J. Riedl¹, M. Pichler¹, A. Gerger¹, J. Szkandera¹, H. Stöger¹, B. Liegl-Atzwanger¹, M. Smolle¹; ¹AT, ²NL
- 13:25 - 13:25 **1626P - Trabectedin and radiotherapy in advanced sarcoma: Experience of a reference center**
I. Carrasco Garcia, N. Hindi, J. Peinado, I. Rincon, M. Cordeiro, F. Jimenez, A. Falcon Gonzalez, R. Lasso de la Vega, M. Noguera Mediavilla, P. Sancho Marquez, J. Martin-Broto; ES
- 13:25 - 13:25 **1627P - Single arm prospective study evaluating the role of neoadjuvant chemotherapy in soft tissue sarcoma**
A. Tiwari, S. Rastogi, S.V.S. Deo, D.N. Sharma, M. Sharma, S. Bakshi; IN
- 13:25 - 13:25 **1628P - Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: Interim analysis of prospective phase II clinical trial**
M. Spalek¹, H. Kosela Paterczyk¹, A. Borkowska¹, M. Wagrodzki¹, A. Cieszanowski¹, P. Castaneda-Wysocka¹, T. Switaj², M. Dudzisz-Sledz¹, A. Czarnecka¹, E. Dabrowska-Szewczyk¹, P. Rutkowski¹; ¹PL, ²IR
- 13:25 - 13:25 **1629P - Basket trial in advanced cancers: A clinical observation of apatinib in lung metastases and non-lung metastases**
C. Tu, Y. Zhou, K. Yao, Y. Luo, W. Zhang, H. Duan, L. Min; CN
- 13:25 - 13:25 **1630P - Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification**
Y. Yao¹, Y. Chi¹, Z. Fang¹, S. Wang², G. Huang¹, Q. Cai¹, G. Shang¹, G. Wang¹, G. Qu¹, Q. Wu¹, Y. Jiang³, J. Song¹, J. Chen¹, X. Zhu¹, Z. Cai¹, C. Bai¹, Y. Lu¹, Z. Yu¹, J. Shen¹, J. Cai¹; ¹CN, ²Guangdong/CN, ³Sichuan/CN

- 13:25 - 13:25 **1631P - Efficacy and safety of apatinib in advanced sarcoma**
J. Chen, T. Ye, Z. Zhang, Z. Wang, S. Yang, K. Yang, T. Li; CN
- 13:25 - 13:25 **1632P_PR - Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration**
A. Bellesoeur¹, I. Gataa¹, A. Jouinot², S. El Mershati², J. Arrondeau¹, C. Tlemsani¹, B. Blanchet¹, J. Alexandre³, F. Goldwasser¹, A. Thomas-Schoemann², P. Boudou Rouquette¹; ¹CEDEX 14/FR, ²FR, ³CEDEX 4/FR
- 13:25 - 13:25 **1633P - Evaluation of hypertension and hand-foot syndrome as markers of anlotinib efficacy in advanced soft tissue sarcoma**
Z. Fang¹, Y. Chi¹, Y. Yao¹, S. Wang², G. Huang¹, Q. Cai¹, G. Shang¹, G. Wang¹, G. Qu¹, Q. Wu¹, Y. Jiang³, J. Song¹, J. Chen¹, X. Zhu¹, Z. Cai¹, C. Bai¹, Y. Lu¹, Z. Yu¹, J. Shen¹, J. Cai¹; ¹CN, ²Guangdong/CN, ³Sichuan/CN
- 13:25 - 13:25 **1634P - Evolution of novel, low cost, sustainable osteosarcoma care over two decades: Reducing ine&&**
J. Bajpai¹, T. Mondal¹, V. Simha¹, A. Chandrashekharan¹, S. Hingmire², B. Rangarajan³, N. Shetty¹, K. Shah¹, R. Dusane¹, B. Rekhi¹, T. Vora¹, J. Ghosh¹, S. Banavali¹, S. Gupta¹; ¹IN, ²Maharashtra/IN, ³Tamil Nadu/IN
- 13:25 - 13:25 **1635P - HBP-bound doxorubicin: Promising new therapy for bone cancer**
E. David, S. Cagnol, J.-Y. Goujon, M. Egorov, R. Le Bot; FR
- 13:25 - 13:25 **1636P - Perceptions of clinical trial enrollment in patients with bone and soft tissue sarcoma**
A. Rosenberg¹, S. Kircher², E. Hahn¹, A. Rademaker¹, K. Bilimoria¹, J. Wayne¹, M. Agulnik²; ¹IL/US, ²US
- 13:25 - 13:25 **1637P - Pneumothorax is a novel sensitivity biomarker for targeting VEGFR2 in lung metastatic sarcoma**
Q. Bao, Y. Shen, W. Zhang; CN
- 13:25 - 13:25 **1638P - Do Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems predict survival in patients with bone sarcoma?**
W. Alselwi¹, F. Azam², M. Latif³, I. Osman², W. Taha², K. Bawazir², A. Farooq⁴, N. Bukhari², F. Ibnshamsah²; ¹YE, ²SA, ³Merseyside/GB, ⁴GB
- 13:25 - 13:25 **1639P - The study of molecular and genetic markers of apoptosis and proliferation, their role in the treatment and prevention of osteogenic sarcoma**
M. Tillyashaykhov, D. Polatova, M.-A. Gafur-Akhunov, K. Abdikarimov, U. Islamov, R. Davletov; UZ
- 13:25 - 13:25 **1640P - Outcome of treatment in giant cell tumors of bones: A single institutional retrospective review**

M. Elshenawy¹, A. Badran², M. Memon³, A. Elshentenawy², T. Elhassan³; ¹Menoufia Governorate/EG, ²EG, ³SA

- 13:25 - 13:25 **1641P - Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients**
T. Assi¹, A. Le Cesne², E. Nassif¹, A. Cavalcanti¹, M. Faron¹, T. Ibrahim³, C. Le Pechoux², O. Mir¹, J. Adam¹, S. Dumont¹, P. Terrier¹, C. Honore¹; ¹FR, ²CEDEX/FR, ³LB
- 13:25 - 13:25 **1642P - Determination of biological behavior of solitary fibrous tumors**
L. Krsková, M. Kalinova, I. Odintsov, P. Galgonková, R. Kodet; CZ
- 13:25 - 13:25 **1643P - Pazopanib in advanced or metastatic synovial sarcoma: The Gustave Roussy experience**
M. Sroussi¹, S. De Percin¹, A.M. Grecea¹, M.A. Benderra¹, M. Velev¹, S. Akla¹, N. Lezghed¹, S. Dumont¹, C. Le Pécoux¹, C. Honore¹, L. Haddag¹, M. Faron¹, P. Terrier¹, O. Mir¹, A. Le Cesne²; ¹FR, ²CEDEX/FR
- 13:25 - 13:25 **1644P - Identification of effective drug combinations with regorafenib (REG) for the treatment of pediatric rhabdomyosarcomas (RMS)**
Y. Tsvetkova, J. Hoffmann, D. Zopf; DE
- 13:25 - 13:25 **1645P - KS in the era of HAART: A single institutional retrospective review**
K. Sankar¹, K. Foster¹, C. Achenbach¹, M. Agulnik²; ¹IL/US, ²US
- 13:25 - 13:25 **1646P - Carcinosarcoma: Clinical and epidemiological patterns in the United States**
M. Gouda, Menoufia Governorate/EG
- 13:25 - 13:25 **1647P - First-line treatment of desmoid tumor: Systemic therapy versus upfront surgery**
J. Souza, H. Lourenço, G. Mendes; BR
- 13:25 - 13:25 **1648P - Adult rhabdomyosarcoma in Tunisia: Clinical presentation, treatment and outcome**
M. Saadi, D. Tajina, F. Letaief-Ksontini, K. Meddeb, A. Gabsi, Y. Yahyaoui, A. Mokrani, M. Ayadi, N. Chraiet, H. Rais, A. Mezlini; TN
- 13:25 - 13:25 **1649P - A pan-cancer landscape analysis reveals a subset of endometrial stromal and pediatric tumors defined by internal tandem duplications of BCOR**
L. Juckett¹, D. Lin², R. Madison¹, C. Patriquin¹, G. Frampton², V. Miller², J. Ross², J. Chung², A. Schrock², S. Ali², J. Elvin²; ¹US, ²MA/US
- 13:25 - 13:25 **1650P - The efficacy of eribulin for patients with taxane-resistant cutaneous angiosarcoma: Interim result of multi-center, prospective observational study**

Y. Fujisawa¹, K. Yoshino², T. Fujimura², S. Matsushita², H. Uchi², Y. Yamamoto², H. Hata², A. Otsuka², T. Miyagi², M. Ishii², T. Funakoshi²; ¹Ibaraki/JP, ²JP

- 13:25 - 13:25 **1651P - Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma**
M. Agulnik¹, B. van Tine², S. Attia¹, A. Rademaker³, M. Milhem¹, S. Okuno¹; ¹US, ²Missouri/US, ³IL/US
- 13:25 - 13:25 **1653P - Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: Results of a retrospective series in a tertiary care center**
C. Honoré¹, M. Faron¹, O. Mir¹, L. Haddag¹, S. Dumont¹, P. Terrier¹, J. Adam¹, C. Lepéchoux¹, A. Le Cesne²; ¹FR, ²CEDEX/FR
- 13:25 - 13:25 **1652P - Outcomes and prognostic factors for angiosarcoma: A 19-year single institution experience**
M. Chirila, D. Eniu, N. Todor, V.M. Nagy, M. Galatir, D. Coza, V. Cernea, D. Martin, Z. Fekete; RO
- 13:25 - 13:25 **1654P - Soft tissue sarcomas (STS) in elder patients: No impact of age on overall survival (OS) in an unselected cohort**
J.A. Perez Fidalgo¹, A. Lopez², V. Gambardella¹, S. Navarro², A. Iranzo², N. Diaz Fernandez², P. Tolosa², A. Silvestre², E. Iriarte Moncho², M.C. Garcia Mora², A. De la Paz², J.J. Soler², A. Cervantes¹; ¹Valencia/ES, ²ES
- 13:25 - 13:25 **1655P_PR - The use of complementary and alternative medicine (CAM) in sarcoma patients**
K.-T. Sungu-Winkler, J. Hübner, F. Menge, B. Kasper, P. Hohenberger; DE
- 13:25 - 13:25 **1657P - Return to work and quality of life in disease-free adult sarcoma patients**
A. Kollar, S. Müller, N. Fankhauser, I. Briner, F. Klenke, J. Bernhard; CH
- 13:25 - 13:25 **1658P - No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: Results from a single center propensity-matched analysis**
M. Faron¹, S. Dumont¹, J. Adam¹, O. Mir¹, L. Haddag¹, C. Le Pechoux², P. Terrier¹, A. Le Cesne²; ¹FR, ²CEDEX/FR
- 13:25 - 13:25 **1659P - Combination of eribulin plus gemcitabine in L-sarcomas**
D. Moura, M. Lopez-Alvarez, A. Salinas-Villegas, P. Sanchez-Bustos, N. Hindi, M. Taron Roca, J. Martin-Broto; ES
- 13:25 - 13:25 **1660P - The role of chemotherapy in the landscape of liposarcoma**
A. De Vita¹, F. Recine¹, L. Mercatali¹, G. Miserocchi¹, C. Liverani¹, C. Spadazzi¹, R. Casadei¹, D. Cavaliere¹, A. Bongiovanni², F. Pieri¹, L. Medri¹, N. Riva¹, V. Fausti², T. Ibrahim²; ¹IT, ²Forlì-Cesena/IT

- 13:25 - 13:25 **1661TiP - A randomized phase III study of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group study JCOG1610**
H. Urakawa, J. Mizusawa, K. Tanaka, J. Eba, H. Hiraga, M. Hosaka, A. Kawai, F. Nakatani, E. Kobayashi, Y. Nishida, T. Okamoto, T. Matsunobu, Y. Iwamoto, H. Fukuda, T. Ozaki; JP
- 13:25 - 13:25 **1662TiP - VOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)**
S. Bauer¹, S. George², Y.-K. Kang³, W. Tap², T. Zhou², N. Picazio², A. Boral², M. Heinrich²; ¹DE, ²US, ³KR
- 13:25 - 13:25 **Supportive care**
- 13:25 - 13:25 **1691P - Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients**
K. Thein¹, S. Ball², M. Zaw³, A. Tun³, M. Quirch², F. Hardwicke², N. D'Cunha², L. Tijani², C. Jones², T. Oo²; ¹US, ²TX/US, ³NY/US
- 13:25 - 13:25 **1692P - Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey**
M. Lambertini¹, M. Di Maio², F. Poggio², O. Pagani³, G. Curigliano², L. Del Mastro², S. Paluch-Shimon⁴, S. Loibl⁵, A. Partridge⁶, H. Azim Jr.⁷, F. Peccatori², I. Demeestere¹; ¹BE, ²IT, ³CH, ⁴IL, ⁵DE, ⁶US, ⁷LB
- 13:25 - 13:25 **1693P - Analysis of parameters to predict the effectiveness of scalp cooling to prevent chemotherapy-induced alopecia in breast cancer patients**
C. Kurbacher, S. Herz, A.T. Kurbacher, G. Kolberg, N. Kettelhoit, A. Schott, J. Kurbacher; DE
- 13:25 - 13:25 **1694P - A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results**
M. Lacouture¹, H. Dion², S. Ravipaty³, V. Akmaev³, R. Sarangarajan², J. Jimenez⁴, N. Narain², B. Berman⁴, S. Goldfarb¹; ¹NY/US, ²US, ³MA/US, ⁴FL/US
- 13:25 - 13:25 **1695P - Acupuncture for peripheral neuropathy in cancer patients: TCM diagnosis as a predictor of treatment response**
W. Liu, A. Qdaisat, G. Lopez, S. Underwood, M. Spano, A.R. Akhila Reddy, Y. Guo, S.-C. Yeung, E. Bruera, M.K. Garcia, L. Cohen; US
- 13:25 - 13:25 **1696P - A randomized, open-label, non-inferiority study comparing the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B-cell non-Hodgkin lymphomas (B-NHL): AVOID neutropenia**
H. Link¹, G. Illerhaus¹, U. Martens¹, A. Salar², R. Depenbusch¹, A. Kohler¹, M. Engelhardt¹, S. Mahlmann¹, M. Zaiss¹, A. Lammerich¹, P. Bias¹, A. Buchner¹; ¹DE, ²ES

- 13:25 - 13:25 **1697P - Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: Pan-European non-interventional study**
G. Steger¹, P. Pichler¹, M. Airolidi², P. Mazza², C. Fontaine³, J. Timmer Bonte⁴, J. Walewski⁵, J. Katolicka⁶, M. Mikulova⁷, M. Gasparic⁴; ¹AT, ²IT, ³BE, ⁴NL, ⁵PL, ⁶South Moravian/CZ, ⁷Slovak republic/SK
- 13:25 - 13:25 **1698P - Safety analysis of proposed biosimilar pegfilgrastim in phase I and phase III studies**
N. Harbeck¹, J. Wang², G. Otto¹, A. Krendyukov¹; ¹DE, ²US
- 13:25 - 13:25 **1699P - New approach to evaluate survival benefit of granulocyte colony-stimulating factor in cancer patients receiving myelosuppressive chemotherapy**
A. Krendyukov, L. Yau; DE
- 13:25 - 13:25 **1700P - Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials**
A. Illes¹, L. Perjesi¹, K. Horvat-Karajz¹, N. Jeszenoi¹, I. Aradi¹, N. Singh², S. Mair², Z. Kahan¹; ¹HU, ²GB
- 13:25 - 13:25 **1701P - Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: Findings from a large study in German clinical practice (PROTECT)**
C. Kurbacher, M. Schmidt, M. Geberth, B. Otremba, H. Eschenburg, P. Ramdohr; DE
- 13:25 - 13:25 **1702P - Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: A pooled analysis of two randomized trials**
A. Kristensen, T. Solheim, Ø. Fløtten, B. Grønberg; NO
- 13:25 - 13:25 **1703P - Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)**
R. von Moos, H. Hawle, S. Hayoz, R. Cathomas, A. Müller, S. Schmid, O. Pagani, T. Wehrhahn, D. Rauch, S. Anchisi, T. Hermanns, M. Fehr, S. Stoll, P. Bützberger, M. Zweifel, U. Huber, A. Fuhrer, C. Schär, S. Gillessen, A. Templeton; CH
- 13:25 - 13:25 **1704P - A prospective randomized controlled trial of metoclopramide combined with triple antiemetic therapy to prevent anthracycline-based chemotherapy-induced nausea and vomiting in patients with breast cancer**
U. Oflazoglu, U. Varol, A. Alacacioglu, T. Salman, Y. Kucukzeybek, H. Taskaynatan, Y. Yildiz, G. Dissiz, S. Iriz, M. TARHAN; TR
- 13:25 - 13:25 **1705P - Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting**

J.H. Kwon, J.-H. Kang, Y.-G. Lee, K.U. Park, H.J. An, J. Sohn, Y.M. Seol, H. Lee, H.-J. Yun, J.S. Ahn, H.J. Kim; KR

- 13:25 - 13:25 **1706P - Prognostic factors associated with prevalence of nausea, and time to development of nausea in patients receiving guideline-based anti-emetic prophylaxis: A prospective, observational, real world study**
T. Smit, B. Rapoport; ZA
- 13:25 - 13:25 **1707P - Usefulness of bone modifying agents for non-weight bearing bone metastasis in breast cancer**
K. KAWAGUCHI, M. Latif, K. Hayashi, S. Ogita; JP
- 13:25 - 13:25 **1708P - Analysis of bone events in patients with aromatase inhibitors (AI)**
S. Arrojo, E. Garcia-Carús, C. Gómez, P. Rodriguez, D. Rivas, L. Faez, C. Iglesias Gomez, M.E. Izquierdo Manuel, Y. Fernandez Perez; ES
- 13:25 - 13:25 **1709P - Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study**
R. Lopez Lopez¹, J.J. Reina Zoilo², D. Monge², F. Caballero², V. Guillem Porta², E. Aranda Aguilar², A. Carrato Mena², E. Diaz Rubio², J. Garcia Foncillas², M. Feyjoo², C. Camps²; ¹La Coruña/ES, ²ES
- 13:25 - 13:25 **1710P - Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project**
J. Salvador Bofill¹, V. Guillem Porta¹, M. Feyjoo¹, A. Anton Torres¹, E. Aranda Aguilar¹, C. Camps¹, A. Carrato Mena¹, M. Constenla Figueiras¹, J.J. Cruz Hernandez¹, E. Diaz Rubio¹, J. Garcia Foncillas¹, P. Gascon¹, R. Lopez Lopez², B. Soler¹, Y. Escobar¹; ¹ES, ²La Coruña/ES
- 13:25 - 13:25 **1711P - Opioid-induced constipation in patients with cancer pain in Japan: Prospective observational study using Rome IV OIC diagnostic criteria (OIC-J Study)**
H. Imai¹, S. Fumita¹, T. Harada¹, T. Noriyuki¹, M. Gamoh², Y. Akashi¹, H. Sato¹, Y. Kizawa¹, A. Tokoro¹; ¹JP, ²Miyagi/JP
- 13:25 - 13:25 **1712P - Efficacy and tolerability of naldemedine in patient with cancer and opioid-induced constipation: A pooled subgroup analysis of 2 randomized placebo-controlled studies**
E. Satomi¹, H. Ishiki¹, T. Yokota², Y. Tada¹, H. Sato¹, M. Okamoto¹, I. Osaka¹; ¹JP, ²GB
- 13:25 - 13:25 **1713P - Left ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance**
J.H. Yeo, H. Ahn, I. Park, Y.S. Kim, S.J. Sym, E.K. Cho, D.B. Shin; KR
- 13:25 - 13:25 **1714P - Predicting the occurrence and prevention of early anthracycline cardiotoxicity of chemotherapy in patients with breast cancer**

A. Askolskyi, L. Syvak, O. Zharinov, N. Khranovska; UA

- 13:25 - 13:25 **1715P - Baseline prevalence of cardiovascular disease (CVD) risk factors in women with breast cancer**
N. Bhoo-Pathy, S. Subramaniam, H. Zaharah, Y.C. Kong, N.A. Taib, A. Deniel, K.-H. Chee, R.S. Bustamam, M.-H. See, A. Fong, C.H. Yip; MY
- 13:25 - 13:25 **1716P - Cardiovascular and other competing causes of death among cancer patients, 2006-2015: An Australian population-based study**
Y. Ye¹, P. Otahal², T. Marwick³, K. Wills², A. Neil², A. Venn²; ¹AU, ²TAS/AU, ³VIC/AU
- 13:25 - 13:25 **1717P - Cancer associated thrombosis with primary prophylaxis in a tertiary hospital in the Philippines from 2010-2015**
A.T. Gerona, PH
- 13:25 - 13:25 **1718P - The incidence of recurrent venous thromboembolism (VTE) and bleeding depending on practical treatment pattern of anticoagulation in the cancer patients with VTE**
S.-M. Bang, J.-H. Kang, M.H. Hong, J.S. Ahn, S.Y. Oh, J.H. Baek, Y.J. Choi, S.H. Shin, Y.-J. Kim, J.-H. Cha, J. Lee; KR
- 13:25 - 13:25 **1719P - Prevention and prophylaxis of thrombosis in cancer patients**
N. Tsoukalas¹, P. Papakotoulas¹, A. Christopoulou², A. Ardavanis¹, G. Koumakis¹, C. Papandreou¹, G. Papatsimpas¹, P. Papakostas¹, C. Andreadis¹, G. Aravantinos³, N. Ziras¹, H. Kalofonos¹, E. Samantas³, M. Sougleri¹, P. Makrantonakis¹, G. Pentheroudakis¹, A. Athanasiadis¹, E. Bournakis¹, I.I. Varthalitis¹, I. Boukovinas¹; ¹GR, ²West Greece/GR, ³Attica/GR
- 13:25 - 13:25 **1720P - Is it appropriate to use a fixed prophylactic dose of enoxaparin for hospitalized cancer patients? Results from a prospective tertiary referral single center study**
C. Maurice-Dror, M. Litvak, A. Keren, S. Akerman, B. Brenner, N. Haim, Y. Nadir; IL
- 13:25 - 13:25 **1721P - Long-term prognosis of acute pulmonary embolism: A focus on idiopathic and neoplastic etiologies**
I. Guerreiro, H. Magalhães, S. Coelho, A.M. Ribeiro, S. Ferreira, E. Araújo, M. Fontes-Sousa, P. Bettencourt, P. Lourenço; PT
- 13:25 - 13:25 **1722P - Systematic literature review and network meta-analysis of oral anticoagulants for the treatment of venous thromboembolism in patients with cancer**
H. Park, J.-C. Kim, J. Cho, J.H. Lim, M.H. Lee; KR
- 13:25 - 13:25 **1723P - Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy**
K. Talasiewicz, P. Ozdowska, B. Milanowska, K. Gepner, B. Jagielska; PL

- 13:25 - 13:25 **1724P - Personalised nutritional care during chemotherapy using survey on taste changes during chemotherapy: First experience from tertiary chemotherapy day care center in Northern India**
A. Vora, S. Chatterjee, A. Upadhyay, N. Hazarika, G.S. Bhattacharya; IN
- 13:25 - 13:25 **1725P - Role of megestrol acetate versus dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: A randomized controlled pilot trial**
S. Ostwal, N. Salins, J. Deodhar, M. Maryann; IN
- 13:25 - 13:25 **1726P - Population pharmacokinetics (PPK) of anamorelin (ANAM), an oral selective ghrelin receptor agonist**
A. Bernareggi¹, S. Kaasa², M. Fallon³, R. Skipworth³, D. Currow⁴; 1CH, 2NO, 3GB, 4AU
- 13:25 - 13:25 **1727P - Health care providers' experiences of positive and negative effects of parenteral nutrition therapy in cancer patients**
K. Sand, L. Thoresen, T. Solheim, R. Helgås, E. Løhre, T. Balstad; NO
- 13:25 - 13:25 **1728P - Assessment of anorexia and weight loss in newly diagnosed upper gastrointestinal cancer patients with localised and metastatic disease, using the functional assessment of anorexia cachexia therapy anorexia/cachexia subscale (FAACT A/CS)**
M. Abraham, Z. Kordatou, W. Mansoor; GB
- 13:25 - 13:25 **1729P - Body composition factor is independent prognosticator in advanced pancreatic cancer patients**
S. Kang, H.S. Park, H.-C. Jeung; KR
- 13:25 - 13:25 **1730P - Current use of clinical nutrition in oncology patients: Real world evidence from big data in Italy**
F. Di Costanzo¹, R. Caccialanza¹, A. Santoro², C. Gavazzi¹, P. Pedrazzoli¹; 1IT, 2(MI)/IT
- 13:25 - 13:25 **1731P - Nutritional cancer care: Slowly evolving clinical practice reveals regional and professional HCP variability**
F. Strasser¹, J. Arends², A. Laviano³, A. O'Callaghan⁴, R. Audisio⁵, M. Sawyer⁶, S. Kaasa⁷; 1CH, 2DE, 3IT, 4NL, 5Merseyside/GB, 6Alberta/CA, 7NO
- 13:25 - 13:25 **1732P - Unidentified cachexia patients in the oncologic setting: Cachexia UFO's do exist**
E. De Waele¹, J. Demol¹, R. Caccialanza², P. Cotogni², H. Spapen¹, M. Malbrain¹, J. De Grève¹, J. Pen¹; 1BE, 2IT
- 13:25 - 13:25 **1733P - The effect of sarcopenia on acute chemotherapy toxicity in gastrointestinal cancer patients undergoing systemic therapy**
N. Ozdemir, O. Yazici, K. Silay, G. Ucar, T. Eren, D. sener dede, M.A.N. Sendur, M. Akinci, A. Baykal, B. Yalcin, N. Zengin; TR

- 13:25 - 13:25 **1734P - Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer**
S. Mitsunaga¹, M. Takada¹, S. Nishikawa¹, A. Imaizumi¹, M. Ishii¹, M. Ikeda²; ¹JP, ²Chiba/JP
- 13:25 - 13:25 **1735P - Trajectory of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) predicts time to progression (TTP) in metastatic colorectal cancer (mCRC) patients**
S.A. Kurk, R. Stellato, P. Peeters, M. Oskam, B. Dorresteijn, M. Jourdan, C. Punt, M. Koopman, A. May; NL
- 13:25 - 13:25 **1736P - Clinical impact of whey protein and nutritional counseling in gastrointestinal cancer patients**
M. Roberto¹, E. Sarfati¹, M. Di Girolamo¹, F.M. Schipilliti¹, E. Crimini¹, A. Botticelli¹, L. Marchetti¹, M. Muscaritoli², P. Marchetti¹, F. Mazzuca¹; ¹IT, ²RM/IT
- 13:25 - 13:25 **1737P - Impact of taste alterations during systemic anti-tumour therapy on the liking of oral nutritional supplements with adapted flavours**
J. De Haan, Y. Moshage, D. Kluifhooft, R. Renken, C. Corbier, H. Blanchard, A. Reyners; NL
- 13:25 - 13:25 **1738P - Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study**
A. Di Meglio¹, M. El-Mouhebb¹, S. Michiels¹, L. Jones², M. Annonay³, A. Zingarello¹, M. Matias¹, S. Everhard¹, A.L. Martin¹, P. Arveux¹, O. Tredan¹, P. Soulie¹, P. Cottu⁴, A. Partridge⁵, L. Del Mastro⁶, J. Ligibel⁵, F. André¹, I. Vaz-Luis¹; ¹FR, ²NY/US, ³CEDEX/FR, ⁴CEDEX 5/FR, ⁵US, ⁶IT
- 13:25 - 13:25 **1739P - Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)**
A. Di Meglio¹, M. El-Mouhebb¹, S. Michiels¹, L. Jones², E. Martin¹, M. Matias¹, A.E. Lohmann Palhares³, F. Joly¹, L. Vanlemmens⁴, S. Everhard¹, A.L. Martin¹, J. Lemonnier¹, P. Arveux¹, P. Cottu⁵, C. Coutant⁶, L. Del Mastro⁷, A. Partridge⁸, F. André¹, J. Ligibel⁸, I. Vaz-Luis¹; ¹FR, ²NY/US, ³RJ/BR, ⁴CEDEX/FR, ⁵CEDEX 5/FR, ⁶Cedex/FR, ⁷IT, ⁸US
- 13:25 - 13:25 **1740P - Patient reported outcomes: Web-monitoring versus nurse assessment to improve anticancer therapies**
M. Korostelev¹, K. Sejean¹, C. Lepage¹, J. Stevens¹, B. Bonan¹, P. Beuzeboc², F. Scotté¹; ¹FR, ²CEDEX 5/FR
- 13:25 - 13:25 **1741P - Polymedication in elderly cancer patients treated with chemotherapy**
A.-L. COUDERC¹, F. Correard¹, C. Tabele¹, E. Nouguerede¹, L. Greillier¹, F. Duffaud², P. Auquier¹, A. Daumas¹, P. Bertault-Peres¹, P. Villani¹, S. Honore¹; ¹FR, ²CEDEX 5/FR
- 13:25 - 13:25 **1742P - Geriatric oncology (GO): Long term follow-up of a prospective series of the GO unit at A.C. Camargo Cancer Center**

A. DETTINO, M. Donadio, A. Cabral, V. Jesus, M. Fanelli, S. Sanches; BR

- 13:25 - 13:25 **1743P - Developing a predictive model for chemotherapy related toxicities in older Asian adults**
S.L.A. Pang, F. Ho, Y.S. Ng, C. Cai, M. Wang, W.C. Yong, B.C. Tai; SG
- 13:25 - 13:25 **1744P - Palliative local therapy of advanced breast cancer**
T. Letodiani, M. Shavdia, N. Shavdia, K. Chaava, N. Gegeshidze; GE
- 13:25 - 13:25 **1745P - General and dedicated cancer emergency room: Clinical and financial implications**
N. Malavasi, C. Fiorani, L. Ferrara, R. Postiglione, L. Scarabelli, F. Cantile, A. Saviola, G. Longo, A. Luciani, S. Cascinu; IT
- 13:25 - 13:25 **1746P - Comparing cancer patients&&**
A. Herrmann, R. Sanson-Fisher, A. Hall, L. Wall, N. Zdenkowski, A. Waller; AU
- 13:25 - 13:25 **1747P - EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC)**
M. Harrison¹, P. Davis², M. Khouri², R. Gupta¹, A. Armstrong¹, M. McNamara², T. Zhang², M. Anand², K. Onyenwoke², H. Hood², S. Edwardson², D. Craig², Y. Wu², P. Healy², B. Coyne², L. Jones³, D. George²; ¹US, ²NC/US, ³NY/US
- 13:25 - 13:25 **1748P - Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer**
L. Eng¹, J. Bender², K. Hueniken², S. Kassirian², D. Yang², L. Mitchell², C. Paulo², A. Magony², E.C. Smith², M. Liang², M.C. Brown², W. Xu², S. Alibhai², G. Liu², A. Gupta²; ¹Ontario/CA, ²CA
- 13:25 - 13:25 **1749P - Ultrasound-guided femoro-popliteal block in lower limb sarcoma and cutaneous malignancy patients: Is it the time to abandon spinal anaesthesia for foot and ankle surgeries?**
N. Moda, IN
- 13:25 - 13:25 **1750P - Assessment of socio-economic, physical and mental health status of long-term cancer survivors**
A. Gallego Martínez, B. Martínez, I. Ghanem, E. Espinosa, B. Castelo, M.P. Zamora Aunon, A. Pinto Marin, L. Ruiz-Giménez, A. Redondo, J. Feliu Batlle; ES
- 13:25 - 13:25 **1751P - Usability testing of EirV3-a computer-based tool for patient reported outcome measures in cancer**
H. Krogstad, S. Sundt-Hansen, M. Hjermstad, L. Hågensen, S. Kaasa, J.H. Loge, S. Raj, A. Steinsbekk, K. Sand; NO

- 13:25 - 13:25 **1752P - Monitoring quality of life in Dutch women with breast cancer: The Care Notebook study**
R.T. Lugtenberg¹, M. Fischer¹, F. de Jongh¹, K. Inoue², A. Matsuda², S.R.S. Ramai¹, J. Nortier¹, H. Putter¹, K. Yamaoka², K. Kubota², K. Kobayashi², A.A. Kaptein¹, J. Kroep¹; ¹NL, ²JP
- 13:25 - 13:25 **1753P_PR - Benefits of physical activity and sport integrated into the care pathway of oncology patient**
L. Vanlemmens¹, H. Mocaer², T. Ginsbourger², J.M. Descotes², N. Masselin², H. Deroubaix², C. Fabre², J. Devriendt², T. Bouillet², E. Lartigau²; ¹CEDEX/FR, ²FR
- 13:25 - 13:25 **1754P - Prognostic factors for critically ill patients with solid cancer tumours admitted to a medical intensive care unit**
C. Baylot, A. Francopoulo, A. Quivy, O. Guisset, G. Hilbert, E. Frison, A. Ravaud, A. Daste; FR
- 13:25 - 13:25 **1755P - A pilot study of exercise intervention in patients with metastatic cancer: Feasibility, safety, and patient reported outcome**
J.-H. Park¹, E.Y. Kim¹, K.D. Park¹, S.M. Kang², H. Ahn¹, Y.S. Kim¹, I. Park¹, S.J. Sym¹, D.B. Shin¹; ¹KR, ²KP
- 13:25 - 13:25 **1756P - A prospective analysis of 30-day mortality following palliative chemotherapy at an Australian tertiary cancer centre**
J. McCracken-Skeggs¹, A. Dabscheck¹, M. Coperchini¹, I. Hornung¹, A. Jalali², G. Akers¹, A. Karahalios², L. Lipton²; ¹AU, ²VIC/AU
- 13:25 - 13:25 **1757P - Characterisation of oncologic patient visits at the ED at an Austrian tertiary care center**
B. Pauzenberger, T. Fuereder, A. Laggner, C. Zielinski, C. Minichsdorfer; AT
- 13:25 - 13:25 **1758P - High proportion of prostate cancer survivors continue to experience a negative impact on quality of life long after diagnosis: Patient reported outcomes for an Australian population-based sample**
Q. Tran¹, A. Ward², K. Lisy², J. Bishop², M. Jefford²; ¹QLD/AU, ²VIC/AU
- 13:25 - 13:25 **1759P - A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada**
W. Evans¹, E. cameron², M. Haque², N. Schwartz², S. Khan², R. Truscott²; ¹Ontario/CA, ²CA
- 13:25 - 13:25 **1760P - A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity**
A. Matsuoka¹, O. Maeda², A. Mitsuma², K. Uehara², G. Nakayama¹, M. Nagino², Y. Kodera², Y. Ando¹; ¹Aichi/JP, ²JP

- 13:25 - 13:25 **1761P - Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance**
K. Thein¹, A. Sultan², M. Zaw³, M. Han², N. Yu³, H. Igid², C. Jones², N. D'Cunha², S. Awasthi², F. Hardwicke²; ¹US, ²TX/US, ³NY/US
- 13:25 - 13:25 **1762P - Chemotherapy-induced peripheral neurotoxicity (CIPN): What are patients telling us?**
G. Cavaletti, IT
- 13:25 - 13:25 **1763P - Malnutrition in cancer patients: Is late diagnosis a missed opportunity to improve care?**
C. Tlemsani¹, G. Zalcman¹, R. Bernard¹, A. Zerouali¹, F. Goldwasser²; ¹FR, ²CEDEX 14/FR
- 13:25 - 13:25 **1764P - A survey on acceptable nomenclature in addressing patient needs among the delegates of a national conference on supportive medicine**
R. Arora, IN
- 13:25 - 13:25 **1765P - A survey on purview of palliative medicine services among the delegates of a national conference on supportive medicine**
R. Arora, IN
- 13:25 - 13:25 **1766P - Sexual functioning and depression among Egyptian breast cancer patients following surgery and neoadjuvant/adjuvant chemotherapy**
S. Al Hassanin, S. Alsirafy; EG
- 13:25 - 13:25 **1767P - Supportive care: Patient expectations, availability and uptake**
H. Simon¹, J. Viguier¹, G. Ganem¹, C. Touboul¹, C. Lhomel¹, H. Naman¹, J.F. Morère¹, F. Eisinger²; ¹FR, ²CEDEX 9/FR
- 13:25 - 13:25 **1768P - Novel approach for counselling of young cancer patients**
U. Seifart, T. Langer, I.-K. Na, J. Schulze, M. Freund; DE
- 13:25 - 13:25 **1769P - Health-related quality of life priorities in adolescents and young adults (AYA) with cancer: Discrepancies with health care professionals' perceptions**
S. Kaal¹, J. Prins¹, R. Jansen¹, E. Manten-Horst¹, P. Servaes¹, W. van der Graaf², O. Husson³; ¹NL, ²Surrey/GB, ³GB
- 13:25 - 13:25 **1770P - What information and features do young and older adults with cancer want in their hospital-based social media cancer resource?**
C. Paulo, L. Eng, L. Mitchell, I. Geist, S. Kassirian, A. Magony, E.C. Smith, C. Brown, M. Liang, K. Hueniken, D. Yang, W. Xu, G. Liu, A. Gupta, J. Bender; CA

- 13:25 - 13:25 **1771P - Hypothyroidism in cancer patients received multikinase inhibitors: Risk factors and outcomes**
S. Hansuranant, H. Nimitphong, O. Pattanaprteep, R. Phraewphiphat, D. Muntham, T. Reungwetwattana; TH
- 13:25 - 13:25 **1772P - Immune related adverse events across cancer types: Incidence, risk factors and survival**
D. Owen¹, J. Burkart², S. Patel², L. Wei², G. Tinoco², D. Liebner², K. He², P. Shields², E. Bertino², C. Presley², A. Johns², E. Folefac², T. Olencki², D. Carbone², C. Verschraegen³, G. Otterson², K. Kendra²; ¹US, ²OH/US, ³Vermont/US
- 13:25 - 13:25 **1773P - Effect of yoga on chemo-radiotherapy induced diabetes and hypertension (CRID-H) among cervical cancer patients at a regional cancer institute in south India**
N. Nelson¹, I. Khaleel¹, M. ROY¹, R. C¹, H.B. Govardhan², N. Jasti¹, S. Suresh¹, R. Kashyap¹, L. Lokanath¹; ¹IN, ²Karnatka/IN
- 13:25 - 13:25 **1774P - Fatigue prevalence and adherence to treatment: A real-world data survey and mathematical model application**
D. Vorobiof¹, E. Malki², I. Deutsch², M. Bivasbenita²; ¹Gauteng/IL, ²ZA
- 13:25 - 13:25 **1775P - A survey on attitude towards euthanasia among delegates of a national conference on supportive medicine**
R. Arora, IN
- 13:25 - 13:25 **1776P - Acute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer: A prospective study**
E. Dewaele¹, P.J. van Dam¹, B. De Laere², C. Verschueren¹, P. Specenier¹; ¹BE, ²Antwerp/BE
- 13:25 - 13:25 **1777P_PR - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study**
Q. Tran¹, A. Schimdt², Z. Lwin¹, B. Hughes²; ¹QLD/AU, ²AU
- 13:25 - 13:25 **1778P - Chemotherapy effect on daytime sleepiness and contributing factors in older adults with cancer**
S. Sadighi, B. Saberzadeh-Ardestani, B. Khosravi, J. Zebardast; IR
- 13:25 - 13:25 **1779P - Group pre-chemotherapy education: Improving patient experience through education and empowerment**
K. McIntyre, R. Blackwood, V. Riley, L. Carballo, H. Plant, T. Marler-Hausen; GB
- 13:25 - 13:25 **1780P - Clinical and psychometric validation of the BreSAS questionnaire for symptom assessment among breast cancer survivors**
R. Giusti, E. Scarpi, K. Cannita, R.R. Silva, M. Filetti, M. Mazzotta, R. Rossi, V. Cocciolone, T. Sidoni, M. Tudini, C. Ficorella, A. Botticelli, P. Marchetti, G. Porzio, L. Verna; IT

- 13:25 - 13:25 **1781P - Association of phase angle and chemotherapy toxicity among Mexican patients with non-metastatic breast cancer**
M.T. Nieto Coronel, C. Arce- Salinas, A. Peña-Ruiz, M. Espinoza Cuevas, J. Santamaria-Galicia; MX
- 13:25 - 13:25 **1782P - Hepatitis screening for patients to undergo chemotherapy in Cyprus**
P. Kountourakis¹, A. Agathocleous¹, E. Kakouri¹, Y. Marcou¹, G. Orphanos¹, F. Kyriacou¹, D. Papamichael¹, H. Charalambous²; ¹CY, ²Nicosia/CY
- 13:25 - 13:25 **1783P - Hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) screening prior to chemotherapy initiation among patients with solid tumors**
S. Giordano¹, Z. Duan², H. Zhao², J. Hwang², M. Chavez Mac Gregor¹; ¹TX/US, ²US
- 13:25 - 13:25 **1784P - Rapid identification of bloodstream infection pathogens**
N. Panova, O. Kit, O. Kutsevalova, I. Lysenko, V. Dmitrieva, D. Rozenko, Y. Gevorkyan, E. Pak, O. Kozyuk, E. Kapuza, O. Shatokhina, N. Nikolaeva, E. Kalabanova, I. Mitashok, L. Vladimirova; RU
- 13:25 - 13:25 **1785P - Pathogens and characteristics of candidemia in hospitals of Rostov-on-Don: Multicenter study in Russia**
O. Kutsevalova, O. Kit, N. Panova, I. Lysenko, V. Dmitrieva, D. Rozenko, E. Kalabanova, I. Mitashok, G. Klyasova, Y. Shatokhin, I. Snezhko, D. Martynov, V. Malygin, O. Korosteleva, A. Matsuga, K. Aslanyan, L. Vladimirova; RU
- 13:25 - 13:25 **1786P - Antiviral prophylaxis cannot reduce the risk of hepatitis B reactivation during chemotherapy for non-HCC solid tumor patients with lower HBV DNA titer: A retrospective cohort study**
Q. qin, A. Zhou, L. Yang, D. Zhong; CN
- 13:25 - 13:25 **1787P - Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: Final analysis**
F. Haslbauer¹, A. Petzer¹, M. Safanda², A. Tomova³, M. Porubska⁴, Z. Bajory⁵, D. Niepel⁶, C. Jäger¹, D. Kalinin⁷, R. Greil¹; ¹AT, ²CZ, ³BG, ⁴SK, ⁵HU, ⁶CH, ⁷UA
- 13:25 - 13:25 **1788P - A multicenter retrospective investigation on the efficacy of perioperative oral management in cancer patients**
S.-I. Yamada, S. Soutome, T. Hasegawa, I. Toujou, H. Nakahara, M. Kawakami, M. Hirose, S. Fujita, T. Komori, T. Kirita, Y. Shibuya, M. Umeda, H. Kurita; JP
- 13:25 - 13:25 **1790P - Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): The CIROCO study**
J. Desrame¹, J. Loup Mouysset¹, T. Altwegg¹, L. Zelek¹, N. Baize²; ¹FR, ²CEDEX 9/FR

- 13:25 - 13:25 **1792P - Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study**
M. Araz, M. Karaağaç, L. Korkmaz, L. Koral, F. İnci, I. Beypinar, M. Uysal, M. Artac; TR
- 13:25 - 13:25 **1793P - Painkiller-related dizziness in malignant tumors: A systematic review**
R. Spiegel¹, S. Rothschild², R. Sutter², R. Kalla²; ¹DE, ²CH
- 13:25 - 13:25 **1794P - Prevalence, risk factors and management of opioid-induced constipation in cancer pain: A nationwide, cross-sectional study in Korea**
S.Y. Lee, Y.S. Hong, K.T. Lee, S.H. Shin, M.Y. Choi, S.J. Sym, H.-S. Oh, S.N. Lee, E.-K. Song; KR
- 13:25 - 13:25 **1795P - Bald is beautiful: No more. The stigma of alopecia during chemotherapy: Brindisi oncology department experience**
D. Loparco, L. Orlando, M. Caloro, P. Fedele, P. Schiavone, A. Quaranta, C. Caliolo, M. Cinefra, P. Ferrara, L.L. Falcone, V. Capone, C. Destro, A. Morleo, A. Ricco, V. Bonuso, G. Lotti, M. D'amico, P. Rizzo, A. Marino, S. Cinieri; IT
- 13:25 - 13:25 **1796P - A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approach**
R. Nakov¹, S. Schussler², S. Schier-Mumzhiu¹, A. Skerjanec¹, A. Bellon¹, J. Wang³, A. Krendyukov¹, G. Otto¹; ¹DE, ²NJ/US, ³US
- 13:25 - 13:25 **1797P - Quality of life in breast cancer Tunisian women: A monocentric survey**
S. Labidi, C. Bousrih, M. Saadi, H. El Benna, M. Nesrine, N. Daoud, H. Boussen; TN
- 13:25 - 13:25 **1798P - Anticancer therapy within the last 30 days of life in a regional cancer centre**
M. Nguyen, AU
- 13:25 - 13:25 **1799P - Febrile neutropenia management and concordance of institutional protocol with clinical practice**
A. Oliveira, L. Bretes, I. Furtado, B. Gosalbez Pequeno, J. Magalhaes; PT
- 13:25 - 13:25 **1800P - Salient features of an indigenous integrated inpatient model of delivery of supportive medicine services: A narrative review**
R. Arora, IN
- 13:25 - 13:25 **1801P - Novel online drug-drug interaction resource reveals clinically relevant interactions in&&**
N. Lankheet¹, K. Ferrier¹, S. Gibbons², D. Burger¹, K. McAllister², J. Martin², S. Khoo², N. van Erp¹, F. Jansman¹; ¹NL, ²GB

- 13:25 - 13:25 **1802P - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database**
S. Bun, S. Kunisawa, N. Sasaki, K. Fushimi, K. Matsumoto, A. Yamatani, Y. Imanaka; JP
- 13:25 - 13:25 **1803P - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-paclitaxel induced peripheral neuropathy**
S. Tsuyuki, K. Yamagami, H. Yoshiyoshi, T. Sugie, Y. Mizuno, S. Tanaka, H. Kato, T. Okuno, N. Ogura, H. Yamashiro, H. Takuwa, Y. Kikawa, T. Hashimoto, T. Kato, S. Takahara, A. Yamauchi, T. Inamoto; JP
- 13:25 - 13:25 **1804P - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)**
H. Piessevaux, W. Demey, A. Bols, J. Janssens, M. Polus, H. Rezaei Kalantari, S. Laurent, A. Demols, Y. Humblet, G. Deboever, K. Kargar Samani, M. Ferrante, E. Monsaert, T. Rondou, J.-L. van Laethem, S. Tejpar; BE
- 13:25 - 13:25 **1805TiP - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)**
A. Mersiades¹, A. Tognela², P. Haber², M. Stockler², N. Lintzeris², J. Simes¹, I. McGregor², I. Olver², D. Allsop², C. Gedye², A. Kirby¹, R. Morton¹, K. Briscoe², P. Fox², M. Aghmesheh¹, N. Wong¹, A. Bhardwaj¹, A. Tran², C. Hahn², P. Grimison²; ¹NSW/AU, ²AU

13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 42	ICM - Room 1
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 43	ICM - Room 14b
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 44	ICM - Room 13
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 45	Hall A1 - Room 15
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 46	Hall A1 - Room 16
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 8	Hall B3 - Room 23
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 47	Hall B3 - Room 20
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 48	Hall B3 - Room 22
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 49	Hall B4 - Room 19
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium - EONS 9	Hall B4 - Room 24

13:00 - 14:00 **Type: Young Oncologist session** **ICM -**
Title: YO Clinical Case Discussion: Clinical Cases of Solid Tumours - **Room 14c**
Discussion Forum for Young Oncologists

13:00 - 13:00 **Soft tissue sarcoma**
P.G. Casali, IT

13:00 - 13:00 **Prostate cancer**
J. de Bono, GB

13:00 - 13:00 **Non-small cell lung cancer**
T. Cufer, SI

14:15 - 15:45 **Type: Young Oncologist session** **ICM -**
Title: YO Fellowship Session: Fellowships in Europe: Educational **Room 14a**
opportunities for Young Oncologists
Chair(s): Evandro de Azambuja, BE; Guillem Argiles, ES

14:15 - 14:20 **Introduction**
E. de Azambuja, BE

14:20 - 14:35 **The ESMO Fellowship Programme**
E. de Azambuja, BE

14:35 - 14:50 **Practical tips from a former fellow**
L. Vecchione, NL

14:50 - 15:05 **Best Paper Derived from an ESMO Fellowship: BRAVE project: Brain metastases (BM) and pancreatic metastases (PM): A clinic-pathological comparison of Various facets of the tumor heterogeneity in renal cell carcinoma (RCC)**
L. Derosa, FR

15:05 - 15:20 **Best Fellowship: Tumor infiltrating lymphocytes (TIL) and host immune response as predictive factors in breast cancer**
A. Matikas, SE

15:20 - 15:45 **Award Ceremony: Presentation of the ESMO 2018 Fellowships and Best Examination Award 2017**

14:45 - 16:15 **Type: Special Symposium** **Hall A1 - Room 17**
Title: Early detection of cancer using minimally invasive biomarkers
 Chair(s): Jean-Charles Soria, US; Caroline Dive, GB

14:45 - 14:50 **Introduction**
J.-C. Soria, CEDEX/US

14:50 - 15:05 **Plasma DNA for early cancer screening**
D.(.-M. Lo, HK

15:05 - 15:20 **Changes in the innate immune system as early events in cancer**
E. Vivier, FR

15:20 - 15:35 **Single cells for doing a diagnostic work-up for suspicion of lung cancer**
P. Kuhn, US

15:35 - 15:50 **Circulating microRNA biomarkers for early detection of lung cancer**
G. Sozzi, IT

15:50 - 16:05 **Pharma perspective: Screening, diagnosis or prognosis**
M. Lee, US

16:05 - 16:15 **Conclusions and clinical perspectives**
C. Dive, GB

14:45 - 16:15 **Type: Educational session** **Hall A2 - Room 18**
Title: The force awakens: Immunotherapy in thoracic malignancies
 Chair(s): Martin Reck, DE; Keith Kerr, GB

14:45 - 15:10 **Recent updates on biomarkers for immunotherapy beyond PDL1 expression**
K. Kerr, GB

15:10 - 15:35 **Mechanisms and management of immunotherapy resistance**
N. Rizvi, NY/US

15:35 - 16:00 **Combination and novel approaches to immunotherapy in lung cancer**
M. Reck, DE

16:00 - 16:15 **Discussion**

- 14:45 - 16:15** **Type: Proffered Paper session** **ICM - Room 14b**
Title: Proffered paper session - Head and neck cancer
 Chair(s): Amanda Psyrrri, GR; Lillian Siu, CA
- 14:45 - 15:00 **10440 - A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results**
E. Cohen¹, K. Harrington², D. Hong³, R. Mesia⁴, I. Brana⁴, P. Perez Segura⁴, T. Wise-Draper⁵, M. Scott⁵, P. Mitchell⁵, G. Mugundu⁵, P. McCoon⁵, C. Cook⁵, M. Mehta⁵, U. Keilholz⁶; ¹IL/US, ²GB, ³TX/US, ⁴ES, ⁵US, ⁶DE
- 15:00 - 15:20 **10480 - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β2, in patients (pts) with advanced SCCHN: Results from a phase I cohort**
B.C. Cho¹, A. Daste², A. Ravaud², S. Salas², N. Isambert³, E. McClay⁴, A. Awada⁵, C. Borel⁶, J. Gulley⁷, L. Ojalvo⁸, C. Helwig⁹, P.A. Rolfe⁸, N. Penel⁶; ¹KR, ²FR, ³Cedex/FR, ⁴CA/US, ⁵BE, ⁶CEDEX/FR, ⁷MD/US, ⁸MA/US, ⁹DE
- 15:20 - 15:35 **Invited Discussant 10440 and 10480**
S. Faivre, FR
- 15:35 - 15:50 **10450 - A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)**
A. Psyrrri¹, P. Economopoulou¹, I. Kotsantis¹, G. Koutsodontis¹, M. Cheila¹, G. Papaxoinis², D. Pectasides¹, G. Fountzilias¹, L. Krikoni¹, V. Souliotis¹; ¹GR, ²GB
- 15:50 - 16:05 **10460 - Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations**
A. Ho¹, N. Chau¹, J. Bauman¹, K. Bible¹, A. Chintakuntlawar², M. Cabanillas³, D. Wong¹, I. Braña Garcia⁴, M. Brose¹, V. Boni⁴, C. Even⁵, M. Razaq¹, V. Mishra¹, K. Bracken¹, D. Wages¹, C. Scholz¹, A. Gualberto¹; ¹US, ²MN/US, ³TX/US, ⁴ES, ⁵FR
- 16:05 - 16:20 **Invited Discussant 10450 and 10460**
L. Siu, CA

14:45 - 16:15 **Type: Special Symposium** **ICM - Room 13**
Title: Drugging non-conventional targets
Chair(s): Alex A. Adjei, US; Christian Dittrich, AT

14:45 - 14:50 **Introduction**
C. Dittrich, AT

14:50 - 15:10 **Inhibiting RAS signaling**
A.A. Adjei, MN/US

15:10 - 15:30 **DNA repair and Microsatellite Instability**
A. Duval, FR

15:30 - 15:50 **Nuclear transporters**
M. Mau-Sorensen, DK

15:50 - 16:10 **Tumour metabolism**
B. van Tine, Missouri/US

16:10 - 16:15 **Conclusions and perspectives**
A.A. Adjei, MN/US

14:45 - 16:15 **Type: Proffered Paper session** **Hall A1 - Room 16**
Title: Proffered paper session - NETs and endocrine tumours
 Chair(s): Rocio Garcia-Carbonero, ES; Marianne Pavel, DE

14:45 - 14:57 **13070 - Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)**

J. Capdevila¹, N. Fazio², C. Lopez¹, A. Teule¹, J. Valle³, S. Tafuto², A. Custodio¹, N. Reed³, M. Raderer⁴, E. Grande¹, R. Garcia-Carbonero¹, P. Jimenez Fonseca¹, V. Alonso¹, L. Antonuzzo², A. Spallanzani², A. Berruti², I. Sevilla Garcia¹, A. La Casta¹, J. Hernando¹, T. Ibrahim⁵; ¹ES, ²IT, ³GB, ⁴AT, ⁵Forlì-Cesena/IT

14:57 - 15:09 **Invited Discussant 13070**

E. Baudin, CEDEX/FR

15:09 - 15:21 **18190 - Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer**

S. Leboulleux¹, E. Lee², L. Bastholt³, M. Tahara⁴, L. Wirth⁵, S. Sherman⁶, B. Robinson⁷, A. Teng⁶, P. Joshi⁶, S. Misir⁶, C. Dutcus⁸, R. Tuttle⁶, M. Schlumberger⁹; ¹FR, ²KR, ³DK, ⁴Chiba/JP, ⁵MA/US, ⁶US, ⁷AU, ⁸New Jersey/US, ⁹CEDEX/FR

15:21 - 15:33 **Invited Discussant 18190**

C. Spitzweg, DE

15:33 - 15:45 **13080 - Activity &&**

J. Yao¹, J. Strosberg², N. Fazio³, M. Pavel⁴, P. Ruzniewski⁵, E. Bergsland⁶, D. Li², S. Tafuto³, N. Raj², D. Campana³, S. Hijioka⁷, M. Raderer⁸, R. Guimbaud⁵, P. Gajate⁹, S. Pusceddu³, A. Reising², E. Degtyarev¹⁰, B. Mookerjee¹¹, P. Aimone¹⁰, S. Singh¹²; ¹TX/US, ²US, ³IT, ⁴DE, ⁵FR, ⁶CA/US, ⁷JP, ⁸AT, ⁹ES, ¹⁰CH, ¹¹NJ/US, ¹²ON/CA

15:45 - 15:57 **13090 - Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: A non-randomized, open-label, phase Ib trial**

P. Zhang, M. Lu, J. Li, L. Shen; CN

15:57 - 16:09 **Invited Discussant 13080 and 13090**

K. Oberg, SE

14:45 - 16:15 **Type: Educational session** **Hall B3 - Room 21**
Title: Undifferentiated sarcomas: From MFH to UPS with more distance still to travel
 Chair(s): Jonathan A. Fletcher, US; Antoine Italiano, FR

14:45 - 15:10 **History of UPS over 2 decades: From MFH to UPS**
K. Thway, GB

15:10 - 15:35 **Genomic landscape of sarcomas with complex genomics: Separate the wheat from the chaff**
J.A. Fletcher, MA/US

15:35 - 16:00 **Clinical management of UPS: Retrospective and perspectives in the era of next generation sequencing and immuno-oncology**
A. Italiano, CEDEX/FR

16:00 - 16:15 **Discussion**

14:45 - 16:00 **Type: Poster Discussion session** **Hall B3 - Room 20**
Title: Poster discussion - Basic science
 Chair(s): Therese Sorlie, NO; Leonor David, PT

14:45 - 14:45 **3PD - Human melanoma cells from different disease stages prime amino acid signature of conditional media indicating signalling in the tumor microenvironment**
M. Hohenegger, C. Wasinger, A. Hofer, O. Spadiut; AT

14:45 - 14:45 **1893PD - A joint metabolic profile of plasma and tissue samples or discovering novel biomarkers in breast cancer**
N. Harada, H. Tada, M. Miyashita, Y. Hamanaka, A. Sato, T. Ishida; JP

14:45 - 15:00 **Invited Discussant 3PD and 1893PD**
T. Sorlie, NO

15:00 - 15:10 **Q&A led by Discussant**

15:10 - 15:10 **1894PD - Single-cell RNA sequencing of triple negative breast cancer patient-derived xenograft reveals distinct cellular populations spatially mapped to histological sections**
C. Martinez Ramirez¹, H. Kuasne², M. Park², D. Zuo², C. Kleinman², Y. Yang², A. Blanchet-Cohen², P. Savage², J. Ragoussis²; ¹CA, ²QC/CA

15:10 - 15:10 **1895PD - Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)**

N. Karachaliou¹, M. Lefterova², J. Draper², M.-A. Molina¹, I. Chaib¹, R. Palmero¹, A. Taus¹, S. Viteri¹, M. González Cao¹, M. Majem Tarruella¹, E. Carcereny Costa³, T. Moran¹, J. Garde Noguera¹, E. Felip¹, S. Olsen², M. Jackson², M. Sampayo¹, I. Faull¹, D. Dix², R. Rosell³; ¹ES, ²US, ³Barcelona/ES

- 15:10 - 15:10 **1896PD - Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer**
N. Pecuchet, R. Taouachi, A. Ben Lakhdar, V. Fallet, N. Rabbe, H. Blons, A. Lemoine, M. Antoine, S. Temam, P. Laurent-Puig, M. Wislez; FR
- 15:10 - 15:25 **Invited Discussant 1894PD, 1895PD and 1896PD**
A. Berns, NL
- 15:25 - 15:35 **Q&A led by Discussant**
- 15:35 - 15:35 **1897PD - Differential expression of immune checkpoints (PD-L1, HHLA2, B7x and B7H3) and their association with driver mutations in pulmonary sarcomatoid carcinoma (PSC)**
H. Cheng¹, J. Sharma², C. Su², S. Li¹, X. Zang¹, R. Perez-Soler², B. Halmos², A. Borczuk¹; ¹US, ²NY/US
- 15:35 - 15:35 **4PD - Immunomodulatory effect of hepatocyte growth factor on monocytes in human gastric cancer**
L. Hirsch, J. Palle, A. Lapeyre-Prost, S. Pernot, T. Voron, E. Tartour, J. Taieb, M. Terme; FR
- 15:35 - 15:35 **5PD - Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer**
E. Suzuki, T. Kotake, T. Nishimura, A. Yamaguchi, F. Pu, M. Toi; JP
- 15:35 - 15:50 **Invited Discussant 1897PD, 4PD and 5PD**
L. David, PT
- 15:50 - 16:00 **Q&A led by Discussant**

14:45 - 16:15 **Type: Proffered Paper session** **Hall B3 - Room 22**
Title: Proffered paper session - Public health policy
 Chair(s): Carin Uyl-de Groot, NL; Michel Coleman, GB

14:45 - 14:57 **15550_PR - Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe**
T. Hwang¹, K. Vokinger², A. Tibau³, B. Gyawali⁴, H. Naci⁵, J. Franklin⁶, R. Beall⁶, A. Kesselheim⁶; ¹US, ²CH, ³ES, ⁴Aichi/US, ⁵GB, ⁶MA/US

14:57 - 15:09 **15560 - Potential for value-based prescribing of oral oncology drugs**
M. Ratain¹, A. Lichter²; ¹IL/US, ²VA/US

15:09 - 15:21 **15570 - Relation between center volumes for pancreatic and esophageal cancer surgeries and outcome in Belgium: A plea for centralization**
H. De Schutter, G. Silversmit, K. Haustermans, L. Van Eycken; BE

15:21 - 15:36 **Invited Discussant 15550, 15560 and 15570**
M. Coleman, GB

15:36 - 15:48 **15580 - Worldwide comparison of colorectal cancer survival by topography and stage at diagnosis (CONCORD-2)**
S. Benitez Majano, V. Di Carlo, M. Nikšić, M. Coleman, C. Allemani, CONCORD Working Group; GB

15:48 - 16:00 **15590 - Increasing colorectal cancer incidence among young adults in England diagnosed during 2001-2014**
A. Exarchakou, L. Donaldson, M. Coleman; GB

16:00 - 16:15 **Invited Discussant 15580 and 15590**
B. Jönsson, SE

14:45 - 16:15 **Type: Joint Symposium** **Hall B4 - Room 19**
Title: ESMO-JSMO joint symposium: New predictive biomarkers in breast cancer therapeutics
Chair(s): Fatima Cardoso, PT; Hironobu Minami, JP

14:45 - 14:50 **Introduction**
F. Cardoso, PT

14:50 - 15:10 **Is BRCA good enough to select for PARPi?**
R. Dent, SG

15:10 - 15:30 **CCNE1 expression as a reliable predictor of palbociclib efficacy**

15:30 - 15:50 **Medical oncology in the genome era: Are we ready in breast cancer?**
K. Tamura, JP

15:50 - 16:10 **HER2 and HER3 as predictor of new ADC (DS-8201a and U3-1402)**
H. Iwata, Aichi/JP

16:10 - 16:15 **Conclusions**
H. Minami, Hyogo/JP

14:45 - 16:15 **Type: EONS session** **Hall B4 - Room 24**
Title: New cancer nursing roles: Innovation in action
 Chair(s): Eileen Furlong, IE

14:45 - 15:00 **Linking patient-reported outcomes and symptom management: The e-SMART study**
L. McCann, GB

15:00 - 15:15 **Cancer-related financial toxicity: The role of nurses**
J. Bryce, IT

15:15 - 15:30 **CN2 - The efficacy of nurse-led clinic**
C. Allan, GB

15:30 - 15:45 **CN3 - Introducing the role of the advanced clinical practitioner in haematology and oncology**
M. Fowler, GB

15:45 - 16:00 **CN4 - Nurse navigators in thoracic oncology: A qualitative study of German nurses' attitudes to nursing role expansion**
L. Hagelskamp, S. Berger, M. Villalobos, M. Thomas, M. Wensing, C. Mahler; DE

16:00 - 16:15 **Discussion**
E. Furlong, IE

15:00 - 16:00 **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 15**
Title: Optimal management of bone metastases in 2018
 Chair(s): Prudence Francis, AU

15:00 - 15:10 **Biology and basis for prediction and prevention**
R. Gomis, ES

15:10 - 15:20 **Medical management**
P. Francis, VIC/AU

15:20 - 15:30 **New radiation techniques**
P. Poortmans, FR

15:30 - 16:00 **Discussion**

15:00 - 16:00 **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 23**
Title: The challenges of toxicities from endocrine treatment in men with prostate cancer
 Chair(s): Ignacio Duran, ES

15:00 - 15:20 **Case on bone health**
M. Smith, US

15:20 - 15:40 **Case on cardiac toxicity**
B. Tombal, BE

15:40 - 16:00 **Case on fatigue / cognition**
I. Duran, ES

16:00 - 17:30 **Type: Young Oncologist session** **ICM - Room 14a**
Title: YO Forum: Research projects: From ideas to papers
 Chair(s): Leticia De Mattos-Arruda, ES; Anna Sophie Berghoff, AT

16:00 - 16:20 **How to select and define your project**
A. Ribas, CA/US

16:20 - 16:40 **How to write a proficient project and get it financed**
L. Paz-Ares, ES

16:40 - 17:00 **Dealing with obstacles faced during your project**
D. Olmos, ES

17:00 - 17:20 **Maximising your clinical investigations: How to structure your paper**
F. Ciardiello, IT

17:20 - 17:30 **Discussion**

16:30 - 18:00 **Type: Educational session** **ICM - Room 1**
Title: Clinical implementation of PI3K inhibitors
 Chair(s): Fabrice André, FR; Evandro de Azambuja, BE

16:30 - 16:55 **Who, when and how to test for PIK3CA mutations**
C. Sotiriou, BE

16:55 - 17:20 **What is the true impact of PI3K inhibitors in clinical practice?**
F. André, FR

17:20 - 17:45 **Managing side effects of PI3K inhibitors**
C. Saura, ES

17:45 - 18:00 **Discussion**

16:30 - 18:00 **Type: Educational session** **Hall A1 - Room 15**
Title: State of the art management of GEP- NET
 Chair(s): George Pentheroudakis, GR; Nicola Fazio, IT

16:30 - 16:55 **Pathological diagnosis: What is important for the clinician?**
G. Rindi, IT

16:55 - 17:20 **Therapeutic approaches for syndrome management**
J. Chan, US

17:20 - 17:45 **Therapeutic approaches for tumour growth control**
N. Fazio, IT

17:45 - 18:00 **Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Hall A2 - Room 18**
Title: Presidential Symposium 3
 Chair(s): Solange Peters, CH; Josep Tabernero, ES

16:30 - 16:45 **LBA8_PR - KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)**
B. Burtness¹, K. Harrington², R. Greil³, D. Soulières⁴, M. Tahara⁵, G. De Castro Jr.⁶, A. Psyrri⁷, N. Baste Rotllan⁸, P. Neupane⁹, Å. Bratland¹⁰, T. Fueterer³, B. Hughes¹¹, R. Mesia⁸, N. Ngamphaiboon¹², T. Rordorf¹³, W.Z. Wan Ishak¹⁴, A. Roy¹, J. Cheng¹⁵, F. Jin¹⁶, D. Rischin¹⁷; ¹US, ²GB, ³AT, ⁴QC/CA, ⁵Chiba/JP, ⁶SP/BR, ⁷GR, ⁸ES, ⁹KS/US, ¹⁰NO, ¹¹AU, ¹²TH, ¹³CH, ¹⁴MY, ¹⁵PA/US, ¹⁶NJ/US, ¹⁷VIC/AU

16:45 - 17:00 **Invited discussant**
J.-P. Machiels, BE

17:00 - 17:15 **LBA9_PR - Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy**
H. Mehanna¹, A. Kong², A. Hartley², P. Mistry², M. Dalby², T. Fulton-Lieuw², M. Robinson², A. Gray², B. Foran², M. Sen², L. O'Toole², K. Dyker², H. Al Booz², R. Moleron², S. Brennan³, E. Aynsley², A. Chan², D. Srinivasan², J. Buter⁴, J. Dunn²; ¹West Midlands/GB, ²GB, ³IE, ⁴NL

17:15 - 17:30 **Invited discussant**
A. Psyrri, GR

17:30 - 17:45 **LBA10 - Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC**
C. Zhou¹, Y. Lu¹, S.-W. Kim², T. Reungwetwattana³, J. Zhou¹, Y. Zhang¹, J. He¹, J.-J. Yang¹, Y. Cheng¹, S.H. Lee², L. Bu¹, T. Xu¹, L. Yang¹, C. Wang¹, P. Morcos⁴, E. Mitry⁵, T. Liu¹, L. Zhang¹; ¹CN, ²KR, ³TH, ⁴NY/US, ⁵CH

17:45 - 18:00 **Invited discussant**
T.S.K. Mok, HK

16:30 - 17:30 **Type: Poster Discussion session** **Hall B3 - Room 21**
Title: Poster Discussion session - Supportive and palliative care 2
 Chair(s): Christina Ruhlmann, DK; Juliane Brandt, DE

16:30 - 16:30 **1540PD - Health-related quality of life in randomized controlled trials: A systematic review of prognostic significance**
J. Mierzynska¹, M. Pe¹, C. Piccinin¹, F. Martinelli¹, C. Coens¹, C. Gotay², A. Eggermont³, M. Groenvold⁴, J. Reijneveld⁵, L. Dirven⁵, A. Bottomley¹; ¹BE, ²BC/CA, ³FR, ⁴DK, ⁵NL

- 16:30 - 16:30 **1690PD - Acceptability in cancer outpatients of completing routine assessments of patient reported outcomes of common terminology criteria for adverse events (PRO-CTCAE) versus other patient reported symptom outcome tools**
H. Albaba¹, M.C. Brown¹, S. Shakik¹, S. Su¹, H. Naik², T. Wang³, M. Liang¹, A. Perez-Cosio¹, L. Eng¹, N. Mittmann¹, W. Xu¹, G. Liu¹, D. Howell¹, T. Barnes⁴; ¹CA, ²BC/CA, ³ON/CA, ⁴AU
- 16:30 - 16:45 **Invited Discussant 1540PD and 1690PD**
J. Brandt, DE
- 16:45 - 16:55 **Q&A led by Discussant**
- 16:55 - 16:55 **1686PD - Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment**
D. Blayney¹, S. Ogenstad¹, Y.-K. Shi², Q. Zhang², L. Du², L. Huang³, R. Mohanlal¹; ¹US, ²CN, ³NY/US
- 16:55 - 16:55 **1687PD - Neuropathy and health behaviors in cancer survivors treated with chemotherapy (CT)**
M. Matias¹, A. Di Meglio¹, A. Zingarello¹, S. Michiels¹, A. Partridge², M. Bendiane¹, M. Ducreux³, F. André¹, I. Vaz Luis¹; ¹FR, ²US, ³CEDEX/FR
- 16:55 - 16:55 **1688PD - Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors**
L. Eng¹, S. Liu², D. Farzanfar², E.C. Smith², A. McCartney², A. Basgaran², K. Balaratnam², S. Yeung², M.C. Brown², D. Howell², J. Jones², W. Xu², D. Goldstein³, W. Evans¹, P. Selby², M. Giuliani², G. Liu²; ¹Ontario/CA, ²CA, ³ON/CA
- 16:55 - 16:55 **1689PD - Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates**
I. Vaz Luis¹, A. Di Meglio¹, M. El-Mouhebb¹, A. Dumas¹, C. Charles¹, G. Menvielle¹, C. Mesleard¹, A.L. Martin¹, P. Cottu², F. Lerebours¹, C. Coutant³, A. Lesur¹, S. Dauchy¹, P. Arveux¹, S. Delaloge¹, N. Lin⁴, P. Ganz⁵, A. Partridge⁶, S. Michiels¹, F. André¹; ¹FR, ²CEDEX 5/FR, ³Cedex/FR, ⁴MA/US, ⁵CA/US, ⁶US
- 16:55 - 17:15 **Invited Discussant 1686PD, 1687PD, 1688PD and 1689PD**
C. Ruhlmann, DK
- 17:15 - 17:25 **Q&A led by Discussant**

16:30 - 18:00 **Type: Educational session** **Hall B3 - Room 22**
Title: Affordability and sustainability of new cancer drugs
 Chair(s): Carin Uyl-de Groot, NL; Fredericus Eskens, NL

16:30 - 16:55 **The economics of innovative medicines**
C. Uyl-de Groot, NL

16:55 - 17:20 **The use of scales to determine the magnitude of benefit of drugs**
E.G.E. de Vries, NL

17:20 - 17:45 **Differential pricing across Europe: addressing needs of middle- and low income countries**
Z. Kaló, HU

17:45 - 18:00 **Discussion about the role of social media**

16:30 - 18:00 **Type: EONS session** **Hall B4 - Room 24**
Title: Awards and closing remarks
 Chair(s): Andreas Charalambous, CY

16:30 - 16:45 **Novice Dissemination Award 1**

16:45 - 17:00 **Novice Dissemination Award 2**

17:00 - 17:15 **Lifetime Achievement Award**

17:15 - 17:30 **Recognising Cancer Nursing Award**

17:30 - 17:40 **Poster winner**
L. Sharp, SE

17:40 - 17:40 **Closing remarks**
L. Sharp, SE

18:30 - 20:00 **Type: Industry Satellite Symposium** **ICM - Room 14b**
Title: Industry satellite symposium 50

18:30 - 20:00 **Type: Industry Satellite Symposium** **ICM - Room 13**
Title: Industry satellite symposium 51

18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 52	Hall A1 - Room 15
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 53	Hall A1 - Room 16
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 54	Hall B3 - Room 20
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 55	Hall B3 - Room 22
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 56	Hall B4 - Room 19

23.10.2018

09:00 - 12:40 **Type: Congress Highlights** **Hall A1 - Room 17**
Title: Congress Highlights 2: The best of the Munich 2018 Congress

Chair(s): Andrés Cervantes, ES; Josep Taberero, ES

09:00 - 09:00 **Session DOI**

09:00 - 09:20 **Gastrointestinal tumours, colorectal**
D. Arnold, DE

09:20 - 09:40 **Gastrointestinal tumours, non-colorectal**
M. Hidalgo, US

09:40 - 10:00 **NETs and endocrine tumours**
G. Pentheroudakis, GR

10:00 - 10:20 **Public health policy and health economics**
F. Perrone, IT

10:20 - 10:40 **Haematological malignancies**
M. Ladetto, IT

10:40 - 11:00 **Break**

11:00 - 11:20 **Supportive and palliative care**
F. Scotté, FR

11:20 - 11:40 **Sarcoma**
G.D. Demetri, MA/US

11:40 - 12:00 **Gynaecological cancers**
K. Steffensen, DK

12:00 - 12:20 **Immunotherapy of cancer**
G. Coukos, CH

12:20 - 12:40 **Melanoma**
G. Long, NSW/AU

09:00 - 13:00 **Type: Congress Highlights** **Hall A2 - Room 18**
Title: Congress Highlights 1: The best of the Munich 2018 Congress
 Chair(s): Solange Peters, CH; Anton Berns, NL

09:00 - 09:00 **Session DOI**

09:00 - 09:20 **Basic science**
T. Helleday, GB

09:20 - 09:40 **Translational research**
M.J. de Miguel, ES

09:40 - 10:00 **Genitourinary tumours, prostate**
S. Gillessen, CH

10:00 - 10:20 **Genitourinary tumours, non-prostate**
P. Bono, FI

10:20 - 10:40 **CNS tumours**
C. Balana, Barcelona/ES

10:40 - 11:00 **Break**

11:00 - 11:20 **Head and neck cancer**
L. Licitra, IT

11:20 - 11:40 **Developmental therapeutics**
T. Troiani, IT

11:40 - 12:00 **Breast cancer, early**
A. di Leo, PO/IT

12:00 - 12:20 **Breast cancer, metastatic**
S. Loibl, DE

12:20 - 12:40 **Non-metastatic NSCLC and other thoracic malignancies**
S. Ramalingam, GA/US

12:40 - 13:00 **NSCLC, metastatic**
J. Spicer, GB

